0001792044-22-000010.txt : 20220228 0001792044-22-000010.hdr.sgml : 20220228 20220228161026 ACCESSION NUMBER: 0001792044-22-000010 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 150 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220228 DATE AS OF CHANGE: 20220228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viatris Inc CENTRAL INDEX KEY: 0001792044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 834364296 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39695 FILM NUMBER: 22689559 BUSINESS ADDRESS: STREET 1: 1000 MYLAN BOULEVARD CITY: CANONSBURG STATE: PA ZIP: 15317 BUSINESS PHONE: (724) 514-1465 MAIL ADDRESS: STREET 1: 1000 MYLAN BOULEVARD CITY: CANONSBURG STATE: PA ZIP: 15317 FORMER COMPANY: FORMER CONFORMED NAME: Upjohn Inc DATE OF NAME CHANGE: 20191023 10-K 1 vtrs-20211231.htm 10-K vtrs-20211231
00017920442021-12-31FALSE2021FYDecember 31P5Yhttp://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent750.02.110.5P3YP3Y0MP3Y0Mthree yearsfour yearsten yearsfive years00017920442021-01-012021-12-3100017920442021-06-30iso4217:USD00017920442021-12-31iso4217:USDxbrli:shares00017920442022-02-22xbrli:shares00017920442020-12-310001792044us-gaap:CommonStockMember2021-12-310001792044us-gaap:CommonStockMember2020-12-310001792044us-gaap:ProductMember2021-01-012021-12-310001792044us-gaap:ProductMember2020-01-012020-12-310001792044us-gaap:ProductMember2019-01-012019-12-310001792044us-gaap:ProductAndServiceOtherMember2021-01-012021-12-310001792044us-gaap:ProductAndServiceOtherMember2020-01-012020-12-310001792044us-gaap:ProductAndServiceOtherMember2019-01-012019-12-3100017920442020-01-012020-12-3100017920442019-01-012019-12-310001792044us-gaap:CashFlowHedgingMember2021-01-012021-12-310001792044us-gaap:CashFlowHedgingMember2020-01-012020-12-310001792044us-gaap:CashFlowHedgingMember2019-01-012019-12-310001792044us-gaap:NetInvestmentHedgingMember2021-01-012021-12-310001792044us-gaap:NetInvestmentHedgingMember2020-01-012020-12-310001792044us-gaap:NetInvestmentHedgingMember2019-01-012019-12-310001792044us-gaap:CommonStockMember2018-12-310001792044us-gaap:AdditionalPaidInCapitalMember2018-12-310001792044us-gaap:RetainedEarningsMember2018-12-310001792044us-gaap:TreasuryStockMember2018-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-3100017920442018-12-310001792044us-gaap:RetainedEarningsMember2019-01-012019-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001792044us-gaap:CommonStockMember2019-01-012019-12-310001792044us-gaap:TreasuryStockMember2019-01-012019-12-310001792044us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001792044srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001792044us-gaap:CommonStockMember2019-12-310001792044us-gaap:AdditionalPaidInCapitalMember2019-12-310001792044us-gaap:RetainedEarningsMember2019-12-310001792044us-gaap:TreasuryStockMember2019-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-3100017920442019-12-310001792044us-gaap:RetainedEarningsMember2020-01-012020-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001792044us-gaap:CommonStockMember2020-01-012020-12-310001792044us-gaap:TreasuryStockMember2020-01-012020-12-310001792044us-gaap:AdditionalPaidInCapitalMember2020-12-310001792044us-gaap:RetainedEarningsMember2020-12-310001792044us-gaap:TreasuryStockMember2020-12-310001792044us-gaap:RetainedEarningsMember2021-01-012021-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001792044us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001792044us-gaap:CommonStockMember2021-01-012021-12-310001792044us-gaap:CommonStockMember2021-01-012021-12-310001792044us-gaap:AdditionalPaidInCapitalMember2021-12-310001792044us-gaap:RetainedEarningsMember2021-12-310001792044us-gaap:TreasuryStockMember2021-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31vtrs:moleculevtrs:site0001792044us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2021-01-012021-12-310001792044us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2021-01-012021-12-310001792044us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2021-01-012021-12-310001792044srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2021-01-012021-12-310001792044us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MinimumMember2021-01-012021-12-310001792044srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-01-012021-12-310001792044srt:MinimumMember2021-01-012021-12-310001792044srt:MaximumMember2021-01-012021-12-3100017920442021-12-162021-12-1600017920442021-06-162021-06-1600017920442021-09-162021-09-160001792044us-gaap:SubsequentEventMember2022-01-062022-01-060001792044us-gaap:SubsequentEventMember2022-03-160001792044us-gaap:SubsequentEventMember2022-02-280001792044vtrs:DevelopedMarketsSegmentMembervtrs:BrandsMember2021-01-012021-12-310001792044vtrs:GreaterChinaSegmentMembervtrs:BrandsMember2021-01-012021-12-310001792044vtrs:BrandsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-01-012021-12-310001792044vtrs:EmergingMarketsSegmentMembervtrs:BrandsMember2021-01-012021-12-310001792044vtrs:BrandsMember2021-01-012021-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:DevelopedMarketsSegmentMember2021-01-012021-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:GreaterChinaSegmentMember2021-01-012021-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-01-012021-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:EmergingMarketsSegmentMember2021-01-012021-12-310001792044vtrs:ComplexGXAndBiosimilarsMember2021-01-012021-12-310001792044vtrs:GenericsMembervtrs:DevelopedMarketsSegmentMember2021-01-012021-12-310001792044vtrs:GenericsMembervtrs:GreaterChinaSegmentMember2021-01-012021-12-310001792044vtrs:GenericsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-01-012021-12-310001792044vtrs:EmergingMarketsSegmentMembervtrs:GenericsMember2021-01-012021-12-310001792044vtrs:GenericsMember2021-01-012021-12-310001792044us-gaap:OperatingSegmentsMembervtrs:DevelopedMarketsSegmentMember2021-01-012021-12-310001792044us-gaap:OperatingSegmentsMembervtrs:GreaterChinaSegmentMember2021-01-012021-12-310001792044us-gaap:OperatingSegmentsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-01-012021-12-310001792044us-gaap:OperatingSegmentsMembervtrs:EmergingMarketsSegmentMember2021-01-012021-12-310001792044us-gaap:OperatingSegmentsMember2021-01-012021-12-310001792044vtrs:DevelopedMarketsSegmentMembervtrs:BrandsMember2020-01-012020-12-310001792044vtrs:GreaterChinaSegmentMembervtrs:BrandsMember2020-01-012020-12-310001792044vtrs:BrandsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2020-01-012020-12-310001792044vtrs:EmergingMarketsSegmentMembervtrs:BrandsMember2020-01-012020-12-310001792044vtrs:BrandsMember2020-01-012020-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:DevelopedMarketsSegmentMember2020-01-012020-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:GreaterChinaSegmentMember2020-01-012020-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2020-01-012020-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:EmergingMarketsSegmentMember2020-01-012020-12-310001792044vtrs:ComplexGXAndBiosimilarsMember2020-01-012020-12-310001792044vtrs:GenericsMembervtrs:DevelopedMarketsSegmentMember2020-01-012020-12-310001792044vtrs:GenericsMembervtrs:GreaterChinaSegmentMember2020-01-012020-12-310001792044vtrs:GenericsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2020-01-012020-12-310001792044vtrs:EmergingMarketsSegmentMembervtrs:GenericsMember2020-01-012020-12-310001792044vtrs:GenericsMember2020-01-012020-12-310001792044us-gaap:OperatingSegmentsMembervtrs:DevelopedMarketsSegmentMember2020-01-012020-12-310001792044us-gaap:OperatingSegmentsMembervtrs:GreaterChinaSegmentMember2020-01-012020-12-310001792044us-gaap:OperatingSegmentsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2020-01-012020-12-310001792044us-gaap:OperatingSegmentsMembervtrs:EmergingMarketsSegmentMember2020-01-012020-12-310001792044us-gaap:OperatingSegmentsMember2020-01-012020-12-310001792044vtrs:DevelopedMarketsSegmentMembervtrs:BrandsMember2019-01-012019-12-310001792044vtrs:GreaterChinaSegmentMembervtrs:BrandsMember2019-01-012019-12-310001792044vtrs:BrandsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2019-01-012019-12-310001792044vtrs:EmergingMarketsSegmentMembervtrs:BrandsMember2019-01-012019-12-310001792044vtrs:BrandsMember2019-01-012019-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:DevelopedMarketsSegmentMember2019-01-012019-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:GreaterChinaSegmentMember2019-01-012019-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2019-01-012019-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:EmergingMarketsSegmentMember2019-01-012019-12-310001792044vtrs:ComplexGXAndBiosimilarsMember2019-01-012019-12-310001792044vtrs:GenericsMembervtrs:DevelopedMarketsSegmentMember2019-01-012019-12-310001792044vtrs:GenericsMembervtrs:GreaterChinaSegmentMember2019-01-012019-12-310001792044vtrs:GenericsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2019-01-012019-12-310001792044vtrs:EmergingMarketsSegmentMembervtrs:GenericsMember2019-01-012019-12-310001792044vtrs:GenericsMember2019-01-012019-12-310001792044us-gaap:OperatingSegmentsMembervtrs:DevelopedMarketsSegmentMember2019-01-012019-12-310001792044us-gaap:OperatingSegmentsMembervtrs:GreaterChinaSegmentMember2019-01-012019-12-310001792044us-gaap:OperatingSegmentsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2019-01-012019-12-310001792044us-gaap:OperatingSegmentsMembervtrs:EmergingMarketsSegmentMember2019-01-012019-12-310001792044vtrs:LipitorMember2021-01-012021-12-310001792044vtrs:NorvascMember2021-01-012021-12-310001792044vtrs:LyricaMember2021-01-012021-12-310001792044vtrs:ViagraMember2021-01-012021-12-310001792044vtrs:EpiPenAutoInjectorsMember2021-01-012021-12-310001792044vtrs:CelebrexMember2021-01-012021-12-310001792044vtrs:CreonMember2021-01-012021-12-310001792044vtrs:ZoloftMember2021-01-012021-12-310001792044vtrs:EffexorMember2021-01-012021-12-310001792044vtrs:XalabrandsMember2021-01-012021-12-310001792044vtrs:InfluvacMember2021-01-012021-12-310001792044vtrs:AmitizaMember2021-01-012021-12-310001792044vtrs:XanaxMember2021-01-012021-12-310001792044vtrs:YupelriMember2021-01-012021-12-310001792044vtrs:DymistaMember2021-01-012021-12-310001792044vtrs:ChargebacksMembervtrs:VariableConsiderationMember2020-12-310001792044vtrs:ChargebacksMembervtrs:VariableConsiderationMember2021-01-012021-12-310001792044vtrs:ChargebacksMembervtrs:VariableConsiderationMember2021-12-310001792044vtrs:RebatesPromotionalProgramsandOtherSalesAllowancesMembervtrs:VariableConsiderationMember2020-12-310001792044vtrs:RebatesPromotionalProgramsandOtherSalesAllowancesMembervtrs:VariableConsiderationMember2021-01-012021-12-310001792044vtrs:RebatesPromotionalProgramsandOtherSalesAllowancesMembervtrs:VariableConsiderationMember2021-12-310001792044vtrs:VariableConsiderationMembervtrs:VariableConsiderationReturnsMember2020-12-310001792044vtrs:VariableConsiderationMembervtrs:VariableConsiderationReturnsMember2021-01-012021-12-310001792044vtrs:VariableConsiderationMembervtrs:VariableConsiderationReturnsMember2021-12-310001792044vtrs:GovernmentalRebateProgramsMembervtrs:VariableConsiderationMember2020-12-310001792044vtrs:GovernmentalRebateProgramsMembervtrs:VariableConsiderationMember2021-01-012021-12-310001792044vtrs:GovernmentalRebateProgramsMembervtrs:VariableConsiderationMember2021-12-310001792044vtrs:VariableConsiderationMember2020-12-310001792044vtrs:VariableConsiderationMember2021-01-012021-12-310001792044vtrs:VariableConsiderationMember2021-12-310001792044us-gaap:AllowanceForCreditLossMember2021-12-310001792044us-gaap:AllowanceForCreditLossMember2020-12-310001792044us-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMembervtrs:ThreeCustomersMember2021-01-012021-12-31xbrli:pure0001792044us-gaap:CreditConcentrationRiskMemberus-gaap:AccountsReceivableMembervtrs:ThreeCustomersMember2020-01-012020-12-310001792044vtrs:UpjohnInc.Memberus-gaap:ProductMember2019-07-290001792044vtrs:UpjohnInc.Membervtrs:PfizerInc.Member2019-07-290001792044vtrs:UpjohnInc.Member2019-07-290001792044vtrs:UpjohnInc.Membervtrs:PfizerInc.Member2019-07-292019-07-290001792044vtrs:UpjohnInc.Membervtrs:PfizerInc.Member2020-11-160001792044vtrs:UpjohnInc.Member2020-11-132020-11-130001792044vtrs:UpjohnInc.Member2021-01-012021-12-310001792044vtrs:UpjohnInc.Member2020-01-012020-12-310001792044vtrs:UpjohnInc.Member2019-05-280001792044vtrs:UpjohnInc.Member2020-12-310001792044vtrs:UpjohnInc.Member2021-12-3100017920442020-12-312020-12-31vtrs:market0001792044us-gaap:MachineryAndEquipmentMember2020-11-132020-11-130001792044us-gaap:BuildingMembersrt:MinimumMember2020-11-132020-11-130001792044us-gaap:BuildingMembersrt:MaximumMember2020-11-132020-11-130001792044vtrs:UpjohnInc.Member2020-11-130001792044us-gaap:FiniteLivedIntangibleAssetsMember2020-11-132020-11-130001792044vtrs:UpjohnInc.Member2020-11-132020-12-310001792044vtrs:PfizerInc.Member2020-12-012020-12-310001792044vtrs:AspenGlobalIncorporatedMember2020-09-012020-09-30iso4217:EUR0001792044us-gaap:ScenarioPlanMembervtrs:AspenGlobalIncorporatedMember2021-06-250001792044us-gaap:ContractualRightsMembervtrs:AspenGlobalIncorporatedMember2020-09-012020-09-300001792044us-gaap:MachineryAndEquipmentMember2021-12-310001792044us-gaap:MachineryAndEquipmentMember2020-12-310001792044us-gaap:BuildingAndBuildingImprovementsMember2021-12-310001792044us-gaap:BuildingAndBuildingImprovementsMember2020-12-310001792044us-gaap:ConstructionInProgressMember2021-12-310001792044us-gaap:ConstructionInProgressMember2020-12-310001792044us-gaap:LandAndLandImprovementsMember2021-12-310001792044us-gaap:LandAndLandImprovementsMember2020-12-310001792044us-gaap:OtherAssetsMembervtrs:CleanEnergyPartnershipsMember2021-12-310001792044us-gaap:OtherAssetsMembervtrs:CleanEnergyPartnershipsMember2020-12-310001792044us-gaap:OtherCurrentLiabilitiesMember2021-12-310001792044us-gaap:OtherCurrentLiabilitiesMember2020-12-310001792044vtrs:CleanEnergyPartnershipsMember2021-12-310001792044vtrs:CleanEnergyPartnershipsMember2020-12-310001792044us-gaap:OtherNoncurrentLiabilitiesMember2021-12-310001792044us-gaap:OtherNoncurrentLiabilitiesMember2020-12-310001792044srt:MinimumMember2021-12-310001792044srt:MaximumMember2021-12-3100017920442017-01-012017-12-310001792044us-gaap:ConsolidatedEntityExcludingVieMember2021-12-310001792044us-gaap:ConsolidatedEntityExcludingVieMember2020-12-310001792044us-gaap:ConsolidatedEntityExcludingVieMember2021-01-012021-12-310001792044us-gaap:ConsolidatedEntityExcludingVieMember2020-01-012020-12-310001792044us-gaap:ConsolidatedEntityExcludingVieMember2019-01-012019-12-310001792044vtrs:DevelopedMarketsSegmentMember2019-12-310001792044vtrs:GreaterChinaSegmentMember2019-12-310001792044vtrs:JapanAustraliaAndNewZealandSegmentMember2019-12-310001792044vtrs:EmergingMarketsSegmentMember2019-12-310001792044vtrs:DevelopedMarketsSegmentMember2019-01-012019-12-310001792044vtrs:GreaterChinaSegmentMember2019-01-012019-12-310001792044vtrs:JapanAustraliaAndNewZealandSegmentMember2019-01-012019-12-310001792044vtrs:EmergingMarketsSegmentMember2019-01-012019-12-310001792044vtrs:DevelopedMarketsSegmentMember2020-12-310001792044vtrs:GreaterChinaSegmentMember2020-12-310001792044vtrs:JapanAustraliaAndNewZealandSegmentMember2020-12-310001792044vtrs:EmergingMarketsSegmentMember2020-12-310001792044vtrs:DevelopedMarketsSegmentMember2020-01-012020-12-310001792044vtrs:GreaterChinaSegmentMember2020-01-012020-12-310001792044vtrs:JapanAustraliaAndNewZealandSegmentMember2020-01-012020-12-310001792044vtrs:EmergingMarketsSegmentMember2020-01-012020-12-310001792044vtrs:DevelopedMarketsSegmentMember2021-12-310001792044vtrs:GreaterChinaSegmentMember2021-12-310001792044vtrs:JapanAustraliaAndNewZealandSegmentMember2021-12-310001792044vtrs:EmergingMarketsSegmentMember2021-12-310001792044us-gaap:LicensingAgreementsMembervtrs:DevelopedMarketsSegmentMembervtrs:BrandsMember2021-12-310001792044vtrs:GreaterChinaSegmentMemberus-gaap:LicensingAgreementsMembervtrs:BrandsMember2021-12-310001792044us-gaap:LicensingAgreementsMembervtrs:BrandsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-12-310001792044vtrs:EmergingMarketsSegmentMemberus-gaap:LicensingAgreementsMembervtrs:BrandsMember2021-12-310001792044us-gaap:LicensingAgreementsMembervtrs:BrandsMember2021-12-310001792044vtrs:ComplexGXAndBiosimilarsMemberus-gaap:LicensingAgreementsMembervtrs:DevelopedMarketsSegmentMember2021-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:GreaterChinaSegmentMemberus-gaap:LicensingAgreementsMember2021-12-310001792044vtrs:ComplexGXAndBiosimilarsMemberus-gaap:LicensingAgreementsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:EmergingMarketsSegmentMemberus-gaap:LicensingAgreementsMember2021-12-310001792044vtrs:ComplexGXAndBiosimilarsMemberus-gaap:LicensingAgreementsMember2021-12-310001792044vtrs:GenericsMemberus-gaap:LicensingAgreementsMembervtrs:DevelopedMarketsSegmentMember2021-12-310001792044vtrs:GenericsMembervtrs:GreaterChinaSegmentMemberus-gaap:LicensingAgreementsMember2021-12-310001792044vtrs:GenericsMemberus-gaap:LicensingAgreementsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-12-310001792044vtrs:EmergingMarketsSegmentMembervtrs:GenericsMemberus-gaap:LicensingAgreementsMember2021-12-310001792044vtrs:GenericsMemberus-gaap:LicensingAgreementsMember2021-12-310001792044us-gaap:LicensingAgreementsMembervtrs:DevelopedMarketsSegmentMember2021-12-310001792044vtrs:GreaterChinaSegmentMemberus-gaap:LicensingAgreementsMember2021-12-310001792044us-gaap:LicensingAgreementsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-12-310001792044vtrs:EmergingMarketsSegmentMemberus-gaap:LicensingAgreementsMember2021-12-310001792044us-gaap:LicensingAgreementsMember2021-12-310001792044us-gaap:LicensingAgreementsMembervtrs:DevelopedMarketsSegmentMembervtrs:BrandsMember2020-12-310001792044vtrs:GreaterChinaSegmentMemberus-gaap:LicensingAgreementsMembervtrs:BrandsMember2020-12-310001792044us-gaap:LicensingAgreementsMembervtrs:BrandsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2020-12-310001792044vtrs:EmergingMarketsSegmentMemberus-gaap:LicensingAgreementsMembervtrs:BrandsMember2020-12-310001792044us-gaap:LicensingAgreementsMembervtrs:BrandsMember2020-12-310001792044vtrs:ComplexGXAndBiosimilarsMemberus-gaap:LicensingAgreementsMembervtrs:DevelopedMarketsSegmentMember2020-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:GreaterChinaSegmentMemberus-gaap:LicensingAgreementsMember2020-12-310001792044vtrs:ComplexGXAndBiosimilarsMemberus-gaap:LicensingAgreementsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2020-12-310001792044vtrs:ComplexGXAndBiosimilarsMembervtrs:EmergingMarketsSegmentMemberus-gaap:LicensingAgreementsMember2020-12-310001792044vtrs:ComplexGXAndBiosimilarsMemberus-gaap:LicensingAgreementsMember2020-12-310001792044vtrs:GenericsMemberus-gaap:LicensingAgreementsMembervtrs:DevelopedMarketsSegmentMember2020-12-310001792044vtrs:GenericsMembervtrs:GreaterChinaSegmentMemberus-gaap:LicensingAgreementsMember2020-12-310001792044vtrs:GenericsMemberus-gaap:LicensingAgreementsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2020-12-310001792044vtrs:EmergingMarketsSegmentMembervtrs:GenericsMemberus-gaap:LicensingAgreementsMember2020-12-310001792044vtrs:GenericsMemberus-gaap:LicensingAgreementsMember2020-12-310001792044us-gaap:LicensingAgreementsMembervtrs:DevelopedMarketsSegmentMember2020-12-310001792044vtrs:GreaterChinaSegmentMemberus-gaap:LicensingAgreementsMember2020-12-310001792044us-gaap:LicensingAgreementsMembervtrs:JapanAustraliaAndNewZealandSegmentMember2020-12-310001792044vtrs:EmergingMarketsSegmentMemberus-gaap:LicensingAgreementsMember2020-12-310001792044us-gaap:LicensingAgreementsMember2020-12-310001792044us-gaap:InProcessResearchAndDevelopmentMember2021-01-012021-12-310001792044us-gaap:InProcessResearchAndDevelopmentMember2020-01-012020-12-310001792044us-gaap:InProcessResearchAndDevelopmentMember2019-01-012019-12-310001792044us-gaap:LicensingAgreementsMember2021-01-012021-12-310001792044us-gaap:LicensingAgreementsMember2020-01-012020-12-310001792044us-gaap:LicensingAgreementsMember2019-01-012019-12-310001792044us-gaap:MeasurementInputDiscountRateMemberus-gaap:LicensingAgreementsMembersrt:MinimumMember2021-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:LicensingAgreementsMember2021-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:InProcessResearchAndDevelopmentMember2021-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:InProcessResearchAndDevelopmentMember2021-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:InProcessResearchAndDevelopmentMember2020-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:InProcessResearchAndDevelopmentMember2020-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:InProcessResearchAndDevelopmentMember2019-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:InProcessResearchAndDevelopmentMember2019-12-310001792044vtrs:NorthAmericaSegmentMember2021-04-010001792044vtrs:EuropeSegmentMember2021-04-010001792044vtrs:EmergingMarketsSegmentMember2021-04-010001792044vtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-010001792044vtrs:GreaterChinaSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:EuropeSegmentMember2021-04-012021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:EuropeSegmentMemberus-gaap:MeasurementInputLongTermRevenueGrowthRateMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:MeasurementInputTerminalYearRevenueGrowthRateMembervtrs:EuropeSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:MeasurementInputEstimatedTaxRateMembervtrs:EuropeSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputEbitdaMultipleMembervtrs:EuropeSegmentMembersrt:MinimumMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputEbitdaMultipleMembersrt:MaximumMembervtrs:EuropeSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:EuropeSegmentMemberus-gaap:MeasurementInputControlPremiumMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:MeasurementInputReductionInTerminalYearRevenueGrowthRateMembervtrs:EuropeSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:MeasurementInputIncreaseInDiscountRateMembervtrs:EuropeSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-012021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputLongTermRevenueGrowthRateMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:MeasurementInputTerminalYearRevenueGrowthRateMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:MeasurementInputEstimatedTaxRateMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputEbitdaMultipleMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputControlPremiumMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:MeasurementInputReductionInTerminalYearRevenueGrowthRateMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-010001792044us-gaap:ValuationTechniqueDiscountedCashFlowMembervtrs:MeasurementInputIncreaseInDiscountRateMembervtrs:JapanAustraliaAndNewZealandSegmentMember2021-04-010001792044us-gaap:SeniorNotesMembervtrs:A2024EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2024EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2024EuroSeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2028EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2028SeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2028SeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2025EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2025EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2025EuroSeniorNotesMember2020-12-310001792044vtrs:A2022EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2022EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2022EuroSeniorNotesMember2020-12-310001792044vtrs:A2024EuroSeniorNotes1023Member2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2024EuroSeniorNotes1023Member2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2024EuroSeniorNotes1023Member2020-12-310001792044vtrs:A2027EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2027EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2027EuroSeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2032EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2032EuroSeniorNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2032EuroSeniorNotesMember2020-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2020FloatingRateEuroNotesMember2021-12-310001792044us-gaap:NetInvestmentHedgingMembervtrs:A2020FloatingRateEuroNotesMember2020-12-310001792044us-gaap:NetInvestmentHedgingMember2021-12-310001792044us-gaap:NetInvestmentHedgingMember2020-12-310001792044vtrs:YENTermLoanMemberus-gaap:NetInvestmentHedgingMember2021-12-31iso4217:JPY0001792044vtrs:YENTermLoanMemberus-gaap:NetInvestmentHedgingMember2020-12-310001792044vtrs:YENTermLoanMember2021-12-310001792044us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310001792044us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-12-310001792044us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001792044us-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001792044us-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001792044us-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001792044us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310001792044us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-12-310001792044us-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2021-12-310001792044us-gaap:NondesignatedMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2020-12-310001792044us-gaap:NondesignatedMember2021-12-310001792044us-gaap:NondesignatedMember2020-12-310001792044us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2021-01-012021-12-310001792044us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2020-01-012020-12-310001792044us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMember2019-01-012019-12-310001792044us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMembervtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember2021-01-012021-12-310001792044us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMembervtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember2020-01-012020-12-310001792044us-gaap:InterestExpenseMemberus-gaap:FairValueHedgingMembervtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember2019-01-012019-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:OtherExpenseMemberus-gaap:ForeignExchangeContractMember2021-01-012021-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:OtherExpenseMemberus-gaap:ForeignExchangeContractMember2020-01-012020-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:OtherExpenseMemberus-gaap:ForeignExchangeContractMember2019-01-012019-12-310001792044us-gaap:OtherExpenseMemberus-gaap:ForeignExchangeContractMember2021-01-012021-12-310001792044us-gaap:OtherExpenseMemberus-gaap:ForeignExchangeContractMember2020-01-012020-12-310001792044us-gaap:OtherExpenseMemberus-gaap:ForeignExchangeContractMember2019-01-012019-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-01-012020-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2019-01-012019-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:SalesMemberus-gaap:ForeignExchangeContractMember2021-01-012021-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:SalesMemberus-gaap:ForeignExchangeContractMember2020-01-012020-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:SalesMemberus-gaap:ForeignExchangeContractMember2019-01-012019-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2021-01-012021-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2020-01-012020-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2019-01-012019-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2021-01-012021-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-01-012020-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2019-01-012019-12-310001792044us-gaap:NetInvestmentHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ForeignExchangeContractMember2021-01-012021-12-310001792044us-gaap:NetInvestmentHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ForeignExchangeContractMember2020-01-012020-12-310001792044us-gaap:NetInvestmentHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ForeignExchangeContractMember2019-01-012019-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-310001792044us-gaap:MoneyMarketFundsMember2021-12-310001792044us-gaap:FairValueInputsLevel1Member2021-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:ExchangeTradedFundsMember2021-12-310001792044us-gaap:ExchangeTradedFundsMember2021-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:CommonStockMember2021-12-310001792044us-gaap:CommonStockMember2021-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2021-12-310001792044us-gaap:CorporateBondSecuritiesMember2021-12-310001792044us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001792044us-gaap:USTreasurySecuritiesMember2021-12-310001792044us-gaap:MortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001792044us-gaap:MortgageBackedSecuritiesMember2021-12-310001792044us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001792044us-gaap:AssetBackedSecuritiesMember2021-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMember2021-12-310001792044us-gaap:OtherDebtSecuritiesMember2021-12-310001792044us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001792044us-gaap:DebtSecuritiesMember2021-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2021-12-310001792044us-gaap:ForeignExchangeContractMember2021-12-310001792044us-gaap:FairValueInputsLevel2Member2021-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2021-12-310001792044us-gaap:ForeignExchangeContractMember2021-12-310001792044us-gaap:FairValueInputsLevel3Membervtrs:ContingentConsiderationMember2021-12-310001792044vtrs:ContingentConsiderationMember2021-12-310001792044us-gaap:FairValueInputsLevel3Member2021-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-310001792044us-gaap:MoneyMarketFundsMember2020-12-310001792044us-gaap:FairValueInputsLevel1Member2020-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:ExchangeTradedFundsMember2020-12-310001792044us-gaap:ExchangeTradedFundsMember2020-12-310001792044us-gaap:FairValueInputsLevel1Membervtrs:MarketableSecuritiesMember2020-12-310001792044vtrs:MarketableSecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2020-12-310001792044us-gaap:EquitySecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2020-12-310001792044us-gaap:CorporateBondSecuritiesMember2020-12-310001792044us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001792044us-gaap:USTreasurySecuritiesMember2020-12-310001792044us-gaap:MortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001792044us-gaap:MortgageBackedSecuritiesMember2020-12-310001792044us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001792044us-gaap:AssetBackedSecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMember2020-12-310001792044us-gaap:OtherDebtSecuritiesMember2020-12-310001792044us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310001792044us-gaap:DebtSecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2020-12-310001792044us-gaap:ForeignExchangeContractMember2020-12-310001792044us-gaap:FairValueInputsLevel2Member2020-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2020-12-310001792044us-gaap:ForeignExchangeContractMember2020-12-310001792044us-gaap:FairValueInputsLevel3Membervtrs:ContingentConsiderationMember2020-12-310001792044vtrs:ContingentConsiderationMember2020-12-310001792044us-gaap:FairValueInputsLevel3Member2020-12-310001792044vtrs:RespiratorydeliveryplatformMember2021-12-310001792044us-gaap:MeasurementInputDiscountRateMembervtrs:ContingentConsiderationMembersrt:MinimumMember2021-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMembervtrs:ContingentConsiderationMember2021-12-310001792044us-gaap:OtherCurrentLiabilitiesMember2019-12-310001792044us-gaap:OtherNoncurrentLiabilitiesMember2019-12-310001792044us-gaap:OtherCurrentLiabilitiesMember2020-01-012020-12-310001792044us-gaap:OtherNoncurrentLiabilitiesMember2020-01-012020-12-310001792044us-gaap:OtherCurrentLiabilitiesMember2021-01-012021-12-310001792044us-gaap:OtherNoncurrentLiabilitiesMember2021-01-012021-12-310001792044us-gaap:DebtSecuritiesMember2021-12-310001792044us-gaap:DebtSecuritiesMember2020-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2020-12-310001792044us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2020-12-310001792044us-gaap:CommercialPaperMember2021-12-310001792044us-gaap:CommercialPaperMember2020-12-310001792044vtrs:ReceivablesFacilityMember2021-12-310001792044vtrs:ReceivablesFacilityMember2020-12-310001792044vtrs:NoteSecuritizationFacilityMember2021-12-310001792044vtrs:NoteSecuritizationFacilityMember2020-12-310001792044vtrs:OtherCurrentPortionofLongtermDebtMember2021-12-310001792044vtrs:OtherCurrentPortionofLongtermDebtMember2020-12-310001792044vtrs:CommercialPaperProgramMember2017-06-060001792044vtrs:CommercialPaperProgramMember2017-06-062017-06-060001792044vtrs:ReceivablesFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-01-012021-12-310001792044us-gaap:LondonInterbankOfferedRateLIBORMembervtrs:NoteSecuritizationFacilityMember2021-01-012021-12-310001792044vtrs:SeniorNotes2021Member2021-12-310001792044vtrs:A2020FloatingRateEuroNotesMember2021-12-310001792044vtrs:A2020FloatingRateEuroNotesMember2020-12-310001792044vtrs:A2020EuroSeniorNotesMember2021-12-310001792044vtrs:A2020EuroSeniorNotesMember2020-12-310001792044vtrs:SeniorNotesTwoThousandTwenty3.75PercentMember2021-12-310001792044vtrs:SeniorNotesTwoThousandTwenty3.75PercentMember2020-12-310001792044vtrs:CurrentPortionofLongTermDebtMember2021-12-310001792044vtrs:CurrentPortionofLongTermDebtMember2020-12-310001792044vtrs:A2022EuroSeniorNotesMember2020-12-310001792044vtrs:SeniorNotes2022Member2021-12-310001792044vtrs:SeniorNotes2022Member2020-12-310001792044us-gaap:SeniorNotesMembervtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:SeniorNotesTwoThousandTwentyThree4.2PercentMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:SeniorNotesTwoThousandTwentyThree4.2PercentMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2024EuroSeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2024EuroSeniorNotes1023Member2021-12-310001792044us-gaap:SeniorNotesMembervtrs:A2024EuroSeniorNotes1023Member2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2025EuroSeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2025SeniorNotesMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:A2025SeniorNotesMember2020-12-310001792044vtrs:SeniorNotesTwoThousandTwentySix3.95PrecentMemberus-gaap:SeniorNotesMember2021-12-310001792044vtrs:SeniorNotesTwoThousandTwentySix3.95PrecentMemberus-gaap:SeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2027EuroSeniorNotesMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:A2027EuroSeniorNotesMember2020-12-310001792044vtrs:A2027SeniorNotesMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:A2027SeniorNotesMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:A2027SeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2028EuroSeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2028SeniorNotesMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:A2028SeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2030SeniorNotesMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:A2030SeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2032EuroSeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2040SeniorNotesMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:A2040SeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:SeniorNotesTwoThousandFortyThreeMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:SeniorNotesTwoThousandFortyThreeMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:SeniorNotesTwoThousandFortySix5.25PrecentMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:SeniorNotesTwoThousandFortySix5.25PrecentMember2020-12-310001792044vtrs:A2048SeniorNotesMemberus-gaap:SeniorNotesMember2021-12-310001792044vtrs:A2048SeniorNotesMemberus-gaap:SeniorNotesMember2020-12-310001792044us-gaap:SeniorNotesMembervtrs:A2050SeniorNotesMember2021-12-310001792044us-gaap:SeniorNotesMembervtrs:A2050SeniorNotesMember2020-12-310001792044vtrs:TermLoanMember2021-12-310001792044vtrs:TermLoanMemberus-gaap:SeniorNotesMember2020-12-310001792044vtrs:OtherLongTermDebtMember2021-12-310001792044vtrs:OtherLongTermDebtMember2020-12-3100017920442020-01-012020-03-310001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:UnregisteredUpjohnUSDollarNotesMember2021-06-300001792044vtrs:UpjohnEuroNotesMembervtrs:UpjohnInc.Memberus-gaap:SeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMember2021-09-3000017920442021-10-290001792044vtrs:A2022SeniorNotesMembervtrs:UpjohnInc.Memberus-gaap:SeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:A2025SeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:A2027SeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:A2030SeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:A2040SeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:A2050SeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:A2022EuroSeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:A2024EuroSeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:A2027EuroSeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Memberus-gaap:SeniorNotesMembervtrs:A2032EuroSeniorNotesMember2021-06-300001792044vtrs:UpjohnInc.Member2021-06-300001792044vtrs:USDTermLoanFacilityMemberus-gaap:SeniorNotesMember2020-06-300001792044us-gaap:RevolvingCreditFacilityMembervtrs:A2020RevolvingFacilityMember2020-06-300001792044vtrs:YENTermLoanMemberus-gaap:MediumTermNotesMember2021-07-310001792044us-gaap:RevolvingCreditFacilityMembervtrs:TwentyTwentyOneRevolvingFacilityMember2021-06-300001792044vtrs:TwentyTwentyOneLoanFacilitiesMemberus-gaap:MediumTermNotesMember2021-07-31utr:Rate0001792044us-gaap:SeniorNotesMember2021-12-310001792044us-gaap:SeniorNotesMember2020-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-12-310001792044us-gaap:NetInvestmentHedgingMember2021-12-310001792044us-gaap:NetInvestmentHedgingMember2020-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-12-310001792044us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-12-310001792044us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-12-310001792044us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ForeignExchangeContractMember2021-01-012021-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001792044us-gaap:InterestRateSwapMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-12-310001792044us-gaap:InterestRateSwapMemberus-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001792044us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001792044us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001792044us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001792044us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-12-310001792044us-gaap:NetInvestmentHedgingMember2019-12-310001792044us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310001792044us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001792044us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-01-012020-12-310001792044us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-12-310001792044us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-12-310001792044us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-310001792044us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:InterestRateSwapMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:InterestRateSwapMemberus-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-01-012020-12-310001792044us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001792044us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-12-310001792044us-gaap:NetInvestmentHedgingMember2018-12-310001792044us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310001792044us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310001792044us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310001792044us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-01-012019-12-310001792044us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-12-310001792044us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-12-310001792044us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-12-310001792044us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:InterestRateSwapMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:InterestRateSwapMemberus-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-01-012019-12-310001792044us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001792044us-gaap:CashFlowHedgingMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-01-012019-12-310001792044srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001792044us-gaap:ForeignCountryMember2021-01-012021-12-310001792044us-gaap:ForeignCountryMember2020-01-012020-12-310001792044us-gaap:ForeignCountryMember2019-01-012019-12-310001792044vtrs:U.S.StateTaxAuthorityMember2021-01-012021-12-310001792044vtrs:U.S.StateTaxAuthorityMember2020-01-012020-12-310001792044vtrs:U.S.StateTaxAuthorityMember2019-01-012019-12-310001792044vtrs:NonU.S.statetaxauthorityMember2021-01-012021-12-310001792044vtrs:NonU.S.statetaxauthorityMember2020-01-012020-12-310001792044vtrs:NonU.S.statetaxauthorityMember2019-01-012019-12-310001792044vtrs:OtherMember2021-01-012021-12-310001792044vtrs:OtherMember2020-01-012020-12-310001792044vtrs:OtherMember2019-01-012019-12-310001792044country:US2021-01-012021-12-310001792044country:US2020-01-012020-12-310001792044country:US2019-01-012019-12-310001792044country:LU2021-01-012021-12-310001792044country:LU2020-01-012020-12-310001792044country:LU2019-01-012019-12-310001792044country:GI2021-01-012021-12-310001792044country:GI2020-01-012020-12-310001792044country:GI2019-01-012019-12-310001792044country:IE2021-01-012021-12-310001792044country:IE2020-01-012020-12-310001792044country:IE2019-01-012019-12-310001792044country:FR2021-01-012021-12-310001792044country:FR2020-01-012020-12-310001792044country:FR2019-01-012019-12-310001792044country:PR2021-01-012021-12-310001792044country:PR2020-01-012020-12-310001792044country:PR2019-01-012019-12-310001792044country:CH2021-01-012021-12-310001792044country:CH2020-01-012020-12-310001792044country:CH2019-01-012019-12-310001792044country:SG2021-01-012021-12-310001792044country:SG2020-01-012020-12-310001792044country:SG2019-01-012019-12-310001792044vtrs:OtherforeignMember2021-01-012021-12-310001792044vtrs:OtherforeignMember2020-01-012020-12-310001792044vtrs:OtherforeignMember2019-01-012019-12-310001792044us-gaap:NonUsMember2021-01-012021-12-310001792044us-gaap:NonUsMember2020-01-012020-12-310001792044us-gaap:NonUsMember2019-01-012019-12-310001792044srt:ScenarioForecastMember2025-01-012025-12-310001792044vtrs:U.S.FederalTaxAuthorityMember2021-12-310001792044vtrs:U.S.StateTaxAuthorityMember2021-12-310001792044us-gaap:ForeignCountryMember2021-12-310001792044us-gaap:ForeignCountryMembervtrs:IndefiniteMember2021-12-310001792044us-gaap:ForeignCountryMembervtrs:FutureyearsMember2021-12-310001792044us-gaap:DomesticCountryMemberus-gaap:TaxYear2015Memberus-gaap:InternalRevenueServiceIRSMember2019-12-310001792044us-gaap:ForeignCountryMemberus-gaap:AustralianTaxationOfficeMember2021-01-012021-12-3100017920442016-12-310001792044vtrs:A2020StockIncentivePlanAnd2003LongTermIncentivePlanMember2020-11-160001792044vtrs:LongTermIncentivePlan2003Member2020-11-162020-11-160001792044vtrs:LongTermIncentivePlan2003Member2020-11-160001792044us-gaap:EmployeeStockOptionMembersrt:MinimumMembervtrs:LongTermIncentivePlan2003Member2021-01-012021-12-310001792044us-gaap:EmployeeStockOptionMembersrt:MaximumMembervtrs:LongTermIncentivePlan2003Member2021-01-012021-12-310001792044us-gaap:EmployeeStockOptionMembervtrs:LongTermIncentivePlan2003Member2021-01-012021-12-310001792044us-gaap:RestrictedStockUnitsRSUMember2020-12-310001792044us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001792044us-gaap:RestrictedStockUnitsRSUMember2021-12-310001792044us-gaap:RestrictedStockMembervtrs:VestratablyinfiveyearsorlessMember2021-01-012021-12-310001792044vtrs:VestinthreeyearsorlessMemberus-gaap:PerformanceSharesMembervtrs:NotSubjecttoMarketConditionsMember2021-01-012021-12-310001792044vtrs:SubjectToMarketConditionsMembervtrs:VestinthreeyearsorlessMemberus-gaap:PerformanceSharesMember2021-01-012021-12-310001792044vtrs:LongTermIncentivePlan2003Member2021-12-310001792044vtrs:LongTermIncentivePlan2003Member2021-01-012021-12-310001792044vtrs:LongTermIncentivePlan2003Member2020-01-012020-12-310001792044us-gaap:EmployeeStockOptionMembervtrs:LongTermIncentivePlan2003Member2020-01-012020-12-310001792044us-gaap:EmployeeStockOptionMembervtrs:LongTermIncentivePlan2003Member2019-01-012019-12-310001792044vtrs:A2014ProgramMembervtrs:StockappreciationrightsandperformancesharesMember2021-01-012021-12-310001792044us-gaap:PensionPlansDefinedBenefitMember2021-12-310001792044us-gaap:PensionPlansDefinedBenefitMember2020-12-310001792044us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310001792044us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310001792044us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310001792044us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-12-310001792044us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-12-310001792044us-gaap:PensionPlansDefinedBenefitMember2019-01-012019-12-310001792044us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember2021-01-012021-12-310001792044us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember2020-01-012020-12-310001792044us-gaap:PensionPlansDefinedBenefitMember2019-12-310001792044us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310001792044us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2021-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2021-12-310001792044us-gaap:FairValueInputsLevel3Memberus-gaap:CashAndCashEquivalentsMember2021-12-310001792044us-gaap:CashAndCashEquivalentsMember2021-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2021-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2021-12-310001792044us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2021-12-310001792044us-gaap:EquitySecuritiesMember2021-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMember2021-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMember2021-12-310001792044us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMember2021-12-310001792044us-gaap:FixedIncomeSecuritiesMember2021-12-310001792044us-gaap:FairValueInputsLevel1Membervtrs:AssetsheldbyinsurancecompaniesandotherMember2021-12-310001792044vtrs:AssetsheldbyinsurancecompaniesandotherMemberus-gaap:FairValueInputsLevel2Member2021-12-310001792044vtrs:AssetsheldbyinsurancecompaniesandotherMemberus-gaap:FairValueInputsLevel3Member2021-12-310001792044vtrs:AssetsheldbyinsurancecompaniesandotherMember2021-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2020-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2020-12-310001792044us-gaap:FairValueInputsLevel3Memberus-gaap:CashAndCashEquivalentsMember2020-12-310001792044us-gaap:CashAndCashEquivalentsMember2020-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2020-12-310001792044us-gaap:EquitySecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMember2020-12-310001792044us-gaap:FixedIncomeSecuritiesMember2020-12-310001792044us-gaap:FairValueInputsLevel1Membervtrs:AssetsheldbyinsurancecompaniesandotherMember2020-12-310001792044vtrs:AssetsheldbyinsurancecompaniesandotherMemberus-gaap:FairValueInputsLevel2Member2020-12-310001792044vtrs:AssetsheldbyinsurancecompaniesandotherMemberus-gaap:FairValueInputsLevel3Member2020-12-310001792044vtrs:AssetsheldbyinsurancecompaniesandotherMember2020-12-310001792044us-gaap:PensionPlansDefinedBenefitMember2017-01-012017-12-310001792044us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-12-310001792044us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2017-01-012017-12-310001792044vtrs:FiscalYear2017Member2021-12-310001792044vtrs:DeferredBaseSalaryMember2021-01-012021-12-310001792044us-gaap:DeferredBonusMember2021-01-012021-12-310001792044us-gaap:OperatingSegmentsMember2019-01-012019-12-310001792044us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310001792044us-gaap:MaterialReconcilingItemsMember2020-01-012020-12-310001792044us-gaap:MaterialReconcilingItemsMember2019-01-012019-12-310001792044us-gaap:CorporateNonSegmentMember2021-01-012021-12-310001792044us-gaap:CorporateNonSegmentMember2020-01-012020-12-310001792044us-gaap:CorporateNonSegmentMember2019-01-012019-12-310001792044us-gaap:CustomerConcentrationRiskMembervtrs:MckessonCorporationMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001792044us-gaap:CustomerConcentrationRiskMembervtrs:MckessonCorporationMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001792044us-gaap:CustomerConcentrationRiskMembervtrs:MckessonCorporationMemberus-gaap:SalesRevenueNetMember2019-01-012019-12-310001792044us-gaap:CustomerConcentrationRiskMembervtrs:AmeriSourceBergenCorporationMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001792044us-gaap:CustomerConcentrationRiskMembervtrs:AmeriSourceBergenCorporationMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001792044us-gaap:CustomerConcentrationRiskMembervtrs:AmeriSourceBergenCorporationMemberus-gaap:SalesRevenueNetMember2019-01-012019-12-310001792044us-gaap:CustomerConcentrationRiskMembervtrs:CardinalHealthIncMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001792044us-gaap:CustomerConcentrationRiskMembervtrs:CardinalHealthIncMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001792044us-gaap:CustomerConcentrationRiskMembervtrs:CardinalHealthIncMemberus-gaap:SalesRevenueNetMember2019-01-012019-12-310001792044country:CN2021-01-012021-12-310001792044country:CN2020-01-012020-12-310001792044country:CN2019-01-012019-12-310001792044vtrs:TransitionServiceAgreementsMembervtrs:PfizerInc.Member2021-01-012021-12-310001792044vtrs:PfizerInc.Member2021-12-310001792044vtrs:PfizerInc.Member2021-01-012021-12-310001792044vtrs:PfizerInc.Member2020-01-012020-12-310001792044vtrs:A2020RestructuringPlanMembersrt:MaximumMember2021-10-012021-12-310001792044vtrs:A2020RestructuringPlanMembersrt:MaximumMember2021-12-310001792044us-gaap:EmployeeSeveranceMembervtrs:A2020RestructuringPlanMember2020-01-012020-12-310001792044vtrs:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2020-01-012020-12-310001792044vtrs:A2020RestructuringPlanMember2020-01-012020-12-310001792044us-gaap:EmployeeSeveranceMembervtrs:A2020RestructuringPlanMember2020-12-310001792044vtrs:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2020-12-310001792044vtrs:A2020RestructuringPlanMember2020-12-310001792044us-gaap:EmployeeSeveranceMembervtrs:A2020RestructuringPlanMember2021-01-012021-12-310001792044vtrs:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2021-01-012021-12-310001792044vtrs:A2020RestructuringPlanMember2021-01-012021-12-310001792044us-gaap:EmployeeSeveranceMember2021-01-012021-12-310001792044us-gaap:OtherRestructuringMember2021-01-012021-12-310001792044us-gaap:EmployeeSeveranceMembervtrs:A2020RestructuringPlanMember2021-12-310001792044vtrs:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2021-12-310001792044vtrs:A2020RestructuringPlanMember2021-12-310001792044vtrs:A2016RestructuringProgramMember2016-01-012020-12-310001792044us-gaap:EmployeeSeveranceMember2018-12-310001792044us-gaap:OtherRestructuringMember2018-12-310001792044us-gaap:EmployeeSeveranceMember2019-01-012019-12-310001792044us-gaap:OtherRestructuringMember2019-01-012019-12-310001792044us-gaap:EmployeeSeveranceMember2019-12-310001792044us-gaap:OtherRestructuringMember2019-12-310001792044us-gaap:EmployeeSeveranceMember2020-01-012020-12-310001792044us-gaap:OtherRestructuringMember2020-01-012020-12-310001792044us-gaap:EmployeeSeveranceMember2020-12-310001792044us-gaap:OtherRestructuringMember2020-12-310001792044vtrs:FiscalYear2017Memberus-gaap:CollaborativeArrangementMembersrt:MaximumMember2021-01-012021-12-310001792044vtrs:RevanceMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-01-012020-12-310001792044vtrs:MomentaMember2016-01-08vtrs:drugs0001792044vtrs:TheravanceBiopharmaMember2021-01-012021-12-310001792044vtrs:TheravanceBiopharmaMembersrt:MaximumMember2015-01-302015-01-300001792044vtrs:TheravanceBiopharmaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-12-310001792044vtrs:GenericBiologicCompoundsCollaborationMember2013-02-112013-02-12vtrs:Product0001792044vtrs:FKBMember2018-09-202018-09-200001792044vtrs:FKBMember2019-02-272019-02-270001792044vtrs:OtherCompaniesMemberus-gaap:LicensingAgreementsMember2021-01-012021-12-310001792044vtrs:OtherCompaniesMemberus-gaap:LicensingAgreementsMember2021-12-310001792044us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-12-310001792044srt:ScenarioForecastMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervtrs:BiosimilarsBusinessMember2022-10-012022-12-310001792044us-gaap:ConvertiblePreferredStockMembersrt:ScenarioForecastMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervtrs:BiosimilarsBusinessMember2022-10-012022-12-310001792044srt:ScenarioForecastMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervtrs:BiosimilarsBusinessMember2022-01-012022-12-310001792044vtrs:EpiPenAutoInjectorLitigationMember2021-01-012021-12-31vtrs:agreement0001792044us-gaap:SubsequentEventMembervtrs:EpiPenAutoInjectorLitigationMember2022-02-012022-02-280001792044vtrs:EpiPenAutoInjectorLitigationMember2021-12-310001792044vtrs:EpiPenAutoInjectorLitigationMemberus-gaap:OtherCurrentLiabilitiesMember2021-12-310001792044vtrs:MultiDistrictLitigationMember2021-12-31vtrs:state0001792044vtrs:AnticompetitiveConductwithDoxycyclineHyclateDelayedReleaseDoxycyclineMonohydrateGlipizideMetforminandVerapamilMember2021-12-310001792044vtrs:AnticompetitiveConductwithGenericDrugsMember2021-12-310001792044vtrs:AmendedAnticompetitiveConductwithGenericDrugsMember2021-12-31vtrs:case0001792044srt:SubsidiariesMembervtrs:EUCommissionProceedingsPerindorprilMembervtrs:AntitrustProceedingsMember2014-07-082014-07-090001792044srt:SubsidiariesMembervtrs:EUCommissionProceedingsPerindorprilMembervtrs:AntitrustProceedingsMember2014-10-012014-12-310001792044vtrs:EUCommissionProceedingsCitalopramMember2013-06-012013-06-190001792044vtrs:EUCommissionProceedingsCitalopramMember2021-12-310001792044vtrs:U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember2016-02-122016-02-12iso4217:GBP0001792044srt:ParentCompanyMembervtrs:U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember2016-02-122016-02-120001792044srt:ParentCompanyMembervtrs:U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember2021-12-310001792044vtrs:ProductLiabilityMember2021-12-310001792044us-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-31vtrs:increase0001792044vtrs:InsulinGlargineMember2017-10-242017-10-24vtrs:patent0001792044vtrs:InsulinGlargineMember2017-10-240001792044vtrs:InsulinGlargineMember2019-06-170001792044vtrs:InsulinGlargineMember2019-06-172019-06-170001792044vtrs:InsulinGlargineMember2018-09-102018-09-100001792044vtrs:InsulinGlargineMember2020-04-020001792044vtrs:DimethylFumarateMember2017-06-302017-06-300001792044vtrs:OtherMember2021-12-310001792044us-gaap:AllowanceForCreditLossMember2021-01-012021-12-310001792044us-gaap:AllowanceForCreditLossMember2019-12-310001792044us-gaap:AllowanceForCreditLossMember2020-01-012020-12-310001792044us-gaap:AllowanceForCreditLossMember2018-12-310001792044us-gaap:AllowanceForCreditLossMember2019-01-012019-12-310001792044us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-12-310001792044us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-01-012021-12-310001792044us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310001792044us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-12-310001792044us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-01-012020-12-310001792044us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-12-310001792044us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-01-012019-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Fiscal Year Ended December 31, 2021
OR
Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from              to             
Commission file number 001-39695
VIATRIS INC.
(Exact name of registrant as specified in its charter)
Delaware 83-4364296
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317
(Address of principal executive offices)(Zip Code)
(724) 514-1800
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class:Trading Symbol(s)Name of Each Exchange on Which Registered:
Common Stock, par value $0.01 per shareVTRSThe NASDAQ Stock Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes         No   
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes        No  
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes        No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes        No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer  Accelerated filer
Non-accelerated filer  Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes        No  
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $17,237,737,213.

The number of shares of common stock outstanding, par value $0.01 per share, of the registrant as of February 22, 2022 was 1,209,576,280.
INCORPORATED BY REFERENCE
DocumentPart of Form 10-K into Which
Document is Incorporated
An amendment to this Form 10-K will be filed no later than 120 days after the close of registrant’s fiscal year.III


VIATRIS INC.
INDEX TO FORM 10-K
For the Year Ended December 31, 2021
 
  Page
PART I
ITEM 1.
ITEM 1A.
ITEM 1B.
ITEM 2.
ITEM 3.
ITEM 4.
PART II
ITEM 5.
ITEM 6.
ITEM 7.
ITEM 7A.
ITEM 8.
ITEM 9.
ITEM 9A.
ITEM 9B.
ITEM 9C.
PART III
ITEM 10.
ITEM 11.
ITEM 12.
ITEM 13.
ITEM 14.
PART IV
ITEM 15.


2


Glossary of Defined Terms

Unless the context requires otherwise, references to “Viatris,” “the Company,” “we,” “us” or “our” in this 2021 Form 10-K (defined below) refer to Viatris Inc. and its subsidiaries. We also have used several other terms in this 2021 Form 10-K, most of which are explained or defined below. Some amounts in this Form 10-K may not add due to rounding.
2003 LTIP2003 Long-Term Incentive Plan
2020 Revolving FacilityThe revolving credit facility available pursuant to the revolving credit agreement, dated as of June 16, 2020, by and among Viatris, certain lenders and issuing banks from time to time party thereto and Bank of America, N.A., as administrative agent and repaid in full in July 2021
2021 Revolving FacilityThe $4.0 billion revolving facility dated as of July 1, 2021, by and among Viatris, certain lenders and issuing banks from time to time party thereto and Bank of America, N.A., as administrative agent
AbbVieAbbVie Inc.
ACA
Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act
Adjusted EBITDANon-GAAP financial measure that the Company believes is appropriate to provide information to investors - EBITDA (defined below) is further adjusted for share-based compensation expense, litigation settlements, and other contingencies, net, restructuring and other special items
ANDAAbbreviated New Drug Application
AOCEAccumulated other comprehensive earnings
APIActive pharmaceutical ingredients
ARVAntiretroviral medicines
ASCAccounting Standards Codification
AspenAspen Global Incorporated
ASUAccounting Standards Update
BEATBase Erosion Anti-Abuse Tax
BioconBiocon Limited
Biocon BiologicsBiocon Biologics Limited, a majority owned subsidiary of Biocon
Biocon Biologics Transaction
The pending transaction between Viatris and Biocon Biologics pursuant to which Viatris will contribute its biosimilar products and programs to Biocon Biologics in exchange for cash consideration and a convertible preferred equity interest in Biocon Biologics
Biocon AgreementThe agreement between Viatris and Biocon Biologics, dated February 28, 2022, relating to the Biocon Biologics Transaction
BiogenBiogen MA Inc. and Biogen International GmbH, collectively
BPCIABiologics Price Competition and Innovation Act of 2009
Business Combination AgreementBusiness Combination Agreement, dated as of July 29, 2019, as amended from time to time, among Viatris, Mylan, Pfizer and certain of their affiliates
CARES ActCoronavirus Aid, Relief, and Economic Security Act
cGMPCurrent Good Manufacturing Practices
CIACorporate Integrity Agreement, dated August 16, 2017, entered into between the OIG-HHA, Mylan Inc. and Mylan Specialty L.P.
CJEUEuropean Court of Justice
3

clean energy investmentsUsed to define the three equity method investments the Company has in limited liability companies that own refined coal production plants whose activities qualify for income tax credits under Section 45 of the Code
CMACompetition and Markets Authority
CMSCenters for Medicare & Medicaid Services
CodeThe U.S. Internal Revenue Code of 1986, as amended
CombinationRefers to Mylan combining with Pfizer's Upjohn Business in a Reverse Morris Trust transaction to form Viatris on November 16, 2020
Commercial Paper ProgramThe $1.65 billion unsecured commercial paper program entered into as of November 16, 2020 by Viatris, as issuer, Mylan Inc., Utah Acquisition Sub Inc. and Mylan II B.V., as guarantors, and certain dealers from time to time
CommissionEuropean Commission
ContributionPfizer's contribution of the Upjohn Business to Viatris
COPDChronic obstructive pulmonary disease
COSOCommittee of Sponsoring Organizations of the Treadway Commission
COVID-19Novel coronavirus disease of 2019
CP NotesUnsecured, short-term commercial paper notes issued pursuant to the Commercial Paper Program
DEAU.S. Drug Enforcement Agency
Developed Markets segmentViatris’ business segment that includes our operations primarily in the following markets: North America and Europe
DGCLDelaware General Corporation Law
DistributionPfizer's distribution to Pfizer stockholders all the issued and outstanding shares of Upjohn Inc.
DOJU.S. Department of Justice
EBITDANon-GAAP financial measure that the Company believes is appropriate to provide information to investors - U.S. GAAP net earnings (loss) adjusted for net contribution attributable to equity method investments, income tax provision (benefit), interest expense and depreciation and amortization
EDPAU.S. District Court for the Eastern District of Pennsylvania
EMAEuropean Medicines Agency
Emerging Markets segmentViatris’ business segment that includes, but is not limited to, our operations primarily in the following markets: Parts of Asia, the Middle East, South and Central America, Africa, and Eastern Europe
EPD BusinessAbbott Laboratories’ non-U.S. developed markets specialty and branded generics business, prior to its acquisition by Mylan in February 2015
ERP systemEnterprise resource planning system
EUEuropean Union
EURIBOR Euro Interbank Offered Rate
Exchange Act Securities Exchange Act of 1934, as amended
Exchange OfferThe offer to exchange the Unregistered Upjohn U.S. Dollar Notes for the Registered Upjohn Notes, which was conducted pursuant to a registration statement filed with the SEC in September 2021 by Viatris Inc., Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. and declared effective on September 28, 2021. The exchange offer expired on October 28, 2021 and settled on October 29, 2021.
FASBFinancial Accounting Standards Board
FCA
Financial Conduct Authority in the U.K.
4

FDAU.S. Food and Drug Administration
FKBFujifilm Kyowa Kirin Biologics Co. Ltd
Form 10-K
This annual report on Form 10-K for the fiscal year ended December 31, 2021
FTC U.S. Federal Trade Commission
GDPRThe EU’s General Data Protection Regulation
GILTIGlobal intangible low-taxed income
Greater China segmentViatris’ business segment that includes our operations primarily in the following markets: China, Taiwan and Hong Kong
GxGeneric drugs
Hatch-Waxman Act Drug Price Competition and Patent Term Restoration Act of 1984
HIPAAHealth Insurance Portability and Accountability Act of 1996 and the Health Information Technology for Economic and Clinical Health Act
HIV/AIDSHuman immunodeficiency virus infection and acquired immune deficiency syndrome
INNInternational NonProprietary Name
IPRInter Partes review
IPR&DIn-process research and development
IRSU.S. Internal Revenue Service
IRS Ruling
The private letter ruling issued by the IRS to Pfizer with respect to the Combination, dated as of March 17, 2020
ITInformation technology
JANZ segmentViatris’ business segment that includes our operations in the following markets: Japan, Australia and New Zealand
LAMALong-acting muscarinic antagonist
LIBORLondon Interbank Offered Rate
LillyEli Lilly and Company
LOELoss of exclusivity
maximum leverage ratio The maximum consolidated leverage ratio financial covenant requiring maintenance of a maximum ratio of consolidated total indebtedness as of the end of any quarter to consolidated EBITDA for the trailing four quarters as defined in the related credit agreements from time to time
MDLMultidistrict litigation
MomentaMomenta Pharmaceuticals, Inc.
MPIMylan Pharmaceuticals Inc.
MylanMylan N.V. and its subsidiaries
Mylan IIMylan II B.V., a company incorporated under the laws of the Netherlands and an indirect wholly owned subsidiary of Viatris, in which legacy Mylan merged with and into
Mylan Inc. Euro NotesThe 2.125% Senior Notes due 2025 issued by Mylan Inc., which are fully and unconditionally guaranteed on a senior unsecured basis by Mylan II B.V., Viatris Inc. and Utah Acquisition Sub Inc.
Mylan Inc. U.S. Dollar NotesThe 4.200% Senior Notes due 2023, 3.125% Senior Notes due 2023, 4.550% Senior Notes due 2028, 5.400% Senior Notes due 2043 and 5.200% Senior Notes due 2048 issued by Mylan Inc., which are fully and unconditionally guaranteed on a senior unsecured basis by Mylan II B.V., Viatris Inc. and Utah Acquisition Sub Inc.
Mylan SecuritizationMylan Securitization LLC
NASDAQThe NASDAQ Stock Market
NCDs
noncommunicable diseases
5

NDANew drug application
NHI National Health Insurance of Japan
NHSNational Health Services
NOLsNet Operating Losses
Note Securitization FacilityThe note securitization facility entered into in July 2021 for borrowings up to $200 million and expiring in August 2022
OIG-HHSOffice of Inspector General of the Department of Health and Human Services
OTCOver-the-counter
PBMPharmacy benefit managers
PCAOBPublic Company Accounting Oversight Board
PfizerPfizer Inc.
Pfizer Distribution PaymentsPayments made by Pfizer using the proceeds of the $12 billion cash distribution to (a) repurchase Pfizer common stock, (b) make pro rata special cash distributions to its stockholders and/or (c) repay or repurchase debt (including principal, interest and associated premiums and fees) held by third party lenders
PlanViatris Inc. 2020 Stock Incentive Plan
PMSPharmascience Inc.
PPACAPatient Protection and Affordable Care Act
Profit Sharing 401(k) Plan401(k) retirement plan with a profit sharing component for non-union represented employees
PSUsPerformance awards
PTABU.S. Patent Trial and Appeal Board
QCEQuality consistency evaluation
R&DResearch and development
Receivables FacilityThe $400 million accounts receivable entered into in August 2020 and expiring in April 2022
Registered Upjohn NotesThe 1.125% Senior Notes due 2022, 1.650% Senior Notes due 2025, 2.300% Senior Notes due 2027, 2.700% Senior Notes due 2030, 3.850% Senior Notes due 2040 and 4.000% Senior Notes due 2050 originally issued on October 29, 2021 registered with the SEC in exchange for the corresponding Unregistered Upjohn U.S. Dollar Notes in a similar aggregate principal amount and with terms substantially identical to the corresponding Unregistered Upjohn U.S. Dollar Notes and fully and unconditionally guaranteed by Mylan Inc., Mylan II and Utah Acquisition Sub Inc.
respiratory delivery platformPfizer’s proprietary dry powder inhaler delivery platform
Restoration PlanThe Company’s 401(k) Restoration Plan
restricted stock awardsThe Company’s nonvested restricted stock and restricted stock unit awards, including PSUs
RevanceRevance Therapeutics, Inc.
RICORacketeer Influenced and Corrupt Organizations Act
ROU assetRight-of-use asset
RSUsThe Company's unvested restricted stock unit awards
SanofiSanofi-Aventis U.S., LLC
SARsStock Appreciation Rights
SDA Separation and Distribution Agreement between Viatris and Pfizer, dated as of July 29, 2019, as amended from time to time
SDNYU.S. District Court for the Southern District of New York
SECU.S. Securities and Exchange Commission
Securities ActSecurities Act of 1933, as amended
6

Senior U.S. Dollar NotesThe Registered Upjohn U.S. Dollar Notes, the Utah U.S. Dollar Notes and the Mylan Inc. U.S. Dollar Notes, collectively
SeparationPfizer's transfer to Upjohn of substantially all the assets and liabilities comprising the Upjohn Business
Separation and Distribution AgreementSeparation and Distribution Agreement between Viatris and Pfizer, dated as of July 29, 2019, as amended from time to time
SG&ASelling, general and administrative expenses
SOFRSecured overnight financial rate
Stock awardsStock options and SARs
Tax ActDecember 2017 U.S. Tax Cuts and Jobs Act
Tax Matters Agreement
The agreement entered into by Pfizer and Viatris in connection with the Separation and the Distribution that governs the parties’ respective rights, responsibilities and obligations with respect to taxes, including taxes arising in the ordinary course of business and taxes, if any, incurred as a result of any failure of the Distribution or certain related transactions to qualify as tax-free transactions
Tax Opinion
The tax opinion issued by Pfizer’s tax counsel, David Polk & Wardwell LLP, with respect to the Combination
TevaTeva Pharmaceutical Industries Ltd.
Theravance BiopharmaTheravance Biopharma, Inc.
TSATransition service agreements
U.K.United Kingdom
U.S.United States
U.S. GAAPAccounting principles generally accepted in the U.S.
Unregistered Upjohn U.S. Dollar NotesThe 1.125% Senior Notes due 2022, 1.650% Senior Notes due 2025, 2.300% Senior Notes due 2027, 2.700% Senior Notes due 2030, 3.850% Senior Notes due 2040 and 4.000% Senior Notes due 2050 originally issued on June 22, 2020 by Upjohn Inc. (now Viatris Inc.) in a private offering exempt from the registration requirements of the Securities Act and fully and unconditionally guaranteed by Mylan Inc., Mylan II and Utah Acquisition Sub Inc.
UpjohnUpjohn Inc., a wholly owned subsidiary of Pfizer prior to the Distribution, that combined with Mylan and was renamed Viatris Inc.
Upjohn BusinessPfizer’s off-patent branded and generic established medicines business that, in connection with the Combination, was separated from Pfizer and combined with Mylan to form Viatris
Upjohn Euro Notes
Senior unsecured notes denominated in euros and issued by Upjohn Finance B.V. pursuant to an indenture dated June 23, 2020
Upjohn Senior Notes
The Upjohn U.S. Dollar Notes together with the Upjohn Euro Notes
Upjohn U.S. Dollar Notes
Senior unsecured notes denominated in U.S. dollars and issued by Upjohn Inc. pursuant to an indenture dated June 22, 2020
URPUniversal reimbursement pricing
USD Term Loan FacilityThe $600 million delayed draw term loan credit agreement, dated as of June 16, 2020 by and among Viatris, Mizuho Bank, Ltd. and MUFG Bank, Ltd., as administrative agent, and repaid in full in July 2021
Utah Acquisition SubUtah Acquisition Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Viatris
7

Utah Euro Notes
The 2.250% Senior Notes due 2024 and 3.125% Senior Notes due 2028 issued by Utah Acquisition Sub Inc., which are fully and unconditionally guaranteed on a senior unsecured basis by Mylan Inc., Viatris Inc. and Mylan II B.V.
Utah U.S. Dollar NotesThe 3.950% Senior Notes due 2026 and 5.250% Senior Notes due 2046 issued by Utah Acquisition Sub Inc., which are fully and unconditionally guaranteed on a senior unsecured basis by Mylan Inc., Viatris Inc. and Mylan II B.V.
VADepartment of Veterans Affairs
VBPVolume-based procurement
ViatrisViatris Inc., formerly known as Upjohn Inc. prior to the completion of the Combination
Viatris Board
The board of directors of Viatris Inc.
Viatris Bylaws
The amended and restated bylaws of Viatris Inc.
Viatris CharterAmended and restated certificate of incorporation of Viatris Inc.
WHO
World Health Organization
YEN Term Loan FacilityThe ¥40 billion term loan agreement dated as of July 1, 2021, by and among Viatris, Mizuho Bank, Ltd. and MUFG Bank, Ltd., as administrative agent
8

PART I
ITEM 1.Business
About Viatris
Viatris is a global healthcare company formed in November 2020 whose mission is to empower people worldwide to live healthier at every stage of life, regardless of geography or circumstance. Improving the ability of patients to gain access to sustainable and high-quality healthcare is our relentless pursuit. One that rests on visionary thinking, determination and best-in-class capabilities that were strategically built to remove barriers across the health spectrum and advance access globally.
Viatris’ seasoned management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other stakeholders. With a global workforce of approximately 37,000, the Company has industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise complemented by a strong commitment to quality and unparalleled geographic footprint to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. The Company operates approximately 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.
On November 16, 2020, Viatris, formerly known as Upjohn, Mylan and Pfizer consummated the combination of Mylan with the Upjohn Business through a Reverse Morris Trust transaction. In accordance with the terms and conditions of the BCA and SDA, (1) Pfizer contributed the Upjohn Business to Viatris (the “Contribution”), so that the Upjohn Business was separated from the remainder of Pfizer’s businesses (the “Separation”), (2) following the Separation, Pfizer distributed, on a pro rata basis (based on the number of shares of Pfizer common stock held by holders of Pfizer common stock as of the record date of November 13, 2020 (the “Record Date”)), all of the shares of Viatris common stock held by Pfizer to Pfizer stockholders as of the Record Date (the “Distribution”), and (3) immediately following the Distribution, Viatris and Mylan engaged in a strategic business combination transaction (the “Combination”). In addition, pursuant to the SDA and immediately prior to the Distribution, Viatris made a cash payment to Pfizer equal to $12 billion as partial consideration for the Contribution. As a result of the Combination, Viatris holds the combined Upjohn Business and Mylan business. Upon completion of the Distribution and the Combination, holders of Pfizer’s common stock as of the Record Date owned approximately 57% of the outstanding shares of Viatris common stock, and former Mylan shareholders owned approximately 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted, as-converted and as-exercised basis. In connection with the Combination, on November 16, 2020, Mylan merged with and into Mylan II B.V., a company incorporated under the laws of the Netherlands and an indirect wholly owned subsidiary of Viatris, pursuant to and in accordance with the BCA. As a result of such merger, Mylan ceased to exist as a separate legal entity. In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and all historical financial information of the Company prior to November 16, 2020 represents Mylan’s historical results and the Company’s thereafter.
Prior to the Separation, the legacy Upjohn Business historically received support services from Pfizer. In connection with the Separation and Combination, Viatris entered into several agreements with Pfizer or its subsidiaries, including among others, transition services and the manufacturing and supply agreements, which in general provide for the performance of certain services or obligations by each of Pfizer and Viatris for the benefit of each other for initial transitional periods following the Combination. The Company began the process of transitioning certain capabilities in 2021, but expects significant changes to occur in 2022 as a result of further transitioning of services and information and other systems. For additional information, see “Risk Factors – Viatris could incur operational difficulties or losses if Pfizer is unable to perform under the agreements entered into as part of the Combination, if we are unable to obtain the same types and level of services and resources that historically have been provided to the legacy Upjohn Business by Pfizer, or if we are required to make payments to Pfizer pursuant to indemnities agreed to as part of the Combination.
Unless otherwise indicated, industry data included in this Item 1 are sourced from IQVIA Holdings Inc. and are for the twelve months ended November 2021. Viatris product and other company data included in this Item 1 are from internal sources and are as of November 30, 2021.
9

Organization
Upjohn was incorporated in Delaware on February 14, 2019 as a wholly-owned subsidiary of Pfizer to operate the Upjohn Business. Effective as of November 16, 2020, Upjohn changed its name to “Viatris Inc.” and became the parent entity of the combined Upjohn Business and Mylan business.
The Upjohn Business was a global, primarily off-patent branded and generic established medicines business, which included 20 primarily off-patent solid oral dose legacy brands, such as Lyrica®, Lipitor®, Celebrex® and Viagra®.
Mylan was founded in 1961 as a privately-owned company and grew over time into one of the largest manufacturers of generic drugs in the U.S. Mylan became a publicly traded company in 1973. Mylan’s strategy then led to many acquisitions which have played a significant role in the evolution of the company, including Matrix Laboratories Limited (2007); Merck KGaA’s generic and specialty pharmaceutical business (2007); the EPD Business (2015) and Meda AB (publ.) (2016). These acquisitions assisted in creating robust research, manufacturing, supply chain and commercial platforms on a global scale; substantially expanding its portfolio of medicines; diversifying by geography, product type and channel; maintaining its commitment to quality; and cultivating its global workforce.
Since the consummation of the Combination, the Viatris management team has been focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other stakeholders. This includes our previously disclosed significant global restructuring program, which is described further in Note 17 included in Part II. Item 8 of this Form 10-K.
Business Model and Operations
At Viatris, we see healthcare not as it is, but as it should be. We act courageously and are uniquely positioned to be a source of stability in a world of evolving healthcare needs. Viatris empowers people worldwide to live healthier at every stage of life. We do so via Access, Leadership and Partnership.
vtrs-20211231_g1.jpg
ACCESS
Viatris provides high-quality, trusted medicines, regardless of geography or circumstance. We are committed to improving access to high-quality medicines while working to ensure a reliable supply so patients can get the treatments they need, when and where they need them. Our global portfolio, supported by our science, medical and manufacturing expertise, delivers global iconic and key brands, complex generics, biosimilars, generics - including complex and branded generics - and over-the-counter products. As a company, Viatris:
Covers a broad range of therapeutic areas. We produce medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, Viatris offers quality treatment options across more than 10 major therapeutic areas covering a wide variety of noncommunicable and infectious diseases. We also offer support services such as diagnostic clinics, educational seminars and digital tools to help patients better manage their health.
Helps ease the burden of noncommunicable diseases. According to the WHO, NCDs, such as ischemic heart disease, stroke, diabetes, certain cancers and chronic obstructive pulmonary disease, were among the leading causes of death globally as of 2016. NCDs affect people of every age, gender and socioeconomic status in every corner of the world, and pose a heavy burden on individuals, families and communities. To overcome this global public health threat, patients worldwide need a partner they can trust – one that not only believes everyone deserves good health, but also has the portfolio, experience and expertise to make this belief a reality.
10

Helps hearts stay healthier. According to the WHO, coronary heart disease is the number one cause of death globally. Viatris collaborates with many organizations to help prevent, diagnose, and treat many cardiovascular illnesses. Our deep experience in emerging and developed markets affords a tried-and-true method of achieving high impact across the patient experience, from awareness to adherence. In close collaboration with governments, healthcare providers, technology partners and patients, we at Viatris work to nurture healthcare systems that can adapt and respond to patients’ ever-changing needs. We continue to collaborate with medical associations, patient advocacy groups and academia to develop innovative, integrated solutions and programs to help strengthen both the delivery and quality of healthcare.
Fights infectious disease. We are also a global leader in treating infectious diseases such as HIV/AIDS, hepatitis, and tuberculosis, and offer an extensive portfolio across these disease states. While many important strides have been made to treat these illnesses, there is still more to be done in countries where lack of access to therapeutics, preventative treatment and diagnostics often result in patients not receiving proper care, and those where HIV transmission continues thirty years into the epidemic. From manufacturing a pediatric-friendly antiretroviral used to treat HIV-positive infants to providing HIV self-tests in some low- and middle-income countries, we are innovating to help patients.
An Increasingly Innovative and Differentiated Pipeline
Our confidence in the future delivery of our pipeline is rooted in our strong historic development programs and list of firsts, including the recent approval of the generic version of Allergan's Restasis® and Semglee® (insulin glargine-yfgn), the first interchangeable biosimilar ever approved in the U.S., and the launch of the first biosimilar to Humira® (adalimumab) in Japan. In addition, we are working on many other programs, including the potential to be first to market for our BOTOX® (onabotulinumtoxinA) and Eylea® (aflibercept) biosimilars.
While we will continue to diligently pursue important generics opportunities, we will increasingly focus on limited-competition complex and novel products targeting gaps in care, all with a first-to-market emphasis and serving our mission of patient access. Complex products categories are critical to patient health and are growing at a rapid pace. We believe that Viatris’ early vision and continued commitment has given us one of the deepest complex product pipelines in the industry, and that we are well positioned to capitalize on these growth opportunities in the future.
vtrs-20211231_g2.jpg
LEADERSHIP
Viatris is advancing sustainable operations and innovative solutions to improve patient health. Viatris is committed to providing steady leadership in a world that is constantly evolving. We take that commitment seriously and know that advancing sustainable operations and innovative solutions to improve patient health requires strong global leadership. We know what it takes to reach more patients with more products, and believe that Viatris is uniquely positioned to make a difference through our:
Powerful global operating platform, which combines what we believe to be best-in-class manufacturing and supply chain capabilities. Viatris operates approximately 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs on five different continents. Together with a global, flexible and diverse supply chain, our platform strives to mitigate risks of disruption and ensure supply reliability. Our efforts to build a responsive global network have helped us maintain a reliable supply of much needed medicines as the fight against the COVID-19 pandemic continues. We are committed to advancing responsible and sustainable operations and work diligently to minimize our environmental footprint across the Viatris network while safeguarding access to medicine. Our integrated, comprehensive approach focuses on water, air emissions, waste, climate change and energy.
Robust global technical resources, including thousands of scientists, regulatory experts and medical and product safety professionals working around the world on innovative therapies and solutions for patients everywhere.
Strong global commercial team, including sales team members and marketing professionals whose goal is to ensure that products are shipped to customers around the globe.
11

Diverse and differentiated global portfolio includes products in more than 10 major therapeutic areas, including both infectious diseases and NCDs and medicines that treat 9 out of 10 of the WHO’s leading causes of death. We are a leading supplier of medicines to the HIV/AIDS community around the world, with a legacy of providing access to high-quality and affordable ARVs in more than 100 countries. We also are a leading provider of biosimilars globally, with regulatory approvals for biosimilars in more than 85 countries in the areas of oncology, immunology, endocrinology, ophthalmology and dermatology.
We believe that Viatris’ global leadership in all of these areas uniquely positions us to efficiently and effectively serve patients regardless of geography or circumstance. Together, with our commitment to provide access to a sustainable, affordable, and diverse portfolio of high-quality medicines and our goal to be a Partner of Choice® for companies big and small, Viatris works to improve access and meet evolving healthcare needs around the world.
vtrs-20211231_g3.jpg
PARTNERSHIP
Leveraging our collective expertise to connect people to products and services. We have a strong history of partnering with other pharmaceutical companies, nonprofit organizations, government agencies, policymakers, trade associations and alliances, industry researchers and patient advocacy groups. We engage with around 100 trade associations and not-for-profit organizations across more than 40 countries, as well as patient and industry groups and other partners. Our key collaborations focus on access to medicine; public awareness and disease screening; and healthcare provider education and support.
Our Global Healthcare Gateway® Built to Fuel Growth and Partnerships
Our Global Healthcare Gateway® is open for business. We are actively engaging with potential partners to help them accelerate possibilities of using their own healthcare assets to reach more patients by leveraging our unique global platform – our R&D, supply chain, manufacturing, regulatory, commercial and legal expertise. Although the global platforms and infrastructure supporting our innovative Global Healthcare Gateway are not entirely new, what is new is how we are enhancing our capital allocation approach to business development, and our organic and inorganic R&D investments through a focused governance structure to ensure the highest level of strategic decision-making.
Licensing and Other Partner Agreements
We periodically enter into commercial licensing and other partner agreements with other pharmaceutical companies for the development, manufacture, marketing and/or sale of pharmaceutical products. Doing so helps us share risks and costs, leverage strengths and scale up commercialization, but usually requires us to also share future profits. The result often is that medicines become available sooner and to a significantly larger group of patients.
Our significant licensing and other partner agreements are primarily focused on the development, manufacturing, supply and commercialization of multiple, high-value generic biosimilar compounds, insulin analog products and respiratory products, among other complex products. Refer to Note 18 Licensing and Other Partner Agreements included in Part II. Item 8 of this Form 10-K for more information.
Operations
Viatris has developed an end-to-end experience across the total product life cycle, which includes global regulatory licensing, launch, growth and post-approval lifecycle management. Our research, development and medical platform seeks to maximize the impact of our existing portfolio by examining whether there is an opportunity for new indications, label extensions, formulations, and market registrations for our products. We also use our platform to determine whether there is an opportunity to integrate new products into our portfolio.
12

The manufacturing of APIs and finished dosage forms is performed by a combination of internal and external manufacturing operations. Internally, many of the products we produce are vertically integrated; meaning we manufacture both the APIs and finished dosage forms related to those products. Occasionally, however, resources we need are available from only a single supplier. As a result, we supplement our production footprint through arrangements with other manufacturers.
The Company’s significant manufacturing, warehousing and distribution activities are located primarily in the U.S., Puerto Rico, Singapore, India, Japan, China, and certain E.U. countries, including Ireland. In addition, we maintain administrative facilities around the world. While many of these key facilities are owned, Viatris also leases certain facilities from third parties.
We believe all our facilities are in good operating condition, the machinery and equipment are well-maintained, the facilities are suitable for their intended purposes and they have capacities adequate for the current operations.
Facilities and records related to our products are subject to periodic inspection by the FDA, the EMA and other regulatory authorities in jurisdictions where our products are marketed. In addition, authorities often conduct pre-approval plant inspections to determine whether our systems and processes comply with current GMP and other regulations, and clinical-trial reviews to evaluate regulatory compliance and data integrity. Our suppliers, contract manufacturers, clinical trial partners and other business partners are subject to similar regulations and periodic inspections. The Company remains committed to maintaining the highest quality manufacturing standards at its facilities around the world and to continuous assessment and improvement in a time of evolving industry dynamics and regulatory expectations.
We are committed to advancing sustainable operations and innovative solutions to improve patient health. This means we focus on responsible conduct and have global policies and procedures to support our work. We work systematically and diligently to minimize our environmental footprint. Environmental and human health are interconnected, a relationship underscored by climate change and water stress. Our integrated, comprehensive approach focuses on water, air emissions, waste, climate change and energy. Looking ahead, to help ensure we identify and manage risks and opportunities appropriately, we are conducting a climate scenario analysis and intend to establish science-based greenhouse gas reduction targets and strategies, acknowledging the context of the Paris Agreement, as well as goals for water and waste. While it is impossible to predict accurately the future costs associated with environmental compliance and potential remediation activities, compliance with environmental laws is not expected to require significant capital expenditures and has not had, and is not expected to have, a material adverse effect on our operations or competitive position.
Customers and Marketing
Our customers include retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions such as hospitals; among others. See “Channel Types” below for more information about our customers.
The table below displays the percentage of consolidated net sales to our largest customers during the years ended December 31, 2021, 2020 and 2019.
Percentage of Consolidated Net Sales
202120202019
McKesson Corporation%13 %15 %
AmerisourceBergen Corporation%10 %%
Cardinal Health, Inc.%%%
We serve our customers through a team of highly-skilled sales and marketing professionals, all of whom are focused on establishing Viatris as our customers’ partner of choice. To best meet customers’ needs, the Company manages its business on a geographic basis.
In addition to being dynamic, the pharmaceutical industry is complex. How it functions, how it is regulated and how it provides patients access varies by location. Similarly, competition is affected by many factors. Examples of factors include innovation and development, timely approval of prescription drugs by health authorities, manufacturing capabilities, product quality, marketing effectiveness, portfolio size, customer service, consumer acceptance, product price, political stability and the availability of funding for healthcare.
13

Certain parts of our business also are affected by seasonality, e.g., due to the timing and severity of peak cough, cold and flu incidence, which can cause variability in sales trends for some of our products. While seasonality may affect quarterly comparisons within a fiscal year, it generally is not material to our annual consolidated results.
For these and other reasons, the Company’s sales and marketing efforts vary accordingly by product, market and channel type, each of which is described below.
See the Application of Critical Accounting Policies section in Part II. Item 7 of this Form 10-K for more information related to customer arrangements.
Products
From cardiovascular health to oncology, Viatris offers quality treatment options across more than 10 major therapeutic areas covering a wide variety of noncommunicable and infectious diseases. We also offer support services such as diagnostic clinics, educational seminars and digital tools to help patients better manage their health. We offer a broad and diverse range of treatment options across all our therapeutic areas, with many categories containing several products in a range of dosage forms, formulations and delivery systems that allow physicians to tailor care for optimal treatment.
Viatris markets prescription brand drugs, generic drugs, complex generic drugs, biosimilars and APIs.
Brand drugs typically are prescription pharmaceuticals that are sufficiently novel as to be protected by patents or other forms of exclusivity. As such, these drugs, which bear trade names, may be produced and sold only by those owning the rights, subject to certain challenges that other companies may make. Developing new medicines can take years and significant investment. Only a few promising therapies ever enter clinical trials. Fewer still are approved for sale by health authorities, at which point marketing to healthcare providers and consumers begins. Because patents and exclusivities last many years, they serve as an incentive to developers. During the periods protected, developers often recoup their investments and earn a profit. In many high-income countries, the brand business often is characterized by higher margins on lower volumes - especially as compared with generic manufacturers. Viatris has numerous branded drugs, including iconic brands, as well as several global key brands to help patients manage their health. Brand drugs include branded generics which are off-patent products that are sold under an approved proprietary name for marketing purposes. Brand products often become branded generics once patent protections or other forms of exclusivity expire. Branded generic products are common in many countries outside the U.S., including emerging markets. Brand and branded generic products are more sensitive to promotion than are unbranded generic products. They therefore represent the primary focus of most of our sales representatives and product-level marketing activity. Our OTC products, which are sold directly to consumers without a prescription and without reimbursement, are generally sold under a brand name.
Generic drugs are therapeutically equivalent versions of brand drugs. Generics generally become available once the patents and other exclusivities on their branded counterparts expire. The generics business is generally characterized by lower margins on higher volumes of a relatively large number of products. Our generic medicines work in the same way and provide the same clinical benefits as their as their brand-name counterparts and may cost less, providing patients and the healthcare system important savings and medicine options which we believe are essential to making healthcare accessible. The manufacturing of generic medicines is held to the same standards of GMP by health authorities as the manufacturing of branded medicines. National health authorities inspect our facilities around the world to ensure that generic manufacturing, packaging and testing sites pass the same quality standards as those of brand drugs. Gx products typically are sold under their INNs. INNs facilitate the identification of pharmaceutical substances or APIs. Each INN is unique and globally recognized. A nonproprietary name also is known as a generic name.
Complex generic drugs are generic medicines that could have a complex active ingredient, complex formulation, complex route of delivery or complex drug device combinations. Viatris offers a number of these important medicines to patients, including our Wixela® Inhub®, the first generic of ADVAIR DISKUS® and glatiramer acetate injection, a generic version of Copaxone®, for example.
14

Biosimilars are approved by regulatory authorities as highly similar to the originally approved biologic brand version with no clinically meaningful differences in safety or efficacy. Biosimilar versions are increasingly available as therapeutic alternatives for patients facing many serious diseases, including diabetes, autoimmune disorders and multiple cancers. We offer one of the industry’s largest and most diverse global biosimilars franchises with more than 300 marketing authorizations globally focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology. These vital products can help increase access for current and future patients while supporting the sustainability of healthcare systems, and we continue to invest in bringing more to market, as we believe more than two-thirds of the products we will launch in the coming years will be either complex generics or biosimilars. Biosimilars often are marketed under a brand-name. Viatris offers one of the industry’s largest and most diverse global biosimilars franchises, including Fulphila®, Ogivri®, Hulio®, and SEMGLEE®.
APIs are responsible for the therapeutic effects of medicines. We are one of the world’s largest producers of APIs, providing them to customers in more than 100 countries. We are the leading producer of API used in generic ARVs, which treat HIV/AIDS. We also produce API for products in the following areas: antibacterial; central nervous system agents; antihistamines/antiasthmatics; cardiovascular, antivirals; antidiabetics; antifungals; and proton pump inhibitors. Our API is sold through a dedicated sales and marketing team primarily to pharmaceutical companies throughout the world.
Viatris invests significant sums in R&D and in manufacturing capacity. We also often incur substantial litigation expense as a result of defending or challenging brand patents or exclusivities, which is described further in Note 19 included in Part II. Item 8 of this Form 10-K.

Market Types
Viatris focuses its sales and marketing efforts on the people who make key decisions around pharmaceutical prescribing, dispensing or buying. Decision-makers vary by country or region, reflecting law and custom, giving rise to different types of pharmaceutical markets. Many countries feature a mix of or hybrids of various market types, though the Company may focus on just one type in a particular country.
In prescription markets, physicians decide which medicines patients will take. Pharmacies then dispense the products as directed. Drug companies employ sales forces to educate doctors about the clinical benefits of their products. Representatives call on individual doctors or group practices; the process is known as detailing. Examples of countries served by Viatris that are mainly prescription markets are the U.S. brand business, Japan, China, Russia, Turkey, Poland and Mexico.
In substitution markets, pharmacists generally are authorized (and in some cases required) by law to dispense an unbranded or branded generic, if available, in place of a brand-name medicine, or vice versa. Drug companies may use sales forces in these markets too, with representatives calling on and educating pharmacy personnel about their organization and products. Examples of countries served by Viatris that are mainly substitution markets are France, Italy, Spain, Portugal and Australia.
In tender markets, payers, such as governments or insurance companies, negotiate the lowest price for a drug (or group of drugs) on behalf of their constituents or members. In exchange, the chosen supplier’s product is placed on the payer’s formulary, or list of covered prescriptions. Often, a supplier’s drug is the only one available in an entire class of drugs. Large sales forces are not needed to reach these decision-makers. Examples of generic markets served by Viatris that are mainly tender markets are New Zealand, Sweden, South Africa, as well as Germany.
In distribution markets, retailers and wholesalers make drug-purchasing decisions. Large sales forces are not needed to reach the decision-makers representing these organizations. Note, however, that pharmacists operating in distribution markets also may be authorized to make substitution decisions when dispensing medicines. Examples of countries served by Viatris that are mainly distribution markets are the U.S. generics business, the U.K. and Norway.
The allocation of our sales and marketing resources reflects the characteristics of these different market types.
In the case of OTC products, consumers are the decision-makers. OTC products are commonly sold via retail channels, such as pharmacies, drugstores and supermarkets. This makes their sale and marketing comparable to other retail businesses, with broad advertising and trade-channel promotion. Consumers often are loyal to well-known OTC brands. For this reason, suppliers of OTC products, Viatris included, must invest the time and resources needed to build strong OTC brand names.
Channel Types
Viatris’ products make their way to patients through a variety of intermediaries, or channels.
15

Pharmaceutical wholesalers/distributors purchase prescription medicines and other medical products directly from manufacturers for storage in warehouses and distribution centers. The distributors then fill orders placed by healthcare providers and other authorized buyers.
Pharmaceutical retailers purchase products directly from manufacturers or wholesalers/distributors. They then sell them to consumers in relatively small quantities for personal use.
Institutional pharmacies address the unique needs of hospitals, nursing homes and other such venues. Among the services provided are specialized packaging, including for injectables and unit-dose products, for controlled administration.
Mail-order and e-commerce pharmacies receive prescriptions by mail, fax, phone or the internet at a central location; process them in large, mostly automated centers; and mail the drugs to the consumer.
Specialty pharmacies focus on managing the handling and service requirements associated with high-cost and more-complex drug therapies, such as those used to treat patients with rare or serious diseases.
Business Segments
Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics and biosimilars, and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise.
Developed Markets
The Developed Markets segment comprises our operations primarily in North America and Europe. The Company’s business in North America is driven mainly by our operations in the U.S., where we are one of the largest providers of prescription medicines. The U.S. pharmaceutical industry is very competitive, and the primary means of competition are innovation and development, timely FDA approval, manufacturing capabilities, product quality, marketing, portfolio size, customer service, reputation and price. We rely on cost-effective manufacturing processes to meet the rapidly changing needs of our customers around a reliable, high quality supply of generic pharmaceutical products. Europe, where many governments provide healthcare at a low direct cost to consumers and regulate pharmaceutical prices or patient reimbursement levels, continues to be a highly competitive market, especially in terms of pricing, quality standards, service levels and product portfolio. Our leadership position in a number of countries provides us a platform to fulfill the needs of patients, physicians, pharmacies, customers and payors.
Significant products sold by the Developed Markets segment include Lyrica®, Lipitor®, Creon®, Influvac®, Wixela® Inhub®, the EpiPen® Auto-Injector, Hulio®, Fraxiparine®, and Yupelri®.

New product launches are an important growth driver. Important recent launches include SEMGLEE®, Abiraterone, and Cyclosporine Ophthalmic Emulsion in early 2022.
While our U.S. customer base is extensive, it increasingly comprises a small number of very large firms as the pharmaceutical industry has undergone and continues to undergo tremendous change and consolidation. We believe Viatris is well positioned to serve such customers in the Developed Markets due to the scale we have built in terms of R&D, API and finished-dosage-form manufacturing, and portfolio breadth.
Greater China
The Greater China segment includes our operations in mainland China, Taiwan and Hong Kong. Since the closing of the Combination, the Viatris Greater China portfolio is predominantly branded LOE products.
16

In China, the recent healthcare reform measures are aimed at controlling the overall healthcare costs, while providing better and broader care to the population. Healthcare spending is expected to increase in-line with GDP growth. The VBP policy for LOE molecules is now in its fourth year and includes more than 200 molecules. All major Viatris brands are included in the VBP molecule lists. We have re-balanced our business to expand our focus on the retail pharmacy and e-commerce channels while maintaining our presence in the hospital channel. Healthcare consumerism, increased spending power, and demand for premium medical products have generated strong growth in these new channels and partially absorbed the reductions seen in hospital channel due to VBP. Additional pricing and volume pressure for pharmaceutical products sold in the hospital channels is expected to continue during 2022 and could negatively impact our results of operations. For additional information, see “Risk Factors - We have and may continue to experience pressure on the pricing of and reimbursements for certain of our products due to pricing controls, social or government pressure to lower the cost of drugs, and consolidation across the supply chain.
Significant products within the Greater China segment include Lipitor®, Norvasc®, and Viagra®.
JANZ
The JANZ segment consists of our operations in Japan, Australia and New Zealand. In Japan, the NHI regulates the pricing of pharmaceutical products to healthcare providers. The Company sells products in Japan primarily through a network of wholesalers who then sell the products to doctors, hospitals and pharmacies. In Australia, the healthcare system is a mix of public and private healthcare sectors, with Medicare, Australia’s public healthcare system, covering most of the country’s medical costs. The Department of Health oversees healthcare governance, law, and policy while the various state and territory governments administer the system. Most prescription pharmaceutical products are subsidized under the pharmaceutical benefits scheme by the federal government. Pricing of reimbursed pharmaceutical products is regulated by the government and funded via the Medicare levy and through company and patient contributions. The Company sells products primarily through the wholesale system, while promoting its products to both physicians and pharmacists.
Significant products within the JANZ segment include AMITIZA®, Lipacreon®, Lyrica®, Norvasc®, and Effexor®.
New product launches are an important growth driver. Important recent launches include adalimumab biosimilar in Japan.

Emerging Markets
The Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise. With healthcare at various stages of development across these markets, we believe we are positioned to not only leverage our large geographical footprint to maximize the similarities between these markets, but also tailor solutions to meet local need. There is demand in this segment for better healthcare to serve a growing population and economic expansion. Many countries in this segment are brand-conscious with generic penetration rates lower than developed markets.

Among our products sold in the segment are Lipitor®, Lyrica®, Norvasc®, Celebrex®, and ARVs.

New product launches are an important growth driver. New products sold in the Emerging Markets segment in 2021 include Remdesivir and a number of biosimilars.
Refer to Note 15 Segment Information included in Part II. Item 8 of this Form 10-K for more information about our segments.
17

Government Regulation
Regulation by governmental authorities is a significant factor in the R&D, manufacture, marketing, sales and distribution of pharmaceuticals. Our products are subject to robust developmental studies which include analytical determinations of strength, quality, purity as well as rigorous safety and efficacy determinations using preclinical, pharmacokinetic studies and clinical evaluations to gather data to support regulatory review and approval. This body of work results in extensive data and scientific information that is incorporated into a given product’s regulatory dossier. Manufacturing is conducted under exacting conditions governed by extensive regulation including strict in-process and finished pharmaceutical products specifications and controls. Post-approval activities, such as advertising and promotion, pharmacovigilance, post-marketing regulatory commitments, and pharmacopeial monographs, are subject to extensive regulation and controls as well.

The lengthy process of developing products and obtaining required approvals and the continuing need for post-approval compliance with applicable statutes and regulations require the expenditure of substantial resources. Regulatory approval, if and when obtained, may be limited in scope. Further, approved drugs, as well as their manufacturers, are subject to ongoing post-marketing review and inspection, which can lead to the discovery of previously unknown problems with products or the manufacturing or quality control procedures used in their production, which may result in restrictions on their manufacture, sale or use or in their withdrawal from the market.
Any failure or delay by us, our suppliers of manufactured drug product, collaborators or licensees, in obtaining and maintaining regulatory approvals could adversely affect the marketing of our products and our ability to receive product revenue, license revenue or profit-sharing payments.
Other Regulatory Requirements
Our business is subject to a wide range of various other federal, state, non-governmental, and local agency rules and regulations. They focus on fraud and corruption, pricing and reimbursement, data privacy, and the environment, among many other considerations. For more information about certain of these regulations and the associated risks we face, see Part I. Item 1A. “Risk Factors” of this Form 10-K.
Research and Development
Our R&D organization, which includes researchers and regulatory and clinical experts, work collaboratively across our different R&D centers around the world, which include technology-focused development sites and global R&D centers.

Our research, development and clinical platform, which includes regulatory activities, seeks to deliver new product opportunities across all of our categories and markets and to evaluate opportunities to expand the scope of our existing product portfolio. Our product pipeline includes a variety of dosage forms, including oral solid dosage forms, transdermals, injectables, inhalation, and other delivery systems. While committed to generics and specialty products, over the last several years, a greater portion of our investments has been focused on complex or difficult-to-formulate products, such as biosimilars and extended release injectables, rather than on commodity products, such as conventional oral solid dosage forms. For example, we are working on a number of programs including the potential to be first to market for our BOTOX® (onabotulinumtoxinA) and Eylea® (aflibercept) biosimilars.

Intellectual Property
We consider the protection of our intellectual property rights to be extremely valuable, and we act to protect them from infringement by third parties.
We have an extensive trademark portfolio and routinely apply to register key brand-name, generic, branded generic, biosimilar and trade names in numerous countries around the world. Our registered trademarks are renewable indefinitely, and these registrations are properly maintained in accordance with the laws of the countries in which they are registered.
We also have an extensive patent portfolio and actively file for patent protection in various countries to protect our brand-name, generic, branded generic, biosimilar and OTC products, including processes for making and using them. We have more than 3,400 patents filed globally. For additional information, see Part I. Item 1A “Risk Factors - We rely on the effectiveness of our patents, confidentiality agreements and other measures to protect our intellectual property rights” of this Form 10-K.
18

Further, we have well-established safeguards in place to protect our proprietary know-how and trade secrets, both of which we consider extremely valuable to our intellectual property portfolio.
We look for intellectual property licensing opportunities to or from third parties, related not only to our existing products, but as a means for expanding our product portfolio.
We rely on the aforementioned types of intellectual property, as well as our copyrights, trade dress, regulatory exclusivities and contractual protections, to establish a broad scope of intellectual property rights for our product portfolio.
Human Capital
Our people, our culture
Our approximately 37,000 diverse colleagues are fueled by a shared passion, purpose, and genuine care for the patients we serve, and see healthcare not as it is, but as it should be.
To us, that means empowering patients worldwide to live healthier at every stage of life. It also means empowering our colleagues to be the best they can be every day. This is our mindset as we build our performance-driven, highly engaging and inclusive culture: “The Viatris Way”. Since Day 1, we have had several accomplishments that lay the foundation for the kind of company we want to be, including:
Establishing four inaugural Employee Resource Groups (ERGs): Blacks, Women, LGBTQ+ and Working Parents. We believe that it is only through the diverse experiences and perspectives of all our colleagues that we can elicit the best ideas, drive innovation, and achieve business results; and
Being recognized on the Forbes® 2021 World’s Best Employers list.

Talent, training and development
The careers of our colleagues make a difference in the lives of patients around the world, and we want those careers to make a difference in their own lives as well. We provide tools and resources to help colleagues reach new heights. We are committed to cultivating and acquiring talent, developing capabilities and driving performance. We are systematically reviewing and developing structures, programs and processes to support colleagues’ professional development and ensure that Viatris contains the appropriate competencies to support our mission.

Diversity and inclusion
Diversity and inclusion, including understanding and embracing what makes individuals unique, are essential to Viatris’ mission. The diversity we foster in all aspects of our business can be one of our greatest strengths in redefining healthcare not as it is, but as it should be.

Viatris strives to create a positive, productive work environment where integrity, dignity and mutual respect for all are valued. We are an equal opportunity employer and discrimination and harassment are strictly prohibited. Together, we are building a highly inclusive organization and our goal is to provide a safe, supportive community where employees feel they belong and can use their unique experiences, perspectives and skills to make a difference in the lives of others.

Employee well-being and safety
Viatris is committed to providing a safe and healthy workplace for our employees, contractors and visitors. In addressing the COVID-19 pandemic and helping meet urgent global health needs, tens of thousands of dedicated Viatris employees across the world have worked to help ensure a stable supply of much needed treatments.

Because protecting the health and safety of our workforce remains paramount, we continue to align with government directives and the advice of relevant international, national and local health authorities at every Viatris facility around the world. Many of our colleagues are working in manufacturing facilities, where we have taken extra precautions to protect our site personnel and operations, including implementing social distancing measures, daily health assessments and split shifts where feasible. Others have traded their desks for kitchen tables and are juggling disrupted family schedules as well as work, like so many, during this time. We offer a wide range of benefits and programs that are locally customized to meet the unique needs of employees, and regularly offer advice and support to employees working from home.

19

Approach to restructuring
Viatris is undertaking a global restructuring program intended to ensure that the organization is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders. Any workforce actions taken as part of this restructuring program have been and will continue to be implemented in a way that is consistent with the company’s strong commitment to treating employees fairly and with respect.

Exchange Act Reports
Viatris maintains a website at Viatris.com where you can find certain reports and associated amendments that the Company files with the SEC in accordance with the Exchange Act. These filings will include our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports.
We make this information available on our website free of charge, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The contents of our website are not incorporated by reference in this Annual Report on Form 10-K and shall not be deemed “filed” under the Exchange Act.
The SEC also maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.
ITEM 1A.Risk Factors
We operate in a complex and rapidly changing environment that involves risks, many of which are beyond our control. Our business, financial condition, results of operations, cash flows, ability to pay dividends, and/or stock price could be materially affected by any of these risks, if they occur, or by other factors not currently known to us, or not currently considered to be material. These risk factors should be read in conjunction with the other information in this Form 10-K, as well as our other filings with the SEC.
Our risk factors are organized into six categories: Combination, Strategic, Operational, Compliance, Finance and General.
Summary

Below is a summary of some of the more significant risks and uncertainties we face. This summary is not exhaustive and is qualified by reference to the full set of risk factors set forth in Part I, Item 1A.

Combination Risks
The integration of the Upjohn Business with Mylan following the Combination, as well as our global restructuring program, may present significant challenges.
Viatris may not realize the anticipated benefits from the Combination or its global restructuring program.
Viatris could incur operational difficulties or losses if Pfizer is unable to perform under the agreements entered into as part of the Combination, if we are unable to obtain the same types and level of services and resources that historically have been provided to the legacy Upjohn Business by Pfizer, or if we are required to make payments to Pfizer pursuant to indemnities agreed to as part of the Combination.
Strategic Risks
The risks and uncertainties associated with the pending transaction involving our biosimilars business.
Our strategic initiatives, including our strategic alliances, may not achieve all intended benefits.
We have and may continue to experience pressure on the pricing of and reimbursements for certain of our products due to pricing controls, social or government pressure to lower the cost of drugs, and consolidation across the supply chain.
We have significant operations globally, which exposes us to the risks inherent in conducting our business internationally.
Charges to earnings resulting from acquisitions could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Operational Risks
Public health outbreaks, epidemics and pandemics, including the COVID-19 pandemic, have had and could continue to have a material adverse effect on our business, financial condition, results of operations, cash flows and/or stock price and may impact our ability to pay dividends.
20

Current and changing economic conditions may adversely affect our industry, business, partners and suppliers.
The pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comply with applicable laws and regulations.
The use of legal, regulatory, and legislative strategies by both brand and generic competitors, including but not limited to “authorized generics” and regulatory petitions, may increase costs associated with the introduction or marketing of our generic products, could delay or prevent such introduction, and could significantly reduce our revenue and profit.
If we are unable to successfully introduce new products in a timely manner, our future revenue and profitability may be adversely affected.
We expend a significant amount of resources on R&D efforts that may not lead to successful product introductions.
Even if our products in development receive regulatory approval, such products may not achieve expected levels of market acceptance.
Our business is highly dependent upon market perceptions of us, our products and brands, and the safety and quality of our products and brands, as well as the effectiveness of our sales and marketing activities, and we may be adversely impacted by negative publicity or findings.
We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products, some of which require a highly exacting and complex manufacturing process.
Our future success is highly dependent on our ability to attract, motivate and retain key personnel.
Compliance Risks
We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, Chinese anti-corruption laws and similar worldwide anti-corruption laws, which impose restrictions on certain conduct and may carry substantial fines and penalties.
Our competitors, including branded pharmaceutical companies, and/or other third parties, may allege that we or our suppliers are infringing upon their intellectual property, including in an “at risk launch” situation, which could result in substantial monetary damages, impact our ability to launch a product and/or our ability to continue marketing a product, and/or force us to expend substantial resources in resulting litigation, the outcome of which is uncertain.
We are involved in various legal proceedings and certain government inquiries and may experience unfavorable outcomes of such proceedings or inquiries.
If we fail to comply with our corporate integrity agreement, we could be subject to substantial penalties and exclusion from participation in federal healthcare programs.
We are increasingly dependent on IT and our systems and infrastructure face certain risks, including cybersecurity and data leakage risks.
Finance Risks
There can be no guarantee that we will continue to pay dividends or that we will implement a stock buyback program.
We may not be able to maintain competitive financial flexibility and our corporate tax rate which could adversely affect us and our shareholders
We have significant indebtedness, which could lead to adverse consequences or adversely affect our financial position and prevent us from fulfilling our obligations under such indebtedness, and any refinancing of this debt could be at significantly higher interest rates.
There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with U.S. GAAP. Any future changes in estimates, judgments and assumptions used or necessary revisions to prior estimates, judgments or assumptions or changes in accounting standards could lead to a restatement or revision to previously issued financial statements.
Viatris could suffer additional losses due to asset impairment charges.

21

Combination Risks

The integration of the Upjohn Business with Mylan following the Combination, as well as our global restructuring program, may present significant challenges.

The combination of two independent businesses is a complex, costly and time-consuming process and there is a significant degree of difficulty inherent in the process of integrating the Upjohn Business and Mylan. These difficulties include:
diversion of management’s attention from the ongoing operations of Viatris to integration and restructuring matters;
the challenge of integrating the employees and business cultures of the Upjohn Business and Mylan;
retaining existing customers and suppliers, or obtaining new customers and suppliers;
risks associated with managing a larger and more complex company;
the challenge and cost of integrating manufacturing, logistics, information technology, communications and other systems of the Upjohn Business and Mylan;
the potential difficulty retaining key personnel and other employees of Mylan and the Upjohn Business;
challenges in reducing reliance on certain transition services provided by Pfizer, including difficulty hiring employees or finding other suitable replacements and managing the amounts of related replacement costs, prior to the expiration of any period in which such services are provided; and
reducing costs associated with the transition services provided by Pfizer.
In addition to integration activities with respect to Mylan and the Upjohn Business, Viatris is also implementing a significant global restructuring program in order to achieve specified synergies and ensure the new company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders.
The process of integrating operations and implementing restructuring initiatives could cause an interruption of, or loss of momentum in, the activities of one or more of Viatris’ businesses. These integration and restructuring processes are ongoing and members of Viatris’ senior management are required to devote considerable amounts of time to these processes, which could decrease the time they have to manage and service Viatris’ businesses, and develop new products or strategies. There is no assurance that Viatris will be able to manage this integration or restructuring in the manner or on the timelines currently anticipated. If our senior management is not able to timely and effectively manage these integration or restructuring processes, significant business activities are interrupted, or there is a delay or inability to achieve anticipated integration or restructuring goals, Viatris may not be able to achieve its synergy targets and there could be a material adverse effect on Viatris’ business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Viatris may not realize the anticipated benefits from the Combination or its global restructuring program.

Viatris is expected to realize synergies, growth opportunities, and other financial and operating benefits as a result of the Combination. Viatris’ success in realizing these benefits, and the timing of their realization, depends on the successful integration of the Upjohn Business with Mylan, as well as the success of our global restructuring program. See “The integration of the Upjohn Business with Mylan following the Combination, as well as our global restructuring program, may present significant challenges” above. Even if the integration and global restructuring program are successful, we may not achieve these synergies, growth opportunities and other financial and operating benefits within the timeline we anticipate, or at all. For example, the benefits from the Combination may be offset by significant costs incurred in connection with our global restructuring program and the Combination, including integration and post-closing costs, costs associated with our TSAs with Pfizer, and capital expenditures, which could be higher than currently estimated. The quantification of synergies expected to result from the Combination is based on significant estimates and assumptions that are subjective in nature and inherently uncertain. Realization of any benefits and synergies could be affected by a number of factors beyond our control, including, without limitation, general economic conditions, increased operating costs, regulatory developments, and the other risks described in these risk factors. In addition, our ability to achieve our synergy targets depends in large part on the successful implementation of the initiatives under our global restructuring program, which may not achieve their intended goals. The amount of synergies actually realized as a result of the Combination, if any, and the time periods in which any such synergies are realized, could differ materially from our current expectations and estimates, regardless of whether the two business operations are combined successfully. In addition, if key personnel and other employees depart because of issues relating to the uncertainty and difficulty of integration activities, Viatris’ ability to realize the anticipated benefits of the Combination could be reduced. If the integration or our global restructuring program are unsuccessful, if the estimated costs are higher than anticipated, or if we are unable to realize the anticipated synergies and other benefits of the Combination, there could be a material adverse effect on Viatris’ business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
22

Viatris could incur operational difficulties or losses if Pfizer is unable to perform under the agreements entered into as part of the Combination, if we are unable to obtain the same types and level of services and resources that historically have been provided to the legacy Upjohn Business by Pfizer, or if we are required to make payments to Pfizer pursuant to indemnities agreed to as part of the Combination.

In connection with the Combination, Viatris entered into several agreements with Pfizer or its subsidiaries, including among others, transition services and the manufacturing and supply agreements, which in general provide for the performance of certain services or obligations by each of Pfizer and Viatris for the benefit of each other for a transitional period following the Combination. If either party is unable to satisfy its obligations under such agreements in a timely manner or at all, or if the transitional agreements fail to provide for or cover certain essential services needed by Viatris during the applicable transitional period, we have limited recourse and could incur operational difficulties or losses or face liability.
In particular, the legacy Upjohn Business historically received benefits and services from Pfizer. Viatris no longer benefits from Pfizer’s services or business relationships to the extent not otherwise addressed in the definitive documents entered into in connection with the Combination. While Pfizer has agreed to provide certain transition services to Viatris for a transitional period following the Combination, such services may not provide benefits equivalent to the services provided when the Upjohn Business was operating as a part of Pfizer. Viatris may not be able to adequately replace resources formerly provided by Pfizer, or replace such services at the same or lower cost. Viatris may also need to make significant investments to replicate or outsource from other providers certain facilities, systems, infrastructure, and personnel to which it no longer has access and may incur significant costs to replace such services. In addition, we may experience operational disruptions associated with ending the transition services that Pfizer has agreed to provide Viatris under the transition agreements as Viatris transitions off of and attempts to replace these services. Further, because Viatris is reliant on Pfizer for such services during the transitional period, any interruption, disruption or breach of Pfizer’s systems relating to such services, including information technology and information security systems, could have a material adverse effect on our business, financial condition and results of operations.
In connection with such transition services, Viatris and Pfizer agreed, among other things, that each of them will each bear 50% of the first $380 million of certain reasonable out-of-pocket costs incurred by Pfizer in connection with the services, with Viatris bearing all of such costs in excess of $380 million. As of December 31, 2021, the Company has incurred approximately $83.5 million of such expenses.
In addition, in connection with the Combination, Viatris agreed to indemnify Pfizer for certain liabilities. Any payments pursuant to these indemnities could be significant and could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or stock price. See “We are involved in various legal proceedings and certain government inquiries and may experience unfavorable outcomes of such proceedings or inquiries” below.

Viatris may be subject to significant U.S. tax liabilities, or be obligated to indemnify Pfizer for any such tax liability imposed on Pfizer and is subject to potentially significant restrictions that could limit its ability to undertake certain corporate actions (such as stock issuances or the undertaking of a merger or consolidation).

In connection with the Combination, Pfizer received the IRS Ruling and the Tax Opinion, each to the effect that, for U.S. federal income tax purposes, the Distribution, together with certain related transactions, will qualify as a tax-free “reorganization” within the meaning of Section 368(a)(1)(D) of the Code, the Distribution will qualify as a tax-free distribution within the meaning of Section 355 of the Code and the Pfizer Distribution Payments will qualify as money distributed to Pfizer creditors or stockholders in connection with the reorganization for purposes of Section 361(b) of the Code.
Although the IRS Ruling is generally binding on the IRS, the continuing validity of the IRS Ruling is subject to the accuracy of the factual representations made in the ruling request. An opinion of tax counsel neither binds the IRS nor precludes the IRS or the courts from adopting a contrary position. Accordingly, notwithstanding the IRS Ruling and Tax Opinion, there can be no assurance that the IRS will not assert a position contrary to one or more of the conclusions set forth herein and if the IRS prevails in such challenge, the U.S. federal income tax consequences of the Distribution, together with certain related transactions, to Pfizer, Viatris and the holders of Pfizer common stock could be materially different from, and worse than, the U.S. federal income tax consequences described below.
If the Distribution were determined not to have qualified for tax-free treatment under Section 355 of the Code, Pfizer would generally be subject to tax as if it sold the Viatris common stock in a transaction taxable to Pfizer, which could result in a material tax liability that, under certain circumstances, Viatris may be required to indemnify Pfizer against pursuant to the Tax Matters Agreement.
23

Even if the Distribution were otherwise to qualify as a tax-free transaction under Sections 368(a)(1)(D) and 355 of the Code, the Distribution would be taxable to Pfizer (but not to Pfizer’s stockholders) pursuant to Section 355(e) of the Internal Revenue Code if there were a 50 percent or greater change in ownership of either Pfizer or Viatris, directly or indirectly, as part of a plan or series of related transactions that included the Distribution. For this purpose, any acquisitions of Pfizer or Viatris common stock within the period beginning two years before the Distribution and ending two years after the Distribution (i.e., on November 16, 2022) are presumed to be part of such a plan, although Pfizer may be able to rebut that presumption. For purposes of this test, the Combination will be treated as part of a plan, but the Combination standing alone will not cause the Distribution to be taxable to Pfizer under Section 355(e) of the Code because holders immediately before the Distribution of Pfizer common stock directly owned more than 50 percent of Viatris common stock immediately following the Combination. Nevertheless, if the IRS were to determine that other acquisitions of Pfizer common stock or Viatris common stock, either before or after the Distribution, were part of a plan or series of related transactions that included the Distribution, such determination could result in the recognition of a material amount of taxable gain for U.S. federal income tax purposes by Pfizer under Section 355(e) of the Code. Under the Tax Matters Agreement, Viatris will be required to indemnify Pfizer against any taxes resulting from the Distribution or certain aspects of the Separation that arise as a result of Viatris’ breach of certain representations or covenants in the Tax Matters Agreement or certain other acts or omissions by Viatris, including certain actions that could result in Section 355(e) of the Code applying to the Distribution. If Viatris was required to indemnify Pfizer for taxes resulting from the Distribution or certain aspects of the Separation, that indemnification obligation could be substantial and could have a material adverse effect on Viatris, including with respect to our business, financial condition and results of operations.
In addition, the Tax Matters Agreement generally prohibits Viatris and its affiliates from taking certain actions that could cause the Distribution and certain related transactions to fail to qualify as tax-free transactions to Pfizer and its stockholders. Furthermore, unless an exception applies, for a two-year period following the date of the Distribution (i.e., until November 16, 2022), Viatris and its subsidiaries may not:
engage in transactions in which Viatris’ stock is acquired;
engage in certain mergers or consolidations;
discontinue the active conduct of the Upjohn Business;
sell certain assets;
redeem or repurchase any of Viatris’ stock (other than share repurchases permitted by the IRS Ruling); or
amend the Viatris Charter or take any other action affecting the relative voting rights of any of its stock or stock rights.

If Viatris intends to take certain restricted actions before November 16, 2022, it must notify Pfizer of the proposal to take such action and either (a) obtain a ruling from the IRS or an unqualified opinion acceptable to Pfizer to the effect that such action will not affect the tax-free status of the Distribution and certain related transactions or (b) receive from Pfizer a waiver of such requirement. However, none of the receipt of an IRS ruling, an unqualified tax opinion or a waiver by Pfizer will relieve Viatris of any responsibility to indemnify Pfizer for tax-related losses resulting from such actions. As a result of these restrictions and indemnification obligations under the Tax Matters Agreement, Viatris may be limited in its ability to pursue strategic transactions, equity or convertible debt financings or other transactions that may otherwise be in our best interests.
24

Strategic Risks

There are risks and uncertainties associated with the pending transaction involving our biosimilars business, one or more of which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or stock price.

There are a number of risks and uncertainties associated with the pending Biocon Biologics Transaction, including, among other things, the potential failure of a condition to closing, including the conditions related to obtaining required regulatory and other consents and approvals, which could give rise to the termination of Biocon Agreement and related agreements executed between us, Biocon and Biocon Biologics, as applicable. Either party has the right to terminate the Biocon Agreement if the closing has not occurred by March 31, 2023, subject to extension in certain circumstances. For example, a failure by Biocon Biologics to obtain necessary financing to consummate the transactions contemplated by the Biocon Agreement prior to such date could cause the Biocon Agreement to be terminated. To the extent that the current market price of our common stock reflects an assumption that the transactions contemplated by the Biocon Agreement and related agreements will be consummated in the timeframe and manner currently anticipated, and that a portion of the proceeds to us will be used to pay down debt and/or to fund other important company initiatives, any delay in closing or failure to close could result in a decline in the market price of our common stock. Similarly, any delay in closing or failure to close could result in damage to our relationships with customers, suppliers and employees, including our existing relationships with Biocon and Biocon Biologics, and have an adverse effect on our business. Pending the completion of the transactions contemplated by the Biocon Agreement, the attention of our management may be directed toward such transactions and related matters, and their focus may be diverted from the day-to-day business operations of our company, including from other opportunities that might otherwise be beneficial to us. We have agreed to indemnify Biocon Biologics and certain of its representatives against certain losses suffered as a result of certain breaches of our representations, warranties, covenants and agreements in the Biocon Agreement and related documents. Any event that results in a right for Biocon Biologics to seek indemnity from us could result in substantial liability to us and could adversely affect our financial position and results of operations. In addition, in connection with the closing of the pending transaction with Biocon Biologics, we will enter into a transition services agreement pursuant to which we will provide services to Biocon Biologics, including commercialization services substantially the same as we currently provide to our biosimilar business, generally for a period of up to two years. Once in effect, our obligations under the transition services agreement may result in additional expenses that are borne by us and may divert our focus and resources that would otherwise be invested into maintaining or growing our retained business. Furthermore, a significant portion of the consideration that we will receive in the pending transaction with Biocon will be in the form of equity in Biocon Biologics, which is a privately held Indian company. Although we have negotiated certain “downside” protection regarding the value of that equity in the Biocon Agreement and related documents, such protection does not guarantee any particular liquidity event or our ability to monetize our equity and, even if we are able to successfully liquidate our equity, the downside protection may be inadequate to guarantee a minimum return that we or investors expect. In addition, we believe the success of the Biocon biologics business over at least the first two years after closing, will be highly dependent upon the successful transition of the business to Biocon, including no major disruption in services provided under the transition services agreement, which will also have a significant impact on the value of the equity we will own in Biocon Biologics.

Whether the Biocon Biologics transaction is ultimately consummated or not, the pendency could have a number of negative effects on our current business, including potentially disrupting our regular operations, diverting the attention of our workforce and management team, and increasing workforce turnover. It could also disrupt existing business relationships, make it harder to develop new business relationships, or otherwise negatively impact the way that we operate the business, which could negatively impact Viatris’ results of operations and cash flows during the pendency of the transaction.

If we successfully complete the pending transaction involving our biosimilars business, our total revenues, results of operations and cash flows from operating activities are expected to be negatively impacted in the periods after close. We have expended significant time and resources, and expect to continue to expend significant time and resources, on the transaction involving our biosimilars business, including management time and focus, costs and expenses related to the separation of the biosimilars business from Viatris, the provision of the transition services and other transaction costs. Many of these expenses must be paid regardless of whether the transaction closes, and even if the expected benefits are not achieved. We may also face other challenges as a result of the announcement and completion of the transactions contemplated by the Biocon Agreement, including that we may not be able to realize the anticipated benefits from such transactions, such as deploying the proceeds to pay down our outstanding indebtedness and/or fund other important initiatives, and maintaining employee morale and retaining key management and other employees to provide the transition services and to operate our retained business.

Any of the risks described above could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.

25

Our strategic initiatives, including our strategic alliances, may not achieve all intended benefits.

In addition to the integration and restructuring activities and the Biocon Biologics Transaction, each of which is discussed above, we have entered into and continue to consider and evaluate various strategic transactions and business arrangements on an ongoing basis, including acquisitions, asset purchases, partnerships, collaborations, joint ventures, divestitures, product rationalization and investments. These transactions and arrangements may be material both from a strategic and financial perspective. We may miscalculate the risks associated with our strategic initiatives, including business development transactions, at the time they are made or not have the resources or ability to access all the relevant information to evaluate them properly, including with regard to the potential of R&D pipelines, manufacturing issues, compliance issues, or the outcome of ongoing legal and other proceedings. There can be no assurance that we will be able to fully realize the expected benefits of any such transactions or arrangements. Furthermore, divestitures, product rationalizations or asset sales could result in decreased total revenues, results of operations and cash flows from operating activities in future periods, reduce the size or scope of our business, our market share in particular markets or our opportunities and ability to compete with respect to certain markets, therapeutic areas or products. In addition, should we seek to divest other of our assets and business, we may be unable to dispose of such businesses and assets on satisfactory or commercially reasonable terms or within our anticipated timeline, in part because of competition from other companies in pursuing similar transactions in the pharmaceutical industry.

We have also entered into strategic alliances with partners, including through our Global Healthcare Gateway®, to develop, manufacture, market and/or distribute certain products, and/or certain components of our products, in various markets. We commit substantial effort, funds and other resources to these various collaborations, including with respect to the development of biosimilar products. There is a risk that the investments made by us in these collaborative arrangements will not generate financial returns. While we believe our relationships with our partners generally are successful, disputes or conflicting priorities and regulatory or legal intervention could be a source of delay or uncertainty as to the expected benefits of the collaboration. In addition, we enter into agreements with our collaboration partners that provide for certain services, as well as cross manufacturing, development and licensing arrangements. In addition, our Global Healthcare Gateway® may not achieve all of its expected benefits.

The overall execution of a strategic initiative may result in material unanticipated problems, expenses, liabilities, competitive responses, operational inefficiencies, adverse tax consequences, loss of customer relationships, difficulty attracting and retaining qualified employees, and diversion of management’s and/or employee’s attention, among other potential adverse consequences. In addition, we may have to terminate a strategic alliance, or our collaboration partners may be unable to fulfill their collaboration obligations.

Any of the risks described above could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We have and may continue to experience pressure on the pricing of and reimbursements for certain of our products due to pricing controls, social or government pressure to lower the cost of drugs, and consolidation across the supply chain.

We operate in a challenging environment, with significant pressures on the pricing of our products and on our ability to obtain and maintain satisfactory rates of reimbursement for our products by governments, insurers and other payors. The growth of overall healthcare costs has led governments and payors to implement new measures to control healthcare spending. As a result, we face numerous cost-containment measures by governments and other payors, including certain government-imposed industry-wide price reductions, mandatory rebates or pricing, international reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries), volume-based procurement, tender systems, shifting of the payment burden to patients through higher co-payments, and requirements for increased transparency on pricing, all of which may have an adverse impact on the pricing of our products.
Many markets in which we operate have implemented or may implement tender systems for generic and biosimilar pharmaceuticals in an effort to lower prices. Under such tender systems, manufacturers submit bids which establish prices for generic pharmaceutical products. Upon winning the tender, the winning company will receive a preferential reimbursement for a period of time. If our bids do not win, we may not be able to participate in the given market or may lose out on market share. In addition, if customers to whom we supply API do not win their tender bids, the amount of API that we sell to them may be reduced. While criteria other than price can be included in tenders, tender systems often select the lowest bid, which often results in companies underbidding one another by proposing low pricing in order to win the tender. Other markets may also consider the implementation of a tender system, and even if a tender system or other price controls are ultimately not implemented, the anticipation of such could result in price reductions.
26

In the EU, U.K. and some other international markets, the government provides healthcare at low cost to consumers and regulates pharmaceutical prices, patient eligibility and/or reimbursement levels to control costs for the government-sponsored healthcare system. These systems of price regulations may lead to inconsistent and lower prices. Within the EU and in other countries, the availability of our products in some markets at lower prices undermines our sales in other markets with higher prices. Additionally, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may also impair our ability to obtain acceptable prices in existing and potential new markets and may create the opportunity for third party cross-border trade. In addition to the impacts of these government-sponsored healthcare systems, in the EU, U.K. and other international markets, certain governmental agencies have or are considering enacting further measures to decrease the costs of providing healthcare, including government mandated price reductions and/or other forms of price controls, including retrospective “clawback” price reductions. as a result of the COVID-19 pandemic and the changing healthcare landscape in those markets.

In China, pricing pressures have increased in recent years, and the Chinese government has also increased its focus on patient access and reimbursement for pharmaceutical medicines. For example, in 2013, China began to implement a QCE process for post-LOE products to improve the quality of domestically manufactured generic drugs, primarily by requiring such drugs to pass a test to assess their bioequivalence to a qualified reference drug (typically the originator drug). In addition, VBP policy for post- LOE products is now in its fourth year and includes more than 200 molecules. In addition, the bidding process has resulted in significant price cuts for the molecules included with some bidders reducing the price of their products by as much as 96% as they attempt to secure volumes on the Chinese pharmaceutical market. We expect pricing pressures on our products included in the VBP program to continue to increase as a result of these programs. We have failed, and may continue to fail, to win bids due to various factors, including uncompetitive bidding prices. In addition, the URP policy will cap reimbursement of molecules at their VBP tender winning price. URP will create additional pricing and volume pressure for pharmaceutical products that are subject to the program and is expected to negatively impact our results of operations.

Demand for our products also depends in part on the extent to which reimbursements are available. In the U.S., third-party payors increasingly challenge the pricing of pharmaceutical products. These trends and other trends toward managed healthcare, the vertical consolidation among insurers, PBMs and pharmacies, and legislative healthcare reform create significant uncertainties regarding the future levels of reimbursement for pharmaceutical products. Further, any reimbursement may be reduced in the future to the point that market demand for our products and/or our profitability declines. Changes to Medicare and/or state Medicaid programs, or changes required in the way in which Medicare payment rates are set, the design of the Medicare Part D benefit, and/or the way Medicaid rebates are calculated, could adversely affect the payment we receive for our products. In order to control expenditures on pharmaceuticals, most member states in the EU regulate the pricing of products and, in some cases, limit the range of different forms of pharmaceuticals available for prescription by national health services. These controls can result in considerable price differences between member states.
There has also been increasing U.S. federal and state legislative and enforcement interest with respect to drug pricing, as well as from international organizations like the United Nations, WHO and Organization for Economic Cooperation and Development, in addition to intense publicity and scrutiny regarding such matters, including publicity and pressure resulting from prices charged by competitors and peer companies for new products as well as price increases by competitors and peer companies on older products that some have deemed excessive.
In addition, there have been executive orders, legislation, and legislative and regulatory proposals, including in connection with government programs such as Medicare, concerning drug prices and related issues, including the perceived need to bring more transparency to drug pricing, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs. Although we expect to see continued focus in regulating pricing, we cannot predict what, if any, additional legislative or regulatory developments may transpire at the state or country level, or what the ultimate impact may be.
In the U.S., certain of these pressures are further compounded by increasing consolidation among wholesalers, retailer drug chains, PBMs, private insurers, managed care organizations and other private payors, which can increase their negotiating power, particularly with respect to our generic drugs. Please also refer to “A significant portion of our revenues is derived from sales to a limited number of customers.”
The numerous cost-containment measures by governments and other payors, failing to win tenders, the implementation of price control systems, adverse legislation and regulation, the consolidation of our customers, or continued social or government pressure to lower the cost of pharmaceutical products could have a material adverse impact on our business, reputation, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
27

Healthcare reform legislation could have a material adverse effect on our business.

In recent years, there have been numerous initiatives on the federal and state levels for comprehensive reforms affecting the payment for, the availability of and reimbursement for, healthcare services in the U.S., and it is likely that Congress and state legislatures and health agencies will continue to focus on healthcare reform in the future. While the ACA increased the number of patients who have insurance coverage for our products, it also included provisions such as the assessment of a pharmaceutical manufacturer fee and an increase in the amount of rebates that manufacturers pay for coverage of their drugs by Medicaid programs. The ACA may be subject to revisions and modifications in the future. Further, Congress continues to consider drug pricing legislation that, if passed and signed into law, could impact companies’ ability to increase prices for products beyond the rate of inflation, and could allow Medicare to negotiate prices on a subset of brand drugs.
We are unable to predict the future course of federal or state healthcare legislation or reform, including temporary or permanent healthcare reform measures resulting from the COVID-19 pandemic or the outcome of challenges to such laws or reforms once passed. The ACA and further changes in the law or regulatory framework that reduce our revenues or increase our costs could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price. Additionally, we encounter similar regulatory and legislative issues in most other countries.
Significant additional reforms to the U.S. healthcare system, or to the healthcare systems of other markets in which we operate, could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We have significant operations globally, which exposes us to the risks inherent in conducting our business internationally.

Our operations extend to numerous countries globally and therefore are subject to the risks inherent in this geographic scope. These risks include, but are not limited to:
the impact of the COVID-19 pandemic;
compliance with the national and local laws, regulations and customs of countries in which we do business, including, but not limited to, data privacy and protection, environmental and social regulations, import/export and enforcement of intellectual property protections;
less established legal and regulatory regimes in certain jurisdictions, including China, where the interpretation and enforcement of laws, rules and regulations may involve uncertainties and can be inconsistent;
that litigation, administrative and court proceedings may be protracted, expensive and unpredictable;
that governments in certain jurisdictions may favor local businesses and make it more difficult for foreign businesses to operate on an equal footing;
increased uncertainties related to the enforcement of contracts with certain parties;
compliance with a variety of U.S. laws including, but not limited to, trade controls or sanctions, regulations put forth by the U.S. Treasury’s Office of Foreign Assets Control, the Iran Threat Reduction and Syria Human Rights Act of 2012 and rules relating to the use of certain “conflict minerals” under Section 1502 of the Dodd-Frank Wall Street Reform and the Consumer Protection Act;
increased trade controls or sanctions as a result of the escalation of tensions between Russia and Ukraine that may affect our ability to market or sell pharmaceuticals in either country;
changes in laws, regulations, and practices affecting the pharmaceutical industry and the healthcare system, including but not limited to imports, exports, manufacturing, quality, cost, pricing, reimbursement, approval, inspection, and delivery of healthcare;
changes in policies designed to promote foreign investment, including significant tax incentives, liberalized import and export duties, and preferential rules on foreign investment and repatriation;
increased EU and U.S. scrutiny of overseas pharmaceutical manufacturing, including executive orders and policy proposals related to increasing domestic production of pharmaceutical products and API;
differing local product preferences and product requirements;
adverse changes in the economies in which we or our partners and suppliers operate as a result of a slowdown in overall growth, a change in government or economic policies, or financial, political, or social change or instability in such countries that affects the markets in which we operate, particularly emerging markets;
changes in employment or labor laws, or wage increases in the countries in which we or our partners and suppliers operate;
local, regional and global restrictions on banking and commercial activities in certain markets, especially emerging markets;
longer payment cycles and increased exposure to counterparty risk;
28

volatility in international financial markets and increased foreign currency risk;
changes resulting from the formal withdrawal of the U.K. from the EU, commonly referred to as Brexit, including those related to additional trade agreements, tariffs and customs regulations and currency fluctuations, which could materially impact the way we conduct our operations in those markets;
supply disruptions and increases in energy and transportation costs;
increased tariffs on the import or export of our products or API, including on imports from China to the U.S. as a result of the escalation of trade tensions between the countries or otherwise;
burdens to comply with multiple, changing and potentially conflicting laws, regulations and disclosure requirements, including those relating to environmental, social and governance matters, carbon emissions, health and safety, labor and human rights;
natural or man-made disasters, including droughts, floods, earthquakes, hurricanes and the impact of climate change in the countries in which we or our partners and suppliers operate; and
local disturbances, the outbreak of highly contagious diseases or other health epidemics (such as COVID-19), terrorist attacks, riots, social disruption, wars, or regional hostilities in the countries in which we or our partners and suppliers operate and that could affect the economy, our operations and employees by disrupting operations and communications, making travel and the conduct of our business more difficult, and/or causing our customers to be concerned about our ability to meet their needs.

We also face the risk that some of our competitors have more experience with operations in such countries or with international operations generally and may be able to manage unexpected crises more easily. Moreover, the internal political stability of, or the relationship between, any country or countries where we conduct business operations may deteriorate. Changes in a country’s political stability or the state of relations between any such countries are difficult to predict and the political or social stability in and/or diplomatic relations between any countries in which we or our partners and suppliers do business could meaningfully deteriorate.
The occurrence of any one or more of the above risks could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Charges to earnings resulting from acquisitions could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.

Under U.S. GAAP provisions relating to business acquisition accounting standards, we recognize the identifiable assets acquired, the liabilities assumed, and any noncontrolling interests in acquired companies generally at their acquisition date fair values and, in each case, separately from goodwill. Goodwill as of the acquisition date is measured as the excess amount of consideration transferred, which is also generally measured at fair value, and the net of the acquisition date amounts of the identifiable assets acquired and the liabilities assumed. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain. After we complete an acquisition, the following factors could result in material charges and adversely affect our operating results and may adversely affect our cash flows:
costs incurred to combine the operations of companies we acquire, such as transitional employee expenses and employee retention, redeployment or relocation expenses;
liabilities assumed in purchase accounting;
impairment of goodwill or intangible assets, including acquired IPR&D;
amortization of intangible assets acquired;
a reduction in the useful lives of intangible assets acquired;
identification of or changes to assumed contingent liabilities, including, but not limited to, litigation reserves, contingent purchase price consideration including fair value adjustments, income tax contingencies and other non-income tax contingencies, after our final determination of the amounts for these contingencies or the conclusion of the measurement period (generally up to one year from the acquisition date), whichever comes first;
charges to our operating results to eliminate certain duplicative pre-acquisition activities, including exiting TSAs with Pfizer;
significant costs to restructure our operations and to reduce our cost structure, including cost related to severance payments, plant shutdowns and costs to achieve anticipated synergies; and
charges to our operating results resulting from expenses incurred to effect the acquisition.

A significant portion of these adjustments could be accounted for as expenses that will decrease our net income and earnings per share for the periods in which those costs are incurred.
29

In particular, the amount of goodwill and identifiable intangible assets in our consolidated balance sheets is significant as a result of our acquisitions and other transactions, and may increase further following future potential acquisitions, and we may, from time to time, sell assets that we determine are not critical to our strategy or execution. Future events or decisions may also lead to asset impairments and/or related charges. Certain non-cash impairments may result from a change in our strategic goals, business direction or other factors relating to the overall business environment. Any such charges could cause a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We applied purchase accounting to the Combination and determined that Mylan was the accounting acquirer in the Combination for purposes of applying purchase accounting to the acquired assets and assumed liabilities of the Upjohn Business in connection with the Combination.
The illegal distribution and sale by third parties of counterfeit or IP-infringing versions of our products or of diverted or stolen products could have a negative impact on our reputation and our business.

The pharmaceutical drug supply has been increasingly challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit or IP-infringing products in a growing number of markets and widespread over the internet.
Third parties may illegally distribute and sell counterfeit or IP-infringing versions of our products that do not meet our rigorous manufacturing and testing standards. Counterfeit products are frequently unsafe or ineffective and can be potentially life-threatening. Counterfeit medicines may contain harmful substances, the wrong API, an incorrect dose of API or no API at all, depriving patients of the therapeutic benefit of such medicines. However, to distributors and users, counterfeit products may be visually indistinguishable from the authentic version.
Reports of adverse reactions to counterfeit or IP-infringing drugs or increased levels of counterfeiting could materially affect patient confidence in the authentic product. It is possible that adverse events caused by unsafe counterfeit products will mistakenly be attributed to the authentic product. In addition, unauthorized diversions of products or thefts of inventory at warehouses, plants, or while in-transit could result in improper storage or compromise product integrity and therefore adversely impact patient safety, our reputation, and our business.
Loss of sales or revenues, as well as public loss of confidence in the integrity of pharmaceutical products as a result of counterfeiting, diversion, or theft could have a material adverse effect on our business, reputation, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We face vigorous competition that threatens the commercial acceptance and pricing of our products.

The pharmaceutical industry is highly competitive. We face competition from other pharmaceutical manufacturers globally, some of whom are significantly larger than we are and have stronger, more well-established reputations than us. Our competitors may be able to develop products and processes competitive with or superior to our own for many reasons, including but not limited to the possibility that they may have:
proprietary processes or delivery systems;
larger or more productive R&D and marketing staff;
larger or more efficient production capabilities in a particular therapeutic area;
more experience in preclinical testing and human clinical trials;
more products;
more experience in developing new drugs; or
greater financial resources.

30

We also face increasing competition from lower-cost generic products and other branded products, including our ARV products. Certain of our products are not protected by patent rights or have limited patent life and will soon lose patent protection. Loss of patent protection for a product typically is followed promptly with the launch of generic products. As a result, sales of many of these products may decline or stop growing over time, and may decline faster than has been projected. For example, Perforomist® lost exclusivity and experienced generic competition in June 2021, and the compound patent for Celebrex in Japan expired in November 2019 with generics entering the market in June 2020. In June 2019, Lyrica’s pediatric exclusivity in the United States expired, and multi-source generic competition commenced in the United States in July 2019. Additionally, over the next several years, some products may lose market exclusivity upon entry of generic products prior to patent exclusivity. For example, several companies launched a generic to Lyrica in Japan in December 2020 despite pending patent infringement litigation. The litigation remains ongoing, we have received several unfavorable rulings, and the patents expire in July 2022. We may not be successful in managing competition from non-branded generics or other alternatives, or in generally managing revenues after loss of exclusivity, and our business may be materially adversely affected.

Generic competitors are also becoming more aggressive in terms of pricing in many of the regions in which Viatris operates. In China, for example, we face strong competition from certain generic manufacturers, which may result in price cuts and volume loss on some of Viatris’ branded products. In many emerging markets, we face increased competition and contracting markets for certain of our ARV products, primarily related to competing therapies. We also face competition in the United States, the EU and other mature markets that have a robust generics market and favorable regulatory conditions for generics. In addition, legislative proposals emerge from time to time in various jurisdictions to further encourage the early and rapid approval of generic drugs. Any such proposal that is enacted into law could increase competition and worsen this negative effect on our branded sales.
In addition, certain of our products also face potential competition from products that may be developed in the future that could render our products uncompetitive or obsolete. For example, companies may develop medicines that treat the same indications targeted by our products, and these medicines could be more effective than our products or patients and physicians could prefer these medicines over our medicines. The introduction of these new competing products could also have a negative impact on product sales.
Other related factors that could affect our business include:
Competitors’ products may also be safer, more effective, more effectively marketed or sold, or have lower prices or better performance features than ours;
PBMs and other pharmaceutical manufacturers may utilize contracting strategies that could decrease utilization of or otherwise negatively impact our products;
Vertical integration of pharmacies and large purchasing organizations or consolidation among distribution outlets; and
Our sales may suffer as a result of changes in consumer demand for our products, including those related to fluctuations in consumer buying patterns tied to seasonality or COVID-19, willingness of customers to switch among products of different pharmaceutical manufacturers, importation by consumers or the introduction of new products by competitors.

The occurrence of any of the above risks could have an adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
A relatively small group of products may represent a significant portion of our revenues, net sales, gross profit, or net earnings from time to time.

Sales of a limited number of our products from time to time represent a significant portion of our revenues, net sales, gross profit, and net earnings. For the years ended December 31, 2021 and 2020, Viatris’ top ten products in terms of sales, in the aggregate, represented approximately 33% and 23%, respectively, of the Company’s net sales. The increase in the concentration of our top product sales in 2021 was primarily driven by the impact of the Combination. If the volume or pricing of our largest selling products declines in the future, our business, financial condition, results of operations, cash flows, and/or share price could be materially adversely affected.
31

Operational Risks

Public health outbreaks, epidemics and pandemics, including the COVID-19 pandemic, have had and could continue to have a material adverse effect on our business, financial condition, results of operations, cash flows and/or stock price and may impact our ability to pay dividends.

Public health outbreaks, epidemics and pandemics, including the COVID-19 pandemic, have had and could continue to have a material adverse effect on our business. We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business, including its impact on our workforce, suppliers, vendors, business partners, distribution channels, customers and patients. As the pandemic continues to evolve and new COVID-19 variants are detected, the rate of infection remains high in many countries, including the U.S. Attempts continue to be made to reduce the spread of COVID-19, including quarantines, vaccination programs (including boosters), increased testing, government restrictions on movement, business closures and suspensions, canceled events and activities, self-isolation, and other voluntary and/or mandated changes in behavior. Both the outbreak, and continued spread of COVID-19 and actions to slow its spread have created and continue to create significant uncertainty, economic volatility and disruption, supply chain disruption, and increased unemployment, which have impacted and may continue to impact our business operations and workforce. In addition, recovery from the pandemic may not proceed as anticipated, and may have unpredictable impacts on demand for our products, our workforce and our business operations. All of these factors could have a material adverse impact on our workforce, business operations, financial condition, results of operations, cash flows and/or stock price and may impact our ability to pay dividends.

While our business operations are currently considered essential based on current government guidelines throughout the world due to the important role pharmaceutical manufacturers play within the global healthcare system, many of our administrative offices have been operating under work from home protocols. In addition, certain programs or incentives implemented to ensure employee health and safety, such as subsidized testing, hazard pay, sick leave and bonus payments, have increased our operating costs. Extended changes in work conditions, including work from home protocols, could strain our business continuity plans, reduce productivity and morale, or introduce operational risk, including but not limited to increased cybersecurity risk. For example, remote working environments may be less secure and some may seek to exploit the COVID-19 pandemic to initiate hacking attacks, phishing and social engineering attempts and malware attacks.
Additionally, we have taken extra precautions at our manufacturing facilities to aid in the protection of on-site personnel and operations, including the implementation of social distancing guidelines, daily health assessments of on-site personnel, providing vaccinations on site, and split shifts where feasible. If we experience an increase in reported illnesses or quarantining at any of our facilities, including critical manufacturing sites, it is possible that such facilities may need to close for an extended period of time, which could negatively affect our ability to produce, ship, and supply products to our customers and would impact our business and financial results.
In addition, some of our customer-facing field personnel continue to operate on a remote engagement model to ensure continued support for healthcare professionals, patient care and access to needed products. A remote engagement model may not be as successful as in-person meetings and could result in lower sales of products, particularly new products. We have also taken steps to protect the safety of study participants, employees and staff at clinical trial sites while continuing to ensure regulatory compliance and scientific integrity of trial data.
COVID-19 and related responsive measures have also made, and may continue to make, it difficult for us, our partners or suppliers to source and manufacture products in, and to export our products from, certain affected areas. In addition, we have faced, and may continue to face, delays or difficulty sourcing certain products or raw materials, including APIs. Even if we are able to find alternate sources for such products or raw materials, they may cost more. In addition, we have experienced and may continue to experience increased shipping and freight costs, as well as delays in shipping. These factors have materially adversely affected and could continue to materially adversely affect our ability to produce, ship, and supply products, which could negatively impact our customer relationships, business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price, or result in negative publicity and reputational harm.
Lower retail pharmacy demand, as well as some patients, doctors and hospitals delaying or foregoing routine doctor and hospital visits and elective medical procedures, has led and could continue to lead to decreased demand for certain of our products, which has negatively impacted our sales, results of operations and financial results. At the same time, we have experienced, and could continue to experience, unpredictable increases in demand for certain of our products, which could exceed our capacity to meet such demand and negatively impact our customer relationships, business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Health regulatory agencies globally may also experience disruptions in their operations and greater regulatory uncertainty as a result of the COVID-19 pandemic. For instance, the FDA has announced its intention to temporarily postpone certain inspections of domestic and foreign manufacturing facilities. The FDA and comparable foreign regulatory agencies may have slower response times or reduced resources and, as a result, review of regulatory submissions, inspections, approval of
32

new products and other timelines important to our business may be materially impacted, which could delay our new product launches and have a material adverse effect on our business.
In addition, our continued access to external sources of liquidity depends on multiple factors, including the condition of debt capital markets, our operating performance, and maintaining strong credit ratings. Also, the continuing impact of the COVID-19 pandemic could lead to our customers or suppliers having liquidity problems that could negatively impact our ability to collect cash on our receivables and/or negatively impact our ability to get inventory and materials. If the impacts of the pandemic create further disruptions or turmoil in the financial markets or customer or supplier liquidity issues, or if rating agencies lower our credit ratings, it could adversely affect our ability to access the debt markets, our cost of funds, and other terms for new debt, which could negatively impact our results of operations and financial position.
The extent to which the COVID-19 pandemic will continue to impact us depends on numerous evolving factors and future developments that we are not currently able to predict and may also exacerbate other risks discussed in these risk factors, any of which could have a material adverse effect on us, our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Current and changing economic conditions may adversely affect our industry, business, partners and suppliers.

The global economy continues to experience significant volatility, and the economic environment may become less favorable. Economic volatility, governmental financial restructuring efforts and evolving deficit and spending reduction programs could negatively impact the global economy and the pharmaceutical industry. This has led, or could lead, to reduced consumer and customer spending, reduced or eliminated governmental or third-party payor coverage or reimbursement or reduced spending on healthcare, including but not limited to pharmaceutical products. While generic drugs present an alternative to higher-priced branded products, our sales could be negatively impacted if patients forego obtaining healthcare, patients and customers reduce spending or purchases, or if governments or third-party payors reduce or eliminate coverage or reimbursement amounts for pharmaceuticals or impose price or other controls adversely impacting the price or availability of pharmaceuticals (whether for generics, branded products or both). In addition, reduced consumer and customer spending, reduced government or third-party payor coverage or reimbursement, or new government controls, may drive us and our competitors to decrease prices, may reduce the ability of customers to pay, or may result in reduced demand for our products.
In addition, accelerating rates of inflation are expected to continue in the near future and have resulted, and may continue to result, in increased costs of labor, raw materials, other supplies and freight and distribution costs, among others. For the pharmaceutical industry and the healthcare systems in the markets in which we participate, the pricing dynamics of our products generally does not provide the opportunity to pass on such costs to customers. Inflation may also result in higher interest rates and increased costs of capital.

The occurrence of any of the above risks could have a material adverse effect on our industry, business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Failure to comply with applicable environmental and occupational health and safety laws and regulations worldwide could adversely impact our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.

We are subject globally to various laws and regulations concerning, among other things, the environment, climate change, water, waste, chemicals and employee safety. These requirements include regulation of the handling, manufacture, transportation, storage, use and disposal of materials and wastes, including the discharge of regulated materials and emissions into the environment. We are also subject to related permitting, record-keeping, reporting and registration requirements. In the normal course of our business, we are exposed to risks relating to possible releases of hazardous substances into the environment, which could cause environmental or property damage or personal injuries, and which could result in (i) our noncompliance with such environmental and occupational health and safety laws, regulations and permits and (ii) regulatory enforcement actions or claims for personal injury and property damage against us. If environmental discharge occurs, or if we discover contamination caused by third parties, including by prior owners and operators of properties we acquire or lease, or by neighboring properties or other offsite sources, we could be liable for cleanup or remediation obligations, damages and fines or have relevant permits, authorizations or registrations modified or revoked, regardless of our responsibility for such contamination. In addition, any non-compliance with environmental and occupational health and safety laws and regulations and permits, or emissions into the environment, whether actual or perceived, may result in significant reputational damage. The substantial unexpected costs we may incur could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price. Environmental and occupational health and safety laws and regulations are also complex and subject to change, and our related capital expenditures and costs for compliance may increase substantially in the future as a result of such changes, the development and manufacturing of a new product or increased development or manufacturing activities at any of our facilities. We may be required to expend significant funds and our
33

manufacturing activities could be delayed or suspended or we may lose the ability to purchase or use certain materials, or face restrictions on the amounts of materials we may use or purchase, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
The pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comply with applicable laws and regulations.

The pharmaceutical industry is subject to regulation by various governmental authorities in the jurisdictions in which we operate, including the U.S., EU, China and India. For instance, we must comply with applicable laws and requirements of the FDA and other regulatory agencies, including foreign authorities, with respect to the research, development, manufacture, quality, safety, effectiveness, approval, labeling, tracking, tracing, authentication, storage, record-keeping, reporting, pharmacovigilance, sale, distribution, import, export, marketing, advertising, and promotion of pharmaceutical products. We are committed to conducting our business, including the sale and marketing of our products, in compliance with all applicable laws and regulations. These laws and regulations, however, are numerous, complex and continue to evolve, and it is possible that a governmental authority may challenge our activities, or that an employee or agent could violate these laws and regulations without our knowledge. Failure to comply with these laws and regulations could result in a range of consequences, including, but not limited to, fines, penalties, disgorgement, exclusion from U.S. federal healthcare reimbursement programs, unanticipated compliance expenditures, suspension of review of applications or other submissions, rejection or delay in approval of applications, recall or seizure of products, total or partial suspension of production and/or distribution, our inability to sell products, the return by customers of our products, injunctions, and/or criminal prosecution. Under certain circumstances, a regulator may also have the authority to revoke or vary previously granted drug approvals.
The safety profile of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If such regulatory authorities become aware of new safety information about any of our marketed or investigational products, those authorities may require further inspections, enhancements to manufacturing controls, labeling changes, establishment of a risk evaluation and mitigation strategy or similar strategy, restrictions on a product’s indicated uses or marketing, or post-approval studies or post-market surveillance. In addition, we are subject to regulations in various jurisdictions, including the Federal Drug Supply Chain Security Act in the U.S., the Falsified Medicines Directive in the EU and several other such regulations in other countries that require us to develop electronic systems to serialize, track, trace and authenticate units of our products through the supply chain and distribution system. Compliance with these regulations has in the past and may in the future result in increased expenses for us or impose greater administrative burdens on our organization, and failure to meet these requirements could result in fines or other penalties.
In recent years, the regulatory framework in China regarding the pharmaceutical industry has undergone significant changes and Chinese authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry. We believe that Viatris’ strategies regarding pharmaceutical research, development, manufacturing and commercialization in China are currently aligned with the Chinese government’s policies, but they may in the future diverge, requiring a change in such strategies. Any such change may result in increased compliance costs to us or cause delays in or prevent the successful research, development, manufacturing or commercialization of our products in China, result in the loss of required licenses and permits or the suspension or termination of Viatris’ activities in China.
The FDA and comparable foreign regulatory authorities also regulate the facilities and operational procedures that we use to manufacture our products. We must register our facilities with the FDA and similar regulators in other countries. Products must be manufactured in our facilities in accordance with cGMP or similar standards in each territory in which we manufacture. Compliance with such regulations and with our own quality standards requires substantial expenditures of time, money, and effort in multiple areas, including training of personnel, record-keeping, production, and quality control and quality assurance. The FDA and other comparable regulatory authorities, including foreign authorities, periodically inspect our manufacturing facilities for compliance with cGMP or similar standards in the applicable territory. Regulatory approval to manufacture a drug is granted on a site-specific basis. Failure to comply with cGMP and other regulatory standards at one of our or our partners’ or suppliers’ manufacturing facilities could result in an adverse action brought by the FDA or other regulatory authorities, which could result in the receipt of an untitled or warning letter, fines, penalties, disgorgement, unanticipated compliance expenditures, rejection or delay in approval of applications, suspension of review of applications or other submissions, suspension of ongoing clinical trials, recall or seizure of products, total or partial suspension of production and/or distribution, our inability to sell products, the return by customers of our products, orders to suspend, vary, or withdraw marketing authorizations, injunctions, consent decrees, requirements to modify promotional materials or issue corrective information to healthcare practitioners, refusal to permit import or export, criminal prosecution and/or other adverse actions.
Our business could be adversely affected if any regulatory body were to delay, withhold, or withdraw approval of an application; require a recall or other adverse product action; require one of our manufacturing facilities to cease or limit production; or suspend, vary, or withdraw related marketing authorization. Delay and cost in obtaining FDA or other regulatory approval to manufacture at a different facility also could have a material adverse effect on our business.
34

Although we have established internal quality and regulatory compliance programs and policies, there is no guarantee that these programs and policies, as currently designed, will meet regulatory agency standards in the future or will prevent instances of non-compliance with applicable laws and regulations. Additionally, despite our compliance efforts, from time to time we or our partners receive notices of manufacturing and quality-related observations following inspections by regulatory authorities around the world, as well as official agency correspondence regarding compliance. For example, the FDA has issued warning letters relating to valsartan API and nitrosamine impurities to our API manufacturers Mylan Laboratories Limited Unit 8 and Mylan Laboratories Limited Unit 7. We have provided thorough responses to the FDA regarding the issues identified and remediation is ongoing. We and our partners have in the past and may in the future receive similar observations and correspondence. If we are unable to resolve these observations and address regulatory concerns in a timely fashion, our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price could be materially adversely affected.
We utilize controlled substances in certain of our current products and products in development, and therefore must meet the requirements of the Controlled Substances Act of 1970 and the related regulations administered by the DEA in the U.S., as well as those of similar laws in other countries where we operate. These laws relate to the manufacture, shipment, storage, sale, and use of controlled substances. The DEA and other regulatory agencies limit the availability of the controlled substances used in certain of our current products and products in development and, as a result, our procurement quota of these active ingredients may not be sufficient to meet commercial demand or complete clinical trials. We must annually apply to the DEA and similar regulatory agencies for procurement quotas in order to obtain these substances. Any delay or refusal by the DEA or such similar agencies in establishing our procurement quota for controlled substances could delay or stop our clinical trials or product launches, or could cause trade inventory disruptions for those products that have already been launched. In addition, some states have passed laws and regulations imposing assessments on the sale or distribution of certain controlled substances, and other states are considering and may implement similar laws and regulations in the future.
The occurrence of any of the above risks could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
The use of legal, regulatory, and legislative strategies by both brand and generic competitors, including but not limited to “authorized generics” and regulatory petitions, may increase costs associated with the introduction or marketing of our generic products, could delay or prevent such introduction, and could significantly reduce our revenue and profit.

Our competitors, both branded and generic, often pursue strategies that could prevent or delay generic alternatives to branded products. These strategies include, but are not limited to:
entering into agreements whereby other generic companies will begin to market an authorized generic, which is the approved brand-name drug without the brand-name on its label, at the same time or after generic competition initially enters the market;
launching their own authorized generic product prior to or at the same time or after generic competition initially enters the market;
pricing a branded product at a discount equivalent to generic pricing;
filing frivolous petitions with the FDA or other regulatory bodies seeking to prevent or delay approvals, including timing the frivolous filings so as to thwart generic competition by causing delays of our product approvals;
contracting strategies among pharmaceutical manufacturers and PBMs that could decrease generic or biosimilar utilization and negatively impact our product launches;
seeking to establish regulatory and legal obstacles that would make it more difficult to demonstrate bioequivalence or to meet other requirements for approval, and/or to prevent regulatory agency review of applications;
initiating legislative or other efforts to limit the substitution of generic versions of brand pharmaceuticals;
filing suits for patent infringement and other claims that may delay or prevent regulatory approval, manufacture, and/or sale of generic products;
introducing “next-generation” products prior to the expiration of market exclusivity for the reference product, which often materially reduces the demand for the generic or the reference product for which we seek regulatory approval;
persuading regulatory bodies to withdraw the approval of brand-name drugs for which the patents are about to expire and converting the market to another product of the brand company on which longer patent protection exists;
obtaining extensions of market exclusivity by conducting clinical trials of brand drugs in pediatric populations or by other methods; and
seeking to obtain new patents on drugs for which patent protection is about to expire.

35

In the U.S., some companies have lobbied Congress for amendments to Hatch-Waxman Act that would give them additional advantages over generic competitors. For example, although the term of a company’s drug patent can be extended to reflect a portion of the time an NDA (which is filed in the U.S. with the FDA when approval is sought to market a newly developed branded product and, in certain instances, for a new dosage form, a new delivery system or a new indication for a previously approved drug) is under regulatory review, some companies have proposed extending the patent term by a full year for each year spent in clinical trials rather than the one-half year that is currently permitted.
If proposals like these in the U.S., EU, or in other countries where we or our partners and suppliers operate were to become effective, or if any other actions by our competitors and other third parties to prevent or delay activities necessary to the approval, manufacture, or distribution of our products are successful, our entry into the market and our ability to generate revenues associated with new products may be delayed, reduced, or eliminated, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
If we are unable to successfully introduce new products in a timely manner, our future revenue and profitability may be adversely affected.

Our future revenues and profitability will depend, in part, upon our ability to successfully and timely develop, license, or otherwise acquire and commercialize new products. Product development is inherently risky, especially for new drugs for which safety and efficacy have not been established and/or the market is not yet fully developed as well as for complex generic drugs and biosimilars. Likewise, product licensing involves inherent risks, including, among others, uncertainties due to matters that may affect the achievement of milestones, as well as the possibility of contractual disagreements with regard to whether the supply of product meets certain specifications or terms such as license scope or termination rights. As Viatris focuses more on complex products, the development and commercialization process requires substantial time, effort and financial resources. We, or a partner, may not be successful in commercializing such products on a timely basis, or at all, which could adversely affect our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Before any prescription drug product, including generic drug products, can be marketed, marketing authorization approval is required by the relevant regulatory authorities and/or national regulatory agencies (for example, the FDA in the U.S., the EMA in the EU and other regulatory authorities). The process of obtaining regulatory approval to manufacture and market new branded and generic pharmaceutical products is rigorous, time consuming, costly, and inherently unpredictable. In addition, these regulatory agencies may be delayed in reviewing and approving products as a result of lapsed or insufficient funding, insufficient staffing, travel or work restrictions (including as a result of the COVID-19 pandemic), or other factors beyond our control. Any delay in regulatory approval could impact the commercial or financial success of a product.
Outside the U.S., the approval process may be more or less rigorous, depending on the country, and the time required for approval may be longer or shorter than that required in the U.S. Bioequivalence, clinical, or other studies conducted in one country may not be accepted in other countries, the requirements for approval may differ among countries, and the approval of a pharmaceutical product in one country does not necessarily mean that the product will be approved in another country. We, or a partner or supplier, may be unable to obtain requisite approvals on a timely basis, or at all, for new products that we may develop, license or otherwise acquire. Moreover, if we obtain regulatory approval for a drug, it may be limited, for example, with respect to the indicated uses and delivery methods for which the drug may be marketed, or may include warnings, precautions or contraindications in the labeling, which could restrict our potential market for the drug. A regulatory approval may also include post-approval study or risk management requirements that may substantially increase the resources required to market the drug. Also, for products pending approval, we may obtain raw materials or produce batches of inventory to be used in efficacy and bioequivalence testing, as well as in anticipation of the product’s launch. In the event that regulatory approval is denied or delayed, we could be exposed to the risk of this inventory becoming obsolete.
The approval process for generic pharmaceutical products often results in the relevant regulatory agency granting final approval to a number of generic pharmaceutical products at the time a patent claim for a corresponding branded product or other market exclusivity expires. This often forces us to face immediate competition when we introduce a generic product into the market. Additionally, further generic approvals often continue to be granted for a given product subsequent to the initial launch of the generic product. These circumstances generally result in significantly lower prices, as well as reduced margins, for generic products compared to branded products. New generic market entrants generally cause continued price, margin, and sales erosion over the generic product life cycle.
36

In the U.S., the Hatch-Waxman Act provides for a period of 180 days of generic marketing exclusivity for a “first applicant,” that is the first submitted ANDA (which is filed in the U.S. with the FDA when approval is sought to market a generic equivalent of a drug product previously approved under an NDA and listed in the FDA publication entitled Approved Drug Products with Therapeutic Equivalence Evaluations, popularly known as the “Orange Book” or for a new dosage strength for a drug previously approved under an ANDA) containing a certification of invalidity, non-infringement or unenforceability related to a patent listed with the ANDA’s reference drug product, commonly referred to as a Paragraph IV certification. During this exclusivity period, which under certain circumstances may be shared with other ANDAs filed on the same day, the FDA cannot grant final approval to later-submitted ANDAs for the same generic equivalent. If an ANDA is awarded 180-day exclusivity, the applicant generally enjoys higher market share, net revenues, and gross margin for that generic product. However, our ability to obtain 180 days of generic marketing exclusivity may be dependent upon our ability to obtain FDA approval or tentative approval within an applicable time period of the FDA’s acceptance of our ANDA. If we are unable to obtain approval or tentative approval within that time period, we may risk forfeiture of such marketing exclusivity. By contrast, if we are not a “first applicant” to challenge a listed patent for such a product, we may lose significant advantages to a competitor with 180-day exclusivity, even if we obtain FDA approval for our generic drug product. The same would be true in situations where we are required to share our exclusivity period with other ANDA sponsors with Paragraph IV certifications.
In the EU and other countries and regions, there is no exclusivity period for the first generic product. The Commission or national regulatory agencies may grant marketing authorizations to any number of generics.
If we are unable to navigate our products through the approval process in a timely manner, there could be an adverse effect on our product introduction plans, business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We expend a significant amount of resources on R&D efforts that may not lead to successful product introductions.

Much of our development effort is focused on technically difficult-to-formulate products and/or products that require advanced manufacturing technology, including our biosimilars program and respiratory platform. We conduct R&D primarily to enable us to gain approval for, manufacture, and market pharmaceuticals in accordance with applicable laws and regulations. We also partner with third parties to develop products. Typically, research expenses related to the development of innovative or complex compounds and the filing of marketing authorization applications for innovative and complex compounds (such as NDAs and biosimilar applications in the U.S.) are significantly greater than those expenses associated with the development of and filing of marketing authorization applications for most generic products (such as ANDAs in the U.S. and abridged applications in Europe). As we and our partners continue to develop new and/or complex products, our research expenses will likely increase. Because of the inherent risk associated with R&D efforts in our industry, including the high cost and uncertainty of conducting clinical trials (where required) particularly with respect to new and/or complex drugs, our, or a partner’s, R&D expenditures may not result in the successful introduction of new pharmaceutical products approved by the relevant regulatory bodies. Also, after we submit a marketing authorization application for a new compound or generic product, the relevant regulatory authority may change standards and/or request that we conduct additional studies or evaluations and, as a result, we may incur approval delays as well as R&D costs in excess of what we anticipated.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. We or our partners may experience delays in our ongoing or future clinical trials, and we do not know whether planned clinical trials will begin or enroll subjects on time, need to be redesigned, or be completed on schedule, if at all.
Clinical trials may be delayed, suspended or prematurely terminated for a variety of reasons. If we experience delays in the completion of, or the termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.
Finally, we cannot be certain that any investment made in developing products will be recovered, even if we are successful in commercialization. To the extent that we expend significant resources on R&D efforts and are not able, ultimately, to introduce successful new and/or complex products as a result of those efforts, there could be a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
37

Even if our products in development receive regulatory approval, such products may not achieve expected levels of market acceptance.

Even if we are able to obtain regulatory approvals for our new products, the success of those products is dependent upon market acceptance. Levels of market acceptance for our products could be impacted by several factors, including but not limited to:
the availability, perceived advantages, and relative safety and efficacy of alternative products from our competitors;
the degree to which the approved labeling supports promotional initiatives for commercial success;
the prices of our products relative to those of our competitors;
the timing of our market entry;
the effectiveness of our marketing, sales, and distribution strategy and operations; and
other competitor actions, including legal actions.

Additionally, studies of the proper utilization, safety, and efficacy of pharmaceutical products are being conducted by the industry, government agencies, and others. Such studies, which increasingly employ sophisticated methods and techniques, can call into question the utilization, safety, and efficacy of previously marketed as well as future products. In some cases, such studies have resulted, and may in the future result, in the discontinuation or variation of product marketing authorizations or requirements for risk management programs, such as a patient registry. Any of these events could adversely affect our profitability, business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
The development, approval process, manufacture and commercialization of biosimilar products involve unique challenges and uncertainties, and our failure to successfully introduce biosimilar products could have a negative impact on our business and future operating results.

We and our partners and suppliers are actively working to develop and commercialize biosimilar products. Although the BPCIA established a framework for the review and approval of biosimilar products and the FDA has begun to review and approve biosimilar product applications, there continues to be significant uncertainty regarding the regulatory pathway in the U.S., with the FDA continuing to issue and revise guidance related to its interpretation and implementation of the BPCIA. There is also uncertainty regarding the pathway to obtain approval for biosimilar products in other countries as well as uncertainty regarding the commercial pathway to successfully market and sell such products.
Moreover, biosimilar products generally involve extensive patent clearances and often involve patent infringement litigation related to multiple patents, which could delay or prevent the commercial launch of a biosimilar product for many years. If we are unable to obtain FDA or other non-U.S. regulatory authority approval for our products, we will be unable to market them. In addition, the development and manufacture of biosimilars pose unique challenges related to the supply of the materials needed to manufacture biosimilars. Access to and the supply of necessary biological materials may be limited, and government regulations restrict access to and regulate the transport and use of such materials.
Even if our biosimilar products are approved for marketing, the products may not be commercially successful, may require more time than expected to achieve market acceptance, and may not generate profits in amounts that are sufficient to offset the amount invested to obtain such approvals. Market success of biosimilar products will depend on demonstrating to regulators, patients, physicians and payors (such as insurance companies) that such products are safe and effective yet offer a more competitive price or other benefit over existing therapies. In addition, manufacturers of biologic products may try to dissuade physicians from prescribing or accepting biosimilar products. We may not be able to generate future sales of biosimilar products in certain jurisdictions and may not realize the anticipated benefits of our investments in the development, manufacture and sale of such products. If our development efforts do not result in the development and timely approval of biosimilar products or if such products, once developed and approved, are not commercially successful, or upon the occurrence of any of the above risks, our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price could be materially adversely affected.
Our business is highly dependent upon market perceptions of us, our products and brands, and the safety and quality of our products and brands, as well as the effectiveness of our sales and marketing activities, and we may be adversely impacted by negative publicity or findings.

Market perceptions of us are very important to our business, especially market perceptions of our company, products, brands and the safety and quality of our products and brands. If we, our partners and suppliers, or our products or brands suffer from negative publicity, are subject to market withdrawal or recall or are proven to be, or are claimed to be, ineffective or harmful to consumers, then this could have a material adverse effect on our reputation and business. In addition, Viatris believes that maintaining and enhancing certain of its brands is important and often provides certain competitive advantages.
38

Viatris’ sales and marketing efforts are anchored by promoting its products to physicians, pharmacists, clinics and hospitals. Therefore, Viatris’ sales and marketing force, whether in-house sales representatives or third-party commercial partners, must possess a relatively high level of technical knowledge, up-to-date understanding of industry trends and expertise in the relevant therapeutic areas and products, as well as promotion and communication skills. Marketing, advertising and promotions may be expensive and may not achieve their intended benefits. If Viatris is unable to effectively train its in-house sales representatives and third-party commercial partners or monitor and evaluate their marketing performances, our sales and marketing may be less successful than desired. In addition, fewer in-person sales and marketing efforts as a result of restrictions put in place in order to contain the COVID-19 pandemic, or other similar limitations, may result in less successful sales and marketing activities.
Given our dependence on market perception and sales and marketing efforts, negative publicity associated with product or brand quality, patient illness, or other adverse effects resulting from, or perceived to be resulting from, our products or brands, or our partners’ and suppliers’ manufacturing facilities, or an inability to increase or maintain the effectiveness and efficiency of our sales and marketing activities could have a material adverse effect on our reputation, business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
A significant portion of our revenues is derived from sales to a limited number of customers.

A significant portion of our revenues is derived from sales to a limited number of customers. If we were to experience a significant reduction in or loss of business with one or more such customers, or if one or more such customers were to experience difficulty in paying us on a timely basis, our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price could be materially adversely affected.
In addition, a significant amount of our sales are to a relatively small number of drug wholesalers and retail drug chains. These customers represent an essential part of the distribution chain of generic pharmaceutical products. Drug wholesalers and retail drug chains have undergone, and are continuing to undergo, significant consolidation. This consolidation has resulted in these groups gaining additional purchasing leverage and, consequently, increasing the product pricing pressures facing our business. We expect this trend of increased pricing pressures to continue. Additionally, the emergence of large buying groups representing independent retail pharmacies and the prevalence and influence of managed care organizations and similar institutions increases the negotiating power of these groups, enabling them to attempt to extract price discounts, rebates, and other restrictive pricing terms on our products. These factors could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products, some of which require a highly exacting and complex manufacturing process.

A substantial portion of our capacity, as well as our current production, is attributable to a limited number of manufacturing facilities and certain third-party suppliers. A significant disruption at any one of such facilities within our internal or third-party supply chain, even on a short-term basis, whether due to the failure of a third-party supplier to fulfill the terms of their agreement with us, labor disruption, adverse quality or compliance observation, other regulatory action, infringement of brand or other third-party intellectual property rights, natural disaster, civil or political unrest, export or import restrictions, or other events could impair our ability to produce and ship products to the market on a timely basis and could, among other consequences, subject us to exposure to claims from customers. Any of these events could have a material adverse effect on our reputation, business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price. The adverse effects of any of these events could be exacerbated as a result of our previously announced global restructuring program, which includes the closing, downsizing or divesting of a number of facilities globally. If we or our third-party suppliers’ face significant manufacturing issues, this could lead to shutdowns, delays or product shortages, or to our being entirely unable to supply certain products to customers for an extended period of time. In addition, our facilities may be required to close for periods of time, be required to staff at reduced capacity, or suffer other manufacturing delays as the result of an outbreak of disease, epidemic or pandemic, such as the COVID-19 pandemic, in or near any of our facilities. Such shortages, delays or shutdowns have led and could continue to lead to significant losses of sales revenue, third-party litigation, or negative publicity. See also “The pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comply with applicable laws and regulations.”
39

We purchase certain API and other materials and supplies that we use in our manufacturing operations, as well as certain finished products, from many different foreign and domestic suppliers. The price of API and other materials and supplies is subject to volatility, including as a result of global supply chain disruptions due to COVID-19 or other events. In certain cases, we have listed only one supplier in our applications with regulatory agencies. There is no guarantee that we will always have timely, sufficient or affordable access to critical raw materials or finished product supplied by third parties, even when we have more than one supplier, which could lead to our or our partners’ and suppliers’ inability to supply sufficient quantities of our products to meet market demand. In addition, quality deficiencies in the products which we or our suppliers provide, or at our or their manufacturing facilities, have in the past and could in the future adversely impact our manufacturing and supply capabilities, cause supply interruptions, or lead to voluntary market withdrawals or product recalls. For example, the EU has implemented particularly stringent regulations with respect to manufacturing standards for API imported into Europe that place the certification requirement on the regulatory bodies of the exporting countries. An increase in the price, or an interruption in the supply, of a single-sourced or any other raw material, including the relevant API, or in the supply of finished product, could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
In connection with the Combination, Viatris entered into certain manufacturing and supply agreements with Pfizer. Reliance on Pfizer under those agreements entails risks related to regulatory and quality assurance (including cGMP compliance), unforeseen disruption of the manufacture or supply or our products, the possible breach of the agreement by Pfizer, the possible misappropriation of our proprietary information or the possible termination of the agreements at a time that is costly or inconvenient to Viatris, any of which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price. See also “Viatris could incur operational difficulties or losses if we are unable to obtain the same types and level of services and resources that historically had been provided to the legacy Upjohn Business by Pfizer, if Pfizer is unable to perform under the agreements entered into as part of the Combination or if we are required to make payments to Pfizer pursuant to indemnities agreed to as part of the Combination.
In addition, the manufacture of some of our products is a highly exacting and complex process, due in part to strict regulatory requirements. Problems may arise during manufacturing at our or our third-party suppliers’ facilities for a variety of reasons, including, among others, equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, natural disasters, power outages, labor disputes or other civil unrest, cybersecurity or compliance issues, and environmental, health and safety issues, laws, regulations and permits. If problems arise during the production of a batch of product, that batch of product may have to be discarded. This could, among other things, lead to increased costs, contractual penalties, lost revenue, damage to customer relations, time and expense spent investigating the cause, and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.
If we or one of our suppliers experience any of the problems described above, such problems could have a material adverse effect on our reputation, business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Our future success is highly dependent on our ability to attract, motivate and retain key personnel.

Given the size, complexity and global reach of our business, it is important that we attract, motivate and retain qualified management and other key employees in order to develop and commercialize new products, manage our business, and compete effectively. Our ability to do so also depends in part on how well we maintain a strong, diverse and inclusive workplace culture that is attractive to employees. Competition for qualified personnel in the pharmaceutical industry is intense. Current or prospective Viatris employees may have changing expectations around workplace flexibility, and a failure to meet these evolving expectations may result in reduced ability to attract and retain talent. In addition, current or prospective Viatris employees may experience uncertainty about their future roles at the Company as a result of the continued integration process with respect to the Combination, the end of certain TSA arrangements, our global restructuring program, or other strategic initiatives. As a result, we may lose key personnel or may be unable to attract, retain and motivate qualified individuals, or the associated costs may increase. If we fail to attract, develop, incentivize and retain key scientific, technical, commercial, regulatory, information security/privacy, or management personnel, this could lead to loss of customers, business disruption, and a decline in revenues, adversely affect the progress of pipeline products, or otherwise adversely affect our operations. Additionally, while we work to ensure that we have effective plans in place for management succession throughout the organization, any anticipated or unanticipated management transition could create uncertainty, which could disrupt or result in changes to our strategy and have a negative impact on our business. If we are unsuccessful in retaining our key employees or enforcing certain post-employment contractual provisions such as confidentiality or non-competition provisions, it may have a material adverse impact on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.

40

Compliance Risks

We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, Chinese anti-corruption laws and similar worldwide anti-corruption laws, which impose restrictions on certain conduct and may carry substantial fines and penalties.
We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, Chinese anti-corruption laws and similar anti-corruption laws in other jurisdictions. These laws generally prohibit companies and their intermediaries from engaging in bribery or making other prohibited payments to government officials for the purpose of obtaining or retaining business, and some have record keeping requirements. The failure to comply with these laws could result in substantial criminal and/or monetary penalties. We operate in jurisdictions that have experienced corruption, bribery, pay-offs and other similar practices from time-to-time and, in certain circumstances, such practices may be local custom. We have implemented and trained relevant employees and third party agents regarding internal control policies and procedures that mandate compliance with these anti-corruption laws. However, we cannot be certain that these policies and procedures will protect us against liability. There can be no assurance that our employees or other agents will not engage in such conduct for which we might be held responsible. If our employees or agents are found to have engaged in such practices, we could suffer severe criminal or civil penalties, reputational harm and other consequences that could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Our competitors, including branded pharmaceutical companies, and/or other third parties, may allege that we or our suppliers are infringing upon their intellectual property, including in an “at risk launch” situation, which could result in substantial monetary damages, impact our ability to launch a product and/or our ability to continue marketing a product, and/or force us to expend substantial resources in resulting litigation, the outcome of which is uncertain.

Companies that produce branded pharmaceutical products and other patent holders routinely bring litigation against entities selling or seeking regulatory approval to manufacture and market generic forms of their branded products, as well as other entities involved in the manufacture, supply, and other aspects relating to API and finished pharmaceutical products. These companies and other patent holders may allege patent infringement or other violations of intellectual property rights as the basis for filing suit against an applicant for a generic product as well as others who may be involved in some aspect of research, supply, production, distribution, testing, packaging or other processes. Litigation often involves significant expense and can delay or prevent introduction or sale of our generic products. If patents are held valid and infringed by our products in a particular jurisdiction, we and/or our supplier(s) or partner(s) may, unless we or the supplier(s) or partner(s) could obtain a license from the patent holder, need to cease manufacturing and other activities, including but not limited to selling in that jurisdiction. We may also need to pay damages, surrender or withdraw the product, or destroy existing stock in that jurisdiction.
There also may be situations, such as the decision to launch our insulin glargine and dimethyl fumarate products, where we use our business judgment and decide to market and sell products directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) and other third-party rights have not been finally resolved by the courts (i.e., an “at-risk launch”). The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement may include, among other things, a reasonable royalty on sales, damages measured by the profits lost by the patent holder, or by profits earned by the infringer. If there is a finding by a court of willful infringement, the definition of which is subjective, such damages may be increased by up to three times. Moreover, because of the discount pricing typically involved with bioequivalent products, patented branded products generally realize a substantially higher profit margin than generic or biosimilar products. An adverse decision in a case such as this, or a judicial order preventing us or our suppliers and partners from manufacturing, marketing, selling, and/or other activities necessary to the manufacture and distribution of our products, could result in substantial penalties, and/or have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We rely on the effectiveness of our patents, trademarks, confidentiality agreements and other measures to protect our intellectual property rights.

Our ability to commercialize any branded product successfully will largely depend upon our or any partner’s or supplier’s ability to obtain, maintain and enforce patents and trademarks of sufficient scope to lawfully prevent third parties from developing and/or marketing infringing products. In the absence of adequate intellectual property protections or other barriers to entry, competitors may adversely affect our branded products business by independently developing and/or marketing substantially equivalent products. It is also possible that we could incur substantial costs if we initiate litigation against others to protect or enforce our intellectual property rights.
41

We may submit patent filings covering the API, formulation, methods of making, and/or methods of using for our branded products and branded product candidates. We may not be issued patents based on patent applications already filed or that we file in the future. Further, due to other factors that affect patentability, and if patents are issued, they may be insufficient in scope to protect our branded products from generic competition, as generics may be able to design around our patents. Patents are national in scope and therefore the issuance of a patent in one country does not ensure the issuance of a patent in any other country. Furthermore, the patent position of companies in the pharmaceutical industry generally involves complex legal and factual questions and has been and remains the subject of significant litigation. Legal standards relating to scope and validity of patent claims are evolving and may differ in various countries. Any patents we have obtained, or obtain in the future, may be challenged, invalidated or circumvented. Moreover, the U.S. Patent and Trademark Office or any other governmental agency may commence or institute post-grant review, inter partes review, interference proceedings, or other challenges to our patents or patent applications. Although many of our products do not have patent protection, we continue to take steps to defend our patents for certain of our products. For example, many companies launched a generic to Lyrica in Japan in December 2020 despite pending patent litigation and the fact that these patents expire in July 2022. The patent litigation remains ongoing and we have received several unfavorable rulings.
In addition, branded products often have market viability based upon the goodwill of the product name, which typically is the subject of a trademark registration or filing. Our branded products may therefore also be subject to risks related to the loss of a trademark or patent or to competition from generic or other branded products. Challenges can come from other businesses, individuals or governments, and governments could require compulsory licensing of our intellectual property. Any challenge to, or invalidation or circumvention of, our intellectual property (including patents or patent applications, copyrights and trademark protection) would be costly, would require significant time and attention of our management, and could cause a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We also rely on trade secrets, unpatented proprietary know-how, trade dress, regulatory exclusivity and continuing technological innovation that we seek to protect, in part by confidentiality agreements with licensees, suppliers, employees and consultants. These measures may not provide adequate protection for our unpatented technology. If these agreements are breached, it is possible that we will not have adequate remedies. Disputes may arise concerning the ownership of intellectual property or the applicability of confidentiality agreements. Furthermore, our trade secrets and proprietary technology may otherwise become known or be independently developed by our competitors or we may not be able to maintain the confidentiality of information relating to such products.
Our ability to enforce intellectual property rights also depends on the laws of individual countries, each country’s practices with respect to enforcement of intellectual property rights, and the extent to which certain countries may seek to engage in policies or practices that may weaken its intellectual property framework (e.g., a policy of routine compulsory licensing, or threat of compulsory licensing, of pharmaceutical intellectual property). If we are unable to adequately protect our technology, trade secrets or proprietary know-how, or enforce our intellectual property rights, this could cause a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Our reporting and payment obligations related to our participation in U.S. federal healthcare programs, including Medicare, Medicaid and the VA, are complex and often involve subjective decisions that could change as a result of new business circumstances, new regulations or agency guidance, or advice of legal counsel. Any failure to comply with those obligations could subject us to investigation, penalties, and sanctions.

U.S. federal laws regarding reporting and payment obligations with respect to a pharmaceutical company’s participation in federal healthcare programs, including Medicare, Medicaid and the VA, are complex. Because our processes for calculating applicable government prices and the judgments involved in making these calculations involve subjective decisions and complex methodologies, these calculations are subject to risk of errors and differing interpretations. In addition, they are subject to review and challenge by the applicable governmental agencies, and it is possible that such reviews could result in changes that may have material adverse legal, regulatory, or economic consequences.
42

Any governmental agencies or authorities that have commenced, or may commence, an investigation of us relating to the sales, marketing, pricing, quality, or manufacturing of pharmaceutical products could seek to impose, based on a claim of violation of anti-fraud and false claims laws or otherwise, civil and/or criminal sanctions, including fines, penalties, and possible exclusion from federal healthcare programs, including Medicare, Medicaid and/or the VA. Some of the applicable laws may impose liability even in the absence of specific intent to defraud. Furthermore, should there be ambiguity with regard to how to properly calculate and report payments—and even in the absence of any such ambiguity—a governmental authority may take a position contrary to a position we have taken, and may impose or pursue civil and/or criminal sanctions. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. There can be no assurance that our submissions will not be found by CMS or the VA to be incomplete or incorrect. Any failure to comply with the above laws and regulations, and any such penalties or sanctions could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We are involved in various legal proceedings and certain government inquiries and may experience unfavorable outcomes of such proceedings or inquiries.

We are or may be involved in various legal proceedings and certain government inquiries or investigations, including, but not limited to, patent infringement, product liability, personal injury, securities fraud, claims with respect to the manufacture, sale marketing and distribution of opioid products, antitrust matters, breach of contract, and claims involving Medicare, Medicaid and/or VA reimbursements, or laws relating to sales, marketing, and pricing practices. These proceedings may involve claims for, or the possibility of, fines and penalties involving substantial amounts of money or other relief, including but not limited to civil or criminal fines and penalties and exclusion from participation in various government healthcare-related programs.
Viatris is subject to investigations and extensive regulation by government agencies in the United States, China and other developed markets and emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on Viatris’ ability to conduct business in applicable jurisdictions, as well as reputational harm and increased public interest in the matter could result from government investigations With respect to government enforcement of state and federal laws, including antitrust laws, as well as private plaintiff litigation of so-called “pay for delay” patent settlements, large verdicts, settlements or government fines are possible, especially in the U.S. and EU. Additionally, some state legislatures have and the U.S. federal government or additional state legislatures could, enact legislation to limit patent settlements between pharmaceutical companies and deem such patent agreements as anticompetitive. These changes could impact our ability to launch generic products prior to the originator’s patent expiry.
In connection with the Combination, the Company has generally assumed liability for, and control of, pending and threatened legal matters relating to the Upjohn Business and has agreed to indemnify Pfizer for liabilities arising out of such assumed legal matters. Pfizer, however, has agreed to retain various matters – including certain specified competition law matters – to the extent they arise from conduct during the pre-Distribution period and has agreed to indemnify the Company for liabilities arising out of such matters. If Pfizer were to dispute its retention of these matters, or if there is an adverse outcome in the matters that Pfizer has agreed to retain, this could have an adverse impact on Viatris. In addition, Viatris has agreed to pay Pfizer an amount equal to 57% of any losses actually incurred or suffered by Viatris, its predecessors or subsidiaries, since July 29, 2019, arising out of third-party actions relating to the manufacture, distribution, marketing, promotion or sale of opioids by or on behalf of Viatris, its predecessors or subsidiaries. If any of these legal proceedings or inquiries were to result in an adverse outcome, the impact could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Emerging developments in the U.S. legal landscape relative to the liability of generic pharmaceutical manufacturers for certain product liabilities claims could increase our exposure to litigation costs and damages, including in connection with third party defense and indemnification demands. Although we maintain a combination of self-insurance and commercial insurance, no reasonable amount of insurance can fully protect against all risks because of the potential liability inherent in the business of producing pharmaceuticals for human consumption. To the extent that a loss occurs, depending on the nature of the loss and the level of insurance coverage maintained, it could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
In addition, in limited circumstances, entities that we have acquired are party to litigation in matters under which we are, or may be, entitled to indemnification by the previous owners. Even in the case of indemnification, there are risks inherent in such indemnities and, accordingly, there can be no assurance that we will receive the full benefits of such indemnification, or that we will not experience an adverse result in a matter that is not indemnified, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
43

Refer to Note 19 Litigation included in Part II, Item 8 in this Form 10-K for further discussion of certain proceedings and litigation matters.
If we fail to comply with our corporate integrity agreement, we could be subject to substantial penalties and exclusion from participation in federal healthcare programs.

In August 2017, Mylan Inc. and Mylan Specialty L.P., then subsidiaries of Mylan and now subsidiaries of Viatris, entered into the CIA with the OIG-HHS. The CIA has a five-year term and requires, among other things, enhancements to our compliance program, fulfillment of reporting and monitoring obligations, management certifications and resolutions from Mylan Inc.’s board, as well as that an independent review organization annually review various matters relating to the Medicaid Drug Rebate Program, among other things. If we fail to comply with the CIA, the OIG-HHS may impose substantial monetary penalties or exclude us from federal healthcare programs, including Medicare, Medicaid or the VA, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We are increasingly dependent on IT and our systems and infrastructure face certain risks, including cybersecurity and data leakage risks.

Significant disruptions to our IT systems or breaches of information security could adversely affect our business. We are increasingly dependent on sophisticated IT systems and infrastructure to operate our business. The number of new vulnerabilities identified to these systems combined with the increased number of systems that reach end of life each year creates an opportunity for successful malicious attacks. Such attacks are increasingly sophisticated and are made by groups and individuals with a wide range of motives and expertise, including state and quasi-state actors, criminal groups, “hackers” and others. Any security breach or other disruption to our or our vendors’ IT infrastructure could also interfere with or disrupt our business operations, including our manufacturing, distribution, R&D, sales and/or marketing activities.

We outsource significant elements of our operations to third parties, including as part of our TSAs with Pfizer. Some of these third parties are outside the U.S., including significant elements of our IT infrastructure, and as a result we are managing many independent vendor relationships with third parties who may or could have access to our confidential information. The overall increase in supply chain attacks on companies generally, such as SolarWinds, Kronos, and Accellion, and our interdependency on third party suppliers increases the potential for supply disruptions and service IT outages. In addition to our reliance upon third parties to provide IT and information security services, the market for such services continues to contract and converge, increasing both the challenges in identifying competent providers and the impact of a breach incident with any single vendor. In the ordinary course of business, we and our vendors collect, store and transmit large amounts of confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), and it is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. The size and complexity of our and our vendors’ systems and the large amounts of confidential information that is present on them also makes them potentially vulnerable to security breaches from inadvertent or intentional actions by our employees, partners or vendors, or from attacks by malicious third parties. Maintaining the security, confidentiality and integrity of this confidential information (including trade secrets or other intellectual property, proprietary business information and personal information) is important to our competitive business position. However, such information can be difficult to protect. While we have taken steps to identify and protect such information, and to ensure that the third-party vendors’ on which we rely have taken adequate steps to protect such information, there can be no assurance that our or our vendors’ efforts will prevent service interruptions or security breaches in our systems or the unauthorized or inadvertent wrongful use or disclosure of confidential or material non-public information that could adversely affect our business operations or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information.
A breach of our or our vendors’ security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse of trade secrets, proprietary information, or other confidential information, whether as a result of theft, hacking, fraud, trickery or other forms of deception, or for any other cause, could enable others to produce competing products, use our proprietary technology or information, and/or adversely affect our business position. Further, any such interruption, security breach, or loss, misappropriation, and/or unauthorized access, use or disclosure of confidential information, including personal information regarding our patients and employees, could result in financial, legal, business, and reputational harm to us and could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from a breakdown, breach, cyber-attack or other compromise of or interruption to our IT systems or confidential and other sensitive information. We also cannot ensure that any limitation of liability or indemnity provisions in our contracts, including with vendors and service providers, for a security lapse or breach or other security incident would be enforceable or adequate or would otherwise protect us from any liabilities or damages with respect to any particular claim.
44


We are subject to data privacy and security laws and regulations in many different jurisdictions and countries where we do business, and our or our vendors’ inability to comply could result in fines, penalties, or reputational damage, and could impact the way we operate our business.

We are subject to federal, state and international data privacy and security laws and regulations governing the collection, use, disclosure, transmission and protection of personal information, including health-related information. As the legislative and regulatory landscape for data privacy and security continues to evolve around the world, there has been an increasing focus on data privacy and security matters that may affect our business.
In the U.S., federal laws include HIPAA, which governs the use, disclosure, and security of protected health information by HIPAA covered entities and business associates. Several U.S. states, including California, Virginia, Colorado, Pennsylvania and Florida, have enacted or proposed broad data privacy laws and regulations governing the confidentiality, security, use and disclosure of personal information, which may impose greater restrictions than federal data privacy and security laws and regulations and provide transparency and privacy rights for their citizens. We may also be subject to other state data privacy and security breach notification laws, state health information privacy laws, and federal and state consumer protection laws such as the federal Controlling the Assault of Non-Solicited Pornography and Marketing (CAN-SPAM) Act, which impose requirements for the collection, use, disclosure, transmission and protection of personal information. Each of these laws are subject to varying interpretations by courts and regulatory or government agencies, creating complex compliance issues for us. If we, or the third-party vendors on which we rely, fail to comply with applicable laws and regulations we could be subject to fines, penalties or sanctions, including criminal penalties.
Outside of the U.S., the EU’s and U.K.’s GDPR and local implementing regulations impose significant compliance obligations on our organization. The GDPR contains data protection requirements in the EU and U.K. and imposes a framework of obligations and restrictions governing the collection, processing, and the transmission of personal information to jurisdictions outside of the EU and U.K.. The GDPR affords individuals with a series of privacy rights related to the collection, processing, and transmission of their personal information. The GDPR imposes significant compliance obligations, including required processes and policies governing our collection, transmission, processing and use of individuals personal information. In addition, the GDPR includes significant penalties for non-compliance, with fines up to the higher of €20 million or 4% of total annual worldwide revenue. In general, GDPR, and other data protection laws and regulations, could require adaptation of our technologies or practices to satisfy local country data protection requirements and standards.
Other countries in which we operate, such as Australia, Brazil, Canada, India, Japan, South Korea, Russia and South Africa, have, or are developing, laws and regulations governing the collection, use, securing and transmission of personal information as well that may affect our business or require us to adapt our technologies or practices. Recently, China enhanced its Cybersecurity Law and Data Security Law framework by enacting a significant and omnibus data privacy law, the Personal Information Protection Law (PIPL), which became effective in November 2021. The PIPL is China’s first comprehensive data protection law which aims to protect the rights and interests of individuals by introducing stringent requirements for companies doing business in China regarding the protection, control, and use of personal information.

These and similar initiatives could increase the cost of developing, implementing or maintaining our IT systems, require us to allocate more resources to compliance initiatives or increase our costs. In addition, a failure by us, or our third-party vendors, to comply with applicable data privacy and security laws may lead to government enforcement actions and private litigation, which could result in financial, legal, business, and reputational harm to us and could have a material adverse effect on the way we operate our business, our financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Increasing scrutiny and evolving expectations from customers, regulators, investors, employees, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.
Companies are facing increasing expectations and scrutiny from customers, regulators, investors, employees and other stakeholders related to their environmental, social and governance practices and disclosure. Investor advocacy groups, investment funds and influential investors are also increasingly focused on these practices, especially as they relate to the environment, climate change, health and safety, supply chain management, diversity, labor conditions and human rights, both in our own operations and in our supply chain. Failure to adapt to or comply with regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation, ability to do business with certain partners, access to investors and capital, and our stock price.
45

In addition, a growing number of our customers, including certain government purchasers, have adopted, or may adopt, procurement policies that include social and environmental requirements, including, for example, requirements to monitor and conduct third party audits, or these customers may seek to include such provisions in their procurement contract terms and conditions. These social and environmental responsibility provisions and initiatives are subject to change, vary from jurisdiction to jurisdiction, and certain elements may be difficult and/or cost prohibitive for us to comply with given the inherent complexity of our external supply chain and the global scope of our operations. In certain circumstances, in order to meet the requirements or standards of our customers, we may be obligated to modify our sourcing practices or make other operational choices which may require additional investments and increase our costs or result in inefficiencies. Alternatively, we may be ineligible to participate in bids or tenders in certain markets, which may result in lost sales and revenues.
Any of the factors mentioned above, or the perception that we or our suppliers or contract manufacturers have not responded appropriately to the growing concern for such issues, regardless of whether we are legally required to do so, may damage our reputation and have a material adverse effect on our business, employees relations, access to investors and capital, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Our business and operations are subject to risks related to climate change.

The effects of global climate change present risks to our business. Extreme weather, natural disasters, power outages, or other conditions caused by climate change could adversely impact our supply chain and the availability and cost of raw materials, water supply, and other components required for the operation of our business, or result in the delay and/or disruption of our ability to deliver products. Such conditions could also result in physical damage to our or our partners’ products, plants and distribution centers, as well as the infrastructure and facilities of hospitals, medical care facilities and other customers. Our programs to plan for and mitigate risk and build resilience to the impacts of climate change may not be successful. Current or future insurance arrangements may not provide protection for costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. In addition, regulations intended to limit greenhouse gas emissions or water usage, such as carbon pricing, taxes on emissions, fuel and energy, or to mitigate the impacts of climate change may become more prevalent, which could increase our operating costs and the costs charged by suppliers. These events could have a material adverse effect on the way we operate our business, our financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Finance Risks

There can be no guarantee that we will continue to pay dividends or that we will implement repurchases under our stock buyback program.
Although Viatris currently intends to continue to pay quarterly dividends to its stockholders, there is no assurance that Viatris will declare and pay, or have the ability to declare and pay, any dividends on its common stock in the future. Whether dividends will be paid, and the amount and frequency of any such dividend payments, will depend upon a number of factors, including Viatris’ results of operations, cash flows, financial position, competitive or commercial developments, contractual or statutory restrictions and any other factors considered relevant by the Viatris Board. Such payments, and the amount and frequency thereof, are also subject to the other risks set forth in these risk factors. In addition, although the Board of Directors has authorized a stock buyback program, there is no guarantee that we will implement repurchases under the program or, if we do, the timing or amount of any future share repurchases under such program. Even if implemented, we will not be obligated to repurchase shares under any such stock buyback program and, until November 2022, such a program may be impacted by certain conditions in our Tax Matters Agreement. Other factors, including changes in tax or securities laws, could also impact our stock buybacks. A stock buyback program could affect our stock price and increase volatility, and any announcement of a pause in, or termination of, a share buyback program may result in a decrease in our stock price. Payment of a cash dividend or share repurchases will reduce the amount of cash available to the Company for other activities, including repayment of debt, investment in the business or other capital expenditures.

If the intercompany terms of cross border arrangements that we have among our subsidiaries are determined to be inappropriate or ineffective, our tax liability may increase.
We have potential tax exposures resulting from the varying application of statutes, regulations, and interpretations which include exposures on intercompany terms of cross-border arrangements among our subsidiaries (including intercompany loans, sales, and services agreements) in relation to various aspects of our business, including manufacturing, marketing, sales, and delivery functions. Although we believe our cross-border arrangements among our subsidiaries are based upon internationally accepted standards and applicable law, tax authorities in various jurisdictions may disagree with and subsequently challenge the amount of profits taxed in their country, which may result in increased tax liability, including accrued interest and penalties, which would cause our tax expense to increase and could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
46

We may not be able to maintain competitive financial flexibility and our corporate tax rate which could adversely affect us and our shareholders.
We believe that our structure and operations give us the ability to achieve competitive financial flexibility and a competitive worldwide effective corporate tax rate. We must make material assumptions underlying our expected tax rates, including regarding the effect of certain internal reorganization transactions, including various intercompany transactions. We cannot give any assurance as to what our effective tax rate will be, however, because of, among other reasons, uncertainty regarding the tax policies of the jurisdictions where we operate, potential changes of laws and interpretations thereof, and the potential for tax audits or challenges. Our actual effective tax rate may vary from our expectation and that variance may be material. Furthermore, the tax laws of other jurisdictions could change in the future, and such changes could cause a material change in our effective tax rate.
Any of the factors discussed above could materially increase our overall effective income tax rate and income tax expense and could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Unanticipated changes in our tax provisions or exposure to additional income tax liabilities and changes in income tax laws and tax rulings may have a significant adverse impact on our effective tax rate and income tax expense.
We are subject to income taxes in many jurisdictions. Significant analysis and judgment are required in determining our worldwide provision for income taxes. In the ordinary course of business, there are many transactions and calculations where the ultimate tax determination is uncertain. We are currently subject to tax audits and investigations in several jurisdictions, and may be subject to other audits and investigations in the future. The final determination of any tax audits or related litigation could be materially different from our income tax provisions and accruals.

Additionally, changes in the effective tax rate as a result of a change in the mix of earnings in countries with differing statutory tax rates, changes in our overall profitability, changes in the valuation of deferred tax assets and liabilities, changes in tax laws or in their application, the results of audits and the examination of previously filed tax returns and related challenges and assessments by taxing authorities, and continuing assessments of our tax exposures could impact our tax liabilities and affect our income tax expense, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Currency fluctuations and changes in exchange rates could adversely affect our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Although we report our financial results in U.S. Dollars, a significant portion of our revenues, indebtedness and other liabilities and our costs are denominated in non-U.S. currencies, including among others the Chinese Renminbi, Euro, Swedish Krona, Indian Rupee, Korean Won, Japanese Yen, Australian Dollar, Canadian Dollar, British Pound Sterling, South African Rand and Brazilian Real. Our results of operations and, in some cases, cash flows, have in the past been and may in the future be adversely affected by certain movements in currency exchange rates. Defaults or restructurings in other countries could have a similar adverse impact. In addition, there remains significant international pressure on the Chinese government to adopt a more flexible currency policy, including from the U.S. government, which designated China as a “currency manipulator” in August 2019 and subsequently removed such designation in January 2020, which could result in greater fluctuation of the Renminbi against the U.S. dollar. From time to time, we may implement currency hedges intended to reduce our exposure to changes in foreign currency exchange rates. However, our hedging strategies may not be successful, and any of our unhedged foreign exchange exposures will continue to be subject to market fluctuations.
In addition, Viatris also faces risks arising from currency devaluations and the imposition of cash repatriation restrictions and exchange controls. Currency devaluations result in a diminished value of funds denominated in the currency of the country instituting the devaluation. Cash repatriation restrictions and exchange controls may limit our ability to convert foreign currencies into U.S. dollars or to remit dividends and other payments by its foreign subsidiaries or businesses located in or conducted within a country imposing restrictions or controls. For example, in China the conversion of currency in the “capital account” (e.g., capital items such as direct investments or loans) requires the approval of the State Administration for Foreign Exchange in China or its local branches which could materially and adversely affect the ability of our Chinese operating subsidiaries and affiliated companies to obtain foreign currencies through equity financing or for capital expenditures, therefore impeding our overall business operations. While we currently have no need, and do not intend, to repatriate or convert cash held in countries that have significant restrictions or controls in place, should we need to do so to fund our operations, we may be unable to repatriate or convert such cash, or be unable to do so without incurring substantial costs.
The occurrence of any of the above risks could cause a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
47

We have significant indebtedness, which could lead to adverse consequences or adversely affect our financial position and prevent us from fulfilling our obligations under such indebtedness, and any refinancing of this debt could be at significantly higher interest rates.
Our level of indebtedness could have important consequences, including but not limited to:
increasing our vulnerability to general adverse economic and industry conditions;
requiring us to dedicate a substantial portion of our cash flow from operations to make debt service payments, thereby reducing the availability of cash flow to fund working capital, capital expenditures, acquisitions and investments, dividend payments and other general corporate purposes;
limiting our flexibility in planning for, or reacting to, challenges and opportunities, and changes in our businesses and the markets in which we operate;
limiting our ability to obtain additional financing to fund our working capital, capital expenditures, acquisitions and debt service requirements and other financing needs;
increasing our vulnerability to increases in interest rates in general related to any of our indebtedness that bears interest at floating rates;
increasing our exposure to currency fluctuations, since a significant portion of our indebtedness is denominated in currencies other than the U.S. dollar, such as our Euro and Japanese yen denominated debt; and
placing us at a competitive disadvantage to our competitors that have less debt.

Our ability to service our indebtedness will depend on our future operating performance and financial results, which will be subject, in part, to factors beyond our control, including interest rates, general economic, financial and business conditions and impacts of the COVID-19 pandemic. If we do not have sufficient cash flow to service our indebtedness, including the repayment of significant near-term indebtedness, we may need to refinance all or part of our existing indebtedness, borrow more money or sell securities or assets, some or all of which may not be available to us at acceptable terms or at all. In addition, we may need to incur additional indebtedness in the future in the ordinary course of business. Although the terms of our credit agreements and our bond indentures allow us to incur additional debt, this is subject to certain limitations which may preclude us from incurring the amount of indebtedness we otherwise desire.
Although Viatris expects to maintain an investment grade credit rating, a downgrade in the credit rating of Viatris or any indebtedness of Viatris or its subsidiaries could increase the cost of further borrowings or refinancings of such indebtedness, limit access to sources of financing in the future or lead to other adverse consequences.
If we incur additional debt, the risks described above could intensify. If global credit markets contract, future debt financing may not be available to us when required or may not be available on acceptable terms or at all, and as a result we may be unable to grow our business, take advantage of business opportunities, respond to competitive pressures or satisfy our obligations under our indebtedness. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
From time to time, we issue variable rate debt based on LIBOR or undertake interest rate swaps that contain a variable element based on LIBOR. On March 5, 2021, the FCA, the regulatory supervisor of LIBOR’s administrator, announced the
cessation or loss of representativeness of certain LIBOR benchmark settings by the end of 2021, including the
one-week and two-month U.S. dollar LIBOR settings, with publication of the overnight and one-, three-, six- and 12-month U.S. dollar LIBOR settings ceasing at the end of June 2023. U.S. federal banking agencies also issued a joint statement in November 2020 encouraging banks to stop using LIBOR for new contracts as soon as possible but in any event by the end of the year. As of December 31, 2021, we had no outstanding debt linked to LIBOR. Our credit facilities provide that, should LIBOR cease to exist, we may amend the credit facilities to replace LIBOR with (i) in the case of U.S. dollars, one or more rates based on SOFR or (ii) another alternate benchmark rate giving due consideration to any evolving or then existing convention for similarly syndicated credit facilities syndicated in the U.S. and denominated in the applicable currency for such alternative benchmarks and, in each case, including any mathematical or other adjustments to such benchmark giving due consideration to any evolving or then existing convention for similar syndicated credit facilities syndicated in the U.S. and denominated in the applicable currency for such benchmarks. SOFR or any other benchmark replacement may not be the economic equivalent of LIBOR or achieve market acceptance similar to LIBOR. As a result, our interest expense could increase. In addition, the overall financial market may be disrupted and there could be significant increases in benchmark rates or borrowing costs to borrowers as a result of the phase-out or replacement of LIBOR. Disruption in the financial market, significant increases in benchmark rates or borrowing costs or our inability to renegotiate agreements on favorable terms could have a material adverse effect on our business, financing activities, financial condition and operations.

48

Our credit facilities, senior unsecured notes, commercial paper program, other outstanding indebtedness and any additional indebtedness we incur in the future impose, or may impose, significant operating and financial restrictions on us. These restrictions limit our ability to, among other things, incur additional indebtedness, make investments, pay certain dividends, prepay other indebtedness, sell assets, incur certain liens, enter into agreements with our affiliates or restricting our subsidiaries’ ability to pay dividends, merge or consolidate. In addition, our credit facilities require us to maintain specified financial ratios. A breach of any of these covenants or our inability to maintain the required financial ratios could result in a default under the related indebtedness. If a default occurs, the relevant lenders could elect to declare our indebtedness, together with accrued interest and other fees, to be immediately due and payable. These factors could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with U.S. GAAP. Any future changes in estimates, judgments and assumptions used or necessary revisions to prior estimates, judgments or assumptions or changes in accounting standards could lead to a restatement or revision to previously issued financial statements.
The consolidated and condensed consolidated financial statements included in the periodic reports we file with the SEC are prepared in accordance with U.S. GAAP. The preparation of financial statements in accordance with U.S. GAAP involves making estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues, expenses and income. Estimates, judgments and assumptions are inherently subject to change in the future and any necessary revisions to prior estimates, judgments or assumptions could lead to a restatement. Furthermore, although we have recorded reserves for certain critical accounting estimates, including litigation related contingencies based on estimates of probable future costs, actual costs in the future could be substantially in excess of those reserves. Also, any new or revised accounting standards may require adjustments to previously issued financial statements. Any such changes could result in corresponding changes to the amounts of liabilities, revenues, expenses and income and could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
We must maintain adequate internal controls and be able to provide an assertion as to the effectiveness of such controls on an annual basis.
Effective internal controls are necessary for us to provide reasonable assurance with respect to our financial reports. We spend a substantial amount of management and other employee time and resources to comply with laws, regulations and standards relating to corporate governance and public disclosure. In the U.S., such regulations include the Sarbanes-Oxley Act of 2002, SEC regulations and the NASDAQ listing standards. In particular, Section 404 of the Sarbanes-Oxley Act of 2002 requires management’s annual review and evaluation of our internal control over financial reporting and attestation as to the effectiveness of these controls by our independent registered public accounting firm. During the third quarter of 2021, we began to transition certain support services from Pfizer, as well as certain subsidiaries, to a new ERP system. We have modified and will continue to modify our internal controls relating to our business and financial processes throughout the transition period, which is expected through the end of calendar year 2022. While we believe that this new system and the related changes to internal controls will ultimately strengthen our internal control over financial reporting, there are inherent risks in implementing any new ERP system. If we fail to maintain the adequacy of our internal controls, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting. Additionally, internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Therefore, even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. In addition, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that the control may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, this could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.

49

Viatris could suffer additional losses due to asset impairment charges.
Viatris has significant amounts of goodwill and intangible assets on its balance sheet. Viatris tests goodwill for impairment during the second quarter of every fiscal year, and on an interim date should events or changes in circumstances indicate the carrying value of goodwill may not be recoverable in accordance with ASC 350 “Goodwill and Other Intangible Assets.” If the fair value of a reporting unit is revised downward due to declines in business performance or other factors, an impairment under ASC 350 could result and a non-cash charge could be required. Viatris tests intangible assets with indefinite lives for impairment on an annual basis and intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. This assessment of the recoverability of intangible assets could result in an impairment and a non-cash charge could be required. Such impairments could materially affect Viatris’ reported net earnings, business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Viatris may be adversely affected by disruptions in the credit markets, including disruptions that reduce customers’ access to credit and increase the costs to customers of obtaining credit.
The credit markets have historically been volatile and therefore it is not possible to predict the ability of Viatris’ customers to access short-term financing and other forms of capital. If a disruption in the credit markets were to occur, Viatris could be unable to refinance its outstanding indebtedness on reasonable terms or at all. Such a disruption could also pose a risk to Viatris’ business if customers or suppliers are unable to obtain financing to meet their payment or delivery obligations. In addition, customers may decide to downsize, defer or cancel contracts which could negatively affect our revenue.
Further, Viatris had approximately $1.84 billion of floating rate debt as of December 31, 2021. A one percentage point increase in the average interest rate of this debt would increase the combined interest expense by approximately $18.4 million per year. Accordingly, a spike in interest rates would adversely affect our results of operations and cash flows.
In connection with the Combination, Viatris assumed or retained certain material obligations relating to defined benefit pension and termination benefits and retiree medical and dental benefits associated with legacy employees of the Upjohn Business and/or sponsored by Upjohn entities. These liabilities and the related future funding obligations could restrict cash available for Viatris’ operations, capital expenditures, dividend payments and other requirements, and may materially adversely affect Viatris’ financial condition and liquidity.
In connection with the Combination, Viatris assumed material pension obligations associated with the Upjohn Business. In particular, Viatris retained all liabilities relating to the Puerto Rico defined benefit pension plans and Pfizer Puerto Rico Retiree Medical and Dental Plan. In addition, with respect to non-U.S. defined benefit pension and termination benefit plans, Viatris generally established or designated plans similar to the Pfizer plans to assume assets and liabilities for the benefit of legacy employees of the Upjohn Business. Viatris also retained liabilities for legacy employees of the Upjohn Business who participate in the Japan defined benefit pension plan, to the extent such employees were employed by the Upjohn Business on the date of the Combination. Each of these liabilities and the related future payment obligations could restrict cash available for Viatris’ operations, capital expenditures, dividend payments and other requirements, and may materially affect Viatris’ financial condition and liquidity.
General Risks
The market price of our common stock may be volatile, and the value of your investment could materially decline.
Investors who hold shares of Viatris common stock may not be able to sell their shares at or above the price at which they acquired them. The price of Viatris’ common stock may fluctuate materially from time to time, including as a result of the other risks described herein, and we cannot predict the price of our common stock at any given time. In addition, the stock market in general, including the market for pharmaceutical companies, has experienced significant price and volume fluctuations which may materially harm the market price of our common stock, regardless of our operating performance. In addition, the price of our common stock may be affected by the valuations and recommendations of the analysts who cover us, and if our results do not meet the analysts’ forecasts and expectations, the price of our common stock could decline as a result of analysts lowering their valuations and recommendations or otherwise. Following periods of volatility in the market and/or in the price of a company’s stock, securities class-action litigation actions have been instituted against companies (including Mylan and Viatris) and may be instituted against us in the future. Such litigation may result in substantial costs and diversion of management’s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price. In addition, if we or our stockholders offer or sell shares of our common stock or securities convertible into or exchangeable or exercisable for shares of our common stock, this or the possibility thereof may depress the future trading price of our common stock and the voting power of our then existing stockholders may be diluted if such a transaction were to occur.
50

The expansion of social media platforms presents new risks and challenges.
To the extent that we seek to use social media tools as a means to communicate about our products and/or business, there are uncertainties as to the rules that apply to such communications, or as to the interpretations that authorities will apply to the rules that exist. As a result, despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that our use of social media for such purposes may cause us to be found in violation of them. Our employees may knowingly or inadvertently make use of social media tools in ways that may not be aligned with our social media strategy, may give rise to liability, or could lead to the loss of material non-public information, trade secrets or other intellectual property, or public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers, and others. In addition, negative posts or comments about us on any social media website could damage our reputation. Any of the above risks could have a material adverse effect on our business, reputation, financial condition, results of operations, cash flows, and/or stock price.
Provisions in the Viatris Charter and Viatris Bylaws and of applicable law may prevent or delay an acquisition of Viatris, which could decrease the trading price of Viatris common stock.
The Viatris Charter, Viatris Bylaws and Delaware law contain provisions that may have the effect of deterring takeovers by making such takeovers more expensive to the acquiror and by encouraging prospective acquirors to negotiate with the Viatris Board rather than to attempt a hostile takeover. These provisions include the division of the Viatris Board into three classes of directors until the 2023 annual meeting of Viatris stockholders, which could have the effect of making the replacement of incumbent directors more time-consuming and difficult, rules regarding how stockholders may present proposals or nominate directors for election at stockholder meetings and the right of the Viatris Board to issue preferred stock without stockholder approval. Delaware law also imposes some restrictions on mergers and other business combinations between Viatris and any holder of 15% or more of Viatris’ outstanding common stock.
These provisions are intended to protect Viatris’ stockholders from coercive or otherwise unfair takeover tactics by requiring potential acquirors to negotiate with the Viatris Board and by providing the Viatris Board with more time to assess any acquisition proposal. These provisions are not intended to make Viatris immune from takeovers. However, these provisions apply even if the offer may be considered beneficial by some stockholders and could delay or prevent an acquisition that the Viatris Board determines is not in the best interests of Viatris and its stockholders. Accordingly, if the Viatris Board determines that a potential business combination transaction is not in the best interests of Viatris and its stockholders, but certain stockholders believe that such a transaction would be beneficial to Viatris and its stockholders, such stockholders may elect to sell their shares in Viatris and the trading price of Viatris common stock could decrease. These and other provisions of the Viatris Charter, the Viatris Bylaws and the DGCL could have the effect of delaying, deferring or preventing a proxy contest, tender offer, merger or other change in control, which may have a material adverse effect on Viatris’ business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
The Viatris Charter designates the Court of Chancery of the State of Delaware, or, if such court lacks subject matter jurisdiction, another state court of the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware), as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by Viatris’ stockholders, which could discourage lawsuits against Viatris and its directors and officers.
The Viatris Charter provides that unless Viatris, through approval of the Viatris Board, otherwise consents in writing, the Court of Chancery of the State of Delaware or, if and only if the Court of Chancery of the State of Delaware dismisses such action for lack of subject matter jurisdiction, another state court sitting in the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware), will be the sole and exclusive forum for any derivative action or proceeding brought on behalf of Viatris, any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director or officer or other employees of Viatris to Viatris or its stockholders, creditors or other constituents, any action asserting a claim against Viatris or any of its directors, officers or other employees arising pursuant to, or seeking to enforce any right, obligation or remedy under, any provision of the DGCL or the Viatris Charter or the Viatris Bylaws, as each may be amended from time to time, any action or proceeding asserting a claim against Viatris or any of its directors, officers or other employees governed by the internal affairs doctrine or any action or proceeding as to which the DGCL (as it may be amended from time to time) confers jurisdiction on the Court of Chancery of the State of Delaware.
51

To the fullest extent permitted by law, this exclusive forum provision will apply to state and federal law claims, including claims under the federal securities laws, including the Securities Act and the Exchange Act. However, Viatris stockholders will not be deemed to have waived Viatris’ compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other companies’ charters and bylaws has been challenged in legal proceedings, and it is possible that, in connection with claims arising under federal securities laws or otherwise, a court could find the exclusive forum provision contained in the Viatris Charter to be inapplicable or unenforceable.
This exclusive forum provision may limit the ability of Viatris’ stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with Viatris or its directors or officers, which may discourage such lawsuits against Viatris or its directors or officers. Alternatively, if a court were to find this exclusive forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings described above, Viatris may incur additional costs associated with resolving such matters in other jurisdictions or forums, which could materially and adversely affect Viatris’ business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Our business and operations could be negatively affected by pressures from outside of the control of the company, including, but not limited to, shareholder actions, government regulations and disclosure requirements, and other market dynamics, which could cause us to incur significant expenses, hinder execution of our business strategy and negatively impact our share price.

In recent years, shareholder actions, government regulations and disclosure requirements, and other market dynamics, involving corporate governance, environmental and social matters, human capital, strategic direction and operations has become increasingly prevalent. In the event we become the subject of shareholder challenges or more extensive government regulation or intervention in these areas, this may create a significant distraction for our management and employees, negatively impact our ability to execute our business plans, require our management to expend significant time and resources, create uncertainties with respect to our financial position and operations, adversely affect our ability to attract and retain key employees or result in loss of potential business opportunities with our current and potential customers and business partners. In addition, such actions, regulation and intervention may cause significant fluctuations in our share price based on temporary or speculative market perceptions, uncertainties or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business, which could cause the market value of our common stock to decline.

ITEM 1B.Unresolved Staff Comments
None.
ITEM 2.Properties
For information regarding properties, refer to Item 1 “Business” in Part I of this Form 10-K.
ITEM 3.Legal Proceedings
For information regarding legal proceedings, refer to Note 19 Litigation included in Item 8 in Part II of this 10-K.
ITEM 4.Mine Safety Disclosures
Not applicable.
52

PART II
ITEM 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is traded on the NASDAQ Stock Market under the symbol “VTRS”.
As of February 22, 2021, there were approximately 113,007 holders of record of shares of Viatris common stock.
The Company paid quarterly cash dividends of $0.11 per share on the Company’s issued and outstanding common stock on June 16, 2021, September 16, 2021 and December 16, 2021. On January 4, 2022, the Company’s Board of Directors declared a quarterly cash dividend of $0.12 per share on the Company’s issued and outstanding common stock, which will be payable on March 16, 2022 to shareholders of record as of the close of business on February 24, 2022. The declaration and payment of future dividends to holders of the Company’s common stock will be at the discretion of the Board of Directors, and will depend upon factors, including but not limited to, the Company’s financial condition, earnings, capital requirements of its businesses, legal requirements, regulatory constraints, industry practice, and other factors that the Board of Directors deems relevant. The Company did not pay any dividends in 2020.
UNREGISTERED SALES OF DEBT SECURITIES
In the past three years, we have issued unregistered securities in connection with the following transactions:
In June 2020, Upjohn issued $7.45 billion aggregate principal amount of senior unsecured debt securities, comprised of 1.125% Senior Notes due 2022, 1.650% Senior Notes due 2025, 2.300% Senior Notes due 2027, 2.700% Senior Notes due 2030, 3.850% Senior Notes due 2040 and 4.000% Senior Notes due 2050 (collectively, the “Unregistered Upjohn U.S. Dollar Notes”). The Unregistered Upjohn U.S. Dollar Notes were issued in a private offering exempt from the registration requirements of the Securities Act, to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to persons outside of the U.S. pursuant to Regulation S under the Securities Act. In September 2021, Viatris filed a registration statement with the SEC with respect to an offer to exchange up to $7.45 billion aggregate principal amount of Unregistered Upjohn U.S. Dollar Notes with Registered Upjohn Notes in the same aggregate principal amount and with terms substantially identical in all material respects, which was declared effective on September 28, 2021. The exchange offer expired on October 28, 2021 and settled on October 29, 2021. More than 99.9% of the aggregate principal amount of the Unregistered Upjohn U.S. Dollar Notes were exchanged for Registered Upjohn Notes.

In June 2020, Upjohn Finance B.V., a wholly owned financing subsidiary of Upjohn, issued €3.60 billion aggregate principal amount of senior unsecured debt securities, comprised of 0.816% Senior Notes due 2022, 1.023% Senior Notes due 2024, 1.362% Senior Notes due 2027 and 1.908% Senior Notes due 2032. These notes were issued in a private offering exempt from the registration requirements of the Securities Act, to persons outside of the U.S. pursuant to Regulation S under the Securities Act.

53

STOCK PERFORMANCE GRAPH
Viatris common stock has been listed on the NASDAQ under the symbol “VTRS” since November 17, 2020. Prior to that time, there was no public market for our common stock. Upon consummation of the Combination, Pfizer stockholders received approximately 0.124079 shares of Viatris common stock for every one share of Pfizer common stock held as of the close of business on the record date (which was November 13, 2020). Former Mylan ordinary shareholders received one share of Viatris common stock for every one share of Mylan ordinary share held. The graph below compares Viatris Inc.’s cumulative total shareholder return on common stock with the cumulative total returns of the S&P 500 index and the Dow Jones US Pharmaceuticals index. The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from November 16, 2020 to December 31, 2021.

vtrs-20211231_g4.jpg
November 16,
2020
December 31,
2020
December 31,
2021
Viatris Inc.100.00 118.20 87.32 
S&P 500100.00 115.21 148.28 
Dow Jones U.S. Pharmaceuticals100.00 113.12 141.38 
ITEM 6.[Reserved]

54

ITEM 7.Management’s Discussion and Analysis of Financial Condition And Results of Operations
The following discussion and analysis addresses material changes in the financial condition and results of operations of Viatris Inc. and subsidiaries for the periods presented. Unless context requires otherwise, the “Company,” “Viatris,” “our” or “we” refer to Viatris Inc. and its subsidiaries.
This discussion and analysis should be read in conjunction with the consolidated financial statements and the related notes to consolidated financial statements included in Part II, Item 8 in this Form 10-K, and our other SEC filings and public disclosures.
This Form 10-K contains “forward-looking statements”. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the Biocon Biologics Transaction; statements about the Combination, the benefits and synergies of the Combination or our global restructuring program, future opportunities for the Company and its products and any other statements regarding the Company’s future operations, financial or operating results, capital allocation, dividend policy and payments, debt ratio and covenants, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, commitments, confidence in future results, efforts to create, enhance or otherwise unlock the value of our unique global platform, and other expectations and targets for future periods. Forward-looking statements may often be identified by the use of words such as “will”, “may”, “could”, “should”, “would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “pipeline”, “intend”, “continue”, “target”, “seek” and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to:

the integration of Mylan and the Upjohn Business or the implementation of the Company’s global restructuring program being more difficult, time consuming or costly than expected;
the pending Biocon Biologics Transaction may not achieve its intended benefits;
the possibility that the Company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the Combination or its global restructuring program within the expected timeframe or at all;
the possibility that the Company may be unable to successfully integrate Mylan and the Upjohn Business or implement its global restructuring program;
operational or financial difficulties or losses associated with the Company’s reliance on agreements with Pfizer in connection with the Combination, including with respect to transition services;
the possibility that the Company may be unable to achieve all intended benefits of its strategic initiatives;
the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic;
the Company’s failure to achieve expected or targeted future financial and operating performance and results;
actions and decisions of healthcare and pharmaceutical regulators;
changes in relevant laws and regulations, including but not limited to changes in tax, healthcare and pharmaceutical laws and regulations globally (including the impact of potential tax reform in the U.S.);
the ability to attract and retain key personnel;
the Company’s liquidity, capital resources and ability to obtain financing;
any regulatory, legal or other impediments to the Company’s ability to bring new products to market, including but not limited to “at-risk launches”;
success of clinical trials and the Company’s or its partners’ ability to execute on new product opportunities and develop, manufacture and commercialize products;
any changes in or difficulties with the Company’s manufacturing facilities, including with respect to inspections, remediation and restructuring activities, supply chain or inventory or the ability to meet anticipated demand;
the scope, timing and outcome of any ongoing legal proceedings, including government inquiries or investigations, and the impact of any such proceedings on the Company;
any significant breach of data security or data privacy or disruptions to our information technology systems;
risks associated with having significant operations globally;
the ability to protect intellectual property and preserve intellectual property rights;
changes in third-party relationships;
the effect of any changes in the Company’s or its partners’ customer and supplier relationships and customer purchasing patterns, including customer loss and business disruption being greater than expected following the Combination;
the impacts of competition, including decreases in sales or revenues as a result of the loss of market exclusivity for certain products;
changes in the economic and financial conditions of the Company or its partners;
uncertainties regarding future demand, pricing and reimbursement for the Company’s products;
uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, inflation rates and global exchange rates; and
55

inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with U.S. GAAP and related standards or on an adjusted basis.

For more detailed information on the risks and uncertainties associated with Viatris, see the risks described in Part I, Item 1A in this Form 10-K, and our other filings with the SEC. You can access Viatris’ filings with the SEC through the SEC website at www.sec.gov or through our website and Viatris strongly encourages you to do so. Viatris routinely posts information that may be important to investors on our website at investor.viatris.com, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated by reference in this Form 10-K and shall not be deemed “filed” under the Securities Exchange Act of 1934, as amended. Viatris undertakes no obligation to update any statements herein for revisions or changes after the filing date of this Form 10-K other than as required by law.


Explanatory Note
In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and all historical financial information of the Company prior to November 16, 2020 represents Mylan’s historical results and the Company’s thereafter.
Company Overview
Viatris is a global healthcare company formed in November 2020 whose mission is to empower people worldwide to live healthier at every stage of life, regardless of geography or circumstance. Improving the ability of patients to gain access to sustainable and high-quality healthcare is our relentless pursuit. One that rests on visionary thinking, determination and best-in-class capabilities that were strategically built to remove barriers across the health spectrum and advance access globally.
Viatris’ seasoned management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other stakeholders. With a global workforce of approximately 37,000, the Company has industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise complemented by a strong commitment to quality and unparalleled geographic footprint to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. The Company operates approximately 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.
Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics and biosimilars, and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise.

Certain Market and Industry Factors
The global pharmaceutical industry is a highly competitive and highly regulated industry. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. The following discussion highlights some of these key factors and market conditions.
Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on the Company’s financial results. The entrance into the market of additional competition generally has a negative impact on the volume and pricing of the affected products. Additionally, pricing is often affected by factors outside of the Company’s control. Conversely, generic products generally experience less volatility over a longer period of time in Europe as compared to the U.S., primarily due to the role of government oversight of healthcare systems in the region.
56

For branded products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S. and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.
Certain markets in which we do business outside of the U.S. have undergone government-imposed price reductions, and further government-imposed price reductions are expected in the future. Such measures, along with the tender systems discussed below, are likely to have a negative impact on sales and gross profit in these markets. However, government initiatives in certain markets that appear to favor generic products could help to mitigate this unfavorable effect by increasing rates of generic substitution and penetration.
Additionally, a number of markets in which we operate outside of the U.S. have implemented, or may implement, tender systems for generic pharmaceuticals in an effort to lower prices. Generally speaking, tender systems can have an unfavorable impact on sales and profitability. Under such tender systems, manufacturers submit bids that establish prices for generic pharmaceutical products. Upon winning the tender, the winning company will receive priority placement for a period of time. The tender system often results in companies underbidding one another by proposing low pricing in order to win the tender. The loss of a tender by a third party to whom we supply API can also have a negative impact on our sales and profitability. Sales continue to be negatively affected by the impact of tender systems in certain countries.
Recent Developments
Biocon Biologics Agreement
On February 28, 2022, the Company entered into an agreement to contribute its biosimilars business to Biocon Biologics. Under the terms of the Biocon Agreement, at closing Viatris will receive an up-front cash payment of $2.0 billion, $1.0 billion of convertible preferred equity and up to $335 million as additional cash payments that are expected to be paid in 2024. Viatris will own a stake of at least 12.9% of Biocon Biologics, on a fully-diluted basis, and will have certain priority rights with respect to certain liquidity events. The companies will also enter into a two-year transition services agreement, subject to extension in certain circumstances, during which time Viatris will provide certain commercial and administrative services for an applicable service fee. The transaction is expected to close in the second half of 2022 and is subject to customary closing conditions (including regulatory approvals).

Share Repurchase Program
On February 28, 2022, the Company announced that its Board of Directors had authorized a share repurchase program for the repurchase of up to $1.0 billion of the Company’s shares of common stock. The Company has not yet repurchased any shares of common stock under the share repurchase program and the share repurchase program does not obligate the Company to acquire any particular amount of common stock.
Cyclosporine Ophthalmic Emulsion
On February 3, 2022, the Company announced that it had received approval from the FDA for its ANDA for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis®. Cyclosporine Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, also known as dry eye. The commercial launch of the product occurred in February 2022.
SEMGLEE®
On June 11, 2020, the FDA approved the SEMGLEE® vial and pen products, which the Company began selling on August 31, 2020. On July 28, 2021, Viatris and Biocon announced that the FDA had approved SEMGLEE® (insulin glargine-yfgn) injection as the first interchangeable biosimilar product under the 351(k) regulatory pathway. The interchangeable SEMGLEE® product, which allows substitution of SEMGLEE® for the reference product, Lantus®, at the pharmacy counter, was launched in the fourth quarter of 2021. The Company has exclusivity for 12 months from launch before the FDA can approve another biosimilar interchangeable to Lantus®.
57

2020 Restructuring Program
During the fourth quarter of 2020, Viatris announced a significant global restructuring program in order to achieve synergies and ensure that the organization is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders. Viatris’ restructuring initiative incorporates and expands on the restructuring program announced by Mylan N.V. earlier in 2020 as part of its business transformation efforts. As part of the restructuring, the Company is optimizing its commercial capabilities and enabling functions, and closing, downsizing or divesting certain manufacturing facilities globally that are deemed to be no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex products.
For the committed restructuring actions, the Company expects to incur total pre-tax charges of up to approximately $1.4 billion. Such charges are expected to include up to approximately $450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including inventory write-offs. The remaining estimated cash costs of up to approximately $950 million are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations and other plant disposal costs. In addition, management believes the potential annual savings related to these committed restructuring activities to be up to approximately $900 million once fully implemented, with most of these savings expected to improve operating cash flow.
Impact of the Coronavirus Pandemic
As a leading global pharmaceutical company, Viatris is committed to continue doing its part in support of public health needs amid the evolving COVID-19 pandemic. The Company’s priorities remain protecting the health and safety of our workforce, continuing to produce critically needed medicines, deploying resources and expertise in the fight against COVID-19 through potential prevention and treatment efforts, supporting the communities in which we operate and maintaining the health of our overall business. As a result, many Viatris administrative offices continue operating under work from home protocols and some of our customer facing field personnel continue on a remote engagement model to ensure continued support for healthcare professionals, patient care and access to needed products. Additionally, all of our manufacturing facilities, and those of our key global partners, are currently operational and, at this time, we are not experiencing any significant disruptions. Current inventory levels, both ours and those in our distribution channel, remain in-line with normal levels.

The global spread of COVID-19 has created and continues to create significant volatility, uncertainty and economic disruption affecting the markets we serve, including impacts on supply chain partners, third-party manufacturers, logistics providers and other vendors. The extent to which the COVID-19 pandemic will impact our business, operations and financial results in future periods will depend on numerous evolving factors that are beyond our control and that we may not be able to accurately predict, and could adversely impact our results of operations in future periods. Due to the Company’s ability to generate significant cash flows from operations, combined with our access to borrowing facilities and capital markets, we believe that we currently have, and will maintain, the ability to meet foreseeable liquidity needs. For additional information, see Results of Operations in Part II. Item 7.

58

Financial Summary
The table below is a summary of the Company’s financial results for the year ended December 31, 2021 compared to the prior year period:
Year Ended December 31,
(In millions, except per share amounts and %s)20212020Change% Change
Total revenues$17,886.3 $11,946.0 $5,940.3 50 %
Gross profit5,575.5 3,796.7 1,778.8 47 %
Loss from operations(34.0)(210.8)176.8 nm
Net loss(1,269.1)(669.9)(599.2)(89)%
Diluted loss per share$(1.05)$(1.11)$0.06 %
A detailed discussion of the Company’s financial results can be found below in the section titled “Results of Operations.” As part of this discussion, we also report sales performance using the non-GAAP financial measures of “constant currency” net sales and total revenues. These measures provide information on the change in net sales and total revenues assuming that foreign currency exchange rates had not changed between the prior and current period. The comparisons presented at constant currency rates reflect comparative local currency sales at the prior year’s foreign exchange rates. We routinely evaluate our net sales and total revenues performance at constant currency so that sales results can be viewed without the impact of foreign currency exchange rates, thereby facilitating a period-to-period comparison of our operational activities, and believe that this presentation also provides useful information to investors for the same reason.
More information about non-GAAP measures used by the Company as part of this discussion, including adjusted cost of sales, adjusted gross margins, adjusted net earnings, and adjusted EBITDA (all of which are defined below) are discussed further in this Part II. Item 7 under Results of Operations and Results of Operations — Use of Non-GAAP Financial Measures.
Results of Operations
2021 Compared to 2020
Year Ended December 31,
(In millions, except %s)20212020% Change
2021 Currency Impact (1)
2021 Constant Currency Revenues
Constant Currency % Change (2)
Net sales
Developed Markets$10,428.7 $8,510.9 23 %$(185.1)$10,243.6 20 %
Greater China2,212.8 259.9 nm(9.3)2,203.5 nm
JANZ2,027.4 1,195.3 70 %(2.7)2,024.7 69 %
Emerging Markets3,144.7 1,853.8 70 %(9.3)3,135.4 69 %
Total net sales17,813.6 11,819.9 51 %(206.4)17,607.2 49 %
Other revenues (3)
72.7 126.1 (42)%(1.0)71.7 (43)%
Consolidated total revenues (4)
$17,886.3 $11,946.0 50 %$(207.4)$17,678.9 48 %
____________
(1)Currency impact is shown as unfavorable (favorable).
(2)The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period exchange rates, and in doing so shows the percentage change from 2021 constant currency net sales or revenues to the corresponding amount in the prior year.
(3)For the year ended December 31, 2021, other revenues in Developed Markets, JANZ, and Emerging Markets were approximately $51.0 million, $1.5 million, and $20.2 million, respectively.
(4)Amounts exclude intersegment revenue which eliminates on a consolidated basis.
59

Total Revenues
For the year ended December 31, 2021, the Company reported total revenues of $17.89 billion, compared to $11.95 billion for the comparable prior year period, representing an increase of $5.94 billion, or 50%. Total revenues include both net sales and other revenues from third parties. Net sales for the year ended December 31, 2021 were $17.81 billion, compared to $11.82 billion for the comparable prior year period, representing an increase of $5.99 billion, or 51%. Other revenues for the year ended December 31, 2021 were $72.7 million, compared to $126.1 million for the comparable prior year period, a decrease of $53.4 million.
The increase in net sales was primarily driven by the incremental net sales from the Upjohn Business totaling $5.80 billion and the favorable impact of foreign currency translation, primarily reflecting changes in the U.S. Dollar as compared to the currencies of subsidiaries in countries within the EU, of approximately $206.4 million, or 2%. New product sales of $698.7 million were offset by a decrease in net sales from existing products as a result of lower pricing and volumes of $710.9 million. New product sales include new products launched in 2021 and the carryover impact of new products, including business development, launched within the last twelve months. We estimate that the COVID-19 pandemic positively impacted our 2021 net sales compared to the prior year by approximately 2%, primarily driven by a partial recovery of customer buying patterns in the current year.

From time to time, a limited number of our products may represent a significant portion of our net sales, gross profit and net earnings. Generally, this is due to the timing of new product introductions and the amount, if any, of additional competition in the market. Our top ten products in terms of net sales, in the aggregate, represented approximately 33% and 23% for the years ended December 31, 2021 and 2020, respectively, with the year over year increase a result of the Combination. This percentage may fluctuate based upon the timing of new product launches, seasonality and the impact of competition.
Net sales are derived from our four reporting segments: Developed Markets, Greater China, JANZ and Emerging Markets.

Developed Markets Segment
Net sales from Developed Markets increased by $1.92 billion or 23% during the year ended December 31, 2021 when compared to the prior year. Net sales within North America totaled approximately $4.59 billion and net sales within Europe totaled approximately $5.84 billion. This increase was primarily the result of the incremental net sales from the Upjohn Business in the current year of $1.83 billion and new product sales, including the portfolio of thrombosis products in Europe acquired from Aspen in the fourth quarter of 2020. This increase was partially offset by lower pricing and volumes on net sales of existing products, including Wixela® Inhub®, Perforomist®, Xulane®, and Miacalcin® within the U.S., due to additional competition. Lower volumes were also due to the impact of product divestitures, including certain North American OTC products during the second quarter of 2021 and other products during 2020 as a result of the Combination. The favorable impact of foreign currency translation on current period net sales was approximately $185.1 million, or 2%. Constant currency net sales increased by approximately $1.73 billion, or 20% when compared to the prior year.
Greater China Segment
Net sales from Greater China increased by $1.95 billion for the year ended December 31, 2021 when compared to the prior year. This increase was primarily the result of the incremental net sales from the Upjohn Business of $1.93 billion. The favorable impact of foreign currency translation was approximately $9.3 million or 4%. Constant currency net sales increased by approximately $1.94 billion when compared to the prior year.
JANZ Segment
Net sales from JANZ increased by $832.1 million or 70% for the year ended December 31, 2021 when compared to the prior year. This increase was primarily the result of the incremental net sales from the Upjohn Business of $666.6 million, and higher net sales of existing products driven by higher volumes primarily related to Amitiza® and Creon®, as well as the impact of the termination of the collaboration arrangement with Pfizer in the prior year in Japan. These increases were partially offset by lower pricing driven by government price reductions and product competition. Foreign currency translation had a favorable impact of approximately $2.7 million, or less than 1%. Constant currency net sales increased by approximately $829.4 million, or 69% when compared to the prior year.
60

Emerging Markets Segment
Net sales from Emerging Markets increased by $1.29 billion or 70% for the year ended December 31, 2021 when compared to the prior year. This increase was primarily the result of the incremental net sales from the Upjohn Business of $1.37 billion and COVID-19 related product sales in India, primarily remdesivir and ambisome. These increases were partially offset by lower volumes and, to a lesser extent, pricing as a result of customer purchasing patterns and competitive market conditions, including for ARV products. The increase in net sales was partially offset by the favorable impact of foreign currency translation of $9.3 million, or less than 1%. Constant currency net sales increased by approximately $1.28 billion, or 69%.
Cost of Sales and Gross Profit
Cost of sales increased from $8.15 billion for the year ended December 31, 2020 to $12.31 billion for the year ended December 31, 2021. Cost of sales was primarily impacted by purchase accounting related amortization of acquired intangible assets and other special items, which are described further in the section titled Use of Non-GAAP Financial Measures. Additional incremental cost of sales from the Upjohn Business, including the impact of amortization expense, was $3.57 billion for the year ended December 31, 2021. This includes incremental amortization expense of $2.01 billion primarily for purchase accounting related amortization of intangible assets and the fair value step-up of acquired inventory.
Gross profit from net sales of existing products was impacted by lower pricing and to a lesser extent, lower volumes. Gross margins were 31% and 32% for the years ended December 31, 2021 and 2020, respectively. Adjusted gross margins were approximately 59% and 54% for the years ended December 31, 2021 and 2020, respectively, with the year-over-year increase driven by the impact of the Combination.
A reconciliation between cost of sales, as reported under U.S. GAAP, and adjusted cost of sales and adjusted gross margin for the year ended December 31, 2021 compared to the year ended December 31, 2020 is as follows:
Year Ended December 31,
(In millions, except %s)20212020
U.S. GAAP cost of sales$12,310.8 $8,149.3 
Deduct:
Purchase accounting amortization and other related items(4,039.7)(1,933.6)
Acquisition related items(13.9)(16.9)
Restructuring and related costs(534.7)(207.7)
Share-based compensation expense(2.3)(1.5)
Other special items(333.0)(438.1)
Adjusted cost of sales$7,387.2 $5,551.5 
Adjusted gross profit (a)
$10,499.1 $6,394.5 
Adjusted gross margin (a)
59 %54 %
____________
(a)Adjusted gross profit is calculated as total revenues less adjusted cost of sales. Adjusted gross margin is calculated as adjusted gross profit divided by total revenues.
Operating Expenses
Research & Development Expense
R&D expense for the year ended December 31, 2021 was $751.1 million, compared to $555.1 million for the prior year, an increase of $196.0 million. This increase was primarily due to additional incremental costs associated with the Upjohn Business of $81.7 million, higher expenses related to licensing arrangements for products in development, and increased costs for inventory validation batches for certain products under development.
61

Selling, General & Administrative Expense
SG&A expense for the year ended December 31, 2021 was $4.53 billion, compared to $3.34 billion for the prior year, an increase of $1.18 billion. The increase was primarily due to additional incremental costs associated with the Upjohn Business of $1.21 billion and an increase of approximately $236.4 million in restructuring costs due to the implementation of the 2020 restructuring program. Partially offsetting these increases were lower selling and promotional expenses, including through our active management related to synergies and certain lower expenses as a result of COVID-19. In addition, the Company incurred lower acquisition related costs of approximately $386.9 million, as the prior year costs included approximately $200.9 million for advisory and consulting fees related to the closing of the Combination, $303.5 million related to the Company’s obligation to reimburse Pfizer for certain financing and transaction related costs under the BCA and SDA and approximately $69.3 million of employee related to change in control and retention amounts.
Litigation Settlements and Other Contingencies, Net
The following table includes the losses recognized in litigation settlements and other contingencies, net during the years ended December 31, 2021 and 2020, respectively:
Year Ended December 31,
(In millions)20212020
Contingent consideration adjustment (primarily related to respiratory delivery platform)$50.3 $73.1 
Litigation settlements, net278.9 34.7 
Total litigation settlements and other contingencies, net$329.2 $107.8 
Litigation settlements in 2021 include a $264.0 million charge for the EpiPen® related settlement.
Interest Expense
Interest expense for the year ended December 31, 2021 totaled $636.2 million, compared to $497.8 million for the year ended December 31, 2020, an increase of $138.4 million. The increase is primarily due to additional incremental interest expense related to the debt assumed in the Combination of approximately $247.6 million, partially offset by amortization of debt premium of $60.1 million and by the impact of debt repayments in 2021.
Other Expense, Net
Other expense (income), net includes losses from equity affiliates, foreign exchange gains and losses, expense (income) related to post-employment benefit plans and interest and dividend income. Other expense (income), net was comprised of the following for the years ended December 31, 2021 and 2020, respectively:
Year Ended December 31,
(In millions)20212020
Losses from equity affiliates, primarily clean energy investments$61.9 $48.4 
Foreign exchange losses, net2.1 2.2 
Other gains, net(69.8)(38.0)
Other expense, net$(5.8)12.6 
Income Tax (Benefit) Provision
For the year ended December 31, 2021, the Company recognized an income tax provision of $604.7 million, compared to an income tax benefit of $51.3 million for the comparable prior year, a change in the provision of $656.0 million. The income tax provision for the year ended December 31, 2021 was negatively impacted by the tax rates applied to the reversal of intercompany profit in inventory reserve which was recorded on the opening balance sheet as part of the Combination. This reserve eliminates the profit in inventory related to intercompany transactions and changes to this reserve occur as products are sold to third parties. During the year ended December 31, 2020, the Company recognized a net charge as a result of adjustments to reserves for uncertain tax positions, partially offset by changes in the assessment of the realizability of deferred tax assets. Also impacting the current year income tax expense for both periods was the changing mix of income earned in jurisdictions with differing tax rates.
62

2020 Compared to 2019
Discussions of 2019 items and year-to-year comparisons between 2020 and 2019 are not included in this Form 10-K, and can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Use of Non-GAAP Financial Measures
Whenever the Company uses non-GAAP financial measures, we provide a reconciliation of the non-GAAP financial measures to their most directly comparable U.S. GAAP financial measure. Investors and other readers are encouraged to review the related U.S. GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable U.S. GAAP measure and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with U.S. GAAP. Additionally, since these are not measures determined in accordance with U.S. GAAP, non-GAAP financial measures have no standardized meaning across companies, or as prescribed by U.S. GAAP and, therefore, may not be comparable to the calculation of similar measures or measures with the same title used by other companies.
Management uses these measures internally for forecasting, budgeting, measuring its operating performance, and incentive-based awards. Primarily due to acquisitions and other significant events which may impact comparability of our periodic operating results, we believe that an evaluation of our ongoing operations (and comparisons of our current operations with historical and future operations) would be difficult if the disclosure of our financial results was limited to financial measures prepared only in accordance with U.S. GAAP. We believe that non-GAAP financial measures are useful supplemental information for our investors and when considered together with our U.S. GAAP financial measures and the reconciliation to the most directly comparable U.S. GAAP financial measure, provide a more complete understanding of the factors and trends affecting our operations. The financial performance of the Company is measured by senior management, in part, using adjusted metrics as described below, along with other performance metrics. The Company’s use of such non-GAAP measures is governed by an adjusted reporting policy maintained by the Company and such non-GAAP measures are reviewed in detail with the Audit Committee of the Board of Directors.
Adjusted Cost of Sales and Adjusted Gross Margin
We use the non-GAAP financial measure “adjusted cost of sales” and the corresponding non-GAAP financial measure “adjusted gross margin.” The principal items excluded from adjusted cost of sales include restructuring, acquisition related and other special items and purchase accounting related amortization, which are described in greater detail below.
Adjusted Net Earnings
Adjusted net earnings is a non-GAAP financial measure and provides an alternative view of performance used by management. Management believes that, primarily due to acquisition activity and other significant events, an evaluation of the Company’s ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with U.S. GAAP. Management believes that adjusted net earnings is an important internal financial metric related to the ongoing operating performance of the Company, and is therefore useful to investors and that their understanding of our performance is enhanced by this measure. Actual internal and forecasted operating results and annual budgets used by management include adjusted net earnings.
EBITDA and Adjusted EBITDA
EBITDA and adjusted EBITDA are non-GAAP financial measures that the Company believes are appropriate to provide additional information to investors to demonstrate the Company’s ability to comply with financial debt covenants and assess the Company’s ability to incur additional indebtedness. The Company also believes that adjusted EBITDA better focuses management on the Company’s underlying operational results and true business performance and, is used, in part, for management’s incentive compensation. We calculate EBITDA as U.S. GAAP net earnings (loss) adjusted for net contribution attributable to equity method investments, income tax provision (benefit), interest expense and depreciation and amortization. EBITDA is further adjusted for share-based compensation expense, litigation settlements and other contingencies, net, and restructuring, acquisition related and other special items to determine adjusted EBITDA. These adjustments are generally permitted under our credit agreement in calculating adjusted EBITDA for determining compliance with our debt covenants.
The significant items excluded from adjusted cost of sales, adjusted net earnings, and adjusted EBITDA include:
63

Purchase Accounting Amortization and Other Related Items
The ongoing impact of certain amounts recorded in connection with acquisitions of both businesses and assets is excluded from adjusted cost of sales, adjusted net earnings, and adjusted EBITDA. These amounts include the amortization of intangible assets, inventory step-up, property, plant and equipment step-up, and intangible asset impairment charges, including for in-process research and development. For the acquisition of businesses accounted for under the provisions of ASC 805, Business Combinations, these purchase accounting impacts are excluded regardless of the financing method used for the acquisitions, including the use of cash, long-term debt, the issuance of common stock, contingent consideration or any combination thereof.
Upfront and Milestone-Related R&D Expenses
These expenses and payments are excluded from adjusted net earnings and adjusted EBITDA because they generally occur at irregular intervals and are not indicative of the Company’s ongoing operations.
Accretion of Contingent Consideration Liability and Other Fair Value Adjustments
The impact of changes to the fair value of contingent consideration and accretion expense are excluded from adjusted net earnings and adjusted EBITDA because they are not indicative of the Company’s ongoing operations due to the variability of the amounts and the lack of predictability as to the occurrence and/or timing and management believes their exclusion is helpful to understanding the underlying, ongoing operational performance of the business.
Share-based Compensation Expense
Share-based compensation expense is excluded from adjusted net earnings and adjusted EBITDA. Our share-based compensation programs have become increasingly weighted toward performance-based compensation, which leads to variability and to a lack of predictability as to the occurrence and/or timing of amounts incurred. As such, management believes the exclusion of such amounts on an ongoing basis is helpful to understanding the underlying operational performance of the business.
Restructuring, Acquisition Related and Other Special Items
Costs related to restructuring, acquisition and integration activities and other actions are excluded from adjusted cost of sales, adjusted net earnings and adjusted EBITDA, as applicable. These amounts include items such as:
Costs related to formal restructuring programs and actions, including costs associated with facilities to be closed or divested, employee separation costs, impairment charges, accelerated depreciation, incremental manufacturing variances, equipment relocation costs, decommissioning and other restructuring related costs;
Certain acquisition related remediation and integration and planning costs, as well as other costs associated with acquisitions such as advisory and legal fees, certain financing related costs, certain reimbursements related to the Company’s obligation to reimburse Pfizer for certain financing and transaction related costs under the BCA and SDA, certain other TSA related exit costs, and other business transformation and/or optimization initiatives, which are not part of a formal restructuring program, including employee separation and post-employment costs;
The pre-tax loss of the Company’s clean energy investments, whose activities qualify for income tax credits under the Code; only included in adjusted net earnings is the net tax effect of the entity’s activities;
Other costs, incurred from time to time, related to certain special events or activities that lead to gains or losses, including, but not limited to, incremental manufacturing variances, asset write-downs, or liability adjustments;
Certain costs to further develop and optimize our global enterprise resource planning systems, operations and supply chain; and
The impact of changes related to uncertain tax positions and certain impacts related to the Combination are excluded from adjusted net earnings. In addition, tax adjustments to adjusted earnings are recorded to present items on an after-tax basis consistent with the presentation of adjusted net earnings.
The Company has undertaken restructurings and other optimization initiatives of differing types, scope and amount during the covered periods and, therefore, these charges should not be considered non-recurring; however, management excludes these amounts from adjusted net earnings and adjusted EBITDA because it believes it is helpful to understanding the underlying, ongoing operational performance of the business.
64

Litigation Settlements, Net
Charges and gains related to legal matters, such as those discussed in Note 19 Litigation included in Part II. Item 8 of this Form 10-K are generally excluded from adjusted net earnings and adjusted EBITDA. Normal, ongoing defense costs of the Company made in the normal course of our business are not excluded.
Reconciliation of U.S. GAAP Net (Loss) Earnings to Adjusted Net Earnings
A reconciliation between net (loss) earnings as reported under U.S. GAAP, and adjusted net earnings for the periods shown follows:
Year Ended December 31,
(In millions)202120202019
U.S. GAAP net (loss) earnings$(1,269.1)$(669.9)$16.8 
Purchase accounting related amortization (primarily included in cost of sales) (a)
4,039.7 1,933.6 1,767.0 
Litigation settlements and other contingencies, net329.2 107.8 (21.4)
Interest expense (primarily amortization of premiums and discounts on long term debt)(53.8)12.6 27.2 
Clean energy investments pre-tax loss61.9 48.4 62.1 
Acquisition related costs (primarily included in SG&A) (b)
234.6 613.6 89.5 
Restructuring related costs (c)
899.4 323.1 104.6 
Share-based compensation expense111.2 79.2 56.8 
Other special items included in:
Cost of sales (d)
333.0 438.1 366.0 
Research and development expense (e)
83.2 47.2 121.1 
Selling, general and administrative expense49.5 44.6 60.2 
Other expense, net(8.0)(16.8)10.7 
Tax effect of the above items and other income tax related items (f)
(343.0)(589.7)(380.1)
Adjusted net earnings$4,467.8 $2,371.8 $2,280.5 

Significant items for the year ended December 31, 2021 include the following:
(a)    Includes amortization of the purchase accounting inventory fair value adjustment related to the Combination totaling approximately $1.19 billion.
(b)    Acquisition related costs consist primarily of transaction costs including legal and consulting fees and integration activities.
(c)    For the year ended December 31, 2021, charges of approximately $534.7 million are included in cost of sales, approximately $13.3 million are included in R&D, and approximately $351.5 million are included in SG&A. Refer to Note 17 Restructuring included in Part II. Item 8 of this Form 10-K for additional information.
(d)    Costs incurred during the year ended December 31, 2021 include incremental manufacturing variances and site remediation activities as a result of the activities at the Company’s Morgantown plant of approximately $123.4 million, and at other plants in the 2020 restructuring program of approximately $143.3 million.
(e)    Adjustments primarily relate to non-refundable payments related to development partner agreements.
(f)    Adjusted for changes for uncertain tax positions and for certain impacts of the Combination.
65

Reconciliation of U.S. GAAP Net (Loss) Earnings to EBITDA and Adjusted EBITDA

Below is a reconciliation of U.S. GAAP net (loss) earnings to EBITDA and adjusted EBITDA for the year ended December 31, 2021 compared to the prior year periods:

Year Ended December 31,
(In millions)202120202019
U.S. GAAP net (loss) earnings$(1,269.1)$(669.9)$16.8 
Add / (deduct) adjustments:
Net contribution attributable to equity method investments61.9 48.4 62.1 
Income tax provision (benefit)604.7 (51.3)137.6 
Interest expense (a)
636.2 497.8 517.3 
Depreciation and amortization (b)
4,506.5 2,216.1 2,019.3 
EBITDA$4,540.2 $2,041.1 $2,753.1 
Add / (deduct) adjustments:
Share-based compensation expense111.2 79.2 56.8 
Litigation settlements and other contingencies, net329.2 107.8 (21.4)
Restructuring, acquisition related and other special items (c)
1,445.5 1,426.0 751.2 
Adjusted EBITDA$6,426.1 $3,654.1 $3,539.7 

(a)    Includes amortization of premiums and discounts on long-term debt.
(b)    Includes purchase accounting related amortization.
(c)    See items detailed in the Reconciliation of U.S. GAAP Net (Loss) Earnings to Adjusted Net Earnings.

Liquidity and Capital Resources
Our primary source of liquidity is net cash provided by operating activities, which was $3.02 billion for the year ended December 31, 2021. We believe that net cash provided by operating activities and available liquidity will continue to allow us to meet our needs for working capital, capital expenditures, interest and principal payments on debt obligations, and dividend payments. Nevertheless, our ability to satisfy our working capital requirements and debt service obligations, fund planned capital expenditures, or dividend payments, will substantially depend upon our future operating performance (which will be affected by prevailing economic conditions), and financial, business and other factors, some of which are beyond our control.
Operating Activities
Net cash provided by operating activities increased by $1.79 billion to $3.02 billion for the year ended December 31, 2021, as compared to net cash provided by operating activities of $1.23 billion for the year ended December 31, 2020. Net cash provided by operating activities is derived from net (loss) earnings adjusted for non-cash operating items, gains and losses attributed to investing and financing activities and changes in operating assets and liabilities resulting from timing differences between the receipts and payments of cash, including changes in cash primarily reflecting the timing of cash collections from customers, payments to vendors and employees and tax payments in the ordinary course of business.
The increase in net cash provided by operating activities was principally due to higher operating earnings after adjusting for non-cash operating items. Non-cash operating items increased significantly during the year reflecting the impacts of purchase accounting related to the Combination and non-cash charges related to the ongoing restructuring initiatives. In addition, net cash provided by operating activities was unfavorably impacted in 2021 by changes in operating assets and liabilities.
Investing Activities
Net cash used in investing activities was $117.8 million for the year ended December 31, 2021, as compared to net cash used in investing activities of $301.1 million for the year ended December 31, 2020, a decrease of $183.3 million.
66

In 2021, significant items in investing activities included the following:
cash received from acquisitions, net totaling approximately $277.0 million related to additional target cash balances received from Pfizer subsequent to the closing of the Combination;
proceeds from the sale of assets of $96.7 million, primarily related to a group of OTC products in the U.S.; and
capital expenditures, primarily for equipment and facilities, totaling approximately $457.2 million. While there can be no assurance that current expectations will be realized, capital expenditures for the 2022 calendar year are expected to be approximately $525 million to $675 million.
In 2020, significant items in investing activities included the following:
cash received from acquisitions, net totaling approximately $415.8 million primarily related to the cash received as part of the Combination;
payments for product rights and other, net totaling approximately $438.2 million, primarily related to the acquisition of Aspen’s thrombosis product portfolio in Europe along with other acquisitions of intellectual property rights and marketing authorizations; and
capital expenditures, primarily for equipment and facilities, totaling approximately $243.0 million.
Financing Activities
Net cash used in financing activities was $3.01 billion for the year ended December 31, 2021, as compared to net cash used in financing activities of $605.7 million for the year ended December 31, 2020, an increase of $2.41 billion.
In 2021, significant items in financing activities included the following:
long-term debt payments of approximately $4.20 billion, consisting of the redemption of $2.25 billion of the 3.150% Senior Notes due 2021, repayment of $1.35 billion of borrowings under the 2020 Revolving Facility and the 2021 Revolving Facility, and repayment of $600.0 million of the USD Term Loan;
long-term borrowings of $1.71 billion, consisting of borrowings of $1.35 billion under the 2020 Revolving Facility and the 2021 Revolving Facility, and borrowings of $360.0 million under the YEN Term Loan;
net short-term borrowings of $392.1 million;
deferred non-contingent payments for product rights totaling approximately $456.0 million primarily related to the acquisition of Aspen’s thrombosis product portfolio in Europe; and
cash dividends paid of $399.0 million.
In 2020, significant items in financing activities included the following:
net short-term and long-term borrowings of $2.08 billion;
long-term debt payments of approximately $2.48 billion, consisting primarily of repayment at maturity of €500.0 million principal amount of Floating Rate Euro Notes due May 2020, repayment at maturity of €750.0 million principal amount of Euro Senior Notes due November 2020, repayment of $983.0 million of borrowings under the 2020 Revolving Facility and repayment at maturity of $50.0 million principal amount of Senior Notes due 2020; and
payments totaling approximately $48.5 million (of the $111.8 million) in profit share payments related to the respiratory delivery platform contingent consideration. The remaining payments related to the respiratory delivery platform contingent consideration are included as a component of other operating assets and liabilities, net within net cash from operating activities.
Refer to the consolidated statements of cash flows in Part II. Item 8 of this Form 10-K for additional details on other significant sources and uses of cash during the years ended December 31, 2021 and 2020.
67

Capital Resources
Our cash and cash equivalents totaled $701.2 million at December 31, 2021, and the majority of these funds are held by our non-U.S. subsidiaries. The Company anticipates having sufficient liquidity, including existing borrowing capacity under the 2021 Revolving Facility, Commercial Paper Program and the Receivables Facility and the Note Securitization Facility combined with cash to be generated from operations, to fund foreseeable cash needs without requiring the repatriation of non-U.S. cash.
In September 2021, Viatris filed a registration statement with the SEC with respect to an offer to exchange up to $7.45 billion aggregate principal amount of Unregistered Upjohn U.S Dollar Notes with Registered Upjohn Notes in the same aggregate principal amount and with terms substantially identical in all material respects, which was declared effective on September 28, 2021. The exchange offer expired on October 28, 2021 and settled on October 29, 2021. More than 99.9% of the aggregate principal amount of the Unregistered Upjohn U.S. Dollar Notes were exchanged for Registered Upjohn Notes.
In July 2021, Viatris entered into (i) the YEN Term Loan Facility and (ii) the 2021 Revolving Facility with various syndicates of banks. The 2021 Revolving Facility amended and restated the 2020 Revolving Facility and proceeds from the 2021 Revolving Facility were used to repay outstanding obligations under the 2020 Revolving Facility and the 2020 Revolving Facility was terminated. Proceeds from the YEN Term Loan Facility and the 2021 Revolving Facility were also used to repay the USD Term Loan Facility in full and the USD Term Loan Facility was terminated. The 2021 Revolving Facility and the YEN Term Loan Facility have substantially identical terms to the 2020 Revolving Facility and USD Term Loan Facility, respectively, with the following exceptions: 1) the maturity of both the YEN Term Loan Facility and the 2021 Revolving Facility is July 2026, 2) the pricing was adjusted to reflect current market prices (which were generally more favorable) and 3) the maximum leverage ratio as of the end of any quarter was set at 4.25 to 1.00 for each quarter ending after June 30, 2021 through and including June 30, 2022, 4.0 to 1.00 for each quarter ending after June 30, 2022 through and including December 31, 2022 and 3.75 to 1.00 thereafter, except in circumstances as defined in the related credit agreement.
The Company has access to $4.0 billion under the 2021 Revolving Facility which matures in July 2026. Up to $1.65 billion of the 2021 Revolving Facility may be used to support borrowings under our Commercial Paper Program. As of December 31, 2021, the Company had $1.17 billion outstanding under the Commercial Paper Program and did not have any borrowings outstanding under the 2021 Revolving Facility.
In addition to the 2021 Revolving Facility, MPI, a wholly owned subsidiary of the Company, has access to $400 million under the Receivables Facility, which expires in April 2022. As of December 31, 2021, the Company had $318.5 million outstanding under the Receivables Facility.
In August 2020, the Company entered into the Note Securitization Facility for borrowings up to $200 million, which was amended on July 1, 2021 to extend the term to August 2022. As of December 31, 2021, the Company did not have any borrowings outstanding under the Note Securitization Facility.

Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. The amount that we may borrow at a given point in time is determined based on the amount of qualifying accounts receivable that are present at such point in time. Borrowings outstanding under the Receivables Facility bear interest at a commercial paper rate plus 0.925% and under the Note Securitization Facility at a rate per annum quoted from time to time by MUFG Bank, Ltd. plus 0.85% and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In addition, the agreements governing the Receivables Facility and Note Securitization Facility contain various customary affirmative and negative covenants, and customary default and termination provisions.

We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $29.6 million and $153.0 million of accounts receivable as of December 31, 2021 and 2020 under these factoring arrangements, respectively.
68

We are continuously evaluating the potential acquisition of products, as well as companies, as a strategic part of our future growth. Consequently, we may utilize current cash reserves or incur additional indebtedness to finance any such acquisitions, which could impact future liquidity. Also, on an ongoing basis, we review our operations including the evaluation of potential divestitures of products and businesses as part of our future strategy. Any divestitures could impact future liquidity. In addition, we plan to continue to explore various other ways to create, enhance or otherwise unlock the value of the Company’s unique global platform in order to create shareholder value.
For information regarding our dividends paid and declared, refer to Note 2 Summary of Significant Accounting Policies in Part II. Item 8 of this Form 10-K.
Long-term Debt Maturity
For information regarding our debt agreements and mandatory minimum repayments remaining on the outstanding notional amount of long-term debt at December 31, 2021, refer to Note 10 Debt in Part II. Item 8 of this Form 10-K.
The YEN Term Loan Facility and the 2021 Revolving Facility contain customary affirmative covenants for facilities of this type, including among others, covenants pertaining to the delivery of financial statements, notices of default and certain material events, maintenance of corporate existence and rights, property, and insurance and compliance with laws, as well as customary negative covenants for facilities of this type, including limitations on the incurrence of subsidiary indebtedness, liens, mergers and certain other fundamental changes, investments and loans, acquisitions, transactions with affiliates, payments of dividends and other restricted payments and changes in our lines of business.
The Company is in compliance with its covenants at December 31, 2021 and expects to remain in compliance for the next twelve months.
Supplemental Guarantor Financial Information
Viatris Inc. is the issuer of the Registered Upjohn Notes, which are fully and unconditionally guaranteed on a senior unsecured basis by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.
Following the Combination, Utah Acquisition Sub Inc. is the issuer of the Utah U.S. Dollar Notes, which are fully and unconditionally guaranteed on a senior unsecured basis by Mylan Inc., Viatris Inc. and Mylan II B.V.
Mylan Inc. is the issuer of the Mylan Inc. U.S. Dollar Notes, which are fully and unconditionally guaranteed on a senior unsecured basis by Mylan II B.V., Viatris Inc. and Utah Acquisition Sub Inc.

The respective obligations of Viatris Inc., Mylan Inc., Utah Acquisition Sub Inc., and Mylan II B.V. as guarantors of the applicable series of Senior U.S. Dollar Notes are senior unsecured obligations of the applicable guarantor and rank pari passu in right of payment with all of such guarantor’s existing and future senior unsecured obligations that are not expressly subordinated to such guarantor’s guarantee of the applicable series of Senior U.S. Dollar Notes, rank senior in right of payment to any future obligations of such guarantor that are expressly subordinated to such guarantor’s guarantee of the applicable series of Senior U.S. Dollar Notes, and are effectively subordinated to such guarantor’s existing and future secured obligations to the extent of the value of the collateral securing such obligations. Such obligations are structurally subordinated to all of the existing and future liabilities, including trade payables, of the existing and future subsidiaries of such guarantor that do not guarantee the applicable series of Senior U.S. Dollar Notes.
69

The guarantees by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. under the applicable series of Senior U.S. Dollar Notes will terminate under certain customary circumstances, each as described in the applicable indenture, including: (1) a sale or disposition of the applicable guarantor in a transaction that complies with the applicable indenture such that such guarantor ceases to be a subsidiary of the issuer of the applicable series of Senior U.S. Dollar Notes; (2) legal defeasance or covenant defeasance or if the issuer’s obligations under the applicable indenture are discharged; (3) with respect to the Utah U.S. Dollar Notes, the earlier to occur of (i) with respect to the guarantee provided by Mylan Inc., (x) the release of Utah Acquisition Sub Inc.’s guarantee under all applicable Mylan Inc. Debt (as defined in the applicable indenture) and (y) Mylan Inc. no longer having any obligations in respect of any Mylan Inc. Debt and (ii) with respect to the guarantee provided by Mylan II B.V., (x) the release of Mylan II B.V.’s guarantee under all applicable Triggering Indebtedness (as defined in the applicable indenture) and (y) the issuer and/or borrower of the applicable Triggering Indebtedness no longer having any obligations with respect to such Triggering Indebtedness; (4) with respect to the guarantees provided by Utah Acquisition Sub Inc. and Mylan II B.V. of the Mylan Inc. U.S. Dollar Notes, subject to certain exceptions set forth in the applicable indenture, such guarantor ceasing to be a guarantor or obligor in respect of any Triggering Indebtedness; and (5) with respect to the Registered Upjohn Notes, (a) upon the applicable guarantor no longer being an issuer or guarantor in respect of (i) Mylan Notes (as defined in the indenture governing the Registered Upjohn Notes) that have an aggregate principal amount in excess of $500.0 million or (ii) any Triggering Indebtedness; in each case, other than in respect of indebtedness or guarantees, as applicable, that are being concurrently released; or (b) upon receipt of the consent of holders of a majority of the aggregate principal amount of the outstanding notes of such series in accordance with the indenture governing the Registered Upjohn Notes.
The guarantee obligations of Viatris Inc., Mylan Inc., Utah Acquisition Sub Inc., and Mylan II B.V. under the Senior U.S. Dollar Notes are subject to certain limitations and terms similar to those applicable to other guarantees of similar instruments, including that (i) the guarantees are subject to fraudulent transfer and conveyance laws and (ii) each guarantee is limited in amount to an amount not to exceed the maximum amount that can be guaranteed by the applicable guarantor without rendering the guarantee, as it relates to such guarantor, voidable under applicable fraudulent transfer and conveyance laws or similar laws affecting the rights of creditors generally.
The following table presents unaudited summarized financial information of Viatris Inc., Mylan Inc., Utah Acquisition Sub Inc., and Mylan II B.V. on a combined basis as of and for the year ended December 31, 2021 and 2020. All intercompany balances have been eliminated in consolidation. This unaudited combined summarized financial information is presented utilizing the equity method of accounting.
Combined Summarized Balance Sheet Information of Viatris Inc., Mylan Inc., Utah Acquisition Sub Inc. and Mylan II B.V.
(In millions)December 31, 2021December 31, 2020
ASSETS
Current assets$280.2 $477.7 
Non-current assets60,298.0 61,272.4 
LIABILITIES AND EQUITY
Current liabilities23,619.9 20,951.7 
Non-current liabilities16,465.6 17,844.2 
Combined Summarized Income Statement Information of Viatris Inc., Mylan Inc., Utah Acquisition Sub Inc. and Mylan II B.V.
(In millions)Year Ended December 31, 2021Year Ended December 31, 2020
Revenues$— $— 
Gross profit— — 
Loss from operations(1,023.9)(929.6)
Net loss(1,269.1)(669.9)
70

Other Commitments
The Company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings and litigation matters, both in the U.S. and abroad, that arise from time to time, some of which could result in losses, including damages, fines and/or civil penalties, and/or criminal charges against the Company. These matters are often complex and have outcomes that are difficult to predict. We have approximately $609 million accrued for legal contingencies at December 31, 2021.
While the Company believes that it has meritorious defenses with respect to the claims asserted against it and the assumed legal matters referenced above, and intends to vigorously defend its position, the process of resolving these matters is inherently uncertain and may develop over a long period of time, and so it is not possible to predict the ultimate resolution of any such matter. It is possible that an unfavorable resolution of any of the ongoing matters could have a material effect on the Company’s business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
In conjunction with the Combination, Viatris entered into a TSA with Pfizer pursuant to which each party will provide certain limited transition services to the other party generally for an initial period of 24 months from closing date of the Combination. In addition to the monthly service fees under the TSA, Viatris has agreed to reimburse Pfizer for fifty percent of the costs, up to the first $380 million incurred, to establish and wind down the TSA services. Viatris will be required to fully reimburse Pfizer for total costs in excess of $380 million. During the years ended December 31, 2021 and 2020, the Company incurred $30.4 million and $53.1 million, respectively, related to this provision of the TSA, and approximately $83.5 million during the period beginning on the closing date of the Combination and ended December 31, 2021.
At December 31, 2021, our material cash requirements from known contractual and other obligations primarily relate to repayment of outstanding borrowings and interest, open purchase orders, post-employment benefit plans, unrecognized tax benefits, capital expenditures, dividends and leases. For additional information, refer to Notes 2, 6, 10, 12, 14, and 16 in Part II. Item 8 of this Form 10-K. We anticipate our cash requirements related to ordinary course purchases of goods and services will be consistent with our past levels.
In the normal course of business, Viatris periodically enters into employment, legal settlement and other agreements which incorporate indemnification provisions. While the maximum amount to which Viatris may be exposed under such agreements cannot be reasonably estimated, the Company maintains insurance coverage, which management believes will effectively mitigate the Company’s obligations under these indemnification provisions. No amounts have been recorded in the consolidated financial statements with respect to the Company’s obligations under such agreements.
We have entered into employment and other agreements with certain executives and other employees that provide for compensation and certain other benefits. These agreements provide for severance payments under certain circumstances.
Licensing and Other Partner Agreements
Under our licensing and other partner agreements, our potential maximum development milestones not accrued for at December 31, 2021 totaled approximately $351 million. We estimate that the amounts that may be paid during the next twelve months to be approximately $18 million. Additionally, these agreements may also include potential sales-based milestones and call for us to pay a percentage of amounts earned from the sale of the product as a royalty or a profit share. Refer to Note 18 Licensing and Other Partner Agreements included in Part II. Item 8 of this Form 10-K for additional information.
Application of Critical Accounting Policies
Our significant accounting policies are described in Note 2 Summary of Significant Accounting Policies included in Part II. Item 8 of this Form 10-K and are in accordance with U.S. GAAP.
Included within these policies are certain policies which contain critical accounting estimates and, therefore, have been deemed to be “critical accounting policies.” Critical accounting estimates are those which require management to make assumptions about matters that were uncertain at the time the estimate was made and for which the use of different estimates, which reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur from period to period could have a material impact on our financial condition or results of operations. We have identified the following to be our critical accounting policies: the determination of net revenue provisions, acquisitions, intangible assets, goodwill and contingent consideration, income taxes and the impact of existing legal matters.
71

Revenue Recognition
We recognize revenues in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Amounts recorded for revenue deductions can result from a complex series of judgements about future events and uncertainties and can rely heavily on estimates and assumptions. As such, they have been identified as critical accounting estimates. The following section briefly describes the nature of our provisions for variable consideration and how such provisions are estimated:
Chargebacks: the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Viatris will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels. We continually monitor our provision for chargebacks and evaluate our reserve and estimates as additional information becomes available. A change of 5% would have an effect on our reserve balance of approximately $29.6 million.
Rebates, promotional programs and other sales allowances: this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products. A change of 5% would have an effect on our reserve balance of approximately $68.7 million.
Returns: consistent with industry practice, Viatris maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. Generally, returned products are destroyed and customers are refunded the sales price in the form of a credit. A change of 5% would have an effect on our reserve balance of approximately $34.3 million.
Governmental rebate programs: government reimbursement programs in the U.S. include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap” based on historical experience of prescriptions and utilization expected to result in the discount of the “coverage gap”.
Outside the U.S., the majority of our pharmaceutical sales are contractually or legislatively governed. In certain European countries, certain rebates are calculated on the governments total pharmaceutical spending or on specific product sale thresholds. We utilize historical data and obtain third party information to determine the adequacy of these accruals. Also, this provision includes price reductions that are mandated by law outside of the U.S.
A change of 5% would have an effect on our reserve balance of approximately $20.0 million.
72

The following is a rollforward of the categories of variable consideration during 2021:
(In millions)Balance at December 31, 2020Current Provision Related to Sales Made in the Current Period Measurement Period Adjustments and ReclassesChecks/ Credits Issued to Third Parties Effects of Foreign ExchangeBalance at December 31, 2021
Chargebacks$585.2 $5,530.1 $63.4 $(5,585.4)$(1.6)$591.7 
Rebates, promotional programs and other sales allowances1,576.3 6,135.6 (57.6)(6,267.1)(14.2)1,373.0 
Returns539.9 384.6 269.0 (499.0)(7.7)686.8 
Governmental rebate programs$313.3 689.5 110.6 (705.2)(9.0)399.2 
Total$3,014.7 $12,739.8 $385.4 $(13,056.7)$(32.5)$3,050.7 
Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net revenues and in accounts receivable and other current liabilities. Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:
(In millions)December 31,
2021
December 31,
2020
Accounts receivable, net$1,688.6 $1,802.9 
Other current liabilities1,362.1 1,211.8 
Total$3,050.7 $3,014.7 
We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves.
Acquisitions, Intangible Assets, Goodwill and Contingent Consideration
The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of ASC 805, Business Combinations, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective estimated fair values. The cost to acquire businesses is allocated to the underlying net assets of the acquired business based on estimates of their respective fair values. Amounts allocated to acquired IPR&D are capitalized at the date of acquisition and, at that time, such IPR&D assets have indefinite lives. As products in development are approved for sale, amounts are allocated to product rights and licenses and will be amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Refer to Note 4 Acquisitions and Other Transactions included in Part II. Item 8 of this Form 10-K for further additional information regarding the Company’s acquisitions, including the acquisition accounting related to the Combination.
Purchases of developed products and licenses that are accounted for as asset acquisitions are capitalized as intangible assets and amortized over an estimated useful life. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses.
The judgments made in determining the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. Fair values and useful lives are determined based on, among other factors, the expected future period of benefit of the asset, the various characteristics of the asset and projected cash flows. Because this process involves management making estimates with respect to future sales volumes, pricing, new product launches, government reform actions, anticipated cost environment and overall market conditions, and because these estimates form the basis for the determination of whether or not an impairment charge should be recorded, these estimates are considered to be critical accounting estimates.
73

The Company records contingent consideration resulting from business acquisitions at its estimated fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as adjustments to litigation settlements and other contingencies, net within the consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, sales targets and profitability. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.
Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations.
The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management’s assessment of the fair value of the Company’s reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we choose to use qualitative factors and determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test would be required. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations.
The Company performed its annual goodwill impairment test as of April 1, 2021 on a quantitative basis for its five reporting units, North America, Europe, Emerging Markets, JANZ, and Greater China. Additionally, the net assets acquired as part of the Combination were included in the respective reporting units and in the annual impairment test for the first time. In estimating each reporting unit’s fair value, the Company performed an extensive valuation analysis, utilizing both income and market-based approaches. The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions that affect the reporting unit’s expected future cash flows. These estimates and assumptions, utilizing Level 3 inputs, primarily include, but are not limited to, market multiples, control premiums, the discount rate, terminal growth rates, operating income before depreciation and amortization, and capital expenditures forecasts. The following describes the valuation methodologies used to derive the estimated fair value of the reporting units.

Income Approach: Under this approach, to determine fair value, we discounted the expected future cash flows of each reporting unit. We used a discount rate, which reflected the overall level of inherent risk and the rate of return an outside investor would have expected to earn. To estimate cash flows beyond the final year of our model, we used a terminal value approach. Under this approach, we used EBITDA in the final year of our model, adjusted to estimate a normalized cash flow, applied a perpetuity growth assumption, and discounted by a perpetuity discount factor to determine the terminal value. We incorporated the present value of the resulting terminal value into our estimate of fair value.

Market-Based Approach: The Company also utilizes a market-based approach to estimate fair value, principally utilizing the guideline company method which focuses on comparing our risk profile and growth prospects to a select group of publicly traded companies with reasonably similar guidelines.
As of April 1, 2021, the allocation of the Company’s total goodwill was as follows: North America $3.66 billion, Europe $5.15 billion, Emerging Markets $1.58 billion, JANZ $0.82 billion and Greater China $0.70 billion.

As of April 1, 2021, the Company determined that the fair value of the North America, Emerging Markets and Greater China reporting units was substantially in excess of the respective unit’s carrying value.
74

For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $0.91 billion or 5.8% for the annual goodwill impairment test. As it relates to the income approach for the Europe reporting unit at April 1, 2021, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately 3.0%. A terminal year value was calculated with a 0.9% revenue growth rate applied. The discount rate utilized was 10.5% and the estimated tax rate was 19.0%. Under the market-based approach, we utilized an estimated range of market multiples of 7.5 to 8.5 times EBITDA plus a control premium of 15.0%. If all other assumptions are held constant, a reduction in the terminal value growth rate by 2.9% or an increase in discount rate by 1.5% would result in an impairment charge for the Europe reporting unit.
For the JANZ reporting unit, the estimated fair value exceeded its carrying value by approximately $0.23 billion or 7.0% for the annual goodwill impairment test. As it relates to the income approach for the JANZ reporting unit at April 1, 2021, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately negative 1.5%. A terminal year value was calculated with a 0.7% revenue growth rate applied. The discount rate utilized was 8.5% and the estimated tax rate was 30.5%. Under the market-based approach, we utilized an estimated market multiple of 6.0 times EBITDA plus a control premium of 15.0%. If all other assumptions are held constant, a reduction in the terminal value growth rate by 4.2% or an increase in discount rate by 2.0% would result in an impairment charge for the JANZ reporting unit.
Due to the inherent uncertainty involved in making these estimates, actual results could differ from those estimates. In addition, changes in underlying assumptions, especially as they relate to the key assumptions detailed, could have a significant impact on the fair value of the reporting units.
The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. We have assessed the recoverability of certain long-lived assets, principally finite-lived intangible assets, contained within the reporting units whenever certain impairment indicators are present. Any impairment of these assets must be considered prior to our impairment review of goodwill. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.
Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. For the years ended December 31, 2021, 2020 and 2019, the Company recorded $83.4 million (related to the sale of a group of OTC products in the U.S.), $45.0 million, and $42.3 million, respectively, of impairment charges for finite-lived intangible assets, which were recorded as a component of amortization expense. At December 31, 2021 and 2020, the Company’s finite-lived intangible assets totaled $26.09 billion and $29.60 billion, respectively. Changes to any of the Company’s assumptions related to the estimated fair value based on the discounted cash flows, including discount rates or the competitive environment related to the assets, could lead to future material impairment charges. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations.
The Company’s indefinite-lived intangible assets, principally IPR&D, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value of IPR&D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested. For the years ended December 31, 2021, 2020 and 2019, the Company recorded $19.4 million, $37.4 million, and $138.3 million, respectively, of impairment charges, which were recorded as a component of amortization expense. At December 31, 2021 and 2020, the Company’s IPR&D assets totaled $46.5 million and $80.7 million, respectively.
The fair value of both IPR&D and finite-lived intangible assets was determined based upon detailed valuations employing the income approach which utilized Level 3 inputs, as defined in Note 9 Financial Instruments and Risk Management included in Part II. Item 8 of this Form 10-K. Changes to any of the Company’s assumptions including changes to or abandonment of development programs, regulatory timelines, discount rates or the competitive environment related to the assets could lead to future material impairment charges.
75

Income Taxes
We compute our income taxes based on the statutory tax rates and tax reliefs available to Viatris in the various jurisdictions in which we generate income. Significant judgment is required in determining our income taxes and in evaluating our tax positions. We establish reserves in accordance with Viatris’ policy regarding accounting for uncertainty in income taxes. Our policy provides that the tax effects from an uncertain tax position be recognized in Viatris’ financial statements, only if the position is more likely than not of being sustained upon audit, based on the technical merits of the position. We adjust these reserves in light of changing facts and circumstances, such as the settlement of a tax audit. Our provision for income taxes includes the impact of reserve provisions and changes to reserves. Favorable resolution would be recognized as a reduction to our provision for income taxes in the period of resolution or expiration of the underlying statutes of limitation. Based on this evaluation, as of December 31, 2021, our reserve for unrecognized tax benefits totaled $322.9 million, of which $264.0 million was recorded in connection with the Combination and is subject to Pfizer’s indemnification obligations to Viatris under the Tax Matters Agreement.

Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred in certain taxing jurisdictions over the three-year period ended December 31, 2021. Such objective evidence limits the ability to consider other subjective evidence such as our projections for future growth.
Based on this evaluation and other factors, as of December 31, 2021, a valuation allowance of $780.4 million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence such as projections for growth. When assessing the realizability of deferred tax assets, management considers all available evidence, including historical information, long-term forecasts of future taxable income and possible tax planning strategies. Amounts recorded for valuation allowances can result from a complex series of estimates, assumptions and judgments about future events. Due to the inherent uncertainty involved in making these estimates, assumptions and judgments, actual results could differ materially. Any future increases to the Company’s valuation allowances could materially impact the Company’s consolidated financial condition and results of operations. At December 31, 2021 and 2020, the Company’s net deferred tax assets totaled $1.33 billion and $2.15 billion, respectively.
A variance of 5% between estimated reserves and valuation allowances and actual resolution and realization of these tax items would have an effect on our reserve balance and valuation allowance of approximately $55.1 million.
Legal Matters
Viatris is involved in various legal proceedings, some of which involve claims for substantial amounts. An estimate is made to accrue for a loss contingency relating to any of these legal proceedings if it is probable that a liability was incurred as of the date of the financial statements and the amount of loss can be reasonably estimated. Because of the subjective nature inherent in assessing the outcome of litigation and because of the potential that an adverse outcome in a legal proceeding could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price, such estimates are considered to be critical accounting estimates.
A variance of 5% between estimated and recorded litigation reserves and actual resolution of certain legal matters would have an effect on our litigation reserve balance of approximately $30.4 million. Refer to Note 19 Litigation included in Part II. Item 8 of this Form 10-K for further discussion of litigation matters.
Impact of Currency Fluctuations and Inflation
Because our results are reported in U.S. Dollars, changes in the rate of exchange between the U.S. Dollar and the local currencies in the markets in which we operate, mainly the Euro, Indian Rupee, Chinese Renminbi, Japanese Yen, Australian Dollar, Canadian Dollar, Pound Sterling and South Korean Won affect our results as previously noted. We do not believe that inflation has had a material impact on our revenues or results of operations in any of the past three years.
Recent Accounting Pronouncements
Refer to Note 2 Summary of Significant Accounting Policies in Part II. Item 8 of this Form 10-K for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted.
76

ITEM 7A.Quantitative and Qualitative Disclosures About Market Risk
Foreign Currency Exchange Risk
A significant portion of our revenues and earnings are exposed to changes in foreign currency exchange rates. We seek to manage this foreign exchange risk in part through operational means, including managing same currency revenues in relation to same currency costs and same currency assets in relation to same currency liabilities.
From time to time, foreign exchange risk is managed through the use of foreign currency forward-exchange contracts. These contracts are used to offset the potential earnings effects from mostly intercompany foreign currency assets and liabilities that arise from operations and from intercompany loans. Any unhedged foreign exchange exposures continue to be subject to market fluctuations.
Our financial instrument holdings at year end were analyzed to determine their sensitivity to foreign exchange rate changes. The fair values of these instruments were determined as follows:
foreign currency forward-exchange contracts — net present values
foreign currency denominated receivables, payables, debt and loans — changes in exchange rates
In this sensitivity analysis, we assumed that the change in one currency’s rate relative to the U.S. Dollar would not have an effect on other currencies’ rates relative to the U.S. Dollar. All other factors were held constant.
If there were an adverse change in foreign currency exchange rates of 10%, the expected net effect on net income related to Viatris’ foreign currency denominated financial instruments would not be material.
The Company is also exposed to translation risk on non-U.S. dollar-denominated net assets. Non-U.S. dollar borrowings, principally our Euro and Yen denominated long-term debt, are used to hedge the foreign currency exposures of our net investment in certain foreign affiliates and are designated as hedges of net investments. The foreign exchange gains or losses on these hedges is included in the foreign currency translation component of accumulated other comprehensive income (loss). If our net investment decreases below the equivalent value of the non-U.S. debt borrowings, the change in the remeasurement basis of the debt would be subject to recognition in net income as changes occur.
Interest Rate and Long-Term Debt Risk
Viatris’ exposure to interest rate risk arises primarily from our U.S. Dollar and Euro borrowings and U.S. Dollar investments. We invest primarily on a variable-rate basis and we borrow on both a fixed and variable basis. In order to maintain a certain ratio of fixed to variable rate debt, from time to time, depending on market conditions, Viatris will use derivative financial instruments such as interest rate swaps to fix interest rates on variable-rate borrowings or to convert fixed-rate borrowings to variable interest rates.
As of December 31, 2021, Viatris’ outstanding fixed rate borrowings consist principally of $20.60 billion notional amount of senior U.S. dollar and Euro notes. Generally, the fair value of fixed interest rate debt will decrease as interest rates rise and increase as interest rates fall. As of December 31, 2021, the fair value of our outstanding fixed rate senior U.S. dollar and Euro notes was approximately $22.01 billion. A 100 basis point change in interest rates on Viatris’ variable rate debt, net of interest rate swaps, would result in a change in interest expense of approximately $18.4 million per year.
77

ITEM 8.Financial Statements And Supplementary Data
Index to Consolidated Financial Statements and
Supplementary Financial Information
78

Management’s Report on Internal Control over Financial Reporting
Management of Viatris Inc. is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. In order to evaluate the effectiveness of internal control over financial reporting, management has conducted an assessment, including testing, using the criteria in Internal Control - Integrated Framework (2013), issued by COSO. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.
As a result of this assessment, management has concluded that the Company maintained effective internal control over financial reporting as of December 31, 2021 based on the criteria in Internal Control - Integrated Framework (2013) issued by COSO.
Our independent registered public accounting firm, Deloitte & Touche LLP (PCAOB ID No. 34), has audited the effectiveness of the Company’s internal control over financial reporting. Deloitte & Touche LLP’s opinion on the Company’s internal control over financial reporting appears on page 83 of this Annual Report on Form 10-K.
79

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of Viatris Inc.:
Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Viatris Inc. and subsidiaries (the "Company") as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive (loss) earnings, equity, and cash flows, for each of the three years in the period ended December 31, 2021, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 2022, expressed an unqualified opinion on the Company's internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Goodwill – Viatris Inc. Europe and JANZ Reporting Units – Refer to Note 8 to the financial statements.

Critical Audit Matter Description

The Company performed its annual goodwill impairment test as of April 1, 2021. As of April 1, 2021, the Company had $11.91 billion of consolidated goodwill, $5.15 billion and $0.82 billion of which was allocated to the Viatris Inc. Europe and JANZ reporting units, respectively. The Company’s evaluation of goodwill for impairment involves the comparison of the estimated fair value of each reporting unit to its carrying value. The Company performed its valuation analysis, using both income and market-based approaches, to determine the fair value of its Europe and JANZ reporting units. The determination of the fair value requires management to make significant estimates and assumptions that affect the reporting unit’s expected future cash flows. These estimates and assumptions, utilizing Level 3 valuation inputs, primarily include, but are not limited to, market multiples, control premiums, discount rates, terminal growth rates, operating income before depreciation and amortization, and capital expenditures forecasts. The fair values of the Europe and the JANZ reporting units exceeded their carrying values by approximately $0.91 billion, or 5.8%, and $0.23 billion, or 7.0%, respectively, as of April 1, 2021 and, therefore, no impairments were recognized.
80


Given that the Europe and JANZ reporting unit’s revenues are sensitive to changes in consumer demand, the approval of new product launches, the expansion of existing products into new jurisdictions (which have differentiated distribution and commercialization models throughout the regions), and the impact of business development activity, auditing management’s judgments regarding forecasts of future revenues, and the selection of the discount rates and terminal growth rates required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the forecasts of future revenues (“forecasts”), and the selection of the discount rates and terminal growth rates for the Europe and the JANZ reporting units included the following procedures, among others:

We tested the effectiveness of controls over the review of the goodwill impairment test, including those over the development of the business forecasts of future revenues and the selection of the discount rates and terminal growth rates.

We evaluated management’s ability to accurately forecast future revenues of the Europe and JANZ reporting units by comparing actual results to management’s historical forecasts.

We evaluated the reasonableness of management’s revenue forecasts by comparing the projections to (1) historical results, (2) internal communications to management and the Board of Directors, and (3) forecasted information included in Company press releases. We also considered third party reports related to macroeconomic and industry trends and made inquiries of management, including various regional commercial and operations leaders to assess key inputs in the forecast assumptions.

With the assistance of our fair value specialists, we evaluated the reasonableness of the valuation methodology, discount rates, and terminal growth rates, including (1) testing the source information underlying the determination of the discount rates and terminal growth rates and the mathematical accuracy of the calculations, (2) developing a range of independent estimates and comparing those to the discount rates selected by management, and (3) considering third party macroeconomic reports.

Net Revenue Provisions – Chargebacks Accrual at Mylan Pharmaceuticals Inc. (“MPI”) – Refer to Note 3 to the financial statements.

Critical Audit Matter Description

The Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies, and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Viatris will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is the most significant and complex provision in the context of the Company’s gross-to-net adjustments in the determination of net revenue. The chargeback accrual recorded at MPI represents the majority of the global chargeback reserve as of December 31, 2021. The Company's recorded estimate is based on expected sell-through levels by the Company’s wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels.

Estimating the amounts to be accrued for chargebacks requires significant estimation as management’s model utilizes historical buying patterns, estimated end-user demand, estimated inventory levels in the distribution channel, contracted sales terms with customers, as well as other competitive factors. Given the volume of chargebacks and the level of estimation uncertainty involved, auditing management’s judgments required a high degree of auditor judgment and an increased extent of effort.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the Net Revenue Provisions – Chargebacks accrual included the following, among others:

We evaluated the Company’s methodology and assumptions in developing their chargeback accruals, including assessing the completeness and accuracy of the underlying data used by management in their estimates.
81


We tested the effectiveness of controls over the calculation of the chargebacks reserves.

We compared prior period chargebacks accruals to chargeback credits subsequently issued to evaluate management’s ability to accurately forecast chargeback activity.

We developed independent expectations of product-level chargeback accruals and chargeback accruals in the aggregate using the following: 1) customer contracts, 2) historical sales and chargeback activity, 3) third-party channel inventory for select wholesalers, and 4) credits subsequently issued to period end and compared those to the recorded amounts.

Net Revenue Provisions – Sales Returns Accrual at MPI – Refer to Note 3 to the financial statements.

Critical Audit Matter Description

The Company provides customers with the ability to return product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. The returns reserve at MPI represents a significant component of the global sales returns reserve as of December 31, 2021.

Estimating the amounts to be accrued for returns requires significant estimation as management’s model utilizes historical experience with actual returns and considers levels of inventory in the distribution channel, product dating and expiration period, size and maturity of the market prior to a product launch, entrance into the market of additional competitors, and changes in the regulatory environment. Given the volume of sales returns and the level of estimation uncertainty involved, auditing management’s judgments required a high degree of auditor judgment and an increased extent of effort.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the Net Revenue Provisions – Sales Returns accrual included the following, among others:

We evaluated the Company’s methodology and assumptions in developing their sales returns accrual model, including assessing the completeness and accuracy of the underlying data used by management in their estimates.

We tested the effectiveness of controls over the calculation of the sales returns reserve at MPI.

We compared prior period sales returns accruals to sales returns credits subsequently issued to evaluate management’s ability to accurately forecast sales returns activity.

We developed independent expectations of product-level sales returns accruals and sales returns accruals in the aggregate using the following: 1) historical sales and returns activity, 2) remaining shelf life information, 3) finished goods inventory on-hand at the end of the period, and 4) adjustments for known or anticipated sales return activity based on market dynamics (market prior to Viatris launch, impact of competition, and overall regulatory environment) and compared those to the recorded amounts.




/s/ DELOITTE & TOUCHE LLP
Pittsburgh, Pennsylvania
February 28, 2022
We have served as the Company's auditor since 1976.


82

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of Viatris Inc.:
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of Viatris, Inc. and subsidiaries (the “Company”) as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2021, of the Company and our report dated February 28, 2022, expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


/s/ DELOITTE & TOUCHE LLP
Pittsburgh, Pennsylvania
February 28, 2022
83

VIATRIS INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(In millions, except share and per share amounts)
December 31,
2021
December 31,
2020
ASSETS
Assets
Current assets:
Cash and cash equivalents$701.2 $844.4 
Accounts receivable, net4,266.4 4,843.8 
Inventories3,977.7 5,471.9 
Prepaid expenses and other current assets1,957.6 1,707.4 
Total current assets10,902.9 12,867.5 
Property, plant and equipment, net3,188.6 3,459.9 
Intangible assets, net26,134.2 29,683.2 
Goodwill12,113.7 12,347.0 
Deferred income tax benefit1,332.7 2,147.9 
Other assets1,170.7 1,047.5 
Total assets$54,842.8 $61,553.0 
LIABILITIES AND EQUITY
Liabilities
Current liabilities:
Accounts payable$1,657.4 $1,904.2 
Short-term borrowings1,493.0 1,100.9 
Income taxes payable236.9 288.6 
Current portion of long-term debt and other long-term obligations1,877.5 2,308.5 
Other current liabilities4,619.6 4,960.7 
Total current liabilities9,884.4 10,562.9 
Long-term debt19,717.1 22,429.2 
Deferred income tax liability2,815.0 3,123.7 
Other long-term obligations1,933.6 2,483.1 
Total liabilities34,350.1 38,598.9 
Equity
Viatris Inc. shareholders’ equity
Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued and outstanding: 1,209,507,463 and 1,206,895,644, respectively
12.1 12.1 
Additional paid-in capital18,536.1 18,438.8 
Retained earnings3,688.8 5,361.2 
Accumulated other comprehensive loss(1,744.3)(858.0)
Total equity20,492.7 22,954.1 
Total liabilities and equity$54,842.8 $61,553.0 

See Notes to Consolidated Financial Statements
84

VIATRIS INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(In millions, except per share amounts)
 Year Ended December 31,
 202120202019
Revenues:
Net sales$17,813.6 $11,819.9 $11,370.3 
Other revenues72.7 126.1 130.2 
Total revenues17,886.3 11,946.0 11,500.5 
Cost of sales12,310.8 8,149.3 7,602.9 
Gross profit5,575.5 3,796.7 3,897.6 
Operating expenses:
Research and development751.1 555.1 639.9 
Selling, general and administrative4,529.2 3,344.6 2,563.6 
Litigation settlements and other contingencies, net329.2 107.8 (21.4)
Total operating expenses5,609.5 4,007.5 3,182.1 
(Loss) earnings from operations(34.0)(210.8)715.5 
Interest expense636.2 497.8 517.3 
Other (income) expense, net(5.8)12.6 43.8 
(Loss) earnings before income taxes(664.4)(721.2)154.4 
Income tax provision (benefit)604.7 (51.3)137.6 
Net (loss) earnings(1,269.1)(669.9)16.8 
(Loss) earnings per share attributable to Viatris Inc. shareholders
Basic$(1.05)$(1.11)$0.03 
Diluted$(1.05)$(1.11)$0.03 
Weighted average shares outstanding:
Basic1,208.8 601.2 515.7 
Diluted1,208.8 601.2 516.5 
See Notes to Consolidated Financial Statements
85


VIATRIS INC. AND SUBSIDIARIES
Consolidated Statements of Comprehensive (Loss) Earnings
(In millions)
Year Ended December 31,
202120202019
Net (loss) earnings$(1,269.1)$(669.9)$16.8 
Other comprehensive (loss) earnings, before tax:
Foreign currency translation adjustment(1,340.9)1,213.0 (415.5)
Change in unrecognized loss and prior service cost related to defined benefit plans73.9 (14.0)(24.8)
Net unrecognized gain on derivatives in cash flow hedging relationships36.1 18.2 37.1 
Net unrecognized gain (loss) on derivatives in net investment hedging relationships456.8 (305.2)59.6 
Net unrealized (loss) gain on marketable securities(1.1)0.6 0.5 
Other comprehensive (loss) earnings, before tax(775.2)912.6 (343.1)
Income tax provision (benefit) 111.1 (26.6)9.2 
Other comprehensive (loss) earnings, net of tax(886.3)939.2 (352.3)
Comprehensive (loss) earnings$(2,155.4)$269.3 $(335.5)

See Notes to Consolidated Financial Statements
86


VIATRIS INC. AND SUBSIDIARIES
Consolidated Statements of Equity
(In millions, except share amounts)
Additional Paid-In CapitalRetained
Earnings
Accumulated Other Comprehensive LossTotal
Equity
 
Common Stock (1)
Treasury Stock
 SharesCostSharesCost
Balance at December 31, 2018539,289,665 $6.0 $8,591.4 $6,010.7 23,490,867 $(999.7)$(1,441.3)$12,167.1 
Net earnings— — — 16.8 — — — 16.8 
Other comprehensive loss, net of tax— — — — — — (352.3)(352.3)
Share-based compensation expense— — 56.8 — — — — 56.8 
Issuance of restricted stock and stock options exercised, net1,457,206 0.1 8.1 — — — — 8.2 
Taxes related to the net share settlement of equity awards— — (12.8)— — — — (12.8)
Cancellation of restricted stock— — — — 1,107,207 — — — 
Cumulative effect of the adoption of new accounting standards— — — 3.6 — — (3.6) 
Balance at December 31, 2019540,746,871 $6.1 $8,643.5 $6,031.1 24,598,074 $(999.7)$(1,797.2)$11,883.8 
Net loss— $— $— $(669.9)— $— $— $(669.9)
Other comprehensive earnings, net of tax— — — — — — 939.2 939.2 
Share-based compensation expense— — 79.2 — — — — 79.2 
Issuance of restricted stock and stock options exercised, net872,802 — 0.6 — — — — 0.6 
Taxes related to the net share settlement of equity awards— — (6.3)— — — — (6.3)
Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock(541,619,673)(6.1)6.1 — — — —  
Issuance of common stock to Mylan N.V. shareholders541,619,673 5.2 (5.2)— — — —  
Issuance of common stock for the Combination 689,874,045 6.9 10,720.6 — — — — 10,727.5 
Retirement of Mylan N.V. treasury stock, net(24,598,074)— (999.7)— (24,598,074)999.7 —  
Balance at December 31, 20201,206,895,644 $12.1 $18,438.8 $5,361.2  $ $(858.0)$22,954.1 
Net loss— $— $— $(1,269.1)— $— $— $(1,269.1)
Other comprehensive loss, net of tax— — — — — — (886.3)(886.3)
Share-based compensation expense— — 111.2 — — — — 111.2 
Issuance of restricted stock and stock options exercised, net 2,611,819 — — — — — — — 
Taxes related to the net share settlement of equity awards— — (13.9)— — — — (13.9)
Cash dividends declared, $0.33 per common share
— — — (403.3)— — — (403.3)
Balance at December 31, 20211,209,507,463 $12.1 $18,536.1 $3,688.8  $ $(1,744.3)$20,492.7 
__________________
(1) Ordinary Shares prior to November 16, 2020.
See Notes to Consolidated Financial Statements
87

VIATRIS INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(In millions)
 Year Ended December 31,
 202120202019
Cash flows from operating activities:
Net (loss) earnings$(1,269.1)$(669.9)$16.8 
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization4,506.5 2,216.1 2,019.3 
Deferred income tax expense (benefit)675.7 (213.2)(192.6)
Litigation settlements and other contingencies, net323.7 101.1 (11.5)
Loss from equity method investments61.9 48.4 62.1 
Share-based compensation expense111.2 79.2 56.8 
Other non-cash items411.8 366.4 360.6 
Changes in operating assets and liabilities:
Accounts receivable59.3 78.7 (20.0)
Inventories(427.6)(741.9)(512.9)
Trade accounts payable(70.4)(82.7)(96.3)
Income taxes(699.6)3.6 57.9 
Other operating assets and liabilities, net(666.5)46.0 63.5 
Net cash provided by operating activities3,016.9 1,231.8 1,803.7 
Cash flows from investing activities:
Cash received (paid) for acquisitions, net of cash acquired277.0 415.8 (148.7)
Capital expenditures(457.2)(243.0)(213.2)
Payments for product rights and other, net(52.2)(438.2)(192.8)
Proceeds from sale of property, plant and equipment18.3 2.1  
Proceeds from sale of assets and subsidiaries96.7 20.0 28.0 
Purchase of marketable securities(30.2)(104.8)(25.8)
Proceeds from the sale of marketable securities29.8 47.0 27.1 
Net cash used in investing activities(117.8)(301.1)(525.4)
Cash flows from financing activities:
Proceeds from issuance of long-term debt1,710.1 983.3 7.4 
Payments of long-term debt(4,201.3)(2,484.2)(1,108.5)
Payments of financing fees(7.0)(2.0)(3.0)
Change in short-term borrowings, net392.1 1,099.6 (1.8)
Proceeds from exercise of stock options 0.6 8.1 
Taxes paid related to net share settlement of equity awards(17.4)(7.9)(8.4)
Contingent consideration payments(28.6)(48.5)(60.3)
Cash dividends paid(399.0)  
Non-contingent payments for product rights(456.0)(143.3) 
Other items, net(4.9)(3.3)(2.5)
Net cash used in financing activities(3,012.0)(605.7)(1,169.0)
Effect on cash of changes in exchange rates(30.9)33.8 (7.5)
Net (decrease) increase in cash, cash equivalents and restricted cash(143.8)358.8 101.8 
Cash, cash equivalents and restricted cash — beginning of period850.0 491.1 389.3 
Cash, cash equivalents and restricted cash — end of period$706.2 $850.0 $491.1 
Supplemental disclosures of cash flow information —
Non-cash transactions:
Common stock issued for the Combination$ $10,727.5 $ 
Cash paid during the period for:
Income taxes$641.7 $324.4 $278.6 
Interest$684.8 $555.4 $470.6 
See Notes to Consolidated Financial Statements
88

Viatris Inc. and Subsidiaries
Notes to Consolidated Financial Statements
1.Nature of Operations
Viatris is a global healthcare company formed in November 2020 whose mission is to empower people worldwide to live healthier at every stage of life, regardless of geography or circumstance. Improving the ability of patients to gain access to sustainable and high-quality healthcare is our relentless pursuit. One that rests on visionary thinking, determination and best-in-class capabilities that were strategically built to remove barriers across the health spectrum and advance access globally.
Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. The Company operates approximately 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs. We conduct our business through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.
In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and all historical financial information of the Company prior to November 16, 2020 represents Mylan’s historical results and the Company’s thereafter.
2.Summary of Significant Accounting Policies
Principles of Consolidation. The consolidated financial statements include the accounts of Viatris and those of its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Investments in equity method affiliates are recorded at cost and adjusted for the Company’s share of the affiliates’ cumulative results of operations, capital contributions and distributions.
Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates.
Foreign Currencies. The consolidated financial statements are presented in U.S. Dollars, the reporting currency of Viatris. Statements of Operations and Cash Flows of all of the Company’s subsidiaries that have functional currencies other than U.S. Dollars are translated at a weighted average exchange rate for the period for inclusion in the consolidated statements of operations and cash flows, whereas assets and liabilities are translated at the end of the period exchange rates for inclusion in the consolidated balance sheets. Translation differences are recorded directly in shareholders’ equity as foreign currency translation adjustments. Gains or losses on transactions denominated in a currency other than the subsidiaries’ functional currency, which arise as a result of changes in foreign currency exchange rates, are recorded in the consolidated statements of operations.
Cash and Cash Equivalents. Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.
Debt and Equity Securities. Debt securities classified as available-for-sale on the date of purchase are recorded at fair value, with net unrealized gains and losses, net of income taxes, reflected in accumulated other comprehensive loss as a component of shareholders’ equity. Net realized gains and losses on sales of available-for-sale debt securities are computed on a specific security basis and are included in other expense, net, in the consolidated statements of operations. Debt securities classified as trading securities are valued using the quoted market price from broker or dealer quotations or transparent pricing sources at the reporting date, with gains and losses included in other expense, net, in the consolidated statements of operations. Fair value is determined based on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit risk or underlying security and overall capital market liquidity. Debt securities are reviewed for impairment by assessing if the decline in market value of the investment below the carrying value is other than temporary.
89

Investments in equity securities with readily determinable fair values are recorded at fair value with changes in fair value recorded in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Investments in entities are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The share of net income or losses of equity method investments are included in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values and investments in equity accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors.
Concentrations of Credit Risk. Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable.
Viatris invests its excess cash in high-quality, liquid money market instruments, principally overnight deposits and highly rated money market funds. The Company maintains deposit balances at certain financial institutions in excess of federally insured amounts. Periodically, the Company reviews the creditworthiness of its counterparties to derivative transactions, and it does not expect to incur a loss from failure of any counterparties to perform under agreements it has with such counterparties.
Inventories. Inventories are stated at the lower of cost and net realizable value, with cost principally determined by the weighted average cost method. Provisions for potentially obsolete or slow-moving inventory, including pre-launch inventory, are made based on our analysis of product dating, inventory levels, historical obsolescence and future sales forecasts. Included as a component of cost of sales is expense related to the net realizable value of inventories.
Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed and recorded on a straight-line basis over the assets’ estimated service lives (3 to 18 years for machinery and equipment and other fixed assets and 15 to 39 years for buildings and improvements). Capitalized software is included in property, plant and equipment and is amortized over estimated useful lives ranging from 3 to 7 years.
Intangible Assets and Goodwill. Intangible assets are stated at cost less accumulated amortization. Amortization is generally recorded on a straight-line basis over estimated useful lives ranging from 3 to 20 years. The Company periodically reviews the estimated useful lives of intangible assets and makes adjustments when events indicate that a shorter life is appropriate.
The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of ASC 805, Business Combinations, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective estimated fair values. The cost to acquire businesses is allocated to the underlying net assets of the acquired business based on estimates of their respective fair values. Amounts allocated to acquired IPR&D are capitalized at the date of acquisition and, at that time, such IPR&D assets have indefinite lives. As products in development are approved for sale, amounts are allocated to product rights and licenses and will be amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
Purchases of developed products and licenses that are accounted for as asset acquisitions are capitalized as intangible assets and amortized over an estimated useful life. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses.
The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management's assessment of the fair value of the Company's reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we choose to use qualitative factors and determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test would be required. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations.
90

Indefinite-lived intangibles, principally IPR&D, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value of IPR&D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested.
Contingent Consideration. Viatris records contingent consideration resulting from business acquisitions at its estimated fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as adjustments to litigation settlements and other contingencies, net within the consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, sales targets and profitability. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.
Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations.
Impairment of Long-Lived Assets. The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.
Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations.
Short-Term Borrowings. The Company’s subsidiaries in India have working capital facilities with several banks which are secured by its current assets. The Company also has the CP Notes, Receivables Facility, which will expire in April 2022 and the Note Securitization Facility, which will expire in August 2022. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. As the accounts receivable do not transfer to the banks, any amounts outstanding under the facilities are recorded as borrowings and the underlying receivables continue to be included in accounts receivable, net, in the consolidated balance sheets.
Revenue Recognition. The Company recognizes revenues in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Amounts recorded for revenue deductions can result from a complex series of judgements about future events and uncertainties and can rely heavily on estimates and assumptions. The following section briefly describes the nature of our provisions for variable consideration and how such provisions are estimated:
Chargebacks: the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Viatris will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels.
91

Rebates, promotional programs and other sales allowances: this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products.
Returns: consistent with industry practice, Viatris maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. Generally, returned products are destroyed and customers are refunded the sales price in the form of a credit.
Governmental rebate programs: government reimbursement programs in the U.S. include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap” based on historical experience of prescriptions and utilization expected to result in the discount of the “coverage gap”.
Outside the U.S., the majority of our pharmaceutical sales are contractually or legislatively governed. In certain European countries, certain rebates are calculated on the governments total pharmaceutical spending or on specific product sale thresholds. We utilize historical data and obtain third party information to determine the adequacy of these accruals. Also, this provision includes price reductions that are mandated by law outside of the U.S.
Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods.
Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenues in the consolidated statements of operations.
Research and Development. R&D expenses are charged to operations as incurred.
Income Taxes. Income taxes have been provided for using an asset and liability approach in which deferred income taxes reflect the tax consequences on future years of events that the Company has already recognized in the financial statements or tax returns. Changes in enacted tax rates or laws may result in adjustments to the recorded tax assets or liabilities in the period that the new tax law is enacted.
Earnings per Share. Basic earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.
92

Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:
Year Ended December 31,
(In millions, except per share amounts)202120202019
Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders$(1,269.1)$(669.9)$16.8 
Shares (denominator):
Weighted average shares outstanding1,208.8 601.2 515.7 
Basic (loss) earnings per share attributable to Viatris Inc. shareholders$(1.05)$(1.11)$0.03 
Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders$(1,269.1)$(669.9)$16.8 
Shares (denominator):
Weighted average shares outstanding1,208.8 601.2 515.7 
Share-based awards  0.8 
Total dilutive shares outstanding1,208.8 601.2 516.5 
Diluted (loss) earnings per share attributable to Viatris Inc. shareholders$(1.05)$(1.11)$0.03 
The weighted average shares outstanding used in the computation of earnings per share for the year ended December 31, 2020 includes the effect of the 689.9 million shares issued for the closing of the Combination.
Additional stock awards and restricted ordinary shares were outstanding during the years ended December 31, 2021, 2020 and 2019 but were not included in the computation of diluted earnings per share for each respective period because the effect would be anti-dilutive. Excluded shares also include certain share-based compensation awards and restricted shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 12.7 million, 10.3 million and 9.1 million shares for the years ended December 31, 2021, 2020 and 2019, respectively.
The Company paid quarterly cash dividends of $0.11 per share on the Company’s issued and outstanding common stock on June 16, 2021, September 16, 2021, and December 16, 2021. On January 4, 2022, the Company’s Board of Directors declared a quarterly cash dividend of $0.12 per share on the Company’s issued and outstanding common stock, which will be payable on March 16, 2022 to shareholders of record as of the close of business on February 24, 2022. The declaration and payment of future dividends to holders of the Company’s common stock will be at the discretion of the Board of Directors, and will depend upon factors, including but not limited to, the Company’s financial condition, earnings, capital requirements of its businesses, legal requirements, regulatory constraints, industry practice, and other factors that the Board of Directors deems relevant.
On February 28, 2022, the Company announced that its Board of Directors had authorized a share repurchase program for the repurchase of up to $1.0 billion of the Company’s shares of common stock. The Company has not yet repurchased any shares of common stock under the share repurchase program and the share repurchase program does not obligate the Company to acquire any particular amount of common stock.
Share-Based Compensation. The fair value of share-based compensation is recognized as expense in the consolidated statements of operations over the vesting period.
Derivatives. From time to time the Company may enter into derivative financial instruments (mainly foreign currency exchange forward contracts, interest rate swaps and purchased equity call options) designed to: 1) hedge the cash flows resulting from existing assets and liabilities and transactions expected to be entered into over the next 24 months in currencies other than the functional currency, 2) hedge the variability in interest expense on floating rate debt, 3) hedge the fair value of fixed-rate notes, 4) hedge against changes in interest rates that could impact future debt issuances, 5) hedge cash or share payments required on conversion of issued convertible notes, 6) hedge a net investment in a foreign operation, or 7) economically hedge the foreign currency exposure associated with the purchase price of non-U.S. acquisitions. Derivatives are recognized as assets or liabilities in the consolidated balance sheets at their fair value. When the derivative instrument qualifies as a cash flow hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged items, are generally included in interest expense. When such instruments do not qualify for hedge accounting the changes in fair value are recorded in the consolidated statements of operations within other expense, net.
93

Financial Instruments. The Company’s financial instruments consist primarily of short-term and long-term debt, interest rate swaps, forward contracts and option contracts. The Company’s financial instruments also include cash and cash equivalents as well as accounts and other receivables and accounts payable, the fair values of which approximate their carrying values. As a policy, the Company does not engage in speculative or leveraged transactions.
The Company carries derivative instruments in the consolidated balance sheets at fair value, determined by reference to market data such as forward rates for currencies, implied volatilities, and interest rate swap yield curves. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. In addition, the Company has designated certain long-term debt instruments as net investment hedges.
Recent Accounting Pronouncements.
Adoption of New Accounting Standards
In January 2020, the FASB issued Accounting Standards Update 2020-01, Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 (“ASU 2020-01”), which clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. In addition, ASU 2020-01 states that for the purpose of applying paragraph 815-10-15-141(a) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The Company applied the provisions of ASU 2020-01 as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.
In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (Topic 740) which is intended to simplify the accounting for income taxes by eliminating certain exceptions and simplifying certain requirements under Topic 740. The Company applied the provisions of ASU 2019-12 on a prospective basis as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.
    Accounting Standards Issued Not Yet Adopted    
In March 2020, the FASB issued Accounting Standards Update 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Entities can apply the provisions of ASU 2020-04 immediately, as applicable, and generally the provisions of the guidance are available through December 31, 2022 as entities transition away from reference rates that are expected to be discontinued. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.
In October 2021, the FASB issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires entities (acquirers) to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. ASU 2021-08 will be effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2022 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.
In November 2021, the FASB issued Accounting Standards Update 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”), which requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 will be effective for fiscal years beginning after December 15, 2021 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its disclosures.

94

3.Revenue Recognition and Accounts Receivable
The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:
(In millions)2021 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands5,759.2 2,207.8 1,197.1 1,677.2 10,841.3 
Complex Gx and Biosimilars1,241.6 0.2 46.5 53.8 1,342.1 
Generics3,427.9 4.8 783.8 1,413.7 5,630.2 
Total Viatris$10,428.7 $2,212.8 $2,027.4 $3,144.7 $17,813.6 

(In millions)2020 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands3,920.7 253.9 617.0 443.3 5,234.9 
Complex Gx and Biosimilars1,202.6 0.7 42.8 49.4 1,295.5 
Generics3,387.6 5.3 535.5 1,361.1 5,289.5 
Total Viatris$8,510.9 $259.9 $1,195.3 $1,853.8 $11,819.9 

(In millions)2019 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands4,199.1 207.6 533.3 422.1 5,362.1 
Complex Gx and Biosimilars1,127.4 0.4 23.8 59.7 1,211.3 
Generics2,913.5 6.6 635.4 1,241.4 4,796.9 
Total Viatris$8,240.0 $214.6 $1,192.5 $1,723.2 $11,370.3 

The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:
(In millions)Year Ended December 31, 2021
Select Key Global Products
Lipitor ®
$1,663.2 
Norvasc ®824.7 
Lyrica ®728.5 
Viagra ®533.8 
EpiPen® Auto-Injectors391.7 
Celebrex ®
344.4 
Effexor ®
316.8 
Creon ®309.8 
Zoloft ®
284.3 
Xalabrands226.0 
Select Key Segment Products
Influvac ®$299.3 
Amitiza ®201.5 
Xanax ®185.9 
Dymista ®168.0 
Yupelri ®161.9 
____________
(a)The Company does not disclose net sales for any products considered competitively sensitive.
95

(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.
(c)Prior periods are not presented due to significance of products acquired as part of the Combination.
Variable Consideration and Accounts Receivable    
The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2021, 2020 and 2019, respectively:
Year Ended December 31,
(In millions)202120202019
Gross sales$30,553.4 $19,899.1 $19,012.2 
Gross to net adjustments:
Chargebacks(5,530.1)(3,656.2)(3,309.6)
Rebates, promotional programs and other sales allowances(6,135.6)(3,765.5)(3,629.3)
Returns(384.6)(329.7)(237.9)
Governmental rebate programs(689.5)(327.8)(465.1)
Total gross to net adjustments$(12,739.8)$(8,079.2)$(7,641.9)
Net sales$17,813.6 $11,819.9 $11,370.3 
The following is a rollforward of the categories of variable consideration during 2021:
(In millions)Balance at December 31, 2020Current Provision Related to Sales Made in the Current Period Measurement Period Adjustments and ReclassesChecks/ Credits Issued to Third Parties Effects of Foreign ExchangeBalance at December 31, 2021
Chargebacks$585.2 $5,530.1 $63.4 $(5,585.4)$(1.6)$591.7 
Rebates, promotional programs and other sales allowances1,576.3 6,135.6 (57.6)(6,267.1)(14.2)1,373.0 
Returns539.9 384.6 269.0 (499.0)(7.7)686.8 
Governmental rebate programs313.3 689.5 110.6 (705.2)(9.0)399.2 
Total$3,014.7 $12,739.8 $385.4 $(13,056.7)$(32.5)$3,050.7 
Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net revenues and as a contra-asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:
(In millions)December 31,
2021
December 31,
2020
Accounts receivable, net$1,688.6 $1,802.9 
Other current liabilities1,362.1 1,211.8 
Total$3,050.7 $3,014.7 
We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves.
96

Accounts receivable, net was comprised of the following at December 31, 2021 and December 31, 2020, respectively:
(In millions)December 31, 2021December 31, 2020
Trade receivables, net$3,774.4 $3,891.3 
Other receivables492.0 952.5 
Accounts receivable, net$4,266.4 $4,843.8 
Total allowances for doubtful accounts were $154.5 million and $159.9 million at December 31, 2021 and 2020, respectively. Viatris performs ongoing credit evaluations of its customers and generally does not require collateral. Approximately 18% and 12% of the accounts receivable balances represent amounts due from three customers at December 31, 2021 and 2020, respectively.
Accounts Receivable Factoring Arrangements
We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $29.6 million and $153.0 million of accounts receivable as of December 31, 2021 and 2020 under these factoring arrangements, respectively.
4.Acquisitions and Other Transactions
Upjohn Business Combination Agreement
On July 29, 2019, Mylan, Pfizer, Upjohn, a wholly-owned subsidiary of Pfizer, and certain other affiliated entities entered into a Business Combination Agreement pursuant to which Mylan would combine with the Upjohn Business in a Reverse Morris Trust transaction. The Upjohn Business was a global, primarily off-patent branded and generic established medicines business, which includes 20 primarily off-patent solid oral dose legacy brands, such as Lyrica®, Lipitor®, Celebrex® and Viagra®. The Combination was completed on November 16, 2020.
Prior to the Combination and pursuant to a Separation and Distribution Agreement, Pfizer had, among other things, transferred to Viatris substantially all of the assets and liabilities comprising the Upjohn Business (the Separation) and, thereafter, Pfizer had distributed to Pfizer stockholders all of the issued and outstanding shares of Viatris (the Distribution). When the Distribution and Combination were complete, Pfizer stockholders as of the record date of the Distribution owned 57% of the outstanding shares of Viatris common stock and Mylan shareholders as of immediately before the Combination owned 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted basis. Viatris also made a cash payment to Pfizer equal to $12 billion, which was funded with the proceeds of debt incurred by Upjohn prior to the Combination.
The transaction involved multiple legal entity restructuring transactions and a reverse merger acquisition with Viatris representing the legal acquirer and Mylan representing the accounting acquirer of the Upjohn Business. In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and Viatris applied purchase accounting to the acquired assets and assumed liabilities of the Upjohn Business as of November 16, 2020. The debt incurred by Upjohn prior to the Combination was a liability assumed in purchase accounting. The fair value of the debt as of November 16, 2020 was $13.08 billion.

The purchase price consists of the issuance of approximately 689.9 million Viatris shares of common stock at a fair value of approximately $10.73 billion based on the closing price of Mylan’s ordinary shares on November 13, 2020, as reported by the NASDAQ. In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction have been recorded at their respective estimated fair values at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company incurred acquisition related costs of approximately $234.6 million and $602.9 million, respectively. Acquisition related costs were recorded primarily in SG&A in the consolidated statements of operations for such periods.

97

During the year ended December 31, 2021, adjustments were made to the preliminary purchase price recorded at December 31, 2020, and are reflected as “Measurement Period and Other Adjustments” in the table below. The allocation of the $10.73 billion purchase price to the assets acquired and liabilities assumed under the Combination is as follows:
(In millions)
Preliminary Purchase Price Allocation as of December 31, 2020 (a)
Measurement Period and Other Adjustments (b)
Purchase Price Allocation as of December 31, 2021 (as adjusted)
Current assets (excluding inventories and net of cash acquired)$2,841.9 $(38.7)$2,803.2 
Inventories2,588.9 (34.2)2,554.7 
Property, plant and equipment1,394.1 (5.0)1,389.1 
Identified intangible assets18,040.0 — 18,040.0 
Goodwill2,107.5 295.6 2,403.1 
Deferred income tax benefit1,481.9 196.3 1,678.2 
Other assets 792.1 (7.4)784.7 
Total assets acquired$29,246.4 $406.6 $29,653.0 
Current liabilities2,760.2 419.7 3,179.9 
Long-term debt, including current portion13,076.2 — 13,076.2 
Deferred tax liabilities1,656.9 1.0 1,657.9 
Other noncurrent liabilities1,441.5 (14.1)1,427.4 
Net assets acquired (net of $415.8 of cash acquired)
$10,311.6 $ $10,311.6 
____________
(a)As previously reported in Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
(b)The measurement period adjustments are primarily for 1) certain working capital adjustments, an increase in litigation reserves to reflect facts and circumstances that existed as of the date of the Combination, and other adjustments and 2) the tax implications of these and other adjustments. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and accordingly, the Company has not retrospectively adjusted those consolidated financial statements.
The Combination enhanced each businesses’ ability to serve patients’ needs and expand their capabilities across more than 165 markets. Mylan brought a diverse portfolio across many geographies and key therapeutic areas, such as central nervous system and anesthesia, infectious disease and cardiovascular, as well as a robust pipeline, high-quality manufacturing and supply chain excellence. The Upjohn Business brought trusted, iconic brands, such as Lipitor® (atorvastatin calcium), Celebrex® (celecoxib) and Viagra® (sildenafil), and proven commercialization capabilities, including leadership positions in China and other emerging markets.

The Company recorded a step-up in the fair value of inventory of approximately $1.43 billion at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company recorded amortization of the inventory step-up of approximately $1.19 billion and $238.2 million, respectively, which is included in cost of sales in the consolidated statements of operations. The inventory step-up was fully amortized during 2021. In addition, a step-up in the fair value of property, plant and equipment of approximately $385.0 million was recognized. The related depreciation is being expensed over a service life of five years for machinery and equipment and between 10 and 20 years for buildings.

The identified intangible assets of $18.04 billion are comprised of product rights and are being amortized over a weighted average useful life of 15 years. Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. The goodwill of $2.40 billion arising from the Combination consisted largely of the value of the employee workforce and products to be sold in new markets leveraging the combined entity. In addition, an allocation of the goodwill was assigned to the respective segments. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes.

The Company recorded a fair value adjustment of approximately $759.4 million related to the long-term debt assumed as part of the acquisition. The fair value of long-term debt as of the Combination date was determined by broker or dealer quotations, which is classified as Level 2 in the fair value hierarchy. The total fair value adjustment is being amortized as a reduction to interest expense over the maturity dates of the related debt instruments.
98


The operating results of the Upjohn Business have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of the Upjohn Business for the period from the acquisition date to December 31, 2020, were $866.5 million and net loss, net of tax, was approximately $360.9 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs.

Unaudited Pro Forma Financial Results

The following table presents supplemental unaudited pro forma information for the Combination, as if it had occurred on January 1, 2019. The unaudited pro forma results reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased depreciation and amortization expense based on the fair value of assets acquired, the impact of transaction costs and the related income tax effects. The unaudited pro forma results do not include any anticipated synergies which may be achievable, or have been achieved, subsequent to the closing of the Combination. Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.
Year Ended December 31,
(Unaudited, in millions, except per share amounts) 20202019
Total revenues$18,284.8 $21,582.7 
Net earnings$1,483.7 $1,873.5 
Earnings per share:
Basic$1.23 $1.55 
Diluted$1.23 $1.55 
Weighted average shares outstanding:
Basic1,206.8 1,205.6 
Diluted1,207.7 1,206.4 

Other Transactions
In December 2020, Viatris and Pfizer terminated their strategic collaboration for generic drugs in Japan pursuant to an amendment and termination agreement. Under the prior collaboration agreement, both parties contributed products, which Pfizer distributed to third-parties in the Japan market. Under the terms of the amendment and termination agreement, Viatris purchased all collaboration related inventory held by Pfizer. As a result of the termination, and the repurchase of collaboration inventory, the Company reduced revenue by $86.5 million during the year ended December 31, 2020.
In September 2020, the Company entered into an agreement to acquire the related intellectual property and commercialization rights of Aspen’s thrombosis product portfolio in Europe for €641.9 million. The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra®, Fraxiparine®, Mono-Embolex® and Orgaran®. Upon closing of the transaction in November 2020, the Company made a payment of €263.2 million to Aspen and the remaining payment of €378.7 million was made on June 25, 2021. The Company accounted for this transaction as an asset acquisition and recognized an intangible asset of €641.9 million for the product rights, which is being amortized over a useful life of 8 years.
5. Balance Sheet Components
Selected balance sheet components consist of the following:
Cash and restricted cash
(In millions)December 31,
2021
December 31,
2020
December 31,
2019
Cash and cash equivalents$701.2 $844.4 $475.6 
Restricted cash, included in other current and non-current assets5.0 5.6 15.5 
Cash, cash equivalents and restricted cash$706.2 $850.0 $491.1 
99

Inventories
(In millions)December 31, 2021December 31, 2020
Raw materials$922.4 $958.4 
Work in process993.3 1,438.1 
Finished goods2,062.0 3,075.4 
Inventories$3,977.7 $5,471.9 
Inventory reserves totaled $519.0 million and $353.6 million at December 31, 2021 and 2020, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $474.9 million, $206.1 million and $399.2 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Prepaid expenses and other current assets
(In millions)December 31, 2021December 31, 2020
Prepaid expenses$256.7 $267.8 
Available-for-sale fixed income securities38.2 39.1 
Fair value of financial instruments144.6 118.6 
Equity securities51.0 45.8 
Other current assets1,467.1 1,236.1 
Prepaid expenses and other current assets$1,957.6 $1,707.4 
Prepaid expenses consist primarily of prepaid rent, insurance and other individually insignificant items.
Property, plant and equipment, net
(In millions)December 31, 2021December 31, 2020
Machinery and equipment$3,054.0 $3,235.0 
Buildings and improvements1,808.5 1,954.8 
Construction in progress588.7 376.3 
Land and improvements137.9 155.8 
Gross property, plant and equipment5,589.1 5,721.9 
Accumulated depreciation2,400.5 2,262.0 
Property, plant and equipment, net$3,188.6 $3,459.9 
Capitalized software costs included in our consolidated balance sheets were $62.3 million and $70.9 million, net of accumulated depreciation, at December 31, 2021 and 2020, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $509.5 million, $289.7 million and $256.1 million for the years ended December 31, 2021, 2020 and 2019, respectively.
Other assets
(In millions)December 31, 2021December 31, 2020
Equity method investments, clean energy investments$ $47.9 
Operating lease right-of-use assets290.8 323.6 
Other long-term assets879.9 676.0 
Other assets$1,170.7 $1,047.5 
100

Accounts payable
(In millions)December 31, 2021December 31, 2020
Trade accounts payable$1,056.1 $1,345.7 
Other payables601.3 558.5 
Accounts payable$1,657.4 $1,904.2 
Other current liabilities
(In millions)December 31, 2021December 31, 2020
Accrued sales allowances$1,362.1 $1,211.8 
Payroll and employee benefit liabilities 741.9 828.2 
Legal and professional accruals, including litigation accruals715.6 362.9 
Contingent consideration66.7 100.5 
Accrued restructuring233.5 149.2 
Equity method investments, clean energy investments10.9 47.5 
Accrued interest86.6 90.9 
Fair value of financial instruments61.0 103.6 
Operating lease liability86.7 92.9 
Other1,254.6 1,973.2 
Other current liabilities$4,619.6 $4,960.7 
Other long-term obligations
(In millions)December 31, 2021December 31, 2020
Employee benefit liabilities$876.4 $1,020.4 
Contingent consideration133.0 123.1 
Tax related items, including contingencies426.1 469.5 
Operating lease liability200.9 229.5 
Accrued restructuring64.3 134.8 
Other232.9 505.8 
Other long-term obligations$1,933.6 $2,483.1 
6.Leases
The Company has operating leases of real estate, consisting primarily of administrative offices, manufacturing and distribution facilities, and R&D facilities. We also have operating leases of certain equipment, primarily automobiles, and certain limited supply arrangements.
We elected to apply the practical expedient to not separate lease and non-lease components for our leases except for those related to certain limited supply arrangements. We have also elected to apply the short-term lease recognition exemption which means we will not recognize ROU assets or lease liabilities for leases with an initial term of 12 months of less.
As of December 31, 2021, the Company recognized ROU assets of $290.8 million and total lease liabilities of $287.6 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance sheets. Refer to Note 5 Balance Sheet Components for additional information.
101

ROU assets and liabilities are recognized at the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use an applicable incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Options to extend or terminate the ROU assets are reviewed at lease inception and these options are accounted for when they are reasonably certain of being exercised.
Other information related to leases was as follows:
As of December 31, 2021
Remaining lease terms
1 year to 23 years
Weighted-average remaining lease term6 years
Weighted-average discount rate2.6 %
As of December 31, 2021, maturities of lease liabilities were as follows:
(In millions)
Year ending December 31,
2022$82.0 
202365.0 
202442.9 
202528.8 
202623.9 
Thereafter68.2 
Total lease payments$310.8 
Less imputed interest23.2 
Total lease liability$287.6 
As of December 31, 2021, we have additional operating leases, primarily for administrative offices, that have not yet commenced totaling approximately $13.6 million. These leases are expected to commence in 2022 and have lease terms of 5 to 9 years. For the years ended December 31, 2021, 2020 and 2019, the Company had operating lease expense of approximately $97.6 million, $80.7 million and $87.6 million, respectively. Operating lease costs are classified primarily as selling, general and administrative expenses and cost of sales in the consolidated statements of operations.
7.Equity Method Investments
The Company had three equity method investments in limited liability companies that owned refined coal production plants whose activities qualified for income tax credits under Section 45 of the Code. The Company did not consolidate these entities as we had determined that we were not the primary beneficiary of these entities and did not have the power to individually direct the activities of these entities. Accordingly, these investments were accounted for under the equity method of accounting. For each of the clean energy investments, the Company had entered into notes payable with the respective project sponsor, which in part were paid to the sponsor as certain production levels were met. The law that provides for IRC Section 45 tax credits expired during the year ended December 31, 2021 for all three clean energy investments and all of the clean energy investments have wound down operations.
During the years ended December 31, 2021, 2020, and 2019, the Company reduced its long-term obligations for its three investments as a result of lower than anticipated production levels and lower expected future variable debt payments to the respective project sponsor. The Company recognized a net gain of approximately $5.7 million, $21.4 million and $7.0 million, respectively, which was recognized as a component of the net loss of the equity method investments in the consolidated statements of operations.
102

The carrying values and respective balance sheet locations of the Company’s clean energy investments were as follows at December 31, 2021 and 2020, respectively:
(In millions)December 31, 2021December 31, 2020
Other assets$ $47.9 
Other current liabilities10.9 47.5 
Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis as of December 31, 2021 and 2020 and for the years ended December 31, 2021, 2020 and 2019 are as follows:
(In millions)December 31, 2021December 31, 2020
Current assets$4.2 $38.9 
Noncurrent assets0.5 1.0 
Total assets4.7 39.9 
Current liabilities2.8 33.0 
Noncurrent liabilities 1.8 
Total liabilities2.8 34.8 
Net assets$1.9 $5.1 
Year Ended December 31,
(In millions)202120202019
Total revenues$326.7 $374.5 $385.0 
Gross loss(4.6)(4.6)(4.4)
Operating and non-operating expense16.8 19.0 20.0 
Net loss$(21.4)$(23.6)$(24.4)
The Company’s net losses from its equity method investments include amortization expense related to the excess of the cost basis of the Company’s investment over the underlying assets of each individual investee. For the years ended December 31, 2021, 2020 and 2019, the Company recognized net losses from equity method investments of $61.9 million, $48.4 million, and $62.1 million, respectively, which were recognized as a component of other expense, net in the consolidated statements of operations. The Company recognizes the income tax credits and benefits from the clean energy investments as part of its provision for income taxes.
103

8.Goodwill and Other Intangible Assets
The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:
(In millions)Developed MarketsGreater ChinaJANZEmerging MarketsTotal
Balance at December 31, 2019:
Goodwill$8,258.0 $67.8 $584.8 $1,065.0 $9,975.6 
Accumulated impairment losses(385.0)   (385.0)
7,873.0 67.8 584.8 1,065.0 9,590.6 
Acquisitions704.3 652.8 217.4 533.0 2,107.5 
Foreign currency translation607.2 17.7 61.8 (37.8)648.9 
9,184.5 738.3 864.0 1,560.2 12,347.0 
Balance at December 31, 2020:
Goodwill9,569.5 738.3 864.0 1,560.2 12,732.0 
Accumulated impairment losses(385.0)   (385.0)
9,184.5 738.3 864.0 1,560.2 12,347.0 
Measurement period and other adjustments67.7 220.4 (30.9)38.4 295.6 
Foreign currency translation(528.8)10.8 (56.8)45.9 (528.9)
8,723.4 969.5 776.3 1,644.5 12,113.7 
Balance at December 31, 2021
Goodwill9,108.4 969.5 776.3 1,644.5 12,498.7 
Accumulated impairment losses(385.0)   (385.0)
$8,723.4 $969.5 $776.3 $1,644.5 $12,113.7 

Intangible assets consist of the following components at December 31, 2021 and 2020:
(In millions)Weighted Average Life (Years)CostAccumulated AmortizationNet Book Value
December 31, 2021
Product rights, licenses and other (1)
15$39,006.2 $12,918.5 $26,087.7 
In-process research and development46.5 — 46.5 
$39,052.7 $12,918.5 $26,134.2 
December 31, 2020
Product rights, licenses and other (1)
15$40,404.1 $10,801.6 $29,602.5 
In-process research and development80.7 — 80.7 
$40,484.8 $10,801.6 $29,683.2 
____________
(1)Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights.
104

Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by product category, is as follows:
(In millions)Developed MarketsGreater ChinaJANZEmerging MarketsDecember 31, 2021
Brands$10,066.6 $6,102.9 $1,174.8 $3,801.7 $21,146.0 
Complex Gx and Biosimilars226.8  1.5  228.3 
Generics4,020.2 12.1 319.5 358.4 4,710.2 
Total Product Rights and Licenses$14,313.6 $6,115.0 $1,495.8 $4,160.1 $26,084.5 
(In millions)Developed MarketsGreater ChinaJANZEmerging MarketsDecember 31, 2020
Brands$10,988.1 $4,372.3 $2,377.0 $4,478.7 $22,216.1 
Complex Gx and Biosimilars272.5  2.3  274.8 
Generics6,253.9 12.7 423.9 417.3 7,107.8 
Total Product Rights and Licenses$17,514.5 $4,385.0 $2,803.2 $4,896.0 $29,598.7 
____________
2021 amounts include the finalization of the allocation of the intangible assets relating to the Combination.
Amortization expense and intangible asset impairment charges, which are included as a component of amortization expense, which is classified primarily within cost of sales in the consolidated statements of operations, for the years ended December 31, 2021, 2020 and 2019 was as follows:
Year ended December 31,
(In millions)202120202019
Intangible asset amortization expense$2,702.2 $1,605.8 $1,582.7 
IPR&D intangible asset impairment charges19.4 37.4 138.3 
Finite-lived intangible asset impairment charges83.4 45.0 42.3 
Total intangible asset amortization expense (including impairment charges)$2,805.0 $1,688.2 $1,763.3 
The assessment for impairment of finite-lived intangibles is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.
Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. The fair value of finite-lived intangible assets was calculated as the present value of the estimated future net cash flows using a market rate of return. The assumptions inherent in the estimated future cash flows include, among other things, the impact of the current competitive environment and future market expectations. Discount rates ranging between 9.0% and 11.0% were utilized in the valuations performed during the years ended December 31, 2021, 2020 and 2019. Any future long-lived assets impairment charges could have a material impact in the Company’s consolidated financial condition and results of operations.
On April 30, 2021, the Company completed an agreement to divest a group of OTC products in the U.S. As a result of this transaction, the Company recognized an intangible asset impairment charge of approximately $83.4 million during the year ended December 31, 2021.
The Company’s IPR&D assets are tested at least annually for impairment or upon the occurrence of a triggering event. Impairment is determined to exist when the fair value of IPR&D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested. The fair value of IPR&D was calculated as the present value of the estimated future net cash flows using a market rate of return. The assumptions inherent in the estimated future cash flows include, among other things, the impact of changes to the development programs, the projected development and regulatory time frames and the current competitive environment. Discount rates ranging between 7.0% and 9.0%, 9.0% and 11.0%, and 9.0% and 11.0% were utilized in the valuations performed during the years ended December 31, 2021, 2020 and 2019, respectively.
105

The fair value of both IPR&D and finite-lived intangible assets was determined based upon detailed valuations employing the income approach which utilized Level 3 inputs, as defined in Note 9, Financial Instruments and Risk Management. Changes to any of the Company’s assumptions including changes to or abandonment of development programs, regulatory timelines, discount rates or the competitive environment related to the assets could lead to future material impairment charges.
The Company performed its annual goodwill impairment test as of April 1, 2021 on a quantitative basis for its five reporting units, North America, Europe, Emerging Markets, JANZ, and Greater China. See Note 15, Segment Information, for further discussion. Additionally, the net assets acquired as part of the Combination were included in the respective reporting units and in the annual impairment test for the first time. In estimating each reporting unit’s fair value, the Company performed an extensive valuation analysis, utilizing both income and market-based approaches. The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions that affect the reporting unit’s expected future cash flows. These estimates and assumptions, utilizing Level 3 inputs, primarily include, but are not limited to, market multiples, control premiums, the discount rate, terminal growth rates, operating income before depreciation and amortization, and capital expenditures forecasts.
As of April 1, 2021, the allocation of the Company’s total goodwill was as follows: North America $3.66 billion, Europe $5.15 billion, Emerging Markets $1.58 billion, JANZ $0.82 billion and Greater China $0.70 billion.
As of April 1, 2021, the Company determined that the fair value of the North America, Emerging Markets and Greater China reporting units was substantially in excess of the respective unit’s carrying value.
For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $0.91 billion or 5.8% for the annual goodwill impairment test. As it relates to the income approach for the Europe reporting unit at April 1, 2021, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately 3.0%. A terminal year value was calculated with a 0.9% revenue growth rate applied. The discount rate utilized was 10.5% and the estimated tax rate was 19.0%. Under the market-based approach, we utilized an estimated range of market multiples of 7.5 to 8.5 times EBITDA plus a control premium of 15.0%. If all other assumptions are held constant, a reduction in the terminal value growth rate by 2.9% or an increase in discount rate by 1.5% would result in an impairment charge for the Europe reporting unit.

For the JANZ reporting unit, the estimated fair value exceeded its carrying value by approximately $0.23 billion or 7.0% for the annual goodwill impairment test. As it relates to the income approach for the JANZ reporting unit at April 1, 2021, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately negative 1.5%. A terminal year value was calculated with a 0.7% revenue growth rate applied. The discount rate utilized was 8.5% and the estimated tax rate was 30.5%. Under the market-based approach, we utilized an estimated market multiple of 6.0 times EBITDA plus a control premium of 15.0%. If all other assumptions are held constant, a reduction in the terminal value growth rate by 4.2% or an increase in discount rate by 2.0% would result in an impairment charge for the JANZ reporting unit.
Due to the inherent uncertainty involved in making these estimates, actual results could differ from those estimates. In addition, changes in underlying assumptions, especially as they relate to the key assumptions detailed, could have a significant impact on the fair value of the reporting units.
Intangible asset amortization expense for the years ending December 31, 2022 through 2026 is estimated to be as follows:
(In millions)
2022$2,577 
20232,414 
20242,320 
20252,222 
20262,164 
9.Financial Instruments and Risk Management
The Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk.
106

Foreign Currency Risk Management
In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the consolidated statements of operations.
The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries and a portion of forecasted intercompany inventory sales denominated in Euro, Japanese Yen and Chinese Renminbi for up to eighteen months. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any changes in the fair value of designated cash flow hedges are deferred in AOCE and are reclassified into earnings when the hedged item impacts earnings.
Net Investment Hedges
The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments.
The Company has designated certain Euro and Yen borrowings as a hedge of its investment in certain Euro-functional and Yen-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro and Yen borrowings not designated as net investment hedges through certain Euro and Yen denominated financial assets and forward currency swaps.
The following table summarizes the principal amounts of the Company’s outstanding Euro and Yen borrowings and the notional amounts of the Euro and Yen borrowings designated as net investment hedges:
Notional Amount Designated as a Net Investment Hedge
(in millions)Principal AmountDecember 31,
2021
December 31,
2020
Euro
2.250% Euro Senior Notes due 2024
1,000.0 1,000.0 1,000.0 
3.125% Euro Senior Notes due 2028
750.0 750.0 750.0 
2.125% Euro Senior Notes due 2025
500.0 500.0 500.0 
0.816% Euro Senior Notes due 2022
750.0 750.0 750.0 
1.023% Euro Senior Notes due 2024
750.0 750.0 750.0 
1.362% Euro Senior Notes due 2027
850.0 850.0 850.0 
1.908% Euro Senior Notes due 2032
1,250.0 1,250.0 1,250.0 
Foreign currency forward contracts105.6  105.6 
Euro Total5,955.6 5,850.0 5,955.6 
Yen
YEN Term Loan¥40,000.0 ¥40,000.0 ¥ 
Yen Total¥40,000.0 ¥40,000.0 ¥ 
At December 31,2021, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedge was $347.6 million.
107

Interest Rate Risk Management
The Company enters into interest rate swaps from time to time in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings.
Cash Flow Hedging Relationships
The Company’s interest rate swaps designated as cash flow hedges fix the interest rate on a portion of the Company’s variable-rate debt or hedge part of the Company’s interest rate exposure associated with the variability in the future cash flows attributable to changes in interest rates. Any changes in fair value are included in earnings or deferred through AOCE, depending on the nature and effectiveness of the offset. Any ineffectiveness in a cash flow hedging relationship is recognized immediately in earnings in the consolidated statements of operations.
Fair Value Hedging Relationships
The Company's interest rate swaps designated as fair value hedges convert the fixed rate on a portion of the Company's fixed-rate senior notes to a variable rate. Any changes in the fair value of these derivative instruments, as well as the offsetting change in fair value of the portion of the fixed-rate debt being hedged, is included in interest expense. The Company’s fair value hedge was terminated during 2020.
Credit Risk Management
The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the consolidated balance sheets. Accordingly, there are no offsetting amounts that net assets against liabilities.
The following table summarizes the classification and fair values of derivative instruments in our consolidated balance sheets:
Asset Derivatives Liability Derivatives
(In millions)Balance Sheet LocationDecember 31, 2021 Fair ValueDecember 31, 2020 Fair ValueBalance Sheet LocationDecember 31, 2021 Fair ValueDecember 31, 2020 Fair Value
Derivatives designated as hedges:
Foreign currency forward contractsPrepaid expenses & other current assets$62.0 $28.3 Other current liabilities$4.3 $0.8 
Total derivatives designated as hedges62.0 28.3 4.3 0.8 
Derivatives not designated as hedges:
Foreign currency forward contractsPrepaid expenses & other current assets82.6 90.3Other current liabilities56.7 102.8
Total derivatives not designated as hedges82.6 90.356.7 102.8
Total derivatives $144.6 $118.6 $61.0 $103.6 
108


The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:

Amount of Gains/(Losses) Recognized in EarningsAmount of Gain Excluded from the Assessment of Hedge Effectiveness
Year Ended December 31,Year Ended December 31,
(In millions)Location of Gain/(Loss)202120202019202120202019
Derivative Financial Instruments in Fair Value Hedge Relationships (1) :
Interest rate swaps
Interest expense (3)
$ $22.1 $18.7 $— $— $— 
2023 Senior Notes (3.125% coupon)
Interest expense (3)
 (22.1)(18.7)— — — 
Derivative Financial Instruments in Cash Flow Hedging Relationships :
Foreign currency forward contracts
Other expense, net (5)
— — —  7.1  
Derivative Financial Instruments Not Designated as Hedging Instruments:
Foreign currency option and forward contracts
Other expense, net (3)
39.3 (10.1)(17.3)— — — 
Total$39.3 $(10.1)$(17.3)$ $7.1 $ 
Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on DerivativesAmount of Gains/(Losses) Reclassified from AOCE into Earnings
Year Ended December 31,Year Ended December 31,
(In millions)Location of Gain/(Loss)202120202019202120202019
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :
Foreign currency forward contracts
Net sales (4)
$45.8 $20.6 $16.6 $30.9 $4.8 $(0.7)
Interest rate swaps
Interest expense (4)
(3.4) 3.0 (4.3)(4.5)(7.1)
Derivative Financial Instruments in Net Investment Hedging Relationships:
Foreign currency borrowings and forward contracts436.6 (346.4)56.7 — — — 
Total$479.0 $(325.8)$76.3 $26.6 $0.3 $(7.8)
____________
(1)In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The amount included in the above tables represents the fair value adjustment recognized at the date the interest rate swaps were settled.
(2)At December 31, 2021, the Company expects that approximately $21.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months.
(3)Represents the location of the gain/(loss) recognized in earnings on derivatives.
(4)Represents the location of the gain/(loss) reclassified from AOCE into earnings.
(5)Represents the location of the gain excluded from the assessment of hedge effectiveness.
Fair Value Measurement
Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
Level 1:        Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2:        Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.
109

Level 3:        Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.

Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:
December 31, 2021
(In millions)Level 1Level 2Level 3Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds$50.9 $— $— $50.9 
Total cash equivalents50.9 — — 50.9 
Equity securities:
Exchange traded funds50.3 — — 50.3 
Marketable securities0.7 — — 0.7 
Total equity securities51.0 — — 51.0 
Available-for-sale fixed income investments:
Corporate bonds— 16.6 — 16.6 
U.S. Treasuries— 14.6 — 14.6 
Agency mortgage-backed securities— 2.0 — 2.0 
Asset backed securities— 4.6 — 4.6 
Other— 0.4 — 0.4 
Total available-for-sale fixed income investments— 38.2 — 38.2 
Foreign exchange derivative assets— 144.6 — 144.6 
Total assets at recurring fair value measurement$101.9 $182.8 $— $284.7 
Financial Liabilities
Foreign exchange derivative liabilities$— $61.0 $— $61.0 
Contingent consideration— — 199.7 199.7 
Total liabilities at recurring fair value measurement$— $61.0 $199.7 $260.7 
110

December 31, 2020
(In millions)Level 1Level 2Level 3Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds$0.9 $— $— $0.9 
Total cash equivalents0.9 — — 0.9 
Equity securities:
Exchange traded funds45.1 — — 45.1 
Marketable securities0.7 — — 0.7 
Total equity securities45.8 — — 45.8 
Available-for-sale fixed income investments:
Corporate bonds— 17.8 — 17.8 
U.S. Treasuries— 14.4 — 14.4 
Agency mortgage-backed securities— 1.9 — 1.9 
Asset backed securities— 4.6 — 4.6 
Other— 0.4 — 0.4 
Total available-for-sale fixed income investments— 39.1 — 39.1 
Foreign exchange derivative assets— 118.6 — 118.6 
Total assets at recurring fair value measurement$46.7 $157.7 $— $204.4 
Financial Liabilities
Foreign exchange derivative liabilities$— $103.6 $— $103.6 
Contingent consideration— — 223.6 223.6 
Total liabilities at recurring fair value measurement$— $103.6 $223.6 $327.2 
For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including the LIBOR yield curve, foreign exchange forward prices, and bank price quotes. For the years ended December 31, 2021 and 2020, there were no transfers between Level 1 and 2 of the fair value hierarchy. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities:
Cash equivalents — valued at observable net asset value prices.
Equity securities, exchange traded funds — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations.
Equity securities, marketable securities valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations.
Available-for-sale fixed income investments — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity.
Interest rate swap derivative assets and liabilities — valued using the LIBOR/EURIBOR yield curves at the reporting date. Counterparties to these contracts are highly rated financial institutions.
Foreign exchange derivative assets and liabilities — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions.
111

Contingent Consideration
In December 2011, the Company completed the acquisition of the exclusive worldwide rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline’s Advair® Diskus incorporating Pfizer’s respiratory delivery platform. The Company accounted for this transaction as a purchase of a business and utilized the acquisition method of accounting. On January 30, 2019, the Company received FDA approval of Wixela® Inhub® (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of GlaxoSmithKline’s Advair Diskus®. The commercial launch of the Wixela® Inhub® occurred in February 2019.
As of December 31, 2021, the Company has a contingent consideration liability of $177.8 million related to the respiratory delivery platform. The fair value measurement of contingent consideration is determined using Level 3 inputs. The Company’s contingent consideration represents a component of the total purchase consideration for Pfizer’s respiratory delivery platform and certain other acquisitions. The measurement is calculated using unobservable inputs based on the Company’s own assumptions primarily related to the probability and timing of future development and commercial milestones and future profit-sharing payments which are discounted using a market rate of return. At December 31, 2021 and 2020, discount rates ranging from 8.0% to 10.5% were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liability.
A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to December 31, 2021 is as follows:
(In millions)
Current Portion (1)
Long-Term Portion (2)
Total Contingent Consideration
Balance at December 31, 2019$120.4 $130.3 $250.7 
Payments(111.8) (111.8)
Reclassifications58.1 (58.1) 
Accretion 11.6 11.6 
Fair value loss (3)
33.8 39.3 73.1 
Balance at December 31, 2020$100.5 $123.1 $223.6 
Payments(83.2) (83.2)
Reclassifications49.4 (49.4) 
Accretion 9.0 9.0 
Fair value loss (3)
 50.3 50.3 
Balance at December 31, 2021$66.7 $133.0 $199.7 
____________
(1)Included in other current liabilities in the consolidated balance sheets.
(2)Included in other long-term obligations in the consolidated balance sheets.
(3)Included in litigation settlements and other contingencies, net in the consolidated statements of operations.
The Company expects to incur approximately $6 million to $8 million of non-cash accretion expense related to the increase in the net present value of the contingent consideration liabilities in 2022.
Although the Company has not elected the fair value option for financial assets and liabilities, any future transacted financial asset or liability will be evaluated for the fair value election.
112

Available-for-Sale Securities
The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows:
(In millions)CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
December 31, 2021
Debt securities$38.1 $0.1 $ $38.2 
$38.1 $0.1 $ $38.2 
December 31, 2020
Debt securities$37.5 $1.6 $ $39.1 
$37.5 $1.6 $ $39.1 
Maturities of available-for-sale debt securities at fair value as of December 31, 2021, were as follows:
(In millions) 
Mature within one year$1.2 
Mature in one to five years19.7 
Mature in five years and later17.3 
$38.2 
10.Debt
Short-Term Borrowings
The Company had $1.49 billion and $1.10 billion of borrowings as of December 31, 2021 and 2020, respectively.
(In millions)December 31, 2021December 31, 2020
Commercial paper notes$1,173.4 $651.3 
Receivables Facility318.5 248.4 
Note Securitization Facility 200.0 
Other1.1 1.2 
Short-term borrowings$1,493.0 $1,100.9 
The following provides an overview of the Company’s short-term credit facilities.
Commercial Paper Program
On November 16, 2020, the Company established the Commercial Paper Program to support its working capital requirements and for general purposes. There was $1.17 billion and $651.3 million of CP Notes outstanding under this program as of December 31, 2021 and 2020, respectively. Amounts available under the Commercial Paper Program may be borrowed, repaid and re-borrowed from time to time, with the aggregate principal amount of CP Notes outstanding at any time not to exceed $1.65 billion. The 2021 Revolving Facility will be available to pay the CP Notes, if necessary. The maturities of the CP Notes will vary but will not exceed 364 days from the date of issue.
Receivables Facility and Note Securitization Facility
The Company has a $400 million Receivables Facility which expires in April 2022. Under the terms of the Receivables Facility, our subsidiary, MPI, sells certain accounts receivable to Mylan Securitization, a wholly-owned special purpose entity which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. Mylan Securitization’s assets have been pledged to MUFG Bank, Ltd., as agent, in support of its obligations under the Receivables Facility. Any amounts outstanding under the facility are recorded as borrowings and the underlying receivables are included in accounts receivable, net, in the consolidated balance sheets.
113

In August 2020, the Company entered into the Note Securitization Facility for borrowings up to $200 million. In July 2021, the Note Securitization Facility was amended to extend its maturity to August 2022. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. The amount that we may borrow at a given point in time is determined based on the amount of qualifying accounts receivable that are present at such point in time.
Borrowings outstanding under the Receivables Facility bear interest at a commercial paper rate plus 0.925% and under the Note Securitization Facility at a rate per annum quoted from time to time by MUFG Bank, Ltd. plus 0.85% and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In addition, the agreements governing the Receivables Facility and Note Securitization Facility contain various customary affirmative and negative covenants, and customary default and termination provisions with which the Company was compliant as of December 31, 2021. As of December 31, 2021 and 2020, the Company had $388.9 million and $389.4 million, respectively, of accounts receivable balances sold to Mylan Securitization.
114

Long-Term Debt
A summary of long-term debt is as follows:
($ in millions)Interest Rate as of December 31, 2021December 31,
2021
December 31,
2020
Current portion of long-term debt:
2021 Senior Notes (a) **
3.150 % 2,249.7 
2022 Euro Senior Notes ****
0.816 %856.6  
2022 Senior Notes ***
1.125 %1,002.9  
Other0.9 8.0 
Deferred financing fees(0.1)(1.4)
Current portion of long-term debt$1,860.3 $2,256.3 
Non-current portion of long-term debt:
2022 Euro Senior Notes ****
0.816 % 928.8 
2022 Senior Notes ***
1.125 % 1,008.8 
2023 Senior Notes (b) *
3.125 %766.1 781.6 
2023 Senior Notes *
4.200 %499.6 499.3 
2024 Euro Senior Notes **
2.250 %1,135.8 1,219.9 
2024 Euro Senior Notes ****
1.023 %871.6 944.6 
2025 Euro Senior Notes *
2.125 %567.8 609.9 
2025 Senior Notes ***
1.650 %763.4 767.1 
2026 Senior Notes **
3.950 %2,241.4 2,239.7 
2027 Euro Senior Notes ****
1.362 %1,013.0 1,097.4 
2027 Senior Notes ***
2.300 %780.8 786.1 
2028 Euro Senior Notes **
3.125 %847.4 909.7 
2028 Senior Notes *
4.550 %748.7 748.6 
2030 Senior Notes ***
2.700 %1,520.5 1,528.0 
2032 Euro Senior Notes ****
1.908 %1,546.6 1,672.6 
2040 Senior Notes ***
3.850 %1,657.1 1,663.3 
2043 Senior Notes *
5.400 %497.3 497.3 
2046 Senior Notes **
5.250 %999.9 999.9 
2048 Senior Notes *
5.200 %747.8 747.7 
2050 Senior Notes ***
4.000 %2,205.1 2,209.3 
USD Term Loan Facility 600.0 
YEN Term Loan Facility347.6 — 
Other1.9 17.4 
Deferred financing fees(42.3)(47.8)
Long-term debt$19,717.1 $22,429.2 
____________    
(a)The 2021 Senior Notes were repaid at maturity in the second quarter of 2021.
(b)In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The fair value adjustment is being amortized to interest expense over the remaining term of the notes.
*     Instrument was issued by Mylan Inc.
**     Instrument was originally issued by Mylan N.V.; now held by Utah Acquisition Sub Inc.
***     Instrument was issued by Viatris Inc.
115

****     Instrument was issued by Upjohn Finance B.V.
Senior Notes
Upjohn Senior Notes
In connection with the Combination, in June 2020, Viatris and Upjohn Finance B.V. completed privately placed debt offerings of $7.45 billion aggregate principal amount of the Unregistered Upjohn U.S. Dollar Notes and €3.60 billion aggregate principal amount of the Upjohn Euro Notes, respectively, and entered into other financing arrangements described below under “USD Term Loan Facility, 2020 Revolving Facility, YEN Term Loan Facility and 2021 Revolving Facility”.
The Unregistered Upjohn U.S. Dollar Notes were issued pursuant to an indenture dated June 22, 2020. The Unregistered Upjohn U.S. Dollar Notes were issued in a private offering exempt from the registration requirements of the Securities Act to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to persons outside of the U.S. pursuant to Regulation S under the Securities Act. Viatris entered into a registration rights agreement, dated as of June 22, 2020 pursuant to which Viatris was required to use commercially reasonable efforts to file a registration statement with respect to an offer to exchange each series of the Unregistered Upjohn U.S. Dollar Notes for new notes with the same aggregate principal amount and terms substantially identical in all material respects. In September 2021, Viatris filed a registration statement with the SEC with respect to an offer to exchange up to $7.45 billion aggregate principal amount of Unregistered Upjohn U.S. Dollar Notes with Registered Upjohn Notes in the same aggregate principal amount and with terms substantially identical in all material respects, which was declared effective on September 28, 2021. The exchange offer expired on October 28, 2021 and settled on October 29, 2021. More than 99.9% of the aggregate principal amount of the Unregistered Upjohn U.S. Dollar Notes were exchanged for Registered Upjohn Notes.
The Upjohn Euro Notes were issued pursuant to an indenture dated June 23, 2020. The Upjohn Euro Notes were guaranteed upon issuance by Viatris and were issued in a private offering exempt from the registration requirements of the Securities Act, to persons outside of the U.S. pursuant to Regulation S under the Securities Act. Viatris and Upjohn Finance B.V. are U.S. dollar functional entities.
The following table provides information about the Upjohn Senior Notes issued in June 2020:
(In millions)Notional Value
2022 Senior Notes$1,000.0 
2025 Senior Notes750.0 
2027 Senior Notes750.0 
2030 Senior Notes1,450.0 
2040 Senior Notes1,500.0 
2050 Senior Notes2,000.0 
2022 Euro Senior Note916.2 
2024 Euro Senior Note916.2 
2027 Euro Senior Note1,038.4 
2032 Euro Senior Note1,527.0 
Total$11,847.8 
The net proceeds from the offerings of the Upjohn Senior Notes, together with the proceeds from the $600 million USD Term Loan Facility, were utilized to fund the $12 billion cash payment by Viatris to Pfizer as partial consideration for Pfizer’s contribution of the Upjohn Business to Viatris and related transaction fees and expenses.
Assumptions and Guarantees of Senior Unsecured Notes
Viatris Inc. is the issuer of the Upjohn U.S. Dollar Notes, which are fully and unconditionally guaranteed on a senior unsecured basis by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.
Upjohn Finance B.V. is the issuer of the Upjohn Euro Notes, which are fully and unconditionally guaranteed on a senior unsecured basis by Viatris Inc., Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.

116

Following the Combination, Utah Acquisition Sub Inc. is the issuer of the Utah U.S. Dollar Notes and the Utah Euro Notes, which are each fully and unconditionally guaranteed on a senior unsecured basis by Mylan Inc., Viatris Inc. and Mylan II B.V.
Mylan Inc. is the issuer of the Mylan Inc. U.S. Dollar Notes and the Mylan Inc. Euro Notes, which are each fully and unconditionally guaranteed on a senior unsecured basis by Mylan II B.V., Viatris Inc. and Utah Acquisition Sub Inc.
USD Term Loan Facility, 2020 Revolving Facility, YEN Term Loan Facility and 2021 Revolving Facility
In June 2020, Viatris entered into (i) the $600 million USD Term Loan Facility and (ii) the $4.0 billion 2020 Revolving Facility with various syndicates of banks. The USD Term Loan Facility and the 2020 Revolving Facility were fully repaid and terminated in July 2021.
In July 2021, Viatris entered into (i) the ¥40 billion YEN Term Loan Facility and (ii) the $4.0 billion 2021 Revolving Facility with various syndicates of banks. The 2021 Revolving Facility amended and restated the 2020 Revolving Facility and proceeds from the 2021 Revolving Facility were used to repay outstanding obligations under the 2020 Revolving Facility and the 2020 Revolving Facility was terminated. Proceeds from the YEN Term Loan Facility and the 2021 Revolving Facility were also used to repay the USD Term Loan Facility in full and the USD Term Loan Facility was terminated. The 2021 Revolving Facility and the YEN Term Loan Facility have substantially identical terms to the 2020 Revolving Facility and USD Term Loan Facility, respectively, with the following exceptions: 1) the maturity of both the YEN Term Loan Facility and the 2021 Revolving Facility is July 2026, 2) the pricing was adjusted to reflect current market prices (which were generally more favorable) and 3) the maximum leverage ratio as of the end of any quarter was set at 4.25 to 1.00 for each quarter ending after June 30, 2021 through and including June 30, 2022, 4.0 to 1.00 for each quarter ending after June 30, 2022 through and including December 31, 2022 and 3.75 to 1.00 thereafter, except in circumstances as defined in the related credit agreement.
The YEN Term Loan Facility and the 2021 Revolving Facility contain customary affirmative covenants for facilities of this type, covenants pertaining to the delivery of financial statements, notices of default and certain material events, maintenance of corporate existence and rights, property, and insurance and compliance with laws, as well as customary negative covenants for facilities of this type, including limitations on the incurrence of subsidiary indebtedness, liens, mergers and certain other fundamental changes, investments and loans, acquisitions, transactions with affiliates, payments of dividends and other restricted payments and changes in our lines of business.
Fair Value
At December 31, 2021 and 2020, the aggregate fair value of the Company’s outstanding notes was approximately $22.01 billion and $25.90 billion, respectively. The fair values of the outstanding notes were valued at quoted market prices from broker or dealer quotations and were classified as Level 2 in the fair value hierarchy.
Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at December 31, 2021 were as follows for each of the periods ending December 31:
(In millions)Total
2022$1,853 
20231,250 
20241,990 
20251,318 
20262,598 
Thereafter11,940 
Total$20,949 
117

11.Comprehensive (Loss) Earnings
Accumulated other comprehensive loss, as reflected in the consolidated balance sheets, is comprised of the following:
(In millions)December 31, 2021December 31, 2020
Accumulated other comprehensive loss:
Net unrealized gain on marketable securities, net of tax$ $1.2 
Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax32.2 (26.1)
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax9.2 (18.0)
Net unrecognized loss on derivatives in net investment hedging relationships, net of tax16.7 (353.6)
Foreign currency translation adjustment(1,802.4)(461.5)
$(1,744.3)$(858.0)
Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following:
Year Ended December 31, 2021
Gains and Losses on Derivatives in Cash Flow Hedging RelationshipsGains and Losses on Net Investment HedgesGains and Losses on Marketable SecuritiesDefined Pension Plan ItemsForeign Currency Translation AdjustmentTotals
(In millions)Foreign Currency Forward ContractsInterest Rate SwapsTotal
Balance at December 31, 2020, net of tax$(18.0)$(353.6)$1.2 $(26.1)$(461.5)$(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax62.7 456.8 (1.1)67.0 (1,340.9)(755.5)
Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales(30.9)(30.9)(30.9)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense4.3 4.3 4.3 
Amortization of prior service costs included in SG&A (0.5)(0.5)
Amortization of actuarial loss included in SG&A 7.4 7.4 
Net other comprehensive earnings (loss), before tax36.1 456.8 (1.1)73.9 (1,340.9)(775.2)
Income tax provision8.9 86.5 0.1 15.6  111.1 
Balance at December 31, 2021, net of tax$9.2 $16.7 $ $32.2 $(1,802.4)$(1,744.3)
118

Year Ended December 31, 2020
Gains and Losses on Derivatives in Cash Flow Hedging RelationshipsGains and Losses on Net Investment HedgesGains and Losses on Marketable SecuritiesDefined Pension Plan ItemsForeign Currency Translation AdjustmentTotals
(In millions)Foreign Currency Forward ContractsInterest Rate SwapsTotal
Balance at December 31, 2019, net of tax$(31.6)$(74.3)$0.6 $(17.4)$(1,674.5)$(1,797.2)
Other comprehensive (loss) earnings before reclassifications, before tax18.5 (305.2)0.6 (12.1)1,213.0 914.8 
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales(4.8)(4.8)(4.8)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense4.5 4.5 4.5 
Amortization of prior service costs included in SG&A   
Amortization of actuarial loss included in SG&A (1.9)(1.9)
Net other comprehensive (loss) earnings, before tax18.2 (305.2)0.6 (14.0)1,213.0 912.6 
Income tax provision (benefit)4.6 (25.9) (5.3) (26.6)
Balance at December 31, 2020, net of tax$(18.0)$(353.6)$1.2 $(26.1)$(461.5)$(858.0)
119

Year Ended December 31, 2019
Gains and Losses on Derivatives in Cash Flow Hedging RelationshipsGains and Losses on Net Investment HedgesGains and Losses on Marketable SecuritiesDefined Pension Plan ItemsForeign Currency Translation AdjustmentTotals
(In millions)Foreign Currency Forward ContractsInterest Rate SwapsTotal
Balance at December 31, 2018, net of tax$(53.1)$(130.9)$ $1.7 $(1,259.0)$(1,441.3)
Other comprehensive earnings (loss) before reclassifications, before tax29.3 59.6 0.5 (21.0)(415.5)(347.1)
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales0.7 0.7 0.7 
Loss on interest rate swaps classified as cash flow hedges, included in interest expense7.1 7.1 7.1 
Amortization of prior service costs included in SG&A (0.9)(0.9)
Amortization of actuarial loss included in SG&A (2.9)(2.9)
Net other comprehensive earnings (loss), before tax37.1 59.6 0.5 (24.8)(415.5)(343.1)
Income tax provision (benefit) 12.2 3.0 (0.1)(5.9) 9.2 
Cumulative effect of the adoption of new accounting standards(3.4)— — (0.2)— (3.6)
Balance at December 31, 2019, net of tax$(31.6)$(74.3)$0.6 $(17.4)$(1,674.5)$(1,797.2)
120

12.Income Taxes
The income tax provision (benefit) consisted of the following components:
 Year Ended December 31,
(In millions)202120202019
U.S. Federal:
Current$12.6 $(6.4)$118.1 
Deferred(182.7)(277.0)(165.5)
(170.1)(283.4)(47.4)
U.S. State:
Current7.7 (0.1)21.1 
Deferred(10.8)7.7 (13.6)
(3.1)7.6 7.5 
Non-U.S.:
Current(91.3)168.7 191.0 
Deferred869.2 55.8 (13.5)
777.9 224.5 177.5 
Income tax provision (benefit)$604.7 $(51.3)$137.6 
Earnings before income taxes:
United States(1,982.5)(945.5)(1,031.4)
Foreign - Other1,318.1 224.3 1,185.8 
Total (loss) earnings before income taxes$(664.4)$(721.2)$154.4 
For all periods presented, the allocation of earnings before income taxes between U.S. and non-U.S. operations includes intercompany interest allocations between certain domestic and foreign subsidiaries. These amounts are eliminated on a consolidated basis.
121

Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows:
(In millions)December 31, 2021December 31, 2020
Deferred tax assets:
Employee benefits$271.3 $273.0 
Litigation reserves94.4 43.5 
Accounts receivable allowances425.9 393.7 
Inventory187.8 1,187.9 
Tax credit and loss carry-forwards1,256.0 1,080.4 
Operating lease assets63.6 66.5 
Interest expense111.6 67.9 
Intangible assets 151.1 156.3 
Other 327.8 396.0 
2,889.5 3,665.2 
Less: Valuation allowance(780.4)(443.6)
Total deferred tax assets2,109.1 3,221.6 
Deferred tax liabilities:
Plant and equipment19.6 50.2 
Operating lease liabilities63.6 66.5 
Intangible assets and goodwill3,468.3 4,058.6 
Other39.9 22.1 
Total deferred tax liabilities3,591.4 4,197.4 
Deferred tax liabilities, net$(1,482.3)$(975.8)
For those foreign subsidiaries whose investments are permanent in duration, income and foreign withholding taxes have not been provided on the unremitted earnings of those subsidiaries. This amount may become taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. The amount of such unremitted earnings is approximately $3.4 billion at December 31, 2021. Determination of the amount of any unrecognized deferred income tax liability on these unremitted earnings is not practicable as such determination involves material uncertainties about the potential extent and timing of any distributions, the availability and complexity of calculating foreign tax credits, and the potential indirect tax consequences of such distributions, including withholding taxes.
122

Prior to the Combination, the applicable income tax rate to Mylan was the U.K. rate of 19%, and following the Combination, the statutory income tax rate applicable to Viatris Inc. is the U.S. rate of 21% for the years ended December 31, 2021 and 2020. A reconciliation of the statutory tax rate to the effective tax rate is as follows:
 Year Ended December 31,
 202120202019
Statutory tax rate21.0 %21.0 %19.0 %
United States Operations
Clean energy and research credits9.8 %12.8 %(43.4)%
U.S. rate differentials % %(3.1)%
Impact of changes in legislation %(9.2)% %
State income taxes and credits(0.6)%(1.6)%(4.1)%
Valuation allowance(0.1)%8.6 %(118.5)%
Tax settlements and resolution of certain tax positions0.1 %0.1 %199.6 %
Incremental US Tax on Foreign Earnings(36.9)%(3.6)%(8.6)%
Waived deductions under IRC § 59A %(3.3)%64.5 %
Impact of the Combination and Divestitures(2.8)%5.8 %7.7 %
Other U.S. items(6.1)%1.5 %6.9 %
Other Foreign Operations
Luxembourg(6.7)%(5.0)%(14.8)%
Gibraltar9.4 %8.0 %(38.8)%
Ireland5.8 %8.2 %(13.7)%
France(1.1)%(2.8)%15.2 %
Puerto Rico4.4 %(2.5)% %
Switzerland1.0 %2.0 % %
Singapore28.8 %1.0 % %
Other(10.2)%(0.4)%12.8 %
Deferred tax impact of tax law changes7.0 %(0.1)%36.7 %
Valuation allowance(8.3)%16.1 %(9.9)%
Impact of the Combination and divestitures(106.9)%(42.2)% %
Withholding taxes(1.3)%(1.6)%7.1 %
Tax settlements and resolution of certain tax positions0.8 %(3.9)%(27.6)%
Other foreign items1.9 %(1.8)%2.1 %
Effective tax rate(91.0)%7.1 %89.1 %
123

In all years, our effective tax rate is impacted by the jurisdictional location of earnings and the corresponding tax rates in those jurisdictions. Subsequent to the Combination, the Company realizes benefits from lower tax rates in Singapore and Puerto Rico due to manufacturing and other incentives..
Tax Act
On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act makes broad and complex changes to the Code including, but not limited to, reducing the U.S. federal corporate income tax rate and requiring a one-time transition tax on certain unrepatriated earnings of non-U.S. corporate subsidiaries of large U.S. shareholders that may electively be paid over eight years.
The Tax Act also puts in place new tax laws that impact our taxable income beginning in 2018, which include, but are not limited to (1) creating a BEAT, which is a new minimum tax, (2) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries, (3) a new provision designed to tax currently GILTI earned by non-U.S. corporate subsidiaries of large U.S. shareholders and a deduction generally equal to 50 percent of GILTI (37.5 percent for tax years beginning after December 31, 2025) to offset the income tax liability, (4) a provision limiting the amount of deductible interest expense in the U.S., (5) limitations on the deductibility of certain executive compensation, and (6) limitations on the utilization of foreign tax credits to reduce the U.S. income tax liability.
As of December 31, 2021, no U.S. deferred income taxes or foreign withholding taxes were recorded on earnings in the Company’s non-U.S. subsidiaries where there would be no U.S. or foreign tax upon repatriation or where the Company’s practice and intention was to reinvest the earnings outside of the U.S. The transition tax noted above resulted in the previously untaxed foreign earnings of U.S. subsidiaries being included in federal and state taxable income. We analyze on an ongoing basis our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries repatriate cash, which include potential local country withholding taxes and U.S. state taxation. The Company has elected to not record deferred taxes associated with the GILTI provision of the Tax Act.
Valuation Allowance
A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2021, a valuation allowance has been applied to certain deferred tax assets in the amount of $780.4 million.
When assessing the realizability of deferred tax assets, management considers all available evidence, including historical information, long-term forecasts of future taxable income and possible tax planning strategies. Amounts recorded for valuation allowances can result from a complex series of estimates, assumptions and judgments about future events. Due to the inherent uncertainty involved in making these estimates, assumptions and judgments, actual results could differ materially. Any future increases to the Company’s valuation allowances could materially impact the Company’s consolidated financial condition and results of operations.
Net Operating Losses
As of December 31, 2021, the Company had the following carryforwards and attributes:
U.S. federal net operating loss carryforwards of $7.9 million.
U.S. state income tax loss carryforwards of approximately $3.10 billion, which are largely offset by a valuation allowance.
Non-U.S. net operating loss carryforwards of approximately $1.57 billion, of which $748.4 million can be carried forward indefinitely, with the remaining $817.8 million expiring in years 2022 through 2041.
Foreign deductible attributes of $39.6 million that can be carried forward indefinitely, which are offset by a full valuation allowance.
U.S. and foreign credit carryovers of $329.2 million, expiring in various amounts through 2041.
Anticipatory foreign tax credits of $230.3 million which will generate from the reversal of future taxable income in certain non-U.S. jurisdictions which are taxed both in their local jurisdictions and in the U.S.
124

On November 16, 2020, the Company had a change in ownership pursuant to Section 382 of the Code. Under this provision of the Code, the utilization of any NOL or tax credit carryforwards incurred prior to the date of ownership change may be limited. Analyses of the limits for each ownership change indicates the annual limitation would not impair the Company's ability to utilize our U.S. federal credit carryovers. While state loss carryforwards may be limited by Section 382 of the Code, the carryforwards are largely offset by a valuation allowance.
CARES Act
On March 27, 2020, the CARES Act was enacted and signed into law. The CARES Act includes several provisions, including increasing the amount of deductible interest, allowing companies to carryback certain NOLs, and increasing the amount of NOLs that corporations can use to offset income.During the year ended December 31, 2020, the CARES Act reduced the Company’s 2020 income tax expense by $22.1 million resulting from additional deductible interest.
Tax Examinations
The Company is subject to income taxes and tax audits in many jurisdictions. A certain degree of estimation is thus required in recording the assets and liabilities related to income taxes. Tax audits and examinations can involve complex issues, interpretations, and judgments and the resolution of matters that may span multiple years, particularly if subject to litigation or negotiation.
Although the Company believes that adequate provisions have been made for these uncertain tax positions, the Company’s assessment of uncertain tax positions, including those arising from legal entity restructuring transactions in connection with the Combination, is based on estimates and assumptions that the Company believes are reasonable but the estimates for unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variations from such estimates could materially affect the Company’s financial condition, results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire.
The Company is subject to ongoing IRS examinations. The years 2015 through 2018 are open years under examination. The years 2012, 2013 and 2014 have one matter open, and a Tax Court petition was filed regarding the matter and a trial was held in December 2018 and is discussed further below.
During the year ended December 31, 2019, Mylan reached an agreement in principle with the IRS to resolve all issues relating to our positions on the February 27, 2015 acquisition by Mylan N.V. of Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business. Under the agreement in principle, which was finalized as part of a closing agreement with the IRS on October 11, 2019, Mylan’s status as a non-U.S. corporation for U.S. Federal income tax purposes was confirmed, and we have adjusted the interest rates used for intercompany loans as necessary. During the year ended December 31, 2019, the Company recorded a reserve of approximately $155.0 million as part of its liability for uncertain tax positions, with a net impact to the income tax provision of approximately $144.9 million related to this matter.
Several international audits are currently in progress. In some cases, the tax auditors have proposed adjustments or issued assessments to our tax positions, including with respect to intercompany transactions, and we are in ongoing discussions with some of the auditors regarding the validity of their positions.
In instances where assessments have been issued, we disagree with these assessments and believe they are without merit and incorrect as a matter of law. As a result, we anticipate that certain of these matters may become the subject of litigation before tax courts where we intend to vigorously defend our position.
In Australia, the tax authorities have issued notices of assessments to the Company for the years ended December 2009 to December 2019, subject to additional interest and penalties, concerning our tax position with respect to certain intercompany transactions. The tax authorities denied our objections to the assessments and we have commenced litigation in the Australian Federal Court challenging that decision. During 2021, the Company made a partial payment of $56.0 million in order to stay potential interest and penalties resulting from this litigation.
In France, the tax authorities have issued notices of assessments to the Company for the years ended December 2013 to December 2016 concerning our tax position with respect to (i) certain intercompany transactions and (ii) whether income earned by a Company entity not domiciled in France should be subject to French tax. We have resolved our position concerning certain intercompany transactions with the tax authorities. Concerning the remaining issue, we have commenced litigation before the French tax courts where the tax authorities will seek unpaid taxes, penalties, and interest.
125

In India, the tax authorities have issued notices of assessments to the Company seeking unpaid taxes and interest for the financial years covering 2013 to 2018 concerning our tax position with respect to certain corporate tax deductions and certain intercompany transactions. Some of these assessments remain in the audit phase where we are challenging them before the tax authorities while we are challenging some of the other assessments in the Indian tax courts.
The Company has recorded a net reserve for uncertain tax positions of $315.6 million, including interest and penalties, in connection with its international audits at December 31, 2021. The reserve balance at December 31, 2021 reflects the impact of current year settlement payments. In connection with our international tax audits, it is possible that we will incur material losses above the amounts reserved.
The Company’s major U.S. state taxing jurisdictions remain open from fiscal year 2013 through 2020, with several state audits currently in progress. The Company’s major international taxing jurisdictions remain open from 2012 through 2020.
Tax Court Proceedings     
The Company's U.S. federal income tax returns for 2012 through 2014 had been subject to proceedings in U.S. Tax Court involving a dispute with the IRS regarding whether certain costs related to ANDAs were eligible to be expensed and deducted immediately or required to be amortized over longer periods. A trial was held in U.S. Tax Court in December 2018 and on April 27, 2021, the Court affirmed Mylan’s position and held that patent litigation expenses related to ANDAs are immediately deductible. The IRS has appealed this decision.
Accounting for Uncertainty in Income Taxes
The impact of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of an uncertain tax position will be recognized if the position has less than a 50% likelihood of being sustained.
As of December 31, 2021 and 2020, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $322.9 million and $391.1 million, respectively, of which $230.2 million as of December 31, 2021 would affect the Company’s effective tax rate if recognized, with the remainder being offset by potential correlative adjustments. Related accrued interest and penalties included in the consolidated balance sheets were $96.8 million and $86.7 million as of December 31, 2021 and 2020, respectively. For the years ended December 31, 2021, 2020 and 2019, the Company recognized $18.5 million of tax expense, $6.0 million, and $35.2 million of tax benefits, respectively, related to interest and penalties on uncertain tax positions. Interest and penalties related to income taxes are included in the tax provision.

A reconciliation of the unrecognized tax benefits is as follows:
Year Ended December 31,
(In millions)202120202019
Unrecognized tax benefit — beginning of year$391.1 $92.1 $96.3 
Additions for current year tax positions 13.4  
Additions for prior year tax positions 35.7 154.9 
Reductions for prior year tax positions(9.1)(5.2)(11.7)
Settlements(47.3)(8.9)(112.5)
Reductions due to expirations of statute of limitations(7.0) (34.9)
(Reduction) addition due to acquisition(4.8)264.0  
Unrecognized tax benefit — end of year$322.9 $391.1 $92.1 
The Company believes that it is reasonably possible that the amount of unrecognized tax benefits will decrease in the next twelve months by approximately $55.0 million, involving international and state audits and settlements and expiring statutes of limitations. The Company does not anticipate significant increases to the reserve within the next twelve months.
126

13.Share-Based Incentive Plan
Prior to the Distribution, Viatris adopted and Pfizer, in the capacity as Viatris’ sole stockholder at such time, approved the Plan (the Viatris Inc. 2020 Stock Incentive Plan) which became effective as of the Distribution. In connection with the Combination, as of November 16, 2020, the Company assumed the 2003 LTIP (Mylan N.V. Amended and Restated 2003 Long-Term Incentive Plan), which had previously been approved by Mylan shareholders. The Plan and 2003 LTIP include (i) 72,500,000 shares of Common Stock authorized for grant pursuant to the Plan, which may include dividend payments payable in Common Stock on unvested shares granted under awards, (ii) 6,757,640 shares of Common Stock to be issued pursuant to the exercise of outstanding stock options granted to participants under the 2003 LTIP and assumed by Viatris in connection with the Combination and (iii) 13,535,627 shares of Common Stock subject to outstanding equity-based awards, other than stock options, assumed by Viatris in connection with the Combination, or that otherwise remain available for issuance under the 2003 LTIP.
Under the Plan and 2003 LTIP, shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, SARs, restricted stock and units, PSUs, other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the shares underlying the stock options at the date of the grant, generally become exercisable over periods ranging from three to four years, and generally expire in ten years.
The following table summarizes stock awards (stock options and SARs) activity under the Plan and 2003 LTIP:
Number of Shares
Under Stock Awards
Weighted
Average
Exercise Price
per Share
Outstanding at December 31, 20186,815,278 $36.61 
Granted829,322 26.18 
Exercised(580,950)14.40 
Forfeited(715,941)39.40 
Outstanding at December 31, 20196,347,709 $36.97 
Granted814,351 17.37 
Exercised(27,615)21.13 
Forfeited(422,714)25.74 
Outstanding at December 31, 20206,711,731 $35.36 
Forfeited(1,135,241)26.39 
Outstanding at December 31, 20215,576,490 $37.19 
Vested and expected to vest at December 31, 20215,487,788 $37.45 
Exercisable at December 31, 20214,969,602 $39.21 
As of December 31, 2021, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had average remaining contractual terms of 4.6 years, 4.6 years and 4.2 years, respectively. Also, at December 31, 2021, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had no aggregate intrinsic value.
A summary of the status of the Company’s nonvested restricted stock awards (restricted stock and restricted stock unit awards, including PSUs), as of December 31, 2020 and the changes during the year ended December 31, 2021 are presented below:
Number of Restricted
Stock Awards
Weighted Average
Grant-Date
Fair Value Per Share
Nonvested at December 31, 202012,073,790 $18.34 
Granted9,850,443 14.46 
Released(3,168,152)24.65 
Forfeited(1,897,953)15.33 
Nonvested at December 31, 202116,858,128 $15.12 
127

Of the 9,850,443 restricted stock awards granted during the year ended December 31, 2021, 6,057,602 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining restricted stock awards granted, 587,025 are not subject to market conditions and will cliff vest within a three-year period, and 3,205,816 are subject to market or performance conditions and will cliff vest in three years or less.
As of December 31, 2021, the Company had $143.1 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 1.7 years. The total intrinsic value of stock awards exercised and restricted stock units released during the years ended December 31, 2021 and 2020 was $78.1 million and $20.9 million, respectively.
With respect to options granted under the Plan and 2003 LTIP, the fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield and employee exercise behavior. Expected volatilities utilized in the model are based mainly on the implied volatility of the Company’s stock price and other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The model incorporates exercise and post-vesting forfeiture assumptions based on an analysis of historical data. The expected lives of the grants are derived from historical and other factors.
There were no options granted during the year ended December 31, 2021. The assumptions used for options granted under the Plan and 2003 LTIP during the years ended December 31, 2020 and 2019, respectively, are as follows:
Year Ended December 31,
20202019
Volatility46.7%38.1%
Risk-free interest rate1.0%2.5%
Expected term (years)6.56.5
Forfeiture rate 5.5%5.5%
Weighted average grant date fair value per option$8.07$11.03
14.Employee Benefit Plans
Defined Benefit Plans
The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. Employees in the U.S., Puerto Rico and certain international locations are also provided retirement benefits through defined contribution plans.
The Company also sponsors other postretirement benefit plans including plans that provide for postretirement supplemental medical coverage. Benefits from these plans are provided to employees and their spouses and dependents who meet various minimum age and service requirements. In addition, the Company sponsors other plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees.
In connection with the Combination, the Company assumed certain post retirement defined benefit pension plans sponsored by Upjohn. The most significant plans include those in Puerto Rico, Ireland and Japan. Upjohn is also the sponsor of one postretirement medical plan in Puerto Rico. As part of the acquisition accounting, the Company has recorded the fair value of these plans. Upon completion of the Combination, the excess of projected benefit obligation over the plan assets was recognized as a liability and any existing unrecognized actuarial gains or losses and unrecognized service costs or benefits were eliminated in purchase accounting.

Accounting for Defined Benefit Pension and Other Postretirement Plans
The Company recognizes on its balance sheet an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension and other postretirement plan. Actuarial gains or losses and prior service costs or credits that arise during the period are not recognized as components of net periodic benefit cost, but are recognized, net of tax, as a component of other comprehensive (loss) earnings.
128

Included in accumulated other comprehensive loss as of December 31, 2021 and 2020 are:
Pension BenefitsOther Postretirement Benefits
December 31,December 31,
(In millions)2021202020212020
Unrecognized actuarial (gain) loss$(59.9)$33.9 $21.7 $5.7 
Unrecognized prior service cost (credit)6.6 (1.4)(3.7)0.6 
Total$(53.3)$32.5 $18.0 $6.3 
The unrecognized net actuarial losses exceeded 10% of the higher of the market value of plan assets or the projected benefit obligation at the beginning of the year for certain of the plans, therefore, amortization of such excess has been included in net periodic benefit costs for pension and other postretirement benefits in each of the last three years. The amortization period is the average remaining service period that active employees are expected to receive benefits, unless a plan is mostly inactive in which case the amortization period is the average remaining life expectancy of the plan participants. Unrecognized prior service cost is amortized over the future service periods of those employees who are active at the dates of the plan amendments and who are expected to receive benefits. If all or almost all of a plan's participants are inactive, unrecognized prior service cost is amortized over the remaining life expectancy of those participants. The increase in accumulated other comprehensive loss in 2021 relating to pension benefits and other postretirement benefits consists of:
(In millions)Pension BenefitsOther Postretirement Benefits
Unrecognized actuarial (gain) loss$(102.2)$16.2 
Amortization of actuarial gain/(loss)7.6 (0.2)
Unrecognized prior service credit (cost)8.0 (4.3)
Amortization of prior service costs(0.5) 
Impact of foreign currency translation1.3  
Net change$(85.8)$11.7 
Components of net periodic benefit cost, change in projected benefit obligation, change in plan assets, funded status, fair value of plan assets, assumptions used to determine net periodic benefit cost, funding policy and estimated future benefit payments are summarized below for the Company’s pension plans and other postretirement plans.
Net Periodic Benefit Cost
Components of net periodic benefit cost for the years ended December 31, 2021, 2020 and 2019 were as follows:
Pension BenefitsOther Postretirement Benefits
December 31,December 31,
(In millions)202120202019202120202019
Service cost$38.6 $23.5 $20.7 $3.4 $1.2 $0.6 
Interest cost31.6 13.5 13.6 2.6 1.4 1.5 
Expected return on plan assets(66.1)(19.9)(12.1)   
Plan curtailment, settlement and termination(16.5)1.1 (0.3)  3.2 
Amortization of prior service costs0.9  0.9    
Recognized net actuarial losses (gains) 1.3 0.4 (0.8)0.2 0.3 0.2 
Net periodic benefit cost$(10.2)$18.6 $22.0 $6.2 $2.9 $5.5 
During the year ended December 31, 2021, the Company recognized a settlement gain as a result of cash payments from lump sum elections related to the U.S. and Puerto Rico pension plans.
129

Change in Projected Benefit Obligation, Change in Plan Assets and Funded Status
The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2021 and 2020.
Pension BenefitsOther Postretirement Benefits
(In millions)2021202020212020
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year$2,145.8 $674.7 $188.8 $33.8 
Service cost38.6 23.5 3.4 1.1 
Interest cost31.6 13.5 2.6 1.4 
Participant contributions2.0 1.8 2.4 0.1 
Acquisitions4.0 1,389.4  153.1 
Plan settlements and terminations(128.6)(23.1)(4.3)(0.2)
Actuarial (gains) losses (26.1)37.2 16.2 1.1 
Benefits paid(52.8)(24.6)(20.7)(1.6)
Impact of foreign currency translation(67.9)53.4   
Projected benefit obligation, end of year$1,946.6 $2,145.8 $188.4 $188.8 
Change in Plan Assets
Fair value of plan assets, beginning of year$1,354.6 $315.7 $ $ 
Actual return on plan assets141.7 46.0   
Company contributions97.0 58.2 18.3 1.7 
Participant contributions2.0 1.8 2.4 0.1 
Acquisitions(2.1)959.3   
Plan settlements(128.9)(23.1) (0.2)
Benefits paid(52.8)(24.6)(20.7)(1.6)
Impact of foreign currency translation(45.1)21.3   
Fair value of plan assets, end of year1,366.4 1,354.6   
Funded status of plans$(580.2)$(791.2)$(188.4)$(188.8)
Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheets at December 31, 2021 and 2020:
Pension BenefitsOther Postretirement Benefits
December 31,December 31,
(In millions)2021202020212020
Noncurrent assets$117.2 $70.7 $ $ 
Current liabilities(14.6)(15.1)(16.1)(16.3)
Noncurrent liabilities(682.8)(846.8)(172.3)(172.5)
Net accrued benefit costs$(580.2)$(791.2)$(188.4)$(188.8)
The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, but does not include the effects of estimated future pay increases. The accumulated benefit obligation for the Company’s pension plans was $1.86 billion and $2.04 billion at December 31, 2021 and 2020, respectively.
130

The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of the fair value of plan assets at December 31, 2021 and 2020 were as follows:
December 31,
(In millions)20212020
Plans with accumulated benefit obligation in excess of plan assets:
Projected benefit obligation$1,591.8 $1,747.2 
Accumulated benefit obligation1,546.4 1,678.2 
Fair value of plan assets904.1 893.9 
Fair Value of Plan Assets
The Company measures the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy described in Note 9 Financial Instruments and Risk Management. The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:
December 31, 2021
(In millions)Level 1Level 2Level 3Total
Cash and cash equivalents$63.1 $1.9 $ $65.0 
Equity securities53.9 497.2  551.1 
Fixed income securities211.4 405.5  616.9 
Assets held by insurance companies and other10.2 41.6 81.6 133.4 
Total$338.6 $946.2 $81.6 $1,366.4 
December 31, 2020
(In millions)Level 1Level 2Level 3Total
Cash and cash equivalents$51.2 $0.6 $ $51.8 
Equity securities145.3 468.1  613.4 
Fixed income securities292.6 299.4  592.0 
Assets held by insurance companies and other4.0 20.0 73.4 97.4 
Total$493.1 $788.1 $73.4 $1,354.6 
Risk tolerance on invested pension plan assets is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Investment risk is measured and monitored on an ongoing basis through annual liability measures, periodic asset/liability studies and investment portfolio reviews. The Company’s investment strategy is to maintain, where possible, a diversified investment portfolio across several asset classes that, when combined with the Company’s contributions to the plans, will ensure that required benefit obligations are met.
Assumptions
The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2021 and 2020:
Pension BenefitsOther Postretirement Benefits
2021202020212020
Discount rate2.3 %1.9 %2.5 %1.9 %
Expected return on plan assets5.1 %4.3 % % %
Rate of compensation increase3.1 %2.9 % % %
131

The following weighted average assumptions were used to determine the net periodic benefit cost for the Company’s defined benefit pension and other postretirement benefit plans for the three years in the period ended December 31, 2021:
Pension BenefitsOther Postretirement Benefits
202120202019202120202019
Discount rate1.9 %1.6 %2.3 %1.9 %3.3 %4.3 %
Expected return on plan assets5.1 %4.3 %4.3 % % % %
Rate of compensation increase2.9 %2.7 %2.9 % % % %
The assumptions for each plan are reviewed on an annual basis. The discount rate reflects the current rate at which the pension and other benefit liabilities could be effectively settled at the measurement date. In setting the discount rates, we utilize comparable corporate bond indices as an indication of interest rate movements and levels. Corporate bond indices were selected based on individual plan census data and duration. The expected return on plan assets was determined using historical market returns and long-term historical relationships between equities and fixed income securities. The Company compares the expected return on plan assets assumption to actual historic returns to ensure reasonableness. Current market factors such as inflation and interest rates are also evaluated.
The weighted-average healthcare cost trend rate used for 2021 was 5.7% declining to a projected 4.5% in the year 2037. For 2022, the assumed weighted-average healthcare cost trend rate used will be 6.3% declining to a projected 4.0% in the year 2045. In selecting rates for current and long-term healthcare cost assumptions, the Company takes into consideration a number of factors including the Company’s actual healthcare cost increases, the design of the Company’s benefit programs, the demographics of the Company’s active and retiree populations and external expectations of future medical cost inflation rates.
Estimated Future Benefit Payments
The Company’s funding policy for its funded pension plans is based upon local statutory requirements. The Company’s funding policy is subject to certain statutory regulations with respect to annual minimum and maximum company contributions. Plan benefits for the non-qualified plans are paid as they come due.
Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows:
(In millions)Pension BenefitsOther Postretirement Benefits
2022$101.8 $16.1 
202397.1 16.5 
2024103.0 16.9 
2025100.7 16.8 
2026104.3 16.6 
Thereafter528.5 73.0 
Total$1,035.4 $155.9 
Defined Contribution Plans
The Company sponsors defined contribution plans covering its employees in the U.S. and Puerto Rico, as well as certain employees in a number of countries outside the U.S. The Company’s domestic defined contribution plans consist primarily of a Profit Sharing 401(k) Plan and a 401(k) retirement plan for union-represented employees. Profit sharing contributions are made at the discretion of the Board of Directors. The Company’s non-domestic plans vary in form depending on local legal requirements. The Company’s contributions are based upon employee contributions, service hours, or pre-determined amounts depending upon the plan. Obligations for contributions to defined contribution plans are recognized as expense in the consolidated statements of operations when they are earned.
132

The Company maintains a 401(k) Restoration Plan, which permits employees who earn compensation in excess of the limits imposed by Section 401(a)(17) of the Code to (i) defer a portion of base salary and bonus compensation, (ii) be credited with a Company matching contribution in respect of deferrals under the Restoration Plan, and (iii) be credited with Company non-elective contributions (to the extent so made by the Company), in each case, to the extent that participants otherwise would be able to defer or be credited with such amounts, as applicable, under the Profit Sharing 401(k) Plan if not for the limits on contributions and deferrals imposed by the Code.
The Company maintains an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50% of base salary and up to 100% of bonus compensation, in each case, in addition to any amounts that may be deferred by such participants under the Profit Sharing 401(k) Plan and the Restoration Plan. In addition, under the Income Deferral Plan, eligible participants may be granted employee deferral awards, which awards will be subject to the terms and conditions (including vesting) as determined by the plan administrator at the time such awards are granted.
Total employer contributions to defined contribution plans were approximately $107.4 million, $115.5 million and $95.6 million for the years ended December 31, 2021, 2020 and 2019, respectively.
Other Benefit Arrangements
The Company participated in a multi-employer pension plan under previous collective bargaining agreements. The PACE Industry Union-Management Pension Fund (the “PACE Plan”) provides defined benefits to certain retirees and certain production and maintenance employees at the Company’s manufacturing plant in Morgantown, West Virginia who were covered by the previous collective bargaining agreements. Pursuant to a collective bargaining agreement entered into on April 16, 2012, the Company withdrew from the PACE Plan effective May 10, 2012. In 2013, the PACE Plan trustee notified the Company that its withdrawal liability was approximately $27.3 million, which was accrued by the Company in 2013. The withdrawal liability is being paid over a period of approximately nine years; payments began in March 2014. The withdrawal liability was approximately $5.5 million and $8.9 million at December 31, 2021 and 2020, respectively. The Employer Identification Number for the PACE Plan is 11-6166763.
15.Segment Information
Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics and biosimilars, and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise.

The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability.
Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following:
Intangible asset amortization expense and impairments of intangible assets;
R&D expense;
Net charges or net gains for litigation settlements and other contingencies;
Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.
133

Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs.
The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker.
The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies.
Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.
Net Sales
Segment Profitability
Years Ended December 31, Years Ended December 31,
(in millions)202120202019202120202019
Reportable Segments:
Developed Markets$10,428.7 $8,510.9 $8,240.0 $5,143.1 $4,243.9 $4,137.3 
Greater China2,212.8 259.9 214.6 1,397.1 52.7 89.9 
JANZ2,027.4 1,195.3 1,192.5 762.4 364.6 323.2 
Emerging Markets3,144.7 1,853.8 1,723.2 1,402.4 610.4 561.9 
Total reportable segments$17,813.6 $11,819.9 $11,370.3 $8,705.0 $5,271.6 $5,112.3 
Reconciling items:
Intangible asset amortization expense(2,702.2)(1,605.8)(1,582.7)
Intangible asset impairment charges(102.8)(82.4)(180.6)
Globally managed research and development costs(751.1)(555.1)(639.9)
Litigation settlements & other contingencies(329.2)(107.8)21.4 
Transaction related and other special items(2,832.2)(1,739.7)(682.2)
Corporate and other unallocated(2,021.5)(1,391.6)(1,332.8)
(Loss) earnings from operations$(34.0)$(210.8)$715.5 

The following table represents the percentage of consolidated net sales to Viatris’ major customers during the years ended December 31, 2021, 2020, and 2019:
Percentage of Consolidated Net Sales
202120202019
McKesson Corporation9 %13 %15 %
AmerisourceBergen Corporation9 %10 %9 %
Cardinal Health, Inc.5 %8 %8 %
134

Sales by Country Information
Net sales by country are presented on the basis of geographic location of our subsidiaries:
Year Ended December 31,
(In millions)202120202019
United States$4,176.4 $3,746.1 $3,965.9 
China1,981.5 216.1 171.1 
____________
No other country’s net sales represents more than 10% of consolidated net sales.

16.Commitments
The Company has entered into employment and other agreements with certain executives and other employees that provide for compensation, retirement and certain other benefits. These agreements provide for severance payments under certain circumstances. Additionally, the Company has split-dollar life insurance agreements with certain retired executives.
In conjunction with the Combination, Viatris entered into a TSA with Pfizer pursuant to which each party will provide certain limited transition services to the other party generally for an initial period of 24 months from closing date. In addition to the monthly service fees under the TSA, Viatris has agreed to reimburse Pfizer for fifty percent of the costs, up to the first $380 million incurred, to establish and wind down the TSA services. Viatris will be required to fully reimburse Pfizer for total costs in excess of $380 million. During the years ended December 31, 2021 and 2020, the Company incurred $30.4 million and $53.1 million, respectively, related to this provision of the TSA.

In conjunction with the Combination, during the year ended December 31, 2020, the Company accrued approximately $26.9 million due to change in control clauses in employment arrangements for certain former Mylan employees, which was paid during 2021. In addition, the Company entered into retention agreements with certain key employees, whereby they agreed to continue to provide service to the Company for a period of time after the Combination. The Company is recording the expense for these agreements over the applicable service periods.

In the normal course of business, Viatris periodically enters into employment, legal settlement and other agreements which incorporate indemnification provisions. While the maximum amount to which Viatris may be exposed under such agreements cannot be reasonably estimated, the Company maintains insurance coverage, which management believes will effectively mitigate the Company’s obligations under these indemnification provisions. No amounts have been recorded in the consolidated financial statements with respect to the Company’s obligations under such agreements.
17.Restructuring
2020 Restructuring Program
During the fourth quarter of 2020, Viatris announced a significant global restructuring program in order to achieve synergies and ensure that the organization is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders. Viatris’ restructuring initiative incorporates and expands on the restructuring program announced by Mylan N.V. earlier in 2020 as part of its business transformation efforts. As part of the restructuring, the Company is optimizing its commercial capabilities and enabling functions, and closing, downsizing or divesting certain manufacturing facilities globally that are deemed to be no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex products.
For the committed restructuring actions, the Company expects to incur total pre-tax charges of up to approximately $1.4 billion. Such charges are expected to include up to approximately $450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including inventory write-offs. The remaining estimated cash costs of up to approximately $950 million are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations and other plant disposal costs. In addition, management believes the potential annual savings related to these committed restructuring activities to be up to approximately $900 million once fully implemented, with most of these savings expected to improve operating cash flow.
135

The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program:
(In millions)Employee Related CostsOther Exit CostsTotal
Charges (2)
$195.6 $75.7 $271.3 
Acquired in the Combination91.7 0.3 92.0 
Cash payment(25.1)(0.4)(25.5)
Utilization (70.8)(70.8)
Foreign currency translation0.4  0.4 
Balance at December 31, 2020$262.6 $4.8 $267.4 
Charges (1)
396.1 496.1 892.2 
Reimbursable restructuring charges26.4  26.4 
Cash payment(385.5)(151.7)(537.2)
Utilization (345.0)(345.0)
Foreign currency translation(7.0)(0.1)(7.1)
Balance at December 31, 2021$292.6 $4.1 $296.7 

As part of the Combination, the Company acquired reserve balances related to restructuring activities initiated by the Upjohn Business prior to the Combination, primarily related to accrued severance.

2016 Restructuring Program
Mylan previously announced a restructuring program representing a series of actions in certain locations to further streamline its operations globally. We incurred total restructuring related costs of approximately $733.0 million through December 31, 2020. The 2016 Restructuring Program was substantially completed at December 31, 2020.
In April 2018, the FDA completed an inspection at Mylan’s plant in Morgantown, West Virginia and made observations through a Form 483. In the fourth quarter of 2018, Mylan received a warning letter related to the previously disclosed observations at the plant. The issues raised in the warning letter were addressed within the context of the Mylan’s comprehensive restructuring and remediation activities. On May 11, 2020, Mylan received the close-out of the warning letter. On December 11, 2020, the Company announced that it expects the Morgantown plant to be closed or divested as part of the 2020 Restructuring Program. The Morgantown plant was closed during the third quarter of 2021.

The following table summarizes the restructuring charges and the reserve activity for the 2016 restructuring program from December 31, 2018 to December 31, 2020:
(In millions)Employee Related CostsOther Exit CostsTotal
Balance at December 31, 2018:$60.8 $11.8 $72.6 
Charges (3)
16.6 88.0 $104.6 
Cash payment(48.9)(10.5)$(59.4)
Reclassifications (8.1)$(8.1)
Utilization (78.3)$(78.3)
Foreign currency translation(2.1)(0.1)$(2.2)
Balance at December 31, 2019:$26.4 $2.8 $29.2 
Charges (2)
9.9 40.6 50.5 
Cash payment(18.1)(7.6)(25.7)
Utilization (32.9)(32.9)
Foreign currency translation$1.8 $(0.1)$1.7 
Balance at December 31, 2020:$20.0 $2.8 $22.8 
136

(1)     For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively.
(2)     For the year ended December 31, 2020, total restructuring charges, for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively.
(3)     For the year ended December 31, 2019, total restructuring charges for the 2016 Restructuring Program in Developed Markets and JANZ were approximately $100.4 million and $4.2 million, respectively.
At December 31, 2021 and 2020, accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities and other long-term obligations in the consolidated balance sheets.
18.Licensing and Other Partner Agreements
We periodically enter into licensing and other partner agreements with other pharmaceutical companies for the development, manufacture, marketing and/or sale of pharmaceutical products. Our significant licensing and other partner agreements are primarily focused on the development, manufacturing, supply and commercialization of multiple, high-value generic biologic compounds, insulin analog products and respiratory products, among other complex products. Under these agreements, we have future potential milestone payments and co-development expenses payable to third parties as part of our licensing, development and co-development programs. Payments under these agreements generally become due and are payable upon the satisfaction or achievement of certain developmental, regulatory or commercial milestones or as development expenses are incurred on defined projects. Milestone payment obligations are uncertain, including the prediction of timing and the occurrence of events triggering a future obligation and are not reflected as liabilities in the consolidated balance sheets, except for obligations reflected as acquisition related contingent consideration. Refer to Note 9 Financial Instruments and Risk Management for further discussion of contingent consideration. Our potential maximum development milestones not accrued for at December 31, 2021 totaled approximately $351 million. We estimate that the amounts that may be paid during the next twelve months to be approximately $18 million. These agreements may also include potential sales-based milestones and call for us to pay a percentage of amounts earned from the sale of the product as a royalty or a profit share. The amounts disclosed do not include sales-based milestones or royalty or profit share obligations on future sales of product as the timing and amount of future sales levels and costs to produce products subject to these obligations is not reasonably estimable. These sales-based milestones or royalty or profit share obligations may be significant depending upon the level of commercial sales for each product.
Revance
On February 28, 2018, the Company and Revance entered into an agreement with Revance pursuant to which the Company and Revance are collaborating exclusively, on a world-wide basis (excluding Japan), to develop, manufacture and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. Under the agreement, the Company is primarily responsible for (a) clinical development activities outside of North America (excluding Japan) (b) regulatory activities, and (c) commercialization for any approved product. Revance is primarily responsible for (a) non-clinical development activities, (b) clinical development activities in North America, and (c) manufacturing and supply of clinical drug substance and drug product; Revance is solely responsible for an initial portion of non-clinical development costs. The remaining portion of any non-clinical development costs and clinical development costs for obtaining approval in the U.S. and Europe is being shared equally between the parties, and the Company is responsible for all other clinical development costs and commercialization expenses. During the year ended December 31, 2020, the Company recorded $30 million of R&D expense for a milestone payment that was due upon the decision to continue the development program.
Momenta
On January 8, 2016, the Company entered into an agreement with Momenta to develop, manufacture and commercialize up to six of Momenta’s biosimilar candidates. Under the terms of the agreement, the Company and Momenta were jointly responsible for product development and equally shared in the costs and profits of the products with Viatris leading the worldwide commercialization efforts. In January 2019, the parties agreed to the termination of all collaboration activities, except for the continued development of M710, a proposed biosimilar to EYLEA®. In October 2020, Momenta was acquired by Johnson & Johnson. The parties continue to collaborate on the development of M710.
137

Theravance Biopharma
On January 30, 2015, the Company entered into a development and commercialization collaboration with Theravance Biopharma, for revefenacin. On November 9, 2018, the Company announced that the FDA approved the NDA for YUPELRI® (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. YUPELRI®, a LAMA, is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the U.S. Viatris is responsible for commercial manufacturing and commercialization. Theravance Biopharma is co-promoting the product in the hospital channel under a profit-sharing arrangement.
In 2019, the Company acquired exclusive development and commercialization rights to nebulized revefenacin in China and adjacent territories, which include Hong Kong SAR, the Macau SAR and Taiwan. Theravance Biopharma received an upfront payment of $18.5 million and will be eligible to receive additional potential development and sales milestones together with tiered royalties on net sales of nebulized revefenacin, if approved. Viatris is responsible for all aspects of development and commercialization in the partnered regions, including pre- and post-launch activities and product registration and all associated costs. The upfront payment was recorded as R&D expense during the year ended December 31, 2019.
Under the terms of the agreements, Theravance Biopharma is eligible to receive potential development and sales milestone payments totaling approximately $293 million in the aggregate. As of December 31, 2021, the Company has paid a total of $50.0 million in milestone payments to Theravance Biopharma.
Biocon
The Company has entered into exclusive collaborations with Biocon on the development, manufacturing, supply and commercialization of multiple, high value biosimilar compounds and three insulin analog products for the global marketplace. Under the agreements with Biocon, the Company has exclusive commercialization rights for the products under the collaborations in the U.S., Canada, Japan, Australia, New Zealand and in the EU and European Free Trade Association countries.
In December 2017, the FDA approved Ogivri® (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab). Ogivri® has been approved for all indications included in the label of the reference product, Herceptin, including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). On December 2, 2019, the Company and Biocon announced the U.S. launch of Ogivri®
In June 2018, the Company and Biocon announced that the FDA approved Fulphila® (pegfilgrastim-jmdb), a biosimilar to Neulasta® (pegfilgrastim). Fulphila® has been approved to reduce the duration of febrile neutropenia (fever or other signs of infection with a low count of neutrophils, a type of white blood cells) in patients treated with chemotherapy in certain types of cancer. The commercial launch of Fulphila® occurred in 2018.
In August, 2020, the Company and Biocon announced the U.S. launch of SEMGLEE® (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.
On July 28, 2021, Viatris and Biocon announced that the FDA had approved SEMGLEE® (insulin glargine-yfgn) injection as the first interchangeable biosimilar product under the 351(k) regulatory pathway. The interchangeable SEMGLEE® product, which allows substitution of SEMGLEE® for the reference product, Lantus®. The commercial launch occurred in the fourth quarter of 2021. The Company has exclusivity for 12 months from launch before the FDA can approve another biosimilar interchangeable to Lantus®.
In addition to profit sharing payments to Biocon for the commercialized products, the Company continues to provide development funding related to this collaboration. As the timing of cash expenditures is dependent upon a number of factors, many of which are out of the Company’s control, it is difficult to forecast the amount of payments to be made over the next few years, which could be significant.
138

FKB
On February 22, 2018, the Company entered into a collaboration license and distribution agreement with FKB for the distribution of Hulio®, a biosimilar to AbbVie's Humira® (adalimumab). Under the agreement, the Company has exclusive commercialization rights for the product in the EU and the European Economic Area countries and FKB is responsible for development, manufacturing and supply of the product.
On September 20, 2018, the Company received final approval from the Commission to market Hulio® for all adalimumab indications in all 28 EU member states and the European Economic Area. Under the agreement, FKB received an upfront payment of $25.0 million, an approval milestone of $10.0 million and is eligible for a royalty based upon net sales.
On February 27, 2019, the Company amended its agreements with FKB for the commercialization of Hulio®. Under the amended agreements, the Company received the exclusive global commercialization rights for Hulio® and FKB received an additional upfront payment of $33.0 million, of which $23.3 million was recorded as a component of R&D expense during the year ended December 31, 2019. In addition, FKB is eligible to receive additional commercial milestones and royalty payments under the amended agreements.
On July 9, 2020, the Company announced that the FDA approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie's Humira® (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis (4 years and older), psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations. In accordance with its patent license agreement with AbbVie, the Company will be able to launch Hulio® in the U.S. in July 2023.
Other Development Agreements
On December 20, 2019, the Company entered into a Master Development Agreement with a privately owned research company to grant the Company rights with respect to acquiring certain pharmaceutical products. The Company expects to provide funding for select programs through upfront payments and development milestones and the Company will have the right and obligation to acquire the products at fair market value upon regulatory approval or other regulatory trigger dates.
The Company made an initial upfront payment of $10.0 million which was accounted for as R&D expense during the year ended December 31, 2019. Additionally, under the terms of the agreement, the Company acquired $25.0 million worth of equity shares in the privately owned research company during the year ended December 31, 2020. The investment is accounted for in accordance with ASC 321, Investments - Equity Securities. During the year ended December 31, 2021, the Company entered into an agreement with this entity for the future development of an ophthalmic product. The agreement included an upfront payment of $40.0 million which was accounted for as R&D expense.    
We are actively pursuing, and are currently involved in, joint projects related to the development, distribution and marketing of both generic and branded products. Many of these arrangements provide for payments by us upon the attainment of specified milestones. While these arrangements help to reduce the financial risk for unsuccessful projects, fulfillment of specified milestones or the occurrence of other obligations may result in fluctuations in cash flows and R&D expense.
Biocon Biologics Agreement
On February 28, 2022, the Company entered into an agreement to contribute its biosimilars business to Biocon Biologics. Under the terms of the Biocon Agreement, at closing Viatris will receive an up-front cash payment of $2.0 billion, $1.0 billion of convertible preferred equity and up to $335 million as additional cash payments that are expected to be paid in 2024. Viatris will own a stake of at least 12.9% of Biocon Biologics, on a fully-diluted basis, and will have certain priority rights with respect to certain liquidity events. The companies will also enter into a two-year transition services agreement, subject to extension in certain circumstances, during which time Viatris will provide certain commercial and administrative services for an applicable service fee. The transaction is expected to close in the second half of 2022 and is subject to customary closing conditions (including regulatory approvals).
19.Litigation
The Company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings and litigation matters, both in the U.S. and abroad, that arise from time to time, some of which could result in losses, including damages, fines and/or civil penalties, and/or criminal charges against the Company. These matters are often complex and have outcomes that are difficult to predict.
139

In addition, in connection with the Combination, the Company has generally assumed liability for, and control of, pending and threatened legal matters relating to the Upjohn Business – including certain matters initiated against Pfizer described below – and has agreed to indemnify Pfizer for liabilities arising out of such assumed legal matters. Pfizer, however, has agreed to retain various matters – including certain specified competition law matters – to the extent they arise from conduct during the pre-Distribution period and has agreed to indemnify the Company for liabilities arising out of such matters.
While the Company believes that it has meritorious defenses with respect to the claims asserted against it and the assumed legal matters referenced above, and intends to vigorously defend its position, the process of resolving these matters is inherently uncertain and may develop over a long period of time, and so it is not possible to predict the ultimate resolution of any such matter. It is possible that an unfavorable resolution of any of the ongoing matters could have a material effect on the Company’s business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
Some of these governmental inquiries, investigations, proceedings and litigation matters with which the Company is involved are described below, and unless otherwise disclosed, the Company is unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. The Company records accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is also involved in other pending proceedings for which, in the opinion of the Company based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s business, financial position, results of operations, cash flows, ability to pay dividends and/or stock price. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in the opinion of the Company, become material, the Company will disclose such matters.
Legal costs are recorded as incurred and are classified in SG&A in the Company’s consolidated statements of operations.
EpiPen® Auto-Injector Litigation
The Company and a former Mylan N.V. officer (collectively the “Mylan Defendants”) have been named as defendants in indirect purchaser class actions relating to the pricing and/or marketing of the EpiPen® Auto-Injector. The plaintiffs in these cases asserted violations of various federal and state antitrust and consumer protection laws, RICO as well as common law claims. Plaintiffs’ seek monetary damages, attorneys’ fees and costs. These lawsuits were filed in various federal and state courts and have either been dismissed or transferred into a MDL in the U.S. District Court for the District of Kansas and have been consolidated or centralized. The District Court initially certified an antitrust class that applied to 17 states and a RICO class. On June 23, 2021, the Court granted – in substantial part – the Mylan Defendants’ motion for summary judgment by dismissing certain antitrust claims and the RICO claims, which included RICO claims asserted against the former Mylan N.V. officer. Plaintiffs’ motions for reconsideration and to certify an interlocutory appeal of the summary judgment decision with respect to the RICO claims were denied. On July 8, 2021, the Mylan Defendants filed a motion to decertify the class action with respect to the remaining antitrust theory, which concerns a patent settlement between Pfizer and Teva and other alleged actions regarding the launch of Teva’s generic epinephrine auto-injector. The motion to decertify was granted in part, decertifying portions of the class action asserting claims under the laws of certain states and dismissing one named plaintiff, and was denied in all other respects. The Mylan Defendants had filed a motion for reconsideration of this decision, which was pending. In February 2022, the parties reached an agreement to fully resolve this matter for $264 million. The settlement is subject to court approval and contains an express provision disclaiming and denying any wrongdoing or liability by the Mylan Defendants. During the year ended December 31, 2021, the Company recognized an accrual of approximately $264.0 million related to this litigation.

On February 14, 2020, the Company, together with other non-Viatris affiliated companies, were named as defendants in a putative direct purchaser class action filed in the U.S. District Court for the District of Kansas relating to the pricing and/or marketing of the EpiPen® Auto-Injector. On September 21, 2021, after Plaintiffs’ then operative complaint was dismissed with an option to file a limited amended complaint, Plaintiffs filed an amended complaint asserting federal antitrust claims which are based on allegations that are similar to those in the putative indirect purchaser class actions discussed above. Plaintiffs’ seek monetary damages, declaratory relief, attorneys’ fees and costs.

140

Beginning in March 2020, the Company, together with other non-Viatris affiliated companies, were named as defendants in putative direct purchaser class actions filed in the U.S. District Court for the District of Minnesota relating to contracts with certain pharmacy benefit managers concerning EpiPen® Auto-Injector. The plaintiffs claim that the alleged conduct resulted in the exclusion or restriction of competing products and the elimination of pricing constraints in violation of RICO and federal antitrust law. These actions have been consolidated. Plaintiffs’ seek monetary damages, attorneys’ fees and costs.
On April 24, 2017, Sanofi Aventis U.S., LLC (“Sanofi”) filed a lawsuit against the Company in the U.S. District Court for the District of New Jersey. This lawsuit has been transferred into the aforementioned MDL and alleges exclusive dealing and anti-competitive marketing practices in violation of the antitrust laws in connection with the sale and marketing of the EpiPen® Auto-Injector. Sanofi seeks monetary damages, declaratory relief, attorneys’ fees and costs. The Court granted the Company’s motion for summary judgment and dismissed Sanofi’s claims. Sanofi’s appeal is pending.
The Company has a total accrual of approximately $274.0 million related to these matters at December 31, 2021, which is included in other current liabilities in the consolidated balance sheets. Although it is reasonably possible that the Company may incur additional losses from these matters, any amount cannot be reasonably estimated at this time. In addition, the Company expects to incur additional legal and other professional service expenses associated with such matters in future periods and will recognize these expenses as services are received. The Company believes that the ultimate amount paid for these services and claims could have a material effect on the Company's business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price in future periods.
Drug Pricing Matters
Department of Justice
On December 3, 2015, the Company received a subpoena from the Antitrust Division of the DOJ seeking information relating to the marketing, pricing, and sale of certain of our generic products and any communications with competitors about such products. On September 8, 2016, the Company, as well as certain employees and a member of senior management, received subpoenas from the DOJ seeking similar information. Related search warrants also were executed.
On May 10, 2018, the Company received a civil investigative demand from the Civil Division of the DOJ seeking information relating to the pricing and sale of its generic drug products.
We are fully cooperating with these investigations, which we believe are related to a broader industry-wide investigation of the generic pharmaceutical industry.
Civil Litigation
Beginning in 2016, the Company, along with other manufacturers, has been named as a defendant in lawsuits generally alleging anticompetitive conduct with respect to generic drugs. The lawsuits have been filed by plaintiffs, including putative classes of direct purchasers, indirect purchasers, and indirect resellers, as well as individual direct and indirect purchasers and certain cities and counties. They allege harm under federal and state laws, including federal and state antitrust laws, state consumer protection laws and unjust enrichment claims. Some of the lawsuits also name as defendants the Company’s President, including allegations against him with respect to a single drug product, and one of the Company’s sales employees, including allegations against him with respect to certain generic drugs. The vast majority of the lawsuits have been consolidated in an MDL proceeding in the Eastern District of Pennsylvania (“EDPA”). Plaintiffs generally seek monetary damages, restitution, declaratory and injunctive relief, attorneys’ fees and costs. The Court has ordered certain plaintiffs’ complaints regarding two single-drug product cases to proceed as bellwethers. The Company is named in those plaintiffs’ complaints that regard one of the two individual drug products.

141

Attorneys General Litigation
On December 21, 2015, the Company received a subpoena and interrogatories from the Connecticut Office of the Attorney General seeking information relating to the marketing, pricing and sale of certain of the Company’s generic products and communications with competitors about such products. On December 14, 2016, attorneys general of certain states originally filed a complaint in the United States District Court for the District of Connecticut against several generic pharmaceutical drug manufacturers, including the Company, alleging anticompetitive conduct with respect to, among other things, a single drug product. The complaint has subsequently been amended, including on June 18, 2018, to add attorneys general alleging violations of federal and state antitrust laws, as well as violations of various states’ consumer protection laws. This lawsuit has been transferred to the aforementioned MDL proceeding in the EDPA. The operative complaint includes attorneys general of forty-seven states, the District of Columbia and the Commonwealth of Puerto Rico. The Company is alleged to have engaged in anticompetitive conduct with respect to four generic drug products. The amended complaint also includes claims asserted by attorneys general of thirty-seven states and the Commonwealth of Puerto Rico against certain individuals, including the Company’s President, with respect to a single drug product. The amended complaint seeks declaratory and injunctive relief, disgorgement, attorneys’ fees and costs, and certain states seek monetary damages, civil penalties, and restitution.
On May 10, 2019, certain attorneys general filed a new complaint in the United States District Court for the District of Connecticut against various drug manufacturers and individuals, including the Company and one of its sales employees, alleging anticompetitive conduct with respect to additional generic drugs. On November 1, 2019, the complaint was amended, adding additional states as plaintiffs. The operative complaint is brought by attorneys general of forty-eight states, certain territories and the District of Columbia. The amended complaint also includes claims asserted by attorneys general of forty-three states and certain territories against several individuals, including a Company sales employee. The amended complaint seeks declaratory and injunctive relief, disgorgement, attorneys’ fees and costs, and certain states seek monetary damages, civil penalties, and restitution. This lawsuit has been transferred to the aforementioned MDL proceeding in the EDPA.
On June 10, 2020, certain attorneys general filed a new complaint in the United States District Court for the District of Connecticut against drug manufacturers, including the Company, and individual defendants (none from the Company), alleging anticompetitive conduct with respect to additional generic drugs. On September 9, 2021, the complaint was amended, adding an additional state as a plaintiff. The operative complaint is brought by attorneys general of forty-seven states, certain territories and the District of Columbia. The amended complaint seeks declaratory and injunctive relief, disgorgement, attorneys’ fees and costs, and certain states seek monetary damages, civil penalties, and restitution. This lawsuit has been transferred to the aforementioned MDL proceeding in the EDPA and has been ordered to proceed as a bellwether.

Securities Related Litigation
Purported class action complaints were filed in October 2016 against Mylan N.V. and Mylan Inc. (collectively “Mylan”), certain of Mylan’s former directors and officers, and certain of the Company’s current directors and officers (collectively, for purposes of this paragraph, the “defendants”) in the United States District Court for the Southern District of New York (“SDNY”) on behalf of certain purchasers of securities of Mylan on the NASDAQ. The complaints alleged that defendants made false or misleading statements and omissions of purportedly material fact, in violation of federal securities laws, in connection with disclosures relating to the classification of their EpiPen® Auto-Injector as a non-innovator drug for purposes of the Medicaid Drug Rebate Program. On March 20, 2017, a consolidated amended complaint was filed alleging substantially similar claims, but adding allegations that defendants made false or misleading statements and omissions of purportedly material fact in connection with allegedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs.

The operative complaint is the third amended consolidated complaint, which was filed on June 17, 2019, and contains the allegations as described above against Mylan, certain of Mylan’s former directors and officers, and certain of the Company’s current directors, officers, and employees (collectively, for purposes of this paragraph, the “defendants”). A class has been certified covering all persons or entities that purchased Mylan common stock between February 21, 2012 and May 24, 2019 excluding defendants, certain of the Company’s current directors and officers, former directors and officers of Mylan, members of their immediate families and their legal representatives, heirs, successors or assigns, and any entity in which defendants have or had a controlling interest. Plaintiffs seek damages and costs and expenses, including attorneys’ fees and expert costs. A decision on Defendants’ motion for summary judgment seeking to dismiss the case in its entirety and Plaintiffs’ cross-motion for partial summary judgment as to portions of certain claims is pending.

142

On April 30, 2017, a similar lawsuit was filed in the Tel Aviv District Court (Economic Division) in Israel, which has been stayed pending a decision in the SDNY class action litigation.
On February 14, 2020, the Abu Dhabi Investment Authority filed a complaint against Mylan in the SDNY asserting allegations pertaining to EpiPen® Auto-Injector and certain generic drugs under the federal securities laws that overlap with those asserted in the third amended complaint identified above. The Abu Dhabi Investment Authority’s complaint seeks monetary damages as well as the plaintiff’s fees and costs.

On February 26, 2019, MYL Litigation Recovery I LLC (“MYL Plaintiff”) (an assignee of entities that purportedly purchased stock of Mylan N.V.) filed an additional complaint in the SDNY against Mylan, certain of Mylan’s former officers and directors, and an officer of the Company asserting allegations pertaining to EpiPen® Auto-Injector under the federal securities laws that overlap in part with those asserted in the third amended complaint identified above. On May 6, 2020, MYL Plaintiff filed an amended complaint including additional allegations in connection with purportedly anticompetitive conduct with respect to EpiPen® Auto-Injector.
MYL Plaintiff subsequently filed a summons on October 30, 2020, naming Mylan, certain of Mylan’s former officers and directors, and certain of the Company’s current officers, directors, and employees in New York State Court, County of New York, claiming investment losses suffered as a result of purportedly false and misleading statements in connection with allegedly anticompetitive conduct concerning generic pharmaceuticals. The parties have resolved both matters filed by MYL Plaintiff and they have been dismissed with prejudice.

On June 26, 2020, a putative class action complaint was filed by the Public Employees Retirement System of Mississippi, which was subsequently amended on November 13, 2020, against Mylan N.V., certain of Mylan N.V.’s former directors and officers, and an officer and director of the Company (collectively for the purposes of this paragraph, the “defendants”) in the U.S. District Court for the Western District of Pennsylvania on behalf of certain purchasers of securities of Mylan N.V. The amended complaint alleges that defendants made false or misleading statements and omissions of purportedly material fact, in violation of federal securities laws, in connection with disclosures relating to the Morgantown manufacturing plant and inspections at the plant by the FDA. Plaintiff seeks certification of a class of purchasers of Mylan N.V. securities between February 16, 2016 and May 7, 2019. The complaint seeks monetary damages, as well as the plaintiff’s fees and costs.
On February 15, 2021, a complaint was filed by Skandia Mutual Life Ins. Co., Lansforsakringar AB, KBC Asset Management N.V., and GIC Private Limited, against the Company, certain of Mylan N.V.’s former directors and officers, a current director and officer of the Company, and current employees of the Company. The Complaint asserts claims which are based on allegations that are similar to those in the SDNY and the Western District of Pennsylvania complaints identified above. Plaintiffs seek compensatory damages, costs and expenses and attorneys’ fees.

On October 28, 2021, the Company and certain of its officers and directors were named as defendants in a putative class action lawsuit filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan shareholders who received Company common stock in connection with the Combination. A non-Viatris affiliated company and persons were also named as defendants. The complaint alleges violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 for purportedly failing to disclose or misrepresenting material information in the registration statement and related prospectus issued in connection with the Combination. Plaintiffs seek monetary damages, reasonable costs and expenses, and certain other equitable and injunctive relief.

Opioids
The Company, along with other manufacturers, distributors, pharmacies, pharmacy benefit managers, and individual healthcare providers is a defendant in more than 1,000 cases in the United States and Canada filed by various plaintiffs, including counties, cities and other local governmental entities, asserting civil claims related to sales, marketing and/or distribution practices with respect to prescription opioid products. In addition, lawsuits have been filed as putative class actions including on behalf of children with Neonatal Abstinence Syndrome due to alleged exposure to opioids.
The lawsuits generally seek equitable relief and monetary damages (including punitive and/or exemplary damages) based on a variety of legal theories, including various statutory and/or common law claims, such as negligence, public nuisance and unjust enrichment. The vast majority of these lawsuits have been consolidated in an MDL in the U.S. District Court for the Northern District Court of Ohio.
143

In November 2019, the Company received a subpoena from the New York Department of Financial Services as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. The Company is fully cooperating with this subpoena request.
European Commission Proceedings
Perindopril
On July 9, 2014, the Commission issued a decision finding that the Company as well as several other companies, had violated EU competition rules relating to the product Perindopril and fined the Company approximately €17.2 million. The Company paid approximately $21.7 million related to this matter during the fourth quarter of 2014. The decision was affirmed on appeal by the General Court of the EU and is now on appeal to the CJEU. The Company has received a notice from an organization representing health insurers in the Netherlands stating an intention to commence follow-on litigation and asserting monetary damages.
Citalopram
On June 19, 2013, the Commission issued a decision finding that the Company as well as several other companies, had violated EU competition rules relating to the product Citalopram and fined the Company approximately €7.8 million, jointly and severally with Merck KGaA. The decision was affirmed on appeal by the General Court of the EU and the CJEU. The Commission’s matter as to the Company is now closed. The Company has received notices from European NHS and health insurers stating an intention to commence follow-on litigation and asserting monetary damages. The NHS England and Wales has instituted litigation against all parties to the Commission’s decision, including the Company.

The Company sought indemnification from Merck KGaA with respect to the €7.8 million portion of the fine for which Merck KGaA and the Company were held jointly and severally liable. Merck KGaA counterclaimed against the Company seeking the same indemnification. In June 2018, the Frankfurt Regional Court issued a judgment ordering the Company to indemnify Merck KGaA with respect to the amount for which the parties were held jointly and severally liable. The parties have resolved this matter.

The Company has accrued approximately €11.4 million as of December 31, 2021 related to this matter. It is reasonably possible that we will incur additional losses above the amount accrued but we cannot estimate a range of such reasonably possible losses at this time. There are no assurances, however, that settlements reached and/or adverse judgments received, if any, will not exceed amounts accrued.
U.K. Competition and Markets Authority
Paroxetine
On August 12, 2011, the Company received notice that the Office of Fair Trading (now the “CMA”) opened an investigation regarding possible infringement of the Competition Act 1998 and Articles 101 and 102 of the Treaty on the Functioning of the EU, with respect to alleged agreements related to Paroxetine. The CMA issued a decision on February 12, 2016, finding that the Company, Merck KGaA, and other companies were liable for infringing EU and U.K. competition rules. The CMA issued a penalty to Merck KGaA of approximately £5.8 million, for which the Company is jointly and severally liable for approximately £2.7 million. On appeal, the Competition Appeals Tribunal affirmed the CMA’s decision but reduced the penalty to Merck KGaA to approximately £3.9 million, and reduced the amount for which the Company is jointly and severally liable to approximately £2.05 million. The CMA’s matter as to the Company is now closed.

The Company has also received a notice from the NHS England and Wales stating an intention to commence follow-on litigation and asserting monetary damages.
The Company has accrued approximately £8.8 million as of December 31, 2021 related to this matter. It is reasonably possible that the Company will incur additional losses above the amount accrued but we cannot estimate a range of such reasonably possible losses at this time. There are no assurances, however, that settlements reached and/or adverse judgments received, if any, will not exceed amounts accrued.
144

Product Liability
Like other pharmaceutical companies, the Company is involved in a number of product liability lawsuits related to alleged personal injuries arising out of certain products manufactured/or distributed by the Company, including but not limited to those discussed below. Plaintiffs in these cases generally seek damages and other relief on various grounds for alleged personal injury and economic loss.
The Company has accrued approximately $74.8 million as of December 31, 2021 for its product liability matters. It is reasonably possible that we will incur additional losses and fees above the amount accrued but we cannot estimate a range of such reasonably possible losses or legal fees related to these claims at this time. There are no assurances, however, that settlements reached and/or adverse judgments received, if any, will not exceed amounts accrued.
Nitrosamines
The Company, along with numerous other manufacturers, retailers, and others, are parties to litigation relating to alleged trace amounts of nitrosamine impurities in certain products, including valsartan and ranitidine. The vast majority of these lawsuits in the United States are pending in two MDLs, namely an MDL pending in the United States District Court for the District of New Jersey concerning valsartan and an MDL pending in the United States District Court for the Southern District of Florida concerning ranitidine. The lawsuits against the Company in the MDLs include putative class actions seeking the refund of the purchase price and other economic and punitive damages allegedly sustained by consumers and end payors as well as individuals seeking compensatory and punitive damages for personal injuries allegedly caused by ingestion of the medications. Similar lawsuits pertaining to valsartan have been filed in other countries. The Company has also received claims and inquiries related to these products, as well as requests to indemnify purchasers of the Company’s API and/ or finished dose forms of these products. The original master complaints concerning ranitidine were dismissed on December 31, 2020. The Company was not named as a defendant in the amended master complaints, though it was still named in certain short form personal injury complaints. The end-payor plaintiffs and certain of the plaintiffs named in the short form personal injury complaints in the ranitidine matter have filed appeals to the U.S. Court of Appeals for the Eleventh Circuit.

Lipitor
A number of individual and multi-plaintiff lawsuits have been filed against Pfizer in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to an MDL in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the MDL were remanded to certain state courts. In 2017, the District Court granted Pfizer’s motion for summary judgment, dismissing all of the cases pending in the MDL. In June 2018, this dismissal was affirmed by the U.S. Court of Appeals for the Fourth Circuit. The state court proceedings remain pending in various jurisdictions, including in California, Missouri, and New York. On January 27, 2021, the California Court granted Pfizer’s motion to exclude the opinions of plaintiffs’ only general causation expert in connection with his opinions involving the three lowest doses of Lipitor (10, 20 and 40 mg). The Company’s motion for summary judgment in connection with the 10, 20, and 40 mg plaintiffs was granted, resulting in their dismissal. On November 3, 2021, the Court granted the Company’s motion seeking the dismissal of the remaining cases involving the highest dose of Lipitor (80 mg).

Viagra
Since April 2016, an MDL has been pending in the U.S. District Court for the Northern District of California, in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Eli Lilly and Company (“Lilly”) with respect to Cialis have also been consolidated in the MDL. Plaintiffs seek compensatory and punitive damages. In January 2020, the District Court granted Pfizer’s and Lilly’s motion to exclude all of plaintiffs’ general causation opinions. As a result, in April 2020, the District Court entered summary judgment in favor of defendants and dismissed all of plaintiffs’ claims. In April 2020, plaintiffs filed a notice of appeal in the U.S. Court of Appeals for the Ninth Circuit. The parties have reached a settlement in principle.
Dilantin
Since 2018, a number of individual and multi-plaintiff lawsuits have been filed against Pfizer and related entities in various federal and state courts, alleging that the plaintiffs developed cerebellar atrophy as a result of the ingestion of Dilantin. Plaintiffs seek compensatory and punitive damages. The parties have resolved this matter.
145

Intellectual Property
The Company is involved in a number of patent litigation lawsuits involving the validity and/or infringement of patents held by branded pharmaceutical manufacturers including but not limited to the matters described below. The Company uses its business judgment to decide to market and sell certain products, in each case based on its belief that the applicable patents are invalid and/or that its products do not infringe, notwithstanding the fact that allegations of patent infringement(s) or other potential third party rights have not been finally resolved by the courts. The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement may include, a reasonable royalty on sales or damages measured by the profits lost by the patent owner. If there is a finding of willful infringement, damages may be increased up to three times. Moreover, because of the discount pricing typically involved with bioequivalent products, patented branded products generally realize a substantially higher profit margin than generic and biosimilar products. The Company also faces challenges to its patents, including suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments, or other parties are seeking damages for allegedly causing delay of generic entry. An adverse decision in any of these matters could have an adverse effect that is material to our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price.
The Company has accrued approximately $226.9 million as of December 31, 2021 for its intellectual property matters. It is reasonably possible that we will incur additional losses and fees above the amount accrued but we cannot estimate a range of such reasonably possible losses or legal fees related to these claims at this time. There are no assurances, however, that settlements reached and/or adverse judgments received, if any, will not exceed amounts accrued.
Insulin Glargine
On October 24, 2017, Sanofi and affiliated entities (collectively for the purposes of this section, “Sanofi”), sued Mylan GmbH and other Mylan entities in the U.S. District Court for the District of New Jersey asserting that Mylan GmbH’s new drug application for insulin glargine injection 100 Units/mL vials and prefilled injection pens (SEMGLEE® vial and pens) infringed 18 U.S. patents. 2 of the 18 patents covered the insulin glargine formulation. Both of these patents have been held invalid and all appeals have concluded. These two patents were the only patents asserted against the SEMGLEE® vial product.
The 16 other asserted patents relate to a pen injection device (“device patents”) and were asserted only against the SEMGLEE® pen injection device. Prior to trial, Sanofi dismissed 12 of those device patents from the case and granted the Company a covenant not to sue with respect to them. On June 17, 2019, following the District Court’s claim construction order, the District Court entered judgment of non-infringement with respect to the asserted claims of three of the four remaining device patents (U.S. Patent Numbers 8,603,044, 8,679,069, 8,992,486).
Only one device patent remained for trial (U.S. Patent Number 9,526,844). On March 9, 2020, the District Court issued an opinion after trial finding all asserted claims of the ‘844 patent not infringed and invalid for lack of written description.
On September 10, 2018, Mylan Pharmaceuticals Inc. (“MPI”) filed IPR petitions challenging five device patents (the ‘844, ‘044, ‘069, ‘486, and ‘008 patents). On April 2, 2020 and May 29, 2020, the PTAB issued final written decisions in the IPR proceedings finding all challenged claims unpatentable except for two claims of the ‘008 patent for which Sanofi granted the Company a covenant not to sue as described above. On appeal, the Federal Circuit affirmed the PTAB’s decisions finding the challenged patents unpatentable, including the ‘844 patent, and dismissed Sanofi’s appeal of the District Court decision as moot.
On March 26, 2021, the PTAB issued a final written decision in an IPR proceeding in which MPI challenged an additional Sanofi device patent (U.S. Patent Number RE47,614) and found all challenged claims unpatentable. Sanofi’s appeal is pending.

On June 11, 2020, the FDA approved the SEMGLEE® vial and pen products, which MPI began selling on August 31, 2020.
146

Dimethyl Fumarate
On June 30, 2017, Biogen MA Inc. and Biogen International GmbH (collectively, “Biogen”) sued MPI in the U.S. District Court for the Northern District of West Virginia asserting that MPI’s abbreviated new drug application for dimethyl fumarate delayed-release capsules containing 120 mg and 240 mg of dimethyl fumarate (generic for Tecfidera®) infringed six U.S. patents that Biogen had listed in the Orange Book: 6,509,376, 7,320,999, 7,619,001, 7,803,840, 8,759,393, and 8,399,514. All patents except for the ‘514 expired during the litigation and were dismissed from the case.
After a trial involving only the ’514 patent on June 18, 2020, the District Court issued a judgment finding all claims of the ’514 patent invalid for lack of adequate written description. On appeal, the Federal Circuit affirmed the District Court’s judgment. Biogen has filed a petition for rehearing.
On July 13, 2018, MPI filed an IPR petition challenging the ’514 patent based only on obviousness. On February 5, 2020, the PTAB issued a final written decision finding the claims not obvious. MPI’s appeal was denied as moot in light of the above-described Federal Circuit decision affirming the District Court’s invalidity judgment.

On August 17, 2020, the FDA approved MPI’s dimethyl fumarate delayed-release capsules, which MPI began selling on August 18, 2020.
Lyrica - United Kingdom
Beginning in 2014, Pfizer was involved in patent litigation in the English courts concerning the validity of its Lyrica pain use patent. In 2015, the High Court of Justice in London ordered that the NHS England issue guidance for prescribers and pharmacists directing the prescription and dispensing of Lyrica by brand when pregabalin was prescribed for the treatment of neuropathic pain and entered a preliminary injunction against certain Sandoz group companies preventing the sale of Sandoz’s full label pregabalin product. Pfizer undertook to compensate certain generic companies and NHS entities for losses caused by these orders, which remained in effect until patent expiration in July 2017. In November 2018, the U.K. Supreme Court ruled that all the relevant claims directed to neuropathic pain were invalid.
Dr. Reddy’s Laboratories filed a claim for monetary damages, interest, and costs in May 2020, followed by the Scottish Ministers and fourteen Scottish Health Boards (together, NHS Scotland) in July 2020. In September 2020, Teva, Sandoz, Ranbaxy, Actavis, and the Secretary of State for Health and Social Care, together with 32 other NHS entities (together, NHS England, Wales, Scotland and Northern Ireland) filed their claims. The claims filed by Sandoz, Teva, Actavis, and Ranbaxy have been resolved.

Lyrica - Canada
In June 2014, Pharmascience Inc. (“PMS”) commenced an action against Pfizer Canada Inc., Warner-Lambert Company and Warner-Lambert Company LLC (the Pfizer Canada Defendants) seeking damages in connection with an earlier unsuccessful patent litigation brought by the Pfizer Canada Defendants involving pregabalin. PMS claimed lost profit damages from November 30, 2010, the date it received tentative regulatory approval for its pregabalin product, to February 13, 2013, the date Pfizer’s patent case against PMS was dismissed. The parties have resolved the matter.

Other Litigation
The Company is involved in various other legal proceedings including commercial, contractual, employment, or other similar matters that are considered normal to its business. The Company has approximately $8.4 million accrued related to these various other legal proceedings at December 31, 2021.
147

ITEM 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosures
None.
ITEM 9A.Controls and Procedures
An evaluation was performed under the supervision and with the participation of the Company’s management, including the Principal Executive Officer and the Principal Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of December 31, 2021. Based upon that evaluation, the Principal Executive Officer and the Principal Financial Officer concluded that the Company’s disclosure controls and procedures were effective.
During the quarter ended December 31, 2021, the Company continued to transition certain support services from Pfizer, as well as certain subsidiaries, to a new ERP system. The Company has modified and will continue to modify its internal controls relating to its business and financial processes throughout the transition period, which is expected through the end of calendar year 2022. While the Company believes that this new system and the related changes to internal controls will ultimately strengthen its internal control over financial reporting, there are inherent risks in implementing any new ERP system and the Company has evaluated and tested control changes in order to provide Management’s Report on Internal Control over Financial Reporting for the year ended December 31, 2021.
Management’s Report on Internal Control over Financial Reporting is on page 79, which is incorporated herein by reference. The effectiveness of the Company’s internal control over financial reporting as of December 31, 2021 has been audited by Deloitte & Touche LLP (PCAOB ID No. 34), an independent registered public accounting firm, as stated in their report on page 83, which is incorporated herein by reference.
ITEM 9B.Other Information
None.
ITEM 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
148

PART III
ITEM 10.Directors, Executive Officers and Corporate Governance
Certain information required by this Item will be provided in an amendment to this Annual Report on Form 10-K in accordance with General Instruction G(3) to Form 10-K.
Code of Ethics
The Viatris board of directors has adopted a Code of Ethics for the Company’s Chief Executive Officer, Chief Financial Officer and Controller. The Viatris board of directors also has adopted a Code of Business Conduct and Ethics applicable to all directors, officers, and employees. The Code of Ethics for our Chief Executive Officer, Chief Financial Officer and Controller and the Code of Business Conduct and Ethics are posted on Viatris’ website at http://www.viatris.com/en/About-Us/Corporate-Governance, and Viatris intends to post any amendments to and waivers from each of the Code of Ethics for the Company’s Chief Executive Officer, Chief Financial Officer and Controller and the Code of Business Conduct and Ethics that are required to be disclosed on that website.
ITEM 11.Executive Compensation
The information required by this Item will be provided in an amendment to this Annual Report on Form 10-K in accordance with General Instruction G(3) to Form 10-K.
ITEM 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The additional information required by this Item will be provided in an amendment to this Form 10-K in accordance with General Instruction G(3) to Form 10-K.
Equity Compensation Plan Information
The following table shows information about the securities authorized for issuance under Viatris’ equity compensation plans as of December 31, 2021:
Number of Securities to be
Issued upon Exercise of
Outstanding Options,
Warrants and Rights
(a)
Weighted-Average Exercise
Price of Outstanding
Options, Warrants and
Rights
(b)
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation Plans
(excluding securities reflected
in column (a))
(c)
Plan Category
Equity compensation plans approved by security holders22,434,618 $20.60 59,591,643 
Equity compensation plans not approved by security holders— — — 
Total22,434,618 $20.60 59,591,643 
ITEM 13.Certain Relationships and Related Transactions, and Director Independence
The information required by this Item will be provided in an amendment to this Annual Report on Form 10-K in accordance with General Instruction G(3) to Form 10-K.
ITEM 14.Principal Accounting Fees and Services
The information required by this Item will be provided in an amendment to this Annual Report on Form 10-K in accordance with General Instruction G(3) to Form 10-K.
149

PART IV
ITEM 15.Exhibits, Consolidated Financial Statement Schedules
1.Consolidated Financial Statements
The Consolidated Financial Statements listed in the Index to Consolidated Financial Statements are filed as part of this Form.
2.Consolidated Financial Statement Schedules
VIATRIS INC. AND SUBSIDIARIES
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
(In millions)
DescriptionBeginning
Balance
Additions Charged to Costs and Expenses
Additions Charged to Other
Accounts
(1)
DeductionsEnding
Balance
Allowance for doubtful accounts:
Year ended December 31, 2021$159.9 16.0  (21.4)$154.5 
Year ended December 31, 2020$72.8 16.9 77.3 (7.1)$159.9 
Year ended December 31, 2019$98.2 14.2  (39.6)$72.8 
Valuation allowance for deferred tax assets:
Year ended December 31, 2021$443.6 82.2 260.8 (6.2)$780.4 
Year ended December 31, 2020$603.5 39.0  (198.9)$443.6 
Year ended December 31, 2019$806.0 36.8  (239.3)$603.5 
____________ 
(1)These amounts include opening balances of the Upjohn Business acquired in the Combination.

3.Exhibits
Business Combination Agreement, dated as of July 29, 2019, by and among Pfizer Inc., Upjohn Inc., Utah Acquisition Sub Inc., Mylan N.V., Mylan I B.V. and Mylan II B.V., included as Annex A to the Information Statement included as Exhibit 99.1 to the Report on Form 8-K filed by Upjohn Inc. with the SEC on August 6, 2020, and incorporated herein by reference.^

Amendment No. 1, dated as of May 29, 2020, to the Business Combination Agreement, dated as of July 29, 2019, by and among Pfizer Inc., Upjohn Inc., Utah Acquisition Sub Inc., Mylan N.V., Mylan I B.V. and Mylan II B.V., included as Annex B to the Information Statement included as Exhibit 99.1 to the Report on Form 8-K filed by Upjohn Inc. with the SEC on August 6, 2020, and incorporated herein by reference.^
Separation and Distribution Agreement, dated as of July 29, 2019, by and between Pfizer Inc. and Upjohn Inc., filed as Exhibit 2.2 to the Report on Form 8-K filed by Mylan N.V. with the SEC on July 29, 2019, and incorporated herein by reference.^
Amendment No. 1, dated as of February 18, 2020, to the Separation and Distribution Agreement, dated as of July 29, 2019, by and between Pfizer Inc. and Upjohn Inc., filed by Mylan N.V. as Exhibit 2.1 to the Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.
Amendment No. 2, dated as of May 29, 2020, to the Separation and Distribution Agreement, dated as of July 29, 2019, by and between Pfizer Inc. and Upjohn Inc., filed as Exhibit 2.2 to the Report on Form 8-K filed by Mylan N.V. with the SEC on June 1, 2020, and incorporated herein by reference. ^
Amendment No. 3, dated as of September 18, 2020, to the Separation and Distribution Agreement, dated as of July 29, 2019, by and between Pfizer Inc. and Upjohn Inc., filed as Exhibit 2.6 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^
150

Amendment No. 4, dated as of November 15, 2020, to the Separation and Distribution Agreement, dated as of July 29, 2019, by and between Pfizer Inc. and Upjohn Inc., filed as Exhibit 2.7 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^
Amended and Restated Certificate of Incorporation of Upjohn Inc., effective as of November 13, 2020, filed as Exhibit 3.1 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Upjohn Inc., effective as of November 16, 2020, filed as Exhibit 3.3 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Amended and Restated Bylaws of Viatris Inc., effective as of November 16, 2020, filed as Exhibit 3.2 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.

Indenture, dated December 21, 2012, between and among Mylan Inc., as issuer, the guarantors named therein, and The Bank of New York Mellon, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K filed by Mylan Inc. with the SEC on December 24, 2012, and incorporated herein by reference.
First Supplemental Indenture, dated February 27, 2015, between and among Mylan Inc., as issuer, Mylan N.V., as guarantor, and The Bank of New York Mellon, as trustee, to the Indenture, dated December 21, 2012, filed as Exhibit 4.4 to the Report on Form 8-K filed by Mylan N.V. with the SEC on February 27, 2015, and incorporated herein by reference.
Second Supplemental Indenture, dated March 12, 2015, between and among Mylan Inc., as issuer, Mylan N.V., as parent, and The Bank of New York Mellon, as trustee, to the Indenture, dated December 21, 2012, filed by Mylan N.V. as Exhibit 4.3(b) to Form 10-Q for the quarter ended March 31, 2015, and incorporated herein by reference.
Third Supplemental Indenture dated November 16, 2020, by and among Mylan Inc., Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V. and the Bank of New York Mellon, as trustee, to the Indenture dated December 21, 2012, by and between Mylan Inc. and the Bank of New York Mellon, as trustee, filed as Exhibit 4.6 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Indenture, dated November 29, 2013, between Mylan Inc. and The Bank of New York Mellon, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K filed by Mylan Inc. with the SEC on November 29, 2013, and incorporated herein by reference.
First Supplemental Indenture, dated November 29, 2013, between Mylan Inc. and The Bank of New York Mellon, as trustee, filed as Exhibit 4.2 to the Report on Form 8-K filed by Mylan Inc. with the SEC on November 29, 2013, and incorporated herein by reference.
Second Supplemental Indenture, dated February 27, 2015, among Mylan Inc., as issuer, Mylan N.V., as guarantor, and The Bank of New York Mellon, as trustee, to the Indenture, dated November 29, 2013, filed as Exhibit 4.6 to the Report on Form 8-K filed by Mylan N.V. with the SEC on February 27, 2015, and incorporated herein by reference.
Third Supplemental Indenture, dated March 12, 2015, between and among Mylan Inc., as issuer, Mylan N.V., as parent, and The Bank of New York Mellon, as trustee, to the Indenture, dated November 29, 2013, filed by Mylan N.V. as Exhibit 4.5(b) to Form 10-Q for the quarter ended March 31, 2015, and incorporated herein by reference.
Fourth Supplemental Indenture dated November 16, 2020, by and among Mylan Inc., Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V. and the Bank of New York Mellon, as trustee, to the Indenture dated November 29, 2013, by and between Mylan Inc. and the Bank of New York Mellon, as trustee, filed as Exhibit 4.7 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Indenture, dated as of December 9, 2015, among Mylan N.V., as issuer, Mylan Inc., as guarantor, and The Bank of New York Mellon, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K filed by Mylan N.V. with the SEC on December 15, 2015, and incorporated herein by reference.
First Supplemental Indenture dated November 16, 2020, by and among Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V., Mylan Inc. and the Bank of New York Mellon, as trustee, to the Indenture dated December 9, 2015, by and among Mylan N.V., Mylan Inc. and the Bank of New York Mellon, as trustee, filed as Exhibit 4.3 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Indenture, dated as of June 9, 2016, among Mylan N.V., as issuer, Mylan Inc., as guarantor, and The Bank of New York Mellon, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K filed by Mylan N.V. with the SEC on June 15, 2016, and incorporated herein by reference.
151

First Supplemental Indenture dated November 16, 2020, by and among Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V., Mylan Inc. and the Bank of New York Mellon, as trustee, to the Indenture dated June 9, 2016, by and among Mylan N.V., Mylan Inc. and the Bank of New York Mellon, as trustee, filed as Exhibit 4.4 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Indenture, dated November 22, 2016, among Mylan N.V., as issuer, Mylan, Inc., as guarantor and Citibank, N.A., London Branch, as trustee, paying agent, transfer agent, registrar and calculation agent, filed by Mylan N.V. as Exhibit 4.9 to Form 10-K for the fiscal year ended December 31, 2016, and incorporated herein by reference.
First Supplemental Indenture dated November 16, 2020, by and among Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V., Mylan Inc. and Citibank, N.A., London Branch, as trustee, paying agent, transfer agent, and registrar, to the Indenture dated November 22, 2016, by and among Mylan N.V., Mylan Inc. and Citibank, N.A., London Branch, as trustee, paying agent, transfer agent, registrar and calculation agent, filed as Exhibit 4.5 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Indenture, dated as of April 9, 2018, among Mylan Inc., as issuer, Mylan N.V., as guarantor, and the Bank of New York Mellon, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K filed by Mylan N.V. with the SEC on April 9, 2018, and incorporated herein by reference.
First Supplemental Indenture dated November 16, 2020, by and among Mylan Inc., Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V. and the Bank of New York Mellon, as trustee, to the Indenture dated April 9, 2018, by and among Mylan Inc., Mylan N.V. and the Bank of New York Mellon, as trustee, filed as Exhibit 4.8 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Indenture, dated as of May 23, 2018, among Mylan Inc., as issuer, Mylan N.V., as guarantor, and Citibank, N.A., London Branch, as trustee, paying agent, transfer agent and registrar, filed as Exhibit 4.1 to the Report on Form 8-K filed by Mylan N.V. with the SEC on May 23, 2018, and incorporated herein by reference.
First Supplemental Indenture dated November 16, 2020, by and among Mylan Inc., Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V. and Citibank, N.A., London Branch, as trustee, paying agent, transfer agent, and registrar, to the Indenture dated May 23, 2018, by and among Mylan Inc., Mylan N.V. and Citibank, N.A., London Branch, as trustee, paying agent, transfer agent, and registrar, filed as Exhibit 4.9 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Indenture, dated as of June 22, 2020, between Upjohn Inc., as issuer, and The Bank of New York Mellon, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K filed by Upjohn Inc. with the SEC on June 26, 2020, and incorporated herein by reference.
First Supplemental Indenture dated November 16, 2020, by and among Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V., Mylan Inc. and the Bank of New York Mellon, as trustee, to the Indenture dated June 22, 2020, by and among Viatris Inc. and the Bank of New York Mellon, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Indenture, dated as of June 23, 2020, among Upjohn Finance B.V., as issuer, Upjohn Inc., as guarantor, and Citibank, N.A., London Branch, as trustee, transfer agent, paying agent and registrar, filed as Exhibit 4.9 to the Report on Form 8-K filed by Upjohn Inc. with the SEC on June 26, 2020, and incorporated herein by reference.
First Supplemental Indenture dated November 16, 2020, by and among Upjohn Finance B.V., Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V., Mylan Inc. and Citibank, N.A., London Branch, as trustee, paying agent, transfer agent, and registrar, to the Indenture dated June 23, 2020, by and among Upjohn Finance B.V., Viatris Inc. and Citibank, N.A., London Branch, as trustee, paying agent, transfer agent, and registrar, filed as Exhibit 4.2 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Description of Viatris Inc. Securities Registered Under Section 12 of the Exchange Act, filed as Exhibit 4.10 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.
152

Viatris Inc. 2020 Stock Incentive Plan, included as Exhibit 10.1 to Amendment No. 1 to Form 10 filed by Upjohn Inc. with the SEC on February 6, 2020, and incorporated herein by reference.*
Form of Make-Whole Restricted Stock Unit Award Agreement under the Viatris 2020 Stock Incentive Plan, filed as Exhibit 10.1(b) to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Form of Retention Restricted Stock Unit Award Agreement under the Viatris 2020 Stock Incentive Plan, filed as Exhibit 10.1(c) to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Form of Restricted Stock Unit Award Agreement under the Viatris 2020 Stock Incentive Plan for Michael Goettler and Sanjeev Narula, filed as Exhibit 10.1(d) to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Value Creation Incentive Award Performance-Based Restricted Stock Unit Award Agreement for Robert J. Coury under the Viatris Inc. 2020 Stock Incentive Plan, effective as of November 23, 2020, filed as Exhibit 10.1(e) to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Form of Restricted Stock Unit Award Agreement under the Viatris Inc. 2020 Stock Incentive Plan for awards granted on or after March 2, 2021, included as Exhibit 10.1 to Form 10-Q for the quarter ended March 31, 2021 and incorporated by reference herein.*
Form of Performance-Based Restricted Stock Unit Award Agreement under the Viatris Inc. 2020 Stock Incentive Plan for awards granted on or after March 2, 2021, included as Exhibit 10.2 to Form 10-Q for the quarter ended March 31, 2021 and incorporated by reference herein.*
Form of Director Restricted Stock Unit Award Agreement under the Viatris Inc. 2020 Stock Incentive Plan for non-employee directors for awards granted on or after March 2, 2021, included as Exhibit 10.3 to Form 10-Q for the quarter ended March 31, 2021 and incorporated by reference herein.*
Letter Agreement entered into on February 6, 2020 by and between Pfizer Inc. and Sanjeev Narula, filed as Exhibit 10.2 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Letter Agreement entered into on June 25, 2019 by and between Pfizer Inc. and Sanjeev Narula, filed as Exhibit 10.3 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Letter Agreement entered into on June 26, 2019 by and between Pfizer Inc. and Michael Goettler, filed as Exhibit 10.4 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Letter Agreement entered into on July 29, 2019 by and between Pfizer Inc. and Michael Goettler, filed as Exhibit 10.5 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Severance Agreement entered into on December 3, 2020 by and between Viatris Inc. and Michael Goettler, filed as Exhibit 10.6 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Retention Agreement entered into on December 3, 2020, by and between Viatris Inc. and Rajiv Malik, filed as Exhibit 10.7 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Retention Agreement entered into on December 3, 2020, by and between Viatris Inc. and Anthony Mauro, filed as Exhibit 10.1 to Amendment No. 1 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Executive Employment Agreement, entered into on November 20, 2020, by and between Viatris Inc. and Robert J. Coury, filed as Exhibit 10.9 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Mylan N.V. Amended and Restated 2003 Long-Term Incentive Plan, filed as Appendix B to Mylan N.V.’s Definitive Proxy Statement on Schedule 14A filed by Mylan N.V. with the SEC on May 25, 2016, and incorporated herein by reference.*
153

Amendment to Mylan N.V. Amended and Restated 2003 Long-Term Incentive Plan, filed as Appendix B to Mylan N.V.’s Definitive Proxy Statement on Schedule 14A filed by Mylan N.V. on May 25, 2016, and incorporated herein by reference.*
Amendment to the Mylan N.V. Amended and Restated 2003 Long-Term Incentive Plan, adopted as of February 23, 2017, filed by Mylan N.V. as Exhibit 10.1 to Form 10-Q for the quarter ended March 31, 2017, and incorporated herein by reference.*
Amended and Restated Form of Stock Option Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for Robert J. Coury and Rajiv Malik, filed by Mylan Inc. as Exhibit 10.2 to Form 10-Q for the quarter ended September 30, 2013, and incorporated herein by reference.*
Amended and Restated Form of Stock Option Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for awards granted following fiscal year 2012, filed by Mylan Inc. as Exhibit 10.4(i) to Form 10-K for the fiscal year ended December 31, 2013, and incorporated herein by reference.*
Form of Stock Option Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for Robert J. Coury and Rajiv Malik for awards granted after February 27, 2015, filed by Mylan N.V. as Exhibit 10.1(i) to Form 10-K for the fiscal year ended December 31, 2015, and incorporated herein by reference.*
Form of Stock Option Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for awards granted after February 27, 2015, filed by Mylan N.V. as Exhibit 10.1(l) to Form 10-K for the fiscal year ended December 31, 2015, and incorporated herein by reference.*
Form of Performance-Based Restricted Stock Unit Award Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for Rajiv Malik for awards granted on or after February 21, 2018, filed by Mylan N.V. as Exhibit 10.2 to Form 10-Q for the quarter ended March 31, 2018, and incorporated herein by reference.*
Form of Performance-Based Restricted Stock Unit Award Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for awards granted on or after February 21, 2018, filed by Mylan N.V. as Exhibit 10.3 to Form 10-Q for the quarter ended March 31, 2018, and incorporated herein by reference.*
Form of Stock Option Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for Rajiv Malik for awards granted on or after February 19, 2019, filed by Mylan N.V. as Exhibit 10.7 to Form 10-Q for the quarter ended March 31, 2019, and incorporated herein by reference.*
Form of Restricted Stock Unit Award Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for Rajiv Malik for awards granted on or after February 19, 2019, filed by Mylan N.V. as Exhibit 10.8 to Form 10-Q for the quarter ended March 31, 2019, and incorporated herein by reference.*
Form of Performance-Based Restricted Stock Unit Award Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for Rajiv Malik for awards granted on or after February 19, 2019, filed by Mylan N.V. as Exhibit 10.6 to Form 10-Q for the quarter ended March 31, 2019, and incorporated herein by reference.*

Form of Restricted Stock Unit Award Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for independent directors for awards granted on or after March 2, 2020, filed by Mylan N.V. as Exhibit 10.1 to Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.*
Form of Stock Option Agreement under the Mylan N.V. 2003 Long-Term Incentive Plan for independent directors for awards granted on or after March 2, 2020, filed by Mylan N.V. as Exhibit 10.2 to Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.*
Mylan N.V. Severance Plan and Global Guidelines, filed by Mylan N.V. as Exhibit 10.1 to Form 10-Q for the quarter ended September 30, 2019, and incorporated herein by reference.*

Retirement Benefit Agreement, dated August 31, 2009, by and between Mylan Inc. and Rajiv Malik, filed by Mylan Inc. as Exhibit 10.4 to Form 10-Q for the quarter ended September 30, 2009, and incorporated herein by reference.*
Transition and Succession Agreement, dated January 31, 2007, between Mylan Inc. and Rajiv Malik, filed by Mylan Inc. as Exhibit 10.5 to Form 10-Q for the quarter ended March 31, 2008, and incorporated herein by reference.*
Amendment No. 1 to Transition and Succession Agreement, dated December 22, 2008, between Mylan Inc. and Rajiv Malik, filed by Mylan Inc. as Exhibit 10.28(b) to Form 10-K for the fiscal year ended December 31, 2008, and incorporated herein by reference.*
154

Transition and Succession Agreement, dated February 25, 2008, by and between Mylan Inc. and Anthony Mauro, filed by Mylan Inc. as Exhibit 10.5(a) to Form 10-Q for the quarter ended March 31, 2012, and incorporated herein by reference.*
Amendment No. 1 to Transition and Succession Agreement, dated December 15, 2008, by and between Mylan Inc. and Anthony Mauro, filed by Mylan Inc. as Exhibit 10.5(b) to Form 10-Q for the quarter ended March 31, 2012, and incorporated herein by reference.*
Amendment No. 2 to Transition and Succession Agreement, dated October 15, 2009, by and between Mylan Inc. and Anthony Mauro, filed by Mylan Inc. as Exhibit 10.5(c) to Form 10-Q for the quarter ended March 31, 2012, and incorporated herein by reference.*
Mylan 401(k) Restoration Plan, dated January 1, 2010, filed by Mylan Inc. as Exhibit 10.1 to the Report on Form 8-K filed by Mylan Inc. with the SEC on December 14, 2009, and incorporated herein by reference.*
Amendment to Mylan 401(k) Restoration Plan, dated November 4, 2014, filed by Mylan Inc. as Exhibit 10.41(b) to Form 10-K for the fiscal year ended December 31, 2014, and incorporated herein by reference.*
Mylan Executive Income Deferral Plan, filed by Mylan Inc. as Exhibit 10.2 to the Report on Form 8-K filed by Mylan Inc. with the SEC on December 14, 2009, and incorporated herein by reference.*
Amendment to Mylan Executive Income Deferral Plan, dated November 4, 2014, filed by Mylan Inc. as Exhibit 10.42(b) to Form 10-K for the fiscal year ended December 31, 2014, and incorporated herein by reference.*
The Executive Nonqualified Excess Plan Adoption Agreement, effective as of December 28, 2007, between Mylan International Holdings, Inc. and Rajiv Malik, filed by Mylan Inc. as Exhibit 10.27(b) to Form 10-K for the fiscal year ended December 31, 2013, and incorporated herein by reference.*
The Executive Nonqualified Excess Plan, effective as of December 28, 2007, between Mylan International Holdings, Inc. and Rajiv Malik, filed by Mylan Inc. as Exhibit 10.57 to Form 10-K for the fiscal year ended December 31, 2013, and incorporated herein by reference.*
Executive Employment Agreement, entered into on April 15, 2020, by and between Mylan N.V., Mylan Inc. and Robert J. Coury, filed by Mylan N.V. as Exhibit 10.3 to Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.*
Third Amended and Restated Executive Employment Agreement, entered into on February 25, 2019, and effective as of April 1, 2019, by and between Mylan Inc. and Rajiv Malik, filed by Mylan N.V. as Exhibit 10.20(c) to Form 10-K for the fiscal year ended December 31, 2018, and incorporated herein by reference.*
Executive Employment Agreement, dated as of February 25, 2019, and effective as of April 1, 2019, by and between Mylan Inc. and Anthony Mauro, filed as Exhibit 10.21(b) to Form 10-K for the fiscal year ended December 31, 2018, and incorporated herein by reference.*
Letter Agreement, dated June 3, 2016, among Mylan N.V., Mylan Inc., and Robert J. Coury, filed by Mylan N.V. as Exhibit 10.5 to Form 10-Q for the quarter ended June 30, 2016, and incorporated herein by reference.*
Form of Waiver Letter with respect to Specified Award Agreements by and between Mylan N.V. and Rajiv Malik, February 23, 2017, filed by Mylan N.V. as Exhibit 10.4 to Form 10-Q for the quarter ended March 31, 2017, and incorporated herein by reference. *
2007 Supplemental Health Insurance Plan for Certain Key Employees of Mylan Laboratories Inc., adopted as of January 29, 2007, filed by Mylan N.V. as Exhibit 10.29 to the Form 10-K for the fiscal year ended December 31, 2019 and incorporated herein by reference.*
Form of Indemnification Agreement between Viatris Inc. and each of its directors and its executive officers, filed as Exhibit 10.25 to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.*
Amended and Restated Form of Indemnification Agreement between Mylan Inc. and each Director, filed by Mylan Inc. as Exhibit 10.38 to Form 10-K for the fiscal year ended December 31, 2013, and incorporated herein by reference.*
155

Form of Indemnification Agreement between Mylan N.V. and directors, filed as Exhibit 10.1 to the Report on Form 8-K filed by Mylan N.V. with the SEC on February 27, 2015, and incorporated herein by reference.*
Revolving Credit Agreement, dated as of June 16, 2020, among Upjohn Inc., the guarantors from time to time party thereto, the lenders and issuing banks from time to time party thereto and Bank of America, N.A., as administrative agent, filed as Exhibit 10.1 to the Report on Form 8-K filed by Upjohn Inc. with the SEC on June 17, 2020, and incorporated herein by reference.
Amended and Restated Revolving Credit Agreement, dated as of July 1, 2021, among Viatris, the guarantors from time to time party thereto, the lenders and issuing banks from time to time party thereto and Bank of America, N.A., as administrative agent, filed as Exhibit 10.1 to the Report on Form 8-K filed by Viatris Inc. with the SEC on July 1, 2021, and incorporated herein by reference. ^
Delayed Draw Term Loan Credit Agreement, dated as of June 16, 2020, among Upjohn Inc., the guarantors from time to time party thereto, the lenders from time to time party thereto and MUFG Bank, Ltd., as administrative agent, filed as Exhibit 10.2 to the Report on Form 8-K filed by Upjohn Inc. with the SEC on June 17, 2020, and incorporated herein by reference.
Term Loan Credit Agreement, dated as of July 1, 2021, among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as administrative agent, filed as Exhibit 10.2 to the Report on Form 8-K filed by Viatris Inc. with the SEC on July 1, 2021, and incorporated herein by reference. ^
Form of Dealer Agreement among Viatris Inc., Utah Acquisition Sub Inc., Mylan II B.V., Mylan Inc. and the dealer thereto, filed as Exhibit 10.1 to the Report on Form 8-K/A filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.
Settlement Agreement with the U.S. Department of Justice and two relators finalizing the Medicaid drug rebate settlement, dated August 16, 2017, filed as Exhibit 10.1 to the Report on Form 8-K filed by Mylan N.V. with the SEC on August 21, 2017, and incorporated herein by reference.
Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and Mylan Inc. and Mylan Specialty L.P., dated August 16, 2017, filed as Exhibit 10.2 to the Report on Form 8-K filed by Mylan N.V. with the SEC on August 21, 2017, and incorporated herein by reference.
Registration Rights Agreement, dated as of June 22, 2020, by and between Upjohn Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., Morgan Stanley and Co. LLC, and Mizuho Securities USA LLC, as representatives of the several initial purchasers of the U.S. Dollar Notes, filed as Exhibit 4.8 to the Report on Form 8-K filed by Upjohn Inc. with the SEC on June 26, 2020, and incorporated herein by reference.
Asset Purchase Agreement, dated as of September 7, 2020, between Aspen Global Incorporated and Mylan Ireland Limited, filed by Mylan N.V. as Exhibit 10.2 to the Form 10-Q for the quarter ended September 30, 2020, and incorporated herein by reference.^
Amendment No. 1, dated as of November 5, 2020, to the Asset Purchase Agreement dated as of September 7, 2020, between Aspen Global Incorporated and Mylan Ireland Limited, filed as Exhibit 10.34(b) to Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference. ^
Transition Services Agreement, dated as of November 16, 2020, by and between Pfizer Inc. (as Service Provider) and Upjohn Inc. (as Service Recipient), filed as Exhibit 10.1 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^
Transition Services Agreement, dated as of November 16, 2020, by and between Upjohn Inc. (as Service Provider) and Pfizer Inc. (as Service Recipient), filed as Exhibit 10.2 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^
156

Tax Matters Agreement, dated as of November 16, 2020, by and between Pfizer Inc. and Upjohn Inc., filed as Exhibit 10.3 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^
Employee Matters Agreement, dated as of November 16, 2020, by and between Pfizer Inc. and Viatris Inc., filed as Exhibit 10.4 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.^
Manufacturing and Supply Agreement, dated as of November 16, 2020, by and between Pfizer Inc. (as Manufacturer) and Viatris Inc. (as Customer), filed as Exhibit 10.5 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.^
Manufacturing and Supply Agreement, dated as of November 16, 2020, by and between Viatris Inc. (as Manufacturer) and Pfizer Inc. (as Customer), filed as Exhibit 10.6 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^
Intellectual Property Matters Agreement, dated as of November 16, 2020, by and between Pfizer Inc. and Viatris Inc., filed as Exhibit 10.7 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^
Trademark License Agreement, dated as of November 16, 2020, by and between Pfizer Inc. and Viatris Inc., filed as Exhibit 10.8 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^
Subsidiaries of the registrant.
List of subsidiary guarantors and issuers of guaranteed securities.
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema
101.CALInline XBRL Taxonomy Extension Calculation Linkbase
101.LABInline XBRL Taxonomy Extension Label Linkbase
101.PREInline XBRL Taxonomy Extension Presentation Linkbase
157

101.DEFInline XBRL Taxonomy Extension Definition Linkbase
104Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101).
*Denotes management contract or compensatory plan or arrangement.
^Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Viatris agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.
158

SIGNATURES
Pursuant to the requirements of section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Form to be signed on its behalf by the undersigned, thereunto duly authorized on February 28, 2022.
Viatris Inc.
by /s/ MICHAEL GOETTLER
Michael Goettler
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this Form has been signed below by the following persons on behalf of the registrant and in the capacities indicated as of February 28, 2022.
 
Signature  Title
/s/    ROBERT J. COURYExecutive Chairman and Director
Robert J. Coury
/s/ MICHAEL GOETTLERChief Executive Officer and Director
Michael Goettler  (Principal Executive Officer)
/s/ SANJEEV NARULAChief Financial Officer
Sanjeev Narula  (Principal Financial Officer)
/s/    PAUL B. CAMPBELLChief Accounting Officer and Corporate Controller
Paul B. Campbell  (Principal Accounting Officer)
/s/    W. DON CORNWELLDirector
W. Don Cornwell  
/s/    JOELLEN LYONS DILLONDirector
JoEllen Lyons Dillon  
/s/    NEIL DIMICKDirector
Neil Dimick  
/s/    MELINA HIGGINSDirector
Melina Higgins  
/s/    JAMES M. KILTSDirector
James M. Kilts
/s/    HARRY A. KORMANDirector
Harry A. Korman
/s/    RAJIV MALIKPresident and Director
Rajiv Malik  
/s/    RICHARD A. MARKDirector
Richard A. Mark
/s/    MARK W. PARRISHDirector
Mark W. Parrish  
/s/    IAN READDirector
Ian Read  
/s/    PAULINE VAN DER MEER MOHRDirector
Pauline van der Meer Mohr
159
EX-21 2 ex_21xvtrsx20211231x10-k.htm EX-21 Document

Exhibit 21
Subsidiaries as of December 31, 2021
NameState or Country of Organization
Agila Australasia Pty LtdAustralia
Alphapharm Pty. Ltd.Australia
Mylan Australia Holding Pty LtdAustralia
Mylan Australia Pty LimitedAustralia
Upjohn Australia Pty LtdAustralia
Viatris Pty. Ltd.Australia
Arcana Arzneimittel GmbHAustria
Mylan Österreich GmbHAustria
Viatris LLCBelarus
Meda Pharma N.V.Belgium
Mylan BVBelgium
Mylan EPD BVBABelgium
Pfizer Innovative Supply Point International BVBABelgium
Upjohn SRLBelgium
Mylan Bermuda Ltd.Bermuda
Viatris BH, drustvo sa ogranicenom odgovornoscu za trgovinu i uslugeBosnia and Herzegovina
Mylan Brasil Distribuidora de Medicamentos LtdaBrazil
Mylan Laboratórios LtdaBrazil
Upjohn Brasil Importadora e Distribuidora de Medicamentos LtdaBrazil
Mylan EOODBulgaria
BGP Pharma ULCCanada
Meda Pharmaceuticals LtdCanada
Mylan Pharmaceuticals ULCCanada
Upjohn Canada ULCCanada
Medicine Meda Pharmaceutical Information Consultancy (Beijing) Co., Ltd.China
Mylan Pharmaceutical Science and Technology (Shanghai) Co., Ltd.China
Pfizer Pharmaceuticals Ltd.China
Pfizer Upjohn Management Co., LtdChina
Viatris Pharmaceutical Co., Ltd.China
Mylan Hrvatska d.o.o.Croatia
Onco Laboratories LimitedCyprus
MEDA Pharma s.r.o.Czech Republic
MYLAN HEALTHCARE CZ s.r.o.Czech Republic
Mylan Pharmaceuticals s.r.o.Czech Republic
Acton Pharmaceuticals, Inc.Delaware
Alaven Pharmaceutical LLCDelaware
ALVP Holdings, LLCDelaware
Delcor Asset CorporationDelaware



Denco Asset, LLCDelaware
Deogun Manufacturing, LLCDelaware
Dey, Inc.Delaware
Dey Limited Partner LLCDelaware
EMD, Inc.Delaware
Ezio Pharma, Inc.Delaware
Franklin Pharmaceutical LLCDelaware
G.D. Searle LLCDelaware
Greenstone LLCDelaware
Madaus Inc.Delaware
Marquis Industrial Company, LLCDelaware
Meda Pharmaceuticals Inc.Delaware
Mylan API Inc.Delaware
Mylan Consumer Healthcare, Inc.Delaware
Mylan D.T. (U.S.) Holdings, Inc.Delaware
Mylan D.T. DPT Partner Sub, LLCDelaware
Mylan D.T., Inc.Delaware
Mylan Holdings Inc.Delaware
Mylan Holdings I LLCDelaware
Mylan Holdings II LLCDelaware
Mylan Institutional LLCDelaware
Mylan Investment Holdings 4 LLCDelaware
Mylan Investment Holdings 5 LLCDelaware
Mylan Investment Holdings 6 LLCDelaware
Mylan Securitization LLCDelaware
Mylan Special Investments LLCDelaware
Mylan Special Investments II, LLCDelaware
Mylan Special Investments III, LLCDelaware
Mylan Special Investments IV, LLCDelaware
Mylan Special Investments V, LLCDelaware
Mylan Special Investments VI, LLCDelaware
Mylan Specialty L.P.Delaware
Nimes Inc.Delaware
PFE Wyeth Holdings LLCDelaware
Pfizer Enterprises LLCDelaware
Pfizer PFE US Holdings 4 LLCDelaware
Pfizer PFE US Holdings 5 LLCDelaware
Pfizer Pharmaceuticals LLCDelaware
Powder Street, LLCDelaware
Prestium Pharma, Inc.Delaware
Somerset Pharmaceuticals, Inc.Delaware
Upjohn US 2 LLCDelaware
Upjohn US Employment Inc.Delaware



Upjohn US Holdings Inc.Delaware
Upjohn Worldwide Holdings Inc.Delaware
Utah Acquisition Holdco Inc.Delaware
Utah Acquisition Sub Inc.Delaware
Viatris Specialty LLCDelaware
Wallace Pharmaceuticals Inc.Delaware
Mylan ApSDenmark
Viatris ApSDenmark
Pfizer Africa & Middle East for Pharmaceuticals, Veterinarian Products & Chemicals S.A.E.Egypt
Viatris Egypt S.A.E.Egypt
Viatris Health CareEgypt
Agila Specialties Investments LimitedEngland & Wales
Generics (U.K.) LimitedEngland & Wales
Mylan Holdings Acquisition LimitedEngland & Wales
Mylan Holdings Acquisition 2 LimitedEngland & Wales
Mylan Holdings Ltd.England & Wales
Mylan Pharma UK LimitedEngland & Wales
Mylan Products LimitedEngland & Wales
Upjohn UK 2 Ltd.England & Wales
Upjohn UK LimitedEngland & Wales
Viatris UK Healthcare LimitedEngland & Wales
Meda OyFinland
Viatris OyFinland
Laboratoires Madaus S.A.S.France
Meda Holding S.A.S.France
Meda Manufacturing S.A.S.France
Meda Pharma S.A.S.France
Mylan Generics France Holding S.A.S.France
Mylan Laboratories S.A.S.France
Mylan Medical S.A.S.France
Pfizer PFE FranceFrance
Rottapharm S.A.S.France
Viatris HealthcareFrance
Viatris SanteFrance
Erste Madaus Beteiligungs GmbHGermany
Madaus GmbHGermany
MEDA Germany Holding GmbHGermany
MEDA Manufacturing GmbHGermany
MEDA Pharma GmbH & Co. KGGermany
MWB Pharma GmbHGermany
Mylan dura GmbHGermany
Mylan Germany GmbHGermany



Mylan Healthcare GmbHGermany
Mylan Pharmaceuticals GmbHGermany
Pharmazeutische Union GmbHGermany
PharmLog Pharma Logistik GmbHGermany
Pfizer OFG Germany GmbHGermany
ROTTAPHARM |MADAUS GmbHGermany
VIATRIS GmbHGermany
Zweite Madaus Beteiligungs GmbHGermany
Mylan (Gibraltar) 4 LimitedGibraltar
Mylan (Gibraltar) 5 LimitedGibraltar
Mylan (Gibraltar) 6 LimitedGibraltar
Mylan (Gibraltar) 7 LimitedGibraltar
Mylan (Gibraltar) 8 LimitedGibraltar
Mylan (Gibraltar) 9 LimitedGibraltar
BGP Pharmaceutical Products Ltd.Greece
Generics Pharma Hellas Ltd.Greece
Meda Pharmaceuticals S.A.Greece
Upjohn Hellas Pharmaceutical Limited Liability CompanyGreece
Mylan Pharmaceutical Hong Kong LimitedHong Kong
Viatris Healthcare Hong Kong LimitedHong Kong
Meda Pharma Hungary Kereskedelmi Kft.Hungary
Mylan EPD Kft.Hungary
Mylan Hungary Kft.Hungary
Mylan Kft.Hungary
Mylan Institutional Inc.Illinois
Mylan Laboratories LimitedIndia
Mylan Pharmaceuticals Private LimitedIndia
McDermott Laboratories LimitedIreland
Meda Health Sales Ireland LimitedIreland
Mylan Investments LimitedIreland
Mylan IRE Healthcare LimitedIreland
Mylan Ireland Holdings LimitedIreland
Mylan Ireland Investment Designated Activity CompanyIreland
Mylan Ireland LimitedIreland
Mylan Pharma Acquisition LimitedIreland
Mylan Pharma Group LimitedIreland
Mylan Pharma Holdings LimitedIreland
Mylan Pharmaceuticals LimitedIreland
Mylan TeorantaIreland
Rottapharm LimitedIreland
Upjohn Manufacturing Ireland UnlimitedIreland
Viatris Healthcare LimitedIreland
Viatris LimitedIreland



DERMOGROUP S.r.l.Italy
Meda Pharma S.p.A.Italy
Mylan Italia S.r.l.Italy
Mylan S.p.A.Italy
Viatris Pharma S.r.l.Italy
Rottapharm S.p.A.Italy
Mylan EPD G.K.Japan
Mylan Seiyaku Ltd.Japan
Pfizer UPJ G.K.Japan
Viatris Pharmaceuticals Japan Inc.Japan
Viatris Limited Liability PartnershipKazakhstan
SIA Meda PharmaLatvia
SIA Mylan HealthcareLatvia
Mylan Healthcare UABLithuania
BGP Products S.à.r.l.Luxembourg
Integral S.A.Luxembourg
Meda Pharma S.à r.l.Luxembourg
Mylan Luxembourg 1 S.à r.l.Luxembourg
Mylan Luxembourg 2 S.à r.l.Luxembourg
Mylan Luxembourg 3 S.à r.l.Luxembourg
Mylan Luxembourg 6 S.à r.l.Luxembourg
Mylan Luxembourg 7 S.à r.l.Luxembourg
Mylan Luxembourg S.à r.l.Luxembourg
SIM S.A.Luxembourg
Mylan Healthcare Sdn. Bhd.Malaysia
Mylan Malaysia SDN. BHD.Malaysia
Pfizer Parke Davis Sdn. Bhd.Malaysia
Viatris Sdn Bhd.Malaysia
MP Laboratories (Mauritius) Ltd.Mauritius
Meda Phama, S. de R.L. de C.V.Mexico
Meda Pharma Servicios, S. de R.L. de C.V.Mexico
Upjohn Pharma México, S. de R.L. de C.V.Mexico
Viatris Pharmaceuticals S.A.S.Morocco
Viatris Pharmaceuticals Pty LtdNigeria
Meda Pharma B.V.Netherlands
Mylan B.V.Netherlands
Mylan Group B.V.Netherlands
Mylan Healthcare B.V.Netherlands
Mylan II B.V.Netherlands
PF Asia Manufacturing B.V.Netherlands
PF OFG Ireland 1 B.V.Netherlands
PF OFG Mexico B.V.Netherlands
PF OFG Philippines B.V.Netherlands



PF OFG Spain B.V.Netherlands
Pfizer Enterprise Holdings B.V.Netherlands
Pfizer PFE Ireland Pharmaceuticals Holdings 1 B.V.Netherlands
Pfizer PFE Turkey Holding 1 B.V.Netherlands
Upjohn Belgium B.V.Netherlands
Upjohn EESVNetherlands
Upjohn Europe Holdings B.V.Netherlands
Upjohn Export B.V.Netherlands
Upjohn Finance B.V.Netherlands
Upjohn Global Holdings B.V.Netherlands
Upjohn Group Holdings B.V.Netherlands
Upjohn Intermediate Holdings B.V.Netherlands
Upjohn International Holdings B.V.Netherlands
Upjohn Vietnam Dutch B.V.Netherlands
Viatris Netherlands B.V.Netherlands
Agila Specialties Inc.New Jersey
BGP ProductsNew Zealand
Upjohn New Zealand ULCNew Zealand
Viatris LimitedNew Zealand
Mylan Health Management LLCNorth Carolina
Meda ASNorway
Mylan Hospital ASNorway
Viatris ASNorway
ZpearPoint ASNorway
MLRE LLCPennsylvania
Mylan Holdings Sub Inc.Pennsylvania
Mylan Inc.Pennsylvania
Synerx Pharma, LLCPennsylvania
Mylan Philippines Inc.Philippines
PF OFG Philippines, Inc.Philippines
Mylan EPD Sp. z o.o.Poland
Mylan Healthcare S.p. z o.o.Poland
BGP Products, Unipessoal, LDAPortugal
Laboratorios Anova - Produtos Farmaceuticos, LDAPortugal
Laboratorios Delta, S.A.Portugal
Mylan EPD Lda.Portugal
Mylan, LdaPortugal
BGP Products S.r.l.Romania
Mylan Pharma LLCRussian Federation
Viatris LLCRussian Federation
Viatris Healthcare Drustvo SA Ogranicenom Odgovornoscu BeogradSerbia
Mylan Pharmaceuticals Pte. Ltd.Singapore
Pfizer Asia Pacific Pte Ltd.Singapore



Pfizer PFE Private LimitedSingapore
Pfizer PFE Singapore Pte. Ltd.Singapore
BGP Products s.r.o.Slovakia
Meda Pharma spol. s.r.o.Slovakia
Mylan s.r.o.Slovakia
Mylan Healthcare, farmacevtsko podjetje, d.o.o.Slovenia
Meda Pharma South Africa (Pty) LimitedSouth Africa
Mylan (Proprietary) LimitedSouth Africa
Mylan Pharmaceuticals (Pty) Ltd.South Africa
SCP Pharmaceuticals (Proprietary) LimitedSouth Africa
Upjohn South Africa Proprietary LimitedSouth Africa
Xixia Pharmaceuticals (Proprietary) LimitedSouth Africa
Viatris KoreaSouth Korea
Fundacion Viatris para la SaludSpain
Laboratorios Parke Davis, S.L.U.Spain
Meda Pharma, S.L.Spain
PEMB OFG Spain Holding, S.L.Spain
Pfizer PFE Spain Holding, S.L.Spain
Viatris Healthcare S.L.Spain
Viatris Pharmaceuticals S.L.Spain
Abbex ABSweden
BGP Products ABSweden
Ipex ABSweden
Ipex Medical ABSweden
Meda ABSweden
Meda OTC ABSweden
Mylan ABSweden
Mylan Sweden Holdings ABSweden
Recip ABSweden
Scandinavian Pharmaceuticals-Generics ABSweden
Viatris ABSweden
BGP Products Operations GmbHSwitzerland
BGP Products Switzerland GmbHSwitzerland
MEDA Pharma GmbHSwitzerland
MEDA Pharmaceuticals Switzerland GmbHSwitzerland
Mylan Holdings GmbHSwitzerland
Mylan Pharma GmbHSwitzerland
Pfizer PFE Switzerland GmbHSwitzerland
Mylan (Taiwan) LimitedTaiwan
Viatris Pharmaceutical Company LimitedTaiwan
DPT Laboratories, Ltd.Texas
Mylan Bertek Pharmaceuticals Inc.Texas
Meda Pharma (Thailand) Co., Ltd.Thailand



Pfizer Parke Davis (Thailand) Ltd.Thailand
Upjohn (Thailand) LimitedThailand
Meda Pharma Ilaç Sanayi ve Ticaret Limited SirketiTurkey
Pfizer Ilaclari Limited SirketiTurkey
Meda Pharmaceuticals MEA FZ-LLCUnited Arab Emirates
Mylan FZ-LLCUnited Arab Emirates
Upjohn Middle East FZ-LLCUnited Arab Emirates
American Triumvirate Insurance CompanyVermont
Mylan International Holdings, Inc.Vermont
Viatris Vietnam Limited CompanyVietnam
MP AIR, Inc.West Virginia
Mylan Pharmaceuticals Inc.West Virginia
Mylan Technologies, Inc.West Virginia
Mylan ASI LLCWyoming


EX-22 3 ex_22xvtrsx20211231x10-k.htm EX-22 Document

Exhibit 22

List of Subsidiary Guarantors and Issuers of Guaranteed Securities

As of December 31, 2021, Viatris Inc., a Delaware corporation (“Viatris”), Mylan Inc., a Pennsylvania corporation (“Mylan Inc.”), and Mylan II B.V., a company incorporated under the laws of the Netherlands (“Mylan II”), were the guarantors of the 3.950% Senior Notes due 2026 and 5.250% Senior Notes due 2046 issued by Utah Acquisition Sub Inc., a Delaware corporation (“Utah”).

As of December 31, 2021, Viatris, Utah and Mylan II were the guarantors of the 4.200% Senior Notes due 2023, 3.125% Senior Notes due 2023, 4.550% Senior Notes due 2028, 5.400% Senior Notes due 2043 and 5.200% Senior Notes due 2048 issued by Mylan Inc.

As of December 31, 2021, Utah, Mylan Inc. and Mylan II were the guarantors of the 1.125% Senior Notes due 2022, 1.650% Senior Notes due 2025, 2.300% Senior Notes due 2027, 2.700% Senior Notes due 2030, 3.850% Senior Notes due 2040 and 4.000% Senior Notes due 2050 issued by Viatris.


EX-23 4 ex_23-vtrsx20211231x10xk.htm EX-23 Document

Exhibit 23

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement No. 333-250845 on Form S-8 of our reports dated February 28, 2022, relating to the consolidated financial statements of Viatris Inc. and subsidiaries (the “Company”) and the effectiveness of the Company's internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2021.

/s/ Deloitte & Touche LLP
Pittsburgh, Pennsylvania
February 28, 2022

EX-31.1 5 vtrs_ex311x20211231-10k.htm EX-31.1 Document

EXHIBIT 31.1
Certification of Principal Executive Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Michael Goettler, certify that:
1.I have reviewed this Form 10-K of Viatris Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ Michael Goettler
Michael Goettler
Chief Executive Officer
(Principal Executive Officer)
Date: February 28, 2022



EX-31.2 6 vtrs_ex312x20211231-10k.htm EX-31.2 Document

EXHIBIT 31.2
Certification of Principal Financial Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Sanjeev Narula, certify that:
1.I have reviewed this Form 10-K of Viatris Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ SANJEEV NARULA
Sanjeev Narula
Chief Financial Officer
(Principal Financial Officer)
Date: February 28, 2022

EX-32 7 vtrs_ex32x20211231-10k.htm EX-32 Document

EXHIBIT 32
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND
PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Form 10-K of Viatris Inc. (the “Company”) for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 28, 2022
/s/ MICHAEL GOETTLER
Michael Goettler
Chief Executive Officer
(Principal Executive Officer)
 
/s/ SANJEEV NARULA
Sanjeev Narula
Chief Financial Officer
(Principal Financial Officer)
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
The foregoing certification is being furnished in accordance with Securities and Exchange Commission Release No. 34-47551 and shall not be considered filed as part of the Form 10-K.

EX-101.SCH 8 vtrs-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 100010002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100040005 - Statement - Consolidated Statements of Comprehensive Earnings link:presentationLink link:calculationLink link:definitionLink 100050006 - Statement - Consolidated Statements of Equity link:presentationLink link:calculationLink link:definitionLink 140064001 - Statement - Consolidated Statements of Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100070007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 210011001 - Disclosure - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 240024002 - Disclosure - Nature of Operations (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 210031002 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 220042001 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 230053001 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 240064003 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240074004 - Disclosure - Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details) link:presentationLink link:calculationLink link:definitionLink 210081003 - Disclosure - Acquisitions and Other Transactions link:presentationLink link:calculationLink link:definitionLink 230093002 - Disclosure - Acquisitions and Other Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 240104005 - Disclosure - Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240114006 - Disclosure - Acquisitions and Other Transactions (Purchase Price Allocations) (Details) link:presentationLink link:calculationLink link:definitionLink 240124007 - Disclosure - Acquisitions and Other Transactions (Unaudited Pro Forma Financial Results) (Details) link:presentationLink link:calculationLink link:definitionLink 210131004 - Disclosure - Revenue Recognition and Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 230143003 - Disclosure - Revenue Recognition and Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 240154008 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details) link:presentationLink link:calculationLink link:definitionLink 240164009 - Disclosure - Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details) link:presentationLink link:calculationLink link:definitionLink 240174010 - Disclosure - Revenue Recognition and Accounts Receivable (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240184011 - Disclosure - Revenue Recognition and Accounts Receivable Variable Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 240194012 - Disclosure - Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) link:presentationLink link:calculationLink link:definitionLink 240204013 - Disclosure - Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 210211005 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 230223004 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 240234014 - Disclosure - Balance Sheet Components (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240244015 - Disclosure - Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details) link:presentationLink link:calculationLink link:definitionLink 240254016 - Disclosure - Balance Sheet Components (Accounts receivable, net) (Details) link:presentationLink link:calculationLink link:definitionLink 240264017 - Disclosure - Balance Sheet Components (Inventories) (Details) link:presentationLink link:calculationLink link:definitionLink 240274018 - Disclosure - Balance Sheet Components (Prepaids and other current assets) (Details) link:presentationLink link:calculationLink link:definitionLink 240284019 - Disclosure - Balance Sheet Components (Property, Plant and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 240294020 - Disclosure - Balance Sheet Components (Other Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 240304021 - Disclosure - Balance Sheet Components (Trade Accounts Payable) (Details) link:presentationLink link:calculationLink link:definitionLink 240314022 - Disclosure - Balance Sheet Components (Other Current Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 240324023 - Disclosure - Balance Sheet Components (Other noncurrent liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 210331006 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 230343005 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 240354024 - Disclosure - Leases (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240364025 - Disclosure - Leases (Lease Information) (Details) link:presentationLink link:calculationLink link:definitionLink 240374026 - Disclosure - Leases (Lease Maturities) (Details) link:presentationLink link:calculationLink link:definitionLink 240374026 - Disclosure - Leases (Lease Maturities) (Details) link:presentationLink link:calculationLink link:definitionLink 210381007 - Disclosure - Equity Method Investments link:presentationLink link:calculationLink link:definitionLink 230393006 - Disclosure - Equity Method Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 240404027 - Disclosure - Equity Method Investments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240414028 - Disclosure - Equity Method Investments (Balance Sheet) (Details) link:presentationLink link:calculationLink link:definitionLink 240424029 - Disclosure - Equity Method Investments (Net Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 240434030 - Disclosure - Equity Method Investments (Income Statement) (Details) link:presentationLink link:calculationLink link:definitionLink 210441008 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 230453007 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 240464031 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240474032 - Disclosure - Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 240484033 - Disclosure - Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 240494034 - Disclosure - Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) link:presentationLink link:calculationLink link:definitionLink 240504035 - Disclosure - Goodwill and Other Intangible Assets (Amortization Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 240514036 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details) link:presentationLink link:calculationLink link:definitionLink 210521009 - Disclosure - Financial Instruments and Risk Management link:presentationLink link:calculationLink link:definitionLink 230533008 - Disclosure - Financial Instruments and Risk Management (Tables) link:presentationLink link:calculationLink link:definitionLink 240544037 - Disclosure - Financial Instruments and Risk Management (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240554038 - Disclosure - Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 240564039 - Disclosure - Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 240574040 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) link:presentationLink link:calculationLink link:definitionLink 240584041 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details) link:presentationLink link:calculationLink link:definitionLink 240594042 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details) link:presentationLink link:calculationLink link:definitionLink 240604043 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) link:presentationLink link:calculationLink link:definitionLink 240614044 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 240624045 - Disclosure - Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 240634046 - Disclosure - Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 240644047 - Disclosure - Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 240654048 - Disclosure - Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 210661010 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 230673009 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 240684049 - Disclosure - Debt (Short-term borrowings) (Details) link:presentationLink link:calculationLink link:definitionLink 240694050 - Disclosure - Debt Debt (Receivables Facility and Commercial Paper Program) (Details) link:presentationLink link:calculationLink link:definitionLink 240704051 - Disclosure - Debt (Summary of Long-term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 240714052 - Disclosure - Debt (Revolving Facilities and Term Facilities) (Details) link:presentationLink link:calculationLink link:definitionLink 240724053 - Disclosure - Debt (Issuance of 2018 Senior Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 240734054 - Disclosure - Debt (Senior Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 240744055 - Disclosure - Debt (Fair Value) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240754056 - Disclosure - Debt (Upjohn Senior Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 240764057 - Disclosure - Debt (Minimum Repayments on Outstanding Borrowings) (Details) link:presentationLink link:calculationLink link:definitionLink 210771011 - Disclosure - Comprehensive Earnings link:presentationLink link:calculationLink link:definitionLink 230783010 - Disclosure - Comprehensive Earnings (Tables) link:presentationLink link:calculationLink link:definitionLink 240794058 - Disclosure - Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 240804059 - Disclosure - Comprehensive Earnings (Components of Other Comprehensive Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 210811012 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 230823011 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 240834060 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240844061 - Disclosure - Income Taxes (Schedule of Components of Income Tax Provision) (Details) link:presentationLink link:calculationLink link:definitionLink 240854062 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 240864063 - Disclosure - Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 240874064 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) link:presentationLink link:calculationLink link:definitionLink 210881013 - Disclosure - Share-Based Incentive Plan link:presentationLink link:calculationLink link:definitionLink 230893012 - Disclosure - Share-Based Incentive Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 240904065 - Disclosure - Share-Based Incentive Plan (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240914066 - Disclosure - Share-Based Incentive Plan (Stock Awards) (Details) link:presentationLink link:calculationLink link:definitionLink 240924067 - Disclosure - Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 240934068 - Disclosure - Share-Based Incentive Plan (Valuation Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 210941014 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 230953013 - Disclosure - Employee Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 240964069 - Disclosure - Employee Benefit Plans (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240974070 - Disclosure - Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 240984071 - Disclosure - Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details) link:presentationLink link:calculationLink link:definitionLink 240994072 - Disclosure - Employee Benefit Plans (Net Periodic Benefit Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 241004073 - Disclosure - Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details) link:presentationLink link:calculationLink link:definitionLink 241014074 - Disclosure - Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details) link:presentationLink link:calculationLink link:definitionLink 241024075 - Disclosure - Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 241034076 - Disclosure - Employee Benefit Plans (Fair Values of Plan Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 241044077 - Disclosure - Employee Benefit Plans (Weighted Average Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 241054078 - Disclosure - Employee Benefit Plans (Effect of One Percentage Point Increase or Decrease in Health Care Cost Trend Rates) (Details) link:presentationLink link:calculationLink link:definitionLink 241064079 - Disclosure - Employee Benefit Plans (Estimated Future Benefit Payments) (Details) link:presentationLink link:calculationLink link:definitionLink 211071015 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 231083014 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 241094080 - Disclosure - Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details) link:presentationLink link:calculationLink link:definitionLink 241104081 - Disclosure - Segment Information (Third Party Net Sales by Major Customers) (Details) link:presentationLink link:calculationLink link:definitionLink 241114082 - Disclosure - Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details) link:presentationLink link:calculationLink link:definitionLink 211121016 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 241134083 - Disclosure - Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 211141017 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 231153015 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 241164084 - Disclosure - Restructuring (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 241174085 - Disclosure - Restructuring (2020 Restructuring Plan) (Details) link:presentationLink link:calculationLink link:definitionLink 211181018 - Disclosure - Collaboration and Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 241194086 - Disclosure - Collaboration and Licensing Agreements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 211201019 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 241214087 - Disclosure - Litigation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 211221020 - Disclosure - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 241234088 - Disclosure - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 000020008 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 000030009 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 vtrs-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 vtrs-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 vtrs-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cash paid during the period for: Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Gains and Losses on Marketable Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Accounts Receivable, Variable Consideration [Roll Forward] Accounts Receivable, Variable Consideration [Roll Forward] Accounts Receivable, Variable Consideration [Roll Forward] Contingencies Legal Matters and Contingencies [Text Block] Actuarial (gains) losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) North America Generics [Member] North America Generics [Member] North America Generics [Member] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Number of restricted stock awards, released Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period U.S. State Current Current State and Local Tax Expense (Benefit) Consolidated Entities [Axis] Consolidated Entities [Axis] Taxes related to the net share settlement of equity awards Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Available-for-sale fixed income securities Debt Securities, Available-for-sale, Current Basic (in usd per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Receivable Type [Axis] Receivable Type [Axis] Business Combination, Acquisition Related Costs Business Combination, Acquisition Related Costs Respiratory delivery platform [Member] Respiratory delivery platform [Member] Respiratory delivery platform [Member] Schedule of Property Subject to or Available for Operating Lease Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block] Cash dividends declared, $0.33 per common share Dividends, Common Stock, Cash Security Exchange Name Security Exchange Name Weighted average grant-date fair value per share, forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Payment for Contingent Consideration Liability, Financing Activities Payment for Contingent Consideration Liability, Financing Activities Yupelri ® Yupelri ® [Member] Yupelri ® Number of shares under stock awards, forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Foreign Currencies Policy Foreign Currency Transactions and Translations Policy [Policy Text Block] Loss Contingency, Patents Allegedly Infringed, Number Loss Contingency, Patents Allegedly Infringed, Number Current liabilities Liability, Defined Benefit Plan, Current Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Investment, Name [Axis] Investment, Name [Axis] Derivatives Policy Derivatives, Policy [Policy Text Block] Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Variable Consideration Category [Domain] Variable Consideration Category [Domain] [Domain] for Variable Consideration Category [Axis] Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Reduction in Share-based Compensation Expense Reduction in Share-based Compensation Expense Reduction in Share-based Compensation Expense Vesting Period [Domain] Vesting Period [Domain] [Domain] for Vesting Period [Axis] Partial payment of anticipated tax expense Income Tax Examination, Partial Payment Of Income Tax Expense Income Tax Examination, Partial Payment Of Income Tax Expense U.S. State Tax Authority U.S. State Tax Authority [Member] U.S. State Tax Authority [Member] 2022 Long-Term Debt, Maturity, Year Two Intangible assets and goodwill Deferred Tax Liabilities, Intangible Assets Income taxes Increase (Decrease) in Income Taxes Payable Foreign exchange derivative liabilities Foreign Currency Contracts, Liability, Fair Value Disclosure 2032 Euro Senior Notes 2032 Euro Senior Notes [Member] 2032 Euro Senior Notes Deferred Bonus Deferred Bonus [Member] 2043 Senior Notes (5.400%) SeniorNotesTwoThousandFortyThree [Member] Senior notes two thousand forty three Other companies Other Companies [Member] Other companies Fair value hedging relationships Fair Value Hedging [Member] Additions Charged to Costs and Expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Other Comprehensive Income, Other, Net of Tax Other Comprehensive Income, Other, Net of Tax Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Intangible asset amortization expense Intangible asset amortization expense Amortization of Intangible Assets Identified intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Acquired intangible assets, weighted average useful life, in years Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Additions for prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Program Name [Axis] Program Name [Axis] Program Name Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Inventories Schedule of Inventory, Current [Table Text Block] Anti-dilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Upfront payments Payments To Acquire Collaborative Agreement Payments To Acquire Collaborative Agreement Property, plant and equipment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Business Acquisition [Axis] Business Acquisition [Axis] Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Cash flow hedging relationships Cash Flow Hedging [Mem Cash Flow Hedging [Member] North America Segment North America Segment [Member] North America Segment Three Customers Three Customers [Member] Three Customers Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Award Type [Domain] Award Type [Domain] Local Phone Number Local Phone Number Schedule of Available-for-Sale Securities Reconciliation Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Amortization of actuarial gain/(loss) Defined Benefit Plan, Amortization of Gain (Loss) Number of shares under stock awards, exercisable at period end Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Intangible Assets and Goodwill Policy Goodwill and Intangible Assets, Policy [Policy Text Block] Maturities Of Available-for-Sale Debt Securities At Fair Value Investments Classified by Contractual Maturity Date [Table Text Block] Other Defined Benefit Plan, Other Cost (Credit) Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Damages awarded Loss Contingency, Damages Awarded, Value Deferred Base Salary Deferred Base Salary [Member] Deferred Base Salary [Member] Retained Earnings Retained Earnings [Member] Fair value of long-term debt Debt Instrument, Fair Value Disclosure CHINA CHINA 2020 Euro Senior Notes 2020 Euro Senior Notes [Member] 2020 Euro Senior Notes [Member] Schedule of Other Assets [Table] Schedule of Other Assets [Table] Schedule of Other Assets [Table] Chargebacks [Member] Chargebacks [Member] Chargebacks [Member] Noncontrolling Interest, Ownership Percentage by Parent Noncontrolling Interest, Ownership Percentage by Parent Available-for-sale fixed income investments Debt securities Debt Securities [Member] Earnings (loss) before income taxes and noncontrolling interest: Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Upjohn Inc. Upjohn Inc. [Member] Upjohn Inc. [Member] Concentration risk, number of major customers Concentration risk, number of major customers Concentration risk, number of major customers Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Accounting Policies [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Measurement Input, Estimated Tax Rate [Member] Measurement Input, Estimated Tax Rate [Member] Measurement Input, Estimated Tax Rate [Member] Comprehensive earnings Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Tax Period [Domain] Tax Period [Domain] Number Of Manufacturing Sites Number Of Manufacturing Sites Number Of Manufacturing Sites 2020 Restructuring Plan 2020 Restructuring Plan [Member] 2020 Restructuring Plan Basic (in USD per share) Basic (loss) earnings per share attributable to Viatris Inc. shareholders Earnings Per Share, Basic Revenue Recognition and Accounts Receivable Revenue from Contract with Customer [Text Block] Goodwill Impairment, Measurement Input, Term Goodwill Impairment, Measurement Input, Term Goodwill Impairment, Measurement Input, Term Cash Acquired from Acquisition Cash Acquired from Acquisition Number of restricted stock awards, nonvested beginning balance Number of restricted stock awards, nonvested ending balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Collaborations [Abstract] Collaborations [Abstract] Collaborations [Abstract] 2021 Long-Term Debt, Maturity, Year One Unamortized Debt Issuance Expense Unamortized Debt Issuance Expense Other Current Portion of Long-term Debt Other Current Portion of Long-term Debt [Member] Other Current Portion of Long-term Debt [Member] Current assets (excluding inventories and net of cash acquired) Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets, Current Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets, Current SWITZERLAND SWITZERLAND Inventories Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Schedule II - Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Liability, Defined Benefit Pension Plan, Noncurrent Liability, Defined Benefit Pension Plan, Noncurrent Measurement Input, Terminal Year Revenue Growth Rate Measurement Input, Terminal Year Revenue Growth Rate [Member] Measurement Input, Terminal Year Revenue Growth Rate Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Noncurrent assets Assets for Plan Benefits, Defined Benefit Plan Machinery and equipment Machinery and Equipment [Member] Commercial Paper Commercial Paper [Member] Deferred tax liabilities, net Deferred Tax Liabilities, Net Other non-cash items Other Noncash Income (Expense) Fair value of financial instruments Derivative Asset, Fair Value, Gross Asset Business Combination [Abstract] Business Combination [Abstract] Business Combination [Abstract] Plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Net unrecognized gain (loss) on derivatives in hedging relationships Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Period [Domain] Period [Domain] [Domain] for Period [Axis] Other payables Accounts Payable, Other Accounts receivable, net Trade receivables, net Receivables, Net, Current Term Loan Term Loan [Member] Term Loan Transition Service Agreements Transition Service Agreements [Member] Transition Service Agreements Net Third Party Sales Classified Based on Geographic Location of Subsidiaries Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Entity Voluntary Filers Entity Voluntary Filers Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Plan Name [Axis] Plan Name [Axis] Long-term debt Long-term Debt Liabilities, Other than Long-term Debt, Noncurrent Liabilities, Other than Long-term Debt, Noncurrent Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Other liabilities Other Liabilities Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Schedule of Cash, Cash Equivalents, and Restricted Cash Schedule of Cash, Cash Equivalents and Restricted Cash [Table Text Block] [Table Text Block] for Schedule of Cash, Cash Equivalents and Restricted Cash [Table] Entity Small Business Entity Small Business Cash and cash equivalents Cash and Cash Equivalents [Member] Current liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities, Current Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities, Current Impact of foreign currency translation OtherComprehensiveIncomeDefinedBenefitPlanForeignCurrencyTranslationBeforeTax Other Comprehensive Income Defined Benefit Plan Foreign Currency Translation Before Tax Additions for current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Equity Method Investments Net Gain (Loss) From Impairment and Reduction In Obligations Equity Method Investments Net Gain (Loss) From Impairment and Reduction In Obligations Equity Method Investments Net Gain (Loss) From Impairment and Reduction In Obligations Incremental US Tax on Foreign Earnings Effective Income Tax Rate Reconciliation, GILTI, Percent Effective Income Tax Rate Reconciliation, GILTI, Percent Intangible Assets Excluding Goodwill [Line Items] Finite-Lived Intangible Assets [Line Items] Commitments Commitments Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Common stock issued for the Combination Other Significant Noncash Transaction, Value of Consideration Given Number Of Molecules Number Of Molecules Number Of Molecules Additional paid-in capital Additional Paid in Capital IPR&D intangible asset impairment charges Intangible asset impairment charges Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Unrecognized tax benefits that impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Number of equity method investments Number of equity method investments Number of equity method investments Interest rate swaps Interest rate swap derivatives Interest Rate Swap [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] 2026 Senior Notes (3.950%) SeniorNotesTwoThousandTwentySix3.95Precent [Member] 2026 Senior Notes 3.950% Agency mortgage-backed securities Collateralized Mortgage Backed Securities [Member] Entity Interactive Data Current Entity Interactive Data Current Thereafter Long-Term Debt, Maturity, after Year Five 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Clean energy and research credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Issuance of restricted stock and stock options exercised, net Stock Issued During Period, Value, Stock Options Exercised Recognized net actuarial losses Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Deduction limit of GILTI tax Deduction limit of GILTI tax Deduction limit of GILTI tax Liability for Uncertainty in Income Taxes, Noncurrent Liability for Uncertainty in Income Taxes, Noncurrent Limited transition services period Business Combination, Limited Transition Services Payment Period Business Combination, Limited Transition Services Payment Period Not subject to market conditions Not Subject to Market Conditions [Member] Not Subject to Market Conditions [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Mylan Laboratories Limited Subsidiaries [Member] Unrecognized tax benefit Unrecognized tax benefit — beginning of year Unrecognized tax benefit — end of year Unrecognized Tax Benefits Total deferred tax assets, gross Deferred Tax Assets, Gross Income Tax Authority [Domain] Income Tax Authority [Domain] 2019 Senior Notes (2.550%) SeniorNotesTwoThousandNineteen [Member] Senior notes two thousand nineteen France FRANCE Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Entity Address, State or Province Entity Address, State or Province Restructuring Reserve Restructuring Reserve Senior Notes 2022 Senior Notes 2022 [Member] Senior Notes 2022 Leases Leases of Lessee Disclosure [Text Block] Deferred income tax benefit Deferred Income Tax Assets, Net Issuance of common stock for the Combination Stock Issued During Period, Value, Acquisitions Current liabilities: Liabilities, Current [Abstract] Receivable [Domain] Receivable [Domain] Restructuring Plan [Domain] Restructuring Plan [Domain] GIBRALTAR GIBRALTAR 2018 Senior Revolving Credit Facility [Member] 2018 Senior Revolving Credit Facility [Member] 2018 Senior Revolving Credit Facility [Member] Weighted average exercise price per share, exercisable at period end Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Restructuring Reserve, Settled without Cash Restructuring Reserve, Settled without Cash Total equity securities Equity securities Equity Securities [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity consideration Noncash or Part Noncash Divestiture, Amount of Consideration Received 2022 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Average remaining contractual term for options outstanding, in years Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Derivative Instrument [Axis] Derivative Instrument [Axis] Withholding taxes Effective Income Tax Rate Reconciliation, Withholding Taxes, Percent Effective Income Tax Rate Reconciliation, Withholding Taxes, Percent Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Loss Contingency, Patents Found Not Infringed, Number Loss Contingency, Patents Found Not Infringed, Number Vest ratably in five years or less [Member] Vest ratably in five years or less [Member] Vest ratably in five years or less [Member] U.S. Federal Current Current Federal Tax Expense (Benefit) Total lease liability Operating Lease, Liability Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] Balance Sheet Components Document Transition Report Document Transition Report Accumulated other comprehensive income expected to be recognized as net periodic benefit costs Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued and outstanding: 1,209,507,463 and 1,206,895,644, respectively Common Stock, Value, Issued Maximum Leverage Ratio, Period Three Maximum Leverage Ratio, Period Three Maximum Leverage Ratio, Period Three Weighted-average period over which total unrecognized compensation expense expected to be recognized (years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Customer Concentration Risk Customer Concentration Risk [Member] Weighted average grant-date fair value per share, nonvested beginning balance Weighted average grant-date fair value per share, nonvested ending balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Lessee, Operating Leases Lessee, Operating Leases [Text Block] Effects of Foreign Exchange Accounts Receivable, Effects of Foreign Exchange Rates Accounts Receivable, Effects of Foreign Exchange Rates Rebates, promotional programs and other sales allowances Accrued Sales Allowances Accrued Sales Allowances Dividends Payable, Amount Per Share Dividends Payable, Amount Per Share Funded status of plans Defined Benefit Plan, Funded (Unfunded) Status of Plan Defined Benefit Plan, Plan Assets, Business Combination Defined Benefit Plan, Plan Assets, Business Combination 2020 Senior Notes (3.750% coupon) Senior Notes Two Thousand Twenty - 3.75 Percent [Member] Senior Notes Two Thousand Twenty - 3.75 Percent Returns Revenue from Contract with Customer, Returns Revenue from Contract with Customer, Returns Acquisitions and Other Transactions Business Combination Disclosure [Text Block] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Auditor [Line Items] Other Commitments [Table] Other Commitments [Table] Stock-Based Compensation Plans, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] 2027 Senior Notes 2027 Senior Notes [Member] 2027 Senior Notes 2.250% Euro Senior Notes due 2024 2024 Euro Senior Notes [Member] 2024 Euro Senior Notes [Member] Other assets Schedule of Other Assets, Noncurrent [Table Text Block] Ownership [Axis] Ownership [Axis] Non-U.S. Deferred Deferred Foreign Income Tax Expense (Benefit) Aspen Global Incorporated Aspen Global Incorporated [Member] Aspen Global Incorporated Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Goodwill [Line Items] Goodwill [Line Items] Amortization of prior service costs Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax Defined benefit plan, ultimate health care cost trend rate Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Marketable Securities Policy Marketable Securities, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Net earnings Business Acquisition, Pro Forma Net Income (Loss) Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Income Tax Authority [Axis] Income Tax Authority [Axis] Work in process Inventory, Work in Process, Net of Reserves MDL Multi District Litigation [Member] Multi District Litigation [Member] Senior Notes 2021 Senior Notes 2021 [Member] Senior Notes 2021 Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock (in shares) Stock Exchanged During Period, Shares, Exchanged Stock Exchanged During Period, Shares, Exchanged Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Common Stock, Dividends, Per Share, Declared Common Stock, Dividends, Per Share, Declared Net sales Net sales Revenue from Contract with Customer, Excluding Assessed Tax Non-contingent payments for product rights Payments for Non-Contingent Consideration for Product Rights, Financing Activities Payments for Non-Contingent Consideration for Product Rights, Financing Activities Schedule of Other Noncurrent Liabilities [Table] Schedule of Other Noncurrent Liabilities [Table] Schedule of Other Noncurrent Liabilities [Table] Accrued interest and penalties Income Tax Examination, Penalties and Interest Accrued Finished goods Inventory, Finished Goods, Net of Reserves Corporate costs Corporate costs Corporate costs Consolidated Entity Consolidated Entity, Excluding VIE [Member] Stock options Share-based Payment Arrangement, Option [Member] Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax Equity Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] State income taxes and credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Measurement Input Type [Domain] Measurement Input Type [Domain] Effect on cash of changes in exchange rates Effect of Exchange Rate on Cash and Cash Equivalents LUXEMBOURG LUXEMBOURG Rest of World Segment Rest of World Segment [Member] Rest of World Segment Variable Rate [Axis] Variable Rate [Axis] Securitized accounts receivable Accounts Receivable from Securitization Segment Information Segment Reporting Disclosure [Text Block] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] 2.125% Euro Senior Notes due 2025 2024 Euro Senior Notes, 1.023% [Member] 2024 Euro Senior Notes, 1.023% Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Mature in one to five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Trailing Four Quarters Trailing Four Quarters [Member] Trailing Four Quarters Variable Consideration Returns [Member] Variable Consideration Returns [Member] Variable Consideration Returns [Member] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Variable Rate [Domain] Variable Rate [Domain] Additional Paid-In Capital Additional Paid-in Capital [Member] Intangible assets Deferred Tax Assets Intangible Assets Deferred Tax Assets Intangible Assets Biosimilars Business Biosimilars Business [Member] Biosimilars Business Net unrecognized gains (losses) on derivatives, net of tax, beginning of period Net unrecognized gains (losses) on derivatives, net of tax, end of period Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax Repayments of Debt Repayments of Debt Thereafter Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Dividends paid per share Common Stock, Dividends, Per Share, Cash Paid Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Commercial Paper Program [Member] Commercial Paper Program [Member] Commercial Paper Program [Member] Generics Generics [Member] Generics Goodwill, Transfers Goodwill, Transfers Operating lease liabilities Deferred Tax Liabilities, Operating Lease, Liability Deferred Tax Liabilities, Operating Lease, Liability Other assets Other Assets [Member] Waived deductions under IRC § 59A Effective Income Tax Rate Reconciliation, Waived Deductions, Percent Effective Income Tax Rate Reconciliation, Waived Deductions, Percent Other (income) expense, net Other Nonoperating Income (Expense) Other Pension, Postretirement and Supplemental Plans Other Pension, Postretirement and Supplemental Plans [Member] Inventory Recall Expense Inventory Recall Expense Payments for product rights and other, net Payments for (Proceeds from) Other Investing Activities Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Business Combinations [Abstract] Business Combinations [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Rebates, Promotional Programs and Other Sales Allowances [Member] Rebates, Promotional Programs and Other Sales Allowances [Member] Rebates, Promotional Programs and Other Sales Allowances [Member] Maximum Maximum [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-based Payment Arrangement [Abstract] 2028 Euro Senior Notes 2028 Euro Senior Notes [Member] 2028 Euro Senior Notes [Member] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Raw materials Inventory, Raw Materials, Net of Reserves Other current liabilities Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Rate used to discount net cash inflows to present values Goodwill Impairment Test, Measurement Input Goodwill Impairment Test, Measurement Input Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Revenue by Major Customers by Reporting Segments Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Restructuring and Related Cost, Expected Cost Remaining Restructuring and Related Cost, Expected Cost Remaining City Area Code City Area Code Restricted cash, included in other current and non-current assets Restricted cash Restricted Cash and Cash Equivalents, Current Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Designated as hedging instrument Designated as Hedging Instrument [Member] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] IRELAND IRELAND Property, plant and equipment, estimated service life (years) Property, Plant and Equipment, Useful Life India INDIA Viatris Inc. shareholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Number of states Number of states Number of states Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Concentrations of Credit Risk Policy Concentration Risk, Credit Risk, Policy [Policy Text Block] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Total assets acquired Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Governmental Rebate Programs [Member] Governmental Rebate Programs [Member] Governmental Rebate Programs [Member] Unrecognized net actuarial losses exceed higher of market value of plan assets or the projected benefit obligation at the beginning of the year Accumulated net actuarial losses exceed higher of market value of plan assets or PBO Accumulated net actuarial losses exceed higher of market value of plan assets or PBO Aggregate principal amount Debt Instrument, Face Amount Debt Instrument, Face Amount U.K. Competition and Markets Authority Proceedings Paroxetine U.K. Competition and Markets Authority Proceedings Paroxetine [Member] U.K. Competition and Markets Authority Proceedings Paroxetine Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period Net unrealized gains on marketable securities, net of tax, end of period Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Cardinal Health Inc Cardinal Health Inc [Member] Cardinal Health Inc [Member] Decrease in the aggregate of service and interest cost components of annual expense Defined Benefit Plan, Effect of One Percentage Point Decrease on Service and Interest Cost Components Interest expense (income) related to uncertain tax positions Income Tax Examination, Interest Expense Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Operating Segments Operating Segments [Member] Finite-Lived Intangible Assets, Period Increase (Decrease) Finite-Lived Intangible Assets, Period Increase (Decrease) Remaining lease terms Lessee, Operating Lease, Term of Contract PUERTO RICO PUERTO RICO Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Restricted Stock Awards Restricted Stock Units (RSUs) [Member] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Additions Charged to Other Accounts SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account Anticompetitive Conduct with Generic Drugs Anticompetitive Conduct with Generic Drugs [Member] Anticompetitive Conduct with Generic Drugs [Member] Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Subject to Market Conditions [Domain] Subject to Market Conditions [Domain] [Domain] for Subject to Market Conditions [Axis] Total deferred tax liabilities Deferred Tax Liabilities, Gross Business Acquisition [Line Items] Business Acquisition [Line Items] Other Long Term Debt Other Long Term Debt [Member] Other long term debt. Valuation Technique, Discounted Cash Flow Valuation Technique, Discounted Cash Flow [Member] Investments in subsidiaries Equity Method Investments Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Asset Class [Domain] Asset Class [Domain] Diluted (in usd per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Weighted average exercise price per share, forfeited Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Income tax provision (benefit) Income tax related to items of other comprehensive (loss) earnings, derivatives Income Tax Expense (Benefit) Other Commitments [Domain] Other Commitments [Domain] 2021 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Accounts receivable, net Accounts receivable, net Beginning of period End of period Accounts Receivable, after Allowance for Credit Loss, Current Inventory Deferred Tax Assets, Inventory Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Tax Identification Number Entity Tax Identification Number Basic (in shares) Weighted Average Basic Shares Outstanding, Pro Forma Change in Plan Assets Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Assets Other comprehensive (loss) earnings, before tax: Other Comprehensive Income (Loss), before Tax [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Assets, Current Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Total lease payments Lessee, Operating Lease, Liability, to be Paid Trade accounts payable Accounts Payable, Trade Accounts Receivable Accounts Receivable [Member] Number of restricted stock awards, forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Stock appreciation rights and performance shares Stock appreciation rights and performance shares [Member] Stock appreciation rights and performance shares 2016 through 2035 Future years [Member] Future years [Member] Product rights and licenses by therapeutic category Product Rights And Licenses By Therapeutic Category [Table Text Block] Product rights and licenses by therapeutic category Stock-Based Compensation Policy Share-based Payment Arrangement [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Current portion of long-term debt and other long-term obligations Long-term Debt, Current Maturities Loss Contingency, Number of States Loss Contingency, Number of States Loss Contingency, Number of States Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Lyrica ® Lyrica ® [Member] Lyrica ® Restructuring Plan [Axis] Restructuring Plan [Axis] Pfizer, Inc. Pfizer, Inc. [Member] Pfizer, Inc. [Member] Third party net sales Revenue Benchmark [Member] Weighted average grant date fair value per option Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Disposal Group Name [Domain] Disposal Group Name [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Revance [Member] Revance [Member] Revance [Member] Multiemployer plans, withdrawal obligation Multiemployer Plans, Withdrawal Obligation Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Aspen Pharmacare Holdings Limited Aspen Pharmacare Holdings Limited [Member] Aspen Pharmacare Holdings Limited Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Variable Consideration Category [Axis] Variable Consideration Category [Axis] Variable Consideration Category [Axis] Litigation Case [Axis] Litigation Case [Axis] Derivative Financial Instruments in Cash Flow Hedging Relationships (2) : Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Issuance of common stock for the Combination (in shares) Stock Issued During Period, Shares, Acquisitions Impairment of products rights and licenses intangible assets Impairment of Intangible Assets, Finite-lived Zoloft ® Zoloft ® [Member] Zoloft ® 2040 Senior Notes 2040 Senior Notes [Member] 2040 Senior Notes Restructuring and Related Cost, Incurred Cost Restructuring and Related Cost, Incurred Cost Unrecognized Tax Benefits, Decrease Resulting from Acquisition Unrecognized Tax Benefits, Decrease Resulting from Acquisition Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Liabilities Liabilities [Abstract] Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Deferred tax liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities Inventory, Firm Purchase Commitment, Loss Inventory, Firm Purchase Commitment, Loss Counterparty Name [Domain] Counterparty Name [Domain] Retirement of Mylan N.V. treasury stock, net Treasury Stock, Retired, Cost Method, Amount Intangible assets, gross, excluding goodwill Intangible Assets, Gross (Excluding Goodwill) 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four 2025 Senior Notes 2025 Senior Notes [Member] 2025 Senior Notes Purchase of marketable securities Payments to Acquire Marketable Securities Measurement Input, Long-term Revenue Growth Rate [Member] Measurement Input, Long-term Revenue Growth Rate [Member] (Loss) earnings before income taxes Operating and non-operating expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Reduction in Equity Method Investment Long-Term Obligation Reduction in Equity Method Investment Long-Term Obligation Reduction in Equity Method Investment Long-Term Obligation Auditor Location Auditor Location USD Term Loan Facility USD Term Loan Facility [Member] USD Term Loan Facility Amount of loss recognized in earnings on derivatives Derivative, Gain (Loss) on Derivative, Net Derivative, Gain (Loss) on Derivative, Net Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock Stock Exchanged During Period, Value Stock Exchanged During Period, Value Type of Restructuring [Domain] Type of Restructuring [Domain] Segment Reporting [Abstract] Segment Reporting [Abstract] One-Time Special Performance-Based Five-Year Realizable Value Incentive Program One-Time Special Performance-Based Five-Year Realizable Value Incentive Program [Member] One-Time Special Performance-Based Five-Year Realizable Value Incentive Program Subject to Market Conditions Subject to Market Conditions [Member] Subject to Market Conditions Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Finite-lived intangible asset, estimated useful life, in years Finite-Lived Intangible Asset, Useful Life Use of Estimates in the Preparation of Financial Statements Policy Use of Estimates, Policy [Policy Text Block] Earnings Per Common Share Attributable To Mylan Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Foreign currency translation Goodwill, Translation and Purchase Accounting Adjustments Antitrust Proceedings Antitrust Proceedings [Member] Antitrust proceedings Title of 12(b) Security Title of 12(b) Security Expected foreign tax credits Deferred Tax Assets, Tax Credit Carryforwards, Foreign Investment, Name [Domain] Investment, Name [Domain] CARES Act, Income Tax Expense (Benefit) CARES Act, Income Tax Expense (Benefit) CARES Act, Income Tax Expense (Benefit) Cash dividends paid Payments to Noncontrolling Interests Ordinary shares, number of shares authorized Common Stock, Shares Authorized Tax settlements and resolution of certain tax positions Effective Income Tax Rate Reconciliation, Tax Settlement, Percent SINGAPORE SINGAPORE Document Type Document Type Trade accounts payable Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Product and Service [Domain] Product and Service [Domain] Fair value loss (gain) Business Combination, Contingent Consideration, Liability, Fair Value Gain (Loss) Business Combination, Contingent Consideration, Liability, Fair Value Gain (Loss) Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Unrecognized prior service credit (cost) Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Contingent consideration liability Purchase consideration, contingent consideration Balance at beginning of period Balance at end of period Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Litigation settlements and other contingencies, net Change in noncash litigation settlements, net Change in noncash litigation settlements, net Revolving Credit Facility Revolving Credit Facility [Member] 2023 Senior Notes (4.200%) SeniorNotesTwoThousandTwentyThree4.2Percent [Member] Senior notes two thousand twenty three - 4.2 percent Valuation allowance for deferred tax assets SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Lease, Cost Lease, Cost [Table Text Block] Corporate bonds Corporate Bond Securities [Member] Geographical [Axis] Geographical [Axis] Proceeds from Sale of Securities, Operating Activities Proceeds from Sale of Securities, Operating Activities Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Sales Revenue, Gross to net adjustments Sales Revenue, Gross to net adjustments Sales Revenue, Gross to net adjustments Net sales Product [Member] Net Investment Hedging Net Investment Hedging [Member] Subject to Market Conditions [Axis] Subject to Market Conditions [Axis] Subject to Market Conditions [Axis] Long-term Debt, Weighted Average Interest Rate, at Point in Time Long-term Debt, Weighted Average Interest Rate, at Point in Time Hedging Relationship [Axis] Hedging Relationship [Axis] Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Interest Expense [Member] Interest Expense [Member] Mature in five years and later Available for Sale Securities Debt Maturities after Five Years and Later Fair Value Available for sale securities debt maturities after five years and later fair value. Amortization of prior service costs included in SG&A Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities 2019 Senior Notes (2.500%) SeniorNotesTwoThousandNineteen2.50Precent [Member] 2019 Senior Notes (2.500%) Contingent consideration Contingent Consideration [Member] Contingent Consideration. Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Stock option award vesting period, in years Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Variable Consideration [Member] Variable Consideration [Member] Variable Consideration [Member] 2030 Senior Notes 2030 Senior Notes [Member] 2030 Senior Notes Loss from equity method investments Income (Loss) from Equity Method Investments Equity securities — exchange traded funds Exchange Traded Funds [Member] Nonvested Restricted Stock and Restricted Stock Unit, Including Performance Units, Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Period [Axis] Period [Axis] Period [Axis] Restructuring and Related Cost, Cost Incurred to Date Restructuring Charges Concentration Risk Type [Axis] Concentration Risk Type [Axis] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Foreign Foreign Tax Authority Foreign Tax Authority [Member] Estimated Litigation Liability, Current Estimated Litigation Liability, Current Accounts Payable, Current [Abstract] Accounts Payable, Current [Abstract] Contingent Consideration Policy Business Combinations Policy [Policy Text Block] Derivative [Table] Derivative [Table] Cancellation of restricted stock Treasury Stock, Shares, Retired Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Revenues: Revenues [Abstract] Deferred tax liabilities: Deferred Tax Liabilities, Net [Abstract] Document Period End Date Document Period End Date Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Proceeds from Sale and Collection of Receivables Proceeds from Sale and Collection of Receivables Fixed income securities Fixed Income Securities [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Consolidated Entities [Domain] Consolidated Entities [Domain] Insulin Analog Products Insulin Analog Products Insulin Analog Products Total Expected Future Benefit Payments Expected Future Benefit Payments Complex Gx and Biosimilars Complex GX and Biosimilars [Member] Complex GX and Biosimilars U.S. State Deferred Deferred State and Local Income Tax Expense (Benefit) Emerging Markets Emerging Markets Segment [Member] Emerging Markets Segment Property, plant and equipment Property, Plant and Equipment [Table Text Block] Greater China Greater China Segment [Member] Greater China Segment Receivables Facility [Member] Receivables Facility [Member] Receivables facility. Debt Instrument, Term Debt Instrument, Term Income Statement Location [Domain] Income Statement Location [Domain] Medicaid and other governmental rebates Medicaid and other governmental rebates Medicaid and other governmental rebates Derivative Asset (Liability) Net, Measurement Input Derivative Asset (Liability) Net, Measurement Input Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Land and improvements Land and Land Improvements [Member] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Payments of long-term debt Repayments of Long-term Debt Goodwill, Impaired, Change in Estimate, Period Goodwill, Impaired, Change in Estimate, Period Goodwill, Impaired, Change in Estimate, Period (Loss) earnings per share attributable to Viatris Inc. shareholders Earnings Per Share [Abstract] Earnings Per Share [Abstract] Collaborative Arrangement Collaborative Arrangement [Member] Property, plant and equipment, gross Property, Plant and Equipment, Gross Rate used to discount net cash inflows to present values Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets, Measurement Input Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets, Measurement Input Total revenues Total revenues Revenues Income tax provision (benefit), Non-U.S. Foreign Income Tax Expense (Benefit), Continuing Operations Contingent consideration Other Liabilities, Fair Value Disclosure Foreign Exchange Contract Foreign currency borrowings and forward contracts Foreign Exchange Contract [Member] Loss contingency accrual Loss Contingency Accrual 2022 Euro Senior Notes 2022 Euro Senior Notes [Member] 2022 Euro Senior Notes Fiscal Year 2017 Fiscal Year 2017 [Member] Fiscal Year 2017 [Member] Other Commitments [Line Items] Other Commitments [Line Items] Weightedaverage exercise price per share, outstanding at beginning of period Weighted average exercise price per share, outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Deferred income tax benefit Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Assets Asset Acquisition [Domain] Asset Acquisition [Domain] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Entity Current Reporting Status Entity Current Reporting Status Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Fair value of plan assets, beginning of year Fair value of plan assets, end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Net accrued benefit costs Net accrued benefit costs Net accrued benefit costs Other Other Debt Obligations [Member] Debt, Current Debt, Current Counterparty Name [Axis] Counterparty Name [Axis] Proceeds from the sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Dymista ® Dymista ® [Member] Dymista ® Shares issued Balance (in shares) Balance (in shares) Shares, Issued Amounts accrued Business Combination, Contractual Reimbursement Amount, Amounts Accrued Business Combination, Contractual Reimbursement Amount, Amounts Accrued United States UNITED STATES Measurement Input, Discount Rate [Member] Measurement Input, Discount Rate [Member] Amounts incurred Business Combination, Contractual Reimbursement Amount, Amounts Expensed Business Combination, Contractual Reimbursement Amount, Amounts Expensed Restructuring Reserve, Reimbursable Restructuring Charges Restructuring Reserve, Reimbursable Restructuring Charges Restructuring Reserve, Reimbursable Restructuring Charges Common stock shares reserved for issuance to employees Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Leases [Abstract] Income Taxes Policy Income Tax, Policy [Policy Text Block] London Interbank Offered Rate (LIBOR) [Member] London Interbank Offered Rate (LIBOR) [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Other Postretirement Benefits, Individual Contracts, Type of Deferred Compensation [Axis] Other Postretirement Benefits, Individual Contracts, Type of Deferred Compensation [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Revenue Recognition Policy Revenue from Contract with Customer [Policy Text Block] Diluted (in shares) Total dilutive shares outstanding Weighted Average Number of Shares Outstanding, Diluted Earnings before income taxes and noncontrolling interest, United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Total intangible asset amortization expense (including impairment charges) Amortization Income Taxes Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Stock Awards Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Insulin Glargine Insulin Glargine [Member] Insulin Glargine Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] 2018 Senior Notes (2.600%) Senior Notes Two Thousand Eighteen - 2.6 Percent [Member] Senior Notes Two Thousand Eighteen - 2.6% [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Goodwill Impairment, Measurement Input Goodwill Impairment, Measurement Input Goodwill Impairment, Measurement Input 2020 Floating Rate Euro Notes 2020 Floating Rate Euro Notes [Member] 2020 Floating Rate Euro Notes Not designated as hedging instrument Not Designated as Hedging Instrument [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Restructuring Reserve, Noncurrent Restructuring Reserve, Noncurrent Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Principles of Consolidation Policy Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Schedule of Short-term Debt Schedule of Short-term Debt [Table Text Block] Net assets Equity Method Investment Summarized Financial Information, Net Assets Equity Method Investment Summarized Financial Information, Net Assets Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Current liabilities Liabilities, Current Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Supply Commitment [Axis] Supply Commitment [Axis] Foreign Exchange Forward Foreign Exchange Forward [Member] EURIBOR [Member] EURIBOR [Member] EURIBOR [Member] Money market funds Money Market Funds [Member] Accounts payable Accounts payable Accounts Payable, Trade, Current Loss Contingencies [Table] Loss Contingencies [Table] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Plans with Accumulated Benefit Obligation in Excess of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Financial Instruments And Risk Management Financial Instruments Disclosure [Text Block] Loss Contingency, Damages Awarded On Appeal, Value Loss Contingency, Damages Awarded On Appeal, Value Loss Contingency, Damages Awarded On Appeal, Value Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Long Term Incentive Plan 2003 Long Term Incentive Plan 2003 [Member] Long-Term Incentive 2003 Plan. Statement [Table] Accounting Policies [Table] Statement [Table] Business Acquisition, expected future payments, next twelve months Business Acquisition, expected future payments, next twelve months Business Acquisition, expected future payments, next twelve months Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other Deferred Tax Assets, Other Other Commitments [Axis] Other Commitments [Axis] 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Goodwill [Member] Goodwill [Member] Total unrecognized compensation expense, net of estimated forfeitures Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Range [Axis] Statistical Measurement [Axis] Accounts receivable, net Accounts Receivable [Policy Text Block] Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent Subsequent Event Subsequent Event [Member] Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Tax Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Tax Finite-lived intangible assets, net Finite-lived intangible assets, net book value Finite-Lived Intangible Assets, Net Goodwill Goodwill, net, ending balance Goodwill Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Measurement Input, Increase in Discount Rate Measurement Input, Increase in Discount Rate [Member] Measurement Input, Increase in Discount Rate U.S. rate differentials Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Changes in carrying amount of goodwill Schedule of Goodwill [Table Text Block] Scenario, Unspecified [Domain] Scenario [Domain] Three Full Fiscal Quarters Following Qualifying Acquisition Three Full Fiscal Quarters Following Qualifying Acquisition [Member] Three Full Fiscal Quarters Following Qualifying Acquisition [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Defined Pension Plan Items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Defined contribution plan, maximum annual contribution per employee, percent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Deferred income tax expense (benefit) Deferred Income Tax Expense (Benefit) Average remaining contractual term for options vested and expected to vest, in years Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Xalabrands Xalabrands [Member] Xalabrands Australian Taxation Office Australian Taxation Office [Member] Deferred income tax benefit Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Hedging Designation [Domain] Hedging Designation [Domain] Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Asset Acquisition [Axis] Asset Acquisition [Axis] Other noncurrent liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities Number of drugs Number of drugs Number of drugs Statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Earnings Per Common Share Policy Earnings Per Share, Policy [Policy Text Block] Restructuring Reserve, Acquired During Period Restructuring Reserve, Acquired During Period Restructuring Reserve, Acquired During Period TOBI TOBI [Member] TOBI [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Operating Lease, Right-of-Use Asset Right-of-use asset Operating Lease, Right-of-Use Asset Interest cost Defined Benefit Plan, Interest Cost Employee-related Liabilities, Current Employee-related Liabilities, Current Receivables, Net, Current [Abstract] Receivables, Net, Current [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Finite-lived intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Range [Domain] Statistical Measurement [Domain] EU Commission Proceedings Perindorpril EU Commission Proceedings Perindorpril [Member] EU Commission Proceedings Perindorpril Minimum Repayments on Outstanding Borrowings Schedule of Maturities of Long-term Debt [Table Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan 2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan [Member] 2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan Senior Notes 2023 3.125% SeniorNotesTwoThousandTwentyThree3.125Percent [Member] Senior notes two thousand twenty three - 3.125 percent Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Restructuring Type [Axis] Restructuring Type [Axis] Other assets Other assets Other Assets, Noncurrent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Defined benefit plan, ultimate health care cost trend rate, projected Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Segments [Axis] Segments [Axis] Retirement Benefits [Abstract] Retirement Benefits [Abstract] In-process research and development In Process Research and Development [Member] Entity File Number Entity File Number 2021 Senior Notes (3.150%) SeniorNotesTwoThousandTwentyOne3.15Precent [Member] 2021 Senior Notes 3.15% Share-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Viagra ® Viagra ® [Member] Viagra ® Effect on Future Cash Flows, Amount Effect on Future Cash Flows, Amount Credit Concentration Risk Credit Concentration Risk [Member] Accumulated benefit obligation Defined Benefit Pension Plans with Projected Benefit Obligation In Excess of Plan Assets Aggregate Projected Benefit Obligation Defined Benefit Pension Plans with Projected Benefit Obligation In Excess of Plan Assets Aggregate Projected Benefit Obligation Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Vesting Period [Axis] Vesting Period [Axis] Vesting Period [Axis] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Payments of financing fees Payments of Financing Costs Employee benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Clean energy investments Clean Energy Partnerships [Member] Clean Energy Partnerships Liability Class [Axis] Liability Class [Axis] Building Building [Member] Twenty Twenty One Loan Facilities Twenty Twenty One Loan Facilities [Member] Twenty Twenty One Loan Facilities EpiPen® Auto-Injectors EpiPen® Auto-Injectors [Member] EpiPen® Auto-Injectors Equity Method Investment, Other than Temporary Impairment Equity Method Investment, Other than Temporary Impairment Accretion expense expected within 12 months Accretion Expense to be Recognized within the Next Twelve Months Accretion Expense to be Recognized within the Next Twelve Months Weighted average grant-date fair value per share, granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Impact of foreign currency translation Defined Benefit Plan, Foreign Currency Translation Impact on Plan Assets Defined Benefit Plan, Foreign Currency Translation Impact on Plan Assets Disposal Group Name [Axis] Disposal Group Name [Axis] Noncurrent liabilities Liability, Defined Benefit Plan, Noncurrent Derivative Financial Instruments Not Designated as Hedging Instruments: Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Assets Assets [Abstract] Reimbursement amount, tranche one Business Combination, Contractual Reimbursement Amount, Tranche One Business Combination, Contractual Reimbursement Amount, Tranche One Goodwill Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill 2023 Long-Term Debt, Maturity, Year Three Goodwill, Impaired, Accumulated Impairment Loss Accumulated impairment losses, beginning balance Accumulated impairment losses, ending balance Goodwill, Impaired, Accumulated Impairment Loss Weighted average exercise price per share, vested and expected to vest at period end Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Debt Instrument, Covenant Description Debt Instrument, Covenant Description Segment Reconciling Segment Reconciling Items [Member] Number of restricted stock awards, granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Maximum Leverage Ratio, Period One Maximum Leverage Ratio, Period One Maximum Leverage Ratio, Period One Anticompetitive conduct with respect to additional generic drugs Anticompetitive conduct with respect to additional generic drugs [Member] Anticompetitive conduct with respect to additional generic drugs Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Concentration risk, percentage Concentration Risk, Percentage Property, Plant and Equipment Policy Property, Plant and Equipment, Policy [Policy Text Block] Other Postretirement Benefits, Individual Contracts, Type of Deferred Compensation [Domain] Other Postretirement Benefits, Individual Contracts, Type of Deferred Compensation [Domain] Impairment of Equity Method Investments Impairment of Equity Method Investments Impairment of Equity Method Investments Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of shares under stock awards, outstanding at beginning of period Number of shares under stock awards, outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Debt Instrument [Axis] Debt Instrument [Axis] Term of operating leases not yet commenced Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Increase in the benefit obligation Defined Benefit Plan, Effect of One Percentage Point Increase on Accumulated Postretirement Benefit Obligation Participant contributions DefinedBenefitPlanContributionsByPlanParticipantsBenefitObligation Defined Benefit Plan Contributions By Plan Participants Benefit Obligation Series of Individually Immaterial Business Acquisitions Series of Individually Immaterial Business Acquisitions [Member] Accounts receivable securitization facility maximum borrowing capacity Accounts Receivable Facility Maximum Borrowing Capacity Accounts receivable facility maximum borrowing capacity. Increased Discount Rate [Domain] Increased Discount Rate [Domain] Increased Discount Rate [Domain] Rate used to discount net cash inflows to present values Business Combination, Contingent Consideration, Liability, Measurement Input Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Member] Net assets acquired (net of $415.8 of cash acquired) Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Interest expense Deferred Tax Assets, Deferred tax expense, interest expense Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from interest expense. Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Acquisition, Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Unrecognized actuarial (gain) loss Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Other noncurrent liabilities Other Noncurrent Liabilities [Table Text Block] Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Equity securities Equity Securities, FV-NI Tax settlements and resolution of certain tax positions Effective Income Tax Rate Reconciliation, India Amagulation Effective Income Tax Rate Reconciliation, India Amagulation Other comprehensive (loss) earnings, before tax Other comprehensive (loss) earnings, before tax Other Comprehensive Income (Loss), before Tax Indefinite Indefinite [Member] Indefinite amount of time Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Loss Contingency, Remaining Claims, Number Loss Contingency, Remaining Claims, Number Loss Contingency, Remaining Claims, Number 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three 2014 Program 2014 Program [Member] 2014 Program Allowance for doubtful accounts SEC Schedule, 12-09, Allowance, Credit Loss [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Expected return on plan assets Defined Benefit Plan, Assumptions Used Calculating Projected Benefit Obligation, Expected Long-term Return on Assets Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Expected Long-term Return on Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Prepaid expenses Prepaid Expense, Current Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] 2025 Long-Term Debt, Maturity, Year Five Total employer contributions Defined Contribution Plan, Cost Reporting Unit, Amount of Fair Value in Excess of Carrying Amount Reporting Unit, Amount of Fair Value in Excess of Carrying Amount Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Tax credit and loss carry-forwards Deferred Tax Assets, Tax Credit Carryforwards Amount of common stock shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Change in short-term borrowings, net Proceeds from (Repayments of) Short-term Debt Number of cases Number of cases Number of cases JANZ Japan, Australia and New Zealand Segment [Member] Japan, Australia and New Zealand Segment Research and Development Policy Research and Development Expense, Policy [Policy Text Block] Theravance Theravance Biopharma [Member] Theravance Biopharma Acquisition purchase price Business Combination, Consideration Transferred Income tax provision (benefit), U.S. Federal Federal Income Tax Expense (Benefit), Continuing Operations Schedule of other current liabilities [Table] Schedule of other current liabilities [Table] Schedule of other current liabilities [Table] Voluntary Recall of Valsartan and Certain Combinations Valsartan Medicines [Member] Voluntary Recall of Valsartan and Certain Combinations Valsartan Medicines [Member] Voluntary Recall of Valsartan and Certain Combinations Valsartan Medicines [Member] Long-term Debt, Gross Total Long-term Debt, Gross Other noncurrent liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Liabilities Total assets at recurring fair value measurement Assets, Fair Value Disclosure 2020 Revolving Facility 2020 Revolving Facility [Member] 2020 Revolving Facility Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Total liabilities and equity Liabilities and Equity Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other Accrued Liabilities, Current Other Accrued Liabilities, Current AmeriSourceBergen Corporation AmeriSourceBergen Corporation [Member] AmeriSourceBergen Corporation Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Net unrealized (loss) gain on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Weighted average exercise price per share, exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted Cash Restricted Cash Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Supplemental disclosures of cash flow information — Supplemental Cash Flow Elements [Abstract] Generic Biologic Compounds Collaboration [Member] Generic Biologic Compounds Collaboration [Member] Generic Biologic Compounds Collaboration 2022 Senior Notes 2022 Senior Notes [Member] 2022 Senior Notes 2025 Euro Senior Notes 2025 Euro Senior Notes [Member] 2025 Euro Senior Notes [Member] Derivative [Line Items] Derivative [Line Items] Foreign exchange derivative assets Foreign Currency Contract, Asset, Fair Value Disclosure Current Provision Related to Sales Made in the Current Period Accounts Receivable, Sales Provisions, Current Accounts Receivable, Sales Provisions, Current Schedule of Other Current Assets Schedule of Other Current Assets [Table Text Block] Income Tax Contingency [Table] Income Tax Contingency [Table] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Increase in the aggregate of service and interest cost components of annual expense Defined Benefit Plan, Effect of One Percentage Point Increase on Service and Interest Cost Components Operating expenses: Operating Expenses [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Prepaid Expense and Other Assets, Current [Abstract] Prepaid Expense and Other Assets, Current [Abstract] 2020 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Minimum Minimum [Member] Other operating assets and liabilities, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Restructuring Reserve, Period Increase (Decrease) Restructuring Reserve, Period Increase (Decrease) Note Securitization Facility [Member] Note Securitization Facility [Member] Note Securitization Facility [Member] Gross profit Gross loss Gross Profit 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Total liabilities at recurring fair value measurement Financial and Nonfinancial Liabilities, Fair Value Disclosure Selling, general and administrative Selling, General and Administrative Expense Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Net realizable value of inventory recognized as expense Net realizable value of inventory recognized as expense Net realizable value of inventory recognized as expense April 2018 Senior Notes [Member] April 2018 Senior Notes [Member] April 2018 Senior Notes [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Other Assets, Noncurrent [Abstract] Other Assets, Noncurrent [Abstract] Influvac ® Influvac ® [Member] Influvac ® Restructuring Reserve, Translation and Other Adjustment Restructuring Reserve, Translation and Other Adjustment Other comprehensive earnings (loss) before reclassifications, before tax Other Comprehensive Income (Loss), before Reclassifications, before Tax U.S. Federal Tax Authority U.S. Federal Tax Authority [Member] U.S. Federal Tax Authority [Member] Business Acquisition, Percentage of Voting Interests Acquired Business Acquisition, Percentage of Voting Interests Acquired 2024 Long-Term Debt, Maturity, Year Four Stock Issued During Period, Value, New Issues Stock Issued During Period, Value, New Issues Future unrecognized actuarial losses Defined Benefit Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year Measurement Period Adjustments and Reclasses Accounts Receivable, Increase Due to Acquisition, Current Accounts Receivable, Increase Due to Acquisition, Current Cash received (paid) for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Debt Debt Disclosure [Text Block] Other Restructuring Other Restructuring [Member] Schedule of Components of Income Tax Provision Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Line of Credit Line of Credit [Member] Scenario, Plan Scenario, Plan [Member] Share-Based Incentive Plan Share-based Payment Arrangement [Text Block] Senior Notes Senior Notes [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Divestiture of Business, Deferred Cash Consideration. Divestiture of Business, Deferred Cash Consideration. Divestiture of Business, Deferred Cash Consideration. Tax Year 2015 Tax Year 2015 [Member] Net unrealized gain on marketable securities, net of tax Net unrealized gains on marketable securities, net of tax, beginning of period Net unrealized gains on marketable securities, net of tax, end of period AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax Issuance of common stock to Mylan N.V. shareholders (in shares) Stock Issued During Period, Shares, New Issues Schedule of other current liabilities [Line Items] Schedule of other current liabilities [Line Items] [Line Items] for Schedule of other current liabilities [Table] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Inventory, Net [Abstract] Inventory, Net [Abstract] Acquisitions Goodwill, Acquired During Period Other Postretirement Benefits Other Postretirement Benefits Plan [Member] Performance Shares Performance Shares [Member] Noncurrent assets Assets, Noncurrent Contractual Rights Contractual Rights [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss, net of tax, beginning of period Accumulated other comprehensive loss, net of tax, end of period Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Supply Commitment Arrangement [Domain] Supply Commitment Arrangement [Domain] Medium-term Notes Medium-term Notes [Member] Impact of foreign currency translation Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Restricted stock Restricted Stock [Member] Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt Auditor Name Auditor Name Cover [Abstract] Cover [Abstract] Diluted (in shares) Pro Forma Weighted Average Shares Outstanding, Diluted Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Derivative Financial Instruments in Net Investment Hedging Relationships: Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Cash and Cash Equivalents Policy Cash and Cash Equivalents, Policy [Policy Text Block] Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block] Fair value loss (gain) Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Financial Instrument [Axis] Short-term Debt [Line Items] Short-term Debt [Line Items] Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Schedule of Other Assets [Line Items] Schedule of Other Assets [Line Items] [Line Items] for Schedule of Other Assets [Table] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Other revenues Revenue Not from Contract with Customer Payments for Restructuring Payments for Restructuring Other Foreign Operations Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent Common Stock Marketable securities Common Stock [Member] Sales Milestone Payments Sales Milestone Payments Sales Milestone Payments Earnings before income taxes and noncontrolling interest, foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign (Loss) earnings from operations Segment profitability Operating Income (Loss) 2018 Senior Notes (3.000% coupon) Senior Notes Two Thousand Eighteen - 3.0 Percent [Member] Senior Notes Two Thousand Eighteen - 3.0 Percent Amount of Gain Excluded from the Assessment of Hedge Effectiveness Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net Operating Lease, Liability, Current Operating Lease, Liability, Current Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Collaborative and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Measurement Input, Reduction in Terminal Year Revenue Growth Rate Measurement Input, Reduction in Terminal Year Revenue Growth Rate [Member] Measurement Input, Reduction in Terminal Year Revenue Growth Rate Hedging Designation [Axis] Hedging Designation [Axis] Foreign currency translation adjustment Foreign currency translation adjustment, beginning of period Foreign currency translation adjustment, end of period Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Share-based compensation expense Share-based Payment Arrangement, Noncash Expense Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation Depreciation Other foreign Other foreign [Member] Other foreign [Member] 2046 Senior Notes (5.250%) SeniorNotesTwoThousandFortySix5.25Precent [Member] 2046 Senior Note (5.250%) Treasury Stock Treasury Stock [Member] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Dimethyl Fumarate Dimethyl Fumarate [Member] Dimethyl Fumarate Income taxes Income Taxes Paid McKesson Corporation McKesson Corporation [Member] McKesson Corporation [Member] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Income Tax Examination, Reserve Impact On Income Tax Provision Income Tax Examination, Reserve Impact On Income Tax Provision Income Tax Examination, Reserve Impact On Income Tax Provision Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Plan curtailment, settlement and termination Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment Unregistered Upjohn U.S. Dollar Notes Unregistered Upjohn U.S. Dollar Notes [Member] Unregistered Upjohn U.S. Dollar Notes Capital expenditures Payments to Acquire Property, Plant, and Equipment Other current liabilities Other Liabilities, Current Other Liabilities, Current Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Business Combinations, Number of Agreements Business Combinations, Number of Agreements Business Combinations, Number of Agreements Operating leases expense Operating Leases, Rent Expense, Net Total liabilities Total liabilities Liabilities Deferred tax assets: Deferred Tax Assets, Net [Abstract] 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Weighted average exercise price per share, granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Aggregate intrinsic value for options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Goodwill Impairment Test, Measurement Input, Increase Goodwill Impairment Test, Measurement Input, Increase Goodwill Impairment Test, Measurement Input, Increase Schedule of Activity in Contingent Consideration [Roll Forward] Schedule of Activity in Contingent Consideration [Roll Forward] Schedule of Activity in Contingent Consideration [Roll Forward] Measurement Input Type [Axis] Measurement Input Type [Axis] Consolidation Items [Axis] Consolidation Items [Axis] Creon ® Creon ® [Member] Creon ® Net operating loss carryforwards Operating Loss Carryforwards Total Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Change in unrecognized loss and prior service cost related to defined benefit plans Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Net change Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Schedule of Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Entity Address, City or Town Entity Address, City or Town Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Current portion of long-term debt Current Portion of Long-Term Debt [Member] Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Non-cash transactions: Noncash Investing and Financing Items [Abstract] North America Specialty [Member] North America Specialty [Member] North America Specialty [Member] Capitalized software Software and Software Development Costs [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Comprehensive Earnings Comprehensive Income (Loss) Note [Text Block] 2050 Senior Notes 2050 Senior Notes [Member] 2050 Senior Notes Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Interest expense Interest expense Interest Expense Product rights and licenses Licensing Agreements [Member] Expected return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets (Reduction) addition due to acquisition Unrecognized Tax Benefits, Increase Resulting from Acquisition Debt instrument, interest rate at period end Debt Instrument, Interest Rate, Effective Percentage Other assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Assets Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Business Acquisition, expected future payment, year two Business Acquisition, expected future payment, year two 2019 Defined Benefit Plan, Expected Future Benefit Payment, Year One Retained earnings Retained Earnings (Accumulated Deficit) Amount of unrecognized deferred tax liability Increase in Unrecognized Tax Benefits is Reasonably Possible Litigation Case [Domain] Litigation Case [Domain] Stock option award expiration period, in years Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Contingent consideration payments Payments of Merger Related Costs, Financing Activities Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Equity Method Investments Equity Method Investments [Table Text Block] Entity Filer Category Entity Filer Category Developed Markets Developed Markets Segment [Member] Developed Markets Segment Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Effect of Derivative Instruments on the Consolidated Statements of Operations Derivative Instruments, Gain (Loss) [Table Text Block] U.S. Treasuries US Treasury Securities [Member] Celebrex ® Celebrex ® [Member] Celebrex ® 2028 Senior Notes 2028 Senior Notes [Member] 2028 Senior Notes [Member] [Member] Accretion Accretion Expense In-process research and development Indefinite-lived Intangible Assets (Excluding Goodwill) Capitalized Computer Software, Net Capitalized Computer Software, Net Proceeds from exercise of stock options Proceeds from Stock Options Exercised Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil [Member] Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total equity Balance Balance Total equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Amendment Flag Amendment Flag Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Equity Components [Axis] Equity Components [Axis] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Gains and Losses on Derivatives in Cash Flow Hedging Relationships Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Inventories Inventories Inventory, Net Reconciliation of Segment Information to Total Consolidated Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Number of shares under stock awards, granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures U.S. Federal Deferred Deferred Federal Income Tax Expense (Benefit) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five EU Commission Proceedings Citalopram EU Commission Proceedings Citalopram [Member] EU Commission Proceedings Citalopram Reclassifications Business Combination, Contingent Consideration Arrangements, Reclassifications Business Combination, Contingent Consideration Arrangements, Reclassifications Deferred tax liability not recognized, amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries Product and Service [Axis] Product and Service [Axis] Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Transferred assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan Jai Pharma Limited Jai Pharma Limited [Member] Jai Pharma Limited Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract] Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract] Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax 2016 Term Loans 2016 Term Loans [Member] 2016 Term Loans [Member] Statement [Line Items] Statement [Line Items] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Divestiture Of Business, Transition Services Agreement, Term Divestiture Of Business, Transition Services Agreement, Term Divestiture Of Business, Transition Services Agreement, Term Current assets (excluding inventories and net of cash acquired) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Amount awarded to other party Litigation Settlement, Amount Awarded to Other Party Loss Contingency, Other Asserted Patents, Number Loss Contingency, Other Asserted Patents, Number Loss Contingency, Other Asserted Patents, Number Retirement Plan Type [Domain] Retirement Plan Type [Domain] Domestic Tax Authority Domestic Tax Authority [Member] Fair Value Available-for-sale securities, debt securities Debt Securities, Available-for-sale YEN Term Loan YEN Term Loan [Member] YEN Term Loan Debt Instrument, Conversion Of Unregistered Notes To Registered Notes, As A Percentage Debt Instrument, Conversion Of Unregistered Notes To Registered Notes, As A Percentage Debt Instrument, Conversion Of Unregistered Notes To Registered Notes, As A Percentage Debt Disclosure [Abstract] Debt Disclosure [Abstract] Chargebacks Chargebacks Chargebacks Tax Period [Axis] Tax Period [Axis] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Valuation allowance, amount Less: Valuation allowance Deferred Tax Assets, Valuation Allowance Corporate (Other) Corporate, Non-Segment [Member] Marketable Securities Marketable Securities [Member] Marketable Securities Number Of Markets Business Combination, Number Of Markets Served Business Combination, Number Of Markets Served Decrease in the benefit obligation Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation Other expense Other income Other Expense [Member] Customer [Axis] Customer [Axis] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Employee Benefits Retirement Benefits [Text Block] Trade accounts payable Increase (Decrease) in Accounts Payable, Trade Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Twenty Twenty One Revolving Facility Twenty Twenty One Revolving Facility [Member] Twenty Twenty One Revolving Facility Asset Class [Axis] Asset Class [Axis] Document Annual Report Document Annual Report Scenario, Forecast Forecast [Member] Income tax provision (benefit), U.S. State State and Local Income Tax Expense (Benefit), Continuing Operations Program Name [Domain] Program Name [Domain] [Domain] for Program Name Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Income tax provision (benefit) Other Comprehensive Income (Loss), Tax Total assets Total assets Assets Litigation settlements and other contingencies, net Litigation settlements & other contingencies Gain (Loss) Related to Litigation Settlement EpiPen Auto-Injector Litigation EpiPen Auto-Injector Litigation [Member] EpiPen Auto-Injector Litigation Plan Name [Domain] Plan Name [Domain] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Mylan N.V. Mylan Parent Company [Member] Research and development Globally managed research and development costs Research and Development Expense Schedule of Accounts Receivable, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Unrecognized prior service cost (credit) Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Derivative Contract Type [Domain] Derivative Contract [Domain] FKB FKB [Member] FKB [Member] Acquisitions Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Assets Transferred to (from) Plan Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Assets Transferred to (from) Plan Other long-term assets Other long-term assets Other long-term assets Noncurrent liabilities Liabilities, Noncurrent Summary Of Significant Accounting Policies Significant Accounting Policies [Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Short-term borrowings Short-term borrowings Short-term Debt Credit carryforward Tax Credit Carryforward, Amount Revenue Recognition And Accounts Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Summary of Long-Term Debt Schedule of Debt [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Other receivables Other Receivables, Net, Current Agila Specialties Agila Specialties Private Limited [Member] Agila Specialties Private Limited Impact of the Combination and Divestitures Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Basic (in shares) Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Diluted (in USD per share) Diluted (loss) earnings per share attributable to Viatris Inc. shareholders Earnings Per Share, Diluted Segments [Domain] Segments [Domain] Service cost Defined Benefit Plan, Service Cost Loss contingency accrual Loss Contingency, Damages Paid, Value Unrecognized actuarial (gain) loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Xanax ® Xanax ® [Member] Xanax ® Sales [Member] Sales [Member] Other Foreign Operations Non-US [Member] Business Acquisition, Date of Acquisition [Abstract] Business Acquisition, Date of Acquisition [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Finite-lived Intangible Assets Amortization Expense [Table Text Block] Finite-lived Intangible Assets Amortization Expense [Table Text Block] Intangible assets, net Intangible assets, net book value, excluding goodwill Intangible Assets, Net (Excluding Goodwill) Employee Severance Employee Severance [Member] Restructuring Reserve, Current Restructuring Reserve, Current Restructuring and Related Cost, Expected Number of Positions Eliminated Restructuring and Related Cost, Expected Number of Positions Eliminated Intrinsic value of stock-based awards exercised and restricted stock units converted Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Total Intrinsic Value And Equity Instruments Other Than Options, Vested In Period, Intrinsic Value Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Total Intrinsic Value And Equity Instruments Other Than Options, Vested In Period, Intrinsic Value Net Accrued Benefit Costs Classification on Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Short-Term Borrowings Debt, Policy [Policy Text Block] Deferred income tax liability Deferred Income Tax Liabilities, Net Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Components of Other Comprehensive Loss Comprehensive Income (Loss) [Table Text Block] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Statutory Tax Rate to Effective Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] 2027 Euro Senior Notes 2027 Euro Senior Notes [Member] 2027 Euro Senior Notes Accounts receivable allowances Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss Depreciation and amortization Depreciation, Depletion and Amortization Measurement Input, Control Premium [Member] Measurement Input, Control Premium [Member] Number of times damages may be increased in cases of willful infringement Number of times damages may be increased in cases of willful infringement Number of times damages may be increased in cases of willful infringement Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Impact of changes in legislation Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Financial Assets and Liabilities Carried at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] AOCI Attributable to Parent [Member] Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year Inventories Increase (Decrease) in Inventories Schedule of Other Noncurrent Liabilities [Line Items] Schedule of Other Noncurrent Liabilities [Line Items] [Line Items] for Schedule of Other Noncurrent Liabilities [Table] Convertible Preferred Stock Convertible Preferred Stock [Member] Restructuring and Related Costs [Table Text Block] Restructuring and Related Costs [Table Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Cost of sales Cost of Goods and Services Sold Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] [Line Items] for Schedule of Product Rights and Licenses by Therapeutic Class Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Proceeds from sale of assets and subsidiaries Proceeds from Divestiture of Businesses Entity Central Index Key Entity Central Index Key Other revenues Product and Service, Other [Member] Reduction in Terminal Value Growth Rate [Domain] Reduction in Terminal Value Growth Rate [Domain] Reduction in Terminal Value Growth Rate [Domain] Amitiza ® Amitiza ® [Member] Amitiza ® Plan settlements and terminations Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Reductions for prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Loss Contingencies [Line Items] Loss Contingencies [Line Items] Foreign deductible attributes Deferred Tax Assets, Tax Deferred Expense Development and sales milestone payments Development and sales milestone payments Development and sales milestone payments Long-term debt, including current portion Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Other long-term obligations Other Liabilities, Noncurrent Other Liabilities, Noncurrent Assets held by insurance companies and other Assets held by insurance companies and other [Member] Assets held by insurance companies and other [Member] Projected benefit obligation, beginning of year Projected benefit obligation, end of year Defined Benefit Plan, Benefit Obligation Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Schedule of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block] Interest rate swap derivative assets Derivative Asset Total revenues Business Acquisition, Pro Forma Revenue Other Deferred Tax Liabilities, Other AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax 2016 Restructuring Program 2016 Restructuring Program [Member] 2016 Restructuring Program Number of shares under stock awards, vested and expected to vest at period end Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Other current liabilities Other Current Liabilities [Member] Uncertain tax positions Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Issuance of restricted stock and stock options exercised, net Restricted Stock, Value, Shares Issued Net of Tax Withholdings Line of Credit Facility [Table] Line of Credit Facility [Table] Non-U.S. state tax authority Non-U.S. state tax authority [Member] Non-U.S. state tax authority [Member] Amortization of actuarial loss included in SG&A Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Participant contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Goodwill, gross, beginning balance Goodwill, gross, ending balance Goodwill, Gross Lipitor ® Lipitor ® [Member] Lipitor ® Long-term debt Long-term Debt, Excluding Current Maturities Schedule of Goodwill [Table] Schedule of Goodwill [Table] Upjohn Euro Notes Upjohn Euro Notes [Member] Upjohn Euro Notes Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Divestiture Of Business, Percentage Ownership In Combined Company After Transaction Divestiture Of Business, Percentage Ownership In Combined Company After Transaction Divestiture Of Business, Percentage Ownership In Combined Company After Transaction Reserve for Uncertain Tax Positions, Including Interest And Penalties Reserve for Uncertain Tax Positions, Including Interest And Penalties Reserve for Uncertain Tax Positions, Including Interest And Penalties Average remaining contractual term for options exercisable, in years Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restructuring and Related Cost, Expected Number of Facilities to be Eliminated Restructuring and Related Cost, Expected Number of Facilities to be Eliminated Restructuring and Related Cost, Expected Number of Facilities to be Eliminated Plan settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Development Milestone Payments Development Milestone Payments Development Milestone Payments Other Liabilities, Current [Abstract] Other Liabilities, Current [Abstract] Amortization of Inventory Step Up Amortization of Inventory Step Up Amortization of Inventory Step Up Other Foreign Operations Other [Member] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Net (loss) earnings Net loss Net earnings Net (loss) earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Amount of operating leases not yet commenced Lessee, Operating Lease, Lease Not yet Commenced, Amount Lessee, Operating Lease, Lease Not yet Commenced, Amount Brands Brands [Member] Brands Inventory reserves Inventory Valuation Reserves Vest after three years Vest in three years or less [Member] Vest in three years or less Construction in progress Construction in Progress [Member] Cash, cash equivalents and restricted cash — beginning of period Cash, cash equivalents and restricted cash — end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common Stock, Par or Stated Value Per Share Ordinary shares, par value, in USD per share Common Stock, Par or Stated Value Per Share Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Operating lease assets Deferred Tax Assets, Operating Lease, Right-of-Use Assets Deferred Tax Assets, Operating Lease, Right-of-Use Assets Measurement Input, EBITDA Multiple [Member] Measurement Input, EBITDA Multiple [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets: Assets, Current [Abstract] Other items, net Proceeds from (Payments for) Other Financing Activities Finite-lived intangible assets, original cost Finite-Lived Intangible Assets, Gross Number Of Products Number Of Products Number Of Products Components of intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Impairment of Long-Lived Assets Policy Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Number of shares exercised Number of shares under stock awards, exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Contingent consideration payments Payments Business Combination Contingent Consideration Liability Payments Business Combination Contingent Consideration Liability Payments Other comprehensive (loss) earnings, net of tax Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Estimated Litigation Liability Estimated Litigation Liability Amended Anticompetitive Conduct with Generic Drugs Amended Anticompetitive Conduct with Generic Drugs [Member] Amended Anticompetitive Conduct with Generic Drugs [Member] Maximum Leverage Ratio, Period Two Maximum Leverage Ratio, Period Two Maximum Leverage Ratio, Period Two Accrued interest Interest Payable, Current Gain (Loss) on Fair Value Hedges Recognized in Earnings Gain (Loss) on Fair Value Hedges Recognized in Earnings Payments for Business Separation Payments for Business Separation Payments for Business Separation Reductions due to expirations of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Five Other current assets Other Current Assets [Text Block] Financial Instruments Policy Fair Value of Financial Instruments, Policy [Policy Text Block] Auditor Firm ID Auditor Firm ID Product Liability Product Liability [Member] Product Liability Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Projected benefit obligation, beginning of year Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Buildings and improvements Building and Building Improvements [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Issuance of restricted stock and stock options exercised, net (in shares) Stock Issued During Period, Value, Stock Options Exercised, Net of Shares Tendered for Payment Stock Issued During Period, Value, Stock Options Exercised, Net of Shares Tendered for Payment Notional amount of derivative Derivative Asset, Notional Amount Europe Segment Europe Segment [Member] Europe Segment Weighted average grant-date fair value per share, released Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax Effexor ® Effexor ® [Member] Effexor ® Class of Stock [Domain] Class of Stock [Domain] Cash paid to acquire asset Payments to Acquire Businesses, Gross Norvasc ® Norvasc ® [Member] Norvasc ® Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Ownership [Domain] Ownership [Domain] Checks/ Credits Issued to Third Parties Accounts Receivable, Credits Issued to Third Parties Accounts Receivable, Credits Issued to Third Parties Gross sales Revenue from Contract with Customer, Gross Revenue from Contract with Customer, Gross Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Other current assets Other Assets, Current Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Equity Method Investments, Reduction In Long-Term Obligations Equity Method Investments, Reduction In Long-Term Obligations Equity Method Investments, Reduction In Long-Term Obligations Litigation reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Asset-backed Securities [Member] Asset-backed Securities [Member] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Liability derivatives, fair value Derivative Liability, Fair Value, Gross Liability Forfeiture rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Share-based compensation arrangement by Share-based payment award, fair value assumptions, Forfeiture rate Income Tax Examination, Reserve for Uncertain Tax Position Income Tax Examination, Reserve for Uncertain Tax Position Income Tax Examination, Reserve for Uncertain Tax Position SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Payments for Rent Payments for Rent Schedule of Product Rights and Licenses by Therapeutic Class [Table] Schedule of Product Rights and Licenses by Therapeutic Class [Table] Schedule of Product Rights and Licenses by Therapeutic Class Income taxes payable Accrued Income Taxes, Current 2016 Senior Revolving Credit Facility 2016 Senior Revolving Credit Facility [Member] 2016 Senior Revolving Credit Facility [Member] Inventories Policy Inventory, Policy [Policy Text Block] Non-U.S. Current Current Foreign Tax Expense (Benefit) Nature of Operations Nature of Operations [Text Block] Pension Benefits Pension Plan [Member] Intellectual Property Developed Technology Rights [Member] Mature within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Goodwill Impairment Test, Measurement Input, Reduction Goodwill Impairment Test, Measurement Input, Reduction Goodwill Impairment Test, Measurement Input, Reduction Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Transaction related and other special items Other One-Time Nonoperating Expense Other One-Time Nonoperating Expense Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Momenta Momenta [Member] Momenta [Member] 2048 Senior Notes [Member] 2048 Senior Notes [Member] 2048 Senior Notes [Member] EX-101.PRE 12 vtrs-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 vtrs-20211231_g1.jpg begin 644 vtrs-20211231_g1.jpg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�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end GRAPHIC 14 vtrs-20211231_g2.jpg begin 644 vtrs-20211231_g2.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1"X17AI9@ 34T *@ @ ! $[ ( M 7 (2H=I 0 ! (8IR= $ N 0@NH< < @, /@ M FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB M861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W M=RYW,RYO&UL;G,Z#IX;7!M971A M/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^ M_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L= M)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ_\ $0@"'0(X P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! M @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-1 M80'EZ@X2%AH>(B8J2DY25EI>8 MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;G MZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D* M"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1" MD:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6F MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V M]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BB@G YH ;)(D49>1@JCJ37/6OC.QNM9EL!L4Q]'\S.?PQ7/?$GQE'I%C M):0R8ED7C!KPBRU^[M]86]\SYV8%C^-?4Y9D,L70E5GIV/4PN!=6#E+Y'UT# MN4$=",TM3755\Y7HSH5'3FM4>=.#A)QD%%%%8D!111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[XN\2P:!I;R M,R[F!7!K7U*_BTZQDN)F "#.,U\W?$'Q;+KVJRQ1N3;9RJGZU[N39;+'5M?A M6YW8/#.O/79&!X@UN?6-1DEE=F&XXR>U9-%%?JU.$:<5&.R/JXQ459'4^"O% M$V@ZM$V\^4#DKGBOI;0]7AU?38KB)@2XR0.U?(%>H?#'QN^GW8M+V0F-L*@] M*^6X@RI8BG[>FO>7XGE9AA?:1YX[H^@:*CAE6:%70@@@'@U)7YLU;0^;"BBB MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V1Q&A9N !FG9QUKS_ M .(_C--&TUX+=\3=.#73A<-/%552ANS6E3E5FHQ./^*/CGS)/L5E)E<%7P>E M>0?-)( 22S'%37MV][=R32')=LUU'@+PG+K^K*"G[M<-DCBOU>A1HY7A-=EN M?54X0PM(QY?#]S;V)GGC*C&162B[W5?4XKVKXH6,>FZ;%!"NW$0!Q]*\7@_X M^(_]X5>78QXNA[5E8>LZT.E9EO.]M.DL9(*G/%>]> M%-"CU_P+/;NH+L0 3^->.>*-!ET359H70A%; ..*PP.8QQ-6="?Q1?X&=#$J MI*5-[H]D^%_C9=0M$LKJ0><3@ GFO40:J?-D]Z^/X@RIX>I[>FO=?X'D9AA?9RYX[,Z>BBBODSR0HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@#/UNYEM-)N)8!EU3(%?+OBW5;W4] M:DDO*/9B51@DCFN=^'_ M ,/UT)I)+P+)(&RI]*](K3/LV^M3]C2?NK\2L?B_:ODCL>2_&3[@_P!S^E>& M0?\ 'Q'_ +PKW/XR?<'^Y_2O#(/^/B/_ 'A7U/#W^X(]3+_X"/I7X6?\BVW^ M\/ZU!\1O!L>MZ<98D^>,%CM&*G^%?_(MM_O#^M=M(@EC9'&0PP17PN(Q,\-F M,JL'JF>%4J2I8ARCW/CB]M);*Y:*9=I!-==\.=:U#3]76.T!=)' ;)Z"O0/& MWPR.K:OY]B5B4CD 5T_A+P#9:+;(TT*/+C[WO7UV+SS"5,%[RNY+8]>MCJ4J M.NK?0Z^VD:2!6<8) J6D50JX7@4M?G+U9\X%%%%( HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BH_M$6[&\9IX8'H&0?\?$?^\*]S^,GW!_N?TKPR#_ (^(_P#>%?J?#W^X(^IR_P#@(^E?A7_R M+;?[P_K7<5P_PK_Y%MO]X?UKN*_/,R_WRIZGSV)_C2$*@]0#^%+117GG.%%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 444C.J_>.* %HIBSQNV% M<$^E/IV: ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4V3_ %;8ZX-.I&&5(]J /#/&_C+6=!U8+ X"ECC-9EG\8=9CP)I5 MQ5GXT6?E:G;L!U&:\LK]3R_ X3%8.$YP5VCZG#T*-6BFXGM%G\9.GVJ7ZXK> ML_C#H[X$TQS7SS2@D=.*=3AW SZ6'++J$NA]0VWQ*T*YQLE.36M;>*=.NL>7 M*/SKY-2[GC^Y*P^AJPFLZC']R[D7Z&O-J<*TG\$K'-+*H?99]>17D,PRDB_G M4P=3T8'\:^2[;Q=J]N1_ILQ_X%78^$/'&I7>L002-(ZLX!R:\K$<,5J47-33 M2.2IEDX*Z9]"44V/F-2?2G5\D>2%%%% !1110 4444 %%%% !1110 4444 > M2_&3[@_W/Z5X9!_Q\1_[PKW/XR?<'^Y_2O#(/^/B/_>%?J?#W^X(^IR_^ CZ M5^%?_(MM_O#^M=Q7#_"O_D6V_P!X?UKN*_/,R_WRIZGSV)_C2"BBBO/.<*** M* "BBB@ HHHH **** "BBB@ II=!U9?SJIK$S6^CW,J?>1,C%?.^N>/-46\> M-9)8^?6O7RW*JF87Y':QUX;"RQ%^5GT9-J%O /GD7\ZR[GQ=IEKGS)>GO7S) M<>*=6G)S?3#\:I/J]_)]^ZD;ZFOI*?"G\\STHY5_-(^DKKXGZ#;@[I3D5A7G MQBTI,"F[!Q]:]+'=C*L0!2VNB MW-Y8OIZ#:DFDSUE/A4NI6RRZ<(\$#N*R[ MSX.ZU%DILQ47@#Q_/I%U':W;EHB/1V/$KU\3AI6>J/FJZ^'6L6N=Z@X]!6_P##WPS=P:SNGC(V..U>_M9V M[_?A0_44V.QM86W10(A]0*X:O$M:M1=.4=S">93G!Q:)UX0?2EHHKY,\D*** M* "BBB@ HHHH **** "BBB@ HHHH \E^,GW!_N?TKPR#_CXC_P!X5[G\9/N# M_<_I7AD'_'Q'_O"OU/A[_<$?4Y?_ $?2OPK_P"1;;_>']:[BN'^%?\ R+;? M[P_K7<5^>9E_OE3U/GL3_&D%%%%>>,?Q)BOG#Q3X4OIO$,BP1G!_P!FOID@$8/(JLVGVCOO>WC+>I6O8RO- M)9?)M*]SLPN*>';:1\T6OPTUJZQL"CZBMRR^#>L28,OEXKW];6!/N1*/H*R] M?UZTT*Q:69U0X. :]9\1XZM+DI)7?D=7]HUYNT4>.:E\-[?1-/DFU (2HSP1 M7F5\(1=N+<8C[5TWC+QG=:_?,%=DC4D8!X(KEH89+F4)&"S$XK[3+Z>(A3Y\ M3*[?X'M8>-11YJCU(J?$NZ95]35W4M(GTPJ+E"C,NX U7L%WZA OJX%>ASQE M#FCL=',FKH^C/A+:"W\+'(P=V?YUWMTQ4Y= MV?'8B7-5DPHHHKA, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** .:\=VOG^%;PXR0E?*\\?E3%#VKZY\21>=X?ND]5KY5\00 M?9M9ECZ8K] X4J?NYP\SW\JE[LHGH?PG\B[M9+&Y&Y)'Y%0?$7X?2Z;6< M?[ECP%&<5G_"N[\KQ#;Q9^\]?1%]8PW]J\4R*P8$RZ7&S7#=T_P/43IXJF?86F:G!J=JLT#J00.AS5VOG+ MX?\ CZ;1[J.UNW_<9Y9CFOH#3-3@U.S2:!PP89XK\US3+*F J6?P]&?-XK"R MH2\B[1117D'&%%%% !1110 4444 %%%% !1110 4444 >2_&3[@_W/Z5X9!_ MQ\1_[PKW/XR?<'^Y_2O#(/\ CXC_ -X5^I\/?[@CZG+_ . CZ5^%?_(MM_O# M^M=Q7#_"O_D6V_WA_6NXK\\S+_?*GJ?/8G^-(****\\YPHHHH **** "BBB@ M HHHH **** "BBL?Q!X@M=#L6FN) N/6KITY5)*$%=LJ,7)V0>(-?MM$L))I MG&57(&[FOG3QGXTN?$5[(%D/V8G*J>U'C3QEB2+A43;CZ8KE="A,VM6H'_/45H^-+K[5KDASG:S M#]:E\#6OVG7(N,[7!KZ6C^XP"OT1Z4/W>'^1]-Z/!]GTV)1_<7^57ZCMQMM8 MAZ(/Y5)7Y#.7-)L^0D[NX4445 @HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** *]_'YUE(GJ*^6_'UO\ 9_%]TF, ?XFOJLC( MP:\-\?> ]5U;Q/<7%C;;T<\'\:^JX:Q4*%>2J.R:/5RVK&%1\S.&\!W/V?Q; M:'.!NKZELY?.M4<#_$#X>3:=.]W:)F-CD*HS@5]! M57O+.*]MWBF16##'(S7D9;F57 U.:.W5''AL3*A*ZV/CAD:)R&!4@]Z]"\ _ M$"?2+E;:\D9XV.U?85H?$7X=OI\LEY81EH1R3[UY:RM#(5.593VK]+C+#9MA MNZ?X'TJ=+%TS[!TO5;?5+59H'4@]@KYL\ ^/9]#NXX+F3_1QW8YKZ$TG5 M8-6LTFMWW97)K\XS3*ZF J=X]&?.8K"RH2\B_1117C'&%%%% !1110 4444 M%%%% !1110!Y+\9/N#_<_I7AD'_'Q'_O"O<_C)]P?[G]*\,@_P"/B/\ WA7Z MGP]_N"/J']:[BOSS,O]\J>I\]B M?XT@HHHKSSG"BBB@ HHHH **** "BBB@ HHK$\2>)+70+%YIY I7UK2G3G5F MH05VRHQ25UW!<@9KYV\9^-+GQ#?2!)&%N>B&H?&'C"Z\0W M[Y-"SDKGRCJTQFU.X8_\ /1OYUVOPEM/M.M2' M&=N#4FI?"C6?.ED@M68,Q/4^M=E\*_!]_H>H3R:A!Y89>*_2LPS'#/ 25.:; ML?28C$4W0:BSU>,8C4>@%.H'2BOR\^8"BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "FF-2V2.:=10 4444 %%%% %> M\LH;ZW,-R@=#U!KPKXB?#R2PF:[LUW(YW$*.E>^U7O;.*^M7AF4%7&#Q7J9= MF-7 U>:.W5'5A\1*A*ZV/CAT:)\,"K ]Z[WP%X\GT:\2WNI&>-VP,G@"M3XB M?#N33Y9+RQB/D^M>7,K12%3PRFOTV$\-FN&[I_@?3)T\53/L#2M6M]5M%FMW M4ANP-7Z^;? /CZ;0[J.WNI,6XP 2:^A-)U6#5;-)H&W J":_-\TRNI@*EOL] M&?-XK"RH2\B]1117C'&%%%% !1110 4444 %%%% 'DOQD^X/]S^E>&0?\?$? M^\*]S^,GW!_N?TKPR#_CXC_WA7ZGP]_N"/J']:[BOSS,O]\J>I\]B?XT@HHHKSSG"BBB@ HHHH **** "BBL3Q M'XCM=!L'FG?:5K2G3E5DH05VRHQXE"1C+&OTS)\GA@H>UJ_%^1]+@ M\&J,>:6X6]O)=3+'$I9F..*]I^''PZ"+'?ZB@/\ L,*3X=?#C8%OM2BQT:/W MKV&*)8D"H /05Y&>9Y>^'P[]6$?$/X>2:?.UU9*71B6(4=*]_JO>V45]:O!.N4<8->IEN95<#5Y MH[=4=6&Q,J$KK8^.&5XGPP*L*[[P#X\GT:\2VNG9XV;JQX K2^(GP\?39I+R MPBQ 3QQ7E[JT4A5L@@XK]-C+#9KANZ?X'TR=/%4S[!TK5;?5;1)K>16W=@:O M5\W> ?'\^B726]U(?(X517T'I>J0:I:)- P((!/-?FV:974P%2S^'HSYO%86 M5"7D7J***\2YZN'Q_L:?)8YSX8V\UOX= M99XVC;<.#^-=I44%NENFV,8%2U\[B:WMZTJMMSSJD^>;EW"BBBN6XMO;R74RQQ*69CCBO9_AO\ #K8([_44SC_EFXH^ M'7PX "7VI1<$!DXKV**)88PB# Q7DYYGE[X?#OU9R8['?\ +NF)#"D$2QQ* M%51@ 5)117PS=]6>&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** *][90WUNT4\:NI!ZBO!_B'\/)=.G:ZLD+QG+':.!7T!5>^LH;^U M>"X7IEN95<#5YH[=4=6&Q,J$KK8^.&5XI,-E6!KO\ P!X]GT>[CMKI MRT3'EF/2K_Q$^'DFFS/>6,>(6/ R17F+HT;E6!!!QR*_38RPV:X;NG^!],G M3Q5,^P=*U6WU6T2:"16W#/%7J^.<84444 %%%% !1110 4444 %% M%% !1110 445C^(==AT/3Y)Y<_*,\5=.G*I)0BM65&+D[(3Q#XAM=$L7DFE5 M6P< ^M?.7C'QC=>(+]L,R1*2-H/!I?&?C*Y\1WK@2$VV2YF6.)2S,<<5[-\./AUM\N_U!,%3 M_JW'44GPY^' PE]J4096&5&.0:]DAB6&-408"C KRL\SS?#X=^K.7'8[_EW3 M$A@2WB6.)0JKT J2BBOAFVW=GA!1112 **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** *U[90WUNT4Z*P8$ MZL49XN6)':OH&J]Y907]NT-RF^-NHKUL:BKW$;1HA# CO7T5I.G+IEBL"L6P!UIUCI5IIJXM(]@QBKE:9IFM3'SUT MBNA6*Q4L1+R"BBBO&.,**0D*,L<#U-<=XL\?V/A]'0G>X_N'-;T,/5Q$^2FK MLTITY5) M'-?44>%L1*-YR2/3AE=1J[9]2_VG:?\ /44?VG:?\]17RS_PF^N_\_AH_P"$ MWUW_ )_#6W^JE7^=%_V5+N?4W]IVG_/44Y+^VO M1L"+PTGPI5MI-!_94^Y]6A@PR*6OGK0?BU>VDB_VE,\JCJ!FO8_#7B^R\06X M:%@K8Y#-S7AX[)\3@]9JZ[G#7P=6CJUH=%1117CG&%8?B?05US3)868J67'% M;E%:4ZDJ4U..Z*C)Q=T?*WB/P;>Z/JC0I$S1;@JL>_->A?#GX<[2E]J*%64Y M"L.HKU:^T*PU%@UW"'(.1]:O10I!&$C&% P!7TN*XBK5\,J4='U9Z57,9SI\ MBW$A@CMXPD2A5'0 5)117R[;>K/+"BBBD 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1SRB&%G;@ M4TKNP'%_$+QBF@:>88W&^9<#-?.>IZI<:G=--.[$GL6S70_$'6Y-4UV:)V)6 M&0@5S^DZ;)JE\D$0))(Z"OU7)\!3P.&4Y;O5L^JP="-"ES/ M]LXK?A^'GB"5 RV38KW'P=X$L=+T^.2X@5I&4'/I79):Q1KA$P*\7&<4.%1Q MH1NEW..MFC4K01\P?\*W\0_\^3?K1_PK?Q#_ ,^3?K7U#Y*?W:/)3^[7%_K5 MB?Y48?VK5[(^7O\ A6_B'_GR:H+KP#KUJFZ2S( ZU]4>2G]VHIK&WG0K+&&! MJH\58B^L4-9K4OJCX\N;66TE\N==K>E:GAWQ!S?$/X? M6USI\MU80JC@<8'->"W5NUK=/#)]Y#@U];@<;0S.@]/5'KT*\,5 ^J?"'B6/ MQ#I*3[@7/&!715\^_"+7G@UJ.R9CY>.E?0*,'0,.AK\XS?!?4\4X+9ZH^;QE M#V-5I;"T445Y!R!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%0W-U%:1&2=U0 M9Y->7>./B?%:)):6!W/VD0]*[<'@:V,GR4D;T:$ZTK11WUUXJTNTO%MII\2L MVT#WK85@ZAEZ&OD6;Q%?3ZF+N2=V(?< :]Z^&OBXZSIL<$V3+ZDU[69Y#+!T M55B[]SLQ. =&"DM3T&BBBOF#S HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "LGQ+*8='D9>M:U8OBO_ ) A_!G_D8U_W:_5LRDXY=*W\I]7B7;#.W M8]_C4)&%'0"G4#I17Y$?(A1110 4444 1SPK/$4<9!]:^5O'%HMMXEN]@P#) M7U:>AKY;^(7_ ",EU_UTK[#A636(FO(]C*F_:-$'@.8P^)(V6OJ+3FWZ= Q[ MI7RQX*_Y&"/_ #WKZETO_D%V_P#N"M.*DO:P96:_&BW1117Q9XH4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !45S"6.=\ ]!7NG@WXCVNL0K%M>QF>05<)[]/WHG9B8%%%% !1110 4444 %%%% !1137=8U+.=JCJ30 ZLO M6=>M-%MFENGP%&>M,+[7;IF,KI'R-F>*^ MCRS(JV+:G4TB>CA<#.L[RT1U/C7XFW.IN]O8R?N^#0+G[K"OO/]CRJAV7XL][]SA8=CE/#OA2^ MUZZ5;>/* _-D=J]_\%^!K?P] DI5EF%;FB^'++1K9(X84W*,%@.M:]?"9KGE M7&-PAI$\+%8Z5;W8Z(****^;/-"BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH *Q?%?\ R Y*VJQ?%?\ R Y*WPW\:/J:4_C1\JZS_P AFZ_WS7H? MP9_Y&-?]VO/-9_Y#-U_OFO0_@S_R,:_[M?JF:?\ (ME_A/J<5_NS]#Z!'2B@ M=**_)#Y(**** "BBB@ /0U\M_$+_ )&2Z_ZZ5]2'H:^6_B%_R,EU_P!=*^NX M5_WF?H>OE?\ $93\%?\ (P1_Y[U]2Z7_ ,@NW_W!7RUX*_Y&"/\ SWKZETO_ M )!=O_N"M^*_XD"\U^)%NBBBOBCQ0HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** C((KS7QU\.(M6C:XM$+2@9Y]:]*H(##!Y%=>%Q=7"5/:4G9F MM*K*E+FB?(.L:#>:-7NB7#/;H\T9))(' K]'RW/*&-CR5-)'T>&QT*RY9:,ZOP1\5& MA\NUU67"=!]:]DT_4H-1MUEMW!!&>M?'A$D$F""CBNP\)^/[W0IE65WF3/0F MN+->'H5DZN&T?8QQ67J?O4]SZ>HKE_#/C2QUVV0^:B2$!.$H.TD%%%%8D!1110 4444 5[R]AL8#+.P"@=S7D/C?XI@![72 MI2.Q^M=IX_T&[UC3'%I/)&VL_\+DE_P">IH_X7)+_ ,]37DWV*X_YYFC[%9H^Q7'_/,T?V+E_P#*'U+#]CUG_AIKR;[%3?8KC_GF:/L5Q_SS-']BY?_ "A]2P_8]9_X7)+_ ,]31_PN M27_GJ:\F^Q7'_/,T?8KC_GF:/[%R_P#E#ZEA^QZS_P +DE_YZFC_ (7)+_SU M->3?8KC_ )YFC[%%;2==:C)C/4?SKZDTT8TNW!_YYBOC^(,'0PLXJBK7/'S"C3I-A M_!G_ )&-?]VO/-9_Y#-U_OFO0_@S_P C&O\ NU^J9I_R+9?X3ZG%?[L_0^@1 MTHH'2BOR0^2"BBB@ HHHH #T-?+?Q"_Y&2Z_ZZ5]2'H:^6_B%_R,EU_UTKZ[ MA7_>9^AZ^5_Q&4_!7_(P1_Y[U]2Z7_R"[?\ W!7RUX*_Y&"/_/>OJ72_^07; M_P"X*WXK_B0+S7XD6Z***^*/%"BBB@ K/UN__LW2Y+D'&VM"L/Q@I;PW.%&3 M6U"*E5C%[7+II.:3/,KSXO2V]W)$)3\IQ4'_ N27_GJ:\RU>RG.J3D1G[U4 M_L5Q_P \S7ZA#)L XIN)]/'!X=I:'K/_ N27_GJ:/\ AIKR;[%3?8KC_GF:/L5Q_S MS-']BY?_ "A]2P_8]9_X7)+_ ,]31_PN27_GJ:\F^Q7'_/,T?8KC_GF:/[%R M_P#E#ZEA^QZS_P +DE_YZFC_ (7)+_SU->3?8KC_ )YFC[%L_\+DE_YZFJ]Y\5UOK9X;AR588->7?8KC_GF:/L-P?^61H638"+ND'U.@NA M8UBZ@N[YY;<$*>E9]/DB>)L.N#3*]J$5&*2.V*25D:6CZW=:-=+-:OM.1FO< M/!7Q/@U%$MM0D)F. "37S[UKHO#/AS4]5O4^RK(B$_ZQ>U>1FF PN)I.5;1K MJ<>*P]*I&\]#ZKAF2>(21D%3Z&I*Q/"NG3:9HT<-Q(TC[1DM6W7Y/5C&$W&+ MND?*224FD%%%%9DA1110 $9&*YGQ-X,L-?MGWP@S8^4FNFHK:C6J49J=-V9< M)R@[Q9\N^+? M]H%R[;-T6< *N:Y%E*G# @^XK["U'2;;4K=HYXD.01DKFO% MO''PN>T9[G3$:0=>*_0X^'M,\(:_:K)!;!3P"&89S^5?/%Q:S6DQCG78Z]16AHOB*\T6Z6:"1R%_A MW<5Z>99=+%QYZ,VI>NATXG#NJN:#LSZ5'P_\.D9%H#^(_P */^%?^'O^?/\ M4?X5@>#/B3:ZI"D-](L<@& /4UZ%%*DR!HSD&OSK%2QV%FX59-?-GSM5UZ4N M639SG_"O_#W_ #Y_J/\ "C_A7_A[_GS_ %'^%=-17+]=Q/\ ._O,O;5/YFA_!G_D8U_W:\\UG_D,W7^^:]#^#/\ R,:_[M?JF:?\BV7^$^IQ M7^[/T/H$=**!THK\D/D@HHHH **** ]#7RW\0O^1DNO^NE?4AZ&OEOXA?\ M(R77_72OKN%?]YGZ'KY7_$93\%?\C!'_ )[U]2Z7_P @NW_W!7RUX*_Y&"/_ M #WKZETO_D%V_P#N"M^*_P") O-?B1;HHHKXH\4**** "HKFVCNX#%.NY&ZB MI:*:;3N@V.TRQZG(_PIG_"O_#W_/G^H_PKIJ*Z?KF)7VW]YK[: MI_,SF?\ A7_A[_GS_4?X4?\ "O\ P]_SY_J/\*Z:BG]=Q/\ ._O#VU3^9G,_ M\*_\/?\ /G^H_P */^%?^'O^?/\ 4?X5TU%'UW$_SO[P]M4_F9S/_"O_ ]_ MSY_J/\*/^%?^'O\ GS_4?X5TU%'UW$_SO[P]M4_F9S/_ K_ ,/?\^?ZC_"C M_A7_ (>_Y\_U'^%=-11]=Q/\[^\/;5/YF_Y M\_U'^%=-11]=Q/\ ._O#VU3^9G,_\*_\/?\ /G^H_P */^%?^'O^?/\ 4?X5 MTU0W5W#9PM).VU5&2::QF*;LIO[Q^VJO[3.>;P#X=49:T 'N1_A7)>*X_"&@ M6[K]FW2D?*48''Z57\<_%%+99+;3'63MD5XOJ&JW.HW#2SRN=QS@MG%?795E M>,KVJXB;4>USU\+A:T_>J2=AVKW<-W?/);*5C/0&J21O(V$4L?0#-6M/TRYU M*X$5K&78D9 KV7P/\+DA"7>HJ5<'CJ[:'X;L=#MECM(MA &?K6C:6<-G"(X(U4#T&*GK\VS'- MJ^.EJ[1['S>(Q>PC6.3DD^M>%ZUH-WHUVT4\;X!/S;>*^O",]>:YSQ+X/L?$% MJZ3(%9NZKS7U659_4PS5.MK'\CU<+CY4O=GJCY8M;N:SF62!MK Y%>Z?"WQ% MJ.I+'%>-(Z_WB#BN*O\ X7:C;:Y&D-NQMVDQN.>E>V^%/#L&@:4D$:C(YR1S M7KY]F&$JX9*-I-[>1UX_$4I4]-6S>HHHK\^/GPHHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "L7Q7_R Y*VJQ?%7.AR5OAOXT?4TI_&CY5UG_D,W M7^^:]#^#/_(QK_NUY[K/_(9NO]\UZ%\&?^1C7_=K]4S3_D6R_P )]3BO]V?H M?0(Z44#I17Y(?)!1110 4444 !Z&OEOXA?\ (R77_72OJ0]#7RW\0O\ D9+K M_KI7UW"O^\S]#U\K_B,I^"O^1@C_ ,]Z^I=+_P"07;_[@KY:\%<^((Z^IM+_ M .07;_[@K?BO^) O-?B1:HHHKXH\4**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@!&X4_2O#/B;XHU6WN3;PO)'&20>#@BO=*XSQ]X1BU_37D1/WT M:Y4*.IKV,GQ%&ABDZRNCLP=2$*J&O"-[KUTJQHR*3C) M7BNK\+?"N\N[U3JD+1Q#G(S7MVB:!::-:K%!&IP,9*C-?9YIG]+#1]G0UE^! M[.*Q\*:Y:>K.?\)?#^RT.!&GB5IP.6%=HJA5"CH!@4M%?GF(Q%7$3YZCNSYZ MI4E4ES284445SF84444 %%%% !1110 4444 %%%% !1110 QX4<@LN2.E/HH MHN 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q7Q'UZ+2 M_#\JE@9/3/-==>7"VMG+,QP$7)KYM^(_B=M9UIUA?=#C'6O>R/ /%XE-_#$[ M\#0=6KY(XZ\G^TWDLW]]LUZ=\&;:7^W5FV'9MZXXKS/3[5KV_BMT&3(V!7TO M\/O#2Z)H40D3;,.O%?9\08J&'PCI=9:'LYA5C3H\O<[$4445^7'RX4444 %% M%% >E?,'Q&MI8?$$[R*0K2'!(KZ?KS+XJ>$AJ5B+J!,F(%F(%?0\/XN&&Q= MI[2T/0R^LJ=77J>&:)?_ -G:DD_7!%?4OA758M3T6W,3 E8QG!Z5\ENICD(/ M!!KU3X4>+C97)LKB3_6MM4$U];Q#@'B:'M8;Q/6S##^TI\RW1[W12*0PR*6O MS$^9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1@&4@\@TM% # M$B2,808I]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4-9U./2=-DNIFP MJ=:J,7.2C'=C2;=D<)\4O%BZ9IXMX'RT@*L >E?/#AE^$O+?=GUF%HK#TM3OOA3X2-_=M=W" M8$3!EW#K7OJ($4*HP!6+X5T6+2-'@1%PY0!JW*_.LVQTL9B7/HMCYW%UW6J- M] HHHKR3D"BBB@ HHHH *KWUJEY9RP. 0ZXYJQ133<7=#3L[GS)\1O#+:+K< MAB3]UZ@<5RFFWKV%_%<(2"C9XKZ2^(GAE-:T.3RDS-UZ5\U7ULUG?2P.,&-L M5^JY+CHXW"\D]UHSZG!5U7I6>Z/IOP!XC36]!A9W!F/4$\UUU?-/PU\4-HVL MJDSXAP *^D+2=;FUCF4Y#J#7PV=X!X/$NWPO8\/&X?V-339DU%%%>$<(4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% ",P52QX ZUXU\7/%NW?IEL^0ZYR#7I'BW7(M%TF1Y&PSH0 MO/>OEW6]3EU74I)IFW'<0/IFOKN&\N]M5]O-:(]?+@2ZUK$6QQI:0!1110 V1%DC*L,@BOG_XJ^$VTZ]6YMDRL MA+,0.E?058/BS1(M8T6=&3=)LPM>OE..E@\2I='N=>$KNC43Z'RA#*T,RNAP M5(-?0_PO\5KJNFF&=\/& J@GK7@VNZ5+H^IR6LRX*^U:7@O7I-&UN []L6[+ M"OT/-<'#'X2\=]T?18JBL12T/JVBJ.CZE'JNFQW41RK].:O5^3RBX2<9;H^3 M::=F%%%%2(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH *;)(L2%Y#A1U-.KB_B)XECTC1)HD?$S+E<&NC#4)8B MJJ<>II3INI)11YA\5?%;:A>M8POA8FZ@]:\TBB>>39&-S'M4M]=O?7CSRG+. M>37:?#3PN^K:U#/,F8 <$$>]?K,(TLLP>NR7XGUD5'#4?0]0^%_A5-*TY;N1 M/FF3/(Z5Z+4-I;K:6J01C"H, 5-7Y3C,3+%5I59=3Y2M4=6;DPHHHKD,@HHH MH \V^*&MW.E*/LY8?+G@UY)%X\U,S(#+)U'\5>E?&3[@_P!S^E>&0?\ 'Q'_ M +PK]+R+"T:F"4I1NSZ7 TH2H)M'T_\ #O49M2T)I9R2V>YKKJX?X5_\BVW^ M\/ZUW%?!9C%1QGO#.NX;3@?A7S!XQT"71=7D#KA7.U?HW#>8^ MUI?5YO5;'T>6XCGC[.6Z/3/A'XM$BKIMR^!&O!)]J]A4AE!'0U\A:%JDVE:E M'-"VW+ 'Z9KZB\*ZY#K6DQR1,"54 \]Z\;B/+O85?;P6DCBS'#\D^>.S-RBB MBODCR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@"M?W<=G9R2R-C:A(_*OF?Q_XGDUW6&(?Y$)7 ->F_%CQ:+2 MP^R6K[9 V&P>U>"2,9)6<\EB37Z#PUEW)#ZS-:O8^@RW#V7M9%K2[&2_OXH8 MUSN< U].>!O#<>@Z,L>SYFPV2.:\T^$WA'SKHWETF4(RN17N:KM15'0#%<'$ MN8^TG]7@]%N89EB.:7LXBT445\:>,%%%% !1110!Y+\9/N#_ '/Z5X9!_P ? M$?\ O"O<_C)]P?[G]*\,@_X^(_\ >%?J?#W^X(^IR_\ @(^E?A7_ ,BVW^\/ MZUW%\C3YXDXP*]$J&ZMTNK9X9!E6&"*Z\)B986M&K'H:T:CI34D?'$T+V\Q M20;66O2?A7XL;3[^.PF?Y)&Y)-4/B9X7?2M8FNHTQ"S8 ]ZXBRNI+*Z6>([ M67H:_5IQI9G@_5?B?5M1Q-'U/L>*59HP\9RIZ&GUQ/PZ\2IJ^C0P.V947YB3 M7;5^38FA+#U73ET/DZE-TYN+"BBBN@&:\0^ M+7B[S)Q9VK_*1A@IKT\LP4L9B(TUMU.G"T76J*)YUXJUM];UN:Y+95SD<\4S MPQHSZUK4-L%RKG!Q60B&215'5CBO=_A-X2%K9?;+E/W@;*EA7Z5F&*AEV#]W MT1]+B*LD)H^CPVZKAD&#Q6O117Y+4G*I-SENSY.4G)W85%/<1VZ M;I3@5+7 _%:\N+/PO-):RF-P>"*VPE#ZQ6C2O:[+I4_:34.YU_\ ;-G_ ,]* M/[9L_P#GI7RF?$^L9_X_I/SH_P"$GUC_ )_I/SK[#_5.7\YZ_P#9+_F/JS^V M;/\ YZ4?VS9_\]*^4_\ A)]8_P"?Z3\Z/^$GUC_G^D_.C_5.7\X?V2_YCUKX MN7UO<1CRGS\E>)0_Z]/]X5:N]6OK[_CZN&D^M4@<'(KZO+L$\'AU1;N>KAZ/ ML:?(?1WPRU*V@\/,LCX.1_6NT_MFS_YZ5\FVVNZC:1[+>Z=%]!4W_"3ZQ_S_ M $GYU\YB>&95ZTJG/N>=5RQSFY7W/JS^V;/_ )Z4?VS9_P#/2OE/_A)]8_Y_ MI/SH_P"$GUC_ )_I/SKG_P!4Y?SF?]DO^8^K/[9LS_RTJ['(LBAD.0:^2(O$ M^L&5/].D^\*^FO!\TD^@VSRL68Q@DFO'S7)GE\(S*=S?HHHKYX M\\Y7QWX;37]%9-F60%N!7S%J-G)8WTL4@QM<@?G7V,ZAXV4]&A'Q9\)&W MO/MEJF(PN6VBOL^&LQ]G/ZM-Z/8]G+<1RR]G(YCX?>)GT+6%R^%D(7DU]+V5 MTEW:QRQG(*@G\J^.8G,,RN."IR*]^^%'BP7NFBTN7S*6P,GG%=O$N7<\?K,% MJMS?,L/=>UB>H4445^?GSX4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 445'<3+;V[RN<*HR2::3;L@.>\;>(4T'17F+[2V5KYAU:_ M?4-0EF=L[G)%=O\ %'Q4VI:Q-9POF%3D$'CK7 6MN]W _#3Z_K*ILRL9#?E7TWIUFEE9111C&U #^5<; M\-/#":5HT-U(@$S+ALCGI7>5\?GV8/%XAQC\,3Q\?B/:U++9!1117SQYX5QW MQ$T*ZUWP_);6:[G8\"NQI" >HK?#UY8>JJL=T73FZ(/^> _6OI3RT_NBCRT_NBOI/\ 6C&=D>E_:E;LCYK_ .%3>(/^> _6 MC_A4WB#_ )X#]:^E/+3^Z*/+3^Z*/]:,9V0?VI6[(^4M<\&:EH(S>Q[>,USR M@LP ZDXKW7XQJH08'\%>&P?\?$?^\*^URK&3Q>&56>Y[6%K2K4N>1T^C_#[6 M-9M3/:1!DS6A_P *F\0?\\!^M>N?"U%/AMLC^(?UKN/+3^Z*^4QG$>*HUY4X MI63/*K9C5A4<4?-?_"IO$'_/ ?K1_P *F\0?\\!^M?2GEI_=%'EI_=%6J98X/WNJLSZS#U(XFCJ?7F@:HFJZ3!<*V2ZY-:=>)?" M7Q=MD:SNGPH&U-QKVQ3N4$=QFOS/,\%+!XB5-[=#YK$T71J.(M%%%>: M9,#!KLM1O8["S>:9@J@'DU\Q^.O$\7B.:2]V)Z& M!P_M:EWLCF9YWN9C)*&0?\?$?^\*_4^'O]P1]3E_\ 1]*_"O_ )%MO]X?UKN*X?X5 M_P#(MM_O#^M=Q7YYF7^^5/4^>Q/\:04445YYSA1110 4444 %%%% %34[)+Z MPEA<9W(0*^8O'7AQ] UIH]F%?+=*^J*X#XF^%UU31IKJ),S*, <]*^BR',' MA,1R2?NR/1P&(]E4L]F?/FCZ@^G:E#,C8"N":^G_ 9X@37M%222>*^NS_ +%X?VL-X_D>OC\.JM/F6 MZ/HFBHX)EG@25#E6&0:DK\P:L['RX4444@"BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "CIUHK*\1:FFF://*S88(2M73@ZDE&.['&+D[(\[^+7BL6UI)I MUN^),]C7A+NTLA9N68\UK^)M:DUK5I+B1CSQC-/\*Z-+J^LP1JA:/?ACZ5^M M9?A89=@_>]6?6X>E'#T=3T7X1^$_,F34KA,QLO&17MZ*$0*O0# K,\/Z1%HV ME1VL0&%[XK4K\US/&RQF(=1[=#YK$UG6J.04445YAS!1110 4444 %%%% !1 M110!Y+\9/N#_ '*\,@_X^(_]X5])_$#PM+X@ \H,<+CBO-X_A)=K(IV2<&OT M3)BUK1Y-RC=&A* M\5\PZI82Z=?/#,I4@G@U^HY#CUB\/[.?Q(^IP&(5:GRO='T9\-_%":UI*P,_ MSP( -CL/[&I=;,L4445\^>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4 M_&763:6=O#&V/,!!Q^->K5X%\9I6>Z@4G@-_C7O9!157'1YNAWX""E75SRT? M-)]37O'PD\,);6CW-P@+, RGTKPNT3S+J,'^\/YU]7>$;=8/#UKM&,Q#/%?6 M<38F5+#*G'[1ZV9U'&FHKJ;M%%%?FI\T%%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 -=!(A5AD$8->%?%WPTMO>27\ M";4 KW>N$^+%JDO@^=R.<_TKVLEQ,J&,A;KH=N"J.G65NI\VV\I@N$D7@J[UY]\5-".J:4LR+GR$)->UDF(5#&PE+8[<#44*R;/G.W?R[A&'9A_.O MJ?P-J*7N@P*C F., \U\K,"DA'<&O4_A7XS73IC9W4F/-;"@FOM^(<'+$X;F MAO$]O,*+JTKKH>^44R*9)HP\9R#3Z_+MCY<**** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\X^+NII%X9FM]PWGMFN] MU"^CL+22:5L!5S7SC\1O%?\ ;FL.MN^Z'&.M?0Y#@IXC%*=M(ZGH8"BZE5/H MCAV.YB?6O?/@[:,NBQ3D<5X9IML;O4H( ,F1L5]0^!-(.D>&XH&7:PYKZKB; M$1IX54^K/5S.HHTN7N=-1117YH?-!1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !5;4+1+ZQE@< AUQS5FBG%N+NAIV=SYH^(/@^;1M5D>&-C#Z@<5Q4,TE MK,)(V*.IX([5];Z[H-KKEBUO=)D'VKP;QA\-;[2[AYK:+]SDG\*_2,GSNGB* M:HUW:7YGT>#QL:D>2>Y>\'_%6;3$2"^5IL=V->FV/Q(TV[C#/)'&3V)KYFE@ ME@D*NK CVIF^0?Q,/QKJQ6083$RYUHWV-:N7TJKYEH?5'_"=:3_S]0_]]4?\ M)UI/_/U#_P!]5\L>;)_?;\Z/-D_OM^=;)_?;\Z/-D_OM^='^JM#^=A_95/N?4__"=:3_S] M0_\ ?5'_ G6D_\ /U#_ -]5\L>;)_?;\Z/-D_OM^='^JM#^=A_95/N?4_\ MPG6D_P#/U#_WU1_PG6D_\_4/_?5?+'FR?WV_.CS9/[[?G1_JK0_G8?V53[GU M/_PG6D_\_4/_ 'U1_P )UI/_ #]0_P#?5?+'FR?WV_.CS9/[[?G1_JK0_G8? MV53[GU/_ ,)UI/\ S]0_]]4?\)UI/_/U#_WU7RQYLG]]OSH\V3^^WYT?ZJT/ MYV']E4^Y]3_\)UI/_/U#_P!]4?\ "=:3_P _4/\ WU7RQYLG]]OSH\V3^^WY MT?ZJT/YV']E4^Y]3_P#"=:3_ ,_4/_?5'_"=:3_S]0_]]5\L>;)_?;\Z/-D_ MOM^='^JM#^=A_95/N?4__"=:3_S]0_\ ?5'_ G6D_\ /U#_ -]5\L>;)_?; M\Z/-D_OM^='^JM#^=A_95/N?4_\ PG6D_P#/U#_WU1_PG6D_\_4/_?5?+'FR M?WV_.CS9/[[?G1_JK0_G8?V53[GU/_PG6D_\_4/_ 'U1_P )UI/_ #]0_P#? M5?+'FR?WV_.CS9/[[?G1_JK0_G8?V53[GU/_ ,)UI7_/U#_WU69J?Q/T^QC+ M1^7*1V!KYK\V3^^WYTFYSU9C^-7#A;#1=Y2;''*Z:>K.\\7_ !(NM;=H[8O" MF>0#U%<)\\TG=F)J6UL9[R41Q(2Q.!Q7J'@GX73W,L=QJ<7[KO7KSJ8/*J-M ME^+.QRHX6'89\,/!$MW=?;+N,J(R&7<.M>]1HL:!5& *K:=I\.G6B00* J# MXJW7YGF683QU9SEMT/F<3B'7GS,****\PY@HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH *AN+2"Z7;<1JX]Q4U%--IW0;'(ZO\.M*U0L5"VY/]V// M]:YF?X&6,S$C5I$]A;C_ .*KU2BO0IYGC*2M"HT=$<36@K1D>2_\*%LO^@W+ M_P" X_\ BJ/^%"V7_0;E_P# M45M_;68?\_7^!?UW$?S'DO\ PH6R M_P"@W+_X#C_XJC_A0ME_T&Y?_ 2_\ "A;+ M_H-R_P#@./\ XJC_ (4+9?\ 0;E_\!Q_\57K5%']M9A_S]?X!]=Q'\QY+_PH M6R_Z#2 M_P#"A;+_ *#M44?VUF'_/U_@'UW$? MS'DO_"A;+_H-R_\ @./_ (JC_A0ME_T&Y?\ P''_ ,57K5%']M9A_P _7^ ? M7<1_,>2_\*%LO^@W+_X#C_XJC_A0ME_T&Y?_ ''_P 57K5%']M9A_S]?X!] M=Q'\QY+_ ,*%LO\ H-R_^ X_^*H_X4+9?]!N7_P''_Q5>M44?VUF'_/U_@'U MW$?S'DO_ H6R_Z#2_\*%LO^@W+_P" X_\ BJLVWP0L+=@6U1Y,=C;C_P"*KU&BD\YQ M[5G5?X \9B']HYK2? VEZ4!^Z28CN4Q_6NBBAC@3;$@5?04^BO.J5JE5WJ2; M.>4Y3=Y,****R("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B 1BB@ HHHH **** "BBB@#_]D! end GRAPHIC 15 vtrs-20211231_g3.jpg begin 644 vtrs-20211231_g3.jpg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vtrs-20211231_g4.jpg begin 644 vtrs-20211231_g4.jpg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

,_B1JGA+P'9'_X2_P"U>(-(M+(W]W_8VM0:9;[Q/;RV MZ^;'.TLOEPIF15\ORDS&?5?@7XIU3Q=\/VN-8NOMU_8:UK&BM>-&J/)=$A\/Z[XDM/^$D^W:/J& MISV-FG]M:I%JE_![P3?> ? XT[4Y;>3 M4KK4]3UFZ2T9GA@EOK^XO7@1V53(L;7!C$A5"X0,43=L !YIX1_:*O+&ULM( MU'0_$'C7Q5J^M>+ETVUT*TMQFUTO7'M%CDDDDAAAV0RP8>5E5_*8%S*\:R]6 MW[0FGWFFZ$="\+^(/$VO:K_:'_%.Z>+.*\M?L%PMK?\ FO<7$5O^XN9(X6V3 M/O9PT7F1AG&3\-_@KKG@_P >Z)K=Y=:?+:6/_"9^8D$DA<_VOKMOJ%K@% /E MAA99,D8<@+O'S#*TGX.^./ .J:/XCT&'P_KVM6-[XMC;3-1U.>PMVM=8UI-1 MCE%PEM,WFQ+!%&T7E;297(D C'F !\-_VBKS5?!>G3'0_$'C;Q)K&M>)FL-( MT^TM["\33+'69K59)4O)+5(_)22RB9'83%I 2C%967M=&_:!\*ZA;VUUJ37' MA>QFAO#]NUPQ06T=U923QZA9/,)&19[8VTS/\VQXTDDA>:.*5H_(+C]E?7)M M)\*WGB3PW\/_ (J:UI-[XIDGT?Q"DEII6L M5K*L,WF>7_IJ^%O$'_"4:#:ZJ--U#2H[G(G='O4*X20+(H<+(D;AD76K)\+?VX-!M5\2?V>VM)NCGETOS!;S;6(65$? MYH]ZA7,19_++%/,E"^8VM0 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !7*>.OB=H'PZ^PIJ\FH37=[O-O8:/I-WJEY(B;?,E%O:Q22 M^4A>-6DV[%:6-2P,B ]77E7QTL_$^H?V);Z=H_B#7O"K^?\ VOI_@[58M,UB M68>6;7;Z MAJ,>J^=]ELM(T:]U"_/DL$N-]G!"]Q%Y,A6*7S(U\J1ECDVNP4^5?L^_!_Q? MX'\0>!KC7=&_L^/3++QO#>?\3@ZGY+ZAX@M+NS7[1*1-<>9!%(_FNH<[?WH1 MVVT>&O _C/X:>(-"\5_\(=J'B7['>^-[671]'N[(7GEZKX@CO[2Y!N+B&$Q> M3;?,/-\Q6FC&P_O"@!ZK\"_B9_PM[X?MXG2?3[NTFUK6+*SNM+??;W%K;:G= M6MO*C;F#;X8(W+ [6+$J " /*K7]M#2-4L_"NIC3=0T'3+SQGJ'AG4?[8T34 M8G>.&'5OLWV3S((S--99$>?R"GFE:]*_9Y\-^(O"OPWEM/%6FV^ MD:[<>(->U*>SM+L7<,:W6KWES'LEVJ74QS(P+(C8(W(C94>:^"? _C-=>\'V M%]X.U#3+3PW\3?$7B&;5+B[LFM[NPOE\0-!-"([AY>#?6BLLD:,#-P"% MJ_\ "]_!G_"*_P!O?;=0\G[;_9O]F_V->_VM]J\OS?L_]G>3]K\WR?W^SRMW MD_OL>5\]=!X)\>:-\0M*EO\ 19[AD@F-M<6U]93V5W:RA5;RY[:=$EA8H\<@ M61%+))&XRKJ3\_\ Q%^"OB+6O$GB+6I=#UC4]-A^(T/B:*Q\.ZV--U._LO\ MA%H=+S;3I

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end XML 17 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover - USD ($)
12 Months Ended
Dec. 31, 2021
Feb. 22, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Document Transition Report false    
Entity File Number 001-39695    
Entity Registrant Name VIATRIS INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 83-4364296    
Entity Address, Address Line One 1000 Mylan Boulevard    
Entity Address, City or Town Canonsburg    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 15317    
City Area Code (724)    
Local Phone Number 514-1800    
Title of 12(b) Security Common Stock, par value $0.01 per share    
Trading Symbol VTRS    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Common Stock, Par or Stated Value Per Share $ 0.01    
Entity Common Stock, Shares Outstanding   1,209,576,280  
Entity Public Float     $ 17,237,737,213
Documents Incorporated by Reference
DocumentPart of Form 10-K into Which
Document is Incorporated
An amendment to this Form 10-K will be filed no later than 120 days after the close of registrant’s fiscal year.III
   
Entity Central Index Key 0001792044    
Amendment Flag false    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --12-31    

XML 18 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Audit Information
12 Months Ended
Dec. 31, 2021
Auditor [Line Items]  
Auditor Name DELOITTE & TOUCHE LLP
Auditor Location Pittsburgh, Pennsylvania
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Audit Information
12 Months Ended
Dec. 31, 2021
Auditor [Line Items]  
Auditor Firm ID 34
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 701,200 $ 844,400
Accounts receivable, net 4,266,400 4,843,800
Inventories 3,977,700 5,471,900
Prepaid expenses and other current assets 1,957,600 1,707,400
Total current assets 10,902,900 12,867,500
Property, plant and equipment, net 3,188,600 3,459,900
Intangible assets, net 26,134,200 29,683,200
Goodwill 12,113,700 12,347,000
Deferred income tax benefit 1,332,700 2,147,900
Other assets 1,170,700 1,047,500
Total assets 54,842,800 61,553,000
Current liabilities:    
Accounts payable 1,657,400 1,904,200
Short-term borrowings 1,493,000 1,100,900
Income taxes payable 236,900 288,600
Current portion of long-term debt and other long-term obligations 1,877,500 2,308,500
Other current liabilities 4,619,600 4,960,700
Total current liabilities 9,884,400 10,562,900
Long-term debt 19,717,100 22,429,200
Deferred income tax liability 2,815,000 3,123,700
Other long-term obligations 1,933,600 2,483,100
Total liabilities 34,350,100 38,598,900
Viatris Inc. shareholders’ equity    
Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued and outstanding: 1,209,507,463 and 1,206,895,644, respectively 12,100 12,100
Additional paid-in capital 18,536,100 18,438,800
Retained earnings 3,688,800 5,361,200
Accumulated other comprehensive loss (1,744,300) (858,000)
Total equity 20,492,700 22,954,100
Total liabilities and equity $ 54,842,800 $ 61,553,000
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parenthetical)
Dec. 31, 2021
$ / shares
shares
Ordinary shares, par value, in USD per share | $ / shares $ 0.01
Ordinary shares, number of shares authorized 3,000,000,000
Common Stock  
Shares issued 1,209,507,463
Treasury Stock  
Shares issued 0
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues:      
Net sales $ 17,813.6 $ 11,819.9 $ 11,370.3
Total revenues 17,886.3 11,946.0 11,500.5
Cost of sales 12,310.8 8,149.3 7,602.9
Gross profit 5,575.5 3,796.7 3,897.6
Operating expenses:      
Research and development 751.1 555.1 639.9
Selling, general and administrative 4,529.2 3,344.6 2,563.6
Litigation settlements and other contingencies, net 329.2 107.8 (21.4)
Total operating expenses 5,609.5 4,007.5 3,182.1
(Loss) earnings from operations (34.0) (210.8) 715.5
Interest expense 636.2 497.8 517.3
Other (income) expense, net (5.8) 12.6 43.8
(Loss) earnings before income taxes (664.4) (721.2) 154.4
Income tax provision (benefit) 604.7 (51.3) 137.6
Net (loss) earnings $ (1,269.1) $ (669.9) $ 16.8
(Loss) earnings per share attributable to Viatris Inc. shareholders      
Basic (in USD per share) $ (1.05) $ (1.11) $ 0.03
Diluted (in USD per share) $ (1.05) $ (1.11) $ 0.03
Weighted average shares outstanding:      
Basic (in shares) 1,208.8 601.2 515.7
Diluted (in shares) 1,208.8 601.2 516.5
Net sales      
Revenues:      
Net sales $ 17,813.6 $ 11,819.9 $ 11,370.3
Other revenues      
Revenues:      
Other revenues $ 72.7 $ 126.1 $ 130.2
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Earnings - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Net loss $ (1,269.1) $ (669.9) $ 16.8
Other comprehensive (loss) earnings, before tax:      
Foreign currency translation adjustment (1,340.9) 1,213.0 (415.5)
Change in unrecognized loss and prior service cost related to defined benefit plans 73.9 (14.0) (24.8)
Net unrealized (loss) gain on marketable securities (1.1) 0.6 0.5
Other comprehensive (loss) earnings, before tax (775.2) 912.6 (343.1)
Income tax provision (benefit) 111.1 (26.6) 9.2
Other comprehensive (loss) earnings, net of tax (886.3) 939.2 (352.3)
Comprehensive earnings (2,155.4) 269.3 (335.5)
Cash flow hedging relationships      
Other comprehensive (loss) earnings, before tax:      
Net unrecognized gain (loss) on derivatives in hedging relationships 36.1 18.2 37.1
Net Investment Hedging      
Other comprehensive (loss) earnings, before tax:      
Net unrecognized gain (loss) on derivatives in hedging relationships $ 456.8 $ (305.2) $ 59.6
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Equity - USD ($)
$ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-In Capital
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Treasury Stock
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Loss
Cumulative Effect, Period of Adoption, Adjustment
Balance at Dec. 31, 2018 $ 12,167.1 $ 0.0 $ 6.0 $ 8,591.4 $ 6,010.7 $ 3.6 $ (999.7) $ (1,441.3) $ (3.6)
Balance (in shares) at Dec. 31, 2018     539,289,665       23,490,867    
Net earnings 16.8       16.8        
Other comprehensive loss, net of tax (352.3)             (352.3)  
Share-based compensation expense 56.8     56.8          
Issuance of restricted stock and stock options exercised, net 8.2   $ 0.1 8.1          
Issuance of restricted stock and stock options exercised, net (in shares)     1,457,206            
Taxes related to the net share settlement of equity awards (12.8)     (12.8)          
Cancellation of restricted stock             (1,107,207)    
Balance at Dec. 31, 2019 11,883.8   $ 6.1 8,643.5 6,031.1   $ (999.7) (1,797.2)  
Balance (in shares) at Dec. 31, 2019     540,746,871       24,598,074    
Net earnings (669.9)       (669.9)        
Other comprehensive loss, net of tax 939.2             939.2  
Share-based compensation expense 79.2     79.2          
Issuance of restricted stock and stock options exercised, net 0.6     0.6          
Issuance of restricted stock and stock options exercised, net (in shares)     872,802            
Taxes related to the net share settlement of equity awards (6.3)     (6.3)          
Cancellation of restricted stock     (24,598,074)       (24,598,074)    
Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock 0.0   $ (6.1) 6.1          
Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock (in shares)     (541,619,673)            
Stock Issued During Period, Value, New Issues 0.0   $ 5.2 (5.2)          
Issuance of common stock to Mylan N.V. shareholders (in shares)     541,619,673            
Issuance of common stock for the Combination 10,727.5   $ 6.9 10,720.6          
Issuance of common stock for the Combination (in shares)     689,874,045            
Retirement of Mylan N.V. treasury stock, net 0.0     (999.7)     $ 999.7    
Balance at Dec. 31, 2020 22,954.1   $ 12.1 18,438.8 5,361.2   $ 0.0    
Balance (in shares) at Dec. 31, 2020     1,206,895,644       0    
Net earnings (1,269.1)       (1,269.1)        
Other comprehensive loss, net of tax (886.3)             (886.3)  
Share-based compensation expense 111.2     111.2          
Issuance of restricted stock and stock options exercised, net (in shares)     2,611,819            
Taxes related to the net share settlement of equity awards (13.9)     (13.9)          
Cash dividends declared, $0.33 per common share         (403.3)        
Balance at Dec. 31, 2021 $ 20,492.7   $ 12.1 $ 18,536.1 $ 3,688.8   $ 0.0 $ (1,744.3)  
Balance (in shares) at Dec. 31, 2021     1,209,507,463       0    
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Net (loss) earnings $ (1,269.1) $ (669.9) $ 16.8
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation and amortization 4,506.5 2,216.1 2,019.3
Deferred income tax expense (benefit) 675.7 (213.2) (192.6)
Litigation settlements and other contingencies, net 323.7 101.1 (11.5)
Loss from equity method investments 61.9 48.4 62.1
Share-based compensation expense 111.2 79.2 56.8
Other non-cash items 411.8 366.4 360.6
Changes in operating assets and liabilities:      
Accounts receivable 59.3 78.7 (20.0)
Inventories (427.6) (741.9) (512.9)
Trade accounts payable (70.4) (82.7) (96.3)
Income taxes (699.6) 3.6 57.9
Other operating assets and liabilities, net (666.5) 46.0 63.5
Net cash provided by operating activities 3,016.9 1,231.8 1,803.7
Cash flows from investing activities:      
Cash received (paid) for acquisitions, net of cash acquired 277.0 415.8 (148.7)
Capital expenditures (457.2) (243.0) (213.2)
Payments for product rights and other, net (52.2) (438.2) (192.8)
Proceeds from sale of property, plant and equipment 18.3 2.1 0.0
Proceeds from sale of assets and subsidiaries 96.7 20.0 28.0
Purchase of marketable securities (30.2) (104.8) (25.8)
Proceeds from the sale of marketable securities 29.8 47.0 27.1
Net cash used in investing activities (117.8) (301.1) (525.4)
Cash flows from financing activities:      
Proceeds from issuance of long-term debt 1,710.1 983.3 7.4
Payments of long-term debt (4,201.3) (2,484.2) (1,108.5)
Payments of financing fees (7.0) (2.0) (3.0)
Change in short-term borrowings, net 392.1 1,099.6 (1.8)
Proceeds from exercise of stock options 0.0 0.6 8.1
Taxes paid related to net share settlement of equity awards (17.4) (7.9) (8.4)
Contingent consideration payments (28.6) (48.5) (60.3)
Cash dividends paid (399.0) 0.0 0.0
Non-contingent payments for product rights (456.0) (143.3) 0.0
Other items, net (4.9) (3.3) (2.5)
Net cash used in financing activities (3,012.0) (605.7) (1,169.0)
Effect on cash of changes in exchange rates (30.9) 33.8 (7.5)
Net (decrease) increase in cash, cash equivalents and restricted cash (143.8) 358.8 101.8
Cash, cash equivalents and restricted cash — beginning of period 850.0 491.1 389.3
Cash, cash equivalents and restricted cash — end of period 706.2 850.0 491.1
Non-cash transactions:      
Common stock issued for the Combination 0.0 10,727.5 0.0
Cash paid during the period for:      
Income taxes 641.7 324.4 278.6
Interest $ 684.8 $ 555.4 $ 470.6
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Equity (Parenthetical)
12 Months Ended
Dec. 31, 2021
$ / shares
Common Stock  
Dividends paid per share $ 0.33
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Operations
12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations Nature of Operations
Viatris is a global healthcare company formed in November 2020 whose mission is to empower people worldwide to live healthier at every stage of life, regardless of geography or circumstance. Improving the ability of patients to gain access to sustainable and high-quality healthcare is our relentless pursuit. One that rests on visionary thinking, determination and best-in-class capabilities that were strategically built to remove barriers across the health spectrum and advance access globally.
Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. The Company operates approximately 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs. We conduct our business through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.
In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and all historical financial information of the Company prior to November 16, 2020 represents Mylan’s historical results and the Company’s thereafter.
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary Of Significant Accounting Policies Summary of Significant Accounting Policies
Principles of Consolidation. The consolidated financial statements include the accounts of Viatris and those of its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Investments in equity method affiliates are recorded at cost and adjusted for the Company’s share of the affiliates’ cumulative results of operations, capital contributions and distributions.
Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates.
Foreign Currencies. The consolidated financial statements are presented in U.S. Dollars, the reporting currency of Viatris. Statements of Operations and Cash Flows of all of the Company’s subsidiaries that have functional currencies other than U.S. Dollars are translated at a weighted average exchange rate for the period for inclusion in the consolidated statements of operations and cash flows, whereas assets and liabilities are translated at the end of the period exchange rates for inclusion in the consolidated balance sheets. Translation differences are recorded directly in shareholders’ equity as foreign currency translation adjustments. Gains or losses on transactions denominated in a currency other than the subsidiaries’ functional currency, which arise as a result of changes in foreign currency exchange rates, are recorded in the consolidated statements of operations.
Cash and Cash Equivalents. Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.
Debt and Equity Securities. Debt securities classified as available-for-sale on the date of purchase are recorded at fair value, with net unrealized gains and losses, net of income taxes, reflected in accumulated other comprehensive loss as a component of shareholders’ equity. Net realized gains and losses on sales of available-for-sale debt securities are computed on a specific security basis and are included in other expense, net, in the consolidated statements of operations. Debt securities classified as trading securities are valued using the quoted market price from broker or dealer quotations or transparent pricing sources at the reporting date, with gains and losses included in other expense, net, in the consolidated statements of operations. Fair value is determined based on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit risk or underlying security and overall capital market liquidity. Debt securities are reviewed for impairment by assessing if the decline in market value of the investment below the carrying value is other than temporary.
Investments in equity securities with readily determinable fair values are recorded at fair value with changes in fair value recorded in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Investments in entities are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The share of net income or losses of equity method investments are included in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values and investments in equity accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors.
Concentrations of Credit Risk. Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable.
Viatris invests its excess cash in high-quality, liquid money market instruments, principally overnight deposits and highly rated money market funds. The Company maintains deposit balances at certain financial institutions in excess of federally insured amounts. Periodically, the Company reviews the creditworthiness of its counterparties to derivative transactions, and it does not expect to incur a loss from failure of any counterparties to perform under agreements it has with such counterparties.
Inventories. Inventories are stated at the lower of cost and net realizable value, with cost principally determined by the weighted average cost method. Provisions for potentially obsolete or slow-moving inventory, including pre-launch inventory, are made based on our analysis of product dating, inventory levels, historical obsolescence and future sales forecasts. Included as a component of cost of sales is expense related to the net realizable value of inventories.
Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed and recorded on a straight-line basis over the assets’ estimated service lives (3 to 18 years for machinery and equipment and other fixed assets and 15 to 39 years for buildings and improvements). Capitalized software is included in property, plant and equipment and is amortized over estimated useful lives ranging from 3 to 7 years.
Intangible Assets and Goodwill. Intangible assets are stated at cost less accumulated amortization. Amortization is generally recorded on a straight-line basis over estimated useful lives ranging from 3 to 20 years. The Company periodically reviews the estimated useful lives of intangible assets and makes adjustments when events indicate that a shorter life is appropriate.
The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of ASC 805, Business Combinations, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective estimated fair values. The cost to acquire businesses is allocated to the underlying net assets of the acquired business based on estimates of their respective fair values. Amounts allocated to acquired IPR&D are capitalized at the date of acquisition and, at that time, such IPR&D assets have indefinite lives. As products in development are approved for sale, amounts are allocated to product rights and licenses and will be amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
Purchases of developed products and licenses that are accounted for as asset acquisitions are capitalized as intangible assets and amortized over an estimated useful life. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses.
The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management's assessment of the fair value of the Company's reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we choose to use qualitative factors and determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test would be required. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations.
Indefinite-lived intangibles, principally IPR&D, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value of IPR&D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested.
Contingent Consideration. Viatris records contingent consideration resulting from business acquisitions at its estimated fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as adjustments to litigation settlements and other contingencies, net within the consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, sales targets and profitability. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.
Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations.
Impairment of Long-Lived Assets. The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.
Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations.
Short-Term Borrowings. The Company’s subsidiaries in India have working capital facilities with several banks which are secured by its current assets. The Company also has the CP Notes, Receivables Facility, which will expire in April 2022 and the Note Securitization Facility, which will expire in August 2022. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. As the accounts receivable do not transfer to the banks, any amounts outstanding under the facilities are recorded as borrowings and the underlying receivables continue to be included in accounts receivable, net, in the consolidated balance sheets.
Revenue Recognition. The Company recognizes revenues in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Amounts recorded for revenue deductions can result from a complex series of judgements about future events and uncertainties and can rely heavily on estimates and assumptions. The following section briefly describes the nature of our provisions for variable consideration and how such provisions are estimated:
Chargebacks: the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Viatris will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels.
Rebates, promotional programs and other sales allowances: this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products.
Returns: consistent with industry practice, Viatris maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. Generally, returned products are destroyed and customers are refunded the sales price in the form of a credit.
Governmental rebate programs: government reimbursement programs in the U.S. include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap” based on historical experience of prescriptions and utilization expected to result in the discount of the “coverage gap”.
Outside the U.S., the majority of our pharmaceutical sales are contractually or legislatively governed. In certain European countries, certain rebates are calculated on the governments total pharmaceutical spending or on specific product sale thresholds. We utilize historical data and obtain third party information to determine the adequacy of these accruals. Also, this provision includes price reductions that are mandated by law outside of the U.S.
Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods.
Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenues in the consolidated statements of operations.
Research and Development. R&D expenses are charged to operations as incurred.
Income Taxes. Income taxes have been provided for using an asset and liability approach in which deferred income taxes reflect the tax consequences on future years of events that the Company has already recognized in the financial statements or tax returns. Changes in enacted tax rates or laws may result in adjustments to the recorded tax assets or liabilities in the period that the new tax law is enacted.
Earnings per Share. Basic earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.
Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:
Year Ended December 31,
(In millions, except per share amounts)202120202019
Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders$(1,269.1)$(669.9)$16.8 
Shares (denominator):
Weighted average shares outstanding1,208.8 601.2 515.7 
Basic (loss) earnings per share attributable to Viatris Inc. shareholders$(1.05)$(1.11)$0.03 
Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders$(1,269.1)$(669.9)$16.8 
Shares (denominator):
Weighted average shares outstanding1,208.8 601.2 515.7 
Share-based awards— — 0.8 
Total dilutive shares outstanding1,208.8 601.2 516.5 
Diluted (loss) earnings per share attributable to Viatris Inc. shareholders$(1.05)$(1.11)$0.03 
The weighted average shares outstanding used in the computation of earnings per share for the year ended December 31, 2020 includes the effect of the 689.9 million shares issued for the closing of the Combination.
Additional stock awards and restricted ordinary shares were outstanding during the years ended December 31, 2021, 2020 and 2019 but were not included in the computation of diluted earnings per share for each respective period because the effect would be anti-dilutive. Excluded shares also include certain share-based compensation awards and restricted shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 12.7 million, 10.3 million and 9.1 million shares for the years ended December 31, 2021, 2020 and 2019, respectively.
The Company paid quarterly cash dividends of $0.11 per share on the Company’s issued and outstanding common stock on June 16, 2021, September 16, 2021, and December 16, 2021. On January 4, 2022, the Company’s Board of Directors declared a quarterly cash dividend of $0.12 per share on the Company’s issued and outstanding common stock, which will be payable on March 16, 2022 to shareholders of record as of the close of business on February 24, 2022. The declaration and payment of future dividends to holders of the Company’s common stock will be at the discretion of the Board of Directors, and will depend upon factors, including but not limited to, the Company’s financial condition, earnings, capital requirements of its businesses, legal requirements, regulatory constraints, industry practice, and other factors that the Board of Directors deems relevant.
On February 28, 2022, the Company announced that its Board of Directors had authorized a share repurchase program for the repurchase of up to $1.0 billion of the Company’s shares of common stock. The Company has not yet repurchased any shares of common stock under the share repurchase program and the share repurchase program does not obligate the Company to acquire any particular amount of common stock.
Share-Based Compensation. The fair value of share-based compensation is recognized as expense in the consolidated statements of operations over the vesting period.
Derivatives. From time to time the Company may enter into derivative financial instruments (mainly foreign currency exchange forward contracts, interest rate swaps and purchased equity call options) designed to: 1) hedge the cash flows resulting from existing assets and liabilities and transactions expected to be entered into over the next 24 months in currencies other than the functional currency, 2) hedge the variability in interest expense on floating rate debt, 3) hedge the fair value of fixed-rate notes, 4) hedge against changes in interest rates that could impact future debt issuances, 5) hedge cash or share payments required on conversion of issued convertible notes, 6) hedge a net investment in a foreign operation, or 7) economically hedge the foreign currency exposure associated with the purchase price of non-U.S. acquisitions. Derivatives are recognized as assets or liabilities in the consolidated balance sheets at their fair value. When the derivative instrument qualifies as a cash flow hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged items, are generally included in interest expense. When such instruments do not qualify for hedge accounting the changes in fair value are recorded in the consolidated statements of operations within other expense, net.
Financial Instruments. The Company’s financial instruments consist primarily of short-term and long-term debt, interest rate swaps, forward contracts and option contracts. The Company’s financial instruments also include cash and cash equivalents as well as accounts and other receivables and accounts payable, the fair values of which approximate their carrying values. As a policy, the Company does not engage in speculative or leveraged transactions.
The Company carries derivative instruments in the consolidated balance sheets at fair value, determined by reference to market data such as forward rates for currencies, implied volatilities, and interest rate swap yield curves. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. In addition, the Company has designated certain long-term debt instruments as net investment hedges.
Recent Accounting Pronouncements.
Adoption of New Accounting Standards
In January 2020, the FASB issued Accounting Standards Update 2020-01, Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 (“ASU 2020-01”), which clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. In addition, ASU 2020-01 states that for the purpose of applying paragraph 815-10-15-141(a) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The Company applied the provisions of ASU 2020-01 as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.
In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (Topic 740) which is intended to simplify the accounting for income taxes by eliminating certain exceptions and simplifying certain requirements under Topic 740. The Company applied the provisions of ASU 2019-12 on a prospective basis as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.
    Accounting Standards Issued Not Yet Adopted    
In March 2020, the FASB issued Accounting Standards Update 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Entities can apply the provisions of ASU 2020-04 immediately, as applicable, and generally the provisions of the guidance are available through December 31, 2022 as entities transition away from reference rates that are expected to be discontinued. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.
In October 2021, the FASB issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires entities (acquirers) to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. ASU 2021-08 will be effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2022 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.
In November 2021, the FASB issued Accounting Standards Update 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”), which requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 will be effective for fiscal years beginning after December 15, 2021 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its disclosures.
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Acquisitions and Other Transactions
12 Months Ended
Dec. 31, 2021
Business Combinations [Abstract]  
Acquisitions and Other Transactions Acquisitions and Other Transactions
Upjohn Business Combination Agreement
On July 29, 2019, Mylan, Pfizer, Upjohn, a wholly-owned subsidiary of Pfizer, and certain other affiliated entities entered into a Business Combination Agreement pursuant to which Mylan would combine with the Upjohn Business in a Reverse Morris Trust transaction. The Upjohn Business was a global, primarily off-patent branded and generic established medicines business, which includes 20 primarily off-patent solid oral dose legacy brands, such as Lyrica®, Lipitor®, Celebrex® and Viagra®. The Combination was completed on November 16, 2020.
Prior to the Combination and pursuant to a Separation and Distribution Agreement, Pfizer had, among other things, transferred to Viatris substantially all of the assets and liabilities comprising the Upjohn Business (the Separation) and, thereafter, Pfizer had distributed to Pfizer stockholders all of the issued and outstanding shares of Viatris (the Distribution). When the Distribution and Combination were complete, Pfizer stockholders as of the record date of the Distribution owned 57% of the outstanding shares of Viatris common stock and Mylan shareholders as of immediately before the Combination owned 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted basis. Viatris also made a cash payment to Pfizer equal to $12 billion, which was funded with the proceeds of debt incurred by Upjohn prior to the Combination.
The transaction involved multiple legal entity restructuring transactions and a reverse merger acquisition with Viatris representing the legal acquirer and Mylan representing the accounting acquirer of the Upjohn Business. In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and Viatris applied purchase accounting to the acquired assets and assumed liabilities of the Upjohn Business as of November 16, 2020. The debt incurred by Upjohn prior to the Combination was a liability assumed in purchase accounting. The fair value of the debt as of November 16, 2020 was $13.08 billion.

The purchase price consists of the issuance of approximately 689.9 million Viatris shares of common stock at a fair value of approximately $10.73 billion based on the closing price of Mylan’s ordinary shares on November 13, 2020, as reported by the NASDAQ. In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction have been recorded at their respective estimated fair values at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company incurred acquisition related costs of approximately $234.6 million and $602.9 million, respectively. Acquisition related costs were recorded primarily in SG&A in the consolidated statements of operations for such periods.
During the year ended December 31, 2021, adjustments were made to the preliminary purchase price recorded at December 31, 2020, and are reflected as “Measurement Period and Other Adjustments” in the table below. The allocation of the $10.73 billion purchase price to the assets acquired and liabilities assumed under the Combination is as follows:
(In millions)
Preliminary Purchase Price Allocation as of December 31, 2020 (a)
Measurement Period and Other Adjustments (b)
Purchase Price Allocation as of December 31, 2021 (as adjusted)
Current assets (excluding inventories and net of cash acquired)$2,841.9 $(38.7)$2,803.2 
Inventories2,588.9 (34.2)2,554.7 
Property, plant and equipment1,394.1 (5.0)1,389.1 
Identified intangible assets18,040.0 — 18,040.0 
Goodwill2,107.5 295.6 2,403.1 
Deferred income tax benefit1,481.9 196.3 1,678.2 
Other assets 792.1 (7.4)784.7 
Total assets acquired$29,246.4 $406.6 $29,653.0 
Current liabilities2,760.2 419.7 3,179.9 
Long-term debt, including current portion13,076.2 — 13,076.2 
Deferred tax liabilities1,656.9 1.0 1,657.9 
Other noncurrent liabilities1,441.5 (14.1)1,427.4 
Net assets acquired (net of $415.8 of cash acquired)
$10,311.6 $— $10,311.6 
____________
(a)As previously reported in Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
(b)The measurement period adjustments are primarily for 1) certain working capital adjustments, an increase in litigation reserves to reflect facts and circumstances that existed as of the date of the Combination, and other adjustments and 2) the tax implications of these and other adjustments. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and accordingly, the Company has not retrospectively adjusted those consolidated financial statements.
The Combination enhanced each businesses’ ability to serve patients’ needs and expand their capabilities across more than 165 markets. Mylan brought a diverse portfolio across many geographies and key therapeutic areas, such as central nervous system and anesthesia, infectious disease and cardiovascular, as well as a robust pipeline, high-quality manufacturing and supply chain excellence. The Upjohn Business brought trusted, iconic brands, such as Lipitor® (atorvastatin calcium), Celebrex® (celecoxib) and Viagra® (sildenafil), and proven commercialization capabilities, including leadership positions in China and other emerging markets.

The Company recorded a step-up in the fair value of inventory of approximately $1.43 billion at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company recorded amortization of the inventory step-up of approximately $1.19 billion and $238.2 million, respectively, which is included in cost of sales in the consolidated statements of operations. The inventory step-up was fully amortized during 2021. In addition, a step-up in the fair value of property, plant and equipment of approximately $385.0 million was recognized. The related depreciation is being expensed over a service life of five years for machinery and equipment and between 10 and 20 years for buildings.

The identified intangible assets of $18.04 billion are comprised of product rights and are being amortized over a weighted average useful life of 15 years. Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. The goodwill of $2.40 billion arising from the Combination consisted largely of the value of the employee workforce and products to be sold in new markets leveraging the combined entity. In addition, an allocation of the goodwill was assigned to the respective segments. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes.

The Company recorded a fair value adjustment of approximately $759.4 million related to the long-term debt assumed as part of the acquisition. The fair value of long-term debt as of the Combination date was determined by broker or dealer quotations, which is classified as Level 2 in the fair value hierarchy. The total fair value adjustment is being amortized as a reduction to interest expense over the maturity dates of the related debt instruments.
The operating results of the Upjohn Business have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of the Upjohn Business for the period from the acquisition date to December 31, 2020, were $866.5 million and net loss, net of tax, was approximately $360.9 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs.

Unaudited Pro Forma Financial Results

The following table presents supplemental unaudited pro forma information for the Combination, as if it had occurred on January 1, 2019. The unaudited pro forma results reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased depreciation and amortization expense based on the fair value of assets acquired, the impact of transaction costs and the related income tax effects. The unaudited pro forma results do not include any anticipated synergies which may be achievable, or have been achieved, subsequent to the closing of the Combination. Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.
Year Ended December 31,
(Unaudited, in millions, except per share amounts) 20202019
Total revenues$18,284.8 $21,582.7 
Net earnings$1,483.7 $1,873.5 
Earnings per share:
Basic$1.23 $1.55 
Diluted$1.23 $1.55 
Weighted average shares outstanding:
Basic1,206.8 1,205.6 
Diluted1,207.7 1,206.4 

Other Transactions
In December 2020, Viatris and Pfizer terminated their strategic collaboration for generic drugs in Japan pursuant to an amendment and termination agreement. Under the prior collaboration agreement, both parties contributed products, which Pfizer distributed to third-parties in the Japan market. Under the terms of the amendment and termination agreement, Viatris purchased all collaboration related inventory held by Pfizer. As a result of the termination, and the repurchase of collaboration inventory, the Company reduced revenue by $86.5 million during the year ended December 31, 2020.
In September 2020, the Company entered into an agreement to acquire the related intellectual property and commercialization rights of Aspen’s thrombosis product portfolio in Europe for €641.9 million. The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra®, Fraxiparine®, Mono-Embolex® and Orgaran®. Upon closing of the transaction in November 2020, the Company made a payment of €263.2 million to Aspen and the remaining payment of €378.7 million was made on June 25, 2021. The Company accounted for this transaction as an asset acquisition and recognized an intangible asset of €641.9 million for the product rights, which is being amortized over a useful life of 8 years.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Accounts Receivable
12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Recognition and Accounts Receivable Revenue Recognition and Accounts Receivable
The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:
(In millions)2021 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands5,759.2 2,207.8 1,197.1 1,677.2 10,841.3 
Complex Gx and Biosimilars1,241.6 0.2 46.5 53.8 1,342.1 
Generics3,427.9 4.8 783.8 1,413.7 5,630.2 
Total Viatris$10,428.7 $2,212.8 $2,027.4 $3,144.7 $17,813.6 

(In millions)2020 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands3,920.7 253.9 617.0 443.3 5,234.9 
Complex Gx and Biosimilars1,202.6 0.7 42.8 49.4 1,295.5 
Generics3,387.6 5.3 535.5 1,361.1 5,289.5 
Total Viatris$8,510.9 $259.9 $1,195.3 $1,853.8 $11,819.9 

(In millions)2019 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands4,199.1 207.6 533.3 422.1 5,362.1 
Complex Gx and Biosimilars1,127.4 0.4 23.8 59.7 1,211.3 
Generics2,913.5 6.6 635.4 1,241.4 4,796.9 
Total Viatris$8,240.0 $214.6 $1,192.5 $1,723.2 $11,370.3 

The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:
(In millions)Year Ended December 31, 2021
Select Key Global Products
Lipitor ®
$1,663.2 
Norvasc ®824.7 
Lyrica ®728.5 
Viagra ®533.8 
EpiPen® Auto-Injectors391.7 
Celebrex ®
344.4 
Effexor ®
316.8 
Creon ®309.8 
Zoloft ®
284.3 
Xalabrands226.0 
Select Key Segment Products
Influvac ®$299.3 
Amitiza ®201.5 
Xanax ®185.9 
Dymista ®168.0 
Yupelri ®161.9 
____________
(a)The Company does not disclose net sales for any products considered competitively sensitive.
(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.
(c)Prior periods are not presented due to significance of products acquired as part of the Combination.
Variable Consideration and Accounts Receivable    
The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2021, 2020 and 2019, respectively:
Year Ended December 31,
(In millions)202120202019
Gross sales$30,553.4 $19,899.1 $19,012.2 
Gross to net adjustments:
Chargebacks(5,530.1)(3,656.2)(3,309.6)
Rebates, promotional programs and other sales allowances(6,135.6)(3,765.5)(3,629.3)
Returns(384.6)(329.7)(237.9)
Governmental rebate programs(689.5)(327.8)(465.1)
Total gross to net adjustments$(12,739.8)$(8,079.2)$(7,641.9)
Net sales$17,813.6 $11,819.9 $11,370.3 
The following is a rollforward of the categories of variable consideration during 2021:
(In millions)Balance at December 31, 2020Current Provision Related to Sales Made in the Current Period Measurement Period Adjustments and ReclassesChecks/ Credits Issued to Third Parties Effects of Foreign ExchangeBalance at December 31, 2021
Chargebacks$585.2 $5,530.1 $63.4 $(5,585.4)$(1.6)$591.7 
Rebates, promotional programs and other sales allowances1,576.3 6,135.6 (57.6)(6,267.1)(14.2)1,373.0 
Returns539.9 384.6 269.0 (499.0)(7.7)686.8 
Governmental rebate programs313.3 689.5 110.6 (705.2)(9.0)399.2 
Total$3,014.7 $12,739.8 $385.4 $(13,056.7)$(32.5)$3,050.7 
Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net revenues and as a contra-asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:
(In millions)December 31,
2021
December 31,
2020
Accounts receivable, net$1,688.6 $1,802.9 
Other current liabilities1,362.1 1,211.8 
Total$3,050.7 $3,014.7 
We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves.
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components
12 Months Ended
Dec. 31, 2021
Balance Sheet Components [Abstract]  
Balance Sheet Components Balance Sheet Components
Selected balance sheet components consist of the following:
Cash and restricted cash
(In millions)December 31,
2021
December 31,
2020
December 31,
2019
Cash and cash equivalents$701.2 $844.4 $475.6 
Restricted cash, included in other current and non-current assets5.0 5.6 15.5 
Cash, cash equivalents and restricted cash$706.2 $850.0 $491.1 
Inventories
(In millions)December 31, 2021December 31, 2020
Raw materials$922.4 $958.4 
Work in process993.3 1,438.1 
Finished goods2,062.0 3,075.4 
Inventories$3,977.7 $5,471.9 
Inventory reserves totaled $519.0 million and $353.6 million at December 31, 2021 and 2020, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $474.9 million, $206.1 million and $399.2 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Prepaid expenses and other current assets
(In millions)December 31, 2021December 31, 2020
Prepaid expenses$256.7 $267.8 
Available-for-sale fixed income securities38.2 39.1 
Fair value of financial instruments144.6 118.6 
Equity securities51.0 45.8 
Other current assets1,467.1 1,236.1 
Prepaid expenses and other current assets$1,957.6 $1,707.4 
Prepaid expenses consist primarily of prepaid rent, insurance and other individually insignificant items.
Property, plant and equipment, net
(In millions)December 31, 2021December 31, 2020
Machinery and equipment$3,054.0 $3,235.0 
Buildings and improvements1,808.5 1,954.8 
Construction in progress588.7 376.3 
Land and improvements137.9 155.8 
Gross property, plant and equipment5,589.1 5,721.9 
Accumulated depreciation2,400.5 2,262.0 
Property, plant and equipment, net$3,188.6 $3,459.9 
Capitalized software costs included in our consolidated balance sheets were $62.3 million and $70.9 million, net of accumulated depreciation, at December 31, 2021 and 2020, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $509.5 million, $289.7 million and $256.1 million for the years ended December 31, 2021, 2020 and 2019, respectively.
Other assets
(In millions)December 31, 2021December 31, 2020
Equity method investments, clean energy investments$— $47.9 
Operating lease right-of-use assets290.8 323.6 
Other long-term assets879.9 676.0 
Other assets$1,170.7 $1,047.5 
Accounts payable
(In millions)December 31, 2021December 31, 2020
Trade accounts payable$1,056.1 $1,345.7 
Other payables601.3 558.5 
Accounts payable$1,657.4 $1,904.2 
Other current liabilities
(In millions)December 31, 2021December 31, 2020
Accrued sales allowances$1,362.1 $1,211.8 
Payroll and employee benefit liabilities 741.9 828.2 
Legal and professional accruals, including litigation accruals715.6 362.9 
Contingent consideration66.7 100.5 
Accrued restructuring233.5 149.2 
Equity method investments, clean energy investments10.9 47.5 
Accrued interest86.6 90.9 
Fair value of financial instruments61.0 103.6 
Operating lease liability86.7 92.9 
Other1,254.6 1,973.2 
Other current liabilities$4,619.6 $4,960.7 
Other long-term obligations
(In millions)December 31, 2021December 31, 2020
Employee benefit liabilities$876.4 $1,020.4 
Contingent consideration133.0 123.1 
Tax related items, including contingencies426.1 469.5 
Operating lease liability200.9 229.5 
Accrued restructuring64.3 134.8 
Other232.9 505.8 
Other long-term obligations$1,933.6 $2,483.1 
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases
12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Lessee, Operating Leases Leases
The Company has operating leases of real estate, consisting primarily of administrative offices, manufacturing and distribution facilities, and R&D facilities. We also have operating leases of certain equipment, primarily automobiles, and certain limited supply arrangements.
We elected to apply the practical expedient to not separate lease and non-lease components for our leases except for those related to certain limited supply arrangements. We have also elected to apply the short-term lease recognition exemption which means we will not recognize ROU assets or lease liabilities for leases with an initial term of 12 months of less.
As of December 31, 2021, the Company recognized ROU assets of $290.8 million and total lease liabilities of $287.6 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance sheets. Refer to Note 5 Balance Sheet Components for additional information.
ROU assets and liabilities are recognized at the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use an applicable incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Options to extend or terminate the ROU assets are reviewed at lease inception and these options are accounted for when they are reasonably certain of being exercised.
Other information related to leases was as follows:
As of December 31, 2021
Remaining lease terms
1 year to 23 years
Weighted-average remaining lease term6 years
Weighted-average discount rate2.6 %
As of December 31, 2021, maturities of lease liabilities were as follows:
(In millions)
Year ending December 31,
2022$82.0 
202365.0 
202442.9 
202528.8 
202623.9 
Thereafter68.2 
Total lease payments$310.8 
Less imputed interest23.2 
Total lease liability$287.6 
As of December 31, 2021, we have additional operating leases, primarily for administrative offices, that have not yet commenced totaling approximately $13.6 million. These leases are expected to commence in 2022 and have lease terms of 5 to 9 years. For the years ended December 31, 2021, 2020 and 2019, the Company had operating lease expense of approximately $97.6 million, $80.7 million and $87.6 million, respectively. Operating lease costs are classified primarily as selling, general and administrative expenses and cost of sales in the consolidated statements of operations.
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Method Investments
12 Months Ended
Dec. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]  
Equity Method Investments Equity Method Investments
The Company had three equity method investments in limited liability companies that owned refined coal production plants whose activities qualified for income tax credits under Section 45 of the Code. The Company did not consolidate these entities as we had determined that we were not the primary beneficiary of these entities and did not have the power to individually direct the activities of these entities. Accordingly, these investments were accounted for under the equity method of accounting. For each of the clean energy investments, the Company had entered into notes payable with the respective project sponsor, which in part were paid to the sponsor as certain production levels were met. The law that provides for IRC Section 45 tax credits expired during the year ended December 31, 2021 for all three clean energy investments and all of the clean energy investments have wound down operations.
During the years ended December 31, 2021, 2020, and 2019, the Company reduced its long-term obligations for its three investments as a result of lower than anticipated production levels and lower expected future variable debt payments to the respective project sponsor. The Company recognized a net gain of approximately $5.7 million, $21.4 million and $7.0 million, respectively, which was recognized as a component of the net loss of the equity method investments in the consolidated statements of operations.
The carrying values and respective balance sheet locations of the Company’s clean energy investments were as follows at December 31, 2021 and 2020, respectively:
(In millions)December 31, 2021December 31, 2020
Other assets$— $47.9 
Other current liabilities10.9 47.5 
Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis as of December 31, 2021 and 2020 and for the years ended December 31, 2021, 2020 and 2019 are as follows:
(In millions)December 31, 2021December 31, 2020
Current assets$4.2 $38.9 
Noncurrent assets0.5 1.0 
Total assets4.7 39.9 
Current liabilities2.8 33.0 
Noncurrent liabilities— 1.8 
Total liabilities2.8 34.8 
Net assets$1.9 $5.1 
Year Ended December 31,
(In millions)202120202019
Total revenues$326.7 $374.5 $385.0 
Gross loss(4.6)(4.6)(4.4)
Operating and non-operating expense16.8 19.0 20.0 
Net loss$(21.4)$(23.6)$(24.4)
The Company’s net losses from its equity method investments include amortization expense related to the excess of the cost basis of the Company’s investment over the underlying assets of each individual investee. For the years ended December 31, 2021, 2020 and 2019, the Company recognized net losses from equity method investments of $61.9 million, $48.4 million, and $62.1 million, respectively, which were recognized as a component of other expense, net in the consolidated statements of operations. The Company recognizes the income tax credits and benefits from the clean energy investments as part of its provision for income taxes.
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management
12 Months Ended
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments And Risk Management Financial Instruments and Risk ManagementThe Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk.
Foreign Currency Risk Management
In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the consolidated statements of operations.
The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries and a portion of forecasted intercompany inventory sales denominated in Euro, Japanese Yen and Chinese Renminbi for up to eighteen months. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any changes in the fair value of designated cash flow hedges are deferred in AOCE and are reclassified into earnings when the hedged item impacts earnings.
Net Investment Hedges
The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments.
The Company has designated certain Euro and Yen borrowings as a hedge of its investment in certain Euro-functional and Yen-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro and Yen borrowings not designated as net investment hedges through certain Euro and Yen denominated financial assets and forward currency swaps.
The following table summarizes the principal amounts of the Company’s outstanding Euro and Yen borrowings and the notional amounts of the Euro and Yen borrowings designated as net investment hedges:
Notional Amount Designated as a Net Investment Hedge
(in millions)Principal AmountDecember 31,
2021
December 31,
2020
Euro
2.250% Euro Senior Notes due 2024
1,000.0 1,000.0 1,000.0 
3.125% Euro Senior Notes due 2028
750.0 750.0 750.0 
2.125% Euro Senior Notes due 2025
500.0 500.0 500.0 
0.816% Euro Senior Notes due 2022
750.0 750.0 750.0 
1.023% Euro Senior Notes due 2024
750.0 750.0 750.0 
1.362% Euro Senior Notes due 2027
850.0 850.0 850.0 
1.908% Euro Senior Notes due 2032
1,250.0 1,250.0 1,250.0 
Foreign currency forward contracts105.6 — 105.6 
Euro Total5,955.6 5,850.0 5,955.6 
Yen
YEN Term Loan¥40,000.0 ¥40,000.0 ¥— 
Yen Total¥40,000.0 ¥40,000.0 ¥— 
At December 31,2021, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedge was $347.6 million.
Interest Rate Risk Management
The Company enters into interest rate swaps from time to time in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings.
Cash Flow Hedging Relationships
The Company’s interest rate swaps designated as cash flow hedges fix the interest rate on a portion of the Company’s variable-rate debt or hedge part of the Company’s interest rate exposure associated with the variability in the future cash flows attributable to changes in interest rates. Any changes in fair value are included in earnings or deferred through AOCE, depending on the nature and effectiveness of the offset. Any ineffectiveness in a cash flow hedging relationship is recognized immediately in earnings in the consolidated statements of operations.
Fair Value Hedging Relationships
The Company's interest rate swaps designated as fair value hedges convert the fixed rate on a portion of the Company's fixed-rate senior notes to a variable rate. Any changes in the fair value of these derivative instruments, as well as the offsetting change in fair value of the portion of the fixed-rate debt being hedged, is included in interest expense. The Company’s fair value hedge was terminated during 2020.
Credit Risk Management
The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the consolidated balance sheets. Accordingly, there are no offsetting amounts that net assets against liabilities.
The following table summarizes the classification and fair values of derivative instruments in our consolidated balance sheets:
Asset Derivatives Liability Derivatives
(In millions)Balance Sheet LocationDecember 31, 2021 Fair ValueDecember 31, 2020 Fair ValueBalance Sheet LocationDecember 31, 2021 Fair ValueDecember 31, 2020 Fair Value
Derivatives designated as hedges:
Foreign currency forward contractsPrepaid expenses & other current assets$62.0 $28.3 Other current liabilities$4.3 $0.8 
Total derivatives designated as hedges62.0 28.3 4.3 0.8 
Derivatives not designated as hedges:
Foreign currency forward contractsPrepaid expenses & other current assets82.6 90.3Other current liabilities56.7 102.8
Total derivatives not designated as hedges82.6 90.356.7 102.8
Total derivatives $144.6 $118.6 $61.0 $103.6 
The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:

Amount of Gains/(Losses) Recognized in EarningsAmount of Gain Excluded from the Assessment of Hedge Effectiveness
Year Ended December 31,Year Ended December 31,
(In millions)Location of Gain/(Loss)202120202019202120202019
Derivative Financial Instruments in Fair Value Hedge Relationships (1) :
Interest rate swaps
Interest expense (3)
$— $22.1 $18.7 $— $— $— 
2023 Senior Notes (3.125% coupon)
Interest expense (3)
— (22.1)(18.7)— — — 
Derivative Financial Instruments in Cash Flow Hedging Relationships :
Foreign currency forward contracts
Other expense, net (5)
— — — — 7.1 — 
Derivative Financial Instruments Not Designated as Hedging Instruments:
Foreign currency option and forward contracts
Other expense, net (3)
39.3 (10.1)(17.3)— — — 
Total$39.3 $(10.1)$(17.3)$— $7.1 $— 
Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on DerivativesAmount of Gains/(Losses) Reclassified from AOCE into Earnings
Year Ended December 31,Year Ended December 31,
(In millions)Location of Gain/(Loss)202120202019202120202019
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :
Foreign currency forward contracts
Net sales (4)
$45.8 $20.6 $16.6 $30.9 $4.8 $(0.7)
Interest rate swaps
Interest expense (4)
(3.4)— 3.0 (4.3)(4.5)(7.1)
Derivative Financial Instruments in Net Investment Hedging Relationships:
Foreign currency borrowings and forward contracts436.6 (346.4)56.7 — — — 
Total$479.0 $(325.8)$76.3 $26.6 $0.3 $(7.8)
____________
(1)In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The amount included in the above tables represents the fair value adjustment recognized at the date the interest rate swaps were settled.
(2)At December 31, 2021, the Company expects that approximately $21.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months.
(3)Represents the location of the gain/(loss) recognized in earnings on derivatives.
(4)Represents the location of the gain/(loss) reclassified from AOCE into earnings.
(5)Represents the location of the gain excluded from the assessment of hedge effectiveness.
Fair Value Measurement
Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
Level 1:        Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2:        Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.
Level 3:        Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.

Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:
December 31, 2021
(In millions)Level 1Level 2Level 3Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds$50.9 $— $— $50.9 
Total cash equivalents50.9 — — 50.9 
Equity securities:
Exchange traded funds50.3 — — 50.3 
Marketable securities0.7 — — 0.7 
Total equity securities51.0 — — 51.0 
Available-for-sale fixed income investments:
Corporate bonds— 16.6 — 16.6 
U.S. Treasuries— 14.6 — 14.6 
Agency mortgage-backed securities— 2.0 — 2.0 
Asset backed securities— 4.6 — 4.6 
Other— 0.4 — 0.4 
Total available-for-sale fixed income investments— 38.2 — 38.2 
Foreign exchange derivative assets— 144.6 — 144.6 
Total assets at recurring fair value measurement$101.9 $182.8 $— $284.7 
Financial Liabilities
Foreign exchange derivative liabilities$— $61.0 $— $61.0 
Contingent consideration— — 199.7 199.7 
Total liabilities at recurring fair value measurement$— $61.0 $199.7 $260.7 
December 31, 2020
(In millions)Level 1Level 2Level 3Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds$0.9 $— $— $0.9 
Total cash equivalents0.9 — — 0.9 
Equity securities:
Exchange traded funds45.1 — — 45.1 
Marketable securities0.7 — — 0.7 
Total equity securities45.8 — — 45.8 
Available-for-sale fixed income investments:
Corporate bonds— 17.8 — 17.8 
U.S. Treasuries— 14.4 — 14.4 
Agency mortgage-backed securities— 1.9 — 1.9 
Asset backed securities— 4.6 — 4.6 
Other— 0.4 — 0.4 
Total available-for-sale fixed income investments— 39.1 — 39.1 
Foreign exchange derivative assets— 118.6 — 118.6 
Total assets at recurring fair value measurement$46.7 $157.7 $— $204.4 
Financial Liabilities
Foreign exchange derivative liabilities$— $103.6 $— $103.6 
Contingent consideration— — 223.6 223.6 
Total liabilities at recurring fair value measurement$— $103.6 $223.6 $327.2 
For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including the LIBOR yield curve, foreign exchange forward prices, and bank price quotes. For the years ended December 31, 2021 and 2020, there were no transfers between Level 1 and 2 of the fair value hierarchy. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities:
Cash equivalents — valued at observable net asset value prices.
Equity securities, exchange traded funds — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations.
Equity securities, marketable securities valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations.
Available-for-sale fixed income investments — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity.
Interest rate swap derivative assets and liabilities — valued using the LIBOR/EURIBOR yield curves at the reporting date. Counterparties to these contracts are highly rated financial institutions.
Foreign exchange derivative assets and liabilities — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions.
Contingent Consideration
In December 2011, the Company completed the acquisition of the exclusive worldwide rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline’s Advair® Diskus incorporating Pfizer’s respiratory delivery platform. The Company accounted for this transaction as a purchase of a business and utilized the acquisition method of accounting. On January 30, 2019, the Company received FDA approval of Wixela® Inhub® (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of GlaxoSmithKline’s Advair Diskus®. The commercial launch of the Wixela® Inhub® occurred in February 2019.
As of December 31, 2021, the Company has a contingent consideration liability of $177.8 million related to the respiratory delivery platform. The fair value measurement of contingent consideration is determined using Level 3 inputs. The Company’s contingent consideration represents a component of the total purchase consideration for Pfizer’s respiratory delivery platform and certain other acquisitions. The measurement is calculated using unobservable inputs based on the Company’s own assumptions primarily related to the probability and timing of future development and commercial milestones and future profit-sharing payments which are discounted using a market rate of return. At December 31, 2021 and 2020, discount rates ranging from 8.0% to 10.5% were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liability.
A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to December 31, 2021 is as follows:
(In millions)
Current Portion (1)
Long-Term Portion (2)
Total Contingent Consideration
Balance at December 31, 2019$120.4 $130.3 $250.7 
Payments(111.8)— (111.8)
Reclassifications58.1 (58.1)— 
Accretion— 11.6 11.6 
Fair value loss (3)
33.8 39.3 73.1 
Balance at December 31, 2020$100.5 $123.1 $223.6 
Payments(83.2)— (83.2)
Reclassifications49.4 (49.4)— 
Accretion— 9.0 9.0 
Fair value loss (3)
— 50.3 50.3 
Balance at December 31, 2021$66.7 $133.0 $199.7 
____________
(1)Included in other current liabilities in the consolidated balance sheets.
(2)Included in other long-term obligations in the consolidated balance sheets.
(3)Included in litigation settlements and other contingencies, net in the consolidated statements of operations.
The Company expects to incur approximately $6 million to $8 million of non-cash accretion expense related to the increase in the net present value of the contingent consideration liabilities in 2022.
Although the Company has not elected the fair value option for financial assets and liabilities, any future transacted financial asset or liability will be evaluated for the fair value election.
Available-for-Sale Securities
The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows:
(In millions)CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
December 31, 2021
Debt securities$38.1 $0.1 $— $38.2 
$38.1 $0.1 $— $38.2 
December 31, 2020
Debt securities$37.5 $1.6 $— $39.1 
$37.5 $1.6 $— $39.1 
Maturities of available-for-sale debt securities at fair value as of December 31, 2021, were as follows:
(In millions) 
Mature within one year$1.2 
Mature in one to five years19.7 
Mature in five years and later17.3 
$38.2 
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Comprehensive Earnings
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Comprehensive Earnings Comprehensive (Loss) Earnings
Accumulated other comprehensive loss, as reflected in the consolidated balance sheets, is comprised of the following:
(In millions)December 31, 2021December 31, 2020
Accumulated other comprehensive loss:
Net unrealized gain on marketable securities, net of tax$— $1.2 
Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax32.2 (26.1)
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax9.2 (18.0)
Net unrecognized loss on derivatives in net investment hedging relationships, net of tax16.7 (353.6)
Foreign currency translation adjustment(1,802.4)(461.5)
$(1,744.3)$(858.0)
Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following:
Year Ended December 31, 2021
Gains and Losses on Derivatives in Cash Flow Hedging RelationshipsGains and Losses on Net Investment HedgesGains and Losses on Marketable SecuritiesDefined Pension Plan ItemsForeign Currency Translation AdjustmentTotals
(In millions)Foreign Currency Forward ContractsInterest Rate SwapsTotal
Balance at December 31, 2020, net of tax$(18.0)$(353.6)$1.2 $(26.1)$(461.5)$(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax62.7 456.8 (1.1)67.0 (1,340.9)(755.5)
Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales(30.9)(30.9)(30.9)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense4.3 4.3 4.3 
Amortization of prior service costs included in SG&A (0.5)(0.5)
Amortization of actuarial loss included in SG&A 7.4 7.4 
Net other comprehensive earnings (loss), before tax36.1 456.8 (1.1)73.9 (1,340.9)(775.2)
Income tax provision8.9 86.5 0.1 15.6 — 111.1 
Balance at December 31, 2021, net of tax$9.2 $16.7 $— $32.2 $(1,802.4)$(1,744.3)
Year Ended December 31, 2020
Gains and Losses on Derivatives in Cash Flow Hedging RelationshipsGains and Losses on Net Investment HedgesGains and Losses on Marketable SecuritiesDefined Pension Plan ItemsForeign Currency Translation AdjustmentTotals
(In millions)Foreign Currency Forward ContractsInterest Rate SwapsTotal
Balance at December 31, 2019, net of tax$(31.6)$(74.3)$0.6 $(17.4)$(1,674.5)$(1,797.2)
Other comprehensive (loss) earnings before reclassifications, before tax18.5 (305.2)0.6 (12.1)1,213.0 914.8 
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales(4.8)(4.8)(4.8)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense4.5 4.5 4.5 
Amortization of prior service costs included in SG&A — — 
Amortization of actuarial loss included in SG&A (1.9)(1.9)
Net other comprehensive (loss) earnings, before tax18.2 (305.2)0.6 (14.0)1,213.0 912.6 
Income tax provision (benefit)4.6 (25.9)— (5.3)— (26.6)
Balance at December 31, 2020, net of tax$(18.0)$(353.6)$1.2 $(26.1)$(461.5)$(858.0)
Year Ended December 31, 2019
Gains and Losses on Derivatives in Cash Flow Hedging RelationshipsGains and Losses on Net Investment HedgesGains and Losses on Marketable SecuritiesDefined Pension Plan ItemsForeign Currency Translation AdjustmentTotals
(In millions)Foreign Currency Forward ContractsInterest Rate SwapsTotal
Balance at December 31, 2018, net of tax$(53.1)$(130.9)$— $1.7 $(1,259.0)$(1,441.3)
Other comprehensive earnings (loss) before reclassifications, before tax29.3 59.6 0.5 (21.0)(415.5)(347.1)
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales0.7 0.7 0.7 
Loss on interest rate swaps classified as cash flow hedges, included in interest expense7.1 7.1 7.1 
Amortization of prior service costs included in SG&A (0.9)(0.9)
Amortization of actuarial loss included in SG&A (2.9)(2.9)
Net other comprehensive earnings (loss), before tax37.1 59.6 0.5 (24.8)(415.5)(343.1)
Income tax provision (benefit) 12.2 3.0 (0.1)(5.9)— 9.2 
Cumulative effect of the adoption of new accounting standards(3.4)— — (0.2)— (3.6)
Balance at December 31, 2019, net of tax$(31.6)$(74.3)$0.6 $(17.4)$(1,674.5)$(1,797.2)
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The income tax provision (benefit) consisted of the following components:
 Year Ended December 31,
(In millions)202120202019
U.S. Federal:
Current$12.6 $(6.4)$118.1 
Deferred(182.7)(277.0)(165.5)
(170.1)(283.4)(47.4)
U.S. State:
Current7.7 (0.1)21.1 
Deferred(10.8)7.7 (13.6)
(3.1)7.6 7.5 
Non-U.S.:
Current(91.3)168.7 191.0 
Deferred869.2 55.8 (13.5)
777.9 224.5 177.5 
Income tax provision (benefit)$604.7 $(51.3)$137.6 
Earnings before income taxes:
United States(1,982.5)(945.5)(1,031.4)
Foreign - Other1,318.1 224.3 1,185.8 
Total (loss) earnings before income taxes$(664.4)$(721.2)$154.4 
For all periods presented, the allocation of earnings before income taxes between U.S. and non-U.S. operations includes intercompany interest allocations between certain domestic and foreign subsidiaries. These amounts are eliminated on a consolidated basis.
Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows:
(In millions)December 31, 2021December 31, 2020
Deferred tax assets:
Employee benefits$271.3 $273.0 
Litigation reserves94.4 43.5 
Accounts receivable allowances425.9 393.7 
Inventory187.8 1,187.9 
Tax credit and loss carry-forwards1,256.0 1,080.4 
Operating lease assets63.6 66.5 
Interest expense111.6 67.9 
Intangible assets 151.1 156.3 
Other 327.8 396.0 
2,889.5 3,665.2 
Less: Valuation allowance(780.4)(443.6)
Total deferred tax assets2,109.1 3,221.6 
Deferred tax liabilities:
Plant and equipment19.6 50.2 
Operating lease liabilities63.6 66.5 
Intangible assets and goodwill3,468.3 4,058.6 
Other39.9 22.1 
Total deferred tax liabilities3,591.4 4,197.4 
Deferred tax liabilities, net$(1,482.3)$(975.8)
For those foreign subsidiaries whose investments are permanent in duration, income and foreign withholding taxes have not been provided on the unremitted earnings of those subsidiaries. This amount may become taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. The amount of such unremitted earnings is approximately $3.4 billion at December 31, 2021. Determination of the amount of any unrecognized deferred income tax liability on these unremitted earnings is not practicable as such determination involves material uncertainties about the potential extent and timing of any distributions, the availability and complexity of calculating foreign tax credits, and the potential indirect tax consequences of such distributions, including withholding taxes.
Prior to the Combination, the applicable income tax rate to Mylan was the U.K. rate of 19%, and following the Combination, the statutory income tax rate applicable to Viatris Inc. is the U.S. rate of 21% for the years ended December 31, 2021 and 2020. A reconciliation of the statutory tax rate to the effective tax rate is as follows:
 Year Ended December 31,
 202120202019
Statutory tax rate21.0 %21.0 %19.0 %
United States Operations
Clean energy and research credits9.8 %12.8 %(43.4)%
U.S. rate differentials— %— %(3.1)%
Impact of changes in legislation— %(9.2)%— %
State income taxes and credits(0.6)%(1.6)%(4.1)%
Valuation allowance(0.1)%8.6 %(118.5)%
Tax settlements and resolution of certain tax positions0.1 %0.1 %199.6 %
Incremental US Tax on Foreign Earnings(36.9)%(3.6)%(8.6)%
Waived deductions under IRC § 59A— %(3.3)%64.5 %
Impact of the Combination and Divestitures(2.8)%5.8 %7.7 %
Other U.S. items(6.1)%1.5 %6.9 %
Other Foreign Operations
Luxembourg(6.7)%(5.0)%(14.8)%
Gibraltar9.4 %8.0 %(38.8)%
Ireland5.8 %8.2 %(13.7)%
France(1.1)%(2.8)%15.2 %
Puerto Rico4.4 %(2.5)%— %
Switzerland1.0 %2.0 %— %
Singapore28.8 %1.0 %— %
Other(10.2)%(0.4)%12.8 %
Deferred tax impact of tax law changes7.0 %(0.1)%36.7 %
Valuation allowance(8.3)%16.1 %(9.9)%
Impact of the Combination and divestitures(106.9)%(42.2)%— %
Withholding taxes(1.3)%(1.6)%7.1 %
Tax settlements and resolution of certain tax positions0.8 %(3.9)%(27.6)%
Other foreign items1.9 %(1.8)%2.1 %
Effective tax rate(91.0)%7.1 %89.1 %
In all years, our effective tax rate is impacted by the jurisdictional location of earnings and the corresponding tax rates in those jurisdictions. Subsequent to the Combination, the Company realizes benefits from lower tax rates in Singapore and Puerto Rico due to manufacturing and other incentives..
Tax Act
On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act makes broad and complex changes to the Code including, but not limited to, reducing the U.S. federal corporate income tax rate and requiring a one-time transition tax on certain unrepatriated earnings of non-U.S. corporate subsidiaries of large U.S. shareholders that may electively be paid over eight years.
The Tax Act also puts in place new tax laws that impact our taxable income beginning in 2018, which include, but are not limited to (1) creating a BEAT, which is a new minimum tax, (2) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries, (3) a new provision designed to tax currently GILTI earned by non-U.S. corporate subsidiaries of large U.S. shareholders and a deduction generally equal to 50 percent of GILTI (37.5 percent for tax years beginning after December 31, 2025) to offset the income tax liability, (4) a provision limiting the amount of deductible interest expense in the U.S., (5) limitations on the deductibility of certain executive compensation, and (6) limitations on the utilization of foreign tax credits to reduce the U.S. income tax liability.
As of December 31, 2021, no U.S. deferred income taxes or foreign withholding taxes were recorded on earnings in the Company’s non-U.S. subsidiaries where there would be no U.S. or foreign tax upon repatriation or where the Company’s practice and intention was to reinvest the earnings outside of the U.S. The transition tax noted above resulted in the previously untaxed foreign earnings of U.S. subsidiaries being included in federal and state taxable income. We analyze on an ongoing basis our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries repatriate cash, which include potential local country withholding taxes and U.S. state taxation. The Company has elected to not record deferred taxes associated with the GILTI provision of the Tax Act.
Valuation Allowance
A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2021, a valuation allowance has been applied to certain deferred tax assets in the amount of $780.4 million.
When assessing the realizability of deferred tax assets, management considers all available evidence, including historical information, long-term forecasts of future taxable income and possible tax planning strategies. Amounts recorded for valuation allowances can result from a complex series of estimates, assumptions and judgments about future events. Due to the inherent uncertainty involved in making these estimates, assumptions and judgments, actual results could differ materially. Any future increases to the Company’s valuation allowances could materially impact the Company’s consolidated financial condition and results of operations.
Net Operating Losses
As of December 31, 2021, the Company had the following carryforwards and attributes:
U.S. federal net operating loss carryforwards of $7.9 million.
U.S. state income tax loss carryforwards of approximately $3.10 billion, which are largely offset by a valuation allowance.
Non-U.S. net operating loss carryforwards of approximately $1.57 billion, of which $748.4 million can be carried forward indefinitely, with the remaining $817.8 million expiring in years 2022 through 2041.
Foreign deductible attributes of $39.6 million that can be carried forward indefinitely, which are offset by a full valuation allowance.
U.S. and foreign credit carryovers of $329.2 million, expiring in various amounts through 2041.
Anticipatory foreign tax credits of $230.3 million which will generate from the reversal of future taxable income in certain non-U.S. jurisdictions which are taxed both in their local jurisdictions and in the U.S.
On November 16, 2020, the Company had a change in ownership pursuant to Section 382 of the Code. Under this provision of the Code, the utilization of any NOL or tax credit carryforwards incurred prior to the date of ownership change may be limited. Analyses of the limits for each ownership change indicates the annual limitation would not impair the Company's ability to utilize our U.S. federal credit carryovers. While state loss carryforwards may be limited by Section 382 of the Code, the carryforwards are largely offset by a valuation allowance.
CARES Act
On March 27, 2020, the CARES Act was enacted and signed into law. The CARES Act includes several provisions, including increasing the amount of deductible interest, allowing companies to carryback certain NOLs, and increasing the amount of NOLs that corporations can use to offset income.During the year ended December 31, 2020, the CARES Act reduced the Company’s 2020 income tax expense by $22.1 million resulting from additional deductible interest.
Tax Examinations
The Company is subject to income taxes and tax audits in many jurisdictions. A certain degree of estimation is thus required in recording the assets and liabilities related to income taxes. Tax audits and examinations can involve complex issues, interpretations, and judgments and the resolution of matters that may span multiple years, particularly if subject to litigation or negotiation.
Although the Company believes that adequate provisions have been made for these uncertain tax positions, the Company’s assessment of uncertain tax positions, including those arising from legal entity restructuring transactions in connection with the Combination, is based on estimates and assumptions that the Company believes are reasonable but the estimates for unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variations from such estimates could materially affect the Company’s financial condition, results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire.
The Company is subject to ongoing IRS examinations. The years 2015 through 2018 are open years under examination. The years 2012, 2013 and 2014 have one matter open, and a Tax Court petition was filed regarding the matter and a trial was held in December 2018 and is discussed further below.
During the year ended December 31, 2019, Mylan reached an agreement in principle with the IRS to resolve all issues relating to our positions on the February 27, 2015 acquisition by Mylan N.V. of Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business. Under the agreement in principle, which was finalized as part of a closing agreement with the IRS on October 11, 2019, Mylan’s status as a non-U.S. corporation for U.S. Federal income tax purposes was confirmed, and we have adjusted the interest rates used for intercompany loans as necessary. During the year ended December 31, 2019, the Company recorded a reserve of approximately $155.0 million as part of its liability for uncertain tax positions, with a net impact to the income tax provision of approximately $144.9 million related to this matter.
Several international audits are currently in progress. In some cases, the tax auditors have proposed adjustments or issued assessments to our tax positions, including with respect to intercompany transactions, and we are in ongoing discussions with some of the auditors regarding the validity of their positions.
In instances where assessments have been issued, we disagree with these assessments and believe they are without merit and incorrect as a matter of law. As a result, we anticipate that certain of these matters may become the subject of litigation before tax courts where we intend to vigorously defend our position.
In Australia, the tax authorities have issued notices of assessments to the Company for the years ended December 2009 to December 2019, subject to additional interest and penalties, concerning our tax position with respect to certain intercompany transactions. The tax authorities denied our objections to the assessments and we have commenced litigation in the Australian Federal Court challenging that decision. During 2021, the Company made a partial payment of $56.0 million in order to stay potential interest and penalties resulting from this litigation.
In France, the tax authorities have issued notices of assessments to the Company for the years ended December 2013 to December 2016 concerning our tax position with respect to (i) certain intercompany transactions and (ii) whether income earned by a Company entity not domiciled in France should be subject to French tax. We have resolved our position concerning certain intercompany transactions with the tax authorities. Concerning the remaining issue, we have commenced litigation before the French tax courts where the tax authorities will seek unpaid taxes, penalties, and interest.
In India, the tax authorities have issued notices of assessments to the Company seeking unpaid taxes and interest for the financial years covering 2013 to 2018 concerning our tax position with respect to certain corporate tax deductions and certain intercompany transactions. Some of these assessments remain in the audit phase where we are challenging them before the tax authorities while we are challenging some of the other assessments in the Indian tax courts.
The Company has recorded a net reserve for uncertain tax positions of $315.6 million, including interest and penalties, in connection with its international audits at December 31, 2021. The reserve balance at December 31, 2021 reflects the impact of current year settlement payments. In connection with our international tax audits, it is possible that we will incur material losses above the amounts reserved.
The Company’s major U.S. state taxing jurisdictions remain open from fiscal year 2013 through 2020, with several state audits currently in progress. The Company’s major international taxing jurisdictions remain open from 2012 through 2020.
Tax Court Proceedings     
The Company's U.S. federal income tax returns for 2012 through 2014 had been subject to proceedings in U.S. Tax Court involving a dispute with the IRS regarding whether certain costs related to ANDAs were eligible to be expensed and deducted immediately or required to be amortized over longer periods. A trial was held in U.S. Tax Court in December 2018 and on April 27, 2021, the Court affirmed Mylan’s position and held that patent litigation expenses related to ANDAs are immediately deductible. The IRS has appealed this decision.
Accounting for Uncertainty in Income Taxes
The impact of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of an uncertain tax position will be recognized if the position has less than a 50% likelihood of being sustained.
As of December 31, 2021 and 2020, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $322.9 million and $391.1 million, respectively, of which $230.2 million as of December 31, 2021 would affect the Company’s effective tax rate if recognized, with the remainder being offset by potential correlative adjustments. Related accrued interest and penalties included in the consolidated balance sheets were $96.8 million and $86.7 million as of December 31, 2021 and 2020, respectively. For the years ended December 31, 2021, 2020 and 2019, the Company recognized $18.5 million of tax expense, $6.0 million, and $35.2 million of tax benefits, respectively, related to interest and penalties on uncertain tax positions. Interest and penalties related to income taxes are included in the tax provision.

A reconciliation of the unrecognized tax benefits is as follows:
Year Ended December 31,
(In millions)202120202019
Unrecognized tax benefit — beginning of year$391.1 $92.1 $96.3 
Additions for current year tax positions— 13.4 — 
Additions for prior year tax positions— 35.7 154.9 
Reductions for prior year tax positions(9.1)(5.2)(11.7)
Settlements(47.3)(8.9)(112.5)
Reductions due to expirations of statute of limitations(7.0)— (34.9)
(Reduction) addition due to acquisition(4.8)264.0 — 
Unrecognized tax benefit — end of year$322.9 $391.1 $92.1 
The Company believes that it is reasonably possible that the amount of unrecognized tax benefits will decrease in the next twelve months by approximately $55.0 million, involving international and state audits and settlements and expiring statutes of limitations. The Company does not anticipate significant increases to the reserve within the next twelve months.
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-Based Incentive Plan
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Share-Based Incentive Plan Share-Based Incentive Plan
Prior to the Distribution, Viatris adopted and Pfizer, in the capacity as Viatris’ sole stockholder at such time, approved the Plan (the Viatris Inc. 2020 Stock Incentive Plan) which became effective as of the Distribution. In connection with the Combination, as of November 16, 2020, the Company assumed the 2003 LTIP (Mylan N.V. Amended and Restated 2003 Long-Term Incentive Plan), which had previously been approved by Mylan shareholders. The Plan and 2003 LTIP include (i) 72,500,000 shares of Common Stock authorized for grant pursuant to the Plan, which may include dividend payments payable in Common Stock on unvested shares granted under awards, (ii) 6,757,640 shares of Common Stock to be issued pursuant to the exercise of outstanding stock options granted to participants under the 2003 LTIP and assumed by Viatris in connection with the Combination and (iii) 13,535,627 shares of Common Stock subject to outstanding equity-based awards, other than stock options, assumed by Viatris in connection with the Combination, or that otherwise remain available for issuance under the 2003 LTIP.
Under the Plan and 2003 LTIP, shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, SARs, restricted stock and units, PSUs, other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the shares underlying the stock options at the date of the grant, generally become exercisable over periods ranging from three to four years, and generally expire in ten years.
The following table summarizes stock awards (stock options and SARs) activity under the Plan and 2003 LTIP:
Number of Shares
Under Stock Awards
Weighted
Average
Exercise Price
per Share
Outstanding at December 31, 20186,815,278 $36.61 
Granted829,322 26.18 
Exercised(580,950)14.40 
Forfeited(715,941)39.40 
Outstanding at December 31, 20196,347,709 $36.97 
Granted814,351 17.37 
Exercised(27,615)21.13 
Forfeited(422,714)25.74 
Outstanding at December 31, 20206,711,731 $35.36 
Forfeited(1,135,241)26.39 
Outstanding at December 31, 20215,576,490 $37.19 
Vested and expected to vest at December 31, 20215,487,788 $37.45 
Exercisable at December 31, 20214,969,602 $39.21 
As of December 31, 2021, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had average remaining contractual terms of 4.6 years, 4.6 years and 4.2 years, respectively. Also, at December 31, 2021, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had no aggregate intrinsic value.
A summary of the status of the Company’s nonvested restricted stock awards (restricted stock and restricted stock unit awards, including PSUs), as of December 31, 2020 and the changes during the year ended December 31, 2021 are presented below:
Number of Restricted
Stock Awards
Weighted Average
Grant-Date
Fair Value Per Share
Nonvested at December 31, 202012,073,790 $18.34 
Granted9,850,443 14.46 
Released(3,168,152)24.65 
Forfeited(1,897,953)15.33 
Nonvested at December 31, 202116,858,128 $15.12 
Of the 9,850,443 restricted stock awards granted during the year ended December 31, 2021, 6,057,602 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining restricted stock awards granted, 587,025 are not subject to market conditions and will cliff vest within a three-year period, and 3,205,816 are subject to market or performance conditions and will cliff vest in three years or less.
As of December 31, 2021, the Company had $143.1 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 1.7 years. The total intrinsic value of stock awards exercised and restricted stock units released during the years ended December 31, 2021 and 2020 was $78.1 million and $20.9 million, respectively.
With respect to options granted under the Plan and 2003 LTIP, the fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield and employee exercise behavior. Expected volatilities utilized in the model are based mainly on the implied volatility of the Company’s stock price and other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The model incorporates exercise and post-vesting forfeiture assumptions based on an analysis of historical data. The expected lives of the grants are derived from historical and other factors.
There were no options granted during the year ended December 31, 2021. The assumptions used for options granted under the Plan and 2003 LTIP during the years ended December 31, 2020 and 2019, respectively, are as follows:
Year Ended December 31,
20202019
Volatility46.7%38.1%
Risk-free interest rate1.0%2.5%
Expected term (years)6.56.5
Forfeiture rate 5.5%5.5%
Weighted average grant date fair value per option$8.07$11.03
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans
12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
Employee Benefits Employee Benefit Plans
Defined Benefit Plans
The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. Employees in the U.S., Puerto Rico and certain international locations are also provided retirement benefits through defined contribution plans.
The Company also sponsors other postretirement benefit plans including plans that provide for postretirement supplemental medical coverage. Benefits from these plans are provided to employees and their spouses and dependents who meet various minimum age and service requirements. In addition, the Company sponsors other plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees.
In connection with the Combination, the Company assumed certain post retirement defined benefit pension plans sponsored by Upjohn. The most significant plans include those in Puerto Rico, Ireland and Japan. Upjohn is also the sponsor of one postretirement medical plan in Puerto Rico. As part of the acquisition accounting, the Company has recorded the fair value of these plans. Upon completion of the Combination, the excess of projected benefit obligation over the plan assets was recognized as a liability and any existing unrecognized actuarial gains or losses and unrecognized service costs or benefits were eliminated in purchase accounting.

Accounting for Defined Benefit Pension and Other Postretirement Plans
The Company recognizes on its balance sheet an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension and other postretirement plan. Actuarial gains or losses and prior service costs or credits that arise during the period are not recognized as components of net periodic benefit cost, but are recognized, net of tax, as a component of other comprehensive (loss) earnings.
Included in accumulated other comprehensive loss as of December 31, 2021 and 2020 are:
Pension BenefitsOther Postretirement Benefits
December 31,December 31,
(In millions)2021202020212020
Unrecognized actuarial (gain) loss$(59.9)$33.9 $21.7 $5.7 
Unrecognized prior service cost (credit)6.6 (1.4)(3.7)0.6 
Total$(53.3)$32.5 $18.0 $6.3 
The unrecognized net actuarial losses exceeded 10% of the higher of the market value of plan assets or the projected benefit obligation at the beginning of the year for certain of the plans, therefore, amortization of such excess has been included in net periodic benefit costs for pension and other postretirement benefits in each of the last three years. The amortization period is the average remaining service period that active employees are expected to receive benefits, unless a plan is mostly inactive in which case the amortization period is the average remaining life expectancy of the plan participants. Unrecognized prior service cost is amortized over the future service periods of those employees who are active at the dates of the plan amendments and who are expected to receive benefits. If all or almost all of a plan's participants are inactive, unrecognized prior service cost is amortized over the remaining life expectancy of those participants. The increase in accumulated other comprehensive loss in 2021 relating to pension benefits and other postretirement benefits consists of:
(In millions)Pension BenefitsOther Postretirement Benefits
Unrecognized actuarial (gain) loss$(102.2)$16.2 
Amortization of actuarial gain/(loss)7.6 (0.2)
Unrecognized prior service credit (cost)8.0 (4.3)
Amortization of prior service costs(0.5)— 
Impact of foreign currency translation1.3 — 
Net change$(85.8)$11.7 
Components of net periodic benefit cost, change in projected benefit obligation, change in plan assets, funded status, fair value of plan assets, assumptions used to determine net periodic benefit cost, funding policy and estimated future benefit payments are summarized below for the Company’s pension plans and other postretirement plans.
Net Periodic Benefit Cost
Components of net periodic benefit cost for the years ended December 31, 2021, 2020 and 2019 were as follows:
Pension BenefitsOther Postretirement Benefits
December 31,December 31,
(In millions)202120202019202120202019
Service cost$38.6 $23.5 $20.7 $3.4 $1.2 $0.6 
Interest cost31.6 13.5 13.6 2.6 1.4 1.5 
Expected return on plan assets(66.1)(19.9)(12.1)— — — 
Plan curtailment, settlement and termination(16.5)1.1 (0.3)— — 3.2 
Amortization of prior service costs0.9 — 0.9 — — — 
Recognized net actuarial losses (gains) 1.3 0.4 (0.8)0.2 0.3 0.2 
Net periodic benefit cost$(10.2)$18.6 $22.0 $6.2 $2.9 $5.5 
During the year ended December 31, 2021, the Company recognized a settlement gain as a result of cash payments from lump sum elections related to the U.S. and Puerto Rico pension plans.
Change in Projected Benefit Obligation, Change in Plan Assets and Funded Status
The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2021 and 2020.
Pension BenefitsOther Postretirement Benefits
(In millions)2021202020212020
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year$2,145.8 $674.7 $188.8 $33.8 
Service cost38.6 23.5 3.4 1.1 
Interest cost31.6 13.5 2.6 1.4 
Participant contributions2.0 1.8 2.4 0.1 
Acquisitions4.0 1,389.4 — 153.1 
Plan settlements and terminations(128.6)(23.1)(4.3)(0.2)
Actuarial (gains) losses (26.1)37.2 16.2 1.1 
Benefits paid(52.8)(24.6)(20.7)(1.6)
Impact of foreign currency translation(67.9)53.4 — — 
Projected benefit obligation, end of year$1,946.6 $2,145.8 $188.4 $188.8 
Change in Plan Assets
Fair value of plan assets, beginning of year$1,354.6 $315.7 $— $— 
Actual return on plan assets141.7 46.0 — — 
Company contributions97.0 58.2 18.3 1.7 
Participant contributions2.0 1.8 2.4 0.1 
Acquisitions(2.1)959.3 — — 
Plan settlements(128.9)(23.1)— (0.2)
Benefits paid(52.8)(24.6)(20.7)(1.6)
Impact of foreign currency translation(45.1)21.3 — — 
Fair value of plan assets, end of year1,366.4 1,354.6 — — 
Funded status of plans$(580.2)$(791.2)$(188.4)$(188.8)
Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheets at December 31, 2021 and 2020:
Pension BenefitsOther Postretirement Benefits
December 31,December 31,
(In millions)2021202020212020
Noncurrent assets$117.2 $70.7 $— $— 
Current liabilities(14.6)(15.1)(16.1)(16.3)
Noncurrent liabilities(682.8)(846.8)(172.3)(172.5)
Net accrued benefit costs$(580.2)$(791.2)$(188.4)$(188.8)
The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, but does not include the effects of estimated future pay increases. The accumulated benefit obligation for the Company’s pension plans was $1.86 billion and $2.04 billion at December 31, 2021 and 2020, respectively.
The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of the fair value of plan assets at December 31, 2021 and 2020 were as follows:
December 31,
(In millions)20212020
Plans with accumulated benefit obligation in excess of plan assets:
Projected benefit obligation$1,591.8 $1,747.2 
Accumulated benefit obligation1,546.4 1,678.2 
Fair value of plan assets904.1 893.9 
Fair Value of Plan Assets
The Company measures the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy described in Note 9 Financial Instruments and Risk Management. The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:
December 31, 2021
(In millions)Level 1Level 2Level 3Total
Cash and cash equivalents$63.1 $1.9 $— $65.0 
Equity securities53.9 497.2 — 551.1 
Fixed income securities211.4 405.5 — 616.9 
Assets held by insurance companies and other10.2 41.6 81.6 133.4 
Total$338.6 $946.2 $81.6 $1,366.4 
December 31, 2020
(In millions)Level 1Level 2Level 3Total
Cash and cash equivalents$51.2 $0.6 $— $51.8 
Equity securities145.3 468.1 — 613.4 
Fixed income securities292.6 299.4 — 592.0 
Assets held by insurance companies and other4.0 20.0 73.4 97.4 
Total$493.1 $788.1 $73.4 $1,354.6 
Risk tolerance on invested pension plan assets is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Investment risk is measured and monitored on an ongoing basis through annual liability measures, periodic asset/liability studies and investment portfolio reviews. The Company’s investment strategy is to maintain, where possible, a diversified investment portfolio across several asset classes that, when combined with the Company’s contributions to the plans, will ensure that required benefit obligations are met.
Assumptions
The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2021 and 2020:
Pension BenefitsOther Postretirement Benefits
2021202020212020
Discount rate2.3 %1.9 %2.5 %1.9 %
Expected return on plan assets5.1 %4.3 %— %— %
Rate of compensation increase3.1 %2.9 %— %— %
The following weighted average assumptions were used to determine the net periodic benefit cost for the Company’s defined benefit pension and other postretirement benefit plans for the three years in the period ended December 31, 2021:
Pension BenefitsOther Postretirement Benefits
202120202019202120202019
Discount rate1.9 %1.6 %2.3 %1.9 %3.3 %4.3 %
Expected return on plan assets5.1 %4.3 %4.3 %— %— %— %
Rate of compensation increase2.9 %2.7 %2.9 %— %— %— %
The assumptions for each plan are reviewed on an annual basis. The discount rate reflects the current rate at which the pension and other benefit liabilities could be effectively settled at the measurement date. In setting the discount rates, we utilize comparable corporate bond indices as an indication of interest rate movements and levels. Corporate bond indices were selected based on individual plan census data and duration. The expected return on plan assets was determined using historical market returns and long-term historical relationships between equities and fixed income securities. The Company compares the expected return on plan assets assumption to actual historic returns to ensure reasonableness. Current market factors such as inflation and interest rates are also evaluated.
The weighted-average healthcare cost trend rate used for 2021 was 5.7% declining to a projected 4.5% in the year 2037. For 2022, the assumed weighted-average healthcare cost trend rate used will be 6.3% declining to a projected 4.0% in the year 2045. In selecting rates for current and long-term healthcare cost assumptions, the Company takes into consideration a number of factors including the Company’s actual healthcare cost increases, the design of the Company’s benefit programs, the demographics of the Company’s active and retiree populations and external expectations of future medical cost inflation rates.
Estimated Future Benefit Payments
The Company’s funding policy for its funded pension plans is based upon local statutory requirements. The Company’s funding policy is subject to certain statutory regulations with respect to annual minimum and maximum company contributions. Plan benefits for the non-qualified plans are paid as they come due.
Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows:
(In millions)Pension BenefitsOther Postretirement Benefits
2022$101.8 $16.1 
202397.1 16.5 
2024103.0 16.9 
2025100.7 16.8 
2026104.3 16.6 
Thereafter528.5 73.0 
Total$1,035.4 $155.9 
Defined Contribution Plans
The Company sponsors defined contribution plans covering its employees in the U.S. and Puerto Rico, as well as certain employees in a number of countries outside the U.S. The Company’s domestic defined contribution plans consist primarily of a Profit Sharing 401(k) Plan and a 401(k) retirement plan for union-represented employees. Profit sharing contributions are made at the discretion of the Board of Directors. The Company’s non-domestic plans vary in form depending on local legal requirements. The Company’s contributions are based upon employee contributions, service hours, or pre-determined amounts depending upon the plan. Obligations for contributions to defined contribution plans are recognized as expense in the consolidated statements of operations when they are earned.
The Company maintains a 401(k) Restoration Plan, which permits employees who earn compensation in excess of the limits imposed by Section 401(a)(17) of the Code to (i) defer a portion of base salary and bonus compensation, (ii) be credited with a Company matching contribution in respect of deferrals under the Restoration Plan, and (iii) be credited with Company non-elective contributions (to the extent so made by the Company), in each case, to the extent that participants otherwise would be able to defer or be credited with such amounts, as applicable, under the Profit Sharing 401(k) Plan if not for the limits on contributions and deferrals imposed by the Code.
The Company maintains an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50% of base salary and up to 100% of bonus compensation, in each case, in addition to any amounts that may be deferred by such participants under the Profit Sharing 401(k) Plan and the Restoration Plan. In addition, under the Income Deferral Plan, eligible participants may be granted employee deferral awards, which awards will be subject to the terms and conditions (including vesting) as determined by the plan administrator at the time such awards are granted.
Total employer contributions to defined contribution plans were approximately $107.4 million, $115.5 million and $95.6 million for the years ended December 31, 2021, 2020 and 2019, respectively.
Other Benefit Arrangements
The Company participated in a multi-employer pension plan under previous collective bargaining agreements. The PACE Industry Union-Management Pension Fund (the “PACE Plan”) provides defined benefits to certain retirees and certain production and maintenance employees at the Company’s manufacturing plant in Morgantown, West Virginia who were covered by the previous collective bargaining agreements. Pursuant to a collective bargaining agreement entered into on April 16, 2012, the Company withdrew from the PACE Plan effective May 10, 2012. In 2013, the PACE Plan trustee notified the Company that its withdrawal liability was approximately $27.3 million, which was accrued by the Company in 2013. The withdrawal liability is being paid over a period of approximately nine years; payments began in March 2014. The withdrawal liability was approximately $5.5 million and $8.9 million at December 31, 2021 and 2020, respectively. The Employer Identification Number for the PACE Plan is 11-6166763.
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information
12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment Information ment Information
Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics and biosimilars, and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise.

The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability.
Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following:
Intangible asset amortization expense and impairments of intangible assets;
R&D expense;
Net charges or net gains for litigation settlements and other contingencies;
Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.
Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs.
The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker.
The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies.
Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.
Net Sales
Segment Profitability
Years Ended December 31, Years Ended December 31,
(in millions)202120202019202120202019
Reportable Segments:
Developed Markets$10,428.7 $8,510.9 $8,240.0 $5,143.1 $4,243.9 $4,137.3 
Greater China2,212.8 259.9 214.6 1,397.1 52.7 89.9 
JANZ2,027.4 1,195.3 1,192.5 762.4 364.6 323.2 
Emerging Markets3,144.7 1,853.8 1,723.2 1,402.4 610.4 561.9 
Total reportable segments$17,813.6 $11,819.9 $11,370.3 $8,705.0 $5,271.6 $5,112.3 
Reconciling items:
Intangible asset amortization expense(2,702.2)(1,605.8)(1,582.7)
Intangible asset impairment charges(102.8)(82.4)(180.6)
Globally managed research and development costs(751.1)(555.1)(639.9)
Litigation settlements & other contingencies(329.2)(107.8)21.4 
Transaction related and other special items(2,832.2)(1,739.7)(682.2)
Corporate and other unallocated(2,021.5)(1,391.6)(1,332.8)
(Loss) earnings from operations$(34.0)$(210.8)$715.5 

The following table represents the percentage of consolidated net sales to Viatris’ major customers during the years ended December 31, 2021, 2020, and 2019:
Percentage of Consolidated Net Sales
202120202019
McKesson Corporation%13 %15 %
AmerisourceBergen Corporation%10 %%
Cardinal Health, Inc.%%%
Sales by Country Information
Net sales by country are presented on the basis of geographic location of our subsidiaries:
Year Ended December 31,
(In millions)202120202019
United States$4,176.4 $3,746.1 $3,965.9 
China1,981.5 216.1 171.1 
____________
No other country’s net sales represents more than 10% of consolidated net sales.
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restructuring
12 Months Ended
Dec. 31, 2021
Restructuring and Related Activities [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] Restructuring
2020 Restructuring Program
During the fourth quarter of 2020, Viatris announced a significant global restructuring program in order to achieve synergies and ensure that the organization is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders. Viatris’ restructuring initiative incorporates and expands on the restructuring program announced by Mylan N.V. earlier in 2020 as part of its business transformation efforts. As part of the restructuring, the Company is optimizing its commercial capabilities and enabling functions, and closing, downsizing or divesting certain manufacturing facilities globally that are deemed to be no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex products.
For the committed restructuring actions, the Company expects to incur total pre-tax charges of up to approximately $1.4 billion. Such charges are expected to include up to approximately $450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including inventory write-offs. The remaining estimated cash costs of up to approximately $950 million are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations and other plant disposal costs. In addition, management believes the potential annual savings related to these committed restructuring activities to be up to approximately $900 million once fully implemented, with most of these savings expected to improve operating cash flow.
The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program:
(In millions)Employee Related CostsOther Exit CostsTotal
Charges (2)
$195.6 $75.7 $271.3 
Acquired in the Combination91.7 0.3 92.0 
Cash payment(25.1)(0.4)(25.5)
Utilization— (70.8)(70.8)
Foreign currency translation0.4 — 0.4 
Balance at December 31, 2020$262.6 $4.8 $267.4 
Charges (1)
396.1 496.1 892.2 
Reimbursable restructuring charges26.4 — 26.4 
Cash payment(385.5)(151.7)(537.2)
Utilization— (345.0)(345.0)
Foreign currency translation(7.0)(0.1)(7.1)
Balance at December 31, 2021$292.6 $4.1 $296.7 

As part of the Combination, the Company acquired reserve balances related to restructuring activities initiated by the Upjohn Business prior to the Combination, primarily related to accrued severance.

2016 Restructuring Program
Mylan previously announced a restructuring program representing a series of actions in certain locations to further streamline its operations globally. We incurred total restructuring related costs of approximately $733.0 million through December 31, 2020. The 2016 Restructuring Program was substantially completed at December 31, 2020.
In April 2018, the FDA completed an inspection at Mylan’s plant in Morgantown, West Virginia and made observations through a Form 483. In the fourth quarter of 2018, Mylan received a warning letter related to the previously disclosed observations at the plant. The issues raised in the warning letter were addressed within the context of the Mylan’s comprehensive restructuring and remediation activities. On May 11, 2020, Mylan received the close-out of the warning letter. On December 11, 2020, the Company announced that it expects the Morgantown plant to be closed or divested as part of the 2020 Restructuring Program. The Morgantown plant was closed during the third quarter of 2021.

The following table summarizes the restructuring charges and the reserve activity for the 2016 restructuring program from December 31, 2018 to December 31, 2020:
(In millions)Employee Related CostsOther Exit CostsTotal
Balance at December 31, 2018:$60.8 $11.8 $72.6 
Charges (3)
16.6 88.0 $104.6 
Cash payment(48.9)(10.5)$(59.4)
Reclassifications— (8.1)$(8.1)
Utilization— (78.3)$(78.3)
Foreign currency translation(2.1)(0.1)$(2.2)
Balance at December 31, 2019:$26.4 $2.8 $29.2 
Charges (2)
9.9 40.6 50.5 
Cash payment(18.1)(7.6)(25.7)
Utilization— (32.9)(32.9)
Foreign currency translation$1.8 $(0.1)$1.7 
Balance at December 31, 2020:$20.0 $2.8 $22.8 
(1)     For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively.
(2)     For the year ended December 31, 2020, total restructuring charges, for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively.
(3)     For the year ended December 31, 2019, total restructuring charges for the 2016 Restructuring Program in Developed Markets and JANZ were approximately $100.4 million and $4.2 million, respectively.
At December 31, 2021 and 2020, accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities and other long-term obligations in the consolidated balance sheets.
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Valuation and Qualifying Accounts
12 Months Ended
Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
VIATRIS INC. AND SUBSIDIARIES
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
(In millions)
DescriptionBeginning
Balance
Additions Charged to Costs and Expenses
Additions Charged to Other
Accounts
(1)
DeductionsEnding
Balance
Allowance for doubtful accounts:
Year ended December 31, 2021$159.9 16.0 — (21.4)$154.5 
Year ended December 31, 2020$72.8 16.9 77.3 (7.1)$159.9 
Year ended December 31, 2019$98.2 14.2 — (39.6)$72.8 
Valuation allowance for deferred tax assets:
Year ended December 31, 2021$443.6 82.2 260.8 (6.2)$780.4 
Year ended December 31, 2020$603.5 39.0 — (198.9)$443.6 
Year ended December 31, 2019$806.0 36.8 — (239.3)$603.5 
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Principles of Consolidation Policy Principles of Consolidation. The consolidated financial statements include the accounts of Viatris and those of its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Investments in equity method affiliates are recorded at cost and adjusted for the Company’s share of the affiliates’ cumulative results of operations, capital contributions and distributions.
Use of Estimates in the Preparation of Financial Statements Policy Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates.
Foreign Currencies Policy Foreign Currencies. The consolidated financial statements are presented in U.S. Dollars, the reporting currency of Viatris. Statements of Operations and Cash Flows of all of the Company’s subsidiaries that have functional currencies other than U.S. Dollars are translated at a weighted average exchange rate for the period for inclusion in the consolidated statements of operations and cash flows, whereas assets and liabilities are translated at the end of the period exchange rates for inclusion in the consolidated balance sheets. Translation differences are recorded directly in shareholders’ equity as foreign currency translation adjustments. Gains or losses on transactions denominated in a currency other than the subsidiaries’ functional currency, which arise as a result of changes in foreign currency exchange rates, are recorded in the consolidated statements of operations.
Cash and Cash Equivalents Policy Cash and Cash Equivalents. Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.
Marketable Securities Policy Debt and Equity Securities. Debt securities classified as available-for-sale on the date of purchase are recorded at fair value, with net unrealized gains and losses, net of income taxes, reflected in accumulated other comprehensive loss as a component of shareholders’ equity. Net realized gains and losses on sales of available-for-sale debt securities are computed on a specific security basis and are included in other expense, net, in the consolidated statements of operations. Debt securities classified as trading securities are valued using the quoted market price from broker or dealer quotations or transparent pricing sources at the reporting date, with gains and losses included in other expense, net, in the consolidated statements of operations. Fair value is determined based on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit risk or underlying security and overall capital market liquidity. Debt securities are reviewed for impairment by assessing if the decline in market value of the investment below the carrying value is other than temporary.Investments in equity securities with readily determinable fair values are recorded at fair value with changes in fair value recorded in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Investments in entities are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The share of net income or losses of equity method investments are included in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values and investments in equity accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors.
Concentrations of Credit Risk Policy
Concentrations of Credit Risk. Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable.
Viatris invests its excess cash in high-quality, liquid money market instruments, principally overnight deposits and highly rated money market funds. The Company maintains deposit balances at certain financial institutions in excess of federally insured amounts. Periodically, the Company reviews the creditworthiness of its counterparties to derivative transactions, and it does not expect to incur a loss from failure of any counterparties to perform under agreements it has with such counterparties.
Inventories Policy Inventories. Inventories are stated at the lower of cost and net realizable value, with cost principally determined by the weighted average cost method. Provisions for potentially obsolete or slow-moving inventory, including pre-launch inventory, are made based on our analysis of product dating, inventory levels, historical obsolescence and future sales forecasts. Included as a component of cost of sales is expense related to the net realizable value of inventories.
Property, Plant and Equipment Policy Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed and recorded on a straight-line basis over the assets’ estimated service lives (3 to 18 years for machinery and equipment and other fixed assets and 15 to 39 years for buildings and improvements). Capitalized software is included in property, plant and equipment and is amortized over estimated useful lives ranging from 3 to 7 years.
Intangible Assets and Goodwill Policy
Intangible Assets and Goodwill. Intangible assets are stated at cost less accumulated amortization. Amortization is generally recorded on a straight-line basis over estimated useful lives ranging from 3 to 20 years. The Company periodically reviews the estimated useful lives of intangible assets and makes adjustments when events indicate that a shorter life is appropriate.
The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of ASC 805, Business Combinations, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective estimated fair values. The cost to acquire businesses is allocated to the underlying net assets of the acquired business based on estimates of their respective fair values. Amounts allocated to acquired IPR&D are capitalized at the date of acquisition and, at that time, such IPR&D assets have indefinite lives. As products in development are approved for sale, amounts are allocated to product rights and licenses and will be amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
Purchases of developed products and licenses that are accounted for as asset acquisitions are capitalized as intangible assets and amortized over an estimated useful life. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses.
The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management's assessment of the fair value of the Company's reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we choose to use qualitative factors and determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test would be required. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations.
Indefinite-lived intangibles, principally IPR&D, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value of IPR&D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested.
Contingent Consideration Policy
Contingent Consideration. Viatris records contingent consideration resulting from business acquisitions at its estimated fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as adjustments to litigation settlements and other contingencies, net within the consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, sales targets and profitability. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.
Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations.
Impairment of Long-Lived Assets Policy
Impairment of Long-Lived Assets. The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.
Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations.
Research and Development Policy Research and Development. R&D expenses are charged to operations as incurred.
Short-Term Borrowings Short-Term Borrowings. The Company’s subsidiaries in India have working capital facilities with several banks which are secured by its current assets. The Company also has the CP Notes, Receivables Facility, which will expire in April 2022 and the Note Securitization Facility, which will expire in August 2022. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. As the accounts receivable do not transfer to the banks, any amounts outstanding under the facilities are recorded as borrowings and the underlying receivables continue to be included in accounts receivable, net, in the consolidated balance sheets.
Revenue Recognition Policy
Revenue Recognition. The Company recognizes revenues in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Amounts recorded for revenue deductions can result from a complex series of judgements about future events and uncertainties and can rely heavily on estimates and assumptions. The following section briefly describes the nature of our provisions for variable consideration and how such provisions are estimated:
Chargebacks: the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Viatris will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels.
Rebates, promotional programs and other sales allowances: this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products.
Returns: consistent with industry practice, Viatris maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. Generally, returned products are destroyed and customers are refunded the sales price in the form of a credit.
Governmental rebate programs: government reimbursement programs in the U.S. include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap” based on historical experience of prescriptions and utilization expected to result in the discount of the “coverage gap”.
Outside the U.S., the majority of our pharmaceutical sales are contractually or legislatively governed. In certain European countries, certain rebates are calculated on the governments total pharmaceutical spending or on specific product sale thresholds. We utilize historical data and obtain third party information to determine the adequacy of these accruals. Also, this provision includes price reductions that are mandated by law outside of the U.S.
Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods.
Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenues in the consolidated statements of operations.
Income Taxes Policy Income Taxes. Income taxes have been provided for using an asset and liability approach in which deferred income taxes reflect the tax consequences on future years of events that the Company has already recognized in the financial statements or tax returns. Changes in enacted tax rates or laws may result in adjustments to the recorded tax assets or liabilities in the period that the new tax law is enacted.
Earnings Per Common Share Policy Earnings per Share. Basic earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.
Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:
Year Ended December 31,
(In millions, except per share amounts)202120202019
Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders$(1,269.1)$(669.9)$16.8 
Shares (denominator):
Weighted average shares outstanding1,208.8 601.2 515.7 
Basic (loss) earnings per share attributable to Viatris Inc. shareholders$(1.05)$(1.11)$0.03 
Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders$(1,269.1)$(669.9)$16.8 
Shares (denominator):
Weighted average shares outstanding1,208.8 601.2 515.7 
Share-based awards— — 0.8 
Total dilutive shares outstanding1,208.8 601.2 516.5 
Diluted (loss) earnings per share attributable to Viatris Inc. shareholders$(1.05)$(1.11)$0.03 
The weighted average shares outstanding used in the computation of earnings per share for the year ended December 31, 2020 includes the effect of the 689.9 million shares issued for the closing of the Combination.
Additional stock awards and restricted ordinary shares were outstanding during the years ended December 31, 2021, 2020 and 2019 but were not included in the computation of diluted earnings per share for each respective period because the effect would be anti-dilutive. Excluded shares also include certain share-based compensation awards and restricted shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 12.7 million, 10.3 million and 9.1 million shares for the years ended December 31, 2021, 2020 and 2019, respectively
Stock-Based Compensation Policy Share-Based Compensation. The fair value of share-based compensation is recognized as expense in the consolidated statements of operations over the vesting period.
Derivatives Policy Derivatives. From time to time the Company may enter into derivative financial instruments (mainly foreign currency exchange forward contracts, interest rate swaps and purchased equity call options) designed to: 1) hedge the cash flows resulting from existing assets and liabilities and transactions expected to be entered into over the next 24 months in currencies other than the functional currency, 2) hedge the variability in interest expense on floating rate debt, 3) hedge the fair value of fixed-rate notes, 4) hedge against changes in interest rates that could impact future debt issuances, 5) hedge cash or share payments required on conversion of issued convertible notes, 6) hedge a net investment in a foreign operation, or 7) economically hedge the foreign currency exposure associated with the purchase price of non-U.S. acquisitions. Derivatives are recognized as assets or liabilities in the consolidated balance sheets at their fair value. When the derivative instrument qualifies as a cash flow hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged items, are generally included in interest expense. When such instruments do not qualify for hedge accounting the changes in fair value are recorded in the consolidated statements of operations within other expense, net
Financial Instruments Policy
Financial Instruments. The Company’s financial instruments consist primarily of short-term and long-term debt, interest rate swaps, forward contracts and option contracts. The Company’s financial instruments also include cash and cash equivalents as well as accounts and other receivables and accounts payable, the fair values of which approximate their carrying values. As a policy, the Company does not engage in speculative or leveraged transactions.
The Company carries derivative instruments in the consolidated balance sheets at fair value, determined by reference to market data such as forward rates for currencies, implied volatilities, and interest rate swap yield curves. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. In addition, the Company has designated certain long-term debt instruments as net investment hedges.
Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
Level 1:        Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2:        Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.
Level 3:        Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value
Recent Accounting Pronouncements
Recent Accounting Pronouncements.
Adoption of New Accounting Standards
In January 2020, the FASB issued Accounting Standards Update 2020-01, Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 (“ASU 2020-01”), which clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. In addition, ASU 2020-01 states that for the purpose of applying paragraph 815-10-15-141(a) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The Company applied the provisions of ASU 2020-01 as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.
In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (Topic 740) which is intended to simplify the accounting for income taxes by eliminating certain exceptions and simplifying certain requirements under Topic 740. The Company applied the provisions of ASU 2019-12 on a prospective basis as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.
    Accounting Standards Issued Not Yet Adopted    
In March 2020, the FASB issued Accounting Standards Update 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Entities can apply the provisions of ASU 2020-04 immediately, as applicable, and generally the provisions of the guidance are available through December 31, 2022 as entities transition away from reference rates that are expected to be discontinued. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.
In October 2021, the FASB issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires entities (acquirers) to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. ASU 2021-08 will be effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2022 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.
In November 2021, the FASB issued Accounting Standards Update 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”), which requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 will be effective for fiscal years beginning after December 15, 2021 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its disclosures.
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Earnings Per Common Share Attributable To Mylan
Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:
Year Ended December 31,
(In millions, except per share amounts)202120202019
Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders$(1,269.1)$(669.9)$16.8 
Shares (denominator):
Weighted average shares outstanding1,208.8 601.2 515.7 
Basic (loss) earnings per share attributable to Viatris Inc. shareholders$(1.05)$(1.11)$0.03 
Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):
Net (loss) earnings attributable to Viatris Inc. common shareholders$(1,269.1)$(669.9)$16.8 
Shares (denominator):
Weighted average shares outstanding1,208.8 601.2 515.7 
Share-based awards— — 0.8 
Total dilutive shares outstanding1,208.8 601.2 516.5 
Diluted (loss) earnings per share attributable to Viatris Inc. shareholders$(1.05)$(1.11)$0.03 
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Acquisitions and Other Transactions (Tables)
12 Months Ended
Dec. 31, 2021
Business Combinations [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
During the year ended December 31, 2021, adjustments were made to the preliminary purchase price recorded at December 31, 2020, and are reflected as “Measurement Period and Other Adjustments” in the table below. The allocation of the $10.73 billion purchase price to the assets acquired and liabilities assumed under the Combination is as follows:
(In millions)
Preliminary Purchase Price Allocation as of December 31, 2020 (a)
Measurement Period and Other Adjustments (b)
Purchase Price Allocation as of December 31, 2021 (as adjusted)
Current assets (excluding inventories and net of cash acquired)$2,841.9 $(38.7)$2,803.2 
Inventories2,588.9 (34.2)2,554.7 
Property, plant and equipment1,394.1 (5.0)1,389.1 
Identified intangible assets18,040.0 — 18,040.0 
Goodwill2,107.5 295.6 2,403.1 
Deferred income tax benefit1,481.9 196.3 1,678.2 
Other assets 792.1 (7.4)784.7 
Total assets acquired$29,246.4 $406.6 $29,653.0 
Current liabilities2,760.2 419.7 3,179.9 
Long-term debt, including current portion13,076.2 — 13,076.2 
Deferred tax liabilities1,656.9 1.0 1,657.9 
Other noncurrent liabilities1,441.5 (14.1)1,427.4 
Net assets acquired (net of $415.8 of cash acquired)
$10,311.6 $— $10,311.6 
____________
(a)As previously reported in Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
(b)The measurement period adjustments are primarily for 1) certain working capital adjustments, an increase in litigation reserves to reflect facts and circumstances that existed as of the date of the Combination, and other adjustments and 2) the tax implications of these and other adjustments. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and accordingly, the Company has not retrospectively adjusted those consolidated financial statements.
Business Acquisition, Pro Forma Information Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.
Year Ended December 31,
(Unaudited, in millions, except per share amounts) 20202019
Total revenues$18,284.8 $21,582.7 
Net earnings$1,483.7 $1,873.5 
Earnings per share:
Basic$1.23 $1.55 
Diluted$1.23 $1.55 
Weighted average shares outstanding:
Basic1,206.8 1,205.6 
Diluted1,207.7 1,206.4 
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Accounts Receivable (Tables)
12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:
(In millions)2021 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands5,759.2 2,207.8 1,197.1 1,677.2 10,841.3 
Complex Gx and Biosimilars1,241.6 0.2 46.5 53.8 1,342.1 
Generics3,427.9 4.8 783.8 1,413.7 5,630.2 
Total Viatris$10,428.7 $2,212.8 $2,027.4 $3,144.7 $17,813.6 

(In millions)2020 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands3,920.7 253.9 617.0 443.3 5,234.9 
Complex Gx and Biosimilars1,202.6 0.7 42.8 49.4 1,295.5 
Generics3,387.6 5.3 535.5 1,361.1 5,289.5 
Total Viatris$8,510.9 $259.9 $1,195.3 $1,853.8 $11,819.9 

(In millions)2019 Net Sales
Product CategoryDeveloped MarketsGreater ChinaJANZEmerging MarketsTotal
Brands4,199.1 207.6 533.3 422.1 5,362.1 
Complex Gx and Biosimilars1,127.4 0.4 23.8 59.7 1,211.3 
Generics2,913.5 6.6 635.4 1,241.4 4,796.9 
Total Viatris$8,240.0 $214.6 $1,192.5 $1,723.2 $11,370.3 

The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:
(In millions)Year Ended December 31, 2021
Select Key Global Products
Lipitor ®
$1,663.2 
Norvasc ®824.7 
Lyrica ®728.5 
Viagra ®533.8 
EpiPen® Auto-Injectors391.7 
Celebrex ®
344.4 
Effexor ®
316.8 
Creon ®309.8 
Zoloft ®
284.3 
Xalabrands226.0 
Select Key Segment Products
Influvac ®$299.3 
Amitiza ®201.5 
Xanax ®185.9 
Dymista ®168.0 
Yupelri ®161.9 
____________
(a)The Company does not disclose net sales for any products considered competitively sensitive.
(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.
(c)Prior periods are not presented due to significance of products acquired as part of the Combination.
The following is a rollforward of the categories of variable consideration during 2021:
(In millions)Balance at December 31, 2020Current Provision Related to Sales Made in the Current Period Measurement Period Adjustments and ReclassesChecks/ Credits Issued to Third Parties Effects of Foreign ExchangeBalance at December 31, 2021
Chargebacks$585.2 $5,530.1 $63.4 $(5,585.4)$(1.6)$591.7 
Rebates, promotional programs and other sales allowances1,576.3 6,135.6 (57.6)(6,267.1)(14.2)1,373.0 
Returns539.9 384.6 269.0 (499.0)(7.7)686.8 
Governmental rebate programs313.3 689.5 110.6 (705.2)(9.0)399.2 
Total$3,014.7 $12,739.8 $385.4 $(13,056.7)$(32.5)$3,050.7 
Schedule of Accounts Receivable, Net Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:
(In millions)December 31,
2021
December 31,
2020
Accounts receivable, net$1,688.6 $1,802.9 
Other current liabilities1,362.1 1,211.8 
Total$3,050.7 $3,014.7 
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Tables)
12 Months Ended
Dec. 31, 2021
Balance Sheet Components [Abstract]  
Schedule of Cash, Cash Equivalents, and Restricted Cash
Cash and restricted cash
(In millions)December 31,
2021
December 31,
2020
December 31,
2019
Cash and cash equivalents$701.2 $844.4 $475.6 
Restricted cash, included in other current and non-current assets5.0 5.6 15.5 
Cash, cash equivalents and restricted cash$706.2 $850.0 $491.1 
Inventories
(In millions)December 31, 2021December 31, 2020
Raw materials$922.4 $958.4 
Work in process993.3 1,438.1 
Finished goods2,062.0 3,075.4 
Inventories$3,977.7 $5,471.9 
Property, plant and equipment
Property, plant and equipment, net
(In millions)December 31, 2021December 31, 2020
Machinery and equipment$3,054.0 $3,235.0 
Buildings and improvements1,808.5 1,954.8 
Construction in progress588.7 376.3 
Land and improvements137.9 155.8 
Gross property, plant and equipment5,589.1 5,721.9 
Accumulated depreciation2,400.5 2,262.0 
Property, plant and equipment, net$3,188.6 $3,459.9 
Other assets
Other assets
(In millions)December 31, 2021December 31, 2020
Equity method investments, clean energy investments$— $47.9 
Operating lease right-of-use assets290.8 323.6 
Other long-term assets879.9 676.0 
Other assets$1,170.7 $1,047.5 
Other current liabilities
Other current liabilities
(In millions)December 31, 2021December 31, 2020
Accrued sales allowances$1,362.1 $1,211.8 
Payroll and employee benefit liabilities 741.9 828.2 
Legal and professional accruals, including litigation accruals715.6 362.9 
Contingent consideration66.7 100.5 
Accrued restructuring233.5 149.2 
Equity method investments, clean energy investments10.9 47.5 
Accrued interest86.6 90.9 
Fair value of financial instruments61.0 103.6 
Operating lease liability86.7 92.9 
Other1,254.6 1,973.2 
Other current liabilities$4,619.6 $4,960.7 
Other noncurrent liabilities
(In millions)December 31, 2021December 31, 2020
Employee benefit liabilities$876.4 $1,020.4 
Contingent consideration133.0 123.1 
Tax related items, including contingencies426.1 469.5 
Operating lease liability200.9 229.5 
Accrued restructuring64.3 134.8 
Other232.9 505.8 
Other long-term obligations$1,933.6 $2,483.1 
Schedule of Other Current Assets
Prepaid expenses and other current assets
(In millions)December 31, 2021December 31, 2020
Prepaid expenses$256.7 $267.8 
Available-for-sale fixed income securities38.2 39.1 
Fair value of financial instruments144.6 118.6 
Equity securities51.0 45.8 
Other current assets1,467.1 1,236.1 
Prepaid expenses and other current assets$1,957.6 $1,707.4 
Schedule of Accounts Payable and Accrued Liabilities
Accounts payable
(In millions)December 31, 2021December 31, 2020
Trade accounts payable$1,056.1 $1,345.7 
Other payables601.3 558.5 
Accounts payable$1,657.4 $1,904.2 
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Tables)
12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Lease, Cost
Other information related to leases was as follows:
As of December 31, 2021
Remaining lease terms
1 year to 23 years
Weighted-average remaining lease term6 years
Weighted-average discount rate2.6 %
Lessee, Operating Lease, Liability, Maturity
As of December 31, 2021, maturities of lease liabilities were as follows:
(In millions)
Year ending December 31,
2022$82.0 
202365.0 
202442.9 
202528.8 
202623.9 
Thereafter68.2 
Total lease payments$310.8 
Less imputed interest23.2 
Total lease liability$287.6 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Method Investments (Tables)
12 Months Ended
Dec. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]  
Equity Method Investments
The carrying values and respective balance sheet locations of the Company’s clean energy investments were as follows at December 31, 2021 and 2020, respectively:
(In millions)December 31, 2021December 31, 2020
Other assets$— $47.9 
Other current liabilities10.9 47.5 
Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis as of December 31, 2021 and 2020 and for the years ended December 31, 2021, 2020 and 2019 are as follows:
(In millions)December 31, 2021December 31, 2020
Current assets$4.2 $38.9 
Noncurrent assets0.5 1.0 
Total assets4.7 39.9 
Current liabilities2.8 33.0 
Noncurrent liabilities— 1.8 
Total liabilities2.8 34.8 
Net assets$1.9 $5.1 
Year Ended December 31,
(In millions)202120202019
Total revenues$326.7 $374.5 $385.0 
Gross loss(4.6)(4.6)(4.4)
Operating and non-operating expense16.8 19.0 20.0 
Net loss$(21.4)$(23.6)$(24.4)
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangible Assets (Tables)
12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in carrying amount of goodwill
The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:
(In millions)Developed MarketsGreater ChinaJANZEmerging MarketsTotal
Balance at December 31, 2019:
Goodwill$8,258.0 $67.8 $584.8 $1,065.0 $9,975.6 
Accumulated impairment losses(385.0)— — — (385.0)
7,873.0 67.8 584.8 1,065.0 9,590.6 
Acquisitions704.3 652.8 217.4 533.0 2,107.5 
Foreign currency translation607.2 17.7 61.8 (37.8)648.9 
9,184.5 738.3 864.0 1,560.2 12,347.0 
Balance at December 31, 2020:
Goodwill9,569.5 738.3 864.0 1,560.2 12,732.0 
Accumulated impairment losses(385.0)— — — (385.0)
9,184.5 738.3 864.0 1,560.2 12,347.0 
Measurement period and other adjustments67.7 220.4 (30.9)38.4 295.6 
Foreign currency translation(528.8)10.8 (56.8)45.9 (528.9)
8,723.4 969.5 776.3 1,644.5 12,113.7 
Balance at December 31, 2021
Goodwill9,108.4 969.5 776.3 1,644.5 12,498.7 
Accumulated impairment losses(385.0)— — — (385.0)
$8,723.4 $969.5 $776.3 $1,644.5 $12,113.7 
Components of intangible assets
Intangible assets consist of the following components at December 31, 2021 and 2020:
(In millions)Weighted Average Life (Years)CostAccumulated AmortizationNet Book Value
December 31, 2021
Product rights, licenses and other (1)
15$39,006.2 $12,918.5 $26,087.7 
In-process research and development46.5 — 46.5 
$39,052.7 $12,918.5 $26,134.2 
December 31, 2020
Product rights, licenses and other (1)
15$40,404.1 $10,801.6 $29,602.5 
In-process research and development80.7 — 80.7 
$40,484.8 $10,801.6 $29,683.2 
____________
(1)Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights.
Product rights and licenses by therapeutic category
Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by product category, is as follows:
(In millions)Developed MarketsGreater ChinaJANZEmerging MarketsDecember 31, 2021
Brands$10,066.6 $6,102.9 $1,174.8 $3,801.7 $21,146.0 
Complex Gx and Biosimilars226.8 — 1.5 — 228.3 
Generics4,020.2 12.1 319.5 358.4 4,710.2 
Total Product Rights and Licenses$14,313.6 $6,115.0 $1,495.8 $4,160.1 $26,084.5 
(In millions)Developed MarketsGreater ChinaJANZEmerging MarketsDecember 31, 2020
Brands$10,988.1 $4,372.3 $2,377.0 $4,478.7 $22,216.1 
Complex Gx and Biosimilars272.5 — 2.3 — 274.8 
Generics6,253.9 12.7 423.9 417.3 7,107.8 
Total Product Rights and Licenses$17,514.5 $4,385.0 $2,803.2 $4,896.0 $29,598.7 
Finite-lived Intangible Assets Amortization Expense [Table Text Block]
Amortization expense and intangible asset impairment charges, which are included as a component of amortization expense, which is classified primarily within cost of sales in the consolidated statements of operations, for the years ended December 31, 2021, 2020 and 2019 was as follows:
Year ended December 31,
(In millions)202120202019
Intangible asset amortization expense$2,702.2 $1,605.8 $1,582.7 
IPR&D intangible asset impairment charges19.4 37.4 138.3 
Finite-lived intangible asset impairment charges83.4 45.0 42.3 
Total intangible asset amortization expense (including impairment charges)$2,805.0 $1,688.2 $1,763.3 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Intangible asset amortization expense for the years ending December 31, 2022 through 2026 is estimated to be as follows:
(In millions)
2022$2,577 
20232,414 
20242,320 
20252,222 
20262,164 
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Tables)
12 Months Ended
Dec. 31, 2021
Derivative [Line Items]  
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]
A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to December 31, 2021 is as follows:
(In millions)
Current Portion (1)
Long-Term Portion (2)
Total Contingent Consideration
Balance at December 31, 2019$120.4 $130.3 $250.7 
Payments(111.8)— (111.8)
Reclassifications58.1 (58.1)— 
Accretion— 11.6 11.6 
Fair value loss (3)
33.8 39.3 73.1 
Balance at December 31, 2020$100.5 $123.1 $223.6 
Payments(83.2)— (83.2)
Reclassifications49.4 (49.4)— 
Accretion— 9.0 9.0 
Fair value loss (3)
— 50.3 50.3 
Balance at December 31, 2021$66.7 $133.0 $199.7 
____________
(1)Included in other current liabilities in the consolidated balance sheets.
(2)Included in other long-term obligations in the consolidated balance sheets.
(3)Included in litigation settlements and other contingencies, net in the consolidated statements of operations.
Financial Assets and Liabilities Carried at Fair Value
Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:
December 31, 2021
(In millions)Level 1Level 2Level 3Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds$50.9 $— $— $50.9 
Total cash equivalents50.9 — — 50.9 
Equity securities:
Exchange traded funds50.3 — — 50.3 
Marketable securities0.7 — — 0.7 
Total equity securities51.0 — — 51.0 
Available-for-sale fixed income investments:
Corporate bonds— 16.6 — 16.6 
U.S. Treasuries— 14.6 — 14.6 
Agency mortgage-backed securities— 2.0 — 2.0 
Asset backed securities— 4.6 — 4.6 
Other— 0.4 — 0.4 
Total available-for-sale fixed income investments— 38.2 — 38.2 
Foreign exchange derivative assets— 144.6 — 144.6 
Total assets at recurring fair value measurement$101.9 $182.8 $— $284.7 
Financial Liabilities
Foreign exchange derivative liabilities$— $61.0 $— $61.0 
Contingent consideration— — 199.7 199.7 
Total liabilities at recurring fair value measurement$— $61.0 $199.7 $260.7 
December 31, 2020
(In millions)Level 1Level 2Level 3Total
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds$0.9 $— $— $0.9 
Total cash equivalents0.9 — — 0.9 
Equity securities:
Exchange traded funds45.1 — — 45.1 
Marketable securities0.7 — — 0.7 
Total equity securities45.8 — — 45.8 
Available-for-sale fixed income investments:
Corporate bonds— 17.8 — 17.8 
U.S. Treasuries— 14.4 — 14.4 
Agency mortgage-backed securities— 1.9 — 1.9 
Asset backed securities— 4.6 — 4.6 
Other— 0.4 — 0.4 
Total available-for-sale fixed income investments— 39.1 — 39.1 
Foreign exchange derivative assets— 118.6 — 118.6 
Total assets at recurring fair value measurement$46.7 $157.7 $— $204.4 
Financial Liabilities
Foreign exchange derivative liabilities$— $103.6 $— $103.6 
Contingent consideration— — 223.6 223.6 
Total liabilities at recurring fair value measurement$— $103.6 $223.6 $327.2 
Schedule of Available-for-Sale Securities Reconciliation
The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows:
(In millions)CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
December 31, 2021
Debt securities$38.1 $0.1 $— $38.2 
$38.1 $0.1 $— $38.2 
December 31, 2020
Debt securities$37.5 $1.6 $— $39.1 
$37.5 $1.6 $— $39.1 
Maturities Of Available-for-Sale Debt Securities At Fair Value
Maturities of available-for-sale debt securities at fair value as of December 31, 2021, were as follows:
(In millions) 
Mature within one year$1.2 
Mature in one to five years19.7 
Mature in five years and later17.3 
$38.2 
Cash flow hedging relationships  
Derivative [Line Items]  
Effect of Derivative Instruments on the Consolidated Statements of Operations
The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:

Amount of Gains/(Losses) Recognized in EarningsAmount of Gain Excluded from the Assessment of Hedge Effectiveness
Year Ended December 31,Year Ended December 31,
(In millions)Location of Gain/(Loss)202120202019202120202019
Derivative Financial Instruments in Fair Value Hedge Relationships (1) :
Interest rate swaps
Interest expense (3)
$— $22.1 $18.7 $— $— $— 
2023 Senior Notes (3.125% coupon)
Interest expense (3)
— (22.1)(18.7)— — — 
Derivative Financial Instruments in Cash Flow Hedging Relationships :
Foreign currency forward contracts
Other expense, net (5)
— — — — 7.1 — 
Derivative Financial Instruments Not Designated as Hedging Instruments:
Foreign currency option and forward contracts
Other expense, net (3)
39.3 (10.1)(17.3)— — — 
Total$39.3 $(10.1)$(17.3)$— $7.1 $— 
Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on DerivativesAmount of Gains/(Losses) Reclassified from AOCE into Earnings
Year Ended December 31,Year Ended December 31,
(In millions)Location of Gain/(Loss)202120202019202120202019
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :
Foreign currency forward contracts
Net sales (4)
$45.8 $20.6 $16.6 $30.9 $4.8 $(0.7)
Interest rate swaps
Interest expense (4)
(3.4)— 3.0 (4.3)(4.5)(7.1)
Derivative Financial Instruments in Net Investment Hedging Relationships:
Foreign currency borrowings and forward contracts436.6 (346.4)56.7 — — — 
Total$479.0 $(325.8)$76.3 $26.6 $0.3 $(7.8)
____________
(1)In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The amount included in the above tables represents the fair value adjustment recognized at the date the interest rate swaps were settled.
(2)At December 31, 2021, the Company expects that approximately $21.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months.
(3)Represents the location of the gain/(loss) recognized in earnings on derivatives.
(4)Represents the location of the gain/(loss) reclassified from AOCE into earnings.
(5)Represents the location of the gain excluded from the assessment of hedge effectiveness.
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt (Tables)
12 Months Ended
Dec. 31, 2021
Debt Instrument [Line Items]  
Schedule of Short-term Debt
Short-Term Borrowings
The Company had $1.49 billion and $1.10 billion of borrowings as of December 31, 2021 and 2020, respectively.
(In millions)December 31, 2021December 31, 2020
Commercial paper notes$1,173.4 $651.3 
Receivables Facility318.5 248.4 
Note Securitization Facility— 200.0 
Other1.1 1.2 
Short-term borrowings$1,493.0 $1,100.9 
The following provides an overview of the Company’s short-term credit facilities.
Minimum Repayments on Outstanding Borrowings
Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at December 31, 2021 were as follows for each of the periods ending December 31:
(In millions)Total
2022$1,853 
20231,250 
20241,990 
20251,318 
20262,598 
Thereafter11,940 
Total$20,949 
Upjohn Inc.  
Debt Instrument [Line Items]  
Summary of Long-Term Debt
The following table provides information about the Upjohn Senior Notes issued in June 2020:
(In millions)Notional Value
2022 Senior Notes$1,000.0 
2025 Senior Notes750.0 
2027 Senior Notes750.0 
2030 Senior Notes1,450.0 
2040 Senior Notes1,500.0 
2050 Senior Notes2,000.0 
2022 Euro Senior Note916.2 
2024 Euro Senior Note916.2 
2027 Euro Senior Note1,038.4 
2032 Euro Senior Note1,527.0 
Total$11,847.8 
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Comprehensive Earnings (Tables)
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Accumulated Other Comprehensive Loss
Accumulated other comprehensive loss, as reflected in the consolidated balance sheets, is comprised of the following:
(In millions)December 31, 2021December 31, 2020
Accumulated other comprehensive loss:
Net unrealized gain on marketable securities, net of tax$— $1.2 
Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax32.2 (26.1)
Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax9.2 (18.0)
Net unrecognized loss on derivatives in net investment hedging relationships, net of tax16.7 (353.6)
Foreign currency translation adjustment(1,802.4)(461.5)
$(1,744.3)$(858.0)
Components of Other Comprehensive Loss
Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following:
Year Ended December 31, 2021
Gains and Losses on Derivatives in Cash Flow Hedging RelationshipsGains and Losses on Net Investment HedgesGains and Losses on Marketable SecuritiesDefined Pension Plan ItemsForeign Currency Translation AdjustmentTotals
(In millions)Foreign Currency Forward ContractsInterest Rate SwapsTotal
Balance at December 31, 2020, net of tax$(18.0)$(353.6)$1.2 $(26.1)$(461.5)$(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax62.7 456.8 (1.1)67.0 (1,340.9)(755.5)
Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales(30.9)(30.9)(30.9)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense4.3 4.3 4.3 
Amortization of prior service costs included in SG&A (0.5)(0.5)
Amortization of actuarial loss included in SG&A 7.4 7.4 
Net other comprehensive earnings (loss), before tax36.1 456.8 (1.1)73.9 (1,340.9)(775.2)
Income tax provision8.9 86.5 0.1 15.6 — 111.1 
Balance at December 31, 2021, net of tax$9.2 $16.7 $— $32.2 $(1,802.4)$(1,744.3)
Year Ended December 31, 2020
Gains and Losses on Derivatives in Cash Flow Hedging RelationshipsGains and Losses on Net Investment HedgesGains and Losses on Marketable SecuritiesDefined Pension Plan ItemsForeign Currency Translation AdjustmentTotals
(In millions)Foreign Currency Forward ContractsInterest Rate SwapsTotal
Balance at December 31, 2019, net of tax$(31.6)$(74.3)$0.6 $(17.4)$(1,674.5)$(1,797.2)
Other comprehensive (loss) earnings before reclassifications, before tax18.5 (305.2)0.6 (12.1)1,213.0 914.8 
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales(4.8)(4.8)(4.8)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense4.5 4.5 4.5 
Amortization of prior service costs included in SG&A — — 
Amortization of actuarial loss included in SG&A (1.9)(1.9)
Net other comprehensive (loss) earnings, before tax18.2 (305.2)0.6 (14.0)1,213.0 912.6 
Income tax provision (benefit)4.6 (25.9)— (5.3)— (26.6)
Balance at December 31, 2020, net of tax$(18.0)$(353.6)$1.2 $(26.1)$(461.5)$(858.0)
Year Ended December 31, 2019
Gains and Losses on Derivatives in Cash Flow Hedging RelationshipsGains and Losses on Net Investment HedgesGains and Losses on Marketable SecuritiesDefined Pension Plan ItemsForeign Currency Translation AdjustmentTotals
(In millions)Foreign Currency Forward ContractsInterest Rate SwapsTotal
Balance at December 31, 2018, net of tax$(53.1)$(130.9)$— $1.7 $(1,259.0)$(1,441.3)
Other comprehensive earnings (loss) before reclassifications, before tax29.3 59.6 0.5 (21.0)(415.5)(347.1)
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales0.7 0.7 0.7 
Loss on interest rate swaps classified as cash flow hedges, included in interest expense7.1 7.1 7.1 
Amortization of prior service costs included in SG&A (0.9)(0.9)
Amortization of actuarial loss included in SG&A (2.9)(2.9)
Net other comprehensive earnings (loss), before tax37.1 59.6 0.5 (24.8)(415.5)(343.1)
Income tax provision (benefit) 12.2 3.0 (0.1)(5.9)— 9.2 
Cumulative effect of the adoption of new accounting standards(3.4)— — (0.2)— (3.6)
Balance at December 31, 2019, net of tax$(31.6)$(74.3)$0.6 $(17.4)$(1,674.5)$(1,797.2)
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Provision
The income tax provision (benefit) consisted of the following components:
 Year Ended December 31,
(In millions)202120202019
U.S. Federal:
Current$12.6 $(6.4)$118.1 
Deferred(182.7)(277.0)(165.5)
(170.1)(283.4)(47.4)
U.S. State:
Current7.7 (0.1)21.1 
Deferred(10.8)7.7 (13.6)
(3.1)7.6 7.5 
Non-U.S.:
Current(91.3)168.7 191.0 
Deferred869.2 55.8 (13.5)
777.9 224.5 177.5 
Income tax provision (benefit)$604.7 $(51.3)$137.6 
Earnings before income taxes:
United States(1,982.5)(945.5)(1,031.4)
Foreign - Other1,318.1 224.3 1,185.8 
Total (loss) earnings before income taxes$(664.4)$(721.2)$154.4 
Schedule of Deferred Tax Assets and Liabilities
Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows:
(In millions)December 31, 2021December 31, 2020
Deferred tax assets:
Employee benefits$271.3 $273.0 
Litigation reserves94.4 43.5 
Accounts receivable allowances425.9 393.7 
Inventory187.8 1,187.9 
Tax credit and loss carry-forwards1,256.0 1,080.4 
Operating lease assets63.6 66.5 
Interest expense111.6 67.9 
Intangible assets 151.1 156.3 
Other 327.8 396.0 
2,889.5 3,665.2 
Less: Valuation allowance(780.4)(443.6)
Total deferred tax assets2,109.1 3,221.6 
Deferred tax liabilities:
Plant and equipment19.6 50.2 
Operating lease liabilities63.6 66.5 
Intangible assets and goodwill3,468.3 4,058.6 
Other39.9 22.1 
Total deferred tax liabilities3,591.4 4,197.4 
Deferred tax liabilities, net$(1,482.3)$(975.8)
Statutory Tax Rate to Effective Tax Rate Reconciliation
Prior to the Combination, the applicable income tax rate to Mylan was the U.K. rate of 19%, and following the Combination, the statutory income tax rate applicable to Viatris Inc. is the U.S. rate of 21% for the years ended December 31, 2021 and 2020. A reconciliation of the statutory tax rate to the effective tax rate is as follows:
 Year Ended December 31,
 202120202019
Statutory tax rate21.0 %21.0 %19.0 %
United States Operations
Clean energy and research credits9.8 %12.8 %(43.4)%
U.S. rate differentials— %— %(3.1)%
Impact of changes in legislation— %(9.2)%— %
State income taxes and credits(0.6)%(1.6)%(4.1)%
Valuation allowance(0.1)%8.6 %(118.5)%
Tax settlements and resolution of certain tax positions0.1 %0.1 %199.6 %
Incremental US Tax on Foreign Earnings(36.9)%(3.6)%(8.6)%
Waived deductions under IRC § 59A— %(3.3)%64.5 %
Impact of the Combination and Divestitures(2.8)%5.8 %7.7 %
Other U.S. items(6.1)%1.5 %6.9 %
Other Foreign Operations
Luxembourg(6.7)%(5.0)%(14.8)%
Gibraltar9.4 %8.0 %(38.8)%
Ireland5.8 %8.2 %(13.7)%
France(1.1)%(2.8)%15.2 %
Puerto Rico4.4 %(2.5)%— %
Switzerland1.0 %2.0 %— %
Singapore28.8 %1.0 %— %
Other(10.2)%(0.4)%12.8 %
Deferred tax impact of tax law changes7.0 %(0.1)%36.7 %
Valuation allowance(8.3)%16.1 %(9.9)%
Impact of the Combination and divestitures(106.9)%(42.2)%— %
Withholding taxes(1.3)%(1.6)%7.1 %
Tax settlements and resolution of certain tax positions0.8 %(3.9)%(27.6)%
Other foreign items1.9 %(1.8)%2.1 %
Effective tax rate(91.0)%7.1 %89.1 %
Schedule of Unrecognized Tax Benefits
A reconciliation of the unrecognized tax benefits is as follows:
Year Ended December 31,
(In millions)202120202019
Unrecognized tax benefit — beginning of year$391.1 $92.1 $96.3 
Additions for current year tax positions— 13.4 — 
Additions for prior year tax positions— 35.7 154.9 
Reductions for prior year tax positions(9.1)(5.2)(11.7)
Settlements(47.3)(8.9)(112.5)
Reductions due to expirations of statute of limitations(7.0)— (34.9)
(Reduction) addition due to acquisition(4.8)264.0 — 
Unrecognized tax benefit — end of year$322.9 $391.1 $92.1 
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-Based Incentive Plan (Tables)
12 Months Ended
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock Awards Activity
The following table summarizes stock awards (stock options and SARs) activity under the Plan and 2003 LTIP:
Number of Shares
Under Stock Awards
Weighted
Average
Exercise Price
per Share
Outstanding at December 31, 20186,815,278 $36.61 
Granted829,322 26.18 
Exercised(580,950)14.40 
Forfeited(715,941)39.40 
Outstanding at December 31, 20196,347,709 $36.97 
Granted814,351 17.37 
Exercised(27,615)21.13 
Forfeited(422,714)25.74 
Outstanding at December 31, 20206,711,731 $35.36 
Forfeited(1,135,241)26.39 
Outstanding at December 31, 20215,576,490 $37.19 
Vested and expected to vest at December 31, 20215,487,788 $37.45 
Exercisable at December 31, 20214,969,602 $39.21 
Nonvested Restricted Stock and Restricted Stock Unit, Including Performance Units, Activity
A summary of the status of the Company’s nonvested restricted stock awards (restricted stock and restricted stock unit awards, including PSUs), as of December 31, 2020 and the changes during the year ended December 31, 2021 are presented below:
Number of Restricted
Stock Awards
Weighted Average
Grant-Date
Fair Value Per Share
Nonvested at December 31, 202012,073,790 $18.34 
Granted9,850,443 14.46 
Released(3,168,152)24.65 
Forfeited(1,897,953)15.33 
Nonvested at December 31, 202116,858,128 $15.12 
Long Term Incentive Plan 2003  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock-Based Compensation Plans, Valuation Assumptions
There were no options granted during the year ended December 31, 2021. The assumptions used for options granted under the Plan and 2003 LTIP during the years ended December 31, 2020 and 2019, respectively, are as follows:
Year Ended December 31,
20202019
Volatility46.7%38.1%
Risk-free interest rate1.0%2.5%
Expected term (years)6.56.5
Forfeiture rate 5.5%5.5%
Weighted average grant date fair value per option$8.07$11.03
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Tables)
12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost
Included in accumulated other comprehensive loss as of December 31, 2021 and 2020 are:
Pension BenefitsOther Postretirement Benefits
December 31,December 31,
(In millions)2021202020212020
Unrecognized actuarial (gain) loss$(59.9)$33.9 $21.7 $5.7 
Unrecognized prior service cost (credit)6.6 (1.4)(3.7)0.6 
Total$(53.3)$32.5 $18.0 $6.3 
Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits The increase in accumulated other comprehensive loss in 2021 relating to pension benefits and other postretirement benefits consists of:
(In millions)Pension BenefitsOther Postretirement Benefits
Unrecognized actuarial (gain) loss$(102.2)$16.2 
Amortization of actuarial gain/(loss)7.6 (0.2)
Unrecognized prior service credit (cost)8.0 (4.3)
Amortization of prior service costs(0.5)— 
Impact of foreign currency translation1.3 — 
Net change$(85.8)$11.7 
Net Periodic Benefit Cost
Components of net periodic benefit cost for the years ended December 31, 2021, 2020 and 2019 were as follows:
Pension BenefitsOther Postretirement Benefits
December 31,December 31,
(In millions)202120202019202120202019
Service cost$38.6 $23.5 $20.7 $3.4 $1.2 $0.6 
Interest cost31.6 13.5 13.6 2.6 1.4 1.5 
Expected return on plan assets(66.1)(19.9)(12.1)— — — 
Plan curtailment, settlement and termination(16.5)1.1 (0.3)— — 3.2 
Amortization of prior service costs0.9 — 0.9 — — — 
Recognized net actuarial losses (gains) 1.3 0.4 (0.8)0.2 0.3 0.2 
Net periodic benefit cost$(10.2)$18.6 $22.0 $6.2 $2.9 $5.5 
During the year ended December 31, 2021, the Company recognized a settlement gain as a result of cash payments from lump sum elections related to the U.S. and Puerto Rico pension plans.
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan
The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2021 and 2020.
Pension BenefitsOther Postretirement Benefits
(In millions)2021202020212020
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year$2,145.8 $674.7 $188.8 $33.8 
Service cost38.6 23.5 3.4 1.1 
Interest cost31.6 13.5 2.6 1.4 
Participant contributions2.0 1.8 2.4 0.1 
Acquisitions4.0 1,389.4 — 153.1 
Plan settlements and terminations(128.6)(23.1)(4.3)(0.2)
Actuarial (gains) losses (26.1)37.2 16.2 1.1 
Benefits paid(52.8)(24.6)(20.7)(1.6)
Impact of foreign currency translation(67.9)53.4 — — 
Projected benefit obligation, end of year$1,946.6 $2,145.8 $188.4 $188.8 
Change in Plan Assets
Fair value of plan assets, beginning of year$1,354.6 $315.7 $— $— 
Actual return on plan assets141.7 46.0 — — 
Company contributions97.0 58.2 18.3 1.7 
Participant contributions2.0 1.8 2.4 0.1 
Acquisitions(2.1)959.3 — — 
Plan settlements(128.9)(23.1)— (0.2)
Benefits paid(52.8)(24.6)(20.7)(1.6)
Impact of foreign currency translation(45.1)21.3 — — 
Fair value of plan assets, end of year1,366.4 1,354.6 — — 
Funded status of plans$(580.2)$(791.2)$(188.4)$(188.8)
Net Accrued Benefit Costs Classification on Balance Sheet
Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheets at December 31, 2021 and 2020:
Pension BenefitsOther Postretirement Benefits
December 31,December 31,
(In millions)2021202020212020
Noncurrent assets$117.2 $70.7 $— $— 
Current liabilities(14.6)(15.1)(16.1)(16.3)
Noncurrent liabilities(682.8)(846.8)(172.3)(172.5)
Net accrued benefit costs$(580.2)$(791.2)$(188.4)$(188.8)
Plans with Accumulated Benefit Obligation in Excess of Plan Assets
The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of the fair value of plan assets at December 31, 2021 and 2020 were as follows:
December 31,
(In millions)20212020
Plans with accumulated benefit obligation in excess of plan assets:
Projected benefit obligation$1,591.8 $1,747.2 
Accumulated benefit obligation1,546.4 1,678.2 
Fair value of plan assets904.1 893.9 
Schedule of Allocation of Plan Assets The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:
December 31, 2021
(In millions)Level 1Level 2Level 3Total
Cash and cash equivalents$63.1 $1.9 $— $65.0 
Equity securities53.9 497.2 — 551.1 
Fixed income securities211.4 405.5 — 616.9 
Assets held by insurance companies and other10.2 41.6 81.6 133.4 
Total$338.6 $946.2 $81.6 $1,366.4 
December 31, 2020
(In millions)Level 1Level 2Level 3Total
Cash and cash equivalents$51.2 $0.6 $— $51.8 
Equity securities145.3 468.1 — 613.4 
Fixed income securities292.6 299.4 — 592.0 
Assets held by insurance companies and other4.0 20.0 73.4 97.4 
Total$493.1 $788.1 $73.4 $1,354.6 
Schedule of Assumptions Used
The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2021 and 2020:
Pension BenefitsOther Postretirement Benefits
2021202020212020
Discount rate2.3 %1.9 %2.5 %1.9 %
Expected return on plan assets5.1 %4.3 %— %— %
Rate of compensation increase3.1 %2.9 %— %— %
The following weighted average assumptions were used to determine the net periodic benefit cost for the Company’s defined benefit pension and other postretirement benefit plans for the three years in the period ended December 31, 2021:
Pension BenefitsOther Postretirement Benefits
202120202019202120202019
Discount rate1.9 %1.6 %2.3 %1.9 %3.3 %4.3 %
Expected return on plan assets5.1 %4.3 %4.3 %— %— %— %
Rate of compensation increase2.9 %2.7 %2.9 %— %— %— %
Schedule of Expected Benefit Payments
Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows:
(In millions)Pension BenefitsOther Postretirement Benefits
2022$101.8 $16.1 
202397.1 16.5 
2024103.0 16.9 
2025100.7 16.8 
2026104.3 16.6 
Thereafter528.5 73.0 
Total$1,035.4 $155.9 
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Reconciliation of Segment Information to Total Consolidated Information
Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.
Net Sales
Segment Profitability
Years Ended December 31, Years Ended December 31,
(in millions)202120202019202120202019
Reportable Segments:
Developed Markets$10,428.7 $8,510.9 $8,240.0 $5,143.1 $4,243.9 $4,137.3 
Greater China2,212.8 259.9 214.6 1,397.1 52.7 89.9 
JANZ2,027.4 1,195.3 1,192.5 762.4 364.6 323.2 
Emerging Markets3,144.7 1,853.8 1,723.2 1,402.4 610.4 561.9 
Total reportable segments$17,813.6 $11,819.9 $11,370.3 $8,705.0 $5,271.6 $5,112.3 
Reconciling items:
Intangible asset amortization expense(2,702.2)(1,605.8)(1,582.7)
Intangible asset impairment charges(102.8)(82.4)(180.6)
Globally managed research and development costs(751.1)(555.1)(639.9)
Litigation settlements & other contingencies(329.2)(107.8)21.4 
Transaction related and other special items(2,832.2)(1,739.7)(682.2)
Corporate and other unallocated(2,021.5)(1,391.6)(1,332.8)
(Loss) earnings from operations$(34.0)$(210.8)$715.5 
Schedule of Revenue by Major Customers by Reporting Segments
The following table represents the percentage of consolidated net sales to Viatris’ major customers during the years ended December 31, 2021, 2020, and 2019:
Percentage of Consolidated Net Sales
202120202019
McKesson Corporation%13 %15 %
AmerisourceBergen Corporation%10 %%
Cardinal Health, Inc.%%%
Net Third Party Sales Classified Based on Geographic Location of Subsidiaries
Net sales by country are presented on the basis of geographic location of our subsidiaries:
Year Ended December 31,
(In millions)202120202019
United States$4,176.4 $3,746.1 $3,965.9 
China1,981.5 216.1 171.1 
____________
No other country’s net sales represents more than 10% of consolidated net sales.
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restructuring (Tables)
12 Months Ended
Dec. 31, 2021
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs [Table Text Block]
The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program:
(In millions)Employee Related CostsOther Exit CostsTotal
Charges (2)
$195.6 $75.7 $271.3 
Acquired in the Combination91.7 0.3 92.0 
Cash payment(25.1)(0.4)(25.5)
Utilization— (70.8)(70.8)
Foreign currency translation0.4 — 0.4 
Balance at December 31, 2020$262.6 $4.8 $267.4 
Charges (1)
396.1 496.1 892.2 
Reimbursable restructuring charges26.4 — 26.4 
Cash payment(385.5)(151.7)(537.2)
Utilization— (345.0)(345.0)
Foreign currency translation(7.0)(0.1)(7.1)
Balance at December 31, 2021$292.6 $4.1 $296.7 
(In millions)Employee Related CostsOther Exit CostsTotal
Balance at December 31, 2018:$60.8 $11.8 $72.6 
Charges (3)
16.6 88.0 $104.6 
Cash payment(48.9)(10.5)$(59.4)
Reclassifications— (8.1)$(8.1)
Utilization— (78.3)$(78.3)
Foreign currency translation(2.1)(0.1)$(2.2)
Balance at December 31, 2019:$26.4 $2.8 $29.2 
Charges (2)
9.9 40.6 50.5 
Cash payment(18.1)(7.6)(25.7)
Utilization— (32.9)(32.9)
Foreign currency translation$1.8 $(0.1)$1.7 
Balance at December 31, 2020:$20.0 $2.8 $22.8 
(1)     For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively.
(2)     For the year ended December 31, 2020, total restructuring charges, for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively.
(3)     For the year ended December 31, 2019, total restructuring charges for the 2016 Restructuring Program in Developed Markets and JANZ were approximately $100.4 million and $4.2 million, respectively.
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Operations (Narrative) (Details)
Dec. 31, 2021
molecule
site
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number Of Molecules | molecule 1,400
Number Of Manufacturing Sites | site 40
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Billions
12 Months Ended
Jan. 06, 2022
Dec. 16, 2021
Sep. 16, 2021
Jun. 16, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Mar. 16, 2022
Feb. 28, 2022
Accounting Policies [Line Items]                  
Finite-lived intangible asset, estimated useful life, in years         15 years 15 years      
Anti-dilutive securities excluded from computation of earnings per share         12.7 10.3 9.1    
Dividends paid per share   $ 0.11 $ 0.11 $ 0.11          
Subsequent Event                  
Accounting Policies [Line Items]                  
Common Stock, Dividends, Per Share, Declared $ 0.12                
Dividends Payable, Amount Per Share               $ 0.12  
Stock Repurchase Program, Authorized Amount                 $ 1
Minimum                  
Accounting Policies [Line Items]                  
Finite-lived intangible asset, estimated useful life, in years         3 years        
Maximum                  
Accounting Policies [Line Items]                  
Finite-lived intangible asset, estimated useful life, in years         20 years        
Machinery and equipment | Minimum                  
Accounting Policies [Line Items]                  
Property, plant and equipment, estimated service life (years)         3 years        
Machinery and equipment | Maximum                  
Accounting Policies [Line Items]                  
Property, plant and equipment, estimated service life (years)         18 years        
Buildings and improvements | Minimum                  
Accounting Policies [Line Items]                  
Property, plant and equipment, estimated service life (years)         15 years        
Buildings and improvements | Maximum                  
Accounting Policies [Line Items]                  
Property, plant and equipment, estimated service life (years)         39 years        
Capitalized software | Minimum                  
Accounting Policies [Line Items]                  
Property, plant and equipment, estimated service life (years)         3 years        
Capitalized software | Maximum                  
Accounting Policies [Line Items]                  
Property, plant and equipment, estimated service life (years)         7 years        
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]      
Net earnings $ (1,269.1) $ (669.9) $ 16.8
Weighted average common shares outstanding 1,208.8 601.2 515.7
Basic (loss) earnings per share attributable to Viatris Inc. shareholders $ (1.05) $ (1.11) $ 0.03
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants 0.0 0.0 0.8
Total dilutive shares outstanding 1,208.8 601.2 516.5
Diluted (loss) earnings per share attributable to Viatris Inc. shareholders $ (1.05) $ (1.11) $ 0.03
Retained Earnings      
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]      
Net earnings $ (1,269.1) $ (669.9) $ 16.8
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details)
€ in Millions, shares in Millions, $ in Millions
1 Months Ended 2 Months Ended 12 Months Ended
Nov. 13, 2020
USD ($)
shares
Jul. 29, 2019
USD ($)
Feb. 27, 2019
USD ($)
Sep. 20, 2018
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
EUR (€)
Dec. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
market
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jun. 25, 2021
EUR (€)
Business Acquisition [Line Items]                      
Research and development               $ 751.1 $ 555.1 $ 639.9  
Contingent consideration liability         $ 223.6   $ 223.6 199.7 223.6 250.7  
Goodwill         12,347.0   12,347.0 12,113.7 12,347.0 $ 9,590.6  
Machinery and equipment                      
Business Acquisition [Line Items]                      
Acquired intangible assets, weighted average useful life, in years 5 years                    
Finite-Lived Intangible Assets                      
Business Acquisition [Line Items]                      
Acquired intangible assets, weighted average useful life, in years 15 years                    
Maximum | Building                      
Business Acquisition [Line Items]                      
Acquired intangible assets, weighted average useful life, in years 20 years                    
Minimum | Building                      
Business Acquisition [Line Items]                      
Acquired intangible assets, weighted average useful life, in years 10 years                    
Upjohn Inc.                      
Business Acquisition [Line Items]                      
Cash paid to acquire asset $ 12,000.0                    
Business Acquisition, Percentage of Voting Interests Acquired   43.00%                  
Property, plant and equipment         1,394.1   1,394.1 1,389.1 1,394.1    
Business Combination, Acquisition Related Costs               234.6 602.9    
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable $ 10,730.0                    
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares 689.9                    
Net earnings             360.9 1,483.7 1,873.5    
Total revenues             866.5 18,284.8 21,582.7    
Goodwill $ 2,400.0       2,107.5   2,107.5 2,403.1 2,107.5    
Inventories 1,430.0             (34.2)      
Property, plant and equipment 385.0             (5.0)      
Identified intangible assets 18,040.0       18,040.0   $ 18,040.0 18,040.0 18,040.0    
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt $ 759.4                    
Amortization of Inventory Step Up               $ 1,190.0 $ 238.2    
Number Of Markets | market               165      
Other companies | Product rights and licenses                      
Business Acquisition [Line Items]                      
Acquisition purchase price               $ 10.0      
Aspen Global Incorporated                      
Business Acquisition [Line Items]                      
Acquisition purchase price | €           € 641.9          
Cash paid to acquire asset | €           € 263.2          
Aspen Global Incorporated | Contractual Rights                      
Business Acquisition [Line Items]                      
Acquired intangible assets, weighted average useful life, in years           8 years          
FKB                      
Business Acquisition [Line Items]                      
Upfront payments     $ 33.0 $ 25.0              
Research and development     $ 23.3                
Net sales | Upjohn Inc.                      
Business Acquisition [Line Items]                      
Number Of Products   20                  
Pfizer, Inc.                      
Business Acquisition [Line Items]                      
Inventory, Firm Purchase Commitment, Loss         $ 86.5            
Pfizer, Inc. | Upjohn Inc.                      
Business Acquisition [Line Items]                      
Noncontrolling Interest, Ownership Percentage by Parent   57.00%                  
Upjohn Inc. | Pfizer, Inc.                      
Business Acquisition [Line Items]                      
Payments for Business Separation   $ 12,000.0                  
Scenario, Plan | Aspen Global Incorporated                      
Business Acquisition [Line Items]                      
Contingent consideration liability | €                     € 378.7
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Acquisitions and Other Transactions (Purchase Price Allocations) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Nov. 13, 2020
Dec. 31, 2021
Dec. 31, 2020
Nov. 16, 2020
Dec. 31, 2019
May 28, 2019
Business Acquisition, Date of Acquisition [Abstract]              
Goodwill $ 12,347.0   $ 12,113.7 $ 12,347.0   $ 9,590.6  
Cash Acquired from Acquisition 415.8            
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]              
Goodwill       295.6      
Other assets     (7.4)        
Deferred tax liabilities     1.0        
Upjohn Inc. | Pfizer, Inc.              
Business Acquisition, Date of Acquisition [Abstract]              
Long-term debt, including current portion         $ 13,080.0    
Upjohn Inc.              
Business Acquisition, Date of Acquisition [Abstract]              
Current assets (excluding inventories and net of cash acquired) 2,841.9   2,803.2 2,841.9      
Inventories 2,588.9   2,554.7 2,588.9      
Property, plant and equipment 1,394.1   1,389.1 1,394.1      
Identified intangible assets 18,040.0 $ 18,040.0 18,040.0 18,040.0      
Goodwill 2,107.5 2,400.0 2,403.1 2,107.5      
Deferred income tax benefit 1,481.9   1,678.2 1,481.9      
Other assets 792.1   784.7 792.1      
Total assets acquired 29,246.4   29,653.0 29,246.4      
Current liabilities 2,760.2   3,179.9 2,760.2      
Long-term debt, including current portion 13,076.2   13,076.2 13,076.2      
Deferred tax liabilities 1,656.9   1,657.9 1,656.9      
Other noncurrent liabilities 1,441.5   1,427.4 1,441.5      
Net assets acquired $ 10,311.6   10,311.6 $ 10,311.6     $ 10,730.0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]              
Current assets (excluding inventories and net of cash acquired)     (38.7)        
Inventories   1,430.0 (34.2)        
Property, plant and equipment   $ 385.0 (5.0)        
Goodwill     295.6        
Deferred income tax benefit     196.3        
Total assets acquired     406.6        
Current liabilities     419.7        
Other noncurrent liabilities     (14.1)        
Net assets acquired (net of $415.8 of cash acquired)     $ 0.0        
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Acquisitions and Other Transactions (Unaudited Pro Forma Financial Results) (Details) - Upjohn Inc. - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
2 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Business Acquisition [Line Items]      
Total revenues $ 866.5 $ 18,284.8 $ 21,582.7
Net earnings $ 360.9 $ 1,483.7 $ 1,873.5
Basic (in usd per share)   $ 1.23 $ 1.55
Diluted (in usd per share)   $ 1.23 $ 1.55
Basic (in shares)   1,206.8 1,205.6
Diluted (in shares)   1,207.7 1,206.4
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]      
Net sales $ 17,813.6 $ 11,819.9 $ 11,370.3
Brands      
Disaggregation of Revenue [Line Items]      
Net sales 10,841.3 5,234.9 5,362.1
Complex Gx and Biosimilars      
Disaggregation of Revenue [Line Items]      
Net sales 1,342.1 1,295.5 1,211.3
Generics      
Disaggregation of Revenue [Line Items]      
Net sales 5,630.2 5,289.5 4,796.9
Net sales      
Disaggregation of Revenue [Line Items]      
Net sales 17,813.6 11,819.9 11,370.3
Developed Markets | Brands      
Disaggregation of Revenue [Line Items]      
Net sales 5,759.2 3,920.7 4,199.1
Developed Markets | Complex Gx and Biosimilars      
Disaggregation of Revenue [Line Items]      
Net sales 1,241.6 1,202.6 1,127.4
Developed Markets | Generics      
Disaggregation of Revenue [Line Items]      
Net sales 3,427.9 3,387.6 2,913.5
Greater China | Brands      
Disaggregation of Revenue [Line Items]      
Net sales 2,207.8 253.9 207.6
Greater China | Complex Gx and Biosimilars      
Disaggregation of Revenue [Line Items]      
Net sales 0.2 0.7 0.4
Greater China | Generics      
Disaggregation of Revenue [Line Items]      
Net sales 4.8 5.3 6.6
JANZ | Brands      
Disaggregation of Revenue [Line Items]      
Net sales 1,197.1 617.0 533.3
JANZ | Complex Gx and Biosimilars      
Disaggregation of Revenue [Line Items]      
Net sales 46.5 42.8 23.8
JANZ | Generics      
Disaggregation of Revenue [Line Items]      
Net sales 783.8 535.5 635.4
Emerging Markets | Brands      
Disaggregation of Revenue [Line Items]      
Net sales 1,677.2 443.3 422.1
Emerging Markets | Complex Gx and Biosimilars      
Disaggregation of Revenue [Line Items]      
Net sales 53.8 49.4 59.7
Emerging Markets | Generics      
Disaggregation of Revenue [Line Items]      
Net sales 1,413.7 1,361.1 1,241.4
Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales 17,813.6 11,819.9  
Operating Segments | Developed Markets      
Disaggregation of Revenue [Line Items]      
Net sales 10,428.7 8,510.9 8,240.0
Operating Segments | Greater China      
Disaggregation of Revenue [Line Items]      
Net sales 2,212.8 259.9 214.6
Operating Segments | JANZ      
Disaggregation of Revenue [Line Items]      
Net sales 2,027.4 1,195.3 1,192.5
Operating Segments | Emerging Markets      
Disaggregation of Revenue [Line Items]      
Net sales $ 3,144.7 $ 1,853.8 $ 1,723.2
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]      
Net sales $ 17,813.6 $ 11,819.9 $ 11,370.3
Lipitor ®      
Disaggregation of Revenue [Line Items]      
Net sales 1,663.2    
Norvasc ®      
Disaggregation of Revenue [Line Items]      
Net sales 824.7    
Lyrica ®      
Disaggregation of Revenue [Line Items]      
Net sales 728.5    
Viagra ®      
Disaggregation of Revenue [Line Items]      
Net sales 533.8    
EpiPen® Auto-Injectors      
Disaggregation of Revenue [Line Items]      
Net sales 391.7    
Celebrex ®      
Disaggregation of Revenue [Line Items]      
Net sales 344.4    
Creon ®      
Disaggregation of Revenue [Line Items]      
Net sales 316.8    
Zoloft ®      
Disaggregation of Revenue [Line Items]      
Net sales 309.8    
Effexor ®      
Disaggregation of Revenue [Line Items]      
Net sales 284.3    
Xalabrands      
Disaggregation of Revenue [Line Items]      
Net sales 226.0    
Influvac ®      
Disaggregation of Revenue [Line Items]      
Net sales 299.3    
Amitiza ®      
Disaggregation of Revenue [Line Items]      
Net sales 201.5    
Xanax ®      
Disaggregation of Revenue [Line Items]      
Net sales 185.9    
Yupelri ®      
Disaggregation of Revenue [Line Items]      
Net sales 168.0    
Dymista ®      
Disaggregation of Revenue [Line Items]      
Net sales $ 161.9    
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Accounts Receivable (Narrative) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Revenue Recognition And Accounts Receivable [Line Items]    
Securitized accounts receivable $ 388.9 $ 389.4
Receivables Facility [Member]    
Revenue Recognition And Accounts Receivable [Line Items]    
Accounts receivable securitization facility maximum borrowing capacity $ 400.0  
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Accounts Receivable Variable Consideration (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]      
Gross sales $ 30,553.4 $ 19,899.1 $ 19,012.2
Chargebacks (5,530.1) (3,656.2) (3,309.6)
Rebates, promotional programs and other sales allowances (6,135.6) (3,765.5) (3,629.3)
Returns (384.6) (329.7) (237.9)
Medicaid and other governmental rebates (689.5) (327.8) (465.1)
Sales Revenue, Gross to net adjustments 12,739.8 8,079.2 7,641.9
Net sales 17,813.6 11,819.9 11,370.3
Net sales      
Disaggregation of Revenue [Line Items]      
Net sales 17,813.6 11,819.9 $ 11,370.3
Operating Segments      
Disaggregation of Revenue [Line Items]      
Net sales $ 17,813.6 $ 11,819.9  
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Accounts receivable, net $ 3,774.4 $ 3,891.3    
Other receivables 492.0 952.5    
Accounts receivable, net 4,266.4 4,843.8    
Proceeds from Sale and Collection of Receivables 29.6 153.0    
Allowance for doubtful accounts        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $ 154.5 $ 159.9 $ 72.8 $ 98.2
Credit Concentration Risk | Accounts Receivable | Three Customers        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Concentration risk, percentage 18.00% 12.00%    
Variable Consideration [Member]        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Accounts receivable, net $ 1,688.6 $ 1,802.9    
Other receivables 1,362.1 1,211.8    
Accounts receivable, net $ 3,050.7 $ 3,014.7    
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details)
$ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
Accounts Receivable, Variable Consideration [Roll Forward]  
Beginning of period $ 4,843.8
End of period 4,266.4
Variable Consideration [Member]  
Accounts Receivable, Variable Consideration [Roll Forward]  
Beginning of period 3,014.7
Current Provision Related to Sales Made in the Current Period 12,739.8
Measurement Period Adjustments and Reclasses 385.4
Checks/ Credits Issued to Third Parties (13,056.7)
Effects of Foreign Exchange (32.5)
End of period 3,050.7
Variable Consideration [Member] | Chargebacks [Member]  
Accounts Receivable, Variable Consideration [Roll Forward]  
Beginning of period 585.2
Current Provision Related to Sales Made in the Current Period 5,530.1
Measurement Period Adjustments and Reclasses 63.4
Checks/ Credits Issued to Third Parties (5,585.4)
Effects of Foreign Exchange (1.6)
End of period 591.7
Variable Consideration [Member] | Rebates, Promotional Programs and Other Sales Allowances [Member]  
Accounts Receivable, Variable Consideration [Roll Forward]  
Beginning of period 1,576.3
Current Provision Related to Sales Made in the Current Period 6,135.6
Measurement Period Adjustments and Reclasses (57.6)
Checks/ Credits Issued to Third Parties (6,267.1)
Effects of Foreign Exchange (14.2)
End of period 1,373.0
Variable Consideration [Member] | Variable Consideration Returns [Member]  
Accounts Receivable, Variable Consideration [Roll Forward]  
Beginning of period 539.9
Current Provision Related to Sales Made in the Current Period 384.6
Measurement Period Adjustments and Reclasses 269.0
Checks/ Credits Issued to Third Parties (499.0)
Effects of Foreign Exchange (7.7)
End of period 686.8
Variable Consideration [Member] | Governmental Rebate Programs [Member]  
Accounts Receivable, Variable Consideration [Roll Forward]  
Beginning of period 313.3
Current Provision Related to Sales Made in the Current Period 689.5
Measurement Period Adjustments and Reclasses 110.6
Checks/ Credits Issued to Third Parties (705.2)
Effects of Foreign Exchange (9.0)
End of period $ 399.2
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]        
Capitalized Computer Software, Net $ 62.3 $ 70.9    
Net realizable value of inventory recognized as expense 474.9 206.1 $ 399.2  
Depreciation 509.5 289.7 256.1  
Other Liabilities, Current 4,619.6 4,960.7    
Allowance for doubtful accounts        
Schedule of Equity Method Investments [Line Items]        
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $ 154.5 $ 159.9 $ 72.8 $ 98.2
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 701.2 $ 844.4 $ 475.6  
Restricted cash, included in other current and non-current assets 5.0 5.6 15.5  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 706.2 $ 850.0 $ 491.1 $ 389.3
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Accounts receivable, net) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Receivables, Net, Current [Abstract]    
Trade receivables, net $ 3,774.4 $ 3,891.3
Other receivables 492.0 952.5
Accounts receivable, net 4,266.4 4,843.8
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Proceeds from Sale and Collection of Receivables $ 29.6 $ 153.0
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Inventories) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Inventory, Net [Abstract]      
Raw materials $ 922.4 $ 958.4  
Work in process 993.3 1,438.1  
Finished goods 2,062.0 3,075.4  
Inventories 3,977.7 5,471.9  
Inventory reserves 519.0 353.6  
Net realizable value of inventory recognized as expense $ 474.9 $ 206.1 $ 399.2
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Prepaids and other current assets) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Prepaid Expense and Other Assets, Current [Abstract]      
Prepaid expenses $ 256.7 $ 267.8  
Restricted cash 5.0 5.6 $ 15.5
Available-for-sale fixed income securities 38.2 39.1  
Fair value of financial instruments 144.6 118.6  
Equity securities 51.0 45.8  
Other current assets 1,467.1 1,236.1  
Prepaid expenses and other current assets $ 1,957.6 $ 1,707.4  
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Property, Plant and Equipment) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 5,589.1 $ 5,721.9
Accumulated depreciation 2,400.5 2,262.0
Property, plant and equipment, net 3,188.6 3,459.9
Land and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 137.9 155.8
Buildings and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 1,808.5 1,954.8
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 3,054.0 3,235.0
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 588.7 $ 376.3
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Other Assets) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Schedule of Other Assets [Line Items]    
Operating Lease, Right-of-Use Asset $ 290.8 $ 323.6
Other long-term assets 879.9 676.0
Other assets 1,170.7 1,047.5
Clean energy investments | Other assets    
Schedule of Other Assets [Line Items]    
Investments in subsidiaries $ 0.0 $ 47.9
XML 77 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Trade Accounts Payable) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Accounts Payable, Current [Abstract]    
Trade accounts payable $ 1,056.1 $ 1,345.7
Other payables 601.3 558.5
Accounts payable $ 1,657.4 $ 1,904.2
XML 78 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Other Current Liabilities) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Schedule of other current liabilities [Line Items]      
Other receivables $ 492.0 $ 952.5  
Employee-related Liabilities, Current 741.9 828.2  
Estimated Litigation Liability, Current 715.6 362.9  
Contingent consideration liability 199.7 223.6 $ 250.7
Restructuring Reserve, Current 233.5 149.2  
Accrued interest 86.6 90.9  
Liability derivatives, fair value 61.0 103.6  
Operating Lease, Liability, Current 86.7 92.9  
Other Accrued Liabilities, Current 1,254.6 1,973.2  
Other current liabilities 4,619.6 4,960.7  
Variable Consideration [Member]      
Schedule of other current liabilities [Line Items]      
Other receivables 1,362.1 1,211.8  
Clean energy investments      
Schedule of other current liabilities [Line Items]      
Other liabilities 10.9 47.5  
Other current liabilities      
Schedule of other current liabilities [Line Items]      
Contingent consideration liability $ 66.7 $ 100.5 $ 120.4
XML 79 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Other noncurrent liabilities) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Schedule of Other Noncurrent Liabilities [Line Items]      
Liability, Defined Benefit Pension Plan, Noncurrent $ 876.4 $ 1,020.4  
Contingent consideration liability 199.7 223.6 $ 250.7
Liability for Uncertainty in Income Taxes, Noncurrent 426.1 469.5  
Operating Lease, Liability, Noncurrent 200.9 229.5  
Restructuring Reserve, Noncurrent 64.3 134.8  
Liabilities, Other than Long-term Debt, Noncurrent 232.9 505.8  
Other Liabilities, Noncurrent 1,933.6 2,483.1  
Other Noncurrent Liabilities      
Schedule of Other Noncurrent Liabilities [Line Items]      
Contingent consideration liability $ 133.0 $ 123.1 $ 130.3
XML 80 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Narrative) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2019
Dec. 31, 2017
Dec. 31, 2020
Lessee, Lease, Description [Line Items]        
Right-of-use asset $ 290,800     $ 323,600
Total lease liability 287,600      
Amount of operating leases not yet commenced $ 13,600      
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Other Assets, Noncurrent     Other Assets, Noncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Other Liabilities, Current     Other Liabilities, Current
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other Liabilities, Noncurrent     Other Liabilities, Noncurrent
Payments for Rent $ 97,600 $ 80,700 $ 87,600  
Minimum        
Lessee, Lease, Description [Line Items]        
Term of operating leases not yet commenced 5 years      
Maximum        
Lessee, Lease, Description [Line Items]        
Term of operating leases not yet commenced 9 years      
XML 81 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Lease Information) (Details)
Dec. 31, 2021
Lessee, Lease, Description [Line Items]  
Weighted-average remaining lease term 6 years
Weighted-average discount rate 2.60%
Minimum  
Lessee, Lease, Description [Line Items]  
Remaining lease terms 1 year
Maximum  
Lessee, Lease, Description [Line Items]  
Remaining lease terms 23 years
XML 82 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Lease Maturities) (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Leases [Abstract]  
2022 $ 82,000
2023 65,000
2024 42,900
2025 28,800
2026 23,900
Thereafter 68,200
Total lease payments 310,800
Less imputed interest 23,200
Total lease liability $ 287,600
XML 83 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Method Investments (Narrative) (Details)
$ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Schedule of Equity Method Investments [Line Items]      
Equity Method Investments Net Gain (Loss) From Impairment and Reduction In Obligations $ 5.7 $ 21.4 $ 7.0
Loss from equity method investments $ 61.9 $ 48.4 $ 62.1
Clean energy investments      
Schedule of Equity Method Investments [Line Items]      
Number of equity method investments 3    
XML 84 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Method Investments (Balance Sheet) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]    
Other current liabilities $ 4,619.6 $ 4,960.7
Other Liabilities, Noncurrent 1,933.6 2,483.1
Clean energy investments    
Schedule of Equity Method Investments [Line Items]    
Other liabilities 10.9 47.5
Other assets | Clean energy investments    
Schedule of Equity Method Investments [Line Items]    
Investments in subsidiaries $ 0.0 $ 47.9
XML 85 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Method Investments (Net Assets) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]    
Assets, Current $ 10,902.9 $ 12,867.5
Total assets 54,842.8 61,553.0
Current liabilities 9,884.4 10,562.9
Total liabilities 34,350.1 38,598.9
Consolidated Entity    
Schedule of Equity Method Investments [Line Items]    
Assets, Current 4.2 38.9
Noncurrent assets 0.5 1.0
Total assets 4.7 39.9
Current liabilities 2.8 33.0
Noncurrent liabilities 0.0 1.8
Total liabilities 2.8 34.8
Net assets $ 1.9 $ 5.1
XML 86 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Method Investments (Income Statement) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]      
Total revenues $ 17,886.3 $ 11,946.0 $ 11,500.5
Gross loss 5,575.5 3,796.7 3,897.6
Operating and non-operating expense (664.4) (721.2) 154.4
Net loss (1,269.1) (669.9) 16.8
Consolidated Entity      
Schedule of Equity Method Investments [Line Items]      
Total revenues 326.7 374.5 385.0
Gross loss (4.6) (4.6) (4.4)
Operating and non-operating expense 16.8 19.0 20.0
Net loss $ (21.4) $ (23.6) $ (24.4)
XML 87 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangible Assets (Narrative) (Details)
12 Months Ended
Apr. 01, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Intangible Assets Excluding Goodwill [Line Items]        
Finite-lived intangible assets, net   $ 26,087,700,000 $ 29,602,500,000  
Contingent consideration liability   199,700,000 223,600,000 $ 250,700,000
Contingent consideration payments   (83,200,000) (111,800,000)  
In-process research and development   46,500,000 80,700,000  
Goodwill, Impaired, Accumulated Impairment Loss   385,000,000.0 385,000,000.0 385,000,000.0
Goodwill   12,113,700,000 12,347,000,000 9,590,600,000
In-process research and development        
Intangible Assets Excluding Goodwill [Line Items]        
IPR&D intangible asset impairment charges   19,400,000 37,400,000 138,300,000
Product rights and licenses        
Intangible Assets Excluding Goodwill [Line Items]        
Finite-lived intangible assets, net   26,084,500,000 29,598,700,000  
Impairment of products rights and licenses intangible assets   83,400,000 45,000,000.0 42,300,000
Europe Segment        
Intangible Assets Excluding Goodwill [Line Items]        
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount $ 910,000,000      
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount 5.80%      
Goodwill $ 5,150,000,000      
Europe Segment | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input, Term 10 years      
North America Segment        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill $ 3,660,000,000      
JANZ        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill, Impaired, Accumulated Impairment Loss   0 0 0
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount $ 230,000,000      
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount 7.00%      
Goodwill $ 820,000,000 776,300,000 864,000,000.0 $ 584,800,000
JANZ | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input, Term 10 years      
JANZ | Product rights and licenses        
Intangible Assets Excluding Goodwill [Line Items]        
Finite-lived intangible assets, net   $ 1,495,800,000 $ 2,803,200,000  
Measurement Input, Discount Rate [Member] | In-process research and development | Minimum        
Intangible Assets Excluding Goodwill [Line Items]        
Rate used to discount net cash inflows to present values   0.070 0.090 0.090
Measurement Input, Discount Rate [Member] | In-process research and development | Maximum        
Intangible Assets Excluding Goodwill [Line Items]        
Rate used to discount net cash inflows to present values   0.090 0.110 0.110
Measurement Input, Discount Rate [Member] | Product rights and licenses | Minimum        
Intangible Assets Excluding Goodwill [Line Items]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   $ 0.090    
Measurement Input, Discount Rate [Member] | Product rights and licenses | Maximum        
Intangible Assets Excluding Goodwill [Line Items]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   0.110    
Measurement Input, Discount Rate [Member] | JANZ | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.085      
Measurement Input, Long-term Revenue Growth Rate [Member] | Europe Segment | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.030      
Measurement Input, Long-term Revenue Growth Rate [Member] | JANZ | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.015      
Measurement Input, Estimated Tax Rate [Member] | Europe Segment | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.190      
Measurement Input, Estimated Tax Rate [Member] | JANZ | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.305      
Measurement Input, EBITDA Multiple [Member] | Europe Segment | Minimum | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 7.5      
Measurement Input, EBITDA Multiple [Member] | Europe Segment | Maximum | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 8.5      
Measurement Input, EBITDA Multiple [Member] | JANZ | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 6.0      
Measurement Input, Control Premium [Member] | Europe Segment | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.150      
Measurement Input, Control Premium [Member] | JANZ | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.150      
Measurement Input, Terminal Year Revenue Growth Rate | Europe Segment | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.009      
Measurement Input, Terminal Year Revenue Growth Rate | JANZ | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.007      
Measurement Input, Reduction in Terminal Year Revenue Growth Rate | Europe Segment | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input (0.029)      
Measurement Input, Reduction in Terminal Year Revenue Growth Rate | JANZ | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input (0.042)      
Measurement Input, Increase in Discount Rate | Europe Segment | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.015      
Measurement Input, Increase in Discount Rate | JANZ | Valuation Technique, Discounted Cash Flow        
Intangible Assets Excluding Goodwill [Line Items]        
Goodwill Impairment, Measurement Input 0.020      
Respiratory delivery platform [Member]        
Intangible Assets Excluding Goodwill [Line Items]        
Contingent consideration liability   177,800,000    
Other current liabilities        
Intangible Assets Excluding Goodwill [Line Items]        
Contingent consideration liability   66,700,000 $ 100,500,000 $ 120,400,000
Contingent consideration payments   $ (83,200,000) $ (111,800,000)  
XML 88 R72.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Apr. 01, 2021
Goodwill [Line Items]        
Goodwill, gross, beginning balance $ 12,732.0 $ 9,975.6    
Accumulated impairment losses, beginning balance (385.0) (385.0)    
Goodwill 12,113.7 12,347.0 $ 9,590.6  
Acquisitions     2,107.5  
Foreign currency translation   (528.9) 648.9  
Goodwill, gross, ending balance 12,498.7 12,732.0 9,975.6  
Accumulated impairment losses, ending balance (385.0) (385.0) (385.0)  
Goodwill, net, ending balance 12,113.7 12,347.0 9,590.6  
Goodwill   295.6    
Developed Markets        
Goodwill [Line Items]        
Goodwill, gross, beginning balance 9,569.5 8,258.0    
Accumulated impairment losses, beginning balance (385.0) (385.0)    
Goodwill 8,723.4 9,184.5 7,873.0  
Acquisitions     704.3  
Foreign currency translation   (528.8) 607.2  
Goodwill, gross, ending balance 9,108.4 9,569.5 8,258.0  
Accumulated impairment losses, ending balance (385.0) (385.0) (385.0)  
Goodwill, net, ending balance 8,723.4 9,184.5 7,873.0  
Goodwill   67.7    
Greater China        
Goodwill [Line Items]        
Goodwill, gross, beginning balance 738.3 67.8    
Accumulated impairment losses, beginning balance 0.0 0.0    
Goodwill 969.5 738.3 67.8 $ 700.0
Acquisitions     652.8  
Foreign currency translation   10.8 17.7  
Goodwill, gross, ending balance 969.5 738.3 67.8  
Accumulated impairment losses, ending balance 0.0 0.0 0.0  
Goodwill, net, ending balance 969.5 738.3 67.8  
Goodwill   220.4    
JANZ        
Goodwill [Line Items]        
Goodwill, gross, beginning balance 864.0 584.8    
Accumulated impairment losses, beginning balance 0.0 0.0    
Goodwill 776.3 864.0 584.8 820.0
Acquisitions     217.4  
Foreign currency translation   (56.8) 61.8  
Goodwill, gross, ending balance 776.3 864.0 584.8  
Accumulated impairment losses, ending balance 0.0 0.0 0.0  
Goodwill, net, ending balance 776.3 864.0 584.8  
Goodwill   (30.9)    
Emerging Markets        
Goodwill [Line Items]        
Goodwill, gross, beginning balance 1,560.2 1,065.0    
Accumulated impairment losses, beginning balance 0.0 0.0    
Goodwill 1,644.5 1,560.2 1,065.0 $ 1,580.0
Acquisitions     533.0  
Foreign currency translation   45.9 (37.8)  
Goodwill, gross, ending balance 1,644.5 1,560.2 1,065.0  
Accumulated impairment losses, ending balance 0.0 0.0 0.0  
Goodwill, net, ending balance $ 1,644.5 1,560.2 $ 1,065.0  
Goodwill   $ 38.4    
XML 89 R73.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Finite-lived intangible asset, estimated useful life, in years 15 years 15 years
Finite-lived intangible assets, original cost $ 39,006.2 $ 40,404.1
Finite-lived intangible assets, accumulated amortization 12,918.5 10,801.6
Finite-lived intangible assets, net book value 26,087.7 29,602.5
In-process research and development 46.5 80.7
Intangible assets, gross, excluding goodwill 39,052.7 40,484.8
Intangible assets, net book value, excluding goodwill $ 26,134.2 $ 29,683.2
XML 90 R74.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net $ 26,087.7 $ 29,602.5
Product rights and licenses    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 26,084.5 29,598.7
Product rights and licenses | Developed Markets    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 14,313.6 17,514.5
Product rights and licenses | Greater China    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 6,115.0 4,385.0
Product rights and licenses | JANZ    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 1,495.8 2,803.2
Product rights and licenses | Emerging Markets    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 4,160.1 4,896.0
Product rights and licenses | Brands    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 21,146.0 22,216.1
Product rights and licenses | Brands | Developed Markets    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 10,066.6 10,988.1
Product rights and licenses | Brands | Greater China    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 6,102.9 4,372.3
Product rights and licenses | Brands | JANZ    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 1,174.8 2,377.0
Product rights and licenses | Brands | Emerging Markets    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 3,801.7 4,478.7
Product rights and licenses | Complex Gx and Biosimilars    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 228.3 274.8
Product rights and licenses | Complex Gx and Biosimilars | Developed Markets    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 226.8 272.5
Product rights and licenses | Complex Gx and Biosimilars | Greater China    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 0.0 0.0
Product rights and licenses | Complex Gx and Biosimilars | JANZ    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 1.5 2.3
Product rights and licenses | Complex Gx and Biosimilars | Emerging Markets    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 0.0 0.0
Product rights and licenses | Generics    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 4,710.2 7,107.8
Product rights and licenses | Generics | Developed Markets    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 4,020.2 6,253.9
Product rights and licenses | Generics | Greater China    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 12.1 12.7
Product rights and licenses | Generics | JANZ    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 319.5 423.9
Product rights and licenses | Generics | Emerging Markets    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net $ 358.4 $ 417.3
XML 91 R75.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangible Assets (Amortization Expense) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Intangible Assets Excluding Goodwill [Line Items]      
Intangible asset amortization expense $ 2,702.2 $ 1,605.8 $ 1,582.7
Total intangible asset amortization expense (including impairment charges) 2,805.0 1,688.2 1,763.3
In-process research and development      
Intangible Assets Excluding Goodwill [Line Items]      
IPR&D intangible asset impairment charges $ 19.4 $ 37.4 $ 138.3
XML 92 R76.htm IDEA: XBRL DOCUMENT v3.22.0.1
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2022 $ 2,577
2023 2,414
2024 2,320
2025 2,222
2026 $ 2,164
XML 93 R77.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Narrative) (Details)
€ in Millions, ¥ in Millions, $ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2021
EUR (€)
Dec. 31, 2021
JPY (¥)
Dec. 31, 2020
EUR (€)
Dec. 31, 2020
JPY (¥)
Derivative [Line Items]              
Notional amount of derivative   $ 750.0          
Gain (Loss) on Fair Value Hedges Recognized in Earnings $ 39.3 (10.1) $ (17.3)        
Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months 21.0            
Purchase consideration, contingent consideration 199.7 223.6 250.7        
Reclassifications 0.0 0.0          
Accretion 9.0 11.6          
Contingent consideration payments (83.2) (111.8)          
Minimum              
Derivative [Line Items]              
Accretion 6.0            
Maximum              
Derivative [Line Items]              
Accretion 8.0            
Respiratory delivery platform [Member]              
Derivative [Line Items]              
Purchase consideration, contingent consideration $ 177.8            
2020 Euro Senior Notes              
Derivative [Line Items]              
Debt instrument, interest rate, stated percentage 0.816%     0.816% 0.816%    
2022 Euro Senior Notes              
Derivative [Line Items]              
Long-term debt $ 0.0 928.8          
Debt instrument, interest rate, stated percentage 0.816%     0.816% 0.816%    
2.125% Euro Senior Notes due 2025              
Derivative [Line Items]              
Debt instrument, interest rate, stated percentage 1.023%     1.023% 1.023%    
2027 Euro Senior Notes              
Derivative [Line Items]              
Debt instrument, interest rate, stated percentage 1.362%     1.362% 1.362%    
YEN Term Loan              
Derivative [Line Items]              
Long-term debt $ 347.6            
Senior Notes | 2.250% Euro Senior Notes due 2024              
Derivative [Line Items]              
Long-term debt $ 1,135.8 1,219.9          
Debt instrument, interest rate, stated percentage 2.25%     2.25% 2.25%    
Senior Notes | 2.125% Euro Senior Notes due 2025              
Derivative [Line Items]              
Long-term debt $ 871.6 944.6          
Senior Notes | 2025 Euro Senior Notes              
Derivative [Line Items]              
Long-term debt $ 567.8 609.9          
Debt instrument, interest rate, stated percentage 2.125%     2.125% 2.125%    
Senior Notes | 2028 Senior Notes              
Derivative [Line Items]              
Long-term debt $ 748.7 748.6          
Debt instrument, interest rate, stated percentage 4.55%     4.55% 4.55%    
Senior Notes | 2027 Euro Senior Notes              
Derivative [Line Items]              
Long-term debt $ 1,013.0 1,097.4          
Senior Notes | 2032 Euro Senior Notes              
Derivative [Line Items]              
Long-term debt $ 1,546.6 1,672.6          
Debt instrument, interest rate, stated percentage 1.908%     1.908% 1.908%    
Senior Notes | 2028 Euro Senior Notes              
Derivative [Line Items]              
Long-term debt $ 847.4 909.7          
Debt instrument, interest rate, stated percentage 3.125%     3.125% 3.125%    
Senior Notes | Senior Notes 2023 3.125%              
Derivative [Line Items]              
Long-term debt $ 766.1 781.6          
Debt instrument, interest rate, stated percentage 3.125%     3.125% 3.125%    
Net Investment Hedging              
Derivative [Line Items]              
Notional amount of derivative       € 5,850.0 ¥ 40,000 € 5,955.6 ¥ 0
Long-term debt       5,955.6 40,000    
Net Investment Hedging | 2022 Euro Senior Notes              
Derivative [Line Items]              
Notional amount of derivative | €       750.0   750.0  
Long-term debt | €       750.0      
Net Investment Hedging | 2.250% Euro Senior Notes due 2024              
Derivative [Line Items]              
Notional amount of derivative | €       1,000.0   1,000.0  
Long-term debt | €       1,000.0      
Net Investment Hedging | 2.125% Euro Senior Notes due 2025              
Derivative [Line Items]              
Notional amount of derivative | €       750.0   750.0  
Long-term debt | €       750.0      
Net Investment Hedging | 2025 Euro Senior Notes              
Derivative [Line Items]              
Notional amount of derivative | €       500.0   500.0  
Long-term debt | €       500.0      
Net Investment Hedging | 2028 Senior Notes              
Derivative [Line Items]              
Notional amount of derivative | €       750.0   750.0  
Long-term debt | €       750.0      
Net Investment Hedging | 2027 Euro Senior Notes              
Derivative [Line Items]              
Notional amount of derivative | €       850.0   850.0  
Long-term debt | €       850.0      
Net Investment Hedging | 2032 Euro Senior Notes              
Derivative [Line Items]              
Notional amount of derivative | €       1,250.0   1,250.0  
Long-term debt | €       1,250.0      
Net Investment Hedging | 2020 Floating Rate Euro Notes              
Derivative [Line Items]              
Notional amount of derivative | €       0.0   € 105.6  
Long-term debt | €       € 105.6      
Net Investment Hedging | YEN Term Loan              
Derivative [Line Items]              
Notional amount of derivative | ¥         40,000   ¥ 0
Long-term debt | ¥         ¥ 40,000    
Other Noncurrent Liabilities              
Derivative [Line Items]              
Purchase consideration, contingent consideration $ 133.0 123.1 130.3        
Reclassifications (49.4) (58.1)          
Accretion 9.0 11.6          
Contingent consideration payments 0.0 0.0          
Other current liabilities              
Derivative [Line Items]              
Purchase consideration, contingent consideration 66.7 100.5 $ 120.4        
Reclassifications 49.4 58.1          
Accretion 0.0 0.0          
Contingent consideration payments $ (83.2) $ (111.8)          
Measurement Input, Discount Rate [Member] | Minimum              
Derivative [Line Items]              
Derivative Asset (Liability) Net, Measurement Input   0.021       0.021 0.021
Measurement Input, Discount Rate [Member] | Maximum              
Derivative [Line Items]              
Derivative Asset (Liability) Net, Measurement Input   0.105       0.105 0.105
Measurement Input, Discount Rate [Member] | Contingent consideration | Minimum              
Derivative [Line Items]              
Rate used to discount net cash inflows to present values 0.080     0.080 0.080    
Measurement Input, Discount Rate [Member] | Contingent consideration | Maximum              
Derivative [Line Items]              
Rate used to discount net cash inflows to present values 0.105     0.105 0.105    
XML 94 R78.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Derivatives, Fair Value [Line Items]    
Fair value of financial instruments $ 144.6 $ 118.6
Liability derivatives, fair value 61.0 103.6
Designated as hedging instrument    
Derivatives, Fair Value [Line Items]    
Fair value of financial instruments 62.0 28.3
Designated as hedging instrument | Prepaid expenses and other current assets | Foreign Exchange Forward    
Derivatives, Fair Value [Line Items]    
Fair value of financial instruments 62.0 28.3
Designated as hedging instrument | Other current liabilities | Foreign Exchange Forward    
Derivatives, Fair Value [Line Items]    
Liability derivatives, fair value $ 4.3 $ 0.8
XML 95 R79.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Derivatives, Fair Value [Line Items]    
Fair value of financial instruments $ 144.6 $ 118.6
Liability derivatives, fair value 61.0 103.6
Not designated as hedging instrument    
Derivatives, Fair Value [Line Items]    
Fair value of financial instruments 82.6 90.3
Liability derivatives, fair value 56.7 102.8
Not designated as hedging instrument | Prepaid expenses and other current assets | Foreign Exchange Contract    
Derivatives, Fair Value [Line Items]    
Fair value of financial instruments 82.6 90.3
Not designated as hedging instrument | Other current liabilities | Foreign Exchange Contract    
Derivatives, Fair Value [Line Items]    
Liability derivatives, fair value $ 56.7 $ 102.8
XML 96 R80.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (Loss) on Fair Value Hedges Recognized in Earnings $ 39.3 $ (10.1) $ (17.3)
Other income | Foreign Exchange Contract      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Financial Instruments Not Designated as Hedging Instruments: 39.3 (10.1) (17.3)
Fair value hedging relationships | Interest Expense [Member] | Interest rate swaps      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative, Gain (Loss) on Derivative, Net 0.0 22.1 18.7
Fair value hedging relationships | Interest Expense [Member] | Senior Notes 2023 3.125%      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (Loss) on Fair Value Hedges Recognized in Earnings $ 0.0 $ (22.1) $ (18.7)
XML 97 R81.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Foreign Exchange Contract | Cash flow hedging relationships | Other income      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount of Gain Excluded from the Assessment of Hedge Effectiveness $ 0.0 $ 7.1 $ 0.0
XML 98 R82.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Financial Instruments in Net Investment Hedging Relationships: $ 479.0 $ (325.8) $ 76.3
Foreign currency borrowings and forward contracts | Cash Flow Hedging [Mem      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) : 45.8 20.6 16.6
Interest rate swaps | Cash Flow Hedging [Mem      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) : (3.4) 0.0 3.0
Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Foreign currency borrowings and forward contracts | Net Investment Hedging      
Derivative Instruments, Gain (Loss) [Line Items]      
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax $ 436.6 $ (346.4) $ 56.7
XML 99 R83.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Financial Instruments in Net Investment Hedging Relationships: $ 479.0 $ (325.8) $ 76.3
Cash flow hedging relationships | Foreign Exchange Contract | Sales [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net 30.9 4.8 (0.7)
Cash flow hedging relationships | Foreign Exchange Contract | Other income      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount of Gain Excluded from the Assessment of Hedge Effectiveness 0.0 7.1 0.0
Cash flow hedging relationships | Interest rate swaps | Interest Expense [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net $ (4.3) $ (4.5) $ (7.1)
XML 100 R84.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]      
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax $ 26.6 $ 0.3 $ (7.8)
Cash Flow Hedging [Mem | Foreign Exchange Contract | Sales [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net 30.9 4.8 (0.7)
Cash Flow Hedging [Mem | Interest rate swaps | Interest Expense [Member]      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net $ (4.3) $ (4.5) $ (7.1)
XML 101 R85.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 50.9 $ 0.9
Equity securities 51.0 45.8
Fair Value 38.2 39.1
Total assets at recurring fair value measurement 284.7 204.4
Total liabilities at recurring fair value measurement 260.7 327.2
Foreign Exchange Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange derivative assets 144.6 118.6
Foreign Exchange Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange derivative liabilities 61.0 103.6
Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 199.7 223.6
Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 50.9 0.9
Equity securities — exchange traded funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 50.3 45.1
Available-for-sale fixed income investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 38.2 39.1
U.S. Treasuries    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 14.6 14.4
Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 16.6 17.8
Agency mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 2.0 1.9
Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 4.6 4.6
Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0.4 0.4
Total equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities   45.8
Marketable securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 0.7  
Marketable Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities   0.7
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 50.9 0.9
Equity securities 51.0  
Total assets at recurring fair value measurement 101.9 46.7
Level 1 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 50.9 0.9
Level 1 | Equity securities — exchange traded funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 50.3 45.1
Level 1 | Total equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities   45.8
Level 1 | Marketable securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 0.7  
Level 1 | Marketable Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities   0.7
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets at recurring fair value measurement 182.8 157.7
Total liabilities at recurring fair value measurement 61.0 103.6
Level 2 | Foreign Exchange Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange derivative assets 144.6 118.6
Level 2 | Foreign Exchange Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign exchange derivative liabilities 61.0 103.6
Level 2 | Available-for-sale fixed income investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 38.2 39.1
Level 2 | U.S. Treasuries    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 14.6 14.4
Level 2 | Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 16.6 17.8
Level 2 | Agency mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 2.0 1.9
Level 2 | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 4.6 4.6
Level 2 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair Value 0.4 0.4
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total liabilities at recurring fair value measurement 199.7 223.6
Level 3 | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration $ 199.7 $ 223.6
XML 102 R86.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Schedule of Activity in Contingent Consideration [Roll Forward]    
Balance at beginning of period $ 223.6 $ 250.7
Payments 83.2 111.8
Accretion 9.0 11.6
Reclassifications 0.0 0.0
Fair value loss (gain) 50.3 73.1
Balance at end of period 199.7 223.6
Other current liabilities    
Schedule of Activity in Contingent Consideration [Roll Forward]    
Balance at beginning of period 100.5 120.4
Payments 83.2 111.8
Accretion 0.0 0.0
Reclassifications 49.4 58.1
Fair value loss (gain) 0.0 33.8
Balance at end of period 66.7 100.5
Other Noncurrent Liabilities    
Schedule of Activity in Contingent Consideration [Roll Forward]    
Balance at beginning of period 123.1 130.3
Payments 0.0 0.0
Accretion 9.0 11.6
Reclassifications (49.4) (58.1)
Fair value loss (gain) 50.3 39.3
Balance at end of period $ 133.0 $ 123.1
XML 103 R87.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 38.1 $ 37.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1 1.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Fair Value 38.2 39.1
Debt securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 38.1 37.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.1 1.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Fair Value $ 38.2 $ 39.1
XML 104 R88.htm IDEA: XBRL DOCUMENT v3.22.0.1
Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Mature within one year $ 1.2  
Mature in one to five years 19.7  
Mature in five years and later 17.3  
Available-for-sale securities, debt securities $ 38.2 $ 39.1
XML 105 R89.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt (Short-term borrowings) (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Short-term Debt [Line Items]    
Short-term borrowings $ 1,493,000 $ 1,100,900
Commercial Paper    
Short-term Debt [Line Items]    
Short-term borrowings 1,173,400 651,300
Receivables Facility [Member]    
Short-term Debt [Line Items]    
Short-term borrowings 318,500 248,400
Note Securitization Facility [Member]    
Short-term Debt [Line Items]    
Short-term borrowings 0 200,000
Other Current Portion of Long-term Debt    
Short-term Debt [Line Items]    
Short-term borrowings $ 1,100 $ 1,200
XML 106 R90.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt Debt (Receivables Facility and Commercial Paper Program) (Details) - USD ($)
$ in Thousands
12 Months Ended
Jun. 06, 2017
Dec. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]      
Short-term borrowings   $ 1,493,000 $ 1,100,900
Securitized accounts receivable   388,900 389,400
Commercial Paper Program [Member]      
Debt Instrument [Line Items]      
Line of Credit Facility, Maximum Borrowing Capacity $ 1,650,000    
Debt Instrument, Term 364 days    
Receivables Facility [Member]      
Debt Instrument [Line Items]      
Short-term borrowings   318,500 248,400
Accounts receivable securitization facility maximum borrowing capacity   400,000  
Note Securitization Facility [Member]      
Debt Instrument [Line Items]      
Short-term borrowings   0 $ 200,000
Accounts receivable securitization facility maximum borrowing capacity   $ 200,000  
London Interbank Offered Rate (LIBOR) [Member] | Receivables Facility [Member]      
Debt Instrument [Line Items]      
Debt Instrument, Basis Spread on Variable Rate   0.925%  
London Interbank Offered Rate (LIBOR) [Member] | Note Securitization Facility [Member]      
Debt Instrument [Line Items]      
Debt Instrument, Basis Spread on Variable Rate   0.85%  
XML 107 R91.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt (Summary of Long-term Debt) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]      
Debt, Current   $ 1,860.3 $ 2,256.3
Unamortized Debt Issuance Expense   (42.3) (47.8)
Long-term debt   19,717.1 22,429.2
Proceeds from Sale of Securities, Operating Activities $ 45.0    
Other Current Portion of Long-term Debt      
Debt Instrument [Line Items]      
Debt, Current   0.9 8.0
2020 Euro Senior Notes      
Debt Instrument [Line Items]      
Debt, Current   $ 856.6 0.0
Debt instrument, interest rate, stated percentage   0.816%  
2020 Senior Notes (3.750% coupon)      
Debt Instrument [Line Items]      
Debt, Current   $ 1,002.9 0.0
Debt instrument, interest rate, stated percentage   1.125%  
Other Long Term Debt      
Debt Instrument [Line Items]      
Long-term debt   $ 1.9 17.4
2020 Floating Rate Euro Notes      
Debt Instrument [Line Items]      
Debt, Current   $ 0.0 2,249.7
Senior Notes 2021      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   3.15%  
2022 Euro Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   0.816%  
Long-term debt   $ 0.0 928.8
Senior Notes 2022      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   1.125%  
Long-term debt   $ 0.0 1,008.8
2.125% Euro Senior Notes due 2025      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   1.023%  
2027 Euro Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   1.362%  
2027 Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   2.30%  
Term Loan      
Debt Instrument [Line Items]      
Long-term debt   $ 0.0  
Senior Notes | Senior Notes 2023 3.125%      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   3.125%  
Long-term debt   $ 766.1 781.6
Senior Notes | 2023 Senior Notes (4.200%)      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   4.20%  
Long-term debt   $ 499.6 499.3
Senior Notes | 2.250% Euro Senior Notes due 2024      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   2.25%  
Long-term debt   $ 1,135.8 1,219.9
Senior Notes | 2025 Euro Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   2.125%  
Long-term debt   $ 567.8 609.9
Senior Notes | 2026 Senior Notes (3.950%)      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   3.95%  
Long-term debt   $ 2,241.4 2,239.7
Senior Notes | 2028 Euro Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   3.125%  
Long-term debt   $ 847.4 909.7
Senior Notes | 2028 Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   4.55%  
Long-term debt   $ 748.7 748.6
Senior Notes | 2043 Senior Notes (5.400%)      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   5.40%  
Long-term debt   $ 497.3 497.3
Senior Notes | 2046 Senior Notes (5.250%)      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   5.25%  
Long-term debt   $ 999.9 999.9
Senior Notes | 2048 Senior Notes [Member]      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   5.20%  
Long-term debt   $ 747.8 747.7
Senior Notes | 2.125% Euro Senior Notes due 2025      
Debt Instrument [Line Items]      
Long-term debt   871.6 944.6
Senior Notes | 2027 Euro Senior Notes      
Debt Instrument [Line Items]      
Long-term debt   1,013.0 1,097.4
Senior Notes | 2027 Senior Notes      
Debt Instrument [Line Items]      
Long-term debt   $ 780.8 786.1
Senior Notes | 2030 Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   2.70%  
Long-term debt   $ 1,520.5 1,528.0
Senior Notes | 2032 Euro Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   1.908%  
Long-term debt   $ 1,546.6 1,672.6
Senior Notes | 2040 Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   3.85%  
Long-term debt   $ 1,657.1 1,663.3
Senior Notes | 2050 Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   4.00%  
Long-term debt   $ 2,205.1 2,209.3
Senior Notes | Term Loan      
Debt Instrument [Line Items]      
Long-term debt     600.0
Senior Notes | 2025 Senior Notes      
Debt Instrument [Line Items]      
Debt instrument, interest rate, stated percentage   1.65%  
Long-term debt   $ 763.4 767.1
Current portion of long-term debt      
Debt Instrument [Line Items]      
Unamortized Debt Issuance Expense   $ (0.1) $ (1.4)
XML 108 R92.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt (Revolving Facilities and Term Facilities) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Line of Credit Facility [Line Items]    
Debt, Current $ 1,860.3 $ 2,256.3
XML 109 R93.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt (Issuance of 2018 Senior Notes) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Long-term debt $ 19,717.1 $ 22,429.2
Senior Notes | 2028 Senior Notes    
Debt Instrument [Line Items]    
Debt instrument, interest rate, stated percentage 4.55%  
Senior Notes | 2048 Senior Notes [Member]    
Debt Instrument [Line Items]    
Debt instrument, interest rate, stated percentage 5.20%  
XML 110 R94.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt (Senior Notes) (Details)
$ in Millions, ¥ in Billions
Dec. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Jul. 31, 2021
JPY (¥)
Rate
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Debt Instrument [Line Items]            
Long-term debt $ 19,717.1       $ 22,429.2  
Long-term Debt, Gross $ 20,949.0          
Upjohn Inc.            
Debt Instrument [Line Items]            
Debt Instrument, Face Amount       $ 11,847.8    
2020 Euro Senior Notes            
Debt Instrument [Line Items]            
Debt instrument, interest rate, stated percentage 0.816%          
YEN Term Loan            
Debt Instrument [Line Items]            
Long-term debt $ 347.6          
Senior Notes | Upjohn Inc.            
Debt Instrument [Line Items]            
Debt Instrument, Face Amount   $ 7,450.0        
Senior Notes | 2.250% Euro Senior Notes due 2024            
Debt Instrument [Line Items]            
Debt instrument, interest rate, stated percentage 2.25%          
Long-term debt $ 1,135.8       1,219.9  
Senior Notes | 2.250% Euro Senior Notes due 2024 | Upjohn Inc.            
Debt Instrument [Line Items]            
Debt Instrument, Face Amount       916.2    
Senior Notes | 2028 Euro Senior Notes            
Debt Instrument [Line Items]            
Debt instrument, interest rate, stated percentage 3.125%          
Long-term debt $ 847.4       909.7  
Senior Notes | 2028 Senior Notes            
Debt Instrument [Line Items]            
Debt instrument, interest rate, stated percentage 4.55%          
Long-term debt $ 748.7       748.6  
Senior Notes | 2048 Senior Notes [Member]            
Debt Instrument [Line Items]            
Debt instrument, interest rate, stated percentage 5.20%          
Long-term debt $ 747.8       747.7  
Senior Notes | 2025 Euro Senior Notes            
Debt Instrument [Line Items]            
Debt instrument, interest rate, stated percentage 2.125%          
Long-term debt $ 567.8       $ 609.9  
Senior Notes | USD Term Loan Facility            
Debt Instrument [Line Items]            
Debt Instrument, Face Amount           $ 600.0
Revolving Credit Facility | Twenty Twenty One Revolving Facility            
Debt Instrument [Line Items]            
Line of Credit Facility, Maximum Borrowing Capacity       $ 4,000.0    
Revolving Credit Facility | 2020 Revolving Facility            
Debt Instrument [Line Items]            
Line of Credit Facility, Maximum Borrowing Capacity           $ 4,000.0
Medium-term Notes | YEN Term Loan            
Debt Instrument [Line Items]            
Debt Instrument, Face Amount | ¥     ¥ 40      
Medium-term Notes | Twenty Twenty One Loan Facilities            
Debt Instrument [Line Items]            
Maximum Leverage Ratio, Period Two | Rate     400.00%      
Maximum Leverage Ratio, Period One | Rate     425.00%      
Maximum Leverage Ratio, Period Three | Rate     375.00%      
XML 111 R95.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt (Fair Value) (Narrative) (Details) - USD ($)
$ in Millions
Nov. 13, 2020
Dec. 31, 2021
Dec. 31, 2020
Upjohn Inc.      
Debt Instrument [Line Items]      
Cash paid to acquire asset $ 12,000    
Senior Notes      
Debt Instrument [Line Items]      
Fair value of long-term debt   $ 22,010 $ 25,900
XML 112 R96.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt (Upjohn Senior Notes) (Details)
€ in Millions, $ in Millions
Oct. 29, 2021
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2021
EUR (€)
Debt Instrument [Line Items]        
Debt Instrument, Conversion Of Unregistered Notes To Registered Notes, As A Percentage 99.90%      
Upjohn Inc.        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     $ 11,847.8  
Upjohn Inc. | Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount   $ 7,450.0    
Upjohn Inc. | Senior Notes | 2022 Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     1,000.0  
Upjohn Inc. | Senior Notes | 2025 Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     750.0  
Upjohn Inc. | Senior Notes | 2027 Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     750.0  
Upjohn Inc. | Senior Notes | 2030 Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     1,450.0  
Upjohn Inc. | Senior Notes | 2040 Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     1,500.0  
Upjohn Inc. | Senior Notes | 2050 Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     2,000.0  
Upjohn Inc. | Senior Notes | 2022 Euro Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     916.2  
Upjohn Inc. | Senior Notes | 2027 Euro Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     1,038.4  
Upjohn Inc. | Senior Notes | 2.250% Euro Senior Notes due 2024        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     916.2  
Upjohn Inc. | Senior Notes | 2032 Euro Senior Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     1,527.0  
Upjohn Inc. | Senior Notes | Upjohn Euro Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount | €       € 3,600
Upjohn Inc. | Senior Notes | Unregistered Upjohn U.S. Dollar Notes        
Debt Instrument [Line Items]        
Debt Instrument, Face Amount     $ 7,450.0  
XML 113 R97.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt (Minimum Repayments on Outstanding Borrowings) (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Debt Disclosure [Abstract]  
2021 $ 1,853
2022 1,250
2023 1,990
2024 1,318
2025 2,598
Thereafter 11,940
Total $ 20,949
XML 114 R98.htm IDEA: XBRL DOCUMENT v3.22.0.1
Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Total equity $ 20,492.7 $ 22,954.1 $ 11,883.8 $ 12,167.1
Net unrealized gain on marketable securities, net of tax 0.0 1.2    
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax (32.2) 26.1    
Foreign currency translation adjustment (1,802.4) (461.5)    
Accumulated Other Comprehensive Income (Loss), Net of Tax (1,744.3) (858.0)    
Net unrealized gain on marketable securities, net of tax 0.0 1.2    
Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax 32.2 (26.1)    
Foreign currency translation adjustment (1,802.4) (461.5)    
Accumulated Other Comprehensive Income (Loss), Net of Tax (1,744.3) (858.0)    
Cumulative Effect, Period of Adoption, Adjustment        
Total equity       0.0
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax     0.2  
Accumulated Other Comprehensive Income (Loss), Net of Tax     (3.6)  
Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax     (0.2)  
Accumulated Other Comprehensive Income (Loss), Net of Tax     (3.6)  
AOCI Attributable to Parent [Member]        
Total equity (1,744.3)   (1,797.2) (1,441.3)
Accumulated Other Comprehensive Income (Loss), Net of Tax     (1,797.2) (1,441.3)
Accumulated Other Comprehensive Income (Loss), Net of Tax     (1,797.2) (1,441.3)
AOCI Attributable to Parent [Member] | Cumulative Effect, Period of Adoption, Adjustment        
Total equity       (3.6)
Foreign Currency Translation Adjustment        
Foreign currency translation adjustment     (1,674.5) (1,259.0)
Foreign currency translation adjustment (1,340.9) 1,213.0 (415.5)  
Foreign currency translation adjustment     (1,674.5) (1,259.0)
Cash flow hedging relationships | Gains and Losses on Derivatives in Cash Flow Hedging Relationships        
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax 9.2 (18.0)    
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax 9.2 (18.0)    
Cash flow hedging relationships | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Cumulative Effect, Period of Adoption, Adjustment        
Other Comprehensive Income, Other, Net of Tax     (3.4)  
Net Investment Hedging        
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 16.7 (353.6) (74.3) (130.9)
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax $ 16.7 $ (353.6) $ (74.3) $ (130.9)
XML 115 R99.htm IDEA: XBRL DOCUMENT v3.22.0.1
Comprehensive Earnings (Components of Other Comprehensive Loss) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Total equity $ 20,492.7 $ 22,954.1 $ 11,883.8 $ 12,167.1
Net unrealized gains on marketable securities, net of tax, beginning of period 1.2      
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period (26.1)      
Foreign currency translation adjustment, beginning of period (461.5)      
Accumulated other comprehensive loss, net of tax, beginning of period (858.0)      
Other comprehensive earnings (loss) before reclassifications, before tax (1.1)      
Net sales 17,813.6 11,819.9 11,370.3  
Interest expense (636.2) (497.8) (517.3)  
Amortization of prior service costs included in SG&A     0.0  
Other comprehensive (loss) earnings, before tax (775.2) 912.6 (343.1)  
Income tax related to items of other comprehensive (loss) earnings, derivatives (604.7) 51.3 (137.6)  
Net unrealized gains on marketable securities, net of tax, end of period 0.0 1.2    
Net unrealized gains on marketable securities, net of tax, end of period 32.2 (26.1)    
Foreign currency translation adjustment, end of period (1,802.4) (461.5)    
Accumulated other comprehensive loss, net of tax, end of period (1,744.3) (858.0)    
Net unrealized (loss) gain on marketable securities (1.1) 0.6 0.5  
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax (73.9) 14.0 24.8  
Income tax provision (benefit) 111.1 (26.6) 9.2  
Cumulative Effect, Period of Adoption, Adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Total equity       0.0
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period   (0.2)    
Accumulated other comprehensive loss, net of tax, beginning of period   (3.6)    
Net unrealized gains on marketable securities, net of tax, end of period     (0.2)  
Accumulated other comprehensive loss, net of tax, end of period     (3.6)  
Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Income tax related to items of other comprehensive (loss) earnings, derivatives (0.1)      
Gains and Losses on Derivatives in Cash Flow Hedging Relationships        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period   (31.6) (53.1)  
Other comprehensive earnings (loss) before reclassifications, before tax     29.3  
Income tax related to items of other comprehensive (loss) earnings, derivatives   (4.6)    
Net unrecognized gains (losses) on derivatives, net of tax, end of period     (31.6)  
Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Net sales     0.7  
Interest expense     7.1  
Income tax related to items of other comprehensive (loss) earnings, derivatives     12.2  
Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Foreign Exchange Contract | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Net sales (30.9) (4.8) 0.7  
Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Interest rate swaps | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Interest expense (4.3) (4.5) 7.1  
Gains and Losses on Marketable Securities        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Net unrealized gains on marketable securities, net of tax, beginning of period   0.6 0.0  
Other comprehensive earnings (loss) before reclassifications, before tax   0.6 0.5  
Net unrealized gains on marketable securities, net of tax, end of period     0.6  
Net unrealized (loss) gain on marketable securities     0.5  
Gains and Losses on Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Income tax related to items of other comprehensive (loss) earnings, derivatives   0.0 (0.1)  
Defined Pension Plan Items        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period   (17.4) 1.7  
Other comprehensive earnings (loss) before reclassifications, before tax 67.0 (12.1) (21.0)  
Net unrealized gains on marketable securities, net of tax, end of period     (17.4)  
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax     (24.8)  
Defined Pension Plan Items | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Amortization of prior service costs included in SG&A (0.5) 0.0 (0.9)  
Amortization of actuarial loss included in SG&A 7.4 (1.9) (2.9)  
Income tax related to items of other comprehensive (loss) earnings, derivatives (15.6) (5.3) (5.9)  
Foreign Currency Translation Adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Foreign currency translation adjustment, beginning of period   (1,674.5) (1,259.0)  
Other comprehensive earnings (loss) before reclassifications, before tax (1,340.9) 1,213.0 (415.5)  
Income tax related to items of other comprehensive (loss) earnings, derivatives   0.0    
Foreign currency translation adjustment, end of period     (1,674.5)  
Foreign currency translation adjustment (1,340.9) 1,213.0 (415.5)  
Foreign Currency Translation Adjustment | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Income tax related to items of other comprehensive (loss) earnings, derivatives 0.0   0.0  
Accumulated Other Comprehensive Loss        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Total equity (1,744.3)   (1,797.2) (1,441.3)
Accumulated other comprehensive loss, net of tax, beginning of period   (1,797.2) (1,441.3)  
Other comprehensive earnings (loss) before reclassifications, before tax (755.5) 914.8 (347.1)  
Other comprehensive (loss) earnings, before tax   912.6 (343.1)  
Accumulated other comprehensive loss, net of tax, end of period     (1,797.2)  
Accumulated Other Comprehensive Loss | Cumulative Effect, Period of Adoption, Adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Total equity       (3.6)
Accumulated Other Comprehensive Loss | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Amortization of prior service costs included in SG&A (0.5) 0.0 (0.9)  
Amortization of actuarial loss included in SG&A 7.4 (1.9) (2.9)  
Income tax provision (benefit) 111.1 (26.6) 9.2  
Accumulated Other Comprehensive Loss | Foreign Exchange Contract | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Net sales (30.9) (4.8) 0.7  
Accumulated Other Comprehensive Loss | Interest rate swaps | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Interest expense (4.3) (4.5) 7.1  
Cash flow hedging relationships | Gains and Losses on Derivatives in Cash Flow Hedging Relationships        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other comprehensive earnings (loss) before reclassifications, before tax 62.7 18.5    
Other comprehensive (loss) earnings, before tax 36.1      
Income tax related to items of other comprehensive (loss) earnings, derivatives (8.9)      
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax     37.1  
Cash flow hedging relationships | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Cumulative Effect, Period of Adoption, Adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other Comprehensive Income, Other, Net of Tax     (3.4)  
Cash flow hedging relationships | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Foreign Exchange Contract        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Net sales (30.9)      
Cash flow hedging relationships | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Foreign Exchange Contract | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Net sales   (4.8)    
Cash flow hedging relationships | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Interest rate swaps        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Interest expense (4.3)      
Cash flow hedging relationships | Gains and Losses on Derivatives in Cash Flow Hedging Relationships | Interest rate swaps | Reclassification out of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Interest expense   (4.5)    
Net Investment Hedging        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 16.7 (353.6) (74.3) $ (130.9)
Other comprehensive earnings (loss) before reclassifications, before tax 456.8 (305.2) 59.6  
Income tax related to items of other comprehensive (loss) earnings, derivatives $ (86.5) $ 25.9 $ (3.0)  
XML 116 R100.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2017
Dec. 31, 2016
Income Tax Contingency [Line Items]            
Deferred tax liability not recognized, amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries   $ 3,400.0        
Statutory tax rate   21.00% 21.00% 19.00%    
Valuation allowance, amount   $ 780.4 $ 443.6      
Expected foreign tax credits   230.3        
Unrecognized tax benefit   322.9 391.1 $ 92.1   $ 96.3
Unrecognized tax benefits that impact effective tax rate   230.2        
Accrued interest and penalties   96.8 86.7      
Interest expense (income) related to uncertain tax positions   18.5   6.0 $ 35.2  
Amount of unrecognized deferred tax liability   $ 55.0        
Deduction limit of GILTI tax   50.00%        
Unrecognized tax benefit — beginning of year   $ 322.9 391.1 92.1   $ 96.3
Reserve for Uncertain Tax Positions, Including Interest And Penalties   315.6        
CARES Act, Income Tax Expense (Benefit)     $ 22.1      
U.S. Federal Tax Authority            
Income Tax Contingency [Line Items]            
Net operating loss carryforwards   7.9        
U.S. State Tax Authority            
Income Tax Contingency [Line Items]            
Net operating loss carryforwards   3,100.0        
Foreign            
Income Tax Contingency [Line Items]            
Net operating loss carryforwards   1,570.0        
Foreign deductible attributes   39.6        
Credit carryforward   329.2        
Foreign | Australian Taxation Office            
Income Tax Contingency [Line Items]            
Partial payment of anticipated tax expense   56.0        
Indefinite | Foreign            
Income Tax Contingency [Line Items]            
Net operating loss carryforwards   748.4        
2016 through 2035 | Foreign            
Income Tax Contingency [Line Items]            
Net operating loss carryforwards   $ 817.8        
Tax Year 2015 | Domestic Tax Authority | Internal Revenue Service (IRS)            
Income Tax Contingency [Line Items]            
Income Tax Examination, Reserve for Uncertain Tax Position       155.0    
Income Tax Examination, Reserve Impact On Income Tax Provision       $ 144.9    
Scenario, Forecast            
Income Tax Contingency [Line Items]            
Deduction limit of GILTI tax 37.50%          
XML 117 R101.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Schedule of Components of Income Tax Provision) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Contingency [Line Items]      
Income tax provision (benefit) $ 604.7 $ (51.3) $ 137.6
Earnings (loss) before income taxes and noncontrolling interest:      
Operating and non-operating expense (664.4) (721.2) 154.4
Foreign Tax Authority      
Income Tax Contingency [Line Items]      
U.S. Federal Current 12.6 (6.4) 118.1
U.S. Federal Deferred (182.7) (277.0) (165.5)
Income tax provision (benefit), U.S. Federal (170.1) (283.4) (47.4)
Earnings (loss) before income taxes and noncontrolling interest:      
Earnings before income taxes and noncontrolling interest, United States (1,982.5) (945.5) (1,031.4)
U.S. State Tax Authority      
Income Tax Contingency [Line Items]      
U.S. State Current 7.7 (0.1) 21.1
U.S. State Deferred (10.8) 7.7 (13.6)
Income tax provision (benefit), U.S. State (3.1) 7.6 7.5
Non-U.S. state tax authority      
Income Tax Contingency [Line Items]      
Non-U.S. Current (91.3) 168.7 191.0
Non-U.S. Deferred 869.2 55.8 (13.5)
Income tax provision (benefit), Non-U.S. 777.9 224.5 177.5
Other Foreign Operations      
Earnings (loss) before income taxes and noncontrolling interest:      
Earnings before income taxes and noncontrolling interest, foreign $ 1,318.1 $ 224.3 $ 1,185.8
XML 118 R102.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Employee benefits $ 271.3 $ 273.0
Litigation reserves 94.4 43.5
Accounts receivable allowances 425.9 393.7
Inventory 187.8 1,187.9
Tax credit and loss carry-forwards 1,256.0 1,080.4
Operating lease assets 63.6 66.5
Interest expense 111.6 67.9
Intangible assets 151.1 156.3
Other 327.8 396.0
Total deferred tax assets, gross 2,889.5 3,665.2
Less: Valuation allowance (780.4) (443.6)
Total deferred tax assets 2,109.1 3,221.6
Deferred tax liabilities:    
Plant and equipment 19.6 50.2
Operating lease liabilities 63.6 66.5
Intangible assets and goodwill 3,468.3 4,058.6
Other 39.9 22.1
Total deferred tax liabilities 3,591.4 4,197.4
Deferred tax liabilities, net $ (1,482.3) $ (975.8)
XML 119 R103.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Contingency [Line Items]      
Statutory tax rate 21.00% 21.00% 19.00%
Valuation allowance (106.90%) (42.20%) 0.00%
Incremental US Tax on Foreign Earnings (36.90%) (3.60%) (8.60%)
Waived deductions under IRC § 59A 0.00% (3.30%) 64.50%
Impact of the Combination and Divestitures (2.80%) 5.80% 7.70%
Effective tax rate (91.00%) 7.10% 89.10%
United States      
Income Tax Contingency [Line Items]      
Clean energy and research credits 9.80% 12.80% (43.40%)
U.S. rate differentials 0.00% 0.00% (3.10%)
Impact of changes in legislation 0.00% (9.20%) 0.00%
State income taxes and credits (0.60%) (1.60%) (4.10%)
Valuation allowance (0.10%) 8.60% (118.50%)
Tax settlements and resolution of certain tax positions 0.10% 0.10% 199.60%
Other (6.10%) 1.50% 6.90%
LUXEMBOURG      
Income Tax Contingency [Line Items]      
Other Foreign Operations (6.70%) (5.00%) (14.80%)
GIBRALTAR      
Income Tax Contingency [Line Items]      
Other Foreign Operations 9.40% 8.00% (38.80%)
IRELAND      
Income Tax Contingency [Line Items]      
Other Foreign Operations 5.80% 8.20% (13.70%)
France      
Income Tax Contingency [Line Items]      
Other Foreign Operations (1.10%) (2.80%) 15.20%
Other foreign      
Income Tax Contingency [Line Items]      
Other Foreign Operations (10.20%) (0.40%) 12.80%
Other Foreign Operations      
Income Tax Contingency [Line Items]      
Valuation allowance (8.30%) 16.10% (9.90%)
Other 1.90% (1.80%) 2.10%
Uncertain tax positions 7.00% (0.10%) 36.70%
Withholding taxes (1.30%) (1.60%) 7.10%
Tax settlements and resolution of certain tax positions 0.80% (3.90%) (27.60%)
PUERTO RICO      
Income Tax Contingency [Line Items]      
Other Foreign Operations 4.40% (2.50%) 0.00%
SWITZERLAND      
Income Tax Contingency [Line Items]      
Other Foreign Operations 1.00% 2.00% 0.00%
SINGAPORE      
Income Tax Contingency [Line Items]      
Other Foreign Operations 28.80% 1.00% 0.00%
XML 120 R104.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2017
Dec. 31, 2016
Income Tax Disclosure [Abstract]          
Unrecognized tax benefit — beginning of year $ 322.9 $ 391.1 $ 92.1   $ 96.3
Additions for current year tax positions 0.0   13.4 $ 0.0  
Additions for prior year tax positions 0.0   35.7 154.9  
Reductions for prior year tax positions (9.1)   (5.2) (11.7)  
Settlements (47.3)   (8.9) (112.5)  
Reductions due to expirations of statute of limitations (7.0)   0.0 $ (34.9)  
Unrecognized Tax Benefits, Decrease Resulting from Acquisition (4.8)        
(Reduction) addition due to acquisition   264.0 0.0    
Unrecognized tax benefit — end of year $ 322.9 $ 391.1 $ 92.1    
XML 121 R105.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-Based Incentive Plan (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Nov. 16, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares exercised     27,615 580,950  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number   5,576,490 6,711,731 6,347,709 6,815,278
Restricted stock | Vest ratably in five years or less [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option award vesting period, in years   3 years      
Number of restricted stock awards, granted   6,057,602      
Restricted Stock Awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of restricted stock awards, granted   9,850,443      
Long Term Incentive Plan 2003          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares exercised 6,757,640        
Common stock shares reserved for issuance to employees 13,535,627        
Total unrecognized compensation expense, net of estimated forfeitures   $ 143.1      
Weighted-average period over which total unrecognized compensation expense expected to be recognized (years)   1 year 8 months 12 days      
Intrinsic value of stock-based awards exercised and restricted stock units converted   $ 78.1 $ 20.9    
Long Term Incentive Plan 2003 | Stock options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option award expiration period, in years   10 years      
Average remaining contractual term for options outstanding, in years   4 years 7 months 6 days      
Average remaining contractual term for options vested and expected to vest, in years   4 years 7 months 6 days      
Average remaining contractual term for options exercisable, in years   4 years 2 months 12 days      
Long Term Incentive Plan 2003 | Minimum | Stock options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option award vesting period, in years   3 years      
Long Term Incentive Plan 2003 | Maximum | Stock options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option award vesting period, in years   4 years      
2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Amount of common stock shares authorized 72,500,000        
2014 Program | Stock appreciation rights and performance shares          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option award vesting period, in years   5 years      
Not subject to market conditions | Performance Shares | Vest after three years          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of restricted stock awards, granted   587,025      
Subject to Market Conditions | Performance Shares | Vest after three years          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option award vesting period, in years   3 years      
Number of restricted stock awards, granted   3,205,816      
XML 122 R106.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-Based Incentive Plan (Stock Awards) (Details) - $ / shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Number of shares under stock awards, outstanding at beginning of period 6,711,731 6,347,709 6,815,278
Weightedaverage exercise price per share, outstanding at beginning of period $ 35.36 $ 36.97 $ 36.61
Number of shares under stock awards, granted   814,351 829,322
Weighted average exercise price per share, granted   $ 17.37 $ 26.18
Number of shares under stock awards, exercised   (27,615) (580,950)
Weighted average exercise price per share, exercised   $ 21.13 $ 14.40
Number of shares under stock awards, forfeited (1,135,241) (422,714) (715,941)
Weighted average exercise price per share, forfeited $ 26.39 $ 25.74 $ 39.40
Number of shares under stock awards, outstanding at end of period 5,576,490 6,711,731 6,347,709
Weighted average exercise price per share, outstanding at end of period $ 37.19 $ 35.36 $ 36.97
Number of shares under stock awards, vested and expected to vest at period end 5,487,788    
Weighted average exercise price per share, vested and expected to vest at period end $ 37.45    
Number of shares under stock awards, exercisable at period end 4,969,602    
Weighted average exercise price per share, exercisable at period end $ 39.21    
XML 123 R107.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) - Restricted Stock Awards
12 Months Ended
Dec. 31, 2021
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Number of restricted stock awards, nonvested beginning balance | shares 12,073,790
Weighted average grant-date fair value per share, nonvested beginning balance | $ / shares $ 18.34
Number of restricted stock awards, granted | shares 9,850,443
Weighted average grant-date fair value per share, granted | $ / shares $ 14.46
Number of restricted stock awards, released | shares (3,168,152)
Weighted average grant-date fair value per share, released | $ / shares $ 24.65
Number of restricted stock awards, forfeited | shares (1,897,953)
Weighted average grant-date fair value per share, forfeited | $ / shares $ 15.33
Number of restricted stock awards, nonvested ending balance | shares 16,858,128
Weighted average grant-date fair value per share, nonvested ending balance | $ / shares $ 15.12
XML 124 R108.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-Based Incentive Plan (Valuation Assumptions) (Details) - Long Term Incentive Plan 2003 - Stock options - $ / shares
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Volatility 46.70% 38.10%
Risk-free interest rate 1.00% 2.50%
Expected term (years) 6 years 6 months 6 years 6 months
Forfeiture rate 5.50% 5.50%
Weighted average grant date fair value per option $ 8.07 $ 11.03
XML 125 R109.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2016
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Unrecognized net actuarial losses exceed higher of market value of plan assets or the projected benefit obligation at the beginning of the year 10.00%      
Accumulated benefit obligation $ 1,860.0 $ 2,040.0    
Defined benefit plan, ultimate health care cost trend rate 5.70%      
Defined benefit plan, ultimate health care cost trend rate, projected 4.50%      
Total employer contributions $ 107.4 115.5 $ 95.6  
Multiemployer plans, withdrawal obligation $ 5.5 $ 8.9   $ 27.3
Fiscal Year 2017        
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Defined benefit plan, ultimate health care cost trend rate 6.30%      
Defined benefit plan, ultimate health care cost trend rate, projected 4.00%      
Deferred Base Salary        
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Defined contribution plan, maximum annual contribution per employee, percent 50.00%      
Deferred Bonus        
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Defined contribution plan, maximum annual contribution per employee, percent 100.00%      
XML 126 R110.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Pension Benefits    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Unrecognized actuarial (gain) loss $ (59.9) $ 33.9
Unrecognized prior service cost (credit) 6.6 (1.4)
Total (53.3) 32.5
Other Postretirement Benefits    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Unrecognized actuarial (gain) loss 21.7 5.7
Unrecognized prior service cost (credit) (3.7) 0.6
Total $ 18.0 $ 6.3
XML 127 R111.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Net change $ 73.9 $ (14.0) $ (24.8)
Pension Benefits      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Unrecognized actuarial (gain) loss (102.2)    
Amortization of actuarial gain/(loss) 7.6    
Unrecognized prior service credit (cost) (8.0)    
Amortization of prior service costs (0.5)    
Impact of foreign currency translation 1.3    
Net change (85.8)    
Other Postretirement Benefits      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Unrecognized actuarial (gain) loss 16.2    
Amortization of actuarial gain/(loss) (0.2)    
Unrecognized prior service credit (cost) 4.3    
Amortization of prior service costs 0.0    
Impact of foreign currency translation 0.0    
Net change $ 11.7    
XML 128 R112.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Net Periodic Benefit Costs) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]      
Service cost     $ 0.6
Interest cost     1.5
Expected return on plan assets     0.0
Plan curtailment, settlement and termination     3.2
Amortization of prior service costs included in SG&A     0.0
Recognized net actuarial losses     0.2
Net periodic benefit cost     5.5
Other Pension, Postretirement and Supplemental Plans      
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 3.4 $ 1.2  
Interest cost 2.6 1.4  
Expected return on plan assets 0.0 0.0  
Plan curtailment, settlement and termination 0.0 0.0  
Amortization of prior service costs included in SG&A 0.0 0.0  
Recognized net actuarial losses 0.2 0.3  
Net periodic benefit cost 6.2 2.9  
Pension Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 38.6 23.5 20.7
Interest cost 31.6 13.5 13.6
Expected return on plan assets (66.1) (19.9) (12.1)
Plan curtailment, settlement and termination (16.5) 1.1 (0.3)
Amortization of prior service costs included in SG&A 0.9 0.0 0.9
Recognized net actuarial losses 1.3 0.4 (0.8)
Net periodic benefit cost (10.2) 18.6 $ 22.0
Other Postretirement Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 3.4 1.1  
Interest cost $ 2.6 $ 1.4  
XML 129 R113.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Projected benefit obligation, beginning of year      
Service cost     $ 0.6
Interest cost     1.5
Change in Plan Assets      
Fair value of plan assets, beginning of year $ 1,354.6    
Fair value of plan assets, end of year 1,366.4 $ 1,354.6  
Pension Benefits      
Projected benefit obligation, beginning of year      
Projected benefit obligation, beginning of year 2,145.8 674.7  
Service cost 38.6 23.5 20.7
Interest cost 31.6 13.5 13.6
Participant contributions 2.0 1.8  
Acquisitions 4.0 1,389.4  
Plan settlements and terminations (128.6) (23.1)  
Actuarial (gains) losses (26.1) 37.2  
Benefits paid (52.8) (24.6)  
Impact of foreign currency translation (67.9) 53.4  
Projected benefit obligation, end of year 1,946.6 2,145.8 674.7
Change in Plan Assets      
Fair value of plan assets, beginning of year 1,354.6 315.7  
Actual return on plan assets 141.7 46.0  
Company contributions 97.0 58.2  
Participant contributions 2.0 1.8  
Defined Benefit Plan, Plan Assets, Business Combination   959.3  
Transferred assets (2.1)    
Plan settlements (128.9) (23.1)  
Impact of foreign currency translation (45.1) 21.3  
Fair value of plan assets, end of year 1,366.4 1,354.6 315.7
Funded status of plans (580.2) (791.2)  
Other Postretirement Benefits      
Projected benefit obligation, beginning of year      
Projected benefit obligation, beginning of year 188.8 33.8  
Service cost 3.4 1.1  
Interest cost 2.6 1.4  
Participant contributions 2.4 0.1  
Acquisitions 0.0 153.1  
Plan settlements and terminations (4.3) (0.2)  
Actuarial (gains) losses 16.2 1.1  
Benefits paid (20.7) (1.6)  
Impact of foreign currency translation 0.0 0.0  
Projected benefit obligation, end of year 188.4 188.8 33.8
Change in Plan Assets      
Fair value of plan assets, beginning of year 0.0 0.0  
Actual return on plan assets 0.0 0.0  
Company contributions 18.3 1.7  
Participant contributions 2.4 0.1  
Defined Benefit Plan, Plan Assets, Business Combination 0.0 0.0  
Plan settlements 0.0 (0.2)  
Impact of foreign currency translation 0.0 0.0  
Fair value of plan assets, end of year 0.0 0.0 $ 0.0
Funded status of plans $ (188.4) $ (188.8)  
XML 130 R114.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Pension Benefits    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Noncurrent assets $ 117.2 $ 70.7
Current liabilities (14.6) (15.1)
Noncurrent liabilities (682.8) (846.8)
Net accrued benefit costs (580.2) (791.2)
Other Postretirement Benefits    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Noncurrent assets 0.0 0.0
Current liabilities (16.1) (16.3)
Noncurrent liabilities (172.3) (172.5)
Net accrued benefit costs $ (188.4) $ (188.8)
XML 131 R115.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details) - Pension Benefits - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Projected benefit obligation $ 1,591.8 $ 1,747.2
Accumulated benefit obligation 1,546.4 1,678.2
Fair value of plan assets $ 904.1 $ 893.9
XML 132 R116.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Fair Values of Plan Assets) (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 1,366.4 $ 1,354.6
Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 65.0 51.8
Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 551.1 613.4
Fixed income securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 616.9 592.0
Assets held by insurance companies and other    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 133.4 97.4
Level 1    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 338.6 493.1
Level 1 | Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 63.1 51.2
Level 1 | Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 53.9 145.3
Level 1 | Fixed income securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 211.4 292.6
Level 1 | Assets held by insurance companies and other    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 10.2 4.0
Level 2    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 946.2 788.1
Level 2 | Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 1.9 0.6
Level 2 | Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 497.2 468.1
Level 2 | Fixed income securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 405.5 299.4
Level 2 | Assets held by insurance companies and other    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 41.6 20.0
Level 3    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 81.6 73.4
Level 3 | Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
Level 3 | Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
Level 3 | Fixed income securities    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
Level 3 | Assets held by insurance companies and other    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 81.6 $ 73.4
XML 133 R117.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Weighted Average Assumptions) (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2019
Dec. 31, 2017
Dec. 31, 2020
Pension Benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Discount rate 2.30%     1.90%
Expected return on plan assets 5.10%     4.30%
Rate of compensation increase 3.10%     2.90%
Discount rate 1.90% 1.60% 2.30%  
Expected return on plan assets 5.10% 4.30% 4.30%  
Rate of compensation increase 2.90% 2.70% 2.90%  
Other Postretirement Benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Discount rate 2.50%     1.90%
Expected return on plan assets 0.00%     0.00%
Rate of compensation increase 0.00%     0.00%
Discount rate 1.90% 3.30% 4.30%  
Expected return on plan assets 0.00% 0.00% 0.00%  
Rate of compensation increase 0.00% 0.00% 0.00%  
XML 134 R118.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans (Estimated Future Benefit Payments) (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Pension Benefits  
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
2019 $ 101.8
2020 97.1
2021 103.0
2022 100.7
2023 104.3
Thereafter 528.5
Total 1,035.4
Other Postretirement Benefits  
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
2019 16.1
2020 16.5
2021 16.9
2022 16.8
2023 16.6
Thereafter 73.0
Total $ 155.9
XML 135 R119.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Reporting Information [Line Items]      
Net sales $ 17,813.6 $ 11,819.9 $ 11,370.3
Segment profitability (34.0) (210.8) 715.5
Intangible asset amortization expense (2,702.2) (1,605.8) (1,582.7)
Globally managed research and development costs (751.1) (555.1) (639.9)
Litigation settlements & other contingencies (329.2) (107.8) 21.4
Operating Segments      
Segment Reporting Information [Line Items]      
Net sales 17,813.6 11,819.9  
Segment profitability 8,705.0 5,271.6 5,112.3
Segment Reconciling      
Segment Reporting Information [Line Items]      
Intangible asset amortization expense (2,702.2) (1,605.8) (1,582.7)
Intangible asset impairment charges (102.8) (82.4) (180.6)
Globally managed research and development costs (751.1) (555.1) (639.9)
Litigation settlements & other contingencies (329.2) (107.8) 21.4
Transaction related and other special items (2,832.2) (1,739.7) (682.2)
Corporate (Other)      
Segment Reporting Information [Line Items]      
Corporate costs (2,021.5) (1,391.6) (1,332.8)
Developed Markets | Operating Segments      
Segment Reporting Information [Line Items]      
Net sales 10,428.7 8,510.9 8,240.0
Segment profitability 5,143.1 4,243.9 4,137.3
Greater China | Operating Segments      
Segment Reporting Information [Line Items]      
Net sales 2,212.8 259.9 214.6
Segment profitability 1,397.1 52.7 89.9
JANZ | Operating Segments      
Segment Reporting Information [Line Items]      
Net sales 2,027.4 1,195.3 1,192.5
Segment profitability 762.4 364.6 323.2
Emerging Markets | Operating Segments      
Segment Reporting Information [Line Items]      
Net sales 3,144.7 1,853.8 1,723.2
Segment profitability $ 1,402.4 $ 610.4 $ 561.9
XML 136 R120.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information (Third Party Net Sales by Major Customers) (Details) - Third party net sales - Customer Concentration Risk
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
McKesson Corporation      
Revenue, Major Customer [Line Items]      
Concentration risk, percentage 9.00% 13.00% 15.00%
AmeriSourceBergen Corporation      
Revenue, Major Customer [Line Items]      
Concentration risk, percentage 9.00% 10.00% 9.00%
Cardinal Health Inc      
Revenue, Major Customer [Line Items]      
Concentration risk, percentage 5.00% 8.00% 8.00%
XML 137 R121.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net sales $ 17,813.6 $ 11,819.9 $ 11,370.3
United States      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net sales 4,176.4 3,746.1 3,965.9
CHINA      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net sales $ 1,981.5 $ 216.1 $ 171.1
XML 138 R122.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments (Details) - Pfizer, Inc. - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Other Commitments [Line Items]    
Reimbursement amount, tranche one $ 380.0  
Amounts incurred 30.4 $ 53.1
Amounts accrued $ 26.9  
Transition Service Agreements    
Other Commitments [Line Items]    
Limited transition services period 24 months  
XML 139 R123.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restructuring (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended 60 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]          
Payments for Restructuring   $ (25.7) $ (59.4)    
Restructuring Reserve, Period Increase (Decrease)     8.1    
Restructuring and Related Cost, Incurred Cost   (32.9) (78.3)    
Restructuring Reserve, Translation and Other Adjustment   1.7 (2.2)    
Restructuring and Related Cost, Cost Incurred to Date   50.5 [1] 104.6    
Restructuring Reserve   22.8 29.2 $ 22.8 $ 72.6
Effect on Future Cash Flows, Amount $ 900.0        
2016 Restructuring Program          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date       733.0  
Employee Severance          
Restructuring Cost and Reserve [Line Items]          
Payments for Restructuring   (18.1) (48.9)    
Restructuring Reserve, Period Increase (Decrease)     0.0    
Restructuring and Related Cost, Incurred Cost   0.0 0.0    
Restructuring Reserve, Translation and Other Adjustment   1.8 (2.1)    
Restructuring and Related Cost, Cost Incurred to Date   9.9 [1] 16.6    
Restructuring Reserve   20.0 26.4 20.0 60.8
Other Restructuring          
Restructuring Cost and Reserve [Line Items]          
Payments for Restructuring   (7.6) (10.5)    
Restructuring Reserve, Period Increase (Decrease)     8.1    
Restructuring and Related Cost, Incurred Cost   (32.9) (78.3)    
Restructuring Reserve, Translation and Other Adjustment   (0.1) (0.1)    
Restructuring and Related Cost, Cost Incurred to Date   40.6 [1] 88.0    
Restructuring Reserve   2.8 2.8 $ 2.8 $ 11.8
Developed Markets | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date 623.8 292.1 100.4    
JANZ | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date 138.1 2.9 $ 4.2    
Greater China | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date $ 5.8 $ 18.4      
[1] For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively.
(2)     For the year ended December 31, 2020, total restructuring charges, for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively.
(3)     For the year ended December 31, 2019, total restructuring charges for the 2016 Restructuring Program in Developed Markets and JANZ were approximately $100.4 million and $4.2 million, respectively.
XML 140 R124.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restructuring (2020 Restructuring Plan) (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve     $ 22.8 $ 29.2 $ 72.6
Payments for Restructuring     (25.7) (59.4)  
Restructuring and Related Cost, Incurred Cost     (32.9) (78.3)  
Restructuring Reserve, Translation and Other Adjustment     1.7 (2.2)  
Restructuring and Related Cost, Cost Incurred to Date     50.5 [1] 104.6  
Restructuring Reserve, Reimbursable Restructuring Charges   $ 26.4      
Corporate (Other)          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date   30.4      
Emerging Markets | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date   94.1 8.4    
Greater China | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date   5.8 18.4    
JANZ | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date   138.1 2.9 4.2  
Developed Markets | Operating Segments          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date   623.8 292.1 100.4  
Employee Severance          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve     20.0 26.4 60.8
Payments for Restructuring     (18.1) (48.9)  
Restructuring and Related Cost, Incurred Cost     0.0 0.0  
Restructuring Reserve, Translation and Other Adjustment     1.8 (2.1)  
Restructuring and Related Cost, Cost Incurred to Date     9.9 [1] 16.6  
Restructuring Reserve, Reimbursable Restructuring Charges   26.4      
Other Restructuring          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve     2.8 2.8 $ 11.8
Payments for Restructuring     (7.6) (10.5)  
Restructuring and Related Cost, Incurred Cost     (32.9) (78.3)  
Restructuring Reserve, Translation and Other Adjustment     (0.1) (0.1)  
Restructuring and Related Cost, Cost Incurred to Date     40.6 [1] $ 88.0  
Restructuring Reserve, Reimbursable Restructuring Charges   0.0      
2020 Restructuring Plan          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve $ 296.7 296.7 267.4    
Payments for Restructuring   (537.2) (25.5)    
Restructuring and Related Cost, Incurred Cost   (345.0) (70.8)    
Restructuring Reserve, Translation and Other Adjustment   (7.1) 0.4    
Restructuring and Related Cost, Cost Incurred to Date   892.2 271.3    
Restructuring Reserve, Acquired During Period     92.0    
2020 Restructuring Plan | Maximum          
Restructuring Cost and Reserve [Line Items]          
Restructuring and Related Cost, Cost Incurred to Date 1,400.0        
Restructuring Reserve, Settled without Cash 450.0        
Restructuring and Related Cost, Expected Cost Remaining 950.0 950.0      
2020 Restructuring Plan | Employee Severance          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve 292.6 292.6 262.6    
Payments for Restructuring   (385.5) (25.1)    
Restructuring and Related Cost, Incurred Cost   0.0 0.0    
Restructuring Reserve, Translation and Other Adjustment   (7.0) 0.4    
Restructuring and Related Cost, Cost Incurred to Date   396.1 195.6    
Restructuring Reserve, Acquired During Period     91.7    
2020 Restructuring Plan | Other Restructuring          
Restructuring Cost and Reserve [Line Items]          
Restructuring Reserve $ 4.1 4.1 4.8    
Payments for Restructuring   (151.7) (0.4)    
Restructuring and Related Cost, Incurred Cost   (345.0) (70.8)    
Restructuring Reserve, Translation and Other Adjustment   (0.1) 0.0    
Restructuring and Related Cost, Cost Incurred to Date   $ 496.1 75.7    
Restructuring Reserve, Acquired During Period     $ 0.3    
[1] For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively.
(2)     For the year ended December 31, 2020, total restructuring charges, for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively.
(3)     For the year ended December 31, 2019, total restructuring charges for the 2016 Restructuring Program in Developed Markets and JANZ were approximately $100.4 million and $4.2 million, respectively.
XML 141 R125.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration and Licensing Agreements (Narrative) (Details)
$ in Millions
3 Months Ended 12 Months Ended
Feb. 27, 2019
USD ($)
Sep. 20, 2018
USD ($)
Jan. 30, 2015
USD ($)
Feb. 12, 2013
Product
Dec. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jan. 08, 2016
drugs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Contingent consideration liability             $ 199.7 $ 223.6 $ 250.7  
Research and development             751.1 555.1 639.9  
Proceeds from sale of assets and subsidiaries             96.7 20.0 $ 28.0  
Momenta                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Number of drugs | drugs                   6
Theravance                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Upfront payments             18.5      
FKB                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Development and sales milestone payments   $ 10.0                
Upfront payments $ 33.0 $ 25.0                
Research and development $ 23.3                  
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Research and development             40.0      
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Scenario, Forecast | Biosimilars Business                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Proceeds from sale of assets and subsidiaries         $ 2,000.0          
Divestiture of Business, Deferred Cash Consideration.           $ 335.0        
Divestiture Of Business, Percentage Ownership In Combined Company After Transaction         12.90%          
Divestiture Of Business, Transition Services Agreement, Term           2 years        
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Scenario, Forecast | Biosimilars Business | Convertible Preferred Stock                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Equity consideration         $ 1,000.0          
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Revance [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Research and development               $ 30.0    
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Theravance                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Research and development             50.0      
Maximum                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Development and sales milestone payments             351.0      
Maximum | Theravance                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Development and sales milestone payments     $ 293.0              
Fiscal Year 2017 | Maximum | Collaborative Arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Development and sales milestone payments             18.0      
Generic Biologic Compounds Collaboration [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Insulin Analog Products | Product       3            
Respiratory delivery platform [Member]                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Contingent consideration liability             177.8      
Product rights and licenses | Other companies                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Acquisition purchase price             10.0      
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned             $ 25.0      
XML 142 R126.htm IDEA: XBRL DOCUMENT v3.22.0.1
Litigation (Narrative) (Details)
£ in Thousands, case in Thousands, € in Millions, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 17, 2019
patent
agreement
Jun. 17, 2019
patent
Sep. 10, 2018
patent
Oct. 24, 2017
patent
Jun. 30, 2017
patent
Feb. 12, 2016
GBP (£)
Jul. 09, 2014
EUR (€)
Feb. 28, 2022
USD ($)
Jun. 19, 2013
EUR (€)
Dec. 31, 2014
USD ($)
Dec. 31, 2021
USD ($)
state
agreement
case
increase
Dec. 31, 2021
GBP (£)
state
case
Apr. 02, 2020
patent
Loss Contingencies [Line Items]                          
Number of cases | case                     1 1  
Product Liability                          
Loss Contingencies [Line Items]                          
Loss contingency accrual                     $ 74.8    
Intellectual Property                          
Loss Contingencies [Line Items]                          
Loss contingency accrual                     $ 226.9    
Number of times damages may be increased in cases of willful infringement | increase                     3    
Other Foreign Operations                          
Loss Contingencies [Line Items]                          
Loss contingency accrual                     $ 8.4    
MDL                          
Loss Contingencies [Line Items]                          
Number of states | state                     47 47  
Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil                          
Loss Contingencies [Line Items]                          
Number of states | state                     37 37  
Anticompetitive Conduct with Generic Drugs                          
Loss Contingencies [Line Items]                          
Number of states | state                     48 48  
Amended Anticompetitive Conduct with Generic Drugs                          
Loss Contingencies [Line Items]                          
Number of states | state                     43 43  
EU Commission Proceedings Perindorpril | Antitrust Proceedings | Mylan Laboratories Limited                          
Loss Contingencies [Line Items]                          
Damages awarded | €             € 17.2            
Loss contingency accrual                   $ 21.7      
U.K. Competition and Markets Authority Proceedings Paroxetine                          
Loss Contingencies [Line Items]                          
Damages awarded | £           £ 5,800              
Loss Contingency, Damages Awarded On Appeal, Value | £           3,900              
U.K. Competition and Markets Authority Proceedings Paroxetine | Mylan                          
Loss Contingencies [Line Items]                          
Loss contingency accrual | £                       £ 8,800  
Damages awarded | £           2,700              
Loss Contingency, Damages Awarded On Appeal, Value | £           £ 2,050              
EU Commission Proceedings Citalopram                          
Loss Contingencies [Line Items]                          
Loss contingency accrual                     $ 11.4    
Damages awarded | €                 € 7.8        
Dimethyl Fumarate                          
Loss Contingencies [Line Items]                          
Loss Contingency, Patents Allegedly Infringed, Number | patent         6                
Insulin Glargine                          
Loss Contingencies [Line Items]                          
Loss Contingency, Patents Allegedly Infringed, Number | patent     5 18                  
Loss Contingency, Patents Found Not Infringed, Number 12 3                      
Loss Contingency, Remaining Claims, Number | patent 4 4   2                 2
Loss Contingency, Other Asserted Patents, Number | patent 16 16                      
EpiPen Auto-Injector Litigation                          
Loss Contingencies [Line Items]                          
Loss contingency accrual                     $ 264.0    
Loss Contingency, Number of States | agreement                     17    
EpiPen Auto-Injector Litigation | Subsequent Event                          
Loss Contingencies [Line Items]                          
Amount awarded to other party               $ 264.0          
EpiPen Auto-Injector Litigation | Other current liabilities                          
Loss Contingencies [Line Items]                          
Estimated Litigation Liability                     $ 274.0    
XML 143 R127.htm IDEA: XBRL DOCUMENT v3.22.0.1
Valuation and Qualifying Accounts (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Allowance for doubtful accounts      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Beginning balance $ 159.9 $ 72.8 $ 98.2
Additions Charged to Costs and Expenses 16.0 16.9 14.2
Additions Charged to Other Accounts 0.0 77.3 0.0
Deductions (21.4) (7.1) (39.6)
Ending balance 154.5 159.9 72.8
Valuation allowance for deferred tax assets      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Beginning balance 443.6 603.5 806.0
Additions Charged to Costs and Expenses 82.2 39.0 36.8
Additions Charged to Other Accounts 260.8 0.0 0.0
Deductions (6.2) (198.9) (239.3)
Ending balance $ 780.4 $ 443.6 $ 603.5
XML 144 vtrs-20211231_htm.xml IDEA: XBRL DOCUMENT 0001792044 2021-01-01 2021-12-31 0001792044 2021-06-30 0001792044 2021-12-31 0001792044 2022-02-22 0001792044 2020-12-31 0001792044 us-gaap:CommonStockMember 2021-12-31 0001792044 us-gaap:CommonStockMember 2020-12-31 0001792044 us-gaap:ProductMember 2021-01-01 2021-12-31 0001792044 us-gaap:ProductMember 2020-01-01 2020-12-31 0001792044 us-gaap:ProductMember 2019-01-01 2019-12-31 0001792044 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0001792044 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0001792044 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001792044 2020-01-01 2020-12-31 0001792044 2019-01-01 2019-12-31 0001792044 us-gaap:CashFlowHedgingMember 2021-01-01 2021-12-31 0001792044 us-gaap:CashFlowHedgingMember 2020-01-01 2020-12-31 0001792044 us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001792044 us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-12-31 0001792044 us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-12-31 0001792044 us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0001792044 us-gaap:CommonStockMember 2018-12-31 0001792044 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001792044 us-gaap:RetainedEarningsMember 2018-12-31 0001792044 us-gaap:TreasuryStockMember 2018-12-31 0001792044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001792044 2018-12-31 0001792044 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001792044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001792044 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001792044 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001792044 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0001792044 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0001792044 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001792044 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001792044 us-gaap:CommonStockMember 2019-12-31 0001792044 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001792044 us-gaap:RetainedEarningsMember 2019-12-31 0001792044 us-gaap:TreasuryStockMember 2019-12-31 0001792044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001792044 2019-12-31 0001792044 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001792044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001792044 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001792044 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001792044 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0001792044 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001792044 us-gaap:RetainedEarningsMember 2020-12-31 0001792044 us-gaap:TreasuryStockMember 2020-12-31 0001792044 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001792044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001792044 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001792044 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001792044 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001792044 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001792044 us-gaap:RetainedEarningsMember 2021-12-31 0001792044 us-gaap:TreasuryStockMember 2021-12-31 0001792044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001792044 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2021-01-01 2021-12-31 0001792044 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2021-01-01 2021-12-31 0001792044 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0001792044 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0001792044 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-12-31 0001792044 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-12-31 0001792044 srt:MinimumMember 2021-01-01 2021-12-31 0001792044 srt:MaximumMember 2021-01-01 2021-12-31 0001792044 2021-12-16 2021-12-16 0001792044 2021-06-16 2021-06-16 0001792044 2021-09-16 2021-09-16 0001792044 us-gaap:SubsequentEventMember 2022-01-06 2022-01-06 0001792044 us-gaap:SubsequentEventMember 2022-03-16 0001792044 us-gaap:SubsequentEventMember 2022-02-28 0001792044 vtrs:BrandsMember vtrs:DevelopedMarketsSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:BrandsMember vtrs:GreaterChinaSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:BrandsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:BrandsMember vtrs:EmergingMarketsSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:BrandsMember 2021-01-01 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:DevelopedMarketsSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:GreaterChinaSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:EmergingMarketsSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember 2021-01-01 2021-12-31 0001792044 vtrs:GenericsMember vtrs:DevelopedMarketsSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:GenericsMember vtrs:GreaterChinaSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:GenericsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:GenericsMember vtrs:EmergingMarketsSegmentMember 2021-01-01 2021-12-31 0001792044 vtrs:GenericsMember 2021-01-01 2021-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:DevelopedMarketsSegmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:GreaterChinaSegmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:EmergingMarketsSegmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0001792044 vtrs:BrandsMember vtrs:DevelopedMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:BrandsMember vtrs:GreaterChinaSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:BrandsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:BrandsMember vtrs:EmergingMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:BrandsMember 2020-01-01 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:DevelopedMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:GreaterChinaSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:EmergingMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember 2020-01-01 2020-12-31 0001792044 vtrs:GenericsMember vtrs:DevelopedMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:GenericsMember vtrs:GreaterChinaSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:GenericsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:GenericsMember vtrs:EmergingMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:GenericsMember 2020-01-01 2020-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:DevelopedMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:GreaterChinaSegmentMember 2020-01-01 2020-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-01-01 2020-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:EmergingMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0001792044 vtrs:BrandsMember vtrs:DevelopedMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:BrandsMember vtrs:GreaterChinaSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:BrandsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:BrandsMember vtrs:EmergingMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:BrandsMember 2019-01-01 2019-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:DevelopedMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:GreaterChinaSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember vtrs:EmergingMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember 2019-01-01 2019-12-31 0001792044 vtrs:GenericsMember vtrs:DevelopedMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:GenericsMember vtrs:GreaterChinaSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:GenericsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:GenericsMember vtrs:EmergingMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:GenericsMember 2019-01-01 2019-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:DevelopedMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:GreaterChinaSegmentMember 2019-01-01 2019-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2019-01-01 2019-12-31 0001792044 us-gaap:OperatingSegmentsMember vtrs:EmergingMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:LipitorMember 2021-01-01 2021-12-31 0001792044 vtrs:NorvascMember 2021-01-01 2021-12-31 0001792044 vtrs:LyricaMember 2021-01-01 2021-12-31 0001792044 vtrs:ViagraMember 2021-01-01 2021-12-31 0001792044 vtrs:EpiPenAutoInjectorsMember 2021-01-01 2021-12-31 0001792044 vtrs:CelebrexMember 2021-01-01 2021-12-31 0001792044 vtrs:CreonMember 2021-01-01 2021-12-31 0001792044 vtrs:ZoloftMember 2021-01-01 2021-12-31 0001792044 vtrs:EffexorMember 2021-01-01 2021-12-31 0001792044 vtrs:XalabrandsMember 2021-01-01 2021-12-31 0001792044 vtrs:InfluvacMember 2021-01-01 2021-12-31 0001792044 vtrs:AmitizaMember 2021-01-01 2021-12-31 0001792044 vtrs:XanaxMember 2021-01-01 2021-12-31 0001792044 vtrs:YupelriMember 2021-01-01 2021-12-31 0001792044 vtrs:DymistaMember 2021-01-01 2021-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:ChargebacksMember 2020-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:ChargebacksMember 2021-01-01 2021-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:ChargebacksMember 2021-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:RebatesPromotionalProgramsandOtherSalesAllowancesMember 2020-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:RebatesPromotionalProgramsandOtherSalesAllowancesMember 2021-01-01 2021-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:RebatesPromotionalProgramsandOtherSalesAllowancesMember 2021-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:VariableConsiderationReturnsMember 2020-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:VariableConsiderationReturnsMember 2021-01-01 2021-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:VariableConsiderationReturnsMember 2021-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:GovernmentalRebateProgramsMember 2020-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:GovernmentalRebateProgramsMember 2021-01-01 2021-12-31 0001792044 vtrs:VariableConsiderationMember vtrs:GovernmentalRebateProgramsMember 2021-12-31 0001792044 vtrs:VariableConsiderationMember 2020-12-31 0001792044 vtrs:VariableConsiderationMember 2021-01-01 2021-12-31 0001792044 vtrs:VariableConsiderationMember 2021-12-31 0001792044 us-gaap:AllowanceForCreditLossMember 2021-12-31 0001792044 us-gaap:AllowanceForCreditLossMember 2020-12-31 0001792044 vtrs:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0001792044 vtrs:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0001792044 us-gaap:ProductMember vtrs:UpjohnInc.Member 2019-07-29 0001792044 vtrs:UpjohnInc.Member vtrs:PfizerInc.Member 2019-07-29 0001792044 vtrs:UpjohnInc.Member 2019-07-29 0001792044 vtrs:UpjohnInc.Member vtrs:PfizerInc.Member 2019-07-29 2019-07-29 0001792044 vtrs:UpjohnInc.Member vtrs:PfizerInc.Member 2020-11-16 0001792044 vtrs:UpjohnInc.Member 2020-11-13 2020-11-13 0001792044 vtrs:UpjohnInc.Member 2021-01-01 2021-12-31 0001792044 vtrs:UpjohnInc.Member 2020-01-01 2020-12-31 0001792044 vtrs:UpjohnInc.Member 2019-05-28 0001792044 vtrs:UpjohnInc.Member 2020-12-31 0001792044 vtrs:UpjohnInc.Member 2021-12-31 0001792044 2020-12-31 2020-12-31 0001792044 us-gaap:MachineryAndEquipmentMember 2020-11-13 2020-11-13 0001792044 srt:MinimumMember us-gaap:BuildingMember 2020-11-13 2020-11-13 0001792044 srt:MaximumMember us-gaap:BuildingMember 2020-11-13 2020-11-13 0001792044 vtrs:UpjohnInc.Member 2020-11-13 0001792044 us-gaap:FiniteLivedIntangibleAssetsMember 2020-11-13 2020-11-13 0001792044 vtrs:UpjohnInc.Member 2020-11-13 2020-12-31 0001792044 vtrs:PfizerInc.Member 2020-12-01 2020-12-31 0001792044 vtrs:AspenGlobalIncorporatedMember 2020-09-01 2020-09-30 0001792044 us-gaap:ScenarioPlanMember vtrs:AspenGlobalIncorporatedMember 2021-06-25 0001792044 vtrs:AspenGlobalIncorporatedMember us-gaap:ContractualRightsMember 2020-09-01 2020-09-30 0001792044 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001792044 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001792044 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0001792044 us-gaap:BuildingAndBuildingImprovementsMember 2020-12-31 0001792044 us-gaap:ConstructionInProgressMember 2021-12-31 0001792044 us-gaap:ConstructionInProgressMember 2020-12-31 0001792044 us-gaap:LandAndLandImprovementsMember 2021-12-31 0001792044 us-gaap:LandAndLandImprovementsMember 2020-12-31 0001792044 vtrs:CleanEnergyPartnershipsMember us-gaap:OtherAssetsMember 2021-12-31 0001792044 vtrs:CleanEnergyPartnershipsMember us-gaap:OtherAssetsMember 2020-12-31 0001792044 us-gaap:OtherCurrentLiabilitiesMember 2021-12-31 0001792044 us-gaap:OtherCurrentLiabilitiesMember 2020-12-31 0001792044 vtrs:CleanEnergyPartnershipsMember 2021-12-31 0001792044 vtrs:CleanEnergyPartnershipsMember 2020-12-31 0001792044 us-gaap:OtherNoncurrentLiabilitiesMember 2021-12-31 0001792044 us-gaap:OtherNoncurrentLiabilitiesMember 2020-12-31 0001792044 srt:MinimumMember 2021-12-31 0001792044 srt:MaximumMember 2021-12-31 0001792044 2017-01-01 2017-12-31 0001792044 us-gaap:ConsolidatedEntityExcludingVieMember 2021-12-31 0001792044 us-gaap:ConsolidatedEntityExcludingVieMember 2020-12-31 0001792044 us-gaap:ConsolidatedEntityExcludingVieMember 2021-01-01 2021-12-31 0001792044 us-gaap:ConsolidatedEntityExcludingVieMember 2020-01-01 2020-12-31 0001792044 us-gaap:ConsolidatedEntityExcludingVieMember 2019-01-01 2019-12-31 0001792044 vtrs:DevelopedMarketsSegmentMember 2019-12-31 0001792044 vtrs:GreaterChinaSegmentMember 2019-12-31 0001792044 vtrs:JapanAustraliaAndNewZealandSegmentMember 2019-12-31 0001792044 vtrs:EmergingMarketsSegmentMember 2019-12-31 0001792044 vtrs:DevelopedMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:GreaterChinaSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:JapanAustraliaAndNewZealandSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:EmergingMarketsSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:DevelopedMarketsSegmentMember 2020-12-31 0001792044 vtrs:GreaterChinaSegmentMember 2020-12-31 0001792044 vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-12-31 0001792044 vtrs:EmergingMarketsSegmentMember 2020-12-31 0001792044 vtrs:DevelopedMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:GreaterChinaSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:EmergingMarketsSegmentMember 2020-01-01 2020-12-31 0001792044 vtrs:DevelopedMarketsSegmentMember 2021-12-31 0001792044 vtrs:GreaterChinaSegmentMember 2021-12-31 0001792044 vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-12-31 0001792044 vtrs:EmergingMarketsSegmentMember 2021-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember vtrs:DevelopedMarketsSegmentMember 2021-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember vtrs:GreaterChinaSegmentMember 2021-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember vtrs:EmergingMarketsSegmentMember 2021-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember vtrs:DevelopedMarketsSegmentMember 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember vtrs:GreaterChinaSegmentMember 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember vtrs:EmergingMarketsSegmentMember 2021-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember 2021-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember vtrs:DevelopedMarketsSegmentMember 2021-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember vtrs:GreaterChinaSegmentMember 2021-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember vtrs:EmergingMarketsSegmentMember 2021-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember 2021-12-31 0001792044 us-gaap:LicensingAgreementsMember vtrs:DevelopedMarketsSegmentMember 2021-12-31 0001792044 us-gaap:LicensingAgreementsMember vtrs:GreaterChinaSegmentMember 2021-12-31 0001792044 us-gaap:LicensingAgreementsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-12-31 0001792044 us-gaap:LicensingAgreementsMember vtrs:EmergingMarketsSegmentMember 2021-12-31 0001792044 us-gaap:LicensingAgreementsMember 2021-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember vtrs:DevelopedMarketsSegmentMember 2020-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember vtrs:GreaterChinaSegmentMember 2020-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember vtrs:EmergingMarketsSegmentMember 2020-12-31 0001792044 vtrs:BrandsMember us-gaap:LicensingAgreementsMember 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember vtrs:DevelopedMarketsSegmentMember 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember vtrs:GreaterChinaSegmentMember 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember vtrs:EmergingMarketsSegmentMember 2020-12-31 0001792044 vtrs:ComplexGXAndBiosimilarsMember us-gaap:LicensingAgreementsMember 2020-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember vtrs:DevelopedMarketsSegmentMember 2020-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember vtrs:GreaterChinaSegmentMember 2020-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember vtrs:EmergingMarketsSegmentMember 2020-12-31 0001792044 vtrs:GenericsMember us-gaap:LicensingAgreementsMember 2020-12-31 0001792044 us-gaap:LicensingAgreementsMember vtrs:DevelopedMarketsSegmentMember 2020-12-31 0001792044 us-gaap:LicensingAgreementsMember vtrs:GreaterChinaSegmentMember 2020-12-31 0001792044 us-gaap:LicensingAgreementsMember vtrs:JapanAustraliaAndNewZealandSegmentMember 2020-12-31 0001792044 us-gaap:LicensingAgreementsMember vtrs:EmergingMarketsSegmentMember 2020-12-31 0001792044 us-gaap:LicensingAgreementsMember 2020-12-31 0001792044 us-gaap:InProcessResearchAndDevelopmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:InProcessResearchAndDevelopmentMember 2020-01-01 2020-12-31 0001792044 us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-12-31 0001792044 us-gaap:LicensingAgreementsMember 2021-01-01 2021-12-31 0001792044 us-gaap:LicensingAgreementsMember 2020-01-01 2020-12-31 0001792044 us-gaap:LicensingAgreementsMember 2019-01-01 2019-12-31 0001792044 srt:MinimumMember us-gaap:LicensingAgreementsMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001792044 srt:MaximumMember us-gaap:LicensingAgreementsMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001792044 srt:MinimumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001792044 srt:MaximumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001792044 srt:MinimumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2020-12-31 0001792044 srt:MaximumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2020-12-31 0001792044 srt:MinimumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0001792044 srt:MaximumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0001792044 vtrs:NorthAmericaSegmentMember 2021-04-01 0001792044 vtrs:EuropeSegmentMember 2021-04-01 0001792044 vtrs:EmergingMarketsSegmentMember 2021-04-01 0001792044 vtrs:JapanAustraliaAndNewZealandSegmentMember 2021-04-01 0001792044 vtrs:GreaterChinaSegmentMember 2021-04-01 0001792044 vtrs:EuropeSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 2021-04-01 0001792044 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember vtrs:EuropeSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:MeasurementInputTerminalYearRevenueGrowthRateMember vtrs:EuropeSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:MeasurementInputEstimatedTaxRateMember vtrs:EuropeSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 srt:MinimumMember us-gaap:MeasurementInputEbitdaMultipleMember vtrs:EuropeSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 srt:MaximumMember us-gaap:MeasurementInputEbitdaMultipleMember vtrs:EuropeSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 us-gaap:MeasurementInputControlPremiumMember vtrs:EuropeSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:MeasurementInputReductionInTerminalYearRevenueGrowthRateMember vtrs:EuropeSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:MeasurementInputIncreaseInDiscountRateMember vtrs:EuropeSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:JapanAustraliaAndNewZealandSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 2021-04-01 0001792044 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember vtrs:JapanAustraliaAndNewZealandSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:MeasurementInputTerminalYearRevenueGrowthRateMember vtrs:JapanAustraliaAndNewZealandSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 us-gaap:MeasurementInputDiscountRateMember vtrs:JapanAustraliaAndNewZealandSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:MeasurementInputEstimatedTaxRateMember vtrs:JapanAustraliaAndNewZealandSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 us-gaap:MeasurementInputEbitdaMultipleMember vtrs:JapanAustraliaAndNewZealandSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 us-gaap:MeasurementInputControlPremiumMember vtrs:JapanAustraliaAndNewZealandSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:MeasurementInputReductionInTerminalYearRevenueGrowthRateMember vtrs:JapanAustraliaAndNewZealandSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:MeasurementInputIncreaseInDiscountRateMember vtrs:JapanAustraliaAndNewZealandSegmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-04-01 0001792044 vtrs:A2024EuroSeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2024EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 vtrs:A2024EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 vtrs:A2028EuroSeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2028SeniorNotesMember us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 vtrs:A2028SeniorNotesMember us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 vtrs:A2025EuroSeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2025EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 vtrs:A2025EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 vtrs:A2022EuroSeniorNotesMember 2021-12-31 0001792044 vtrs:A2022EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 vtrs:A2022EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 vtrs:A2024EuroSeniorNotes1023Member 2021-12-31 0001792044 vtrs:A2024EuroSeniorNotes1023Member us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 vtrs:A2024EuroSeniorNotes1023Member us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 vtrs:A2027EuroSeniorNotesMember 2021-12-31 0001792044 vtrs:A2027EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 vtrs:A2027EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 vtrs:A2032EuroSeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2032EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 vtrs:A2032EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 vtrs:A2020FloatingRateEuroNotesMember us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 vtrs:A2020FloatingRateEuroNotesMember us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 vtrs:YENTermLoanMember us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 vtrs:YENTermLoanMember us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 vtrs:YENTermLoanMember 2021-12-31 0001792044 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001792044 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001792044 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001792044 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001792044 us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0001792044 us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001792044 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0001792044 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-12-31 0001792044 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0001792044 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-12-31 0001792044 us-gaap:NondesignatedMember 2021-12-31 0001792044 us-gaap:NondesignatedMember 2020-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherExpenseMember 2020-01-01 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherExpenseMember 2019-01-01 2019-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:OtherExpenseMember 2021-01-01 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:OtherExpenseMember 2020-01-01 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:OtherExpenseMember 2019-01-01 2019-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2021-01-01 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2020-01-01 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2019-01-01 2019-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001792044 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001792044 us-gaap:MoneyMarketFundsMember 2021-12-31 0001792044 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001792044 us-gaap:ExchangeTradedFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001792044 us-gaap:ExchangeTradedFundsMember 2021-12-31 0001792044 us-gaap:CommonStockMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001792044 us-gaap:CommonStockMember 2021-12-31 0001792044 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001792044 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001792044 us-gaap:MortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:MortgageBackedSecuritiesMember 2021-12-31 0001792044 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001792044 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001792044 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:DebtSecuritiesMember 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember 2021-12-31 0001792044 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember 2021-12-31 0001792044 us-gaap:FairValueInputsLevel3Member vtrs:ContingentConsiderationMember 2021-12-31 0001792044 vtrs:ContingentConsiderationMember 2021-12-31 0001792044 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001792044 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001792044 us-gaap:MoneyMarketFundsMember 2020-12-31 0001792044 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001792044 us-gaap:ExchangeTradedFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001792044 us-gaap:ExchangeTradedFundsMember 2020-12-31 0001792044 vtrs:MarketableSecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001792044 vtrs:MarketableSecuritiesMember 2020-12-31 0001792044 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001792044 us-gaap:EquitySecuritiesMember 2020-12-31 0001792044 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001792044 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001792044 us-gaap:MortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:MortgageBackedSecuritiesMember 2020-12-31 0001792044 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:AssetBackedSecuritiesMember 2020-12-31 0001792044 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:OtherDebtSecuritiesMember 2020-12-31 0001792044 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:DebtSecuritiesMember 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember 2020-12-31 0001792044 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember 2020-12-31 0001792044 us-gaap:FairValueInputsLevel3Member vtrs:ContingentConsiderationMember 2020-12-31 0001792044 vtrs:ContingentConsiderationMember 2020-12-31 0001792044 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001792044 vtrs:RespiratorydeliveryplatformMember 2021-12-31 0001792044 srt:MinimumMember vtrs:ContingentConsiderationMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001792044 srt:MaximumMember vtrs:ContingentConsiderationMember us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001792044 us-gaap:OtherCurrentLiabilitiesMember 2019-12-31 0001792044 us-gaap:OtherNoncurrentLiabilitiesMember 2019-12-31 0001792044 us-gaap:OtherCurrentLiabilitiesMember 2020-01-01 2020-12-31 0001792044 us-gaap:OtherNoncurrentLiabilitiesMember 2020-01-01 2020-12-31 0001792044 us-gaap:OtherCurrentLiabilitiesMember 2021-01-01 2021-12-31 0001792044 us-gaap:OtherNoncurrentLiabilitiesMember 2021-01-01 2021-12-31 0001792044 us-gaap:DebtSecuritiesMember 2021-12-31 0001792044 us-gaap:DebtSecuritiesMember 2020-12-31 0001792044 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2020-12-31 0001792044 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2020-12-31 0001792044 us-gaap:CommercialPaperMember 2021-12-31 0001792044 us-gaap:CommercialPaperMember 2020-12-31 0001792044 vtrs:ReceivablesFacilityMember 2021-12-31 0001792044 vtrs:ReceivablesFacilityMember 2020-12-31 0001792044 vtrs:NoteSecuritizationFacilityMember 2021-12-31 0001792044 vtrs:NoteSecuritizationFacilityMember 2020-12-31 0001792044 vtrs:OtherCurrentPortionofLongtermDebtMember 2021-12-31 0001792044 vtrs:OtherCurrentPortionofLongtermDebtMember 2020-12-31 0001792044 vtrs:CommercialPaperProgramMember 2017-06-06 0001792044 vtrs:CommercialPaperProgramMember 2017-06-06 2017-06-06 0001792044 vtrs:ReceivablesFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-12-31 0001792044 vtrs:NoteSecuritizationFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-12-31 0001792044 vtrs:SeniorNotes2021Member 2021-12-31 0001792044 vtrs:A2020FloatingRateEuroNotesMember 2021-12-31 0001792044 vtrs:A2020FloatingRateEuroNotesMember 2020-12-31 0001792044 vtrs:A2020EuroSeniorNotesMember 2021-12-31 0001792044 vtrs:A2020EuroSeniorNotesMember 2020-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwenty3.75PercentMember 2021-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwenty3.75PercentMember 2020-12-31 0001792044 vtrs:CurrentPortionofLongTermDebtMember 2021-12-31 0001792044 vtrs:CurrentPortionofLongTermDebtMember 2020-12-31 0001792044 vtrs:A2022EuroSeniorNotesMember 2020-12-31 0001792044 vtrs:SeniorNotes2022Member 2021-12-31 0001792044 vtrs:SeniorNotes2022Member 2020-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwentyThree4.2PercentMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwentyThree4.2PercentMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2024EuroSeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2024EuroSeniorNotes1023Member us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2024EuroSeniorNotes1023Member us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2025EuroSeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwentySix3.95PrecentMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:SeniorNotesTwoThousandTwentySix3.95PrecentMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2027EuroSeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2027EuroSeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2027SeniorNotesMember 2021-12-31 0001792044 vtrs:A2027SeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2027SeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2028EuroSeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2030SeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2030SeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2032EuroSeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2040SeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2040SeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:SeniorNotesTwoThousandFortyThreeMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:SeniorNotesTwoThousandFortyThreeMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:SeniorNotesTwoThousandFortySix5.25PrecentMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:SeniorNotesTwoThousandFortySix5.25PrecentMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2048SeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2048SeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:A2050SeniorNotesMember us-gaap:SeniorNotesMember 2021-12-31 0001792044 vtrs:A2050SeniorNotesMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:TermLoanMember 2021-12-31 0001792044 vtrs:TermLoanMember us-gaap:SeniorNotesMember 2020-12-31 0001792044 vtrs:OtherLongTermDebtMember 2021-12-31 0001792044 vtrs:OtherLongTermDebtMember 2020-12-31 0001792044 2020-01-01 2020-03-31 0001792044 vtrs:UpjohnInc.Member vtrs:UnregisteredUpjohnUSDollarNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:UpjohnEuroNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member us-gaap:SeniorNotesMember 2021-09-30 0001792044 2021-10-29 0001792044 vtrs:UpjohnInc.Member vtrs:A2022SeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:A2027SeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:A2030SeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:A2040SeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:A2050SeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:A2022EuroSeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:A2024EuroSeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:A2027EuroSeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member vtrs:A2032EuroSeniorNotesMember us-gaap:SeniorNotesMember 2021-06-30 0001792044 vtrs:UpjohnInc.Member 2021-06-30 0001792044 vtrs:USDTermLoanFacilityMember us-gaap:SeniorNotesMember 2020-06-30 0001792044 vtrs:A2020RevolvingFacilityMember us-gaap:RevolvingCreditFacilityMember 2020-06-30 0001792044 vtrs:YENTermLoanMember us-gaap:MediumTermNotesMember 2021-07-31 0001792044 vtrs:TwentyTwentyOneRevolvingFacilityMember us-gaap:RevolvingCreditFacilityMember 2021-06-30 0001792044 vtrs:TwentyTwentyOneLoanFacilitiesMember us-gaap:MediumTermNotesMember 2021-07-31 0001792044 us-gaap:SeniorNotesMember 2021-12-31 0001792044 us-gaap:SeniorNotesMember 2020-12-31 0001792044 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-12-31 0001792044 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-12-31 0001792044 us-gaap:NetInvestmentHedgingMember 2021-12-31 0001792044 us-gaap:NetInvestmentHedgingMember 2020-12-31 0001792044 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-12-31 0001792044 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-12-31 0001792044 us-gaap:NetInvestmentHedgingMember 2019-12-31 0001792044 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0001792044 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001792044 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001792044 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0001792044 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0001792044 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-12-31 0001792044 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001792044 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0001792044 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0001792044 us-gaap:NetInvestmentHedgingMember 2018-12-31 0001792044 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001792044 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001792044 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001792044 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001792044 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0001792044 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0001792044 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001792044 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001792044 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001792044 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0001792044 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0001792044 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001792044 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001792044 us-gaap:ForeignCountryMember 2021-01-01 2021-12-31 0001792044 us-gaap:ForeignCountryMember 2020-01-01 2020-12-31 0001792044 us-gaap:ForeignCountryMember 2019-01-01 2019-12-31 0001792044 vtrs:U.S.StateTaxAuthorityMember 2021-01-01 2021-12-31 0001792044 vtrs:U.S.StateTaxAuthorityMember 2020-01-01 2020-12-31 0001792044 vtrs:U.S.StateTaxAuthorityMember 2019-01-01 2019-12-31 0001792044 vtrs:NonU.S.statetaxauthorityMember 2021-01-01 2021-12-31 0001792044 vtrs:NonU.S.statetaxauthorityMember 2020-01-01 2020-12-31 0001792044 vtrs:NonU.S.statetaxauthorityMember 2019-01-01 2019-12-31 0001792044 vtrs:OtherMember 2021-01-01 2021-12-31 0001792044 vtrs:OtherMember 2020-01-01 2020-12-31 0001792044 vtrs:OtherMember 2019-01-01 2019-12-31 0001792044 country:US 2021-01-01 2021-12-31 0001792044 country:US 2020-01-01 2020-12-31 0001792044 country:US 2019-01-01 2019-12-31 0001792044 country:LU 2021-01-01 2021-12-31 0001792044 country:LU 2020-01-01 2020-12-31 0001792044 country:LU 2019-01-01 2019-12-31 0001792044 country:GI 2021-01-01 2021-12-31 0001792044 country:GI 2020-01-01 2020-12-31 0001792044 country:GI 2019-01-01 2019-12-31 0001792044 country:IE 2021-01-01 2021-12-31 0001792044 country:IE 2020-01-01 2020-12-31 0001792044 country:IE 2019-01-01 2019-12-31 0001792044 country:FR 2021-01-01 2021-12-31 0001792044 country:FR 2020-01-01 2020-12-31 0001792044 country:FR 2019-01-01 2019-12-31 0001792044 country:PR 2021-01-01 2021-12-31 0001792044 country:PR 2020-01-01 2020-12-31 0001792044 country:PR 2019-01-01 2019-12-31 0001792044 country:CH 2021-01-01 2021-12-31 0001792044 country:CH 2020-01-01 2020-12-31 0001792044 country:CH 2019-01-01 2019-12-31 0001792044 country:SG 2021-01-01 2021-12-31 0001792044 country:SG 2020-01-01 2020-12-31 0001792044 country:SG 2019-01-01 2019-12-31 0001792044 vtrs:OtherforeignMember 2021-01-01 2021-12-31 0001792044 vtrs:OtherforeignMember 2020-01-01 2020-12-31 0001792044 vtrs:OtherforeignMember 2019-01-01 2019-12-31 0001792044 us-gaap:NonUsMember 2021-01-01 2021-12-31 0001792044 us-gaap:NonUsMember 2020-01-01 2020-12-31 0001792044 us-gaap:NonUsMember 2019-01-01 2019-12-31 0001792044 srt:ScenarioForecastMember 2025-01-01 2025-12-31 0001792044 vtrs:U.S.FederalTaxAuthorityMember 2021-12-31 0001792044 vtrs:U.S.StateTaxAuthorityMember 2021-12-31 0001792044 us-gaap:ForeignCountryMember 2021-12-31 0001792044 us-gaap:ForeignCountryMember vtrs:IndefiniteMember 2021-12-31 0001792044 us-gaap:ForeignCountryMember vtrs:FutureyearsMember 2021-12-31 0001792044 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:TaxYear2015Member 2019-12-31 0001792044 us-gaap:ForeignCountryMember us-gaap:AustralianTaxationOfficeMember 2021-01-01 2021-12-31 0001792044 2016-12-31 0001792044 vtrs:A2020StockIncentivePlanAnd2003LongTermIncentivePlanMember 2020-11-16 0001792044 vtrs:LongTermIncentivePlan2003Member 2020-11-16 2020-11-16 0001792044 vtrs:LongTermIncentivePlan2003Member 2020-11-16 0001792044 srt:MinimumMember us-gaap:EmployeeStockOptionMember vtrs:LongTermIncentivePlan2003Member 2021-01-01 2021-12-31 0001792044 srt:MaximumMember us-gaap:EmployeeStockOptionMember vtrs:LongTermIncentivePlan2003Member 2021-01-01 2021-12-31 0001792044 us-gaap:EmployeeStockOptionMember vtrs:LongTermIncentivePlan2003Member 2021-01-01 2021-12-31 0001792044 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001792044 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001792044 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001792044 us-gaap:RestrictedStockMember vtrs:VestratablyinfiveyearsorlessMember 2021-01-01 2021-12-31 0001792044 us-gaap:PerformanceSharesMember vtrs:NotSubjecttoMarketConditionsMember vtrs:VestinthreeyearsorlessMember 2021-01-01 2021-12-31 0001792044 us-gaap:PerformanceSharesMember vtrs:SubjectToMarketConditionsMember vtrs:VestinthreeyearsorlessMember 2021-01-01 2021-12-31 0001792044 vtrs:LongTermIncentivePlan2003Member 2021-12-31 0001792044 vtrs:LongTermIncentivePlan2003Member 2021-01-01 2021-12-31 0001792044 vtrs:LongTermIncentivePlan2003Member 2020-01-01 2020-12-31 0001792044 us-gaap:EmployeeStockOptionMember vtrs:LongTermIncentivePlan2003Member 2020-01-01 2020-12-31 0001792044 us-gaap:EmployeeStockOptionMember vtrs:LongTermIncentivePlan2003Member 2019-01-01 2019-12-31 0001792044 vtrs:StockappreciationrightsandperformancesharesMember vtrs:A2014ProgramMember 2021-01-01 2021-12-31 0001792044 us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0001792044 us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0001792044 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0001792044 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-12-31 0001792044 us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0001792044 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0001792044 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0001792044 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0001792044 us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember 2021-01-01 2021-12-31 0001792044 us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember 2020-01-01 2020-12-31 0001792044 us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001792044 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-12-31 0001792044 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-12-31 0001792044 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001792044 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001792044 us-gaap:CashAndCashEquivalentsMember 2021-12-31 0001792044 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001792044 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001792044 us-gaap:EquitySecuritiesMember 2021-12-31 0001792044 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001792044 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001792044 us-gaap:FixedIncomeSecuritiesMember 2021-12-31 0001792044 vtrs:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001792044 vtrs:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001792044 vtrs:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001792044 vtrs:AssetsheldbyinsurancecompaniesandotherMember 2021-12-31 0001792044 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001792044 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001792044 us-gaap:CashAndCashEquivalentsMember 2020-12-31 0001792044 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001792044 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001792044 us-gaap:EquitySecuritiesMember 2020-12-31 0001792044 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001792044 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001792044 us-gaap:FixedIncomeSecuritiesMember 2020-12-31 0001792044 vtrs:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001792044 vtrs:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001792044 vtrs:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001792044 vtrs:AssetsheldbyinsurancecompaniesandotherMember 2020-12-31 0001792044 us-gaap:PensionPlansDefinedBenefitMember 2017-01-01 2017-12-31 0001792044 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-12-31 0001792044 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-01-01 2017-12-31 0001792044 vtrs:FiscalYear2017Member 2021-12-31 0001792044 vtrs:DeferredBaseSalaryMember 2021-01-01 2021-12-31 0001792044 us-gaap:DeferredBonusMember 2021-01-01 2021-12-31 0001792044 us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0001792044 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-12-31 0001792044 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-12-31 0001792044 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-12-31 0001792044 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0001792044 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0001792044 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-12-31 0001792044 vtrs:MckessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001792044 vtrs:MckessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001792044 vtrs:MckessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001792044 vtrs:AmeriSourceBergenCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001792044 vtrs:AmeriSourceBergenCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001792044 vtrs:AmeriSourceBergenCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001792044 vtrs:CardinalHealthIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001792044 vtrs:CardinalHealthIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001792044 vtrs:CardinalHealthIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001792044 country:CN 2021-01-01 2021-12-31 0001792044 country:CN 2020-01-01 2020-12-31 0001792044 country:CN 2019-01-01 2019-12-31 0001792044 vtrs:PfizerInc.Member vtrs:TransitionServiceAgreementsMember 2021-01-01 2021-12-31 0001792044 vtrs:PfizerInc.Member 2021-12-31 0001792044 vtrs:PfizerInc.Member 2021-01-01 2021-12-31 0001792044 vtrs:PfizerInc.Member 2020-01-01 2020-12-31 0001792044 srt:MaximumMember vtrs:A2020RestructuringPlanMember 2021-10-01 2021-12-31 0001792044 srt:MaximumMember vtrs:A2020RestructuringPlanMember 2021-12-31 0001792044 us-gaap:EmployeeSeveranceMember vtrs:A2020RestructuringPlanMember 2020-01-01 2020-12-31 0001792044 us-gaap:OtherRestructuringMember vtrs:A2020RestructuringPlanMember 2020-01-01 2020-12-31 0001792044 vtrs:A2020RestructuringPlanMember 2020-01-01 2020-12-31 0001792044 us-gaap:EmployeeSeveranceMember vtrs:A2020RestructuringPlanMember 2020-12-31 0001792044 us-gaap:OtherRestructuringMember vtrs:A2020RestructuringPlanMember 2020-12-31 0001792044 vtrs:A2020RestructuringPlanMember 2020-12-31 0001792044 us-gaap:EmployeeSeveranceMember vtrs:A2020RestructuringPlanMember 2021-01-01 2021-12-31 0001792044 us-gaap:OtherRestructuringMember vtrs:A2020RestructuringPlanMember 2021-01-01 2021-12-31 0001792044 vtrs:A2020RestructuringPlanMember 2021-01-01 2021-12-31 0001792044 us-gaap:EmployeeSeveranceMember 2021-01-01 2021-12-31 0001792044 us-gaap:OtherRestructuringMember 2021-01-01 2021-12-31 0001792044 us-gaap:EmployeeSeveranceMember vtrs:A2020RestructuringPlanMember 2021-12-31 0001792044 us-gaap:OtherRestructuringMember vtrs:A2020RestructuringPlanMember 2021-12-31 0001792044 vtrs:A2020RestructuringPlanMember 2021-12-31 0001792044 vtrs:A2016RestructuringProgramMember 2016-01-01 2020-12-31 0001792044 us-gaap:EmployeeSeveranceMember 2018-12-31 0001792044 us-gaap:OtherRestructuringMember 2018-12-31 0001792044 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0001792044 us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0001792044 us-gaap:EmployeeSeveranceMember 2019-12-31 0001792044 us-gaap:OtherRestructuringMember 2019-12-31 0001792044 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-12-31 0001792044 us-gaap:OtherRestructuringMember 2020-01-01 2020-12-31 0001792044 us-gaap:EmployeeSeveranceMember 2020-12-31 0001792044 us-gaap:OtherRestructuringMember 2020-12-31 0001792044 srt:MaximumMember us-gaap:CollaborativeArrangementMember vtrs:FiscalYear2017Member 2021-01-01 2021-12-31 0001792044 vtrs:RevanceMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2020-01-01 2020-12-31 0001792044 vtrs:MomentaMember 2016-01-08 0001792044 vtrs:TheravanceBiopharmaMember 2021-01-01 2021-12-31 0001792044 srt:MaximumMember vtrs:TheravanceBiopharmaMember 2015-01-30 2015-01-30 0001792044 vtrs:TheravanceBiopharmaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-12-31 0001792044 vtrs:GenericBiologicCompoundsCollaborationMember 2013-02-11 2013-02-12 0001792044 vtrs:FKBMember 2018-09-20 2018-09-20 0001792044 vtrs:FKBMember 2019-02-27 2019-02-27 0001792044 vtrs:OtherCompaniesMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-12-31 0001792044 vtrs:OtherCompaniesMember us-gaap:LicensingAgreementsMember 2021-12-31 0001792044 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-12-31 0001792044 srt:ScenarioForecastMember vtrs:BiosimilarsBusinessMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-10-01 2022-12-31 0001792044 srt:ScenarioForecastMember vtrs:BiosimilarsBusinessMember us-gaap:ConvertiblePreferredStockMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-10-01 2022-12-31 0001792044 srt:ScenarioForecastMember vtrs:BiosimilarsBusinessMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0001792044 vtrs:EpiPenAutoInjectorLitigationMember 2021-01-01 2021-12-31 0001792044 vtrs:EpiPenAutoInjectorLitigationMember us-gaap:SubsequentEventMember 2022-02-01 2022-02-28 0001792044 vtrs:EpiPenAutoInjectorLitigationMember 2021-12-31 0001792044 vtrs:EpiPenAutoInjectorLitigationMember us-gaap:OtherCurrentLiabilitiesMember 2021-12-31 0001792044 vtrs:MultiDistrictLitigationMember 2021-12-31 0001792044 vtrs:AnticompetitiveConductwithDoxycyclineHyclateDelayedReleaseDoxycyclineMonohydrateGlipizideMetforminandVerapamilMember 2021-12-31 0001792044 vtrs:AnticompetitiveConductwithGenericDrugsMember 2021-12-31 0001792044 vtrs:AmendedAnticompetitiveConductwithGenericDrugsMember 2021-12-31 0001792044 srt:SubsidiariesMember vtrs:EUCommissionProceedingsPerindorprilMember vtrs:AntitrustProceedingsMember 2014-07-08 2014-07-09 0001792044 srt:SubsidiariesMember vtrs:EUCommissionProceedingsPerindorprilMember vtrs:AntitrustProceedingsMember 2014-10-01 2014-12-31 0001792044 vtrs:EUCommissionProceedingsCitalopramMember 2013-06-01 2013-06-19 0001792044 vtrs:EUCommissionProceedingsCitalopramMember 2021-12-31 0001792044 vtrs:U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember 2016-02-12 2016-02-12 0001792044 srt:ParentCompanyMember vtrs:U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember 2016-02-12 2016-02-12 0001792044 srt:ParentCompanyMember vtrs:U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember 2021-12-31 0001792044 vtrs:ProductLiabilityMember 2021-12-31 0001792044 us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-12-31 0001792044 vtrs:InsulinGlargineMember 2017-10-24 2017-10-24 0001792044 vtrs:InsulinGlargineMember 2017-10-24 0001792044 vtrs:InsulinGlargineMember 2019-06-17 0001792044 vtrs:InsulinGlargineMember 2019-06-17 2019-06-17 0001792044 vtrs:InsulinGlargineMember 2018-09-10 2018-09-10 0001792044 vtrs:InsulinGlargineMember 2020-04-02 0001792044 vtrs:DimethylFumarateMember 2017-06-30 2017-06-30 0001792044 vtrs:OtherMember 2021-12-31 0001792044 us-gaap:AllowanceForCreditLossMember 2021-01-01 2021-12-31 0001792044 us-gaap:AllowanceForCreditLossMember 2019-12-31 0001792044 us-gaap:AllowanceForCreditLossMember 2020-01-01 2020-12-31 0001792044 us-gaap:AllowanceForCreditLossMember 2018-12-31 0001792044 us-gaap:AllowanceForCreditLossMember 2019-01-01 2019-12-31 0001792044 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-12-31 0001792044 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-01-01 2021-12-31 0001792044 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-12-31 0001792044 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0001792044 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-01-01 2020-12-31 0001792044 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0001792044 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 iso4217:USD iso4217:USD shares shares vtrs:molecule vtrs:site pure vtrs:market iso4217:EUR iso4217:JPY utr:Rate vtrs:drugs vtrs:Product vtrs:agreement vtrs:state vtrs:case iso4217:GBP vtrs:increase vtrs:patent 0001792044 2021-12-31 false 2021 FY --12-31 P5Y http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent 750000000.0 0.021 0.105 P3Y P3Y0M P3Y0M P3Y P4Y P10Y P5Y 10-K true false 001-39695 VIATRIS INC. DE 83-4364296 1000 Mylan Boulevard Canonsburg PA 15317 (724) 514-1800 Common Stock, par value $0.01 per share VTRS NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 17237737213 0.01 1209576280 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part of Form 10-K into Which<br/>Document is Incorporated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">An amendment to this Form 10-K will be filed no later than 120 days after the close of registrant’s fiscal year.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">III</span></td></tr></table> 34 34 DELOITTE & TOUCHE LLP Pittsburgh, Pennsylvania 701200000 844400000 4266400000 4843800000 3977700000 5471900000 1957600000 1707400000 10902900000 12867500000 3188600000 3459900000 26134200000 29683200000 12113700000 12347000000 1332700000 2147900000 1170700000 1047500000 54842800000 61553000000 1657400000 1904200000 1493000000 1100900000 236900000 288600000 1877500000 2308500000 4619600000 4960700000 9884400000 10562900000 19717100000 22429200000 2815000000 3123700000 1933600000 2483100000 34350100000 38598900000 0.01 3000000000 1209507463 1206895644 12100000 12100000 18536100000 18438800000 3688800000 5361200000 -1744300000 -858000000.0 20492700000 22954100000 54842800000 61553000000 17813600000 11819900000 11370300000 72700000 126100000 130200000 17886300000 11946000000 11500500000 12310800000 8149300000 7602900000 5575500000 3796700000 3897600000 751100000 555100000 639900000 4529200000 3344600000 2563600000 -329200000 -107800000 21400000 5609500000 4007500000 3182100000 -34000000.0 -210800000 715500000 636200000 497800000 517300000 5800000 -12600000 -43800000 -664400000 -721200000 154400000 604700000 -51300000 137600000 -1269100000 -669900000 16800000 -1.05 -1.11 0.03 -1.05 -1.11 0.03 1208800000 601200000 515700000 1208800000 601200000 516500000 -1269100000 -669900000 16800000 -1340900000 1213000000 -415500000 -73900000 14000000.0 24800000 36100000 18200000 37100000 456800000 -305200000 59600000 -1100000 600000 500000 -775200000 912600000 -343100000 111100000 -26600000 9200000 -886300000 939200000 -352300000 -2155400000 269300000 -335500000 539289665 6000000.0 8591400000 6010700000 23490867 -999700000 -1441300000 12167100000 16800000 16800000 -352300000 -352300000 56800000 56800000 1457206 100000 8100000 8200000 -12800000 -12800000 1107207 3600000 -3600000 0 540746871 6100000 8643500000 6031100000 24598074 -999700000 -1797200000 11883800000 -669900000 -669900000 939200000 939200000 79200000 79200000 872802 600000 600000 -6300000 -6300000 541619673 6100000 -6100000 0 541619673 5200000 -5200000 0 689874045 6900000 10720600000 10727500000 24598074 999700000 24598074 -999700000 0 1206895644 12100000 18438800000 5361200000 0 0 -858000000.0 22954100000 -1269100000 -1269100000 -886300000 -886300000 111200000 111200000 2611819 -13900000 -13900000 0.33 403300000 403300000 1209507463 12100000 18536100000 3688800000 0 0 -1744300000 20492700000 -1269100000 -669900000 16800000 4506500000 2216100000 2019300000 675700000 675700000 -213200000 -192600000 -323700000 -101100000 11500000 -61900000 -48400000 -62100000 111200000 79200000 56800000 -411800000 -411800000 -366400000 -360600000 -59300000 -59300000 -78700000 20000000.0 427600000 741900000 512900000 -70400000 -70400000 -82700000 -96300000 -699600000 -699600000 3600000 57900000 666500000 666500000 -46000000.0 -63500000 3016900000 3016900000 1231800000 1803700000 -277000000.0 -415800000 148700000 457200000 243000000.0 213200000 52200000 438200000 192800000 18300000 2100000 0 96700000 20000000.0 28000000.0 30200000 104800000 25800000 29800000 47000000.0 27100000 -117800000 -301100000 -525400000 1710100000 983300000 7400000 4201300000 2484200000 1108500000 7000000.0 2000000.0 3000000.0 392100000 1099600000 -1800000 0 600000 8100000 17400000 7900000 8400000 28600000 48500000 60300000 399000000.0 0 0 456000000.0 143300000 0 -4900000 -3300000 -2500000 -3012000000 -605700000 -1169000000 -30900000 33800000 -7500000 -143800000 358800000 101800000 850000000.0 491100000 389300000 706200000 850000000.0 491100000 0 10727500000 0 641700000 324400000 278600000 684800000 555400000 470600000 Nature of Operations<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viatris is a global healthcare company formed in November 2020 whose mission is to empower people worldwide to live healthier at every stage of life, regardless of geography or circumstance. Improving the ability of patients to gain access to sustainable and high-quality healthcare is our relentless pursuit. One that rests on visionary thinking, determination and best-in-class capabilities that were strategically built to remove barriers across the health spectrum and advance access globally. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. The Company operates approximately 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs. We conduct our business through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 805, Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Mylan is considered the accounting acquirer of the Upjohn Business and all historical financial information of the Company prior to November 16, 2020 represents Mylan’s historical results and the Company’s thereafter.</span></div> 1400 40 Summary of Significant Accounting Policies<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The consolidated financial statements include the accounts of Viatris and those of its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Investments in equity method affiliates are recorded at cost and adjusted for the Company’s share of the affiliates’ cumulative results of operations, capital contributions and distributions. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currencies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The consolidated financial statements are presented in U.S. Dollars, the reporting currency of Viatris. Statements of Operations and Cash Flows of all of the Company’s subsidiaries that have functional currencies other than U.S. Dollars are translated at a weighted average exchange rate for the period for inclusion in the consolidated statements of operations and cash flows, whereas assets and liabilities are translated at the end of the period exchange rates for inclusion in the consolidated balance sheets. Translation differences are recorded directly in shareholders’ equity as foreign currency translation adjustments. Gains or losses on transactions denominated in a currency other than the subsidiaries’ functional currency, which arise as a result of changes in foreign currency exchange rates, are recorded in the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt and Equity Securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Debt securities classified as available-for-sale on the date of purchase are recorded at fair value, with net unrealized gains and losses, net of income taxes, reflected in accumulated other comprehensive loss as a component of shareholders’ equity. Net realized gains and losses on sales of available-for-sale debt securities are computed on a specific security basis and are included in other expense, net, in the consolidated statements of operations. Debt securities classified as trading securities are valued using the quoted market price from broker or dealer quotations or transparent pricing sources at the reporting date, with gains and losses included in other expense, net, in the consolidated statements of operations. Fair value is determined based on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit risk or underlying security and overall capital market liquidity. Debt securities are reviewed for impairment by assessing if the decline in market value of the investment below the carrying value is other than temporary.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities with readily determinable fair values are recorded at fair value with changes in fair value recorded in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Investments in entities are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The share of net income or losses of equity method investments are included in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values and investments in equity accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viatris invests its excess cash in high-quality, liquid money market instruments, principally overnight deposits and highly rated money market funds. The Company maintains deposit balances at certain financial institutions in excess of federally insured amounts. Periodically, the Company reviews the creditworthiness of its counterparties to derivative transactions, and it does not expect to incur a loss from failure of any counterparties to perform under agreements it has with such counterparties.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventories are stated at the lower of cost and net realizable value, with cost principally determined by the weighted average cost method. Provisions for potentially obsolete or slow-moving inventory, including pre-launch inventory, are made based on our analysis of product dating, inventory levels, historical obsolescence and future sales forecasts. Included as a component of cost of sales is expense related to the net realizable value of inventories. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed and recorded on a straight-line basis over the assets’ estimated service lives (3 to 18 years for machinery and equipment and other fixed assets and 15 to 39 years for buildings and improvements). Capitalized software is included in property, plant and equipment and is amortized over estimated useful lives ranging from 3 to 7 years. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets are stated at cost less accumulated amortization. Amortization is generally recorded on a straight-line basis over estimated useful lives ranging from 3 to 20 years. The Company periodically reviews the estimated useful lives of intangible assets and makes adjustments when events indicate that a shorter life is appropriate.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 805, Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective estimated fair values. The cost to acquire businesses is allocated to the underlying net assets of the acquired business based on estimates of their respective fair values. Amounts allocated to acquired IPR&amp;D are capitalized at the date of acquisition and, at that time, such IPR&amp;D assets have indefinite lives. As products in development are approved for sale, amounts are allocated to product rights and licenses and will be amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of developed products and licenses that are accounted for as asset acquisitions are capitalized as intangible assets and amortized over an estimated useful life. IPR&amp;D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management's assessment of the fair value of the Company's reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we choose to use qualitative factors and determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test would be required. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangibles, principally IPR&amp;D, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&amp;D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value of IPR&amp;D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Viatris records contingent consideration resulting from business acquisitions at its estimated fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as adjustments to litigation settlements and other contingencies, net within the consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, sales targets and profitability. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Borrowings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company’s subsidiaries in India have working capital facilities with several banks which are secured by its current assets. The Company also has the CP Notes, Receivables Facility, which will expire in April 2022 and the Note Securitization Facility, which will expire in August 2022. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. As the accounts receivable do not transfer to the banks, any amounts outstanding under the facilities are recorded as borrowings and the underlying receivables continue to be included in accounts receivable, net, in the consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenues in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Amounts recorded for revenue deductions can result from a complex series of judgements about future events and uncertainties and can rely heavily on estimates and assumptions. The following section briefly describes the nature of our provisions for variable consideration and how such provisions are estimated:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Viatris will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rebates, promotional programs and other sales allowances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: consistent with industry practice, Viatris maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. Generally, returned products are destroyed and customers are refunded the sales price in the form of a credit.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental rebate programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: government reimbursement programs in the U.S. include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap” based on historical experience of prescriptions and utilization expected to result in the discount of the “coverage gap”.</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the majority of our pharmaceutical sales are contractually or legislatively governed. In certain European countries, certain rebates are calculated on the governments total pharmaceutical spending or on specific product sale thresholds. We utilize historical data and obtain third party information to determine the adequacy of these accruals. Also, this provision includes price reductions that are mandated by law outside of the U.S. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenues in the consolidated statements of operations. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R&amp;D expenses are charged to operations as incurred.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income taxes have been provided for using an asset and liability approach in which deferred income taxes reflect the tax consequences on future years of events that the Company has already recognized in the financial statements or tax returns. Changes in enacted tax rates or laws may result in adjustments to the recorded tax assets or liabilities in the period that the new tax law is enacted.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Basic earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) earnings attributable to Viatris Inc. common shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares (denominator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic (loss) earnings per share attributable to Viatris Inc. shareholders</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) earnings attributable to Viatris Inc. common shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares (denominator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total dilutive shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted (loss) earnings per share attributable to Viatris Inc. shareholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average shares outstanding used in the computation of earnings per share for the year ended December 31, 2020 includes the effect of the 689.9 million shares issued for the closing of the Combination.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional stock awards and restricted ordinary shares were outstanding during the years ended December 31, 2021, 2020 and 2019 but were not included in the computation of diluted earnings per share for each respective period because the effect would be anti-dilutive. Excluded shares also include certain share-based compensation awards and restricted shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 12.7 million, 10.3 million and 9.1 million shares for the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid quarterly cash dividends of $0.11 per share on the Company’s issued and outstanding common stock on June 16, 2021, September 16, 2021, and December 16, 2021. On January 4, 2022, the Company’s Board of Directors declared a quarterly cash dividend of $0.12 per share on the Company’s issued and outstanding common stock, which will be payable on March 16, 2022 to shareholders of record as of the close of business on February 24, 2022. The declaration and payment of future dividends to holders of the Company’s common stock will be at the discretion of the Board of Directors, and will depend upon factors, including but not limited to, the Company’s financial condition, earnings, capital requirements of its businesses, legal requirements, regulatory constraints, industry practice, and other factors that the Board of Directors deems relevant.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, the Company announced that its Board of Directors had authorized a share repurchase program for the repurchase of up to $1.0 billion of the Company’s shares of common stock. The Company has not yet repurchased any shares of common stock under the share repurchase program and the share repurchase program does not obligate the Company to acquire any particular amount of common stock. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of share-based compensation is recognized as expense in the consolidated statements of operations over the vesting period.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From time to time the Company may enter into derivative financial instruments (mainly foreign currency exchange forward contracts, interest rate swaps and purchased equity call options) designed to: 1) hedge the cash flows resulting from existing assets and liabilities and transactions expected to be entered into over the next 24 months in currencies other than the functional currency, 2) hedge the variability in interest expense on floating rate debt, 3) hedge the fair value of fixed-rate notes, 4) hedge against changes in interest rates that could impact future debt issuances, 5) hedge cash or share payments required on conversion of issued convertible notes, 6) hedge a net investment in a foreign operation, or 7) economically hedge the foreign currency exposure associated with the purchase price of non-U.S. acquisitions. Derivatives are recognized as assets or liabilities in the consolidated balance sheets at their fair value. When the derivative instrument qualifies as a cash flow hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged items, are generally included in interest expense. When such instruments do not qualify for hedge accounting the changes in fair value are recorded in the consolidated statements of operations within other expense, net. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company’s financial instruments consist primarily of short-term and long-term debt, interest rate swaps, forward contracts and option contracts. The Company’s financial instruments also include cash and cash equivalents as well as accounts and other receivables and accounts payable, the fair values of which approximate their carrying values. As a policy, the Company does not engage in speculative or leveraged transactions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries derivative instruments in the consolidated balance sheets at fair value, determined by reference to market data such as forward rates for currencies, implied volatilities, and interest rate swap yield curves. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. In addition, the Company has designated certain long-term debt instruments as net investment hedges.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued Accounting Standards Update 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-01”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. In addition, ASU 2020-01 states that for the purpose of applying paragraph 815-10-15-141(a) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The Company applied the provisions of ASU 2020-01 as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is intended to simplify the accounting for income taxes by eliminating certain exceptions and simplifying certain requirements under Topic 740. The Company applied the provisions of ASU 2019-12 on a prospective basis as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Issued Not Yet Adopted    </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-04”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Entities can apply the provisions of ASU 2020-04 immediately, as applicable, and generally the provisions of the guidance are available through December 31, 2022 as entities transition away from reference rates that are expected to be discontinued. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued Accounting Standards Update 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2021-08”), which requires entities (acquirers) to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. ASU 2021-08 will be effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2022 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued Accounting Standards Update 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2021-10”), which requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 will be effective for fiscal years beginning after December 15, 2021 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its disclosures.</span></div> Principles of Consolidation. The consolidated financial statements include the accounts of Viatris and those of its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Investments in equity method affiliates are recorded at cost and adjusted for the Company’s share of the affiliates’ cumulative results of operations, capital contributions and distributions. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currencies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The consolidated financial statements are presented in U.S. Dollars, the reporting currency of Viatris. Statements of Operations and Cash Flows of all of the Company’s subsidiaries that have functional currencies other than U.S. Dollars are translated at a weighted average exchange rate for the period for inclusion in the consolidated statements of operations and cash flows, whereas assets and liabilities are translated at the end of the period exchange rates for inclusion in the consolidated balance sheets. Translation differences are recorded directly in shareholders’ equity as foreign currency translation adjustments. Gains or losses on transactions denominated in a currency other than the subsidiaries’ functional currency, which arise as a result of changes in foreign currency exchange rates, are recorded in the consolidated statements of operations.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt and Equity Securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Debt securities classified as available-for-sale on the date of purchase are recorded at fair value, with net unrealized gains and losses, net of income taxes, reflected in accumulated other comprehensive loss as a component of shareholders’ equity. Net realized gains and losses on sales of available-for-sale debt securities are computed on a specific security basis and are included in other expense, net, in the consolidated statements of operations. Debt securities classified as trading securities are valued using the quoted market price from broker or dealer quotations or transparent pricing sources at the reporting date, with gains and losses included in other expense, net, in the consolidated statements of operations. Fair value is determined based on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit risk or underlying security and overall capital market liquidity. Debt securities are reviewed for impairment by assessing if the decline in market value of the investment below the carrying value is other than temporary.</span>Investments in equity securities with readily determinable fair values are recorded at fair value with changes in fair value recorded in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Investments in entities are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The share of net income or losses of equity method investments are included in other expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values and investments in equity accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors. <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viatris invests its excess cash in high-quality, liquid money market instruments, principally overnight deposits and highly rated money market funds. The Company maintains deposit balances at certain financial institutions in excess of federally insured amounts. Periodically, the Company reviews the creditworthiness of its counterparties to derivative transactions, and it does not expect to incur a loss from failure of any counterparties to perform under agreements it has with such counterparties.</span></div> Inventories. Inventories are stated at the lower of cost and net realizable value, with cost principally determined by the weighted average cost method. Provisions for potentially obsolete or slow-moving inventory, including pre-launch inventory, are made based on our analysis of product dating, inventory levels, historical obsolescence and future sales forecasts. Included as a component of cost of sales is expense related to the net realizable value of inventories. Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed and recorded on a straight-line basis over the assets’ estimated service lives (3 to 18 years for machinery and equipment and other fixed assets and 15 to 39 years for buildings and improvements). Capitalized software is included in property, plant and equipment and is amortized over estimated useful lives ranging from 3 to 7 years. P3Y P18Y P15Y P39Y P3Y P7Y <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets are stated at cost less accumulated amortization. Amortization is generally recorded on a straight-line basis over estimated useful lives ranging from 3 to 20 years. The Company periodically reviews the estimated useful lives of intangible assets and makes adjustments when events indicate that a shorter life is appropriate.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 805, Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective estimated fair values. The cost to acquire businesses is allocated to the underlying net assets of the acquired business based on estimates of their respective fair values. Amounts allocated to acquired IPR&amp;D are capitalized at the date of acquisition and, at that time, such IPR&amp;D assets have indefinite lives. As products in development are approved for sale, amounts are allocated to product rights and licenses and will be amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of developed products and licenses that are accounted for as asset acquisitions are capitalized as intangible assets and amortized over an estimated useful life. IPR&amp;D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management's assessment of the fair value of the Company's reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we choose to use qualitative factors and determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test would be required. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations. </span></div>Indefinite-lived intangibles, principally IPR&amp;D, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&amp;D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value of IPR&amp;D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested. P3Y P20Y <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Viatris records contingent consideration resulting from business acquisitions at its estimated fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as adjustments to litigation settlements and other contingencies, net within the consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, sales targets and profitability. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations.</span></div> <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. Any future long-lived assets impairment charges could have a material impact on the Company’s consolidated financial condition and results of operations.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Borrowings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company’s subsidiaries in India have working capital facilities with several banks which are secured by its current assets. The Company also has the CP Notes, Receivables Facility, which will expire in April 2022 and the Note Securitization Facility, which will expire in August 2022. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. As the accounts receivable do not transfer to the banks, any amounts outstanding under the facilities are recorded as borrowings and the underlying receivables continue to be included in accounts receivable, net, in the consolidated balance sheets.</span> <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenues in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Amounts recorded for revenue deductions can result from a complex series of judgements about future events and uncertainties and can rely heavily on estimates and assumptions. The following section briefly describes the nature of our provisions for variable consideration and how such provisions are estimated:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Viatris will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rebates, promotional programs and other sales allowances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: consistent with industry practice, Viatris maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. Generally, returned products are destroyed and customers are refunded the sales price in the form of a credit.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental rebate programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: government reimbursement programs in the U.S. include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap” based on historical experience of prescriptions and utilization expected to result in the discount of the “coverage gap”.</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the majority of our pharmaceutical sales are contractually or legislatively governed. In certain European countries, certain rebates are calculated on the governments total pharmaceutical spending or on specific product sale thresholds. We utilize historical data and obtain third party information to determine the adequacy of these accruals. Also, this provision includes price reductions that are mandated by law outside of the U.S. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods.</span></div>Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenues in the consolidated statements of operations. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R&amp;D expenses are charged to operations as incurred.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income taxes have been provided for using an asset and liability approach in which deferred income taxes reflect the tax consequences on future years of events that the Company has already recognized in the financial statements or tax returns. Changes in enacted tax rates or laws may result in adjustments to the recorded tax assets or liabilities in the period that the new tax law is enacted.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Basic earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.</span><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) earnings attributable to Viatris Inc. common shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares (denominator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic (loss) earnings per share attributable to Viatris Inc. shareholders</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) earnings attributable to Viatris Inc. common shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares (denominator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total dilutive shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted (loss) earnings per share attributable to Viatris Inc. shareholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average shares outstanding used in the computation of earnings per share for the year ended December 31, 2020 includes the effect of the 689.9 million shares issued for the closing of the Combination.</span></div>Additional stock awards and restricted ordinary shares were outstanding during the years ended December 31, 2021, 2020 and 2019 but were not included in the computation of diluted earnings per share for each respective period because the effect would be anti-dilutive. Excluded shares also include certain share-based compensation awards and restricted shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 12.7 million, 10.3 million and 9.1 million shares for the years ended December 31, 2021, 2020 and 2019, respectively <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic (loss) earnings attributable to Viatris Inc. common shareholders (numerator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) earnings attributable to Viatris Inc. common shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares (denominator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic (loss) earnings per share attributable to Viatris Inc. shareholders</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted (loss) earnings attributable to Viatris Inc. common shareholders (numerator):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) earnings attributable to Viatris Inc. common shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,269.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares (denominator):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total dilutive shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted (loss) earnings per share attributable to Viatris Inc. shareholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -1269100000 -669900000 16800000 1208800000 601200000 515700000 -1.05 -1.11 0.03 -1269100000 -669900000 16800000 1208800000 601200000 515700000 0 0 800000 1208800000 601200000 516500000 -1.05 -1.11 0.03 12700000 10300000 9100000 0.11 0.11 0.11 0.12 0.12 1000000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of share-based compensation is recognized as expense in the consolidated statements of operations over the vesting period.</span> Derivatives. From time to time the Company may enter into derivative financial instruments (mainly foreign currency exchange forward contracts, interest rate swaps and purchased equity call options) designed to: 1) hedge the cash flows resulting from existing assets and liabilities and transactions expected to be entered into over the next 24 months in currencies other than the functional currency, 2) hedge the variability in interest expense on floating rate debt, 3) hedge the fair value of fixed-rate notes, 4) hedge against changes in interest rates that could impact future debt issuances, 5) hedge cash or share payments required on conversion of issued convertible notes, 6) hedge a net investment in a foreign operation, or 7) economically hedge the foreign currency exposure associated with the purchase price of non-U.S. acquisitions. Derivatives are recognized as assets or liabilities in the consolidated balance sheets at their fair value. When the derivative instrument qualifies as a cash flow hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged items, are generally included in interest expense. When such instruments do not qualify for hedge accounting the changes in fair value are recorded in the consolidated statements of operations within other expense, net <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company’s financial instruments consist primarily of short-term and long-term debt, interest rate swaps, forward contracts and option contracts. The Company’s financial instruments also include cash and cash equivalents as well as accounts and other receivables and accounts payable, the fair values of which approximate their carrying values. As a policy, the Company does not engage in speculative or leveraged transactions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries derivative instruments in the consolidated balance sheets at fair value, determined by reference to market data such as forward rates for currencies, implied volatilities, and interest rate swap yield curves. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. In addition, the Company has designated certain long-term debt instruments as net investment hedges.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</span></div><div style="margin-bottom:6pt;padding-left:81pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-bottom:6pt;padding-left:81pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span>In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued Accounting Standards Update 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-01”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which clarifies that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. In addition, ASU 2020-01 states that for the purpose of applying paragraph 815-10-15-141(a) an entity should not consider whether, upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in Topic 323 or the fair value option in accordance with the financial instruments guidance in Topic 825. The Company applied the provisions of ASU 2020-01 as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is intended to simplify the accounting for income taxes by eliminating certain exceptions and simplifying certain requirements under Topic 740. The Company applied the provisions of ASU 2019-12 on a prospective basis as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Issued Not Yet Adopted    </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-04”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Entities can apply the provisions of ASU 2020-04 immediately, as applicable, and generally the provisions of the guidance are available through December 31, 2022 as entities transition away from reference rates that are expected to be discontinued. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued Accounting Standards Update 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2021-08”), which requires entities (acquirers) to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. ASU 2021-08 will be effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2022 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued Accounting Standards Update 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2021-10”), which requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 will be effective for fiscal years beginning after December 15, 2021 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its disclosures.</span></div> Revenue Recognition and Accounts Receivable<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Net Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Product Category</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greater China</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JANZ</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,759.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,841.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complex Gx and Biosimilars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,630.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Viatris</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,428.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,813.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Net Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Product Category</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greater China</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JANZ</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,234.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complex Gx and Biosimilars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Viatris</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,510.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,819.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:37.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 Net Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Product Category</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greater China</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JANZ</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,199.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complex Gx and Biosimilars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Viatris</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,240.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,370.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Key Global Products</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lipitor ®</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norvasc ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lyrica ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viagra ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EpiPen® Auto-Injectors</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celebrex ®</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effexor ®</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Creon ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoloft ®</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xalabrands</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Key Segment Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Influvac ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amitiza ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xanax ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dymista ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yupelri ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The Company does not disclose net sales for any products considered competitively sensitive.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.8pt">Prior periods are not presented due to significance of products acquired as part of the Combination.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable Consideration and Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2021, 2020 and 2019, respectively:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:67.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,553.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,899.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,012.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to net adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,530.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,656.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,309.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, promotional programs and other sales allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,135.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,765.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,629.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Governmental rebate programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(689.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross to net adjustments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,739.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,079.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,641.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,813.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,819.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,370.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of the categories of variable consideration during 2021:</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Provision Related to Sales Made in the Current Period </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments and Reclasses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Checks/ Credits Issued to Third Parties </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effects of Foreign Exchange</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,585.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, promotional programs and other sales allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,135.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,267.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Governmental rebate programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,739.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,056.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net revenues and as a contra-asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:76.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves. <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Net Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Product Category</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greater China</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JANZ</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,759.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,841.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complex Gx and Biosimilars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,630.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Viatris</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,428.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,813.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:37.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 Net Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Product Category</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greater China</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JANZ</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,234.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complex Gx and Biosimilars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Viatris</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,510.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,819.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:37.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 Net Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Product Category</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greater China</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JANZ</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,199.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complex Gx and Biosimilars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Viatris</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,240.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,370.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Key Global Products</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lipitor ®</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,663.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norvasc ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lyrica ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viagra ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EpiPen® Auto-Injectors</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celebrex ®</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effexor ®</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Creon ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zoloft ®</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xalabrands</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Key Segment Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Influvac ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amitiza ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xanax ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dymista ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yupelri ®</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">The Company does not disclose net sales for any products considered competitively sensitive.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.8pt">Prior periods are not presented due to significance of products acquired as part of the Combination.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of the categories of variable consideration during 2021:</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.433%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Provision Related to Sales Made in the Current Period </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments and Reclasses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Checks/ Credits Issued to Third Parties </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effects of Foreign Exchange</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,585.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, promotional programs and other sales allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,135.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,267.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Governmental rebate programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,739.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,056.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5759200000 2207800000 1197100000 1677200000 10841300000 1241600000 200000 46500000 53800000 1342100000 3427900000 4800000 783800000 1413700000 5630200000 10428700000 2212800000 2027400000 3144700000 17813600000 3920700000 253900000 617000000.0 443300000 5234900000 1202600000 700000 42800000 49400000 1295500000 3387600000 5300000 535500000 1361100000 5289500000 8510900000 259900000 1195300000 1853800000 11819900000 4199100000 207600000 533300000 422100000 5362100000 1127400000 400000 23800000 59700000 1211300000 2913500000 6600000 635400000 1241400000 4796900000 8240000000 214600000 1192500000 1723200000 11370300000 1663200000 824700000 728500000 533800000 391700000 344400000 316800000 309800000 284300000 226000000.0 299300000 201500000 185900000 168000000.0 161900000 30553400000 19899100000 19012200000 5530100000 3656200000 3309600000 6135600000 3765500000 3629300000 384600000 329700000 237900000 689500000 327800000 465100000 12739800000 8079200000 7641900000 17813600000 11819900000 11370300000 585200000 5530100000 63400000 5585400000 -1600000 591700000 1576300000 6135600000 -57600000 6267100000 -14200000 1373000000 539900000 384600000 269000000.0 499000000.0 -7700000 686800000 313300000 689500000 110600000 705200000 -9000000.0 399200000 3014700000 12739800000 385400000 13056700000 -32500000 3050700000 Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:76.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1688600000 1802900000 1362100000 1211800000 3050700000 3014700000 3774400000 3891300000 492000000.0 952500000 4266400000 4843800000 154500000 159900000 0.18 0.12 29600000 153000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Acquisitions and Other Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Upjohn Business Combination Agreement</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2019, Mylan, Pfizer, Upjohn, a wholly-owned subsidiary of Pfizer, and certain other affiliated entities entered into a Business Combination Agreement pursuant to which Mylan would combine with the Upjohn Business in a Reverse Morris Trust transaction. The Upjohn Business was a global, primarily off-patent branded and generic established medicines business, which includes 20 primarily off-patent solid oral dose legacy brands, such as Lyrica®, Lipitor®, Celebrex® and Viagra®. The Combination was completed on November 16, 2020. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Combination and pursuant to a Separation and Distribution Agreement, Pfizer had, among other things, transferred to Viatris substantially all of the assets and liabilities comprising the Upjohn Business (the Separation) and, thereafter, Pfizer had distributed to Pfizer stockholders all of the issued and outstanding shares of Viatris (the Distribution). When the Distribution and Combination were complete, Pfizer stockholders as of the record date of the Distribution owned 57% of the outstanding shares of Viatris common stock and Mylan shareholders as of immediately before the Combination owned 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted basis. Viatris also made a cash payment to Pfizer equal to $12 billion, which was funded with the proceeds of debt incurred by Upjohn prior to the Combination.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction involved multiple legal entity restructuring transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a reverse merger acquisition with Viatris representing the legal acquirer and Mylan representing the accounting acquirer of the Upjohn Business. In accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 805, Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Mylan is considered the accounting acquirer of the Upjohn Business and Viatris applied purchase accounting to the acquired assets and assumed liabilities of the Upjohn Business as of November 16, 2020. The debt incurred by Upjohn prior to the Combination was a liability assumed in purchase accounting. The fair value of the debt as of November 16, 2020 was $13.08 billion.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price consists of the issuance of approximately 689.9 million Viatris shares of common stock at a fair value of approximately $10.73 billion based on the closing price of Mylan’s ordinary shares on November 13, 2020, as reported by the NASDAQ. In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction have been recorded at their respective estimated fair values at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company incurred acquisition related costs of approximately $234.6 million and $602.9 million, respectively. Acquisition related costs were recorded primarily in SG&amp;A in the consolidated statements of operations for such periods.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, adjustments were made to the preliminary purchase price recorded at December 31, 2020, and are reflected as “Measurement Period and Other Adjustments” in the table below. The allocation of the $10.73 billion purchase price to the assets acquired and liabilities assumed under the Combination is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preliminary Purchase Price Allocation as of December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period and Other Adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase Price Allocation as of December 31, 2021 (as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets (excluding inventories and net of cash acquired)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,841.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,803.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,554.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,040.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,040.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,246.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,653.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,076.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,076.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired (net of $415.8 of cash acquired)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">____________</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">As previously reported in Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The measurement period adjustments are primarily for 1) certain working capital adjustments, an increase in litigation reserves to reflect facts and circumstances that existed as of the date of the Combination, and other adjustments and 2) the tax implications of these and other adjustments. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and accordingly, the Company has not retrospectively adjusted those consolidated financial statements.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Combination enhanced each businesses’ ability to serve patients’ needs and expand their capabilities across more than 165 markets. Mylan brought a diverse portfolio across many geographies and key therapeutic areas, such as central nervous system and anesthesia, infectious disease and cardiovascular, as well as a robust pipeline, high-quality manufacturing and supply chain excellence. The Upjohn Business brought trusted, iconic brands, such as Lipitor® (atorvastatin calcium), Celebrex® (celecoxib) and Viagra® (sildenafil), and proven commercialization capabilities, including leadership positions in China and other emerging markets. </span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a step-up in the fair value of inventory of approximately $1.43 billion at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company recorded amortization of the inventory step-up of approximately $1.19 billion and $238.2 million, respectively, which is included in cost of sales in the consolidated statements of operations. The inventory step-up was fully amortized during 2021. In addition, a step-up in the fair value of property, plant and equipment of approximately $385.0 million was recognized. The related depreciation is being expensed over a service life of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmRmYmYzZWQ0NzRmMjdiMjBlZjE2MTU1YmZkZjcyL3NlYzplMmZkZmJmM2VkNDc0ZjI3YjIwZWYxNjE1NWJmZGY3Ml8xODEvZnJhZzo0ZDA3ZDA0NmRiNjI0NmI4YmVhOTQyM2Y1NmIyMmExZS90ZXh0cmVnaW9uOjRkMDdkMDQ2ZGI2MjQ2YjhiZWE5NDIzZjU2YjIyYTFlXzQ2NzE_7b74b1b4-9fe4-486d-b533-a57949c797fb">five</span> years for machinery and equipment and between 10 and 20 years for buildings.</span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The identified intangible assets of $18.04 billion are comprised of product rights and are being amortized over a weighted average useful life of 15 years. Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. The goodwill of $2.40 billion arising from the Combination consisted largely of the value of the employee workforce and products to be sold in new markets leveraging the combined entity. In addition, an allocation of the goodwill was assigned to the respective segments. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes.</span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a fair value adjustment of approximately $759.4 million related to the long-term debt assumed as part of the acquisition. The fair value of long-term debt as of the Combination date was determined by broker or dealer quotations, which is classified as Level 2 in the fair value hierarchy. The total fair value adjustment is being amortized as a reduction to interest expense over the maturity dates of the related debt instruments.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of the Upjohn Business have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of the Upjohn Business for the period from the acquisition date to December 31, 2020, were $866.5 million and net loss, net of tax, was approximately $360.9 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs.</span></div><div style="text-indent:39.6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unaudited Pro Forma Financial Results</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental unaudited pro forma information for the Combination, as if it had occurred on January 1, 2019. The unaudited pro forma results reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased depreciation and amortization expense based on the fair value of assets acquired, the impact of transaction costs and the related income tax effects. The unaudited pro forma results do not include any anticipated synergies which may be achievable, or have been achieved, subsequent to the closing of the Combination. Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Unaudited, in millions, except per share amounts) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,284.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,582.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483.7 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Transactions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Viatris and Pfizer terminated their strategic collaboration for generic drugs in Japan pursuant to an amendment and termination agreement. Under the prior collaboration agreement, both parties contributed products, which Pfizer distributed to third-parties in the Japan market. Under the terms of the amendment and termination agreement, Viatris purchased all collaboration related inventory held by Pfizer. As a result of the termination, and the repurchase of collaboration inventory, the Company reduced revenue by $86.5 million during the year ended December 31, 2020.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into an agreement to acquire the related intellectual property and commercialization rights of Aspen’s thrombosis product portfolio in Europe for €641.9 million. The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra®, Fraxiparine®, Mono-Embolex® and Orgaran®. Upon closing of the transaction in November 2020, the Company made a payment of €263.2 million to Aspen and the remaining payment of €378.7 million was made on June 25, 2021. The Company accounted for this transaction as an asset acquisition and recognized an intangible asset of €641.9 million for the product rights, which is being amortized over a useful life of 8 years.</span></div> 20 0.57 0.43 12000000000 13080000000.00 689900000 10730000000 234600000 602900000 <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, adjustments were made to the preliminary purchase price recorded at December 31, 2020, and are reflected as “Measurement Period and Other Adjustments” in the table below. The allocation of the $10.73 billion purchase price to the assets acquired and liabilities assumed under the Combination is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preliminary Purchase Price Allocation as of December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period and Other Adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase Price Allocation as of December 31, 2021 (as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets (excluding inventories and net of cash acquired)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,841.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,803.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,554.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,040.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,040.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,246.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,653.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,076.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,076.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired (net of $415.8 of cash acquired)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">____________</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.8pt">As previously reported in Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The measurement period adjustments are primarily for 1) certain working capital adjustments, an increase in litigation reserves to reflect facts and circumstances that existed as of the date of the Combination, and other adjustments and 2) the tax implications of these and other adjustments. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and accordingly, the Company has not retrospectively adjusted those consolidated financial statements.</span></div> 10730000000 2841900000 -38700000 2803200000 2588900000 -34200000 2554700000 1394100000 -5000000.0 1389100000 18040000000 18040000000 2107500000 295600000 2403100000 1481900000 196300000 1678200000 792100000 -7400000 784700000 29246400000 406600000 29653000000 2760200000 419700000 3179900000 13076200000 13076200000 1656900000 1000000.0 1657900000 1441500000 -14100000 1427400000 415800000 10311600000 0 10311600000 165 1430000000 1190000000 238200000 385000000 P10Y P20Y 18040000000.00 P15Y 2400000000 759400000 866500000 360900000 Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Unaudited, in millions, except per share amounts) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,284.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,582.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,483.7 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 18284800000 21582700000 1483700000 1873500000 1.23 1.55 1.23 1.55 1206800000 1205600000 1207700000 1206400000 86500000 641900000 263200000 378700000 641900000 P8Y Balance Sheet Components <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected balance sheet components consist of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and restricted cash</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, included in other current and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,075.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,471.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory reserves totaled $519.0 million and $353.6 million at December 31, 2021 and 2020, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $474.9 million, $206.1 million and $399.2 million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale fixed income securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses consist primarily of prepaid rent, insurance and other individually insignificant items.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,589.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,721.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,188.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,459.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized software costs included in our consolidated balance sheets were $62.3 million and $70.9 million, net of accumulated depreciation, at December 31, 2021 and 2020, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $509.5 million, $289.7 million and $256.1 million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other assets</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments, clean energy investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts payable</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefit liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional accruals, including litigation accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued restructuring</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments, clean energy investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,973.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,960.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other long-term obligations</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax related items, including contingencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued restructuring</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other long-term obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and restricted cash</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, included in other current and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 701200000 844400000 475600000 5000000.0 5600000 15500000 706200000 850000000.0 491100000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,075.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,471.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 922400000 958400000 993300000 1438100000 2062000000 3075400000 3977700000 5471900000 519000000 353600000 474900000 206100000 399200000 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale fixed income securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 256700000 267800000 38200000 39100000 144600000 118600000 51000000.0 45800000 1467100000 1236100000 1957600000 1707400000 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, plant and equipment, net</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,589.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,721.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,188.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,459.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3054000000 3235000000 1808500000 1954800000 588700000 376300000 137900000 155800000 5589100000 5721900000 2400500000 2262000000 3188600000 3459900000 62300000 70900000 509500000 289700000 256100000 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other assets</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments, clean energy investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 47900000 290800000 323600000 879900000 676000000.0 1170700000 1047500000 <div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts payable</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1056100000 1345700000 601300000 558500000 1657400000 1904200000 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefit liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional accruals, including litigation accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued restructuring</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments, clean energy investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,973.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,960.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1362100000 1211800000 741900000 828200000 715600000 362900000 66700000 100500000 233500000 149200000 10900000 47500000 86600000 90900000 61000000.0 103600000 86700000 92900000 1254600000 1973200000 4619600000 4960700000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax related items, including contingencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued restructuring</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other long-term obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 876400000 1020400000 133000000.0 123100000 426100000 469500000 200900000 229500000 64300000 134800000 232900000 505800000 1933600000 2483100000 Leases<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases of real estate, consisting primarily of administrative offices, manufacturing and distribution facilities, and R&amp;D facilities. We also have operating leases of certain equipment, primarily automobiles, and certain limited supply arrangements.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected to apply the practical expedient to not separate lease and non-lease components for our leases except for those related to certain limited supply arrangements. We have also elected to apply the short-term lease recognition exemption which means we will not recognize ROU assets or lease liabilities for leases with an initial term of 12 months of less.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company recognized ROU assets of $290.8 million and total lease liabilities of $287.6 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance sheets. Refer to Note 5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Components</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets and liabilities are recognized at the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use an applicable incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Options to extend or terminate the ROU assets are reviewed at lease inception and these options are accounted for when they are reasonably certain of being exercised.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:82.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease terms</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year to 23 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, maturities of lease liabilities were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:89.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.753%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have additional operating leases, primarily for administrative offices, that have not yet commenced totaling approximately $13.6 million. These leases are expected to commence in 2022 and have lease terms of 5 to 9 years. For the years ended December 31, 2021, 2020 and 2019, the Company had operating lease expense of approximately $97.6 million, $80.7 million and $87.6 million, respectively. Operating lease costs are classified primarily as selling, general and administrative expenses and cost of sales in the consolidated statements of operations.</span></div> 290800000 287600000 <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:82.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease terms</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year to 23 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> P1Y P23Y P6Y 0.026 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, maturities of lease liabilities were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:89.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.753%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 82000000.0 65000000.0 42900000 28800000 23900000 68200000 310800000 23200000 287600000 13600000 P5Y P9Y 97600000 80700000 87600000 Equity Method Investments<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had three equity method investments in limited liability companies that owned refined coal production plants whose activities qualified for income tax credits under Section 45 of the Code. The Company did not consolidate these entities as we had determined that we were not the primary beneficiary of these entities and did not have the power to individually direct the activities of these entities. Accordingly, these investments were accounted for under the equity method of accounting. For each of the clean energy investments, the Company had entered into notes payable with the respective project sponsor, which in part were paid to the sponsor as certain production levels were met. The law that provides for IRC Section 45 tax credits expired during the year ended December 31, 2021 for all three clean energy investments and all of the clean energy investments have wound down operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020, and 2019, the Company reduced its long-term obligations for its three investments as a result of lower than anticipated production levels and lower expected future variable debt payments to the respective project sponsor. The Company recognized a net gain of approximately $5.7 million, $21.4 million and $7.0 million, respectively, which was recognized as a component of the net loss of the equity method investments in the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and respective balance sheet locations of the Company’s clean energy investments were as follows at December 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis as of December 31, 2021 and 2020 and for the years ended December 31, 2021, 2020 and 2019 are as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating and non-operating expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s net losses from its equity method investments include amortization expense related to the excess of the cost basis of the Company’s investment over the underlying assets of each individual investee. For the years ended December 31, 2021, 2020 and 2019, the Company recognized net losses from equity method investments of $61.9 million, $48.4 million, and $62.1 million, respectively, which were recognized as a component of other expense, net in the consolidated statements of operations. The Company recognizes the income tax credits and benefits from the clean energy investments as part of its provision for income taxes.</span></div> 3 5700000 21400000 7000000 <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and respective balance sheet locations of the Company’s clean energy investments were as follows at December 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information, in the aggregate, for the Company’s significant equity method investments on a 100% basis as of December 31, 2021 and 2020 and for the years ended December 31, 2021, 2020 and 2019 are as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating and non-operating expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 47900000 10900000 47500000 4200000 38900000 500000 1000000.0 4700000 39900000 2800000 33000000.0 0 1800000 2800000 34800000 1900000 5100000 326700000 374500000 385000000.0 -4600000 -4600000 -4400000 16800000 19000000.0 20000000.0 -21400000 -23600000 -24400000 -61900000 -48400000 -62100000 <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:38.931%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Developed Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greater China</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JANZ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,258.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,975.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,873.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,590.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,184.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,347.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,569.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,732.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,184.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,347.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,113.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,108.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,498.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,113.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8258000000 67800000 584800000 1065000000 9975600000 385000000.0 0 0 0 385000000.0 7873000000 67800000 584800000 1065000000 9590600000 704300000 652800000 217400000 533000000.0 2107500000 607200000 17700000 61800000 -37800000 648900000 9184500000 738300000 864000000.0 1560200000 12347000000 9569500000 738300000 864000000.0 1560200000 12732000000 385000000.0 0 0 0 385000000.0 9184500000 738300000 864000000.0 1560200000 12347000000 67700000 220400000 -30900000 38400000 295600000 -528800000 10800000 -56800000 45900000 -528900000 8723400000 969500000 776300000 1644500000 12113700000 9108400000 969500000 776300000 1644500000 12498700000 385000000.0 0 0 0 385000000.0 8723400000 969500000 776300000 1644500000 12113700000 <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following components at December 31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights, licenses and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,006.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,918.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,087.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,052.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,918.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,134.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights, licenses and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,404.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,801.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,602.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,484.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,801.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,683.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights.</span></div> P15Y 39006200000 12918500000 26087700000 46500000 46500000 39052700000 12918500000 26134200000 P15Y 40404100000 10801600000 29602500000 80700000 80700000 40484800000 10801600000 29683200000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by product category, is as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Developed Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greater China</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JANZ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,066.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,102.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,801.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,146.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complex Gx and Biosimilars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,020.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,710.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Product Rights and Licenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,313.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,115.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,084.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Developed Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Greater China</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">JANZ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,988.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,478.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,216.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complex Gx and Biosimilars</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,107.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Product Rights and Licenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,514.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,385.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,803.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,598.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10066600000 6102900000 1174800000 3801700000 21146000000 226800000 0 1500000 0 228300000 4020200000 12100000 319500000 358400000 4710200000 14313600000 6115000000 1495800000 4160100000 26084500000 10988100000 4372300000 2377000000 4478700000 22216100000 272500000 0 2300000 0 274800000 6253900000 12700000 423900000 417300000 7107800000 17514500000 4385000000 2803200000 4896000000 29598700000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense and intangible asset impairment charges, which are included as a component of amortization expense, which is classified primarily within cost of sales in the consolidated statements of operations, for the years ended December 31, 2021, 2020 and 2019 was as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,702.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible asset amortization expense (including impairment charges)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,805.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2702200000 1605800000 1582700000 19400000 37400000 138300000 83400000 45000000.0 42300000 2805000000 1688200000 1763300000 0.090 0.110 83400000 0.070 0.090 0.090 0.110 0.090 0.110 3660000000 5150000000 1580000000 820000000 700000000 910000000 0.058 P10Y 0.030 0.009 0.190 7.5 8.5 0.150 -0.029 0.015 230000000 0.070 P10Y 0.015 0.007 0.085 0.305 6.0 0.150 -0.042 0.020 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible asset amortization expense for the years ending December 31, 2022 through 2026 is estimated to be as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:88.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2577000000 2414000000 2320000000 2222000000 2164000000 Financial Instruments and Risk ManagementThe Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk.<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries and a portion of forecasted intercompany inventory sales denominated in Euro, Japanese Yen and Chinese Renminbi for up to eighteen months. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any changes in the fair value of designated cash flow hedges are deferred in AOCE and are reclassified into earnings when the hedged item impacts earnings.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has designated certain Euro and Yen borrowings as a hedge of its investment in certain Euro-functional and Yen-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro and Yen borrowings not designated as net investment hedges through certain Euro and Yen denominated financial assets and forward currency swaps. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the principal amounts of the Company’s outstanding Euro and Yen borrowings and the notional amounts of the Euro and Yen borrowings designated as net investment hedges:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount Designated as a Net Investment Hedge</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250% Euro Senior Notes due 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.125% Euro Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.125% Euro Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.816% Euro Senior Notes due 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.023% Euro Senior Notes due 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.362% Euro Senior Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.908% Euro Senior Notes due 2032</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,955.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,955.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Yen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">YEN Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">¥</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">¥</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">¥</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">¥</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">¥</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">¥</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31,2021, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedge was $347.6 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into interest rate swaps from time to time in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedging Relationships</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s interest rate swaps designated as cash flow hedges fix the interest rate on a portion of the Company’s variable-rate debt or hedge part of the Company’s interest rate exposure associated with the variability in the future cash flows attributable to changes in interest rates. Any changes in fair value are included in earnings or deferred through AOCE, depending on the nature and effectiveness of the offset. Any ineffectiveness in a cash flow hedging relationship is recognized immediately in earnings in the consolidated statements of operations. </span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Hedging Relationships</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's interest rate swaps designated as fair value hedges convert the fixed rate on a portion of the Company's fixed-rate senior notes to a variable rate. Any changes in the fair value of these derivative instruments, as well as the offsetting change in fair value of the portion of the fixed-rate debt being hedged, is included in interest expense. The Company’s fair value hedge was terminated during 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk Management</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the consolidated balance sheets. Accordingly, there are no offsetting amounts that net assets against liabilities. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification and fair values of derivative instruments in our consolidated balance sheets:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021 Fair Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020 Fair Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021 Fair Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020 Fair Value</span></td></tr><tr style="height:15pt"><td colspan="24" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses &amp; other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses &amp; other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total derivatives </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.417%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gains/(Losses) Recognized in Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain Excluded from the Assessment of Hedge Effectiveness</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> :</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Senior Notes (3.125% coupon)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments in Cash Flow Hedging Relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments Not Designated as Hedging Instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency option and forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on Derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gains/(Losses) Reclassified from AOCE into Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain/(Loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments in Cash Flow Hedging Relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments in Net Investment Hedging Relationships:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency borrowings and forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The amount included in the above tables represents the fair value adjustment recognized at the date the interest rate swaps were settled. </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">At December 31, 2021, the Company expects that approximately $21.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Represents the location of the gain/(loss) recognized in earnings on derivatives.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Represents the location of the gain/(loss) reclassified from AOCE into earnings.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Represents the location of the gain excluded from the assessment of hedge effectiveness.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</span></div><div style="margin-bottom:6pt;padding-left:81pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-bottom:6pt;padding-left:81pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:81pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recurring fair value measurements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale fixed income investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale fixed income investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at recurring fair value measurement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities at recurring fair value measurement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recurring fair value measurements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale fixed income investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale fixed income investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at recurring fair value measurement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities at recurring fair value measurement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including the LIBOR yield curve, foreign exchange forward prices, and bank price quotes. For the years ended December 31, 2021 and 2020, there were no transfers between Level 1 and 2 of the fair value hierarchy. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — valued at observable net asset value prices.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity securities, exchange traded funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity securities, marketable securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Available-for-sale fixed income investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Interest rate swap derivative assets and liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — valued using the LIBOR/EURIBOR yield curves at the reporting date. Counterparties to these contracts are highly rated financial institutions.</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign exchange derivative assets and liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2011, the Company completed the acquisition of the exclusive worldwide rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline’s Advair® Diskus incorporating Pfizer’s respiratory delivery platform. The Company accounted for this transaction as a purchase of a business and utilized the acquisition method of accounting. On January 30, 2019, the Company received FDA approval of Wixela® Inhub® (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of GlaxoSmithKline’s Advair Diskus®. The commercial launch of the Wixela® Inhub® occurred in February 2019. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company has a contingent consideration liability of $177.8 million related to the respiratory delivery platform. The fair value measurement of contingent consideration is determined using Level 3 inputs. The Company’s contingent consideration represents a component of the total purchase consideration for Pfizer’s respiratory delivery platform and certain other acquisitions. The measurement is calculated using unobservable inputs based on the Company’s own assumptions primarily related to the probability and timing of future development and commercial milestones and future profit-sharing payments which are discounted using a market rate of return. At December 31, 2021 and 2020, discount rates ranging from 8.0% to 10.5% were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liability. </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to December 31, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term Portion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Included in other current liabilities in the consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Included in other long-term obligations in the consolidated balance sheets.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Included in litigation settlements and other contingencies, net in the consolidated statements of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to incur approximately $6 million to $8 million of non-cash accretion expense related to the increase in the net present value of the contingent consideration liabilities in 2022.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company has not elected the fair value option for financial assets and liabilities, any future transacted financial asset or liability will be evaluated for the fair value election.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-Sale Securities</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of available-for-sale debt securities at fair value as of December 31, 2021, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:89.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in five years and later</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.02250 1000000000 1000000000 1000000000 0.03125 750000000.0 750000000.0 750000000.0 0.02125 500000000.0 500000000.0 500000000.0 0.00816 750000000.0 750000000.0 750000000.0 0.01023 750000000.0 750000000.0 750000000.0 0.01362 850000000.0 850000000.0 850000000.0 0.01908 1250000000 1250000000 1250000000 105600000 0 105600000 5955600000 5850000000 5955600000 40000000000 40000000000 0 40000000000 40000000000 0 347600000 62000000.0 28300000 4300000 800000 62000000.0 28300000 82600000 90300000 56700000 102800000 82600000 90300000 56700000 102800000 144600000 118600000 61000000.0 103600000 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.417%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gains/(Losses) Recognized in Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gain Excluded from the Assessment of Hedge Effectiveness</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> :</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Senior Notes (3.125% coupon)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments in Cash Flow Hedging Relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments Not Designated as Hedging Instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency option and forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on Derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Gains/(Losses) Reclassified from AOCE into Earnings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain/(Loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments in Cash Flow Hedging Relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Financial Instruments in Net Investment Hedging Relationships:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency borrowings and forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The amount included in the above tables represents the fair value adjustment recognized at the date the interest rate swaps were settled. </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">At December 31, 2021, the Company expects that approximately $21.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Represents the location of the gain/(loss) recognized in earnings on derivatives.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Represents the location of the gain/(loss) reclassified from AOCE into earnings.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Represents the location of the gain excluded from the assessment of hedge effectiveness.</span></div> 0 22100000 18700000 0 -22100000 -18700000 0 7100000 0 39300000 -10100000 -17300000 39300000 -10100000 -17300000 0 7100000 0 45800000 20600000 16600000 30900000 4800000 -700000 -3400000 0 3000000.0 -4300000 -4500000 -7100000 436600000 -346400000 56700000 479000000.0 -325800000 76300000 26600000 300000 -7800000 21000000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recurring fair value measurements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale fixed income investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale fixed income investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at recurring fair value measurement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities at recurring fair value measurement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recurring fair value measurements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale fixed income investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale fixed income investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at recurring fair value measurement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities at recurring fair value measurement</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 50900000 50900000 50900000 50900000 50300000 50300000 700000 700000 51000000.0 51000000.0 16600000 16600000 14600000 14600000 2000000.0 2000000.0 4600000 4600000 400000 400000 38200000 38200000 144600000 144600000 101900000 182800000 284700000 61000000.0 61000000.0 199700000 199700000 61000000.0 199700000 260700000 900000 900000 900000 900000 45100000 45100000 700000 700000 45800000 45800000 17800000 17800000 14400000 14400000 1900000 1900000 4600000 4600000 400000 400000 39100000 39100000 118600000 118600000 46700000 157700000 204400000 103600000 103600000 223600000 223600000 103600000 223600000 327200000 177800000 0.080 0.105 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to December 31, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term Portion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Included in other current liabilities in the consolidated balance sheets.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Included in other long-term obligations in the consolidated balance sheets.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Included in litigation settlements and other contingencies, net in the consolidated statements of operations.</span></div> 120400000 130300000 250700000 -111800000 0 -111800000 58100000 -58100000 0 0 11600000 11600000 33800000 39300000 73100000 100500000 123100000 223600000 -83200000 0 -83200000 49400000 -49400000 0 0 9000000.0 9000000.0 0 50300000 50300000 66700000 133000000.0 199700000 6000000 8000000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 38100000 100000 0 38200000 38100000 100000 0 38200000 37500000 1600000 0 39100000 37500000 1600000 0 39100000 <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of available-for-sale debt securities at fair value as of December 31, 2021, were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:89.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature in five years and later</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1200000 19700000 17300000 38200000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Borrowings</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $1.49 billion and $1.10 billion of borrowings as of December 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note Securitization Facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term borrowings</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following provides an overview of the Company’s short-term credit facilities. 1490000000 1100000000 1173400000 651300000 318500000 248400000 0 200000000.0 1100000 1200000 1493000000 1100900000 1170000000 651300000 1650000000 P364D 400000000 200000000 0.00925 0.0085 388900000 389400000 0.03150 0 2249700000 0.00816 856600000 0 0.01125 1002900000 0 900000 8000000.0 100000 1400000 1860300000 2256300000 0.00816 0 928800000 0.01125 0 1008800000 0.03125 766100000 781600000 0.04200 499600000 499300000 0.02250 1135800000 1219900000 0.01023 871600000 944600000 0.02125 567800000 609900000 0.01650 763400000 767100000 0.03950 2241400000 2239700000 0.01362 1013000000 1097400000 0.02300 780800000 786100000 0.03125 847400000 909700000 0.04550 748700000 748600000 0.02700 1520500000 1528000000 0.01908 1546600000 1672600000 0.03850 1657100000 1663300000 0.05400 497300000 497300000 0.05250 999900000 999900000 0.05200 747800000 747700000 0.04000 2205100000 2209300000 0 600000000.0 1900000 17400000 42300000 47800000 19717100000 22429200000 45000000 7450000000 3600000000 7450000000 0.999 <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the Upjohn Senior Notes issued in June 2020:</span></div><div style="margin-bottom:10pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Senior Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040 Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2050 Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Euro Senior Note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Euro Senior Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Euro Senior Note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032 Euro Senior Note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,847.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1000000000 750000000.0 750000000.0 1450000000 1500000000 2000000000 916200000 916200000 1038400000 1527000000 11847800000 600000000 12000000000 600000000 4000000000 40000000000 4000000000 4.25 4.0 3.75 22010000000.00 25900000000 <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at December 31, 2021 were as follows for each of the periods ending December 31:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:89.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,949 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1853000000 1250000000 1990000000 1318000000 2598000000 11940000000 20949000000 Comprehensive (Loss) Earnings<div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss, as reflected in the consolidated balance sheets, is comprised of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:76.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on marketable securities, net of tax</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrecognized loss on derivatives in net investment hedging relationships, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,802.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,744.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr style="height:36pt"><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives in Cash Flow Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Net Investment Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Marketable Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Pension Plan Items</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Forward Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of tax</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (loss) before reclassifications, before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,340.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps classified as cash flow hedges, included in interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs included in SG&amp;A </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss included in SG&amp;A </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive earnings (loss), before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,340.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(775.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,802.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,744.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr style="height:36pt"><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives in Cash Flow Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Net Investment Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Marketable Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Pension Plan Items</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Forward Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of tax</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,674.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) earnings before reclassifications, before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps classified as cash flow hedges, included in interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs included in SG&amp;A </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss included in SG&amp;A </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive (loss) earnings, before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives in Cash Flow Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Net Investment Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Marketable Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Pension Plan Items</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Forward Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018, net of tax</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,259.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,441.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (loss) before reclassifications, before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps classified as cash flow hedges, included in interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs included in SG&amp;A </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss included in SG&amp;A </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive earnings (loss), before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of the adoption of new accounting standards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,674.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss, as reflected in the consolidated balance sheets, is comprised of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:76.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on marketable securities, net of tax</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrecognized loss on derivatives in net investment hedging relationships, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,802.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,744.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 1200000 -32200000 26100000 9200000 -18000000.0 16700000 -353600000 -1802400000 -461500000 -1744300000 -858000000.0 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr style="height:36pt"><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives in Cash Flow Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Net Investment Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Marketable Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Pension Plan Items</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Forward Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of tax</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (loss) before reclassifications, before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,340.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps classified as cash flow hedges, included in interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs included in SG&amp;A </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss included in SG&amp;A </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive earnings (loss), before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,340.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(775.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,802.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,744.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr style="height:36pt"><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives in Cash Flow Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Net Investment Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Marketable Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Pension Plan Items</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Forward Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of tax</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,674.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) earnings before reclassifications, before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps classified as cash flow hedges, included in interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs included in SG&amp;A </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss included in SG&amp;A </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive (loss) earnings, before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives in Cash Flow Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Net Investment Hedges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Marketable Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Pension Plan Items</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Forward Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018, net of tax</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,259.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,441.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive earnings (loss) before reclassifications, before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on foreign exchange forward contracts classified as cash flow hedges, included in net sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps classified as cash flow hedges, included in interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs included in SG&amp;A </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss included in SG&amp;A </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive earnings (loss), before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative effect of the adoption of new accounting standards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,674.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -18000000.0 -353600000 1200000 26100000 -461500000 -858000000.0 62700000 456800000 -1100000 67000000.0 -1340900000 -755500000 -30900000 -30900000 -30900000 4300000 4300000 4300000 500000 500000 -7400000 -7400000 36100000 456800000 -1100000 -73900000 -1340900000 -775200000 8900000 86500000 100000 15600000 0 111100000 9200000 16700000 0 -32200000 -1802400000 -1744300000 -31600000 -74300000 600000 17400000 -1674500000 -1797200000 18500000 -305200000 600000 -12100000 1213000000 914800000 -4800000 -4800000 -4800000 4500000 4500000 4500000 0 0 1900000 1900000 18200000 -305200000 600000 14000000.0 1213000000 912600000 4600000 -25900000 0 5300000 0 -26600000 -18000000.0 -353600000 1200000 26100000 -461500000 -858000000.0 -53100000 -130900000 0 -1700000 -1259000000 -1441300000 29300000 59600000 500000 -21000000.0 -415500000 -347100000 700000 700000 700000 -7100000 -7100000 -7100000 900000 900000 2900000 2900000 37100000 59600000 500000 -24800000 -415500000 -343100000 -12200000 3000000.0 100000 5900000 0 9200000 -3400000 200000 -3600000 -31600000 -74300000 600000 17400000 -1674500000 -1797200000 Income Taxes <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision (benefit) consisted of the following components:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. State:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,982.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(945.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,031.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign - Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (loss) earnings before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(664.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(721.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented, the allocation of earnings before income taxes between U.S. and non-U.S. operations includes intercompany interest allocations between certain domestic and foreign subsidiaries. These amounts are eliminated on a consolidated basis. </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit and loss carry-forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,889.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,109.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets and goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,468.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,591.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,482.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(975.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those foreign subsidiaries whose investments are permanent in duration, income and foreign withholding taxes have not been provided on the unremitted earnings of those subsidiaries. This amount may become taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. The amount of such unremitted earnings is approximately $3.4 billion at December 31, 2021. Determination of the amount of any unrecognized deferred income tax liability on these unremitted earnings is not practicable as such determination involves material uncertainties about the potential extent and timing of any distributions, the availability and complexity of calculating foreign tax credits, and the potential indirect tax consequences of such distributions, including withholding taxes.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Combination, the applicable income tax rate to Mylan was the U.K. rate of 19%, and following the Combination, the statutory income tax rate applicable to Viatris Inc. is the U.S. rate of 21% for the years ended December 31, 2021 and 2020. A reconciliation of the statutory tax rate to the effective tax rate is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clean energy and research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. rate differentials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of changes in legislation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements and resolution of certain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental US Tax on Foreign Earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waived deductions under IRC § 59A</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of the Combination and Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other U.S. items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Foreign Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gibraltar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax impact of tax law changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of the Combination and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Withholding taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements and resolution of certain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all years, our effective tax rate is impacted by the jurisdictional location of earnings and the corresponding tax rates in those jurisdictions. Subsequent to the Combination, the Company realizes benefits from lower tax rates in Singapore and Puerto Rico due to manufacturing and other incentives..</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Act</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act makes broad and complex changes to the Code including, but not limited to, reducing the U.S. federal corporate income tax rate and requiring a one-time transition tax on certain unrepatriated earnings of non-U.S. corporate subsidiaries of large U.S. shareholders that may electively be paid over eight years. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Act also puts in place new tax laws that impact our taxable income beginning in 2018, which include, but are not limited to (1) creating a BEAT, which is a new minimum tax, (2) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries, (3) a new provision designed to tax currently GILTI earned by non-U.S. corporate subsidiaries of large U.S. shareholders and a deduction generally equal to 50 percent of GILTI (37.5 percent for tax years beginning after December 31, 2025) to offset the income tax liability, (4) a provision limiting the amount of deductible interest expense in the U.S., (5) limitations on the deductibility of certain executive compensation, and (6) limitations on the utilization of foreign tax credits to reduce the U.S. income tax liability. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, no U.S. deferred income taxes or foreign withholding taxes were recorded on earnings in the Company’s non-U.S. subsidiaries where there would be no U.S. or foreign tax upon repatriation or where the Company’s practice and intention was to reinvest the earnings outside of the U.S. The transition tax noted above resulted in the previously untaxed foreign earnings of U.S. subsidiaries being included in federal and state taxable income. We analyze on an ongoing basis our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries repatriate cash, which include potential local country withholding taxes and U.S. state taxation. The Company has elected to not record deferred taxes associated with the GILTI provision of the Tax Act.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation Allowance</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2021, a valuation allowance has been applied to certain deferred tax assets in the amount of $780.4 million.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When assessing the realizability of deferred tax assets, management considers all available evidence, including historical information, long-term forecasts of future taxable income and possible tax planning strategies. Amounts recorded for valuation allowances can result from a complex series of estimates, assumptions and judgments about future events. Due to the inherent uncertainty involved in making these estimates, assumptions and judgments, actual results could differ materially. Any future increases to the Company’s valuation allowances could materially impact the Company’s consolidated financial condition and results of operations.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Losses</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company had the following carryforwards and attributes: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. federal net operating loss carryforwards of $7.9 million.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. state income tax loss carryforwards of approximately $3.10 billion, which are largely offset by a valuation allowance.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-U.S. net operating loss carryforwards of approximately $1.57 billion, of which $748.4 million can be carried forward indefinitely, with the remaining $817.8 million expiring in years 2022 through 2041.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign deductible attributes of $39.6 million that can be carried forward indefinitely, which are offset by a full valuation allowance.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and foreign credit carryovers of $329.2 million, expiring in various amounts through 2041.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anticipatory foreign tax credits of $230.3 million which will generate from the reversal of future taxable income in certain non-U.S. jurisdictions which are taxed both in their local jurisdictions and in the U.S.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2020, the Company had a change in ownership pursuant to Section 382 of the Code. Under this provision of the Code, the utilization of any NOL or tax credit carryforwards incurred prior to the date of ownership change may be limited. Analyses of the limits for each ownership change indicates the annual limitation would not impair the Company's ability to utilize our U.S. federal credit carryovers. While state loss carryforwards may be limited by Section 382 of the Code, the carryforwards are largely offset by a valuation allowance.</span></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CARES Act</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was enacted and signed into law. The CARES Act includes several provisions, including increasing the amount of deductible interest, allowing companies to carryback certain NOLs, and increasing the amount of NOLs that corporations can use to offset income.During the year ended December 31, 2020, the CARES Act reduced the Company’s 2020 income tax expense by $22.1 million resulting from additional deductible interest. </span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Examinations</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxes and tax audits in many jurisdictions. A certain degree of estimation is thus required in recording the assets and liabilities related to income taxes. Tax audits and examinations can involve complex issues, interpretations, and judgments and the resolution of matters that may span multiple years, particularly if subject to litigation or negotiation. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the Company believes that adequate provisions have been made for these uncertain tax positions, the Company’s assessment of uncertain tax positions, including those arising from legal entity restructuring transactions in connection with the Combination, is based on estimates and assumptions that the Company believes are reasonable but the estimates for unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variations from such estimates could materially affect the Company’s financial condition, results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to ongoing IRS examinations. The years 2015 through 2018 are open years under examination. The years 2012, 2013 and 2014 have one matter open, and a Tax Court petition was filed regarding the matter and a trial was held in December 2018 and is discussed further below. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, Mylan reached an agreement in principle with the IRS to resolve all issues relating to our positions on the February 27, 2015 acquisition by Mylan N.V. of Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business. Under the agreement in principle, which was finalized as part of a closing agreement with the IRS on October 11, 2019, Mylan’s status as a non-U.S. corporation for U.S. Federal income tax purposes was confirmed, and we have adjusted the interest rates used for intercompany loans as necessary. During the year ended December 31, 2019, the Company recorded a reserve of approximately $155.0 million as part of its liability for uncertain tax positions, with a net impact to the income tax provision of approximately $144.9 million related to this matter. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several international audits are currently in progress. In some cases, the tax auditors have proposed adjustments </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or issued assessments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our tax positions, including with respect to intercompany transactions, and we are in ongoing discussions with some of the auditors regarding the validity of their positions. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In instances where assessments have been issued, we disagree with these assessments and believe they are without merit and incorrect as a matter of law. As a result, we anticipate that certain of these matters may become the subject of litigation before tax courts where we intend to vigorously defend our position.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Australia, the tax authorities have issued notices of assessments to the Company for the years ended December 2009 to December 2019, subject to additional interest and penalties, concerning our tax position with respect to certain intercompany transactions. The tax authorities denied our objections to the assessments and we have commenced litigation in the Australian Federal Court challenging that decision. During 2021, the Company made a partial payment of $56.0 million in order to stay potential interest and penalties resulting from this litigation.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In France, the tax authorities have issued notices of assessments to the Company for the years ended December 2013 to December 2016 concerning our tax position with respect to (i) certain intercompany transactions and (ii) whether income earned by a Company entity not domiciled in France should be subject to French tax. We have resolved our position concerning certain intercompany transactions with the tax authorities. Concerning the remaining issue, we have commenced litigation before the French tax courts where the tax authorities will seek unpaid taxes, penalties, and interest.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In India, the tax authorities have issued notices of assessments to the Company seeking unpaid taxes and interest for the financial years covering 2013 to 2018 concerning our tax position with respect to certain corporate tax deductions and certain intercompany transactions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these assessments remain in the audit phase where we are challenging them before the tax authorities while we are challenging some of the other assessments in the Indian tax courts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded a net reserve for uncertain tax positions of $315.6 million, including interest and penalties, in connection with its international audits at December 31, 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reserve balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reflects the impact of current year settlement payments. In connection with our international tax audits, it is possible that we will incur material losses above the amounts reserved.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s major U.S. state taxing jurisdictions remain open from fiscal year 2013 through 2020, with several state audits currently in progress. The Company’s major international taxing jurisdictions remain open from 2012 through 2020.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Court Proceedings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. federal income tax returns for 2012 through 2014 had been subject to proceedings in U.S. Tax Court involving a dispute with the IRS regarding whether certain costs related to ANDAs were eligible to be expensed and deducted immediately or required to be amortized over longer periods. A trial was held in U.S. Tax Court in December 2018 and on April 27, 2021, the Court affirmed Mylan’s position and held that patent litigation expenses related to ANDAs are immediately deductible. The IRS has appealed this decision.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of an uncertain tax position will be recognized if the position has less than a 50% likelihood of being sustained.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $322.9 million and $391.1 million, respectively, of which $230.2 million as of December 31, 2021 would affect the Company’s effective tax rate if recognized, with the remainder being offset by potential correlative adjustments. Related accrued interest and penalties included in the consolidated balance sheets were $96.8 million and $86.7 million as of December 31, 2021 and 2020, respectively. For the years ended December 31, 2021, 2020 and 2019, the Company recognized $18.5 million of tax expense, $6.0 million, and $35.2 million of tax benefits, respectively, related to interest and penalties on uncertain tax positions. Interest and penalties related to income taxes are included in the tax provision.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.006%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefit — beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions due to expirations of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Reduction) addition due to acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefit — end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is reasonably possible that the amount of unrecognized tax benefits will decrease in the next twelve months by approximately $55.0 million, involving international and state audits and settlements and expiring statutes of limitations. The Company does not anticipate significant increases to the reserve within the next twelve months.</span></div> <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision (benefit) consisted of the following components:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. State:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,982.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(945.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,031.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign - Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (loss) earnings before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(664.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(721.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 12600000 -6400000 118100000 -182700000 -277000000.0 -165500000 -170100000 -283400000 -47400000 7700000 -100000 21100000 -10800000 7700000 -13600000 -3100000 7600000 7500000 -91300000 168700000 191000000.0 869200000 55800000 -13500000 777900000 224500000 177500000 604700000 -51300000 137600000 -1982500000 -945500000 -1031400000 1318100000 224300000 1185800000 -664400000 -721200000 154400000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit and loss carry-forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,889.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,109.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets and goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,468.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,591.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,197.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,482.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(975.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 271300000 273000000.0 94400000 43500000 425900000 393700000 187800000 1187900000 1256000000 1080400000 63600000 66500000 111600000 67900000 151100000 156300000 327800000 396000000.0 2889500000 3665200000 780400000 443600000 2109100000 3221600000 19600000 50200000 63600000 66500000 3468300000 4058600000 39900000 22100000 3591400000 4197400000 1482300000 975800000 3400000000 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Combination, the applicable income tax rate to Mylan was the U.K. rate of 19%, and following the Combination, the statutory income tax rate applicable to Viatris Inc. is the U.S. rate of 21% for the years ended December 31, 2021 and 2020. A reconciliation of the statutory tax rate to the effective tax rate is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clean energy and research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. rate differentials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of changes in legislation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements and resolution of certain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental US Tax on Foreign Earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waived deductions under IRC § 59A</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of the Combination and Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other U.S. items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Foreign Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gibraltar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax impact of tax law changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of the Combination and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Withholding taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax settlements and resolution of certain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.21 0.210 0.210 0.190 -0.098 -0.128 0.434 0 0 -0.031 0 -0.092 0 -0.006 -0.016 -0.041 -0.001 0.086 -1.185 0.001 0.001 1.996 -0.369 -0.036 -0.086 0 -0.033 0.645 -0.028 0.058 0.077 -0.061 0.015 0.069 -0.067 -0.050 -0.148 0.094 0.080 -0.388 0.058 0.082 -0.137 -0.011 -0.028 0.152 0.044 -0.025 0 0.010 0.020 0 0.288 0.010 0 -0.102 -0.004 0.128 0.070 -0.001 0.367 -0.083 0.161 -0.099 -1.069 -0.422 0 -0.013 -0.016 0.071 0.008 -0.039 -0.276 0.019 -0.018 0.021 -0.910 0.071 0.891 0.50 0.375 780400000 7900000 3100000000 1570000000 748400000 817800000 39600000 329200000 230300000 22100000 155000000 144900000 56000000 315600000 322900000 391100000 230200000 96800000 86700000 18500000 6000000 35200000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.006%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefit — beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions due to expirations of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Reduction) addition due to acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefit — end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 391100000 92100000 96300000 0 13400000 0 0 35700000 154900000 9100000 5200000 11700000 47300000 8900000 112500000 7000000.0 0 34900000 4800000 264000000.0 0 322900000 391100000 92100000 55000000 Share-Based Incentive Plan<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Distribution, Viatris adopted and Pfizer, in the capacity as Viatris’ sole stockholder at such time, approved the Plan (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viatris Inc. 2020 Stock Incentive Plan) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which became effective as of the Distribution. In connection with the Combination, as of November 16, 2020, the Company assumed the 2003 LTIP (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mylan N.V. Amended and Restated 2003 Long-Term Incentive Plan)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which had previously been approved by Mylan shareholders. The Plan and 2003 LTIP include (i) 72,500,000 shares of Common Stock authorized for grant pursuant to the Plan, which may include dividend payments payable in Common Stock on unvested shares granted under awards, (ii) 6,757,640 shares of Common Stock to be issued pursuant to the exercise of outstanding stock options granted to participants under the 2003 LTIP and assumed by Viatris in connection with the Combination and (iii) 13,535,627 shares of Common Stock subject to outstanding equity-based awards, other than stock options, assumed by Viatris in connection with the Combination, or that otherwise remain available for issuance under the 2003 LTIP.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Plan and 2003 LTIP, shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, SARs, restricted stock and units, PSUs, other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the shares underlying the stock options at the date of the grant, generally become exercisable over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmRmYmYzZWQ0NzRmMjdiMjBlZjE2MTU1YmZkZjcyL3NlYzplMmZkZmJmM2VkNDc0ZjI3YjIwZWYxNjE1NWJmZGY3Ml8yMjAvZnJhZzpkNTVkMmU5MTUzMjY0ZGY0YjZiN2MyNmQ4MzNkMDY1NC90ZXh0cmVnaW9uOmQ1NWQyZTkxNTMyNjRkZjRiNmI3YzI2ZDgzM2QwNjU0XzE2Mjc_08ccde51-39fc-462c-a345-1572757200f2">three</span> to four years, and generally expire in ten years.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock awards (stock options and SARs) activity under the Plan and 2003 LTIP:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:71.187%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares<br/>Under Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,815,278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,347,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,711,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,576,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,487,788 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had average remaining contractual terms of 4.6 years, 4.6 years and 4.2 years, respectively. Also, at December 31, 2021, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had no aggregate intrinsic value.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company’s nonvested restricted stock awards (restricted stock and restricted stock unit awards, including PSUs), as of December 31, 2020 and the changes during the year ended December 31, 2021 are presented below:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted<br/>Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,073,790 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,168,152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,897,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,858,128 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the 9,850,443 restricted stock awards granted during the year ended December 31, 2021, 6,057,602 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining restricted stock awards granted, 587,025 are not subject to market conditions and will cliff vest within a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmRmYmYzZWQ0NzRmMjdiMjBlZjE2MTU1YmZkZjcyL3NlYzplMmZkZmJmM2VkNDc0ZjI3YjIwZWYxNjE1NWJmZGY3Ml8yMjAvZnJhZzpkNTVkMmU5MTUzMjY0ZGY0YjZiN2MyNmQ4MzNkMDY1NC90ZXh0cmVnaW9uOmQ1NWQyZTkxNTMyNjRkZjRiNmI3YzI2ZDgzM2QwNjU0XzI2NDI_f3b767c1-16ad-4e4f-bd76-18f9bc8ce9a6">three</span>-year period, and 3,205,816 are subject to market or performance conditions and will cliff vest in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZmRmYmYzZWQ0NzRmMjdiMjBlZjE2MTU1YmZkZjcyL3NlYzplMmZkZmJmM2VkNDc0ZjI3YjIwZWYxNjE1NWJmZGY3Ml8yMjAvZnJhZzpkNTVkMmU5MTUzMjY0ZGY0YjZiN2MyNmQ4MzNkMDY1NC90ZXh0cmVnaW9uOmQ1NWQyZTkxNTMyNjRkZjRiNmI3YzI2ZDgzM2QwNjU0XzEyNjQ0MzgzNzI3MzQ5_f3b767c1-16ad-4e4f-bd76-18f9bc8ce9a6">three</span> years or less.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had $143.1 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 1.7 years. The total intrinsic value of stock awards exercised and restricted stock units released during the years ended December 31, 2021 and 2020 was $78.1 million and $20.9 million, respectively.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to options granted under the Plan and 2003 LTIP, the fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield and employee exercise behavior. Expected volatilities utilized in the model are based mainly on the implied volatility of the Company’s stock price and other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The model incorporates exercise and post-vesting forfeiture assumptions based on an analysis of historical data. The expected lives of the grants are derived from historical and other factors.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no options granted during the year ended December 31, 2021. The assumptions used for options granted under the Plan and 2003 LTIP during the years ended December 31, 2020 and 2019, respectively, are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per option</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.03</span></td></tr></table></div> 72500000 6757640 13535627 P4Y P10Y <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock awards (stock options and SARs) activity under the Plan and 2003 LTIP:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:71.187%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares<br/>Under Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,815,278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,347,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,711,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135,241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,576,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,487,788 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969,602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6815278 36.61 829322 26.18 580950 14.40 715941 39.40 6347709 36.97 814351 17.37 27615 21.13 422714 25.74 6711731 35.36 1135241 26.39 5576490 37.19 5487788 37.45 4969602 39.21 P4Y7M6D P4Y7M6D P4Y2M12D <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company’s nonvested restricted stock awards (restricted stock and restricted stock unit awards, including PSUs), as of December 31, 2020 and the changes during the year ended December 31, 2021 are presented below:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted<br/>Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,073,790 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,168,152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,897,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,858,128 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12073790 18.34 9850443 14.46 3168152 24.65 1897953 15.33 16858128 15.12 9850443 6057602 P3Y 587025 3205816 143100000 P1Y8M12D 78100000 20900000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no options granted during the year ended December 31, 2021. The assumptions used for options granted under the Plan and 2003 LTIP during the years ended December 31, 2020 and 2019, respectively, are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value per option</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.03</span></td></tr></table></div> 0.467 0.381 0.010 0.025 P6Y6M P6Y6M 0.055 0.055 8.07 11.03 Employee Benefit Plans<div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Plans</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. Employees in the U.S., Puerto Rico and certain international locations are also provided retirement benefits through defined contribution plans.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also sponsors other postretirement benefit plans including plans that provide for postretirement supplemental medical coverage. Benefits from these plans are provided to employees and their spouses and dependents who meet various minimum age and service requirements. In addition, the Company sponsors other plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combination, the Company assumed certain post retirement defined benefit pension plans sponsored by Upjohn. The most significant plans include those in Puerto Rico, Ireland and Japan. Upjohn is also the sponsor of one postretirement medical plan in Puerto Rico. As part of the acquisition accounting, the Company has recorded the fair value of these plans. Upon completion of the Combination, the excess of projected benefit obligation over the plan assets was recognized as a liability and any existing unrecognized actuarial gains or losses and unrecognized service costs or benefits were eliminated in purchase accounting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Defined Benefit Pension and Other Postretirement Plans</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes on its balance sheet an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension and other postretirement plan. Actuarial gains or losses and prior service costs or credits that arise during the period are not recognized as components of net periodic benefit cost, but are recognized, net of tax, as a component of other comprehensive (loss) earnings.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in accumulated other comprehensive loss as of December 31, 2021 and 2020 are:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized actuarial (gain) loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service cost (credit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized net actuarial losses exceeded 10% of the higher of the market value of plan assets or the projected benefit obligation at the beginning of the year for certain of the plans, therefore, amortization of such excess has been included in net periodic benefit costs for pension and other postretirement benefits in each of the last three years. The amortization period is the average remaining service period that active employees are expected to receive benefits, unless a plan is mostly inactive in which case the amortization period is the average remaining life expectancy of the plan participants. Unrecognized prior service cost is amortized over the future service periods of those employees who are active at the dates of the plan amendments and who are expected to receive benefits. If all or almost all of a plan's participants are inactive, unrecognized prior service cost is amortized over the remaining life expectancy of those participants. The increase in accumulated other comprehensive loss in 2021 relating to pension benefits and other postretirement benefits consists of:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:75.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized actuarial (gain) loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial gain/(loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service credit (cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost, change in projected benefit obligation, change in plan assets, funded status, fair value of plan assets, assumptions used to determine net periodic benefit cost, funding policy and estimated future benefit payments are summarized below for the Company’s pension plans and other postretirement plans.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic Benefit Cost</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost for the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.655%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailment, settlement and termination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized net actuarial losses (gains) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recognized a settlement gain as a result of cash payments from lump sum elections related to the U.S. and Puerto Rico pension plans.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Projected Benefit Obligation, Change in Plan Assets and Funded Status</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2021 and 2020.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements and terminations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,946.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status of plans</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(791.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheets at December 31, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(682.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accrued benefit costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(791.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, but does not include the effects of estimated future pay increases. The accumulated benefit obligation for the Company’s pension plans was $1.86 billion and $2.04 billion at December 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of the fair value of plan assets at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:78.078%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plans with accumulated benefit obligation in excess of plan assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Plan Assets</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy described in Note 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments and Risk Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held by insurance companies and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held by insurance companies and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk tolerance on invested pension plan assets is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Investment risk is measured and monitored on an ongoing basis through annual liability measures, periodic asset/liability studies and investment portfolio reviews. The Company’s investment strategy is to maintain, where possible, a diversified investment portfolio across several asset classes that, when combined with the Company’s contributions to the plans, will ensure that required benefit obligations are met.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumptions</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.034%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to determine the net periodic benefit cost for the Company’s defined benefit pension and other postretirement benefit plans for the three years in the period ended December 31, 2021:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:35.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions for each plan are reviewed on an annual basis. The discount rate reflects the current rate at which the pension and other benefit liabilities could be effectively settled at the measurement date. In setting the discount rates, we utilize comparable corporate bond indices as an indication of interest rate movements and levels. Corporate bond indices were selected based on individual plan census data and duration. The expected return on plan assets was determined using historical market returns and long-term historical relationships between equities and fixed income securities. The Company compares the expected return on plan assets assumption to actual historic returns to ensure reasonableness. Current market factors such as inflation and interest rates are also evaluated. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average healthcare cost trend rate used for 2021 was 5.7% declining to a projected 4.5% in the year 2037. For 2022, the assumed weighted-average healthcare cost trend rate used will be 6.3% declining to a projected 4.0% in the year 2045. In selecting rates for current and long-term healthcare cost assumptions, the Company takes into consideration a number of factors including the Company’s actual healthcare cost increases, the design of the Company’s benefit programs, the demographics of the Company’s active and retiree populations and external expectations of future medical cost inflation rates.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Benefit Payments</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s funding policy for its funded pension plans is based upon local statutory requirements. The Company’s funding policy is subject to certain statutory regulations with respect to annual minimum and maximum company contributions. Plan benefits for the non-qualified plans are paid as they come due. </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:75.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined contribution plans covering its employees in the U.S. and Puerto Rico, as well as certain employees in a number of countries outside the U.S. The Company’s domestic defined contribution plans consist primarily of a Profit Sharing 401(k) Plan and a 401(k) retirement plan for union-represented employees. Profit sharing contributions are made at the discretion of the Board of Directors. The Company’s non-domestic plans vary in form depending on local legal requirements. The Company’s contributions are based upon employee contributions, service hours, or pre-determined amounts depending upon the plan. Obligations for contributions to defined contribution plans are recognized as expense in the consolidated statements of operations when they are earned.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) Restoration Plan, which permits employees who earn compensation in excess of the limits imposed by Section 401(a)(17) of the Code to (i) defer a portion of base salary and bonus compensation, (ii) be credited with a Company matching contribution in respect of deferrals under the Restoration Plan, and (iii) be credited with Company non-elective contributions (to the extent so made by the Company), in each case, to the extent that participants otherwise would be able to defer or be credited with such amounts, as applicable, under the Profit Sharing 401(k) Plan if not for the limits on contributions and deferrals imposed by the Code.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50% of base salary and up to 100% of bonus compensation, in each case, in addition to any amounts that may be deferred by such participants under the Profit Sharing 401(k) Plan and the Restoration Plan. In addition, under the Income Deferral Plan, eligible participants may be granted employee deferral awards, which awards will be subject to the terms and conditions (including vesting) as determined by the plan administrator at the time such awards are granted.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employer contributions to defined contribution plans were approximately $107.4 million, $115.5 million and $95.6 million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Benefit Arrangements</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participated in a multi-employer pension plan under previous collective bargaining agreements. The PACE Industry Union-Management Pension Fund (the “PACE Plan”) provides defined benefits to certain retirees and certain production and maintenance employees at the Company’s manufacturing plant in Morgantown, West Virginia who were covered by the previous collective bargaining agreements. Pursuant to a collective bargaining agreement entered into on April 16, 2012, the Company withdrew from the PACE Plan effective May 10, 2012. In 2013, the PACE Plan trustee notified the Company that its withdrawal liability was approximately $27.3 million, which was accrued by the Company in 2013. The withdrawal liability is being paid over a period of approximately nine years; payments began in March 2014. The withdrawal liability was approximately $5.5 million and $8.9 million at December 31, 2021 and 2020, respectively. The Employer Identification Number for the PACE Plan is 11-6166763.</span></div> <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in accumulated other comprehensive loss as of December 31, 2021 and 2020 are:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized actuarial (gain) loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service cost (credit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 59900000 -33900000 -21700000 -5700000 6600000 -1400000 -3700000 600000 -53300000 32500000 18000000.0 6300000 0.10 The increase in accumulated other comprehensive loss in 2021 relating to pension benefits and other postretirement benefits consists of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:75.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized actuarial (gain) loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial gain/(loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized prior service credit (cost)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -102200000 16200000 7600000 -200000 -8000000.0 4300000 -500000 0 -1300000 0 85800000 -11700000 <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of net periodic benefit cost for the years ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.655%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan curtailment, settlement and termination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized net actuarial losses (gains) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recognized a settlement gain as a result of cash payments from lump sum elections related to the U.S. and Puerto Rico pension plans.</span></div> 38600000 23500000 20700000 3400000 1200000 600000 31600000 13500000 13600000 2600000 1400000 1500000 66100000 19900000 12100000 0 0 0 -16500000 1100000 -300000 0 0 3200000 -900000 0 -900000 0 0 0 -1300000 -400000 800000 -200000 -300000 -200000 -10200000 18600000 22000000.0 6200000 2900000 5500000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2021 and 2020.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements and terminations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,946.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status of plans</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(791.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2145800000 674700000 188800000 33800000 38600000 23500000 3400000 1100000 31600000 13500000 2600000 1400000 2000000.0 1800000 2400000 100000 4000000.0 1389400000 0 153100000 128600000 23100000 4300000 200000 -26100000 37200000 16200000 1100000 52800000 24600000 20700000 1600000 -67900000 53400000 0 0 1946600000 2145800000 188400000 188800000 1354600000 315700000 0 0 141700000 46000000.0 0 0 97000000.0 58200000 18300000 1700000 2000000.0 1800000 2400000 100000 -2100000 959300000 0 0 128900000 23100000 0 200000 52800000 24600000 20700000 1600000 -45100000 21300000 0 0 1366400000 1354600000 0 0 -580200000 -791200000 -188400000 -188800000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheets at December 31, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(682.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(846.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accrued benefit costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(791.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 117200000 70700000 0 0 14600000 15100000 16100000 16300000 682800000 846800000 172300000 172500000 580200000 791200000 188400000 188800000 1860000000 2040000000.00 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of the fair value of plan assets at December 31, 2021 and 2020 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:78.078%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plans with accumulated benefit obligation in excess of plan assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1591800000 1747200000 1546400000 1678200000 904100000 893900000 The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:<div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held by insurance companies and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:53.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held by insurance companies and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 63100000 1900000 0 65000000.0 53900000 497200000 0 551100000 211400000 405500000 0 616900000 10200000 41600000 81600000 133400000 338600000 946200000 81600000 1366400000 51200000 600000 0 51800000 145300000 468100000 0 613400000 292600000 299400000 0 592000000.0 4000000.0 20000000.0 73400000 97400000 493100000 788100000 73400000 1354600000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.034%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to determine the net periodic benefit cost for the Company’s defined benefit pension and other postretirement benefit plans for the three years in the period ended December 31, 2021:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:35.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.023 0.019 0.025 0.019 0.051 0.043 0 0 0.031 0.029 0 0 0.019 0.016 0.023 0.019 0.033 0.043 0.051 0.043 0.043 0 0 0 0.029 0.027 0.029 0 0 0 0.057 0.045 0.063 0.040 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:75.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 101800000 16100000 97100000 16500000 103000000.0 16900000 100700000 16800000 104300000 16600000 528500000 73000000.0 1035400000 155900000 0.50 1 107400000 115500000 95600000 27300000 5500000 8900000 ment Information<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics and biosimilars, and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Intangible asset amortization expense and impairments of intangible assets;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">R&amp;D expense;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Net charges or net gains for litigation settlements and other contingencies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Segment Profitability</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31, </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31, </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reportable Segments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,428.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,510.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,240.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,137.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JANZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,813.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,819.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,370.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,705.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,271.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,112.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,605.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,582.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Globally managed research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlements &amp; other contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related and other special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,832.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,739.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(682.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other unallocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,021.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,391.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,332.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) earnings from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the percentage of consolidated net sales to Viatris’ major customers during the years ended December 31, 2021, 2020, and 2019:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage of Consolidated Net Sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales by Country Information</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales by country are presented on the basis of geographic location of our subsidiaries: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,176.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,746.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div>No other country’s net sales represents more than 10% of consolidated net sales. <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Segment Profitability</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31, </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31, </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reportable Segments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,428.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,510.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,240.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,137.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JANZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reportable segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,813.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,819.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,370.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,705.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,271.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,112.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciling items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,605.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,582.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Globally managed research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlements &amp; other contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction related and other special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,832.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,739.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(682.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other unallocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,021.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,391.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,332.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) earnings from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10428700000 8510900000 8240000000 5143100000 4243900000 4137300000 2212800000 259900000 214600000 1397100000 52700000 89900000 2027400000 1195300000 1192500000 762400000 364600000 323200000 3144700000 1853800000 1723200000 1402400000 610400000 561900000 17813600000 11819900000 11370300000 8705000000 5271600000 5112300000 2702200000 1605800000 1582700000 102800000 82400000 180600000 751100000 555100000 639900000 -329200000 -107800000 21400000 2832200000 1739700000 682200000 2021500000 1391600000 1332800000 -34000000.0 -210800000 715500000 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the percentage of consolidated net sales to Viatris’ major customers during the years ended December 31, 2021, 2020, and 2019:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage of Consolidated Net Sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.09 0.13 0.15 0.09 0.10 0.09 0.05 0.08 0.08 <div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales by country are presented on the basis of geographic location of our subsidiaries: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,176.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,746.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div>No other country’s net sales represents more than 10% of consolidated net sales. 4176400000 3746100000 3965900000 1981500000 216100000 171100000 P24M 380000000 380000000 30400000 53100000 26900000 Restructuring <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Restructuring Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fourth quarter of 2020, Viatris announced a significant global restructuring program in order to achieve synergies and ensure that the organization is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders. Viatris’ restructuring initiative incorporates and expands on the restructuring program announced by Mylan N.V. earlier in 2020 as part of its business transformation efforts. As part of the restructuring, the Company is optimizing its commercial capabilities and enabling functions, and closing, downsizing or divesting certain manufacturing facilities globally that are deemed to be no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex products. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the committed restructuring actions, the Company expects to incur total pre-tax charges of up to approximately $1.4 billion. Such charges are expected to include up to approximately $450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including inventory write-offs. The remaining estimated cash costs of up to approximately $950 million are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations and other plant disposal costs. In addition, management believes the potential annual savings related to these committed restructuring activities to be up to approximately $900 million once fully implemented, with most of these savings expected to improve operating cash flow.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.006%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Exit Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in the Combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursable restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Combination, the Company acquired reserve balances related to restructuring activities initiated by the Upjohn Business prior to the Combination, primarily related to accrued severance. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2016 Restructuring Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan previously announced a restructuring program representing a series of actions in certain locations to further streamline its operations globally. We incurred total restructuring related costs of approximately $733.0 million through December 31, 2020. The 2016 Restructuring Program was substantially completed at December 31, 2020. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the FDA completed an inspection at Mylan’s plant in Morgantown, West Virginia and made observations through a Form 483. In the fourth quarter of 2018, Mylan received a warning letter related to the previously disclosed observations at the plant. The issues raised in the warning letter were addressed within the context of the Mylan’s comprehensive restructuring and remediation activities. On May 11, 2020, Mylan received the close-out of the warning letter. On December 11, 2020, the Company announced that it expects the Morgantown plant to be closed or divested as part of the 2020 Restructuring Program. The Morgantown plant was closed during the third quarter of 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restructuring charges and the reserve activity for the 2016 restructuring program from December 31, 2018 to December 31, 2020:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.006%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Exit Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     For the year ended December 31, 2020, total restructuring charges, for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     For the year ended December 31, 2019, total restructuring charges for the 2016 Restructuring Program in Developed Markets and JANZ were approximately $100.4 million and $4.2 million, respectively.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities and other long-term obligations in the consolidated balance sheets.</span></div> 1400000000 450000000 950000000 900000000 <div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.006%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Exit Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in the Combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursable restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.006%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Exit Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utilization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     For the year ended December 31, 2020, total restructuring charges, for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     For the year ended December 31, 2019, total restructuring charges for the 2016 Restructuring Program in Developed Markets and JANZ were approximately $100.4 million and $4.2 million, respectively.</span></div> 195600000 75700000 271300000 91700000 300000 92000000.0 25100000 400000 25500000 0 -70800000 -70800000 400000 0 400000 262600000 4800000 267400000 396100000 496100000 892200000 26400000 0 26400000 385500000 151700000 537200000 0 -345000000.0 -345000000.0 -7000000.0 -100000 -7100000 292600000 4100000 296700000 733000000 60800000 11800000 72600000 16600000 88000000.0 104600000 48900000 10500000 59400000 0 -8100000 -8100000 0 -78300000 -78300000 -2100000 -100000 -2200000 26400000 2800000 29200000 9900000 40600000 50500000 18100000 7600000 25700000 0 -32900000 -32900000 1800000 -100000 1700000 20000000.0 2800000 22800000 623800000 5800000 138100000 94100000 30400000 292100000 18400000 2900000 8400000 100400000 4200000 351000000 18000000 30000000 6 18500000 293000000 50000000 3 25000000 10000000 33000000 23300000 10000000 25000000 40000000 2000000000 1000000000 335000000 0.129 P2Y 17 264000000 264000000 274000000 47 37 48 43 47 1000 17200000 21700000 7800000 7800000 11400000 5800000 2700000 3900000 2050000.00 8800000 74800000 3 226900000 18 18 2 16 12 3 4 5 2 6 8400000 <div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIATRIS INC. AND SUBSIDIARIES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning<br/>Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions Charged to Costs and Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions Charged to Other<br/>Accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending<br/>Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 159900000 16000000.0 0 21400000 154500000 72800000 16900000 77300000 7100000 159900000 98200000 14200000 0 39600000 72800000 443600000 82200000 260800000 6200000 780400000 603500000 39000000.0 0 198900000 443600000 806000000.0 36800000 0 239300000 603500000 For the year ended December 31, 2021, total restructuring charges for the 2020 Restructuring Program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively. (2)     For the year ended December 31, 2020, total restructuring charges, for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively. (3)     For the year ended December 31, 2019, total restructuring charges for the 2016 Restructuring Program in Developed Markets and JANZ were approximately $100.4 million and $4.2 million, respectively. EXCEL 145 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

>!_]T8C\M ?+\M$7#<&]H@_(K0]_\#4$L# M!!0 ( $6!7%1>YF#F5@D %@8 9 >&PO=V]R:W-H965TKMFU> M75R8?"4J;GS5B!HK"Z4KWN)5+R],HP4O+%%57D1!,+FHN*Q/KB[MMUM]=:FZ MMI2UN-7,=%7%]>9&E&K]^B0\&3[6JI0\75Y<-7XI[T7YN;C7>+D8NA:Q$ M;:2JF1:+UR?7X:N;A/;;#5^D6)N=9T:6S)7Z1B_OB]J_"J+=O7Z9'K""K'@7=G>J?5? M16]/2OQR51K[R]9N;Q*?L+PSK:IZ8FA0R=K]R[_W?M@AF 9'"**>(+)Z.T%6 MR[>\Y5>76JV9IMW@1@_65$L-Y61-0;EO-58EZ-JK^Q77XOP&=A7L?9V+FIS$ M;DM>7UZTX$^[+O*>UXWC%1WA%4;L@ZK;E6'OZD(4^PPNH-BH731H=Q,]R_&M MR'T6AQZ+@BA\AE\\6AM;?O&SULZMM;=\@^1JV;76O%X*^_R/Z[EI-3+EG\\( M2T9AB166_$]<^T=YL5LME6:M8NU*L+<2^LMY1QGOL2^2X\TP7JBF!26O8?9" M_EMHC\G:$N2\X;EL-XR;8?N?_S2-PNPOS*A2,"1@_FVERD)HQEO4;KYB+:K2 M8[QIM'H 5V)C-3FEIT$FM/0I; &[)Q8'6I^Q]4J"U5SDO!),+!;"EB>IH1:/ M3/%!SG)5UWTMKV6[LIO>J&HN:^[,=;0?H50UA[KAQ.9-X T[&UZ3G<"?7FL@ M5\S^]NG]+3ME'S9DPD?_B\^ND0M%[ZX[85I.OG-[5;T\_R1T]<@$@#!&')5_C"Y+"5,@DUA[*5QZDVB[)A1IIO_"[Q(HUVUQ>\="JU'G\%- M"H)(2TJ*7;.\/Z8G&%INK6.\)N]I0/S[. M2V\P&S_@;81^Z'-NY G#OXD-$U53JHT0, 9J&_1)"@Q!3R$:*C&$&@L6<)4V M5DRMZO.!#FFIA5OJ,6$HXG:E5;=<,N)8"\(4-'[5X?.O;^^ MPR^TAU]SF\NNB&I*8TE*WMY_'L-C%_<"9W<:%%Q[WA(^#5NYH;RR7_=* M N&GCP6 :R"SLCVV%+70O+3(E*MJK#&;%\ HS1J!?@*%J2D2]X56%?D;X2"< M6J@23S,S>&4^VVGI& H1@0']VY,"*< G6F8>E$V92]8//$G(?NU=_PTFGEQ%+%HXF/? MN][]*.QT&GBS-$!Q)S[ "O/>0DBB.,W :I:$9RR>T5F88"7UL^0'LM%H@;9AZ&5Q M2+)3/Y[L,@N]$*@5D2DP/Y[]B%W(4B_-)EXR"XA=YL.X+P[W*53B>R/R'G:I M'1QCD4SAC>G4L4C2P6Z;.T^2)-YL,O,F040D,Q]?KFWY/]KI[2?<#M(>K#P\ MIW5=[&_>K0?JY1PU@<-)#Z+DJP&Q;+&B]JUVB3]A&\$U(&-\M,P3/QH6D,6- MFW+*#8:,TBCO21?\?PRK%>/+I19+ @D)DR0.6KG#&F@WG-)&V,$4U!WB<#\I M&D+M7IG'D-KCP9-8^^@C@>]C^+9@?#8,>(\3GUC9879%D[QA1:<'8"3?,S?. M/1YVZKW8@^UWT^?!PM?K(4P\@+LMC+;/&$4S].1AR8 M>=,T\)(DMF S@912V,YR&GOA9.J%:80211:E^^4[G67 J!@8A=*.GU<@I.%W MFH)91*4'"IS-?G.QV\H_%JNA3_VD&ST 3T!C'FK6YI[FU!LV[HA!C<.5 R:$ M4AA7%N3Y6K6[HU+?[)1M0?:V@48)5%LA;0_Q!P.VI?@# SR6 GV"*'U&W):_ MU6LMRY+EI5PLG"G4JFEVZ@UQOT/&3*KCVN!T59,K%@PZR,J>/Q8N%SHM+)24O*]V-',[_+3F MB3%EF/77HD<(HAAENX:_[]+UD.@#\)$;:,'-!20J]#,747=R<28=( CM>PI^ M>KAZLNX-F>5*X2#SS/$*ME,#"FX-;'B137>\34LOHL"?#5\.$?@KC6'])SNK M'QPHGAM0O.V0-MHK.#S=3WWN^$5*;2-X,)6Y+9T9#+TI.:)WG^-82&<*QX'(U+.WG9HT*O_4YJ/"@\8DN[<>KB"/'M?$$9C&@)W9>J<(OC M$7 C1=DWE6$.'P?5N5AQ'&VUCS[>-YQ1B-QJ5 RW"U9M6WTN*RG+ S*K4KP ME[LL-L?ZBTL2-R:39FXL7[AS@TO#(\;A4,(01FG/*&Z4%>RS?P\BC5SKT.&< MP7F'XBAFC17<<8+2?)&87FI'2C2,8VNZURC3+M^5 VV[+=BY)SA\U2 M_.'EQD@+*BL)4V$F*@IYPIW L;F7,,/L3?3N8+%GX Z+IUT%@K6P@/@HY7\2 M\9U:N_9TIC\#_C=%]+-E'O1DX6R_A#UK/&K,'4K,*_9W4OK=$29V/O^RS;5D MXF,GNCF1/Z 2G+[<);\][IU;?,S;Q4_OWEVV8+5U*)/;GZR&@ MNKJW*+"#'XT8?,=>3/T@0^^ [/BI:\B+G=O>2NBEO=,VZ"-=W;J+W_'K>&U^ M[6Z+M]O=G?L'KG'(,^C+"Y &?I:>H)#L/;9[:55C[X[GJFU591]7@B.DM 'K M"Z7:X84$C/^9[@9!4 !1$ 9 >&PO M=V]R:W-H965TO^+O;\O6KHJZR-->WI3+U9A.7]V]T5NQ^>1(]<5]\ M3E?KBKZX>OUJ&Z_T%UU]V]Z6N+ORLRS2C'_U4Z>'6#% MI#95L;&#<;])<_F,?U@^! .FO1,#^G9 G^F6A9C*MW$5OWY5%CM5TM.8C2YX MJSP:Q*4Y">5+5>+7%..JU^\VVZRXUUJ]T;E>II6ZS>+=[( M//T3\T1]];'(J[51[_*%7K0GN )1GK*^H^Q-_^R,;W7258.HH_J]?G1FOH'? MZ8#G&YR8[[.NTE)#GRJW5Z/^]WINJA*:\7]G%ACZ!8:\P/"1K#S*Q9^;0J2A MWN(ZUXN];[^NM;HI-MLXOU=F6^2F*(VZB\NTJ TI)@^9VR%;:T=;'IKFRN@[ M7<:92HHZK\I4FV[#EFU9W*60HEKA&SR4W6,^S+!0F"'3^:I:JV*)* 9,KFD86UV&93+,[7;&:U>@_%OW2[>C;FM=5H7ZG"8%CTUP M"R3!0Y4N4Y=Q MCKF]2&C!/:;L\X''.P4HEDO05LK 39SC=Q[D&<"40K"YA?=="J6T],Y349WV M!F(#SZ,;'2-R0O4Y;S)V^_3[O?JV_:U8YZ)$&YK&I*L\!<5QWE81#0H*0QP) M5;VC/I0ZHYW1O_^.05[7SJE2(^I(E-LUR=:*7)_B'ZVWMT!77<.*X[*BH313 MG$#&)K6.D&T>VMOFSSHV8$=2E*QK^&$90[ONXJS6=AJGED1L0=R',#3/:9>/$.(2[3,XXP- M2B(UQR3>EV<)[!@;KD1WB*7/Z?<:>% ^7]+'<=XOE8Z3]4GU)[*/0B+)BC9_ MCM-;0$]YR.($=B1 #?C :#!T49?$0%8"C5$+QKZ\J/9T@)0.QD (!\IS7=G' MT\133LMT%.">IVB&=_AQ4M7X1T?TR<_&-L:[I*]*O:;=WVEU09NY!(?*'.0Q MZK!=LS9 ">I-G;%R'!M,8VD=S(UH1F_F>,)%-,P>7/2(R!=>2;PK.*HI_M?6 M=*V;"\#B)LTR7LA*OTEQ].VXH%R2_2Z'YJ;H8S;JS2UP,!MT9/OI1=X*/ M$?YOC3\4L+H0Z5ZJ<7>L+J+N\%)=#+J32]7#_=>"7"#-/^@.>/Y^=X2/:-KM MX6/<'; AM"R4I-;0:;6+D$63'*+>,P<_:X3@NG1W2#*^L_NS !9B2V'AYAPH M037IF;E>I3D)W\U[#V78\U4>NPS#'A(+> JHV*8HJ_1W;V>FAIU92"2TG6N= M.T?!"G52G8U$%0^9I(L+1U8%@,]I];+V68?>)^!(0*Y.!\MTZ M!>D)P6SULV1R_"$D "_O0]FP0TR3% A+@YB]I&'2[U+'$/X\"2SS'0$7A$3M4[-YI M?2N6/*_^B M-RKYF^6(/$7\2:!\'EE&OW^T3FD7C;E]=[YE].QBYLBYE0NC8 MHV'G-)&A%) *\BX58>3%D'!S?XEC?A:3CR[5?_['M!_U7ZH/B"P2=G.$30A7 M55*7I28!(@/.329S10!@-^03T C13@X#PQZGH^Z4MTB>X.:Q7MB.I]#I#-:V MGFM@NJ-LV&*JN*KIMA61MI[DZ'XK62+2(;:;A486B>A-GZ.0EN!,KLC21.)* MC8ARPXIJS=W'1/&]M53" *YCL=#F5-QBB X":F;CY*792R3.QE.P&^+ZK2/5 MQ9 W9)B/9+JG@Z%>:>;@0?S1L<$'1R'13(+=F/Q,AKV8OR4BP;)[MU]"($)P M,(61(/@8<(S0[W$,,N@.20UA:$\YI/A M0*(3 8-(GP5T0#\-U9]NL. "%^\ M-R-$*M$'/E<1'VZ<[:P_TDQ.UD0 H",&-&!\565Y/B2 MF[/FB5%= !9@BE$W(J,<',XZ.((:QTRZAUC,C0FO]S\_/Q \,7R92[;V'K@# MJJ84G_7Q;\"?GTYJ%\.=13LKGKZ-W4@B?0X71V#WVR:BYY#II")6QS(?H&W( M4B)80G:(NLX8R! AK!N3Y-I)!@P@PU2N[&O$E0@>N+H3"R@L/;4LM*MN/!C= M>M!REOC/ +2"YT@=KD6/:/+W@EM?&+?8%5;Q/-,6*.#U#-/<3F:(O#^%E[QT M"S(I[#B=>G1_UL@?3BX>Q[K@QV.;:X7BZ93OD:%, MV\#!L,&@,6#3CTYBA(.'VR9T:54+C2+=CK! 'T_U,--U4TDQ:D@_=@;3&7YT MMA^LW+A"["46=6;# ML0"$EQW);.AE=]Q^WI]V\L<4 _P?#7F9031BQ7#$-E?,T.P$[D=#BFA :N]@ MNPZ5VBHQF^#1T938/P5L.?X*F_O$CBTI MZT 9#U/E!V*N)J?@2M$6+E@R<<[U.!0B;3O$Z?T8CS(.!) +=C6M8MT#&/RW MEGX^%;E(NW+*3_'\A!WWI'?">&[L"%=H3 F((M&L:"0AT]A] ,."15I#QE-1 MRBE,C3ZC29\ACSY'Y^3Y6(WX^E!%QU4-/+Q:1]PH^W@X"4X-:&Z MJLTS(/5.<"C$E>_E$G2POARD$W1>YE)C5XL)LN._G7(JE2X*R(C*K@\1#='5:

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�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�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�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end XML 146 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 147 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 148 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 807 734 1 true 243 0 false 18 false false R1.htm 000010001 - Document - Cover Sheet http://www.viatris.com/role/Cover Cover Cover 1 false false R2.htm 000020008 - Document - Audit Information Sheet http://www.viatris.com/role/AuditInformation Audit Information Notes 2 false false R3.htm 000030009 - Document - Audit Information Sheet http://www.viatris.com/role/AuditInformation_1 Audit Information Uncategorized 3 false false R4.htm 100010002 - Statement - Consolidated Balance Sheets Sheet http://www.viatris.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 100020003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 100030004 - Statement - Consolidated Statements of Operations Sheet http://www.viatris.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 6 false false R7.htm 100040005 - Statement - Consolidated Statements of Comprehensive Earnings Sheet http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings Consolidated Statements of Comprehensive Earnings Statements 7 false false R8.htm 100050006 - Statement - Consolidated Statements of Equity Sheet http://www.viatris.com/role/ConsolidatedStatementsofEquity Consolidated Statements of Equity Statements 8 false false R9.htm 100070007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.viatris.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 9 false false R10.htm 140064001 - Statement - Consolidated Statements of Equity (Parenthetical) Sheet http://www.viatris.com/role/ConsolidatedStatementsofEquityParenthetical Consolidated Statements of Equity (Parenthetical) Statements 10 false false R11.htm 210011001 - Disclosure - Nature of Operations Sheet http://www.viatris.com/role/NatureofOperations Nature of Operations Notes 11 false false R12.htm 210031002 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.viatris.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 12 false false R13.htm 210081003 - Disclosure - Acquisitions and Other Transactions Sheet http://www.viatris.com/role/AcquisitionsandOtherTransactions Acquisitions and Other Transactions Notes 13 false false R14.htm 210131004 - Disclosure - Revenue Recognition and Accounts Receivable Sheet http://www.viatris.com/role/RevenueRecognitionandAccountsReceivable Revenue Recognition and Accounts Receivable Notes 14 false false R15.htm 210211005 - Disclosure - Balance Sheet Components Sheet http://www.viatris.com/role/BalanceSheetComponents Balance Sheet Components Notes 15 false false R16.htm 210331006 - Disclosure - Leases Sheet http://www.viatris.com/role/Leases Leases Notes 16 false false R17.htm 210381007 - Disclosure - Equity Method Investments Sheet http://www.viatris.com/role/EquityMethodInvestments Equity Method Investments Notes 17 false false R18.htm 210521009 - Disclosure - Financial Instruments and Risk Management Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagement Financial Instruments and Risk Management Notes 18 false false R19.htm 210771011 - Disclosure - Comprehensive Earnings Sheet http://www.viatris.com/role/ComprehensiveEarnings Comprehensive Earnings Notes 19 false false R20.htm 210811012 - Disclosure - Income Taxes Sheet http://www.viatris.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 210881013 - Disclosure - Share-Based Incentive Plan Sheet http://www.viatris.com/role/ShareBasedIncentivePlan Share-Based Incentive Plan Notes 21 false false R22.htm 210941014 - Disclosure - Employee Benefit Plans Sheet http://www.viatris.com/role/EmployeeBenefitPlans Employee Benefit Plans Notes 22 false false R23.htm 211071015 - Disclosure - Segment Information Sheet http://www.viatris.com/role/SegmentInformation Segment Information Notes 23 false false R24.htm 211141017 - Disclosure - Restructuring Sheet http://www.viatris.com/role/Restructuring Restructuring Notes 24 false false R25.htm 211221020 - Disclosure - Valuation and Qualifying Accounts Sheet http://www.viatris.com/role/ValuationandQualifyingAccounts Valuation and Qualifying Accounts Notes 25 false false R26.htm 220042001 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.viatris.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 230053001 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.viatris.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 230093002 - Disclosure - Acquisitions and Other Transactions (Tables) Sheet http://www.viatris.com/role/AcquisitionsandOtherTransactionsTables Acquisitions and Other Transactions (Tables) Tables http://www.viatris.com/role/AcquisitionsandOtherTransactions 28 false false R29.htm 230143003 - Disclosure - Revenue Recognition and Accounts Receivable (Tables) Sheet http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableTables Revenue Recognition and Accounts Receivable (Tables) Tables http://www.viatris.com/role/RevenueRecognitionandAccountsReceivable 29 false false R30.htm 230223004 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.viatris.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.viatris.com/role/BalanceSheetComponents 30 false false R31.htm 230343005 - Disclosure - Leases (Tables) Sheet http://www.viatris.com/role/LeasesTables Leases (Tables) Tables http://www.viatris.com/role/Leases 31 false false R32.htm 230393006 - Disclosure - Equity Method Investments (Tables) Sheet http://www.viatris.com/role/EquityMethodInvestmentsTables Equity Method Investments (Tables) Tables http://www.viatris.com/role/EquityMethodInvestments 32 false false R33.htm 230453007 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables 33 false false R34.htm 230533008 - Disclosure - Financial Instruments and Risk Management (Tables) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables Financial Instruments and Risk Management (Tables) Tables http://www.viatris.com/role/FinancialInstrumentsandRiskManagement 34 false false R35.htm 230673009 - Disclosure - Debt (Tables) Sheet http://www.viatris.com/role/DebtTables Debt (Tables) Tables 35 false false R36.htm 230783010 - Disclosure - Comprehensive Earnings (Tables) Sheet http://www.viatris.com/role/ComprehensiveEarningsTables Comprehensive Earnings (Tables) Tables http://www.viatris.com/role/ComprehensiveEarnings 36 false false R37.htm 230823011 - Disclosure - Income Taxes (Tables) Sheet http://www.viatris.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.viatris.com/role/IncomeTaxes 37 false false R38.htm 230893012 - Disclosure - Share-Based Incentive Plan (Tables) Sheet http://www.viatris.com/role/ShareBasedIncentivePlanTables Share-Based Incentive Plan (Tables) Tables http://www.viatris.com/role/ShareBasedIncentivePlan 38 false false R39.htm 230953013 - Disclosure - Employee Benefit Plans (Tables) Sheet http://www.viatris.com/role/EmployeeBenefitPlansTables Employee Benefit Plans (Tables) Tables http://www.viatris.com/role/EmployeeBenefitPlans 39 false false R40.htm 231083014 - Disclosure - Segment Information (Tables) Sheet http://www.viatris.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.viatris.com/role/SegmentInformation 40 false false R41.htm 231153015 - Disclosure - Restructuring (Tables) Sheet http://www.viatris.com/role/RestructuringTables Restructuring (Tables) Tables http://www.viatris.com/role/Restructuring 41 false false R42.htm 240024002 - Disclosure - Nature of Operations (Narrative) (Details) Sheet http://www.viatris.com/role/NatureofOperationsNarrativeDetails Nature of Operations (Narrative) (Details) Details http://www.viatris.com/role/NatureofOperations 42 false false R43.htm 240064003 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies (Narrative) (Details) Details http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesTables 43 false false R44.htm 240074004 - Disclosure - Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details) Sheet http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details) Details http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesTables 44 false false R45.htm 240104005 - Disclosure - Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details) Sheet http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details) Details http://www.viatris.com/role/AcquisitionsandOtherTransactionsTables 45 false false R46.htm 240114006 - Disclosure - Acquisitions and Other Transactions (Purchase Price Allocations) (Details) Sheet http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails Acquisitions and Other Transactions (Purchase Price Allocations) (Details) Details http://www.viatris.com/role/AcquisitionsandOtherTransactionsTables 46 false false R47.htm 240124007 - Disclosure - Acquisitions and Other Transactions (Unaudited Pro Forma Financial Results) (Details) Sheet http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails Acquisitions and Other Transactions (Unaudited Pro Forma Financial Results) (Details) Details http://www.viatris.com/role/AcquisitionsandOtherTransactionsTables 47 false false R48.htm 240154008 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details) Sheet http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details) Details 48 false false R49.htm 240164009 - Disclosure - Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details) Sheet http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details) Details 49 false false R50.htm 240174010 - Disclosure - Revenue Recognition and Accounts Receivable (Narrative) (Details) Sheet http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableNarrativeDetails Revenue Recognition and Accounts Receivable (Narrative) (Details) Details http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableTables 50 false false R51.htm 240184011 - Disclosure - Revenue Recognition and Accounts Receivable Variable Consideration (Details) Sheet http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails Revenue Recognition and Accounts Receivable Variable Consideration (Details) Details 51 false false R52.htm 240194012 - Disclosure - Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) Sheet http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) Details http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableTables 52 false false R53.htm 240204013 - Disclosure - Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details) Sheet http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details) Details 53 false false R54.htm 240234014 - Disclosure - Balance Sheet Components (Narrative) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails Balance Sheet Components (Narrative) (Details) Details http://www.viatris.com/role/BalanceSheetComponentsTables 54 false false R55.htm 240244015 - Disclosure - Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsBalanceSheetComponentsCashandCashEquivalentsDetails Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details) Details 55 false false R56.htm 240254016 - Disclosure - Balance Sheet Components (Accounts receivable, net) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails Balance Sheet Components (Accounts receivable, net) (Details) Details http://www.viatris.com/role/BalanceSheetComponentsTables 56 false false R57.htm 240264017 - Disclosure - Balance Sheet Components (Inventories) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails Balance Sheet Components (Inventories) (Details) Details http://www.viatris.com/role/BalanceSheetComponentsTables 57 false false R58.htm 240274018 - Disclosure - Balance Sheet Components (Prepaids and other current assets) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails Balance Sheet Components (Prepaids and other current assets) (Details) Details http://www.viatris.com/role/BalanceSheetComponentsTables 58 false false R59.htm 240284019 - Disclosure - Balance Sheet Components (Property, Plant and Equipment) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails Balance Sheet Components (Property, Plant and Equipment) (Details) Details http://www.viatris.com/role/BalanceSheetComponentsTables 59 false false R60.htm 240294020 - Disclosure - Balance Sheet Components (Other Assets) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails Balance Sheet Components (Other Assets) (Details) Details http://www.viatris.com/role/BalanceSheetComponentsTables 60 false false R61.htm 240304021 - Disclosure - Balance Sheet Components (Trade Accounts Payable) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsTradeAccountsPayableDetails Balance Sheet Components (Trade Accounts Payable) (Details) Details http://www.viatris.com/role/BalanceSheetComponentsTables 61 false false R62.htm 240314022 - Disclosure - Balance Sheet Components (Other Current Liabilities) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails Balance Sheet Components (Other Current Liabilities) (Details) Details http://www.viatris.com/role/BalanceSheetComponentsTables 62 false false R63.htm 240324023 - Disclosure - Balance Sheet Components (Other noncurrent liabilities) (Details) Sheet http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails Balance Sheet Components (Other noncurrent liabilities) (Details) Details http://www.viatris.com/role/BalanceSheetComponentsTables 63 false false R64.htm 240354024 - Disclosure - Leases (Narrative) (Details) Sheet http://www.viatris.com/role/LeasesNarrativeDetails Leases (Narrative) (Details) Details http://www.viatris.com/role/LeasesTables 64 false false R65.htm 240364025 - Disclosure - Leases (Lease Information) (Details) Sheet http://www.viatris.com/role/LeasesLeaseInformationDetails Leases (Lease Information) (Details) Details http://www.viatris.com/role/LeasesTables 65 false false R66.htm 240374026 - Disclosure - Leases (Lease Maturities) (Details) Sheet http://www.viatris.com/role/LeasesLeaseMaturitiesDetails Leases (Lease Maturities) (Details) Details http://www.viatris.com/role/LeasesTables 66 false false R67.htm 240404027 - Disclosure - Equity Method Investments (Narrative) (Details) Sheet http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails Equity Method Investments (Narrative) (Details) Details http://www.viatris.com/role/EquityMethodInvestmentsTables 67 false false R68.htm 240414028 - Disclosure - Equity Method Investments (Balance Sheet) (Details) Sheet http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails Equity Method Investments (Balance Sheet) (Details) Details http://www.viatris.com/role/EquityMethodInvestmentsTables 68 false false R69.htm 240424029 - Disclosure - Equity Method Investments (Net Assets) (Details) Sheet http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails Equity Method Investments (Net Assets) (Details) Details http://www.viatris.com/role/EquityMethodInvestmentsTables 69 false false R70.htm 240434030 - Disclosure - Equity Method Investments (Income Statement) (Details) Sheet http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails Equity Method Investments (Income Statement) (Details) Details http://www.viatris.com/role/EquityMethodInvestmentsTables 70 false false R71.htm 240464031 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) Sheet http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets (Narrative) (Details) Details http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables 71 false false R72.htm 240474032 - Disclosure - Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details) Sheet http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details) Details http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables 72 false false R73.htm 240484033 - Disclosure - Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details) Sheet http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details) Details http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables 73 false false R74.htm 240494034 - Disclosure - Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) Sheet http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) Details http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables 74 false false R75.htm 240504035 - Disclosure - Goodwill and Other Intangible Assets (Amortization Expense) (Details) Sheet http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails Goodwill and Other Intangible Assets (Amortization Expense) (Details) Details http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables 75 false false R76.htm 240514036 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details) Sheet http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsFutureamortizationexpenseDetails Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details) Details 76 false false R77.htm 240544037 - Disclosure - Financial Instruments and Risk Management (Narrative) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails Financial Instruments and Risk Management (Narrative) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 77 false false R78.htm 240554038 - Disclosure - Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 78 false false R79.htm 240564039 - Disclosure - Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 79 false false R80.htm 240574040 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 80 false false R81.htm 240584041 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 81 false false R82.htm 240594042 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 82 false false R83.htm 240604043 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 83 false false R84.htm 240614044 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 84 false false R85.htm 240624045 - Disclosure - Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 85 false false R86.htm 240634046 - Disclosure - Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 86 false false R87.htm 240644047 - Disclosure - Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 87 false false R88.htm 240654048 - Disclosure - Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details) Sheet http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details) Details http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables 88 false false R89.htm 240684049 - Disclosure - Debt (Short-term borrowings) (Details) Sheet http://www.viatris.com/role/DebtShorttermborrowingsDetails Debt (Short-term borrowings) (Details) Details http://www.viatris.com/role/DebtTables 89 false false R90.htm 240694050 - Disclosure - Debt Debt (Receivables Facility and Commercial Paper Program) (Details) Sheet http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails Debt Debt (Receivables Facility and Commercial Paper Program) (Details) Details 90 false false R91.htm 240704051 - Disclosure - Debt (Summary of Long-term Debt) (Details) Sheet http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails Debt (Summary of Long-term Debt) (Details) Details http://www.viatris.com/role/DebtTables 91 false false R92.htm 240714052 - Disclosure - Debt (Revolving Facilities and Term Facilities) (Details) Sheet http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails Debt (Revolving Facilities and Term Facilities) (Details) Details http://www.viatris.com/role/DebtTables 92 false false R93.htm 240724053 - Disclosure - Debt (Issuance of 2018 Senior Notes) (Details) Notes http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails Debt (Issuance of 2018 Senior Notes) (Details) Details http://www.viatris.com/role/DebtTables 93 false false R94.htm 240734054 - Disclosure - Debt (Senior Notes) (Details) Notes http://www.viatris.com/role/DebtSeniorNotesDetails Debt (Senior Notes) (Details) Details http://www.viatris.com/role/DebtTables 94 false false R95.htm 240744055 - Disclosure - Debt (Fair Value) (Narrative) (Details) Sheet http://www.viatris.com/role/DebtFairValueNarrativeDetails Debt (Fair Value) (Narrative) (Details) Details http://www.viatris.com/role/DebtTables 95 false false R96.htm 240754056 - Disclosure - Debt (Upjohn Senior Notes) (Details) Notes http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails Debt (Upjohn Senior Notes) (Details) Details http://www.viatris.com/role/DebtTables 96 false false R97.htm 240764057 - Disclosure - Debt (Minimum Repayments on Outstanding Borrowings) (Details) Sheet http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails Debt (Minimum Repayments on Outstanding Borrowings) (Details) Details http://www.viatris.com/role/DebtTables 97 false false R98.htm 240794058 - Disclosure - Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) Sheet http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) Details http://www.viatris.com/role/ComprehensiveEarningsTables 98 false false R99.htm 240804059 - Disclosure - Comprehensive Earnings (Components of Other Comprehensive Loss) (Details) Sheet http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails Comprehensive Earnings (Components of Other Comprehensive Loss) (Details) Details http://www.viatris.com/role/ComprehensiveEarningsTables 99 false false R100.htm 240834060 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.viatris.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.viatris.com/role/IncomeTaxesTables 100 false false R101.htm 240844061 - Disclosure - Income Taxes (Schedule of Components of Income Tax Provision) (Details) Sheet http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails Income Taxes (Schedule of Components of Income Tax Provision) (Details) Details http://www.viatris.com/role/IncomeTaxesTables 101 false false R102.htm 240854062 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) Sheet http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) Details http://www.viatris.com/role/IncomeTaxesTables 102 false false R103.htm 240864063 - Disclosure - Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details) Sheet http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details) Details http://www.viatris.com/role/IncomeTaxesTables 103 false false R104.htm 240874064 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) Sheet http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) Details http://www.viatris.com/role/IncomeTaxesTables 104 false false R105.htm 240904065 - Disclosure - Share-Based Incentive Plan (Narrative) (Details) Sheet http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails Share-Based Incentive Plan (Narrative) (Details) Details http://www.viatris.com/role/ShareBasedIncentivePlanTables 105 false false R106.htm 240914066 - Disclosure - Share-Based Incentive Plan (Stock Awards) (Details) Sheet http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails Share-Based Incentive Plan (Stock Awards) (Details) Details http://www.viatris.com/role/ShareBasedIncentivePlanTables 106 false false R107.htm 240924067 - Disclosure - Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) Sheet http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) Details http://www.viatris.com/role/ShareBasedIncentivePlanTables 107 false false R108.htm 240934068 - Disclosure - Share-Based Incentive Plan (Valuation Assumptions) (Details) Sheet http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails Share-Based Incentive Plan (Valuation Assumptions) (Details) Details http://www.viatris.com/role/ShareBasedIncentivePlanTables 108 false false R109.htm 240964069 - Disclosure - Employee Benefit Plans (Narrative) (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails Employee Benefit Plans (Narrative) (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 109 false false R110.htm 240974070 - Disclosure - Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 110 false false R111.htm 240984071 - Disclosure - Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 111 false false R112.htm 240994072 - Disclosure - Employee Benefit Plans (Net Periodic Benefit Costs) (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails Employee Benefit Plans (Net Periodic Benefit Costs) (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 112 false false R113.htm 241004073 - Disclosure - Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 113 false false R114.htm 241014074 - Disclosure - Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 114 false false R115.htm 241024075 - Disclosure - Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 115 false false R116.htm 241034076 - Disclosure - Employee Benefit Plans (Fair Values of Plan Assets) (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails Employee Benefit Plans (Fair Values of Plan Assets) (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 116 false false R117.htm 241044077 - Disclosure - Employee Benefit Plans (Weighted Average Assumptions) (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails Employee Benefit Plans (Weighted Average Assumptions) (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 117 false false R118.htm 241064079 - Disclosure - Employee Benefit Plans (Estimated Future Benefit Payments) (Details) Sheet http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails Employee Benefit Plans (Estimated Future Benefit Payments) (Details) Details http://www.viatris.com/role/EmployeeBenefitPlansTables 118 false false R119.htm 241094080 - Disclosure - Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details) Sheet http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details) Details http://www.viatris.com/role/SegmentInformationTables 119 false false R120.htm 241104081 - Disclosure - Segment Information (Third Party Net Sales by Major Customers) (Details) Sheet http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails Segment Information (Third Party Net Sales by Major Customers) (Details) Details http://www.viatris.com/role/SegmentInformationTables 120 false false R121.htm 241114082 - Disclosure - Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details) Sheet http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details) Details http://www.viatris.com/role/SegmentInformationTables 121 false false R122.htm 241134083 - Disclosure - Commitments (Details) Sheet http://www.viatris.com/role/CommitmentsDetails Commitments (Details) Details 122 false false R123.htm 241164084 - Disclosure - Restructuring (Narrative) (Details) Sheet http://www.viatris.com/role/RestructuringNarrativeDetails Restructuring (Narrative) (Details) Details http://www.viatris.com/role/RestructuringTables 123 false false R124.htm 241174085 - Disclosure - Restructuring (2020 Restructuring Plan) (Details) Sheet http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails Restructuring (2020 Restructuring Plan) (Details) Details http://www.viatris.com/role/RestructuringTables 124 false false R125.htm 241194086 - Disclosure - Collaboration and Licensing Agreements (Narrative) (Details) Sheet http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails Collaboration and Licensing Agreements (Narrative) (Details) Details 125 false false R126.htm 241214087 - Disclosure - Litigation (Narrative) (Details) Sheet http://www.viatris.com/role/LitigationNarrativeDetails Litigation (Narrative) (Details) Details 126 false false R127.htm 241234088 - Disclosure - Valuation and Qualifying Accounts (Details) Sheet http://www.viatris.com/role/ValuationandQualifyingAccountsDetails Valuation and Qualifying Accounts (Details) Details http://www.viatris.com/role/ValuationandQualifyingAccounts 127 false false All Reports Book All Reports vtrs-20211231.htm ex_21xvtrsx20211231x10-k.htm ex_22xvtrsx20211231x10-k.htm ex_23-vtrsx20211231x10xk.htm vtrs-20211231.xsd vtrs-20211231_cal.xml vtrs-20211231_def.xml vtrs-20211231_lab.xml vtrs-20211231_pre.xml vtrs_ex311x20211231-10k.htm vtrs_ex312x20211231-10k.htm vtrs_ex32x20211231-10k.htm vtrs-20211231_g1.jpg vtrs-20211231_g2.jpg vtrs-20211231_g3.jpg vtrs-20211231_g4.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 151 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vtrs-20211231.htm": { "axisCustom": 5, "axisStandard": 56, "contextCount": 807, "dts": { "calculationLink": { "local": [ "vtrs-20211231_cal.xml" ] }, "definitionLink": { "local": [ "vtrs-20211231_def.xml" ] }, "inline": { "local": [ "vtrs-20211231.htm" ] }, "labelLink": { "local": [ "vtrs-20211231_lab.xml" ] }, "presentationLink": { "local": [ "vtrs-20211231_pre.xml" ] }, "schema": { "local": [ "vtrs-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 1229, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 17, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 23 }, "keyCustom": 98, "keyStandard": 636, "memberCustom": 123, "memberStandard": 108, "nsprefix": "vtrs", "nsuri": "http://www.viatris.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010001 - Document - Cover", "role": "http://www.viatris.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "if7c969d8800446acace677aeab6fa885_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "140064001 - Statement - Consolidated Statements of Equity (Parenthetical)", "role": "http://www.viatris.com/role/ConsolidatedStatementsofEquityParenthetical", "shortName": "Consolidated Statements of Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "if7c969d8800446acace677aeab6fa885_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240834060 - Disclosure - Income Taxes (Narrative) (Details)", "role": "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240844061 - Disclosure - Income Taxes (Schedule of Components of Income Tax Provision) (Details)", "role": "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails", "shortName": "Income Taxes (Schedule of Components of Income Tax Provision) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9f40df9e1eb0444887127461f9ea3abe_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240854062 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)", "role": "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240864063 - Disclosure - Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details)", "role": "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails", "shortName": "Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240874064 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)", "role": "http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i471cbeca3c824ca0b751c54c81e91480_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240904065 - Disclosure - Share-Based Incentive Plan (Narrative) (Details)", "role": "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "shortName": "Share-Based Incentive Plan (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ib1c2d553da14496cb03b6b87eb3cd0c0_D20210101-20211231", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i36d66b81144849148d1319e8bfed3c96_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240914066 - Disclosure - Share-Based Incentive Plan (Stock Awards) (Details)", "role": "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails", "shortName": "Share-Based Incentive Plan (Stock Awards) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "if8ec92ba24d848d697ba737aeed13c05_I20181231", "decimals": "2", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i108f18c1c1f24f03914b8e2a90171783_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240924067 - Disclosure - Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details)", "role": "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails", "shortName": "Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i108f18c1c1f24f03914b8e2a90171783_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i10a62822cebc4558b2338681f573875e_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240934068 - Disclosure - Share-Based Incentive Plan (Valuation Assumptions) (Details)", "role": "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails", "shortName": "Share-Based Incentive Plan (Valuation Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i10a62822cebc4558b2338681f573875e_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "vtrs:AccumulatednetactuariallossesexceedhigherofmarketvalueofplanassetsorPBO", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240964069 - Disclosure - Employee Benefit Plans (Narrative) (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails", "shortName": "Employee Benefit Plans (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "vtrs:AccumulatednetactuariallossesexceedhigherofmarketvalueofplanassetsorPBO", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210011001 - Disclosure - Nature of Operations", "role": "http://www.viatris.com/role/NatureofOperations", "shortName": "Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240974070 - Disclosure - Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails", "shortName": "Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240984071 - Disclosure - Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails", "shortName": "Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ib2876ac575224b07a3f951b9b7ad8f78_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ifebd4eefd44247d191bd47ca2474ecda_D20190101-20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240994072 - Disclosure - Employee Benefit Plans (Net Periodic Benefit Costs) (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails", "shortName": "Employee Benefit Plans (Net Periodic Benefit Costs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ifebd4eefd44247d191bd47ca2474ecda_D20190101-20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ifebd4eefd44247d191bd47ca2474ecda_D20190101-20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241004073 - Disclosure - Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "shortName": "Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ib2876ac575224b07a3f951b9b7ad8f78_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "vtrs:DefinedBenefitPlanContributionsByPlanParticipantsBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241014074 - Disclosure - Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails", "shortName": "Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241024075 - Disclosure - Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails", "shortName": "Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241034076 - Disclosure - Employee Benefit Plans (Fair Values of Plan Assets) (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails", "shortName": "Employee Benefit Plans (Fair Values of Plan Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "iddab1d45dd6b4fdfaf6d0678d30eb8fc_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241044077 - Disclosure - Employee Benefit Plans (Weighted Average Assumptions) (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails", "shortName": "Employee Benefit Plans (Weighted Average Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241064079 - Disclosure - Employee Benefit Plans (Estimated Future Benefit Payments) (Details)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails", "shortName": "Employee Benefit Plans (Estimated Future Benefit Payments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia9d424a72c6e4901a7dafb47ebf3c114_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241094080 - Disclosure - Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details)", "role": "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails", "shortName": "Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "id2ddd71cee624b009233ae18ff01bcdb_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210031002 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.viatris.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i18815e8bb5a745709ff95e3d9c2c08e4_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241104081 - Disclosure - Segment Information (Third Party Net Sales by Major Customers) (Details)", "role": "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails", "shortName": "Segment Information (Third Party Net Sales by Major Customers) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i18815e8bb5a745709ff95e3d9c2c08e4_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R121": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241114082 - Disclosure - Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details)", "role": "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails", "shortName": "Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i5705c46a88bf43f9b604c129b6396c1b_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R122": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i3bc8daf6f604468691d4e166c4089a06_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtrs:BusinessCombinationContractualReimbursementAmountTrancheOne", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241134083 - Disclosure - Commitments (Details)", "role": "http://www.viatris.com/role/CommitmentsDetails", "shortName": "Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i3bc8daf6f604468691d4e166c4089a06_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtrs:BusinessCombinationContractualReimbursementAmountTrancheOne", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R123": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i471cbeca3c824ca0b751c54c81e91480_D20200101-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsForRestructuring", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241164084 - Disclosure - Restructuring (Narrative) (Details)", "role": "http://www.viatris.com/role/RestructuringNarrativeDetails", "shortName": "Restructuring (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ifebd4eefd44247d191bd47ca2474ecda_D20190101-20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestructuringReservePeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R124": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i36d66b81144849148d1319e8bfed3c96_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241174085 - Disclosure - Restructuring (2020 Restructuring Plan) (Details)", "role": "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "shortName": "Restructuring (2020 Restructuring Plan) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "vtrs:RestructuringReserveReimbursableRestructuringCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R125": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241194086 - Disclosure - Collaboration and Licensing Agreements (Narrative) (Details)", "role": "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "shortName": "Collaboration and Licensing Agreements (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i86776889abae4015b5e341878a1f94e0_I20160108", "decimals": "0", "lang": "en-US", "name": "vtrs:NumberOfDrugs", "reportCount": 1, "unique": true, "unitRef": "drugs", "xsiNil": "false" } }, "R126": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "vtrs:Numberofcases", "reportCount": 1, "unitRef": "case", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241214087 - Disclosure - Litigation (Narrative) (Details)", "role": "http://www.viatris.com/role/LitigationNarrativeDetails", "shortName": "Litigation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i42721f7bfaa74a20b33b1b57026a7ec6_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R127": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i8aaae8d197ef43d0880965d47a937ced_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241234088 - Disclosure - Valuation and Qualifying Accounts (Details)", "role": "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails", "shortName": "Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "idaab369eeea042ca842eb8d98bec6dfb_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210081003 - Disclosure - Acquisitions and Other Transactions", "role": "http://www.viatris.com/role/AcquisitionsandOtherTransactions", "shortName": "Acquisitions and Other Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210131004 - Disclosure - Revenue Recognition and Accounts Receivable", "role": "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivable", "shortName": "Revenue Recognition and Accounts Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210211005 - Disclosure - Balance Sheet Components", "role": "http://www.viatris.com/role/BalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210331006 - Disclosure - Leases", "role": "http://www.viatris.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210381007 - Disclosure - Equity Method Investments", "role": "http://www.viatris.com/role/EquityMethodInvestments", "shortName": "Equity Method Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210521009 - Disclosure - Financial Instruments and Risk Management", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagement", "shortName": "Financial Instruments and Risk Management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210771011 - Disclosure - Comprehensive Earnings", "role": "http://www.viatris.com/role/ComprehensiveEarnings", "shortName": "Comprehensive Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "000020008 - Document - Audit Information", "role": "http://www.viatris.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210811012 - Disclosure - Income Taxes", "role": "http://www.viatris.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210881013 - Disclosure - Share-Based Incentive Plan", "role": "http://www.viatris.com/role/ShareBasedIncentivePlan", "shortName": "Share-Based Incentive Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210941014 - Disclosure - Employee Benefit Plans", "role": "http://www.viatris.com/role/EmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211071015 - Disclosure - Segment Information", "role": "http://www.viatris.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211141017 - Disclosure - Restructuring", "role": "http://www.viatris.com/role/Restructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211221020 - Disclosure - Valuation and Qualifying Accounts", "role": "http://www.viatris.com/role/ValuationandQualifyingAccounts", "shortName": "Valuation and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "220042001 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230053001 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230093002 - Disclosure - Acquisitions and Other Transactions (Tables)", "role": "http://www.viatris.com/role/AcquisitionsandOtherTransactionsTables", "shortName": "Acquisitions and Other Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230143003 - Disclosure - Revenue Recognition and Accounts Receivable (Tables)", "role": "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableTables", "shortName": "Revenue Recognition and Accounts Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "000030009 - Document - Audit Information", "role": "http://www.viatris.com/role/AuditInformation_1", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "vtrs:ScheduleofCashCashEquivalentsandRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230223004 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.viatris.com/role/BalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "vtrs:ScheduleofCashCashEquivalentsandRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230343005 - Disclosure - Leases (Tables)", "role": "http://www.viatris.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230393006 - Disclosure - Equity Method Investments (Tables)", "role": "http://www.viatris.com/role/EquityMethodInvestmentsTables", "shortName": "Equity Method Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230453007 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230533008 - Disclosure - Financial Instruments and Risk Management (Tables)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables", "shortName": "Financial Instruments and Risk Management (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230673009 - Disclosure - Debt (Tables)", "role": "http://www.viatris.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230783010 - Disclosure - Comprehensive Earnings (Tables)", "role": "http://www.viatris.com/role/ComprehensiveEarningsTables", "shortName": "Comprehensive Earnings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230823011 - Disclosure - Income Taxes (Tables)", "role": "http://www.viatris.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230893012 - Disclosure - Share-Based Incentive Plan (Tables)", "role": "http://www.viatris.com/role/ShareBasedIncentivePlanTables", "shortName": "Share-Based Incentive Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230953013 - Disclosure - Employee Benefit Plans (Tables)", "role": "http://www.viatris.com/role/EmployeeBenefitPlansTables", "shortName": "Employee Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010002 - Statement - Consolidated Balance Sheets", "role": "http://www.viatris.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxAssetsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231083014 - Disclosure - Segment Information (Tables)", "role": "http://www.viatris.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231153015 - Disclosure - Restructuring (Tables)", "role": "http://www.viatris.com/role/RestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "vtrs:NumberOfMolecules", "reportCount": 1, "unique": true, "unitRef": "molecule", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240024002 - Disclosure - Nature of Operations (Narrative) (Details)", "role": "http://www.viatris.com/role/NatureofOperationsNarrativeDetails", "shortName": "Nature of Operations (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "vtrs:NumberOfMolecules", "reportCount": 1, "unique": true, "unitRef": "molecule", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240064003 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)", "role": "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240074004 - Disclosure - Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details)", "role": "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails", "shortName": "Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240104005 - Disclosure - Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details)", "role": "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "shortName": "Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ibd8cc0a590a946f6ada83bcfa5b58725_D20201113-20201113", "decimals": null, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i36d66b81144849148d1319e8bfed3c96_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240114006 - Disclosure - Acquisitions and Other Transactions (Purchase Price Allocations) (Details)", "role": "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "shortName": "Acquisitions and Other Transactions (Purchase Price Allocations) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i5b06121292274e728651da9462422d99_D20201231-20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i54dfb4c408114c26bed39da8f1d171f2_D20201113-20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240124007 - Disclosure - Acquisitions and Other Transactions (Unaudited Pro Forma Financial Results) (Details)", "role": "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails", "shortName": "Acquisitions and Other Transactions (Unaudited Pro Forma Financial Results) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i383cdb78da1740a096ade479d7d4de29_D20210101-20211231", "decimals": "2", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240154008 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details)", "role": "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "shortName": "Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i8d43c5886aae45d78bf51b4acef73ab6_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240164009 - Disclosure - Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details)", "role": "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails", "shortName": "Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i84058a24993540f0abbe391aeff14baa_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableFromSecuritization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240174010 - Disclosure - Revenue Recognition and Accounts Receivable (Narrative) (Details)", "role": "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableNarrativeDetails", "shortName": "Revenue Recognition and Accounts Receivable (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtrs:RevenuefromContractwithCustomerGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240184011 - Disclosure - Revenue Recognition and Accounts Receivable Variable Consideration (Details)", "role": "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails", "shortName": "Revenue Recognition and Accounts Receivable Variable Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtrs:RevenuefromContractwithCustomerGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240194012 - Disclosure - Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details)", "role": "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "shortName": "Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i8023e485af7e4af6b209e877aaef3977_D20210101-20211231", "decimals": "2", "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i36d66b81144849148d1319e8bfed3c96_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240204013 - Disclosure - Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details)", "role": "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails", "shortName": "Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i25df0d0412f4491d87734041970219e9_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "vtrs:AccountsReceivableSalesProvisionsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CapitalizedComputerSoftwareNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240234014 - Disclosure - Balance Sheet Components (Narrative) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "shortName": "Balance Sheet Components (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CapitalizedComputerSoftwareNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240244015 - Disclosure - Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsBalanceSheetComponentsCashandCashEquivalentsDetails", "shortName": "Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vtrs:ScheduleofCashCashEquivalentsandRestrictedCashTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "iac503b6d629d4bafb262ea6ec0b8a25e_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240254016 - Disclosure - Balance Sheet Components (Accounts receivable, net) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "shortName": "Balance Sheet Components (Accounts receivable, net) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240264017 - Disclosure - Balance Sheet Components (Inventories) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails", "shortName": "Balance Sheet Components (Inventories) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240274018 - Disclosure - Balance Sheet Components (Prepaids and other current assets) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails", "shortName": "Balance Sheet Components (Prepaids and other current assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240284019 - Disclosure - Balance Sheet Components (Property, Plant and Equipment) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails", "shortName": "Balance Sheet Components (Property, Plant and Equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030004 - Statement - Consolidated Statements of Operations", "role": "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240294020 - Disclosure - Balance Sheet Components (Other Assets) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "shortName": "Balance Sheet Components (Other Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "lang": "en-US", "name": "vtrs:Otherlongtermassets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240304021 - Disclosure - Balance Sheet Components (Trade Accounts Payable) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsTradeAccountsPayableDetails", "shortName": "Balance Sheet Components (Trade Accounts Payable) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherReceivablesNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240314022 - Disclosure - Balance Sheet Components (Other Current Liabilities) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "shortName": "Balance Sheet Components (Other Current Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240324023 - Disclosure - Balance Sheet Components (Other noncurrent liabilities) (Details)", "role": "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails", "shortName": "Balance Sheet Components (Other noncurrent liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240354024 - Disclosure - Leases (Narrative) (Details)", "role": "http://www.viatris.com/role/LeasesNarrativeDetails", "shortName": "Leases (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "lang": "en-US", "name": "vtrs:LesseeOperatingLeaseLeaseNotyetCommencedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240364025 - Disclosure - Leases (Lease Information) (Details)", "role": "http://www.viatris.com/role/LeasesLeaseInformationDetails", "shortName": "Leases (Lease Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240374026 - Disclosure - Leases (Lease Maturities) (Details)", "role": "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails", "shortName": "Leases (Lease Maturities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtrs:EquityMethodInvestmentsNetGainLossFromImpairmentandReductionInObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240404027 - Disclosure - Equity Method Investments (Narrative) (Details)", "role": "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails", "shortName": "Equity Method Investments (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vtrs:EquityMethodInvestmentsNetGainLossFromImpairmentandReductionInObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240414028 - Disclosure - Equity Method Investments (Balance Sheet) (Details)", "role": "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails", "shortName": "Equity Method Investments (Balance Sheet) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240424029 - Disclosure - Equity Method Investments (Net Assets) (Details)", "role": "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails", "shortName": "Equity Method Investments (Net Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i0853510f8095410c8cab4556a87f5fab_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040005 - Statement - Consolidated Statements of Comprehensive Earnings", "role": "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "shortName": "Consolidated Statements of Comprehensive Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240434030 - Disclosure - Equity Method Investments (Income Statement) (Details)", "role": "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails", "shortName": "Equity Method Investments (Income Statement) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia0185425b6174d78bfd3fbdefaaaea64_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240464031 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)", "role": "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9d3ab4b3183547369e21bc16353ca096_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i36d66b81144849148d1319e8bfed3c96_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240474032 - Disclosure - Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details)", "role": "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails", "shortName": "Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ifebd4eefd44247d191bd47ca2474ecda_D20190101-20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240484033 - Disclosure - Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details)", "role": "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240494034 - Disclosure - Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details)", "role": "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "shortName": "Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vtrs:ProductRightsAndLicensesByTherapeuticCategoryTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i6c77a702a1dc4bd4b4d96321e085c678_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240504035 - Disclosure - Goodwill and Other Intangible Assets (Amortization Expense) (Details)", "role": "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails", "shortName": "Goodwill and Other Intangible Assets (Amortization Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240514036 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details)", "role": "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsFutureamortizationexpenseDetails", "shortName": "Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240544037 - Disclosure - Financial Instruments and Risk Management (Narrative) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "shortName": "Financial Instruments and Risk Management (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240554038 - Disclosure - Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "shortName": "Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i2274eaab76e54e488ce05bb95778a8cd_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240564039 - Disclosure - Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "shortName": "Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i7e4405916ad540b9a7f953c2af935d2a_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "if8ec92ba24d848d697ba737aeed13c05_I20181231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050006 - Statement - Consolidated Statements of Equity", "role": "http://www.viatris.com/role/ConsolidatedStatementsofEquity", "shortName": "Consolidated Statements of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i4c63b953f9ab4ca380c2a6718f3499d2_I20181231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240574040 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "shortName": "Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i80c54ac8020646d2ab7569f426de2da7_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ib8d0d63150a443a9a2d4e20b655c9e2f_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240584041 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "shortName": "Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240594042 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "shortName": "Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i5eac979dacba469ba19bc637404defc4_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240604043 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "shortName": "Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240614044 - Disclosure - Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240624045 - Disclosure - Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "shortName": "Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i36d66b81144849148d1319e8bfed3c96_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240634046 - Disclosure - Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails", "shortName": "Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "vtrs:BusinessCombinationContingentConsiderationLiabilityFairValueGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240644047 - Disclosure - Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails", "shortName": "Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240654048 - Disclosure - Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details)", "role": "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails", "shortName": "Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240684049 - Disclosure - Debt (Short-term borrowings) (Details)", "role": "http://www.viatris.com/role/DebtShorttermborrowingsDetails", "shortName": "Debt (Short-term borrowings) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShortTermDebtTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i6348c0871c354006bbb77663df6a8f55_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070007 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240694050 - Disclosure - Debt Debt (Receivables Facility and Commercial Paper Program) (Details)", "role": "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "shortName": "Debt Debt (Receivables Facility and Commercial Paper Program) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "ia14591b7ed4e4ed5b2119d20257b6803_I20170606", "decimals": "-7", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240704051 - Disclosure - Debt (Summary of Long-term Debt) (Details)", "role": "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "shortName": "Debt (Summary of Long-term Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240714052 - Disclosure - Debt (Revolving Facilities and Term Facilities) (Details)", "role": "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "shortName": "Debt (Revolving Facilities and Term Facilities) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240724053 - Disclosure - Debt (Issuance of 2018 Senior Notes) (Details)", "role": "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "shortName": "Debt (Issuance of 2018 Senior Notes) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240734054 - Disclosure - Debt (Senior Notes) (Details)", "role": "http://www.viatris.com/role/DebtSeniorNotesDetails", "shortName": "Debt (Senior Notes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i3861691874974533b0f4beb0f744696d_I20200630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i73d9cbc916614385999dea1173262904_D20201113-20201113", "decimals": "-9", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240744055 - Disclosure - Debt (Fair Value) (Narrative) (Details)", "role": "http://www.viatris.com/role/DebtFairValueNarrativeDetails", "shortName": "Debt (Fair Value) (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i20a65018b503434b88c9fd17e0c1dd18_I20211231", "decimals": "-7", "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i74907a0e3a4245c29c61474d06752931_I20211029", "decimals": "3", "first": true, "lang": "en-US", "name": "vtrs:DebtInstrumentConversionOfUnregisteredNotesToRegisteredNotesAsAPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240754056 - Disclosure - Debt (Upjohn Senior Notes) (Details)", "role": "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "shortName": "Debt (Upjohn Senior Notes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i74907a0e3a4245c29c61474d06752931_I20211029", "decimals": "3", "first": true, "lang": "en-US", "name": "vtrs:DebtInstrumentConversionOfUnregisteredNotesToRegisteredNotesAsAPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240764057 - Disclosure - Debt (Minimum Repayments on Outstanding Borrowings) (Details)", "role": "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails", "shortName": "Debt (Minimum Repayments on Outstanding Borrowings) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240794058 - Disclosure - Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details)", "role": "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "shortName": "Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i9b5b6f53dc884bc28cf189d394d6db66_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240804059 - Disclosure - Comprehensive Earnings (Components of Other Comprehensive Loss) (Details)", "role": "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "shortName": "Comprehensive Earnings (Components of Other Comprehensive Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vtrs-20211231.htm", "contextRef": "i31f0c2ff371749c6802027ab5ab5bcf2_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 243, "tag": { "country_CH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SWITZERLAND", "terseLabel": "SWITZERLAND" } } }, "localname": "CH", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails" ], "xbrltype": "domainItemType" }, "country_FR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FRANCE", "terseLabel": "France" } } }, "localname": "FR", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails", "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails" ], "xbrltype": "domainItemType" }, "country_GI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GIBRALTAR", "terseLabel": "GIBRALTAR" } } }, "localname": "GI", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "IRELAND" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "country_IN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INDIA", "terseLabel": "India" } } }, "localname": "IN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails" ], "xbrltype": "domainItemType" }, "country_LU": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LUXEMBOURG", "terseLabel": "LUXEMBOURG" } } }, "localname": "LU", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "country_PR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PUERTO RICO", "terseLabel": "PUERTO RICO" } } }, "localname": "PR", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "country_SG": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SINGAPORE", "terseLabel": "SINGAPORE" } } }, "localname": "SG", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails", "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/AuditInformation_1" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "localname": "AuditorLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r979" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r974" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r973" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r973" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r973" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r987" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r973" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r973" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r973" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r973" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r1013" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r972" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r975" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viatris.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r183", "r408", "r413", "r421", "r727", "r728", "r734", "r735", "r840", "r967", "r990", "r1001", "r1010", "r1011" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails", "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r183", "r408", "r413", "r421", "r727", "r728", "r734", "r735", "r840", "r967", "r990", "r1001", "r1010", "r1011" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails", "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r183", "r245", "r258", "r259", "r260", "r261", "r263", "r265", "r269", "r408", "r409", "r410", "r411", "r412", "r413", "r415", "r416", "r418", "r420", "r421", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r183", "r245", "r258", "r259", "r260", "r261", "r263", "r265", "r269", "r408", "r409", "r410", "r411", "r412", "r413", "r415", "r416", "r418", "r420", "r421", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r85", "r87", "r180", "r181", "r427", "r462", "r1012" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r0", "r196", "r201", "r207", "r318", "r635", "r636", "r637", "r678", "r679", "r778", "r779", "r780", "r781", "r1014" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r0", "r196", "r201", "r207", "r318", "r635", "r636", "r637", "r678", "r679", "r778", "r779", "r780", "r781", "r1014" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r0", "r196", "r201", "r207", "r318", "r635", "r636", "r637", "r678", "r679", "r778", "r779", "r780", "r781", "r1014" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r276", "r491", "r495", "r940" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r426", "r461", "r595", "r601", "r852", "r853", "r854", "r855", "r856", "r857", "r877", "r937", "r941", "r968", "r969" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/LeasesLeaseInformationDetails", "http://www.viatris.com/role/LeasesNarrativeDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r426", "r461", "r595", "r601", "r852", "r853", "r854", "r855", "r856", "r857", "r877", "r937", "r941", "r968", "r969" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/LeasesLeaseInformationDetails", "http://www.viatris.com/role/LeasesNarrativeDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r276", "r491", "r495", "r940" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ParentCompanyMember": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "The registrant that controls, directly or indirectly, another entity (or entities). The usual condition for control is ownership of a majority (over 50%) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.", "label": "Parent Company [Member]", "terseLabel": "Mylan", "verboseLabel": "Mylan N.V." } } }, "localname": "ParentCompanyMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r272", "r491", "r493", "r880", "r936", "r938" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r272", "r491", "r493", "r880", "r936", "r938" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r426", "r461", "r532", "r595", "r601", "r852", "r853", "r854", "r855", "r856", "r857", "r877", "r937", "r941", "r968", "r969" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/LeasesLeaseInformationDetails", "http://www.viatris.com/role/LeasesNarrativeDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r426", "r461", "r532", "r595", "r601", "r852", "r853", "r854", "r855", "r856", "r857", "r877", "r937", "r941", "r968", "r969" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/LeasesLeaseInformationDetails", "http://www.viatris.com/role/LeasesNarrativeDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r86", "r87", "r180", "r181", "r427", "r462" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r202", "r596", "r988" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]", "terseLabel": "Scenario, Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r202", "r207", "r596" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r191", "r1000" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule II - Valuation and Qualifying Accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/ValuationandQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r273", "r274", "r491", "r494", "r939", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r989", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails", "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r273", "r274", "r491", "r494", "r939", "r954", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r989", "r991" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails", "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r202", "r207", "r393", "r596", "r845" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_SubsidiariesMember": { "auth_ref": [ "r561", "r837", "r838", "r839" ], "lang": { "en-us": { "role": { "documentation": "Entity owned or controlled by another entity.", "label": "Subsidiaries [Member]", "terseLabel": "Mylan Laboratories Limited" } } }, "localname": "SubsidiariesMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2021-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r184", "r185", "r186", "r189", "r190", "r1000" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "verboseLabel": "Revenue Recognition And Accounts Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.", "label": "Legal Entity of Counterparty, Type [Axis]", "terseLabel": "Legal Entity of Counterparty, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current [Abstract]", "terseLabel": "Accounts Payable, Current [Abstract]" } } }, "localname": "AccountsPayableCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": { "auth_ref": [ "r895", "r929" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsTradeAccountsPayableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableTradeCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred and payable classified as other.", "label": "Accounts Payable, Other", "terseLabel": "Other payables" } } }, "localname": "AccountsPayableOtherCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTradeAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r14", "r62" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsTradeAccountsPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "totalLabel": "Accounts payable", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTradeAccountsPayableDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": { "auth_ref": [ "r895", "r929" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsTradeAccountsPayableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableTradeCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable, Trade", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableTradeCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTradeAccountsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableFromSecuritization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount owed to the reporting entity by counterparties in securitized loan transactions.", "label": "Accounts Receivable from Securitization", "terseLabel": "Securitized accounts receivable" } } }, "localname": "AccountsReceivableFromSecuritization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r955" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r42", "r278", "r279" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "totalLabel": "Accounts receivable, net", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r371", "r372", "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Accretion" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r32", "r889", "r919" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r99", "r106", "r115", "r116", "r117", "r733" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Pension Plan Items" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r60", "r366" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "verboseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "auth_ref": [ "r94", "r106", "r732" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "terseLabel": "Gains and Losses on Derivatives in Cash Flow Hedging Relationships" } } }, "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r95", "r96", "r97", "r106", "r115", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Gains and Losses on Marketable Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax", "periodEndLabel": "Net unrealized gains on marketable securities, net of tax, end of period", "periodStartLabel": "Net unrealized gains on marketable securities, net of tax, beginning of period", "terseLabel": "Net unrealized gain on marketable securities, net of tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax": { "auth_ref": [ "r94", "r103", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax", "periodEndLabel": "Net unrecognized gains (losses) on derivatives, net of tax, end of period", "periodStartLabel": "Net unrecognized gains (losses) on derivatives, net of tax, beginning of period" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r100", "r106", "r553" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedPeriodEndLabel": "Net unrealized gains on marketable securities, net of tax, end of period", "negatedPeriodStartLabel": "Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period", "negatedTerseLabel": "Net unrecognized (loss) gain and prior service cost related to defined benefit plans, net of tax", "terseLabel": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r91", "r103", "r105", "r106", "r794" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "periodEndLabel": "Foreign currency translation adjustment, end of period", "periodStartLabel": "Foreign currency translation adjustment, beginning of period", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r45", "r103", "r105", "r106", "r924", "r946", "r947" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Accumulated other comprehensive loss, net of tax, end of period", "periodStartLabel": "Accumulated other comprehensive loss, net of tax, beginning of period", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r115", "r116", "r806", "r807", "r808", "r809", "r810", "r812" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r102", "r106", "r115", "r116", "r117", "r193", "r194", "r195", "r733", "r942", "r943", "r1015" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r92", "r106", "r115", "r116", "r117", "r733", "r807", "r808", "r809", "r810", "r812" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Acquired intangible assets, weighted average useful life, in years" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r43", "r638", "r843" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r193", "r194", "r195", "r635", "r636", "r637", "r780" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r158", "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Total intangible asset amortization expense (including impairment charges)" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net", "terseLabel": "Taxes related to the net share settlement of equity awards" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r603", "r605", "r640", "r641" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r184", "r185", "r186", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r158", "r348", "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedTerseLabel": "Intangible asset amortization expense", "terseLabel": "Intangible asset amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Anti-dilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "terseLabel": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r299", "r533" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r174", "r253", "r260", "r267", "r315", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r417", "r419", "r421", "r422", "r727", "r734", "r800", "r841", "r843", "r887", "r918" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r10", "r80", "r174", "r315", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r417", "r419", "r421", "r422", "r727", "r734", "r800", "r841", "r843" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "terseLabel": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r783" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets at recurring fair value measurement" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r21", "r22", "r23", "r24", "r25", "r26", "r27", "r28", "r174", "r315", "r408", "r409", "r410", "r412", "r413", "r414", "r415", "r417", "r419", "r421", "r422", "r727", "r734", "r800", "r841" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "terseLabel": "Noncurrent assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AustralianTaxationOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Australia.", "label": "Australian Taxation Office [Member]", "terseLabel": "Australian Taxation Office" } } }, "localname": "AustralianTaxationOfficeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r292" ], "calculation": { "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r293" ], "calculation": { "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r290", "r324" ], "calculation": { "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r294", "r297", "r908" ], "calculation": { "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "verboseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r294", "r296", "r907" ], "calculation": { "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "verboseLabel": "Mature within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r286", "r291", "r324", "r894" ], "calculation": { "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value", "totalLabel": "Available-for-sale securities, debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r288", "r324" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Available-for-sale fixed income securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r606", "r633" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/LitigationNarrativeDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r749", "r755" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/LitigationNarrativeDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "verboseLabel": "Buildings and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r591", "r597" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/DebtFairValueNarrativeDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtTables", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r591", "r597", "r701", "r702" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/DebtFairValueNarrativeDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtTables", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Acquisition, Date of Acquisition [Abstract]", "terseLabel": "Business Acquisition, Date of Acquisition [Abstract]" } } }, "localname": "BusinessAcquisitionDateOfAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r716" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r698" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r699", "r700" ], "lang": { "en-us": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "auth_ref": [ "r699", "r700" ], "lang": { "en-us": { "role": { "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r699", "r700" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Business Acquisition, Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r699", "r700" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net earnings" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r699", "r700" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Total revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r697" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r711", "r712", "r714" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Acquisition purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r711", "r712" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r710", "r713", "r717" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Contingent consideration liability", "verboseLabel": "Purchase consideration, contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r787" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Rate used to discount net cash inflows to present values" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions and Other Transactions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "auth_ref": [ "r706" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "terseLabel": "Net assets acquired (net of $415.8 of cash acquired)" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": { "auth_ref": [ "r706" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment": { "auth_ref": [ "r706" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to property, plant, and equipment acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]", "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r704" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "terseLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r704" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "terseLabel": "Current assets (excluding inventories and net of cash acquired)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r704" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "terseLabel": "Current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r704" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Deferred income tax benefit" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r704" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialAssets": { "auth_ref": [ "r703", "r704", "r801" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of financial assets (as defined) recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Assets", "terseLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r704" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Identified intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r703", "r704" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "verboseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r703", "r704" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r703", "r704" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities": { "auth_ref": [ "r704" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r704" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "terseLabel": "Long-term debt, including current portion" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r704" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r703", "r704" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Contingent Consideration Policy" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareNet": { "auth_ref": [ "r970" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.", "label": "Capitalized Computer Software, Net", "terseLabel": "Capitalized Computer Software, Net" } } }, "localname": "CapitalizedComputerSoftwareNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r135" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash Acquired from Acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r56", "r160" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsBalanceSheetComponentsCashandCashEquivalentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsBalanceSheetComponentsCashandCashEquivalentsDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r20", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents Policy" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r151", "r160", "r166" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsBalanceSheetComponentsCashandCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash \u2014 end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash \u2014 beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsBalanceSheetComponentsCashandCashEquivalentsDetails", "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r151", "r804" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r776" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r745" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Mem", "verboseLabel": "Cash flow hedging relationships" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "domainItemType" }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "terseLabel": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan" } } }, "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r172", "r174", "r210", "r214", "r215", "r216", "r218", "r225", "r226", "r227", "r315", "r408", "r413", "r414", "r415", "r421", "r422", "r459", "r460", "r463", "r464", "r800", "r980" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/ConsolidatedStatementsofEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r720", "r721", "r723" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative and Licensing Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtShorttermborrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock shares reserved for issuance to employees" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends paid per share" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquityParenthetical", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common Stock, Dividends, Per Share, Declared" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r193", "r194", "r780" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Marketable securities" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.viatris.com/role/ConsolidatedStatementsofEquity", "http://www.viatris.com/role/ConsolidatedStatementsofEquityParenthetical", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Ordinary shares, par value, in USD per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.viatris.com/role/Cover" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Ordinary shares, number of shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r41", "r843" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued and outstanding: 1,209,507,463 and 1,206,895,644, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r111", "r113", "r124", "r726", "r738", "r900", "r932" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive earnings" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r123", "r134", "r899", "r931" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Comprehensive Earnings" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarnings" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r235", "r236", "r276", "r797", "r798", "r955" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r235", "r236", "r276", "r797", "r798", "r949", "r955" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r235", "r236", "r276", "r797", "r798", "r949", "r955" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r231", "r913" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk Policy" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r235", "r236", "r276", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r235", "r236", "r276", "r797", "r798", "r955" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidatedEntityExcludingVieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated entity, excluding variable interest entity (VIE) for which reporting entity is or is not primary beneficiary.", "label": "Consolidated Entity, Excluding VIE [Member]", "terseLabel": "Consolidated Entity" } } }, "localname": "ConsolidatedEntityExcludingVieMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r168", "r729" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation Policy" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualRightsMember": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).", "label": "Contractual Rights [Member]", "terseLabel": "Contractual Rights" } } }, "localname": "ContractualRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r459", "r460", "r463" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r258", "r259", "r260", "r261", "r263", "r269", "r271" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate (Other)" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r128", "r880" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r799" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r175", "r674", "r682" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "U.S. Federal Current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r175", "r674" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Non-U.S. Current" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r175", "r674", "r682" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "U.S. State Current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r234", "r276" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r65" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Debt, Current" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r171", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r440", "r447", "r448", "r450", "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r30", "r32", "r33", "r173", "r183", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r454", "r455", "r456", "r457", "r819", "r888", "r891", "r915" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtShorttermborrowingsDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r33", "r451", "r891", "r915" ], "calculation": { "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term Debt, Gross", "totalLabel": "Total" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentCovenantDescription": { "auth_ref": [ "r33", "r911" ], "lang": { "en-us": { "role": { "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.", "label": "Debt Instrument, Covenant Description", "terseLabel": "Debt Instrument, Covenant Description" } } }, "localname": "DebtInstrumentCovenantDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r423", "r454", "r455", "r817", "r819", "r820" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt Instrument, Face Amount", "verboseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r438", "r454", "r455", "r796" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of long-term debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r69", "r453", "r817", "r819" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate at period end" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r69", "r424" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtFairValueNarrativeDetails", "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtTables", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r70", "r173", "r183", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r454", "r455", "r456", "r457", "r819" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtShorttermborrowingsDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r70", "r173", "r183", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r454", "r455", "r456", "r457", "r467", "r468", "r469", "r470", "r816", "r817", "r819", "r820", "r912" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtFairValueNarrativeDetails", "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtTables", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt Instrument, Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Short-Term Borrowings" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Available-for-sale fixed income investments", "verboseLabel": "Debt securities" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredBonusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An contractual arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a bonus, as defined in the agreement, of the entity or portion thereof. Employer contributions may be discretionary or may be based on a fixed formula related to individual, group and entity-wide performance goals, compensation, or other factors. It is a form of incentive compensation to employees in addition to their regular salary and profit sharing.", "label": "Deferred Bonus [Member]", "terseLabel": "Deferred Bonus" } } }, "localname": "DeferredBonusMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred compensation related to other postretirement benefit arrangements that are not equivalent to a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Other Postretirement Benefits, Individual Contracts, Type of Deferred Compensation [Axis]", "terseLabel": "Other Postretirement Benefits, Individual Contracts, Type of Deferred Compensation [Axis]" } } }, "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r175", "r675", "r682" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "U.S. Federal Deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r175", "r675", "r682" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Non-U.S. Deferred" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r647", "r648" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "verboseLabel": "Deferred income tax benefit" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r158", "r175", "r675", "r682", "r683", "r684" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income tax expense (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r37", "r38", "r665", "r890", "r914" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r647", "r648" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "verboseLabel": "Deferred income tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r175", "r675", "r682" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "U.S. State Deferred" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r666" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets, gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r672", "r673" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r668" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r672", "r673" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r671", "r672", "r673" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit and loss carry-forwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": { "auth_ref": [ "r671", "r672", "r673" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign", "terseLabel": "Expected foreign tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpense": { "auth_ref": [ "r672", "r673" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.", "label": "Deferred Tax Assets, Tax Deferred Expense", "terseLabel": "Foreign deductible attributes" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "auth_ref": [ "r672", "r673" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "terseLabel": "Employee benefits" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r672", "r673" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Accounts receivable allowances" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r672", "r673" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Litigation reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r667" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: Valuation allowance", "terseLabel": "Valuation allowance, amount" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r648", "r668" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r672", "r673" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "terseLabel": "Intangible assets and goodwill" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r672", "r673" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r672", "r673" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r693" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries.", "label": "Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Deferred tax liability not recognized, amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries" } } }, "localname": "DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": { "auth_ref": [ "r35", "r505", "r506", "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.", "label": "Liability, Defined Benefit Pension Plan, Noncurrent", "terseLabel": "Liability, Defined Benefit Pension Plan, Noncurrent" } } }, "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "auth_ref": [ "r100", "r106", "r553" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "totalLabel": "Total" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "auth_ref": [ "r106", "r553" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "negatedTerseLabel": "Unrecognized actuarial (gain) loss" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r106", "r553" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "terseLabel": "Unrecognized prior service cost (credit)" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r522", "r584" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "terseLabel": "Actuarial (gains) losses" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r507", "r548", "r578", "r584", "r585" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "terseLabel": "Amortization of actuarial gain/(loss)" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r101", "r103", "r552" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax", "terseLabel": "Unrecognized prior service credit (cost)" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r28", "r505", "r506", "r530", "r584", "r886", "r917" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails": { "order": 1.0, "parentTag": "vtrs_Netaccruedbenefitcosts", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Noncurrent assets" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsTransferredToFromPlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from assets transferred into (from) plan.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan", "verboseLabel": "Transferred assets" } } }, "localname": "DefinedBenefitPlanAssetsTransferredToFromPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r557", "r583" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r509" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Projected benefit obligation, end of year", "periodStartLabel": "Projected benefit obligation, beginning of year" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r516", "r588" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets": { "auth_ref": [ "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in plan assets of defined benefit plan from business combination.", "label": "Defined Benefit Plan, Plan Assets, Business Combination", "terseLabel": "Defined Benefit Plan, Plan Assets, Business Combination" } } }, "localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r561", "r584" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Projected benefit obligation, beginning of year" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in Plan Assets" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r524", "r533", "r535", "r582", "r584", "r585" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Company contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanCurtailments": { "auth_ref": [ "r511" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment", "terseLabel": "Plan curtailment, settlement and termination" } } }, "localname": "DefinedBenefitPlanCurtailments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1": { "auth_ref": [ "r560" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in accumulated postretirement benefit obligation from one-percentage-point decrease in assumed health care cost trend rate.", "label": "Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation", "negatedTerseLabel": "Decrease in the benefit obligation" } } }, "localname": "DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEffectofOnePercentagePointIncreaseorDecreaseinHealthCareCostTrendRatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1": { "auth_ref": [ "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in service and interest cost components of net periodic postretirement benefit cost from one-percentage-point decrease in assumed health care cost trend rate.", "label": "Defined Benefit Plan, Effect of One Percentage Point Decrease on Service and Interest Cost Components", "negatedTerseLabel": "Decrease in the aggregate of service and interest cost components of annual expense" } } }, "localname": "DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEffectofOnePercentagePointIncreaseorDecreaseinHealthCareCostTrendRatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation": { "auth_ref": [ "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in accumulated postretirement benefit obligation from one-percentage-point increase in assumed health care cost trend rate.", "label": "Defined Benefit Plan, Effect of One Percentage Point Increase on Accumulated Postretirement Benefit Obligation", "terseLabel": "Increase in the benefit obligation" } } }, "localname": "DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEffectofOnePercentagePointIncreaseorDecreaseinHealthCareCostTrendRatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents": { "auth_ref": [ "r560" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in service and interest cost components of net periodic postretirement benefit cost from one-percentage-point increase in assumed health care cost trend rate.", "label": "Defined Benefit Plan, Effect of One Percentage Point Increase on Service and Interest Cost Components", "terseLabel": "Increase in the aggregate of service and interest cost components of annual expense" } } }, "localname": "DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEffectofOnePercentagePointIncreaseorDecreaseinHealthCareCostTrendRatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear": { "auth_ref": [ "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount included in accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan expected to be recognized in net periodic benefit (cost) credit for fiscal year following most recent annual statement of financial position.", "label": "Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year", "terseLabel": "Accumulated other comprehensive income expected to be recognized as net periodic benefit costs" } } }, "localname": "DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear": { "auth_ref": [ "r567" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount included in accumulated other comprehensive (income) loss for prior service cost (credit) expected to be recognized in net periodic benefit cost (credit) for fiscal year following most recent annual statement of financial position.", "label": "Defined Benefit Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year", "terseLabel": "Future unrecognized actuarial losses" } } }, "localname": "DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r542" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails": { "order": 6.0, "parentTag": "vtrs_ExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "Thereafter" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r542" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails": { "order": 1.0, "parentTag": "vtrs_ExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2019" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r542" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails": { "order": 5.0, "parentTag": "vtrs_ExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r542" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails": { "order": 4.0, "parentTag": "vtrs_ExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2022" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r542" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails": { "order": 3.0, "parentTag": "vtrs_ExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2021" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r542" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails": { "order": 2.0, "parentTag": "vtrs_ExpectedFutureBenefitPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2020" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r507", "r547", "r577", "r584", "r585" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedTerseLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r521", "r533", "r535", "r536", "r584" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Fair value of plan assets, end of year", "periodStartLabel": "Fair value of plan assets, beginning of year", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Impact of foreign currency translation" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r505", "r530", "r584" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "terseLabel": "Funded status of plans" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "terseLabel": "Defined benefit plan, ultimate health care cost trend rate" } } }, "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r507", "r512", "r546", "r576", "r584", "r585" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r544", "r574", "r584", "r585" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanOtherCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of defined benefit plan cost (credit), classified as other.", "label": "Defined Benefit Plan, Other Cost (Credit)", "terseLabel": "Other" } } }, "localname": "DefinedBenefitPlanOtherCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "auth_ref": [ "r570", "r571", "r584" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "auth_ref": [ "r570" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "Projected benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r525" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Participant contributions" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r508", "r551", "r581" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedLabel": "Recognized net actuarial losses" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r510", "r545", "r575", "r584", "r585" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r511" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "negatedTerseLabel": "Plan settlements and terminations" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r529" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedTerseLabel": "Plan settlements" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "terseLabel": "Defined benefit plan, ultimate health care cost trend rate, projected" } } }, "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r568", "r569", "r572", "r573", "r584" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEffectofOnePercentagePointIncreaseorDecreaseinHealthCareCostTrendRatesDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails", "http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEffectofOnePercentagePointIncreaseorDecreaseinHealthCareCostTrendRatesDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails", "http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r589" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Total employer contributions" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Defined contribution plan, maximum annual contribution per employee, percent" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r158", "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r158", "r248" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetLiabilityNetMeasurementInput": { "auth_ref": [ "r787" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure net derivative asset (liability).", "label": "Derivative Asset (Liability) Net, Measurement Input", "terseLabel": "Derivative Asset (Liability) Net, Measurement Input" } } }, "localname": "DerivativeAssetLiabilityNetMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r740", "r741", "r743" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "Notional amount of derivative" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r83", "r84", "r87", "r796" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Interest rate swap derivative assets" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract Type [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r82", "r87", "r88", "r753", "r859" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Fair value of financial instruments" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r82", "r87", "r88", "r753", "r859" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Liability derivatives, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r751" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Amount of loss recognized in earnings on derivatives", "verboseLabel": "Derivative, Gain (Loss) on Derivative, Net" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r87", "r750", "r754", "r762", "r767" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r747", "r750", "r762" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r747", "r750", "r762", "r767", "r768", "r772", "r775" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r759", "r766" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "terseLabel": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "verboseLabel": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": { "auth_ref": [ "r760", "r774" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.", "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net", "terseLabel": "Amount of Gain Excluded from the Assessment of Hedge Effectiveness" } } }, "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r761", "r763" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivative Financial Instruments Not Designated as Hedging Instruments:" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r739", "r742", "r743", "r747", "r748", "r756", "r762", "r769", "r771", "r775", "r777" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r182", "r739", "r742", "r747", "r748", "r770" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives Policy" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Intellectual Property" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r491", "r493", "r494", "r495", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Share-Based Incentive Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r591", "r597" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Cash dividends declared, $0.33 per common share" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Dividends Payable, Amount Per Share" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "(Loss) earnings per share attributable to Viatris Inc. shareholders" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r125", "r199", "r200", "r201", "r202", "r203", "r208", "r210", "r216", "r217", "r218", "r221", "r222", "r781", "r782", "r901", "r933" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in USD per share)", "verboseLabel": "Basic (loss) earnings per share attributable to Viatris Inc. shareholders" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r125", "r199", "r200", "r201", "r202", "r203", "r210", "r216", "r217", "r218", "r221", "r222", "r781", "r782", "r901", "r933" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in USD per share)", "verboseLabel": "Diluted (loss) earnings per share attributable to Viatris Inc. shareholders" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r219", "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Common Share Policy" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r804" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "verboseLabel": "Effect on cash of changes in exchange rates" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectOnFutureCashFlowsAmount": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The quantified amount of the future effect on cash flows.", "label": "Effect on Future Cash Flows, Amount", "terseLabel": "Effect on Future Cash Flows, Amount" } } }, "localname": "EffectOnFutureCashFlowsAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r177", "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Impact of changes in legislation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "verboseLabel": "U.S. rate differentials" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Impact of the Combination and Divestitures" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent", "terseLabel": "Uncertain tax positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "terseLabel": "State income taxes and credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent", "terseLabel": "Other Foreign Operations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Clean energy and research credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "auth_ref": [ "r650", "r686" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "terseLabel": "Tax settlements and resolution of certain tax positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee-related Liabilities, Current" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r632" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "verboseLabel": "Total unrecognized compensation expense, net of estimated forfeitures" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted-average period over which total unrecognized compensation expense expected to be recognized (years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]", "terseLabel": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r115", "r116", "r117", "r193", "r194", "r195", "r198", "r204", "r206", "r224", "r318", "r466", "r471", "r635", "r636", "r637", "r678", "r679", "r780", "r806", "r807", "r808", "r809", "r810", "r812", "r942", "r943", "r944", "r1015" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.viatris.com/role/ConsolidatedStatementsofEquity", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.", "label": "Equity Method Investment, Other than Temporary Impairment", "terseLabel": "Equity Method Investment, Other than Temporary Impairment" } } }, "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r57", "r254", "r311" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Investments in subsidiaries" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]", "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "auth_ref": [ "r793" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r23", "r31", "r306", "r916", "r951", "r952", "r953" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Total equity securities", "verboseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExchangeTradedFundsMember": { "auth_ref": [ "r533", "r790" ], "lang": { "en-us": { "role": { "documentation": "Investment that follows an index, commodity or basket of assets that trades similar to a stock on an exchange.", "label": "Exchange Traded Funds [Member]", "terseLabel": "Equity securities \u2014 exchange traded funds" } } }, "localname": "ExchangeTradedFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r783", "r784", "r785", "r791" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings": { "auth_ref": [ "r789" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset and liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings", "verboseLabel": "Fair value loss (gain)" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r788" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r783", "r791" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r438", "r454", "r455", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r584", "r784", "r849", "r850", "r851" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r790", "r791" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r744" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "verboseLabel": "Fair value hedging relationships" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r438", "r533", "r535", "r540", "r584", "r784", "r849" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r438", "r454", "r455", "r533", "r535", "r540", "r584", "r784", "r850" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r438", "r454", "r455", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r584", "r784", "r851" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r788" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r438", "r454", "r455", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r584", "r849", "r850", "r851" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r792", "r795" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial Instruments Policy" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r749", "r756", "r772" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "stringItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r175", "r649" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "Federal Income Tax Expense (Benefit), Continuing Operations", "totalLabel": "Income tax provision (benefit), U.S. Federal" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r299", "r300", "r307", "r308", "r309", "r319", "r320", "r321", "r322", "r323", "r326", "r327", "r328", "r329", "r449", "r465", "r777", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments And Risk Management" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Finite-lived intangible asset, estimated useful life, in years" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r356" ], "calculation": { "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "verboseLabel": "Finite-lived intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsFutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsFutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsFutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsFutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsFutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r349", "r352", "r356", "r360", "r881", "r882" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r356", "r882" ], "calculation": { "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Finite-lived intangible assets, original cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r349", "r355" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-Lived Intangible Assets [Member]", "terseLabel": "Finite-Lived Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r356", "r881" ], "calculation": { "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-lived intangible assets, net", "totalLabel": "Finite-lived intangible assets, net book value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Finite-Lived Intangible Assets, Period Increase (Decrease)" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixedIncomeSecuritiesMember": { "auth_ref": [ "r533", "r584" ], "lang": { "en-us": { "role": { "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.", "label": "Fixed Income Securities [Member]", "terseLabel": "Fixed income securities" } } }, "localname": "FixedIncomeSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign", "verboseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Foreign exchange derivative assets" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Foreign exchange derivative liabilities" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r814" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currencies Policy" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r87", "r533", "r765" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract", "verboseLabel": "Foreign currency borrowings and forward contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r175" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "Foreign Income Tax Expense (Benefit), Continuing Operations", "totalLabel": "Income tax provision (benefit), Non-U.S." } } }, "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r757" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "terseLabel": "Gain (Loss) on Fair Value Hedges Recognized in Earnings" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r392" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedLabel": "Litigation settlements and other contingencies, net", "terseLabel": "Litigation settlements & other contingencies" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r338", "r339", "r843", "r885" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, net, ending balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r345", "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets and Goodwill Policy" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r340", "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "periodEndLabel": "Goodwill, gross, ending balance", "periodStartLabel": "Goodwill, gross, beginning balance" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r340", "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedPeriodEndLabel": "Accumulated impairment losses, ending balance", "negatedPeriodStartLabel": "Accumulated impairment losses, beginning balance", "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]", "terseLabel": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillTransfers": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Transfers", "terseLabel": "Goodwill, Transfers" } } }, "localname": "GoodwillTransfers", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r342", "r343", "r696" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r127", "r174", "r253", "r259", "r263", "r266", "r269", "r315", "r408", "r409", "r410", "r413", "r414", "r415", "r417", "r419", "r421", "r422", "r800" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross loss", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r747", "r768" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r158", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of products rights and licenses intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r158", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "negatedLabel": "Intangible asset impairment charges", "terseLabel": "IPR&D intangible asset impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r363", "r370" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets Policy" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "verboseLabel": "In-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r176", "r685" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Earnings before income taxes and noncontrolling interest, United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r121", "r253", "r259", "r263", "r266", "r269", "r883", "r898", "r903", "r934" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Operating and non-operating expense", "totalLabel": "(Loss) earnings before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails", "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r176", "r685" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Earnings before income taxes and noncontrolling interest, foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]", "terseLabel": "Earnings (loss) before income taxes and noncontrolling interest:" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r122", "r158", "r250", "r311", "r897", "r930" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Loss from equity method investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows", "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r591", "r597" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r368", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails", "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r655", "r662", "r664", "r677" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails", "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r177", "r651", "r663", "r670", "r680", "r687", "r691", "r692", "r694" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationInterestExpense": { "auth_ref": [ "r652" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination, Interest Expense", "terseLabel": "Interest expense (income) related to uncertain tax positions" } } }, "localname": "IncomeTaxExaminationInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r652" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r178", "r205", "r206", "r251", "r649", "r681", "r689", "r935" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax related to items of other comprehensive (loss) earnings, derivatives", "verboseLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r114", "r645", "r646", "r663", "r664", "r669", "r676" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes Policy" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r154", "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r157" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Trade accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r157" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r157" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r157" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r157" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other operating assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r653" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Increase in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Amount of unrecognized deferred tax liability" } } }, "localname": "IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r211", "r212", "r213", "r218" ], "calculation": { "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r351", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r359" ], "calculation": { "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "In-process research and development" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r351", "r359" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Intangible assets, gross, excluding goodwill" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r347", "r354" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net book value, excluding goodwill" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsComponentsofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r119", "r247", "r815", "r818", "r902" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r766" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r148", "r153", "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r14", "r15", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r764" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swaps", "verboseLabel": "Interest rate swap derivatives" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS)" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r48", "r334" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFirmPurchaseCommitmentLoss": { "auth_ref": [ "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss recognized on firm purchase commitment for inventory.", "label": "Inventory, Firm Purchase Commitment, Loss", "terseLabel": "Inventory, Firm Purchase Commitment, Loss" } } }, "localname": "InventoryFirmPurchaseCommitmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r77", "r843" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory, Net [Abstract]" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r16", "r78", "r169", "r223", "r330", "r331", "r335", "r878" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories Policy" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r50", "r334" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRecallExpense": { "auth_ref": [ "r129" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.", "label": "Inventory Recall Expense", "terseLabel": "Inventory Recall Expense" } } }, "localname": "InventoryRecallExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r77", "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r49", "r334" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Maturities Of Available-for-Sale Debt Securities At Fair Value" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandAndLandImprovementsMember": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Real estate held and assets that are an addition or improvement to real estate held.", "label": "Land and Land Improvements [Member]", "terseLabel": "Land and improvements" } } }, "localname": "LandAndLandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of the other party participating in a financial transaction.", "label": "Legal Entity Type of Counterparty [Domain]", "terseLabel": "Legal Entity Type of Counterparty [Domain]" } } }, "localname": "LegalEntityTypeOfCounterpartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Litigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseInformationDetails", "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r829" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseInformationDetails", "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r828" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Term of operating leases not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r833" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r833" ], "calculation": { "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r833" ], "calculation": { "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r833" ], "calculation": { "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r833" ], "calculation": { "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r833" ], "calculation": { "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r833" ], "calculation": { "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r833" ], "calculation": { "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r833" ], "calculation": { "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r827" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Remaining lease terms" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r835" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lessee, Operating Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r66", "r174", "r261", "r315", "r408", "r409", "r410", "r413", "r414", "r415", "r417", "r419", "r421", "r422", "r728", "r734", "r735", "r800", "r841", "r842" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r46", "r174", "r315", "r800", "r843", "r893", "r926" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r68", "r174", "r315", "r408", "r409", "r410", "r413", "r414", "r415", "r417", "r419", "r421", "r422", "r728", "r734", "r735", "r800", "r841", "r842", "r843" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "terseLabel": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r783" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Total liabilities at recurring fair value measurement" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r17", "r18", "r19", "r33", "r34", "r174", "r315", "r408", "r409", "r410", "r413", "r414", "r415", "r417", "r419", "r421", "r422", "r728", "r734", "r735", "r800", "r841", "r842" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Noncurrent liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.", "label": "Liabilities, Other than Long-term Debt, Noncurrent", "terseLabel": "Liabilities, Other than Long-term Debt, Noncurrent" } } }, "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.", "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "terseLabel": "Liability for Uncertainty in Income Taxes, Noncurrent" } } }, "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r707" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Product rights and licenses" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r63", "r173" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r72", "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Estimated Litigation Liability" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveCurrent": { "auth_ref": [ "r72", "r392", "r401" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.", "label": "Estimated Litigation Liability, Current", "terseLabel": "Estimated Litigation Liability, Current" } } }, "localname": "LitigationReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Amount awarded to other party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r33", "r437", "r452", "r454", "r455", "r891", "r921" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r65" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt and other long-term obligations" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r183", "r406", "r442" ], "calculation": { "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r183", "r406", "r442" ], "calculation": { "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "verboseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r183", "r406", "r442" ], "calculation": { "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "verboseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r183", "r406", "r442" ], "calculation": { "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "verboseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r183", "r406", "r442" ], "calculation": { "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "verboseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r183", "r406", "r442" ], "calculation": { "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "verboseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtMinimumRepaymentsonOutstandingBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r70" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtFairValueNarrativeDetails", "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r70", "r407" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtFairValueNarrativeDetails", "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.", "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Long-term Debt, Weighted Average Interest Rate, at Point in Time" } } }, "localname": "LongtermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r392", "r393", "r394", "r396", "r397", "r398", "r400", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r392", "r393", "r394", "r396", "r397", "r398", "r400", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss contingency accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r392", "r395", "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Damages awarded" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesPaidValue": { "auth_ref": [ "r392", "r395", "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of damages paid to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Paid, Value", "terseLabel": "Loss contingency accrual" } } }, "localname": "LossContingencyDamagesPaidValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r392", "r393", "r394", "r396", "r397", "r398", "r400", "r403", "r404" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of another entity's patents that the entity has allegedly infringed.", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "terseLabel": "Loss Contingency, Patents Allegedly Infringed, Number" } } }, "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPatentsFoundNotInfringedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of another entity's patents that the entity was found not to have infringed.", "label": "Loss Contingency, Patents Found Not Infringed, Number", "terseLabel": "Loss Contingency, Patents Found Not Infringed, Number" } } }, "localname": "LossContingencyPatentsFoundNotInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "verboseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r909" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities Policy" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputControlPremiumMember": { "auth_ref": [ "r786" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using amount above fair value that investor seeking to acquire control of entity will pay.", "label": "Measurement Input, Control Premium [Member]", "terseLabel": "Measurement Input, Control Premium [Member]" } } }, "localname": "MeasurementInputControlPremiumMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r786" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate [Member]" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputEbitdaMultipleMember": { "auth_ref": [ "r786" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using earnings before interest, tax, depreciation and amortization (EBITDA) multiple.", "label": "Measurement Input, EBITDA Multiple [Member]", "terseLabel": "Measurement Input, EBITDA Multiple [Member]" } } }, "localname": "MeasurementInputEbitdaMultipleMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputLongTermRevenueGrowthRateMember": { "auth_ref": [ "r786" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using compounded annualized rate of long-term growth in revenue.", "label": "Measurement Input, Long-term Revenue Growth Rate [Member]", "terseLabel": "Measurement Input, Long-term Revenue Growth Rate [Member]" } } }, "localname": "MeasurementInputLongTermRevenueGrowthRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r786" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Medium-term Notes" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgageBackedSecuritiesMember": { "auth_ref": [ "r289", "r533", "r535", "r584", "r948" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by mortgage loans.", "label": "Collateralized Mortgage Backed Securities [Member]", "terseLabel": "Agency mortgage-backed securities" } } }, "localname": "MortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MultiemployerPlansWithdrawalObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the obligation recognized by withdrawing from a pension or postretirement benefit plan to which two or more unrelated employers contribute where assets contributed by one participating employer may be used to provide benefits to employees of other participating employers.", "label": "Multiemployer Plans, Withdrawal Obligation", "terseLabel": "Multiemployer plans, withdrawal obligation" } } }, "localname": "MultiemployerPlansWithdrawalObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r228", "r240" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/NatureofOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r151" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r151" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r151", "r156", "r159" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Other Foreign Operations" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash transactions:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "auth_ref": [ "r163", "r164", "r165" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "terseLabel": "Equity consideration" } } }, "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not designated as hedging instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r253", "r259", "r263", "r266", "r269" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Segment profitability", "totalLabel": "(Loss) earnings from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r825" ], "calculation": { "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseMaturitiesDetails", "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r825" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r826" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r825" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r826" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r824" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r826" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r831", "r834" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r830", "r834" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesLeaseInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r821" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Operating leases expense" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r258", "r259", "r260", "r261", "r263", "r269" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other Accrued Liabilities, Current" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r79", "r843" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r749", "r772" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "totalLabel": "Other assets", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other Assets, Noncurrent [Abstract]" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r93", "r103", "r802", "r803", "r805" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r103", "r107", "r108", "r552" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "negatedTerseLabel": "Amortization of prior service costs included in SG&A" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax": { "auth_ref": [ "r103", "r107", "r108", "r552" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Amortization of prior service costs" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "auth_ref": [ "r95", "r96", "r103" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax", "terseLabel": "Net unrealized (loss) gain on marketable securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r106", "r115", "r116", "r806", "r808", "r812" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other comprehensive earnings (loss) before reclassifications, before tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r106", "r115", "r116", "r118", "r806", "r808", "r812" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Derivative Financial Instruments in Net Investment Hedging Relationships:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r115", "r116", "r123", "r312", "r806", "r811", "r812", "r899", "r931" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Tax", "terseLabel": "Other comprehensive (loss) earnings, before tax", "totalLabel": "Other comprehensive (loss) earnings, before tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax [Abstract]", "terseLabel": "Other comprehensive (loss) earnings, before tax:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r94", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Net unrecognized loss on derivatives in cash flow hedging relationships, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r94", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r94", "r103", "r752", "r758", "r773" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Net unrecognized gain (loss) on derivatives in hedging relationships" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r91", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r110", "r113", "r115", "r116", "r118", "r123", "r466", "r806", "r811", "r812", "r899", "r931" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive loss, net of tax", "totalLabel": "Other comprehensive (loss) earnings, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "auth_ref": [ "r100", "r103", "r552", "r584" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax", "weight": -1.0 }, "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "negatedTerseLabel": "Change in unrecognized loss and prior service cost related to defined benefit plans", "negatedTotalLabel": "Net change", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r98", "r103", "r552" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "terseLabel": "Unrecognized actuarial (gain) loss" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "auth_ref": [ "r103", "r107", "r108", "r552" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "negatedLabel": "Amortization of actuarial loss included in SG&A" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": { "auth_ref": [ "r103", "r107", "r108", "r552" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r104", "r115", "r123", "r649", "r688", "r690", "r806", "r809", "r812", "r899", "r931" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "terseLabel": "Income tax provision (benefit)" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeOtherNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other comprehensive income, after tax, from changes classified as other.", "label": "Other Comprehensive Income, Other, Net of Tax", "terseLabel": "Other Comprehensive Income, Other, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeOtherNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/LitigationNarrativeDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r301", "r325", "r533", "r790" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r766" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other income", "verboseLabel": "Other expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofComprehensiveEarningsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r896" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r67", "r843" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current [Abstract]", "terseLabel": "Other Liabilities, Current [Abstract]" } } }, "localname": "OtherLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of other liabilities.", "label": "Other Liabilities, Fair Value Disclosure", "terseLabel": "Contingent consideration" } } }, "localname": "OtherLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r71" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Liabilities, Noncurrent", "verboseLabel": "Other long-term obligations" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r159" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r132" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pension plan, other postretirement plan, and supplemental retirement plan, classified as other. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Other Pension, Postretirement and Supplemental Plans [Member]", "terseLabel": "Other Pension, Postretirement and Supplemental Plans" } } }, "localname": "OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r504", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r555", "r557", "r558", "r561", "r564", "r569", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r589", "r590", "r591", "r592", "r593", "r594" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefits" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementBenefitsIndividualContractsTypeOfDeferredCompensationDomain": { "auth_ref": [ "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Deferred compensation related to other postretirement benefit arrangements that are not equivalent to a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Other Postretirement Benefits, Individual Contracts, Type of Deferred Compensation [Domain]", "terseLabel": "Other Postretirement Benefits, Individual Contracts, Type of Deferred Compensation [Domain]" } } }, "localname": "OtherPostretirementBenefitsIndividualContractsTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [ "r375", "r376", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other Restructuring" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": { "auth_ref": [ "r163", "r164", "r165" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Value of Consideration Given", "terseLabel": "Common stock issued for the Combination" } } }, "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "terseLabel": "Payment for Contingent Consideration Liability, Financing Activities" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r137", "r140" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Payments for product rights and other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r155" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent", "terseLabel": "Payments for Rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r149", "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments for Restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r147" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Payments of financing fees" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": { "auth_ref": [ "r147" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for financing costs associated with business combinations.", "label": "Payments of Merger Related Costs, Financing Activities", "negatedTerseLabel": "Contingent consideration payments" } } }, "localname": "PaymentsOfMergerRelatedCostsFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r144" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r138", "r715" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid to acquire asset" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/DebtFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r138" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash received (paid) for acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r287" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r139" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r147" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Cash dividends paid" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r532", "r534", "r540", "r559", "r562", "r563", "r564", "r565", "r566", "r584", "r586", "r587", "r589", "r602" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Employee Benefits" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r32", "r505", "r506", "r530", "r584" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails": { "order": 2.0, "parentTag": "vtrs_Netaccruedbenefitcosts", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedTerseLabel": "Current liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r35", "r505", "r506", "r530", "r584" ], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails": { "order": 3.0, "parentTag": "vtrs_Netaccruedbenefitcosts", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedTerseLabel": "Noncurrent liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r503", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r555", "r557", "r558", "r561", "r564", "r569", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r589", "r590", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Benefits" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEffectofOnePercentagePointIncreaseorDecreaseinHealthCareCostTrendRatesDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Shares" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r561", "r584" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r606", "r633" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanTables", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanTables", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r54", "r55" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "totalLabel": "Prepaid expenses and other current assets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]", "terseLabel": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r7", "r9", "r336", "r337" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementDerivativesNotDesignatedasHedgingInstrumentsFairValuesofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average number of shares or units and dilutive common stock or unit equivalents outstanding in the calculation of proforma diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.", "label": "Pro Forma Weighted Average Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "ProFormaWeightedAverageSharesOutstandingDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r135" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from sale of assets and subsidiaries" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r142" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "verboseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r143", "r147" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other items, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Change in short-term borrowings, net" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndCollectionOfReceivables": { "auth_ref": [ "r137" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the proceeds from sale and collection of receivables during the period.", "label": "Proceeds from Sale and Collection of Receivables", "terseLabel": "Proceeds from Sale and Collection of Receivables" } } }, "localname": "ProceedsFromSaleAndCollectionOfReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from the sale of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r136" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfSecuritiesOperatingActivities": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from sale of investments in debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating.", "label": "Proceeds from Sale of Securities, Operating Activities", "terseLabel": "Proceeds from Sale of Securities, Operating Activities" } } }, "localname": "ProceedsFromSaleOfSecuritiesOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r141", "r634" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other revenues" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Net sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r3", "r109", "r112", "r117", "r150", "r174", "r197", "r205", "r206", "r253", "r259", "r263", "r266", "r269", "r315", "r408", "r409", "r410", "r413", "r414", "r415", "r417", "r419", "r421", "r422", "r726", "r730", "r731", "r737", "r738", "r782", "r800", "r903" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "netLabel": "Net (loss) earnings", "terseLabel": "Net earnings", "totalLabel": "Net (loss) earnings", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "http://www.viatris.com/role/ConsolidatedStatementsofEquity", "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r60", "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r59", "r365" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]", "verboseLabel": "Accounting Policies [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r24", "r25", "r367", "r843", "r910", "r928" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r58", "r367", "r956", "r957" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment Policy" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r24", "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r24", "r365" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, estimated service life (years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r42", "r47", "r843", "r927", "r950" ], "calculation": { "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Trade receivables, net", "verboseLabel": "Accounts receivable, net" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables, Net, Current [Abstract]", "terseLabel": "Receivables, Net, Current [Abstract]" } } }, "localname": "ReceivablesNetCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r145" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r145" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Payments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAmountOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of fair value of reporting unit in excess of carrying amount.", "label": "Reporting Unit, Amount of Fair Value in Excess of Carrying Amount", "terseLabel": "Reporting Unit, Amount of Fair Value in Excess of Carrying Amount" } } }, "localname": "ReportingUnitAmountOfFairValueInExcessOfCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "terseLabel": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount" } } }, "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r643", "r879", "r971" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedTerseLabel": "Globally managed research and development costs", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Policy" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r166", "r884", "r923" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r20", "r160", "r166" ], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsBalanceSheetComponentsCashandCashEquivalentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash, included in other current and non-current assets" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsBalanceSheetComponentsCashandCashEquivalentsDetails", "http://www.viatris.com/role/BalanceSheetComponentsPrepaidsandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents [Axis]", "terseLabel": "Restricted Cash and Cash Equivalents [Axis]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Issuance of restricted stock and stock options exercised, net" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r374", "r376", "r379", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expected cost remaining for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost Remaining", "terseLabel": "Restructuring and Related Cost, Expected Cost Remaining" } } }, "localname": "RestructuringAndRelatedCostExpectedCostRemaining1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "terseLabel": "Restructuring and Related Cost, Expected Number of Positions Eliminated" } } }, "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r375", "r378", "r385", "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Restructuring and Related Cost, Incurred Cost" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r158", "r373", "r382", "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring and Related Cost, Cost Incurred to Date" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r375", "r376", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r376", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r32", "r376", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring Reserve, Current" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveNoncurrent": { "auth_ref": [ "r81", "r376", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Noncurrent", "terseLabel": "Restructuring Reserve, Noncurrent" } } }, "localname": "RestructuringReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReservePeriodIncreaseDecrease": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the accrual for restructuring costs.", "label": "Restructuring Reserve, Period Increase (Decrease)", "negatedTerseLabel": "Restructuring Reserve, Period Increase (Decrease)" } } }, "localname": "RestructuringReservePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r376", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "terseLabel": "Restructuring Reserve, Settled without Cash" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAndOtherAdjustment": { "auth_ref": [ "r376", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the restructuring reserve related to foreign currency translation (gain) loss and other increases (decreases).", "label": "Restructuring Reserve, Translation and Other Adjustment", "terseLabel": "Restructuring Reserve, Translation and Other Adjustment" } } }, "localname": "RestructuringReserveTranslationAndOtherAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r44", "r471", "r638", "r843", "r925", "r945", "r947" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r193", "r194", "r195", "r198", "r204", "r206", "r318", "r635", "r636", "r637", "r678", "r679", "r780", "r942", "r944" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r503", "r504", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r555", "r557", "r558", "r561", "r564", "r569", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r589", "r590", "r591", "r592", "r593", "r594", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEffectofOnePercentagePointIncreaseorDecreaseinHealthCareCostTrendRatesDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r503", "r504", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r555", "r557", "r558", "r561", "r564", "r569", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r589", "r590", "r591", "r592", "r593", "r594", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansAccumulatedOtherComprehensiveIncomeLossPretaxAmountsNotYetReclassifiedinNetPeriodicBenefitCostDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEffectofOnePercentagePointIncreaseorDecreaseinHealthCareCostTrendRatesDetails", "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r244", "r245", "r258", "r264", "r265", "r272", "r273", "r276", "r490", "r491", "r880" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails", "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r170", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r500" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition Policy" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r492", "r500" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition and Accounts Receivable" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueNotFromContractWithCustomer": { "auth_ref": [ "r120" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606.", "label": "Revenue Not from Contract with Customer", "terseLabel": "Other revenues" } } }, "localname": "RevenueNotFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r120", "r174", "r244", "r245", "r258", "r264", "r265", "r272", "r273", "r276", "r315", "r408", "r409", "r410", "r413", "r414", "r415", "r417", "r419", "r421", "r422", "r800", "r903" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues", "verboseLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r766" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales [Member]" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinCashFlowHedgingRelationshipsDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r235", "r276" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Third party net sales" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The scenario under which facts represent plans as distinct from actual.", "label": "Scenario, Plan [Member]", "terseLabel": "Scenario, Plan" } } }, "localname": "ScenarioPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts Receivable, Net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r106", "r811", "r812" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Allocation of Plan Assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "terseLabel": "Net Accrued Benefit Costs Classification on Balance Sheet" } } }, "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.", "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits" } } }, "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Available-for-Sale Securities Reconciliation" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r295", "r298", "r302", "r303", "r304", "r305", "r905", "r906" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r570", "r584" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Plans with Accumulated Benefit Obligation in Excess of Plan Assets" } } }, "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r701", "r702" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.", "label": "Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Components of Other Comprehensive Loss" } } }, "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "verboseLabel": "Summary of Long-Term Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r568", "r569", "r572", "r573", "r584" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r750", "r762", "r768" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "verboseLabel": "Effect of Derivative Instruments on the Consolidated Statements of Operations" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r756" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "verboseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Earnings Per Common Share Attributable To Mylan" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r210", "r214", "r216", "r218", "r222" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Statutory Tax Rate to Effective Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails", "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r3", "r174", "r314", "r315", "r800" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails", "http://www.viatris.com/role/EquityMethodInvestmentsIncomeStatementDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Expected Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r783", "r784" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Financial Assets and Liabilities Carried at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r349", "r355", "r881" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r349", "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "verboseLabel": "Components of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "verboseLabel": "Changes in carrying amount of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r16", "r51", "r52", "r53" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "verboseLabel": "Minimum Repayments on Outstanding Borrowings" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation.", "label": "Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of noncurrent assets.", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "terseLabel": "Other assets" } } }, "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of Other Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r60", "r367" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "auth_ref": [ "r367", "r822", "r836" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block]", "terseLabel": "Schedule of Property Subject to or Available for Operating Lease" } } }, "localname": "ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r375", "r376", "r377", "r378", "r385", "r386", "r388" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r380", "r381", "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of Revenue by Major Customers by Reporting Segments" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r126", "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Net Third Party Sales Classified Based on Geographic Location of Subsidiaries" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r120", "r275" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationNetThirdPartySalesClassifiedBasedonGeographicLocationofEntityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r253", "r256", "r262", "r345" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r253", "r256", "r262", "r345" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "verboseLabel": "Reconciliation of Segment Information to Total Consolidated Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r606", "r633" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanTables", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r612", "r623", "r625" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Stock Awards Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r627" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Stock-Based Compensation Plans, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Nonvested Restricted Stock and Restricted Stock Unit, Including Performance Units, Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtShorttermborrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table Text Block]", "terseLabel": "Schedule of Short-term Debt" } } }, "localname": "ScheduleOfShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.", "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]", "terseLabel": "Schedule of Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r241", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r258", "r259", "r260", "r261", "r263", "r264", "r265", "r266", "r267", "r269", "r276", "r378", "r388", "r936" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r241", "r242", "r243", "r253", "r257", "r263", "r267", "r268", "r269", "r270", "r272", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r130" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "verboseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtFairValueNarrativeDetails", "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r702" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r157" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Stock option award vesting period, in years" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of restricted stock awards, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant-date fair value per share, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Number of restricted stock awards, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant-date fair value per share, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of restricted stock awards, nonvested ending balance", "periodStartLabel": "Number of restricted stock awards, nonvested beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant-date fair value per share, nonvested ending balance", "periodStartLabel": "Weighted average grant-date fair value per share, nonvested beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of restricted stock awards, released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant-date fair value per share, released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanTables", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Amount of common stock shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of shares under stock awards, exercisable at period end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price per share, exercisable at period end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares under stock awards, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "verboseLabel": "Number of shares under stock awards, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value per option" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r633" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Aggregate intrinsic value for options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r614", "r633" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares under stock awards, outstanding at end of period", "periodStartLabel": "Number of shares under stock awards, outstanding at beginning of period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price per share, outstanding at end of period", "periodStartLabel": "Weightedaverage exercise price per share, outstanding at beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Number of shares under stock awards, vested and expected to vest at period end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price per share, vested and expected to vest at period end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r604", "r610" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanNonvestedRestrictedStockRestrictedStockUnitsandPSUsActivityDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price per share, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price per share, forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price per share, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r606", "r611" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation Policy" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Stock option award expiration period, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r628", "r639" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Average remaining contractual term for options exercisable, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Average remaining contractual term for options outstanding, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Average remaining contractual term for options vested and expected to vest, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r29", "r843", "r888", "r920" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term borrowings", "verboseLabel": "Short-term borrowings" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtShorttermborrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]", "terseLabel": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtShorttermborrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtShorttermborrowingsDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtShorttermborrowingsDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r167", "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary Of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Capitalized software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r175", "r649", "r681" ], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "totalLabel": "Income tax provision (benefit), U.S. State" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r241", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r258", "r259", "r260", "r261", "r263", "r264", "r265", "r266", "r267", "r269", "r276", "r345", "r369", "r378", "r388", "r936" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r39", "r40", "r41", "r172", "r174", "r210", "r214", "r215", "r216", "r218", "r225", "r226", "r227", "r315", "r408", "r413", "r414", "r415", "r421", "r422", "r459", "r460", "r463", "r464", "r466", "r800", "r980" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/ConsolidatedStatementsofEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r75", "r115", "r116", "r117", "r193", "r194", "r195", "r198", "r204", "r206", "r224", "r318", "r466", "r471", "r635", "r636", "r637", "r678", "r679", "r780", "r806", "r807", "r808", "r809", "r810", "r812", "r942", "r943", "r944", "r1015" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.viatris.com/role/ConsolidatedStatementsofEquity", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheCondensedConsolidatedStatementsofComprehensiveEarningsDerivativesinNetInvestmentHedgingRelationshipDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "http://www.viatris.com/role/ConsolidatedStatementsofEquity", "http://www.viatris.com/role/ConsolidatedStatementsofEquityParenthetical", "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r193", "r194", "r195", "r224", "r880" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]", "verboseLabel": "Accounting Policies [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.viatris.com/role/ConsolidatedStatementsofComprehensiveEarnings", "http://www.viatris.com/role/ConsolidatedStatementsofEquity", "http://www.viatris.com/role/ConsolidatedStatementsofEquityParenthetical", "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r40", "r41", "r471" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common stock for the Combination (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r40", "r41", "r466", "r471" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock to Mylan N.V. shareholders (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r40", "r41", "r466", "r471", "r617" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of shares under stock awards, exercised", "terseLabel": "Number of shares exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r75", "r466", "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock for the Combination" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r40", "r41", "r466", "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r75", "r466", "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Issuance of restricted stock and stock options exercised, net" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Viatris Inc. shareholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r116", "r174", "r193", "r194", "r195", "r198", "r204", "r315", "r318", "r471", "r635", "r636", "r637", "r678", "r679", "r724", "r725", "r736", "r780", "r800", "r806", "r807", "r812", "r943", "r944", "r1015" ], "calculation": { "http://www.viatris.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Total equity", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails", "http://www.viatris.com/role/ConsolidatedBalanceSheets", "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r813", "r844" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r813", "r844" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r813", "r844" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "verboseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information \u2014" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Cash paid during the period for:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplyCommitmentArrangementMember": { "auth_ref": [ "r36", "r892", "r922" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Supply Commitment Arrangement [Domain]", "terseLabel": "Supply Commitment Arrangement [Domain]" } } }, "localname": "SupplyCommitmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplyCommitmentAxis": { "auth_ref": [ "r36", "r892", "r922" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.", "label": "Supply Commitment [Axis]", "terseLabel": "Supply Commitment [Axis]" } } }, "localname": "SupplyCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxYear2015Member": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2015.", "label": "Tax Year 2015 [Member]", "terseLabel": "Tax Year 2015" } } }, "localname": "TaxYear2015Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r280", "r281", "r282", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts receivable, net" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r299", "r300", "r307", "r308", "r309", "r449", "r465", "r777", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementScheduleofAvailableforsaleSecuritiesReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r74", "r473" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "auth_ref": [ "r41", "r466", "r472" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.", "label": "Treasury Stock, Retired, Cost Method, Amount", "negatedTerseLabel": "Retirement of Mylan N.V. treasury stock, net" } } }, "localname": "TreasuryStockRetiredCostMethodAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesRetired": { "auth_ref": [ "r41", "r466", "r471" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common and preferred stock retired from treasury during the period.", "label": "Treasury Stock, Shares, Retired", "negatedTerseLabel": "Cancellation of restricted stock" } } }, "localname": "TreasuryStockSharesRetired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r375", "r376", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r179", "r533", "r584", "r904" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasuries" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedTerseLabel": "Unamortized Debt Issuance Expense" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r644", "r656" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefit\u00a0\u2014 end of year", "terseLabel": "Unrecognized tax benefit\u00a0\u2014 beginning of year", "verboseLabel": "Unrecognized tax benefit" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Acquisition", "negatedTerseLabel": "Unrecognized Tax Benefits, Decrease Resulting from Acquisition" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r657" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Reductions for prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r659" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "(Reduction) addition due to acquisition" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r658" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions for current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r657" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions for prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r660" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Reductions due to expirations of statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r661" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualOrInfrequentItemAxis": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Axis]", "terseLabel": "Unusual or Infrequent Item, or Both [Axis]" } } }, "localname": "UnusualOrInfrequentItemAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemDomain": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Domain]", "terseLabel": "Unusual or Infrequent Item, or Both [Domain]" } } }, "localname": "UnusualOrInfrequentItemDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r229", "r230", "r232", "r233", "r237", "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates in the Preparation of Financial Statements Policy" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r184", "r185", "r186", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "Valuation allowance for deferred tax assets" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r184", "r190" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r187" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Additions Charged to Costs and Expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": { "auth_ref": [ "r188" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account", "terseLabel": "Additions Charged to Other Accounts" } } }, "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r184", "r185", "r186", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r184", "r185", "r186", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/ValuationandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r786" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r786" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Valuation Technique, Discounted Cash Flow" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r786" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageBasicSharesOutstandingProForma": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.", "label": "Weighted Average Basic Shares Outstanding, Pro Forma", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageBasicSharesOutstandingProForma", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r209", "r218" ], "calculation": { "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Total dilutive shares outstanding", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r208", "r218" ], "calculation": { "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofOperations", "http://www.viatris.com/role/SummaryofSignificantAccountingPoliciesBasicAndDilutedEarningsPerOrdinaryShareAttributableToMylanNVDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r131" ], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "monetaryItemType" }, "vtrs_A2014ProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2014 Program", "label": "2014 Program [Member]", "terseLabel": "2014 Program" } } }, "localname": "A2014ProgramMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanTables", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2016RestructuringProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2016 Restructuring Program", "label": "2016 Restructuring Program [Member]", "terseLabel": "2016 Restructuring Program" } } }, "localname": "A2016RestructuringProgramMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2016SeniorRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2016 Senior Revolving Credit Facility [Member]", "label": "2016 Senior Revolving Credit Facility [Member]", "terseLabel": "2016 Senior Revolving Credit Facility" } } }, "localname": "A2016SeniorRevolvingCreditFacilityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2016TermLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2016 Term Loans [Member]", "label": "2016 Term Loans [Member]", "terseLabel": "2016 Term Loans" } } }, "localname": "A2016TermLoansMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2018SeniorRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Senior Revolving Credit Facility [Member]", "label": "2018 Senior Revolving Credit Facility [Member]", "terseLabel": "2018 Senior Revolving Credit Facility [Member]" } } }, "localname": "A2018SeniorRevolvingCreditFacilityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2020EuroSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Euro Senior Notes [Member]", "label": "2020 Euro Senior Notes [Member]", "terseLabel": "2020 Euro Senior Notes" } } }, "localname": "A2020EuroSeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2020FloatingRateEuroNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Floating Rate Euro Notes", "label": "2020 Floating Rate Euro Notes [Member]", "terseLabel": "2020 Floating Rate Euro Notes" } } }, "localname": "A2020FloatingRateEuroNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2020RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Restructuring Plan", "label": "2020 Restructuring Plan [Member]", "terseLabel": "2020 Restructuring Plan" } } }, "localname": "A2020RestructuringPlanMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2020RevolvingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Revolving Facility", "label": "2020 Revolving Facility [Member]", "terseLabel": "2020 Revolving Facility" } } }, "localname": "A2020RevolvingFacilityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2020StockIncentivePlanAnd2003LongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan", "label": "2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan [Member]", "terseLabel": "2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan" } } }, "localname": "A2020StockIncentivePlanAnd2003LongTermIncentivePlanMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2022EuroSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Euro Senior Notes", "label": "2022 Euro Senior Notes [Member]", "terseLabel": "2022 Euro Senior Notes" } } }, "localname": "A2022EuroSeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2022SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Senior Notes", "label": "2022 Senior Notes [Member]", "terseLabel": "2022 Senior Notes" } } }, "localname": "A2022SeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2024EuroSeniorNotes1023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2024 Euro Senior Notes, 1.023%", "label": "2024 Euro Senior Notes, 1.023% [Member]", "terseLabel": "2.125% Euro Senior Notes due 2025" } } }, "localname": "A2024EuroSeniorNotes1023Member", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2024EuroSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2024 Euro Senior Notes [Member]", "label": "2024 Euro Senior Notes [Member]", "terseLabel": "2.250% Euro Senior Notes due 2024" } } }, "localname": "A2024EuroSeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2025EuroSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2025 Euro Senior Notes [Member]", "label": "2025 Euro Senior Notes [Member]", "terseLabel": "2025 Euro Senior Notes" } } }, "localname": "A2025EuroSeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2025SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2025 Senior Notes", "label": "2025 Senior Notes [Member]", "terseLabel": "2025 Senior Notes" } } }, "localname": "A2025SeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2027EuroSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2027 Euro Senior Notes", "label": "2027 Euro Senior Notes [Member]", "terseLabel": "2027 Euro Senior Notes" } } }, "localname": "A2027EuroSeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2027SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2027 Senior Notes", "label": "2027 Senior Notes [Member]", "terseLabel": "2027 Senior Notes" } } }, "localname": "A2027SeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2028EuroSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2028 Euro Senior Notes [Member]", "label": "2028 Euro Senior Notes [Member]", "terseLabel": "2028 Euro Senior Notes" } } }, "localname": "A2028EuroSeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2028SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2028 Senior Notes [Member] [Member]", "label": "2028 Senior Notes [Member]", "terseLabel": "2028 Senior Notes" } } }, "localname": "A2028SeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2030SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2030 Senior Notes", "label": "2030 Senior Notes [Member]", "terseLabel": "2030 Senior Notes" } } }, "localname": "A2030SeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2032EuroSeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2032 Euro Senior Notes", "label": "2032 Euro Senior Notes [Member]", "terseLabel": "2032 Euro Senior Notes" } } }, "localname": "A2032EuroSeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2040SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2040 Senior Notes", "label": "2040 Senior Notes [Member]", "terseLabel": "2040 Senior Notes" } } }, "localname": "A2040SeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2048SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2048 Senior Notes [Member]", "label": "2048 Senior Notes [Member]", "terseLabel": "2048 Senior Notes [Member]" } } }, "localname": "A2048SeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_A2050SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2050 Senior Notes", "label": "2050 Senior Notes [Member]", "terseLabel": "2050 Senior Notes" } } }, "localname": "A2050SeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_AccountsReceivableCreditsIssuedtoThirdParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Credits Issued to Third Parties", "label": "Accounts Receivable, Credits Issued to Third Parties", "negatedTerseLabel": "Checks/ Credits Issued to Third Parties" } } }, "localname": "AccountsReceivableCreditsIssuedtoThirdParties", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_AccountsReceivableEffectsofForeignExchangeRates": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Effects of Foreign Exchange Rates", "label": "Accounts Receivable, Effects of Foreign Exchange Rates", "terseLabel": "Effects of Foreign Exchange" } } }, "localname": "AccountsReceivableEffectsofForeignExchangeRates", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_AccountsReceivableFacilityMaximumBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts receivable facility maximum borrowing capacity.", "label": "Accounts Receivable Facility Maximum Borrowing Capacity", "terseLabel": "Accounts receivable securitization facility maximum borrowing capacity" } } }, "localname": "AccountsReceivableFacilityMaximumBorrowingCapacity", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_AccountsReceivableIncreaseDueToAcquisitionCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Increase Due to Acquisition, Current", "label": "Accounts Receivable, Increase Due to Acquisition, Current", "terseLabel": "Measurement Period Adjustments and Reclasses" } } }, "localname": "AccountsReceivableIncreaseDueToAcquisitionCurrent", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_AccountsReceivableSalesProvisionsCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Sales Provisions, Current", "label": "Accounts Receivable, Sales Provisions, Current", "terseLabel": "Current Provision Related to Sales Made in the Current Period" } } }, "localname": "AccountsReceivableSalesProvisionsCurrent", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_AccountsReceivableVariableConsiderationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Variable Consideration [Roll Forward]", "label": "Accounts Receivable, Variable Consideration [Roll Forward]", "terseLabel": "Accounts Receivable, Variable Consideration [Roll Forward]" } } }, "localname": "AccountsReceivableVariableConsiderationRollForward", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "stringItemType" }, "vtrs_AccretionExpenseToBeRecognizedWithinTheNextTwelveMonths": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accretion Expense to be Recognized within the Next Twelve Months", "label": "Accretion Expense to be Recognized within the Next Twelve Months", "terseLabel": "Accretion expense expected within 12 months" } } }, "localname": "AccretionExpenseToBeRecognizedWithinTheNextTwelveMonths", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_AccruedSalesAllowances": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails": { "order": 2.0, "parentTag": "vtrs_SalesRevenueGrosstonetadjustments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued Sales Allowances", "label": "Accrued Sales Allowances", "negatedNetLabel": "Rebates, promotional programs and other sales allowances" } } }, "localname": "AccruedSalesAllowances", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_AccumulatedOtherComprehensiveIncomeLossCumulativeChangesinNetGainLossfromNetInvestmentHedgesEffectNetofTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Tax", "label": "Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Net Investment Hedges, Effect Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossCumulativeChangesinNetGainLossfromNetInvestmentHedgesEffectNetofTax", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ComprehensiveEarningsAccumulatedOtherComprehensiveLossDetails", "http://www.viatris.com/role/ComprehensiveEarningsComponentsofOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_AccumulatednetactuariallossesexceedhigherofmarketvalueofplanassetsorPBO": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated net actuarial losses exceed higher of market value of plan assets or PBO", "label": "Accumulated net actuarial losses exceed higher of market value of plan assets or PBO", "terseLabel": "Unrecognized net actuarial losses exceed higher of market value of plan assets or the projected benefit obligation at the beginning of the year" } } }, "localname": "AccumulatednetactuariallossesexceedhigherofmarketvalueofplanassetsorPBO", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "vtrs_AgilaSpecialtiesPrivateLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agila Specialties Private Limited", "label": "Agila Specialties Private Limited [Member]", "terseLabel": "Agila Specialties" } } }, "localname": "AgilaSpecialtiesPrivateLimitedMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_AmendedAnticompetitiveConductwithGenericDrugsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended Anticompetitive Conduct with Generic Drugs [Member]", "label": "Amended Anticompetitive Conduct with Generic Drugs [Member]", "terseLabel": "Amended Anticompetitive Conduct with Generic Drugs" } } }, "localname": "AmendedAnticompetitiveConductwithGenericDrugsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_AmeriSourceBergenCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AmeriSourceBergen Corporation", "label": "AmeriSourceBergen Corporation [Member]", "terseLabel": "AmeriSourceBergen Corporation" } } }, "localname": "AmeriSourceBergenCorporationMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "vtrs_AmitizaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amitiza \u00ae", "label": "Amitiza \u00ae [Member]", "terseLabel": "Amitiza \u00ae" } } }, "localname": "AmitizaMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_AmortizationOfInventoryStepUp": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of Inventory Step Up", "label": "Amortization of Inventory Step Up", "terseLabel": "Amortization of Inventory Step Up" } } }, "localname": "AmortizationOfInventoryStepUp", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_AnticompetitiveConductWithRespectToAdditionalGenericDrugsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anticompetitive conduct with respect to additional generic drugs", "label": "Anticompetitive conduct with respect to additional generic drugs [Member]", "terseLabel": "Anticompetitive conduct with respect to additional generic drugs" } } }, "localname": "AnticompetitiveConductWithRespectToAdditionalGenericDrugsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_AnticompetitiveConductwithDoxycyclineHyclateDelayedReleaseDoxycyclineMonohydrateGlipizideMetforminandVerapamilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil [Member]", "label": "Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil [Member]", "terseLabel": "Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil" } } }, "localname": "AnticompetitiveConductwithDoxycyclineHyclateDelayedReleaseDoxycyclineMonohydrateGlipizideMetforminandVerapamilMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_AnticompetitiveConductwithGenericDrugsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anticompetitive Conduct with Generic Drugs [Member]", "label": "Anticompetitive Conduct with Generic Drugs [Member]", "terseLabel": "Anticompetitive Conduct with Generic Drugs" } } }, "localname": "AnticompetitiveConductwithGenericDrugsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_AntitrustProceedingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Antitrust proceedings", "label": "Antitrust Proceedings [Member]", "terseLabel": "Antitrust Proceedings" } } }, "localname": "AntitrustProceedingsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_April2018SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "April 2018 Senior Notes [Member]", "label": "April 2018 Senior Notes [Member]", "terseLabel": "April 2018 Senior Notes [Member]" } } }, "localname": "April2018SeniorNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtIssuanceof2018SeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_AspenGlobalIncorporatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aspen Global Incorporated", "label": "Aspen Global Incorporated [Member]", "terseLabel": "Aspen Global Incorporated" } } }, "localname": "AspenGlobalIncorporatedMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_AspenPharmacareHoldingsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aspen Pharmacare Holdings Limited", "label": "Aspen Pharmacare Holdings Limited [Member]", "terseLabel": "Aspen Pharmacare Holdings Limited" } } }, "localname": "AspenPharmacareHoldingsLimitedMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "domainItemType" }, "vtrs_AssetsheldbyinsurancecompaniesandotherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held by insurance companies and other [Member]", "label": "Assets held by insurance companies and other [Member]", "terseLabel": "Assets held by insurance companies and other" } } }, "localname": "AssetsheldbyinsurancecompaniesandotherMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansFairValuesofPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "vtrs_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAndLaterFairValue": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities debt maturities after five years and later fair value.", "label": "Available for Sale Securities Debt Maturities after Five Years and Later Fair Value", "terseLabel": "Mature in five years and later" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAndLaterFairValue", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementMaturitiesofAvailableforsaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BalanceSheetComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Balance Sheet Components", "label": "Balance Sheet Components [Abstract]", "terseLabel": "Balance Sheet Components [Abstract]" } } }, "localname": "BalanceSheetComponentsAbstract", "nsuri": "http://www.viatris.com/20211231", "xbrltype": "stringItemType" }, "vtrs_BiosimilarsBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biosimilars Business", "label": "Biosimilars Business [Member]", "terseLabel": "Biosimilars Business" } } }, "localname": "BiosimilarsBusinessMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_BrandsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brands", "label": "Brands [Member]", "terseLabel": "Brands" } } }, "localname": "BrandsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "vtrs_BusinessAcquisitionexpectedfuturepaymentsnexttwelvemonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Acquisition, expected future payments, next twelve months", "label": "Business Acquisition, expected future payments, next twelve months", "terseLabel": "Business Acquisition, expected future payments, next twelve months" } } }, "localname": "BusinessAcquisitionexpectedfuturepaymentsnexttwelvemonths", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessAcquisitionexpectedfuturepaymentyeartwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "", "label": "Business Acquisition, expected future payment, year two", "terseLabel": "Business Acquisition, expected future payment, year two" } } }, "localname": "BusinessAcquisitionexpectedfuturepaymentyeartwo", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination [Abstract]", "label": "Business Combination [Abstract]", "terseLabel": "Business Combination [Abstract]" } } }, "localname": "BusinessCombinationAbstract", "nsuri": "http://www.viatris.com/20211231", "xbrltype": "stringItemType" }, "vtrs_BusinessCombinationContingentConsiderationArrangementsReclassifications": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Reclassifications", "label": "Business Combination, Contingent Consideration Arrangements, Reclassifications", "terseLabel": "Reclassifications" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsReclassifications", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationContingentConsiderationLiabilityFairValueGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Liability, Fair Value Gain (Loss)", "label": "Business Combination, Contingent Consideration, Liability, Fair Value Gain (Loss)", "terseLabel": "Fair value loss (gain)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityFairValueGainLoss", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationContingentConsiderationLiabilityPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination Contingent Consideration Liability Payments", "label": "Business Combination Contingent Consideration Liability Payments", "negatedTerseLabel": "Payments", "terseLabel": "Contingent consideration payments" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityPayments", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationContractualReimbursementAmountAmountsAccrued": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contractual Reimbursement Amount, Amounts Accrued", "label": "Business Combination, Contractual Reimbursement Amount, Amounts Accrued", "terseLabel": "Amounts accrued" } } }, "localname": "BusinessCombinationContractualReimbursementAmountAmountsAccrued", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationContractualReimbursementAmountAmountsExpensed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contractual Reimbursement Amount, Amounts Expensed", "label": "Business Combination, Contractual Reimbursement Amount, Amounts Expensed", "terseLabel": "Amounts incurred" } } }, "localname": "BusinessCombinationContractualReimbursementAmountAmountsExpensed", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationContractualReimbursementAmountTrancheOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contractual Reimbursement Amount, Tranche One", "label": "Business Combination, Contractual Reimbursement Amount, Tranche One", "terseLabel": "Reimbursement amount, tranche one" } } }, "localname": "BusinessCombinationContractualReimbursementAmountTrancheOne", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationLimitedTransitionServicesPaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Limited Transition Services Payment Period", "label": "Business Combination, Limited Transition Services Payment Period", "terseLabel": "Limited transition services period" } } }, "localname": "BusinessCombinationLimitedTransitionServicesPaymentPeriod", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "durationItemType" }, "vtrs_BusinessCombinationNumberOfMarketsServed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Number Of Markets Served", "label": "Business Combination, Number Of Markets Served", "terseLabel": "Number Of Markets" } } }, "localname": "BusinessCombinationNumberOfMarketsServed", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets", "terseLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets, Current", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets, Current", "terseLabel": "Current assets (excluding inventories and net of cash acquired)" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsCurrent", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Assets", "terseLabel": "Deferred income tax benefit" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxAssets", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilities", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill", "terseLabel": "Goodwill" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities, Current", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities, Current", "terseLabel": "Current liabilities" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLongTermDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt", "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLongTermDebt", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNoncurrentAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNoncurrentAssets", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNoncurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Liabilities", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Noncurrent Liabilities", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNoncurrentLiabilities", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIndefiniteLivedIntangibleAssetsMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets, Measurement Input", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets, Measurement Input", "terseLabel": "Rate used to discount net cash inflows to present values" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIndefiniteLivedIntangibleAssetsMeasurementInput", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "decimalItemType" }, "vtrs_BusinessCombinationsNumberOfAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combinations, Number of Agreements", "label": "Business Combinations, Number of Agreements", "terseLabel": "Business Combinations, Number of Agreements" } } }, "localname": "BusinessCombinationsNumberOfAgreements", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_CARESActIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "CARES Act, Income Tax Expense (Benefit)", "label": "CARES Act, Income Tax Expense (Benefit)", "terseLabel": "CARES Act, Income Tax Expense (Benefit)" } } }, "localname": "CARESActIncomeTaxExpenseBenefit", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_CardinalHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardinal Health Inc [Member]", "label": "Cardinal Health Inc [Member]", "terseLabel": "Cardinal Health Inc" } } }, "localname": "CardinalHealthIncMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "vtrs_CelebrexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Celebrex \u00ae", "label": "Celebrex \u00ae [Member]", "terseLabel": "Celebrex \u00ae" } } }, "localname": "CelebrexMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_Changeinnoncashlitigationsettlementsnet": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in noncash litigation settlements, net", "label": "Change in noncash litigation settlements, net", "negatedLabel": "Litigation settlements and other contingencies, net" } } }, "localname": "Changeinnoncashlitigationsettlementsnet", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "vtrs_Chargebacks": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails": { "order": 1.0, "parentTag": "vtrs_SalesRevenueGrosstonetadjustments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Chargebacks", "label": "Chargebacks", "negatedTerseLabel": "Chargebacks" } } }, "localname": "Chargebacks", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_ChargebacksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chargebacks [Member]", "label": "Chargebacks [Member]", "terseLabel": "Chargebacks [Member]" } } }, "localname": "ChargebacksMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "vtrs_CleanEnergyPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clean Energy Partnerships", "label": "Clean Energy Partnerships [Member]", "terseLabel": "Clean energy investments" } } }, "localname": "CleanEnergyPartnershipsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails", "http://www.viatris.com/role/EquityMethodInvestmentsBalanceSheetDetails", "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_CollaborationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborations [Abstract]", "label": "Collaborations [Abstract]", "terseLabel": "Collaborations [Abstract]" } } }, "localname": "CollaborationsAbstract", "nsuri": "http://www.viatris.com/20211231", "xbrltype": "stringItemType" }, "vtrs_CommercialPaperProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial Paper Program [Member]", "label": "Commercial Paper Program [Member]", "terseLabel": "Commercial Paper Program [Member]" } } }, "localname": "CommercialPaperProgramMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails" ], "xbrltype": "domainItemType" }, "vtrs_ComplexGXAndBiosimilarsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Complex GX and Biosimilars", "label": "Complex GX and Biosimilars [Member]", "terseLabel": "Complex Gx and Biosimilars" } } }, "localname": "ComplexGXAndBiosimilarsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "vtrs_Concentrationrisknumberofmajorcustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration risk, number of major customers", "label": "Concentration risk, number of major customers", "terseLabel": "Concentration risk, number of major customers" } } }, "localname": "Concentrationrisknumberofmajorcustomers", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsAccountsreceivablenetDetails", "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_Corporatecosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Corporate costs", "label": "Corporate costs", "negatedTerseLabel": "Corporate costs" } } }, "localname": "Corporatecosts", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_CreonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Creon \u00ae", "label": "Creon \u00ae [Member]", "terseLabel": "Creon \u00ae" } } }, "localname": "CreonMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_CurrentPortionofLongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "", "label": "Current Portion of Long-Term Debt [Member]", "terseLabel": "Current portion of long-term debt" } } }, "localname": "CurrentPortionofLongTermDebtMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_DebtInstrumentConversionOfUnregisteredNotesToRegisteredNotesAsAPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion Of Unregistered Notes To Registered Notes, As A Percentage", "label": "Debt Instrument, Conversion Of Unregistered Notes To Registered Notes, As A Percentage", "terseLabel": "Debt Instrument, Conversion Of Unregistered Notes To Registered Notes, As A Percentage" } } }, "localname": "DebtInstrumentConversionOfUnregisteredNotesToRegisteredNotesAsAPercentage", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "percentItemType" }, "vtrs_DeductionlimitofGILTItax": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deduction limit of GILTI tax", "label": "Deduction limit of GILTI tax", "terseLabel": "Deduction limit of GILTI tax" } } }, "localname": "DeductionlimitofGILTItax", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "vtrs_DeferredBaseSalaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Base Salary [Member]", "label": "Deferred Base Salary [Member]", "terseLabel": "Deferred Base Salary" } } }, "localname": "DeferredBaseSalaryMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_DeferredTaxAssetsDeferredtaxexpenseinterestexpense": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from interest expense.", "label": "Deferred Tax Assets, Deferred tax expense, interest expense", "terseLabel": "Interest expense" } } }, "localname": "DeferredTaxAssetsDeferredtaxexpenseinterestexpense", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DeferredTaxAssetsIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets Intangible Assets", "label": "Deferred Tax Assets Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsIntangibleAssets", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DeferredTaxAssetsOperatingLeaseRightofUseAssets": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Operating Lease, Right-of-Use Assets", "label": "Deferred Tax Assets, Operating Lease, Right-of-Use Assets", "terseLabel": "Operating lease assets" } } }, "localname": "DeferredTaxAssetsOperatingLeaseRightofUseAssets", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DeferredTaxLiabilitiesOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Operating Lease, Liability", "label": "Deferred Tax Liabilities, Operating Lease, Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseLiability", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DefinedBenefitPensionPlanswithProjectedBenefitObligationInExcessofPlanAssetsAggregateProjectedBenefitObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Pension Plans with Projected Benefit Obligation In Excess of Plan Assets Aggregate Projected Benefit Obligation", "label": "Defined Benefit Pension Plans with Projected Benefit Obligation In Excess of Plan Assets Aggregate Projected Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPensionPlanswithProjectedBenefitObligationInExcessofPlanAssetsAggregateProjectedBenefitObligation", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansPlanswithPBOinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DefinedBenefitPlanAssumptionsUsedCalculatingProjectedBenefitObligationExpectedLongtermReturnonAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Expected Long-term Return on Assets", "label": "Defined Benefit Plan, Assumptions Used Calculating Projected Benefit Obligation, Expected Long-term Return on Assets", "terseLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingProjectedBenefitObligationExpectedLongtermReturnonAssets", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "vtrs_DefinedBenefitPlanBenefitObligationIncreaseDecreaseforAssetsTransferredtofromPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Assets Transferred to (from) Plan", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Assets Transferred to (from) Plan", "terseLabel": "Acquisitions" } } }, "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseforAssetsTransferredtofromPlan", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DefinedBenefitPlanContributionsByPlanParticipantsBenefitObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan Contributions By Plan Participants Benefit Obligation", "label": "DefinedBenefitPlanContributionsByPlanParticipantsBenefitObligation", "terseLabel": "Participant contributions" } } }, "localname": "DefinedBenefitPlanContributionsByPlanParticipantsBenefitObligation", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DefinedBenefitPlanForeignCurrencyTranslationImpactonPlanAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Foreign Currency Translation Impact on Plan Assets", "label": "Defined Benefit Plan, Foreign Currency Translation Impact on Plan Assets", "terseLabel": "Impact of foreign currency translation" } } }, "localname": "DefinedBenefitPlanForeignCurrencyTranslationImpactonPlanAssets", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangesinProjectedBenefitObligationsPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DevelopedMarketsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developed Markets Segment", "label": "Developed Markets Segment [Member]", "terseLabel": "Developed Markets" } } }, "localname": "DevelopedMarketsSegmentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "domainItemType" }, "vtrs_DevelopmentMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Development Milestone Payments", "label": "Development Milestone Payments", "terseLabel": "Development Milestone Payments" } } }, "localname": "DevelopmentMilestonePayments", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_Developmentandsalesmilestonepayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development and sales milestone payments", "label": "Development and sales milestone payments", "terseLabel": "Development and sales milestone payments" } } }, "localname": "Developmentandsalesmilestonepayments", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DimethylFumarateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dimethyl Fumarate", "label": "Dimethyl Fumarate [Member]", "terseLabel": "Dimethyl Fumarate" } } }, "localname": "DimethylFumarateMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_DivestitureOfBusinessDeferredCashConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Divestiture of Business, Deferred Cash Consideration.", "label": "Divestiture of Business, Deferred Cash Consideration.", "terseLabel": "Divestiture of Business, Deferred Cash Consideration." } } }, "localname": "DivestitureOfBusinessDeferredCashConsideration", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_DivestitureOfBusinessPercentageOwnershipInCombinedCompanyAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divestiture Of Business, Percentage Ownership In Combined Company After Transaction", "label": "Divestiture Of Business, Percentage Ownership In Combined Company After Transaction", "terseLabel": "Divestiture Of Business, Percentage Ownership In Combined Company After Transaction" } } }, "localname": "DivestitureOfBusinessPercentageOwnershipInCombinedCompanyAfterTransaction", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "vtrs_DivestitureOfBusinessTransitionServicesAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divestiture Of Business, Transition Services Agreement, Term", "label": "Divestiture Of Business, Transition Services Agreement, Term", "terseLabel": "Divestiture Of Business, Transition Services Agreement, Term" } } }, "localname": "DivestitureOfBusinessTransitionServicesAgreementTerm", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "vtrs_DymistaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dymista \u00ae", "label": "Dymista \u00ae [Member]", "terseLabel": "Dymista \u00ae" } } }, "localname": "DymistaMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_EUCommissionProceedingsCitalopramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EU Commission Proceedings Citalopram", "label": "EU Commission Proceedings Citalopram [Member]", "terseLabel": "EU Commission Proceedings Citalopram" } } }, "localname": "EUCommissionProceedingsCitalopramMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_EUCommissionProceedingsPerindorprilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EU Commission Proceedings Perindorpril", "label": "EU Commission Proceedings Perindorpril [Member]", "terseLabel": "EU Commission Proceedings Perindorpril" } } }, "localname": "EUCommissionProceedingsPerindorprilMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_EURIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EURIBOR [Member]", "label": "EURIBOR [Member]", "terseLabel": "EURIBOR [Member]" } } }, "localname": "EURIBORMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_EffectiveIncomeTaxRateReconciliationGILTIPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, GILTI, Percent", "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent", "terseLabel": "Incremental US Tax on Foreign Earnings" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGILTIPercent", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "vtrs_EffectiveIncomeTaxRateReconciliationIndiaAmagulation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, India Amagulation", "label": "Effective Income Tax Rate Reconciliation, India Amagulation", "terseLabel": "Tax settlements and resolution of certain tax positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationIndiaAmagulation", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "vtrs_EffectiveIncomeTaxRateReconciliationWaivedDeductionsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Waived Deductions, Percent", "label": "Effective Income Tax Rate Reconciliation, Waived Deductions, Percent", "terseLabel": "Waived deductions under IRC \u00a7 59A" } } }, "localname": "EffectiveIncomeTaxRateReconciliationWaivedDeductionsPercent", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "vtrs_EffectiveIncomeTaxRateReconciliationWithholdingTaxesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Withholding Taxes, Percent", "label": "Effective Income Tax Rate Reconciliation, Withholding Taxes, Percent", "terseLabel": "Withholding taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTaxesPercent", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "vtrs_EffexorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effexor \u00ae", "label": "Effexor \u00ae [Member]", "terseLabel": "Effexor \u00ae" } } }, "localname": "EffexorMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_EmergingMarketsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Markets Segment", "label": "Emerging Markets Segment [Member]", "terseLabel": "Emerging Markets" } } }, "localname": "EmergingMarketsSegmentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "domainItemType" }, "vtrs_EpiPenAutoInjectorLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EpiPen Auto-Injector Litigation", "label": "EpiPen Auto-Injector Litigation [Member]", "terseLabel": "EpiPen Auto-Injector Litigation" } } }, "localname": "EpiPenAutoInjectorLitigationMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_EpiPenAutoInjectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EpiPen\u00ae Auto-Injectors", "label": "EpiPen\u00ae Auto-Injectors [Member]", "terseLabel": "EpiPen\u00ae Auto-Injectors" } } }, "localname": "EpiPenAutoInjectorsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_EquityMethodInvestmentSummarizedFinancialInformationNetAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment Summarized Financial Information, Net Assets", "label": "Equity Method Investment Summarized Financial Information, Net Assets", "terseLabel": "Net assets" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationNetAssets", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsNetAssetsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_EquityMethodInvestmentsNetGainLossFromImpairmentandReductionInObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investments Net Gain (Loss) From Impairment and Reduction In Obligations", "label": "Equity Method Investments Net Gain (Loss) From Impairment and Reduction In Obligations", "terseLabel": "Equity Method Investments Net Gain (Loss) From Impairment and Reduction In Obligations" } } }, "localname": "EquityMethodInvestmentsNetGainLossFromImpairmentandReductionInObligations", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_EquityMethodInvestmentsReductionInLongTermObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investments, Reduction In Long-Term Obligations", "label": "Equity Method Investments, Reduction In Long-Term Obligations", "terseLabel": "Equity Method Investments, Reduction In Long-Term Obligations" } } }, "localname": "EquityMethodInvestmentsReductionInLongTermObligations", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_EuropeSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Europe Segment", "label": "Europe Segment [Member]", "terseLabel": "Europe Segment" } } }, "localname": "EuropeSegmentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_ExpectedFutureBenefitPayments": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Expected Future Benefit Payments", "label": "Expected Future Benefit Payments", "totalLabel": "Total" } } }, "localname": "ExpectedFutureBenefitPayments", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansEstimatedFutureBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_FKBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FKB [Member]", "label": "FKB [Member]", "terseLabel": "FKB" } } }, "localname": "FKBMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_FairValueInputsLongtermRevenueGrowthRateTerminalYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year", "label": "Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year", "terseLabel": "Fair Value Inputs, Long-term Revenue Growth Rate, Terminal Year" } } }, "localname": "FairValueInputsLongtermRevenueGrowthRateTerminalYear", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "percentItemType" }, "vtrs_FiscalYear2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal Year 2017 [Member]", "label": "Fiscal Year 2017 [Member]", "terseLabel": "Fiscal Year 2017" } } }, "localname": "FiscalYear2017Member", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_FutureyearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Future years [Member]", "label": "Future years [Member]", "terseLabel": "2016 through 2035" } } }, "localname": "FutureyearsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_GenericBiologicCompoundsCollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Generic Biologic Compounds Collaboration", "label": "Generic Biologic Compounds Collaboration [Member]", "terseLabel": "Generic Biologic Compounds Collaboration [Member]" } } }, "localname": "GenericBiologicCompoundsCollaborationMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_GenericsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Generics", "label": "Generics [Member]", "terseLabel": "Generics" } } }, "localname": "GenericsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "vtrs_GoodwillImpairedChangeinEstimatePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill, Impaired, Change in Estimate, Period", "label": "Goodwill, Impaired, Change in Estimate, Period", "terseLabel": "Goodwill, Impaired, Change in Estimate, Period" } } }, "localname": "GoodwillImpairedChangeinEstimatePeriod", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "durationItemType" }, "vtrs_GoodwillImpairmentMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Impairment, Measurement Input", "label": "Goodwill Impairment, Measurement Input", "terseLabel": "Goodwill Impairment, Measurement Input" } } }, "localname": "GoodwillImpairmentMeasurementInput", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "decimalItemType" }, "vtrs_GoodwillImpairmentMeasurementInputTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Impairment, Measurement Input, Term", "label": "Goodwill Impairment, Measurement Input, Term", "terseLabel": "Goodwill Impairment, Measurement Input, Term" } } }, "localname": "GoodwillImpairmentMeasurementInputTerm", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "durationItemType" }, "vtrs_GoodwillImpairmentTestMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Impairment Test, Measurement Input", "label": "Goodwill Impairment Test, Measurement Input", "terseLabel": "Rate used to discount net cash inflows to present values" } } }, "localname": "GoodwillImpairmentTestMeasurementInput", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "decimalItemType" }, "vtrs_GoodwillImpairmentTestMeasurementInputIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Impairment Test, Measurement Input, Increase", "label": "Goodwill Impairment Test, Measurement Input, Increase", "terseLabel": "Goodwill Impairment Test, Measurement Input, Increase" } } }, "localname": "GoodwillImpairmentTestMeasurementInputIncrease", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "decimalItemType" }, "vtrs_GoodwillImpairmentTestMeasurementInputReduction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Impairment Test, Measurement Input, Reduction", "label": "Goodwill Impairment Test, Measurement Input, Reduction", "terseLabel": "Goodwill Impairment Test, Measurement Input, Reduction" } } }, "localname": "GoodwillImpairmentTestMeasurementInputReduction", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "decimalItemType" }, "vtrs_GovernmentalRebateProgramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Governmental Rebate Programs [Member]", "label": "Governmental Rebate Programs [Member]", "terseLabel": "Governmental Rebate Programs [Member]" } } }, "localname": "GovernmentalRebateProgramsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "vtrs_GreaterChinaSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Greater China Segment", "label": "Greater China Segment [Member]", "terseLabel": "Greater China" } } }, "localname": "GreaterChinaSegmentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "domainItemType" }, "vtrs_ImpairmentofEquityMethodInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment of Equity Method Investments", "label": "Impairment of Equity Method Investments", "terseLabel": "Impairment of Equity Method Investments" } } }, "localname": "ImpairmentofEquityMethodInvestments", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_IncomeTaxExaminationPartialPaymentOfIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income Tax Examination, Partial Payment Of Income Tax Expense", "label": "Income Tax Examination, Partial Payment Of Income Tax Expense", "terseLabel": "Partial payment of anticipated tax expense" } } }, "localname": "IncomeTaxExaminationPartialPaymentOfIncomeTaxExpense", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_IncomeTaxExaminationReserveForUncertainTaxPosition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income Tax Examination, Reserve for Uncertain Tax Position", "label": "Income Tax Examination, Reserve for Uncertain Tax Position", "terseLabel": "Income Tax Examination, Reserve for Uncertain Tax Position" } } }, "localname": "IncomeTaxExaminationReserveForUncertainTaxPosition", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_IncomeTaxExaminationReserveImpactOnIncomeTaxProvision": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income Tax Examination, Reserve Impact On Income Tax Provision", "label": "Income Tax Examination, Reserve Impact On Income Tax Provision", "terseLabel": "Income Tax Examination, Reserve Impact On Income Tax Provision" } } }, "localname": "IncomeTaxExaminationReserveImpactOnIncomeTaxProvision", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_IncreasedDiscountRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increased Discount Rate [Domain]", "label": "Increased Discount Rate [Domain]", "terseLabel": "Increased Discount Rate [Domain]" } } }, "localname": "IncreasedDiscountRateDomain", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_IndefiniteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indefinite amount of time", "label": "Indefinite [Member]", "terseLabel": "Indefinite" } } }, "localname": "IndefiniteMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_InfluvacMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Influvac \u00ae", "label": "Influvac \u00ae [Member]", "terseLabel": "Influvac \u00ae" } } }, "localname": "InfluvacMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_InsulinAnalogProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insulin Analog Products", "label": "Insulin Analog Products", "terseLabel": "Insulin Analog Products" } } }, "localname": "InsulinAnalogProducts", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_InsulinGlargineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insulin Glargine", "label": "Insulin Glargine [Member]", "terseLabel": "Insulin Glargine" } } }, "localname": "InsulinGlargineMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_JaiPharmaLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jai Pharma Limited", "label": "Jai Pharma Limited [Member]", "terseLabel": "Jai Pharma Limited" } } }, "localname": "JaiPharmaLimitedMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "vtrs_JapanAustraliaAndNewZealandSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Japan, Australia and New Zealand Segment", "label": "Japan, Australia and New Zealand Segment [Member]", "terseLabel": "JANZ" } } }, "localname": "JapanAustraliaAndNewZealandSegmentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsChangesinCarryingAmountOfGoodwillDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableRevenueDisaggregationDetails", "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "domainItemType" }, "vtrs_LesseeOperatingLeaseLeaseNotyetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Amount", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Amount", "terseLabel": "Amount of operating leases not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotyetCommencedAmount", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_LipitorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lipitor \u00ae", "label": "Lipitor \u00ae [Member]", "terseLabel": "Lipitor \u00ae" } } }, "localname": "LipitorMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_LongTermIncentivePlan2003Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-Term Incentive 2003 Plan.", "label": "Long Term Incentive Plan 2003 [Member]", "terseLabel": "Long Term Incentive Plan 2003" } } }, "localname": "LongTermIncentivePlan2003Member", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanTables", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "vtrs_LossContingencyDamagesAwardedOnAppealValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Damages Awarded On Appeal, Value", "label": "Loss Contingency, Damages Awarded On Appeal, Value", "terseLabel": "Loss Contingency, Damages Awarded On Appeal, Value" } } }, "localname": "LossContingencyDamagesAwardedOnAppealValue", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_LossContingencyNumberOfStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of States", "label": "Loss Contingency, Number of States", "terseLabel": "Loss Contingency, Number of States" } } }, "localname": "LossContingencyNumberOfStates", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_LossContingencyOtherAssertedPatentsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Other Asserted Patents, Number", "label": "Loss Contingency, Other Asserted Patents, Number", "terseLabel": "Loss Contingency, Other Asserted Patents, Number" } } }, "localname": "LossContingencyOtherAssertedPatentsNumber", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_LossContingencyRemainingClaimsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Remaining Claims, Number", "label": "Loss Contingency, Remaining Claims, Number", "terseLabel": "Loss Contingency, Remaining Claims, Number" } } }, "localname": "LossContingencyRemainingClaimsNumber", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_LyricaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lyrica \u00ae", "label": "Lyrica \u00ae [Member]", "terseLabel": "Lyrica \u00ae" } } }, "localname": "LyricaMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities", "label": "Marketable Securities [Member]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementFinancialAssetsandLiabilitiesCarriedatFairValueDetails" ], "xbrltype": "domainItemType" }, "vtrs_MaximumLeverageRatioPeriodOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum Leverage Ratio, Period One", "label": "Maximum Leverage Ratio, Period One", "terseLabel": "Maximum Leverage Ratio, Period One" } } }, "localname": "MaximumLeverageRatioPeriodOne", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "pureItemType" }, "vtrs_MaximumLeverageRatioPeriodThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum Leverage Ratio, Period Three", "label": "Maximum Leverage Ratio, Period Three", "terseLabel": "Maximum Leverage Ratio, Period Three" } } }, "localname": "MaximumLeverageRatioPeriodThree", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "pureItemType" }, "vtrs_MaximumLeverageRatioPeriodTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum Leverage Ratio, Period Two", "label": "Maximum Leverage Ratio, Period Two", "terseLabel": "Maximum Leverage Ratio, Period Two" } } }, "localname": "MaximumLeverageRatioPeriodTwo", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "pureItemType" }, "vtrs_MckessonCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "McKesson Corporation [Member]", "label": "McKesson Corporation [Member]", "terseLabel": "McKesson Corporation" } } }, "localname": "MckessonCorporationMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/SegmentInformationThirdPartyNetSalesbyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "vtrs_MeasurementInputEstimatedTaxRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Estimated Tax Rate [Member]", "label": "Measurement Input, Estimated Tax Rate [Member]", "terseLabel": "Measurement Input, Estimated Tax Rate [Member]" } } }, "localname": "MeasurementInputEstimatedTaxRateMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_MeasurementInputIncreaseInDiscountRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Increase in Discount Rate", "label": "Measurement Input, Increase in Discount Rate [Member]", "terseLabel": "Measurement Input, Increase in Discount Rate" } } }, "localname": "MeasurementInputIncreaseInDiscountRateMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_MeasurementInputReductionInTerminalYearRevenueGrowthRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Reduction in Terminal Year Revenue Growth Rate", "label": "Measurement Input, Reduction in Terminal Year Revenue Growth Rate [Member]", "terseLabel": "Measurement Input, Reduction in Terminal Year Revenue Growth Rate" } } }, "localname": "MeasurementInputReductionInTerminalYearRevenueGrowthRateMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_MeasurementInputTerminalYearRevenueGrowthRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Terminal Year Revenue Growth Rate", "label": "Measurement Input, Terminal Year Revenue Growth Rate [Member]", "terseLabel": "Measurement Input, Terminal Year Revenue Growth Rate" } } }, "localname": "MeasurementInputTerminalYearRevenueGrowthRateMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_Medicaidandothergovernmentalrebates": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails": { "order": 4.0, "parentTag": "vtrs_SalesRevenueGrosstonetadjustments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Medicaid and other governmental rebates", "label": "Medicaid and other governmental rebates", "negatedTerseLabel": "Medicaid and other governmental rebates" } } }, "localname": "Medicaidandothergovernmentalrebates", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_MomentaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Momenta [Member]", "label": "Momenta [Member]", "terseLabel": "Momenta" } } }, "localname": "MomentaMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_MultiDistrictLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multi District Litigation [Member]", "label": "Multi District Litigation [Member]", "terseLabel": "MDL" } } }, "localname": "MultiDistrictLitigationMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_Netaccruedbenefitcosts": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net accrued benefit costs", "label": "Net accrued benefit costs", "negatedTotalLabel": "Net accrued benefit costs" } } }, "localname": "Netaccruedbenefitcosts", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansNetAccruedBenefitCostsClassificationonBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_Netrealizablevalueofinventoryrecognizedasexpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net realizable value of inventory recognized as expense", "label": "Net realizable value of inventory recognized as expense", "terseLabel": "Net realizable value of inventory recognized as expense" } } }, "localname": "Netrealizablevalueofinventoryrecognizedasexpense", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsInventoriesDetails", "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_NonU.S.statetaxauthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-U.S. state tax authority [Member]", "label": "Non-U.S. state tax authority [Member]", "terseLabel": "Non-U.S. state tax authority" } } }, "localname": "NonU.S.statetaxauthorityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "domainItemType" }, "vtrs_NorthAmericaGenericsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "North America Generics [Member]", "label": "North America Generics [Member]", "terseLabel": "North America Generics [Member]" } } }, "localname": "NorthAmericaGenericsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_NorthAmericaSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "North America Segment", "label": "North America Segment [Member]", "terseLabel": "North America Segment" } } }, "localname": "NorthAmericaSegmentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_NorthAmericaSpecialtyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "North America Specialty [Member]", "label": "North America Specialty [Member]", "terseLabel": "North America Specialty [Member]" } } }, "localname": "NorthAmericaSpecialtyMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_NorvascMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Norvasc \u00ae", "label": "Norvasc \u00ae [Member]", "terseLabel": "Norvasc \u00ae" } } }, "localname": "NorvascMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_NotSubjecttoMarketConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Not Subject to Market Conditions [Member]", "label": "Not Subject to Market Conditions [Member]", "terseLabel": "Not subject to market conditions" } } }, "localname": "NotSubjecttoMarketConditionsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_NoteSecuritizationFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Securitization Facility [Member]", "label": "Note Securitization Facility [Member]", "terseLabel": "Note Securitization Facility [Member]" } } }, "localname": "NoteSecuritizationFacilityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtShorttermborrowingsDetails" ], "xbrltype": "domainItemType" }, "vtrs_NumberOfDrugs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of drugs", "label": "Number of drugs", "terseLabel": "Number of drugs" } } }, "localname": "NumberOfDrugs", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_NumberOfManufacturingSites": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Manufacturing Sites", "label": "Number Of Manufacturing Sites", "terseLabel": "Number Of Manufacturing Sites" } } }, "localname": "NumberOfManufacturingSites", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/NatureofOperationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_NumberOfMolecules": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Molecules", "label": "Number Of Molecules", "terseLabel": "Number Of Molecules" } } }, "localname": "NumberOfMolecules", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/NatureofOperationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_NumberOfProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Products", "label": "Number Of Products", "terseLabel": "Number Of Products" } } }, "localname": "NumberOfProducts", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_NumberOfTimesDamagesMayBeIncreasedInCasesOfWillfulInfringement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of times damages may be increased in cases of willful infringement", "label": "Number of times damages may be increased in cases of willful infringement", "terseLabel": "Number of times damages may be increased in cases of willful infringement" } } }, "localname": "NumberOfTimesDamagesMayBeIncreasedInCasesOfWillfulInfringement", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_Numberofcases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of cases", "label": "Number of cases", "terseLabel": "Number of cases" } } }, "localname": "Numberofcases", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_Numberofequitymethodinvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of equity method investments", "label": "Number of equity method investments", "terseLabel": "Number of equity method investments" } } }, "localname": "Numberofequitymethodinvestments", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_Numberofstates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of states", "label": "Number of states", "terseLabel": "Number of states" } } }, "localname": "Numberofstates", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "vtrs_OneTimeSpecialPerformanceBasedFiveYearRealizableValueIncentiveProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One-Time Special Performance-Based Five-Year Realizable Value Incentive Program", "label": "One-Time Special Performance-Based Five-Year Realizable Value Incentive Program [Member]", "terseLabel": "One-Time Special Performance-Based Five-Year Realizable Value Incentive Program" } } }, "localname": "OneTimeSpecialPerformanceBasedFiveYearRealizableValueIncentiveProgramMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_OtherCompaniesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other companies", "label": "Other Companies [Member]", "terseLabel": "Other companies" } } }, "localname": "OtherCompaniesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_OtherComprehensiveIncomeDefinedBenefitPlanForeignCurrencyTranslationBeforeTax": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income Defined Benefit Plan Foreign Currency Translation Before Tax", "label": "OtherComprehensiveIncomeDefinedBenefitPlanForeignCurrencyTranslationBeforeTax", "negatedTerseLabel": "Impact of foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanForeignCurrencyTranslationBeforeTax", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EmployeeBenefitPlansChangeinAccumulatedIncomeLossRelatingtoDefinedBenefitPensionandOtherPostretirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_OtherCurrentPortionofLongtermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Current Portion of Long-term Debt [Member]", "label": "Other Current Portion of Long-term Debt [Member]", "terseLabel": "Other Current Portion of Long-term Debt" } } }, "localname": "OtherCurrentPortionofLongtermDebtMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtShorttermborrowingsDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_OtherLongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other long term debt.", "label": "Other Long Term Debt [Member]", "terseLabel": "Other Long Term Debt" } } }, "localname": "OtherLongTermDebtMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "", "label": "Other [Member]", "terseLabel": "Other Foreign Operations" } } }, "localname": "OtherMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails", "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_OtherOneTimeNonoperatingExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other One-Time Nonoperating Expense", "label": "Other One-Time Nonoperating Expense", "negatedTerseLabel": "Transaction related and other special items" } } }, "localname": "OtherOneTimeNonoperatingExpense", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/SegmentInformationReconciliationofSegmentInformationtoTotalConsolidatedInformationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_OtherforeignMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other foreign [Member]", "label": "Other foreign [Member]", "terseLabel": "Other foreign" } } }, "localname": "OtherforeignMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesStatutoryTaxRatetoEffectiveTaxRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "vtrs_Otherlongtermassets": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other long-term assets", "label": "Other long-term assets", "terseLabel": "Other long-term assets" } } }, "localname": "Otherlongtermassets", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_PaymentsForNonContingentConsiderationForProductRightsFinancingActivities": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for Non-Contingent Consideration for Product Rights, Financing Activities", "label": "Payments for Non-Contingent Consideration for Product Rights, Financing Activities", "negatedTerseLabel": "Non-contingent payments for product rights" } } }, "localname": "PaymentsForNonContingentConsiderationForProductRightsFinancingActivities", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "vtrs_PaymentsToAcquireCollaborativeAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Collaborative Agreement", "label": "Payments To Acquire Collaborative Agreement", "terseLabel": "Upfront payments" } } }, "localname": "PaymentsToAcquireCollaborativeAgreement", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_PaymentsforBusinessSeparation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments for Business Separation", "label": "Payments for Business Separation", "terseLabel": "Payments for Business Separation" } } }, "localname": "PaymentsforBusinessSeparation", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_PeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period [Axis]", "label": "Period [Axis]", "terseLabel": "Period [Axis]" } } }, "localname": "PeriodAxis", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "vtrs_PeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Period [Axis]", "label": "Period [Domain]", "terseLabel": "Period [Domain]" } } }, "localname": "PeriodDomain", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails", "http://www.viatris.com/role/EmployeeBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_PfizerInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pfizer, Inc. [Member]", "label": "Pfizer, Inc. [Member]", "terseLabel": "Pfizer, Inc." } } }, "localname": "PfizerInc.Member", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "domainItemType" }, "vtrs_ProductLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Liability", "label": "Product Liability [Member]", "terseLabel": "Product Liability" } } }, "localname": "ProductLiabilityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_ProductRightsAndLicensesByTherapeuticCategoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product rights and licenses by therapeutic category", "label": "Product Rights And Licenses By Therapeutic Category [Table Text Block]", "terseLabel": "Product rights and licenses by therapeutic category" } } }, "localname": "ProductRightsAndLicensesByTherapeuticCategoryTableTextBlock", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "vtrs_ProgramNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Program Name", "label": "Program Name [Axis]", "terseLabel": "Program Name [Axis]" } } }, "localname": "ProgramNameAxis", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanTables", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "vtrs_ProgramNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Program Name", "label": "Program Name [Domain]", "terseLabel": "Program Name [Domain]" } } }, "localname": "ProgramNameDomain", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanTables", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "vtrs_RebatesPromotionalProgramsandOtherSalesAllowancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rebates, Promotional Programs and Other Sales Allowances [Member]", "label": "Rebates, Promotional Programs and Other Sales Allowances [Member]", "terseLabel": "Rebates, Promotional Programs and Other Sales Allowances [Member]" } } }, "localname": "RebatesPromotionalProgramsandOtherSalesAllowancesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "vtrs_ReceivablesFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Receivables facility.", "label": "Receivables Facility [Member]", "terseLabel": "Receivables Facility [Member]" } } }, "localname": "ReceivablesFacilityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtDebtReceivablesFacilityandCommercialPaperProgramDetails", "http://www.viatris.com/role/DebtShorttermborrowingsDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_ReductioninEquityMethodInvestmentLongTermObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction in Equity Method Investment Long-Term Obligation", "label": "Reduction in Equity Method Investment Long-Term Obligation", "terseLabel": "Reduction in Equity Method Investment Long-Term Obligation" } } }, "localname": "ReductioninEquityMethodInvestmentLongTermObligation", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/EquityMethodInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_ReductioninSharebasedCompensationExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction in Share-based Compensation Expense", "label": "Reduction in Share-based Compensation Expense", "terseLabel": "Reduction in Share-based Compensation Expense" } } }, "localname": "ReductioninSharebasedCompensationExpense", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_ReductioninTerminalValueGrowthRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reduction in Terminal Value Growth Rate [Domain]", "label": "Reduction in Terminal Value Growth Rate [Domain]", "terseLabel": "Reduction in Terminal Value Growth Rate [Domain]" } } }, "localname": "ReductioninTerminalValueGrowthRateDomain", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_ReserveForUncertainTaxPositionsIncludingInterestAndPenalties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reserve for Uncertain Tax Positions, Including Interest And Penalties", "label": "Reserve for Uncertain Tax Positions, Including Interest And Penalties", "terseLabel": "Reserve for Uncertain Tax Positions, Including Interest And Penalties" } } }, "localname": "ReserveForUncertainTaxPositionsIncludingInterestAndPenalties", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_RespiratorydeliveryplatformMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Respiratory delivery platform [Member]", "label": "Respiratory delivery platform [Member]", "terseLabel": "Respiratory delivery platform [Member]" } } }, "localname": "RespiratorydeliveryplatformMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails", "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_RestofWorldSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest of World Segment", "label": "Rest of World Segment [Member]", "terseLabel": "Rest of World Segment" } } }, "localname": "RestofWorldSegmentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.viatris.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_RestructuringAndRelatedCostExpectedNumberOfFacilitiesToBeEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring and Related Cost, Expected Number of Facilities to be Eliminated", "label": "Restructuring and Related Cost, Expected Number of Facilities to be Eliminated", "terseLabel": "Restructuring and Related Cost, Expected Number of Facilities to be Eliminated" } } }, "localname": "RestructuringAndRelatedCostExpectedNumberOfFacilitiesToBeEliminated", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "integerItemType" }, "vtrs_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent", "terseLabel": "Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent" } } }, "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "percentItemType" }, "vtrs_RestructuringReserveAcquiredDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restructuring Reserve, Acquired During Period", "label": "Restructuring Reserve, Acquired During Period", "terseLabel": "Restructuring Reserve, Acquired During Period" } } }, "localname": "RestructuringReserveAcquiredDuringPeriod", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_RestructuringReserveReimbursableRestructuringCharges": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restructuring Reserve, Reimbursable Restructuring Charges", "label": "Restructuring Reserve, Reimbursable Restructuring Charges", "terseLabel": "Restructuring Reserve, Reimbursable Restructuring Charges" } } }, "localname": "RestructuringReserveReimbursableRestructuringCharges", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_RevanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revance [Member]", "label": "Revance [Member]", "terseLabel": "Revance [Member]" } } }, "localname": "RevanceMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_RevenuefromContractwithCustomerGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from Contract with Customer, Gross", "label": "Revenue from Contract with Customer, Gross", "terseLabel": "Gross sales" } } }, "localname": "RevenuefromContractwithCustomerGross", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_RevenuefromContractwithCustomerReturns": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails": { "order": 3.0, "parentTag": "vtrs_SalesRevenueGrosstonetadjustments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue from Contract with Customer, Returns", "label": "Revenue from Contract with Customer, Returns", "negatedTerseLabel": "Returns" } } }, "localname": "RevenuefromContractwithCustomerReturns", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_SalesMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales Milestone Payments", "label": "Sales Milestone Payments", "terseLabel": "Sales Milestone Payments" } } }, "localname": "SalesMilestonePayments", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_SalesRevenueGrosstonetadjustments": { "auth_ref": [], "calculation": { "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales Revenue, Gross to net adjustments", "label": "Sales Revenue, Gross to net adjustments", "totalLabel": "Sales Revenue, Gross to net adjustments" } } }, "localname": "SalesRevenueGrosstonetadjustments", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_ScheduleOfProductRightsAndLicensesByTherapeuticClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Product Rights and Licenses by Therapeutic Class", "label": "Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]", "terseLabel": "Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]" } } }, "localname": "ScheduleOfProductRightsAndLicensesByTherapeuticClassLineItems", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails" ], "xbrltype": "stringItemType" }, "vtrs_ScheduleOfProductRightsAndLicensesByTherapeuticClassTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Product Rights and Licenses by Therapeutic Class", "label": "Schedule of Product Rights and Licenses by Therapeutic Class [Table]", "terseLabel": "Schedule of Product Rights and Licenses by Therapeutic Class [Table]" } } }, "localname": "ScheduleOfProductRightsAndLicensesByTherapeuticClassTable", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/GoodwillandOtherIntangibleAssetsProductRightsandLicensebyTherapeuticCategoryDetails" ], "xbrltype": "stringItemType" }, "vtrs_ScheduleofActivityinContingentConsiderationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Activity in Contingent Consideration [Roll Forward]", "label": "Schedule of Activity in Contingent Consideration [Roll Forward]", "terseLabel": "Schedule of Activity in Contingent Consideration [Roll Forward]" } } }, "localname": "ScheduleofActivityinContingentConsiderationRollForward", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementRollforwardofContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "vtrs_ScheduleofCashCashEquivalentsandRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Table Text Block] for Schedule of Cash, Cash Equivalents and Restricted Cash [Table]", "label": "Schedule of Cash, Cash Equivalents and Restricted Cash [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "ScheduleofCashCashEquivalentsandRestrictedCashTableTextBlock", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "vtrs_ScheduleofOtherAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Other Assets [Table]", "label": "Schedule of Other Assets [Line Items]", "terseLabel": "Schedule of Other Assets [Line Items]" } } }, "localname": "ScheduleofOtherAssetsLineItems", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails" ], "xbrltype": "stringItemType" }, "vtrs_ScheduleofOtherAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Other Assets [Table]", "label": "Schedule of Other Assets [Table]", "terseLabel": "Schedule of Other Assets [Table]" } } }, "localname": "ScheduleofOtherAssetsTable", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherAssetsDetails" ], "xbrltype": "stringItemType" }, "vtrs_ScheduleofOtherNoncurrentLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Other Noncurrent Liabilities [Table]", "label": "Schedule of Other Noncurrent Liabilities [Line Items]", "terseLabel": "Schedule of Other Noncurrent Liabilities [Line Items]" } } }, "localname": "ScheduleofOtherNoncurrentLiabilitiesLineItems", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails" ], "xbrltype": "stringItemType" }, "vtrs_ScheduleofOtherNoncurrentLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Other Noncurrent Liabilities [Table]", "label": "Schedule of Other Noncurrent Liabilities [Table]", "terseLabel": "Schedule of Other Noncurrent Liabilities [Table]" } } }, "localname": "ScheduleofOtherNoncurrentLiabilitiesTable", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOthernoncurrentliabilitiesDetails" ], "xbrltype": "stringItemType" }, "vtrs_ScheduleofothercurrentliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of other current liabilities [Table]", "label": "Schedule of other current liabilities [Line Items]", "terseLabel": "Schedule of other current liabilities [Line Items]" } } }, "localname": "ScheduleofothercurrentliabilitiesLineItems", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "vtrs_ScheduleofothercurrentliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of other current liabilities [Table]", "label": "Schedule of other current liabilities [Table]", "terseLabel": "Schedule of other current liabilities [Table]" } } }, "localname": "ScheduleofothercurrentliabilitiesTable", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "vtrs_SeniorNotes2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2021", "label": "Senior Notes 2021 [Member]", "terseLabel": "Senior Notes 2021" } } }, "localname": "SeniorNotes2021Member", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotes2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 2022", "label": "Senior Notes 2022 [Member]", "terseLabel": "Senior Notes 2022" } } }, "localname": "SeniorNotes2022Member", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandEighteen2.6PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Two Thousand Eighteen - 2.6% [Member]", "label": "Senior Notes Two Thousand Eighteen - 2.6 Percent [Member]", "terseLabel": "2018 Senior Notes (2.600%)" } } }, "localname": "SeniorNotesTwoThousandEighteen2.6PercentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandEighteen3.0PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Two Thousand Eighteen - 3.0 Percent", "label": "Senior Notes Two Thousand Eighteen - 3.0 Percent [Member]", "verboseLabel": "2018 Senior Notes (3.000% coupon)" } } }, "localname": "SeniorNotesTwoThousandEighteen3.0PercentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandFortySix5.25PrecentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2046 Senior Note (5.250%)", "label": "SeniorNotesTwoThousandFortySix5.25Precent [Member]", "terseLabel": "2046 Senior Notes (5.250%)" } } }, "localname": "SeniorNotesTwoThousandFortySix5.25PrecentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandFortyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior notes two thousand forty three", "label": "SeniorNotesTwoThousandFortyThree [Member]", "terseLabel": "2043 Senior Notes (5.400%)" } } }, "localname": "SeniorNotesTwoThousandFortyThreeMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandNineteen2.50PrecentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Senior Notes (2.500%)", "label": "SeniorNotesTwoThousandNineteen2.50Precent [Member]", "terseLabel": "2019 Senior Notes (2.500%)" } } }, "localname": "SeniorNotesTwoThousandNineteen2.50PrecentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior notes two thousand nineteen", "label": "SeniorNotesTwoThousandNineteen [Member]", "terseLabel": "2019 Senior Notes (2.550%)" } } }, "localname": "SeniorNotesTwoThousandNineteenMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandTwenty3.75PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Two Thousand Twenty - 3.75 Percent", "label": "Senior Notes Two Thousand Twenty - 3.75 Percent [Member]", "verboseLabel": "2020 Senior Notes (3.750% coupon)" } } }, "localname": "SeniorNotesTwoThousandTwenty3.75PercentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandTwentyOne3.15PrecentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Senior Notes 3.15%", "label": "SeniorNotesTwoThousandTwentyOne3.15Precent [Member]", "terseLabel": "2021 Senior Notes (3.150%)" } } }, "localname": "SeniorNotesTwoThousandTwentyOne3.15PrecentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandTwentySix3.95PrecentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2026 Senior Notes 3.950%", "label": "SeniorNotesTwoThousandTwentySix3.95Precent [Member]", "terseLabel": "2026 Senior Notes (3.950%)" } } }, "localname": "SeniorNotesTwoThousandTwentySix3.95PrecentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandTwentyThree3.125PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior notes two thousand twenty three - 3.125 percent", "label": "SeniorNotesTwoThousandTwentyThree3.125Percent [Member]", "verboseLabel": "Senior Notes 2023 3.125%" } } }, "localname": "SeniorNotesTwoThousandTwentyThree3.125PercentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementEffectofDerivativeInstrumentsontheConsolidatedStatementsofOperationsDerivativesinFairValueHedgingRelationshipsDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_SeniorNotesTwoThousandTwentyThree4.2PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior notes two thousand twenty three - 4.2 percent", "label": "SeniorNotesTwoThousandTwentyThree4.2Percent [Member]", "terseLabel": "2023 Senior Notes (4.200%)" } } }, "localname": "SeniorNotesTwoThousandTwentyThree4.2PercentMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by Share-based payment award, fair value assumptions, Forfeiture rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "terseLabel": "Forfeiture rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "vtrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValueAndEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Total Intrinsic Value And Equity Instruments Other Than Options, Vested In Period, Intrinsic Value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Total Intrinsic Value And Equity Instruments Other Than Options, Vested In Period, Intrinsic Value", "verboseLabel": "Intrinsic value of stock-based awards exercised and restricted stock units converted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValueAndEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vtrs_StockExchangedDuringPeriodSharesExchanged": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Exchanged During Period, Shares, Exchanged", "label": "Stock Exchanged During Period, Shares, Exchanged", "negatedTerseLabel": "Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock (in shares)" } } }, "localname": "StockExchangedDuringPeriodSharesExchanged", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "vtrs_StockExchangedDuringPeriodValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock Exchanged During Period, Value", "label": "Stock Exchanged During Period, Value", "negatedTerseLabel": "Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock" } } }, "localname": "StockExchangedDuringPeriodValue", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "vtrs_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTenderedForPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Stock Options Exercised, Net of Shares Tendered for Payment", "label": "Stock Issued During Period, Value, Stock Options Exercised, Net of Shares Tendered for Payment", "terseLabel": "Issuance of restricted stock and stock options exercised, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesTenderedForPayment", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "vtrs_StockappreciationrightsandperformancesharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock appreciation rights and performance shares", "label": "Stock appreciation rights and performance shares [Member]", "terseLabel": "Stock appreciation rights and performance shares" } } }, "localname": "StockappreciationrightsandperformancesharesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails", "http://www.viatris.com/role/ShareBasedIncentivePlanValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "vtrs_SubjectToMarketConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subject to Market Conditions", "label": "Subject to Market Conditions [Member]", "terseLabel": "Subject to Market Conditions" } } }, "localname": "SubjectToMarketConditionsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_SubjecttoMarketConditionsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subject to Market Conditions [Axis]", "label": "Subject to Market Conditions [Axis]", "terseLabel": "Subject to Market Conditions [Axis]" } } }, "localname": "SubjecttoMarketConditionsAxis", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "stringItemType" }, "vtrs_SubjecttoMarketConditionsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Subject to Market Conditions [Axis]", "label": "Subject to Market Conditions [Domain]", "terseLabel": "Subject to Market Conditions [Domain]" } } }, "localname": "SubjecttoMarketConditionsDomain", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_TOBIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TOBI [Member]", "label": "TOBI [Member]", "terseLabel": "TOBI" } } }, "localname": "TOBIMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails" ], "xbrltype": "domainItemType" }, "vtrs_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSummaryofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "vtrs_TheravanceBiopharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Theravance Biopharma", "label": "Theravance Biopharma [Member]", "terseLabel": "Theravance" } } }, "localname": "TheravanceBiopharmaMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CollaborationandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_ThreeCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Customers", "label": "Three Customers [Member]", "terseLabel": "Three Customers" } } }, "localname": "ThreeCustomersMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails" ], "xbrltype": "domainItemType" }, "vtrs_ThreeFullFiscalQuartersFollowingQualifyingAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Full Fiscal Quarters Following Qualifying Acquisition [Member]", "label": "Three Full Fiscal Quarters Following Qualifying Acquisition [Member]", "terseLabel": "Three Full Fiscal Quarters Following Qualifying Acquisition" } } }, "localname": "ThreeFullFiscalQuartersFollowingQualifyingAcquisitionMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vtrs_TrailingFourQuartersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trailing Four Quarters", "label": "Trailing Four Quarters [Member]", "terseLabel": "Trailing Four Quarters" } } }, "localname": "TrailingFourQuartersMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtRevolvingFacilitiesandTermFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vtrs_TransitionServiceAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Service Agreements", "label": "Transition Service Agreements [Member]", "terseLabel": "Transition Service Agreements" } } }, "localname": "TransitionServiceAgreementsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/CommitmentsDetails" ], "xbrltype": "domainItemType" }, "vtrs_TwentyTwentyOneLoanFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty Twenty One Loan Facilities", "label": "Twenty Twenty One Loan Facilities [Member]", "terseLabel": "Twenty Twenty One Loan Facilities" } } }, "localname": "TwentyTwentyOneLoanFacilitiesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_TwentyTwentyOneRevolvingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty Twenty One Revolving Facility", "label": "Twenty Twenty One Revolving Facility [Member]", "terseLabel": "Twenty Twenty One Revolving Facility" } } }, "localname": "TwentyTwentyOneRevolvingFacilityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.K. Competition and Markets Authority Proceedings Paroxetine", "label": "U.K. Competition and Markets Authority Proceedings Paroxetine [Member]", "terseLabel": "U.K. Competition and Markets Authority Proceedings Paroxetine" } } }, "localname": "U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/LitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_U.S.FederalTaxAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Federal Tax Authority [Member]", "label": "U.S. Federal Tax Authority [Member]", "terseLabel": "U.S. Federal Tax Authority" } } }, "localname": "U.S.FederalTaxAuthorityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_U.S.StateTaxAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. State Tax Authority [Member]", "label": "U.S. State Tax Authority [Member]", "terseLabel": "U.S. State Tax Authority" } } }, "localname": "U.S.StateTaxAuthorityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/IncomeTaxesNarrativeDetails", "http://www.viatris.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionDetails" ], "xbrltype": "domainItemType" }, "vtrs_USDTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USD Term Loan Facility", "label": "USD Term Loan Facility [Member]", "terseLabel": "USD Term Loan Facility" } } }, "localname": "USDTermLoanFacilityMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_UnregisteredUpjohnUSDollarNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unregistered Upjohn U.S. Dollar Notes", "label": "Unregistered Upjohn U.S. Dollar Notes [Member]", "terseLabel": "Unregistered Upjohn U.S. Dollar Notes" } } }, "localname": "UnregisteredUpjohnUSDollarNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_UpjohnEuroNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Upjohn Euro Notes", "label": "Upjohn Euro Notes [Member]", "terseLabel": "Upjohn Euro Notes" } } }, "localname": "UpjohnEuroNotesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "vtrs_UpjohnInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Upjohn Inc. [Member]", "label": "Upjohn Inc. [Member]", "terseLabel": "Upjohn Inc." } } }, "localname": "UpjohnInc.Member", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/AcquisitionsandOtherTransactionsOtherTransactionsNarrativeDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsPurchasePriceAllocationsDetails", "http://www.viatris.com/role/AcquisitionsandOtherTransactionsUnauditedProFormaFinancialResultsDetails", "http://www.viatris.com/role/DebtFairValueNarrativeDetails", "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/DebtTables", "http://www.viatris.com/role/DebtUpjohnSeniorNotesDetails", "http://www.viatris.com/role/Restructuring2020RestructuringPlanDetails" ], "xbrltype": "domainItemType" }, "vtrs_VariableConsiderationCategoryAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Consideration Category [Axis]", "label": "Variable Consideration Category [Axis]", "terseLabel": "Variable Consideration Category [Axis]" } } }, "localname": "VariableConsiderationCategoryAxis", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "stringItemType" }, "vtrs_VariableConsiderationCategoryDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Variable Consideration Category [Axis]", "label": "Variable Consideration Category [Domain]", "terseLabel": "Variable Consideration Category [Domain]" } } }, "localname": "VariableConsiderationCategoryDomain", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "vtrs_VariableConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Consideration [Member]", "label": "Variable Consideration [Member]", "terseLabel": "Variable Consideration [Member]" } } }, "localname": "VariableConsiderationMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableAccountsReceivableNetDetails", "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "vtrs_VariableConsiderationReturnsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Consideration Returns [Member]", "label": "Variable Consideration Returns [Member]", "terseLabel": "Variable Consideration Returns [Member]" } } }, "localname": "VariableConsiderationReturnsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableVariableConsiderationRollforwardDetails" ], "xbrltype": "domainItemType" }, "vtrs_VestingPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Period [Axis]", "label": "Vesting Period [Axis]", "terseLabel": "Vesting Period [Axis]" } } }, "localname": "VestingPeriodAxis", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "stringItemType" }, "vtrs_VestingPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Vesting Period [Axis]", "label": "Vesting Period [Domain]", "terseLabel": "Vesting Period [Domain]" } } }, "localname": "VestingPeriodDomain", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_VestinthreeyearsorlessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vest in three years or less", "label": "Vest in three years or less [Member]", "terseLabel": "Vest after three years" } } }, "localname": "VestinthreeyearsorlessMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_VestratablyinfiveyearsorlessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vest ratably in five years or less [Member]", "label": "Vest ratably in five years or less [Member]", "terseLabel": "Vest ratably in five years or less [Member]" } } }, "localname": "VestratablyinfiveyearsorlessMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/ShareBasedIncentivePlanNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_ViagraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Viagra \u00ae", "label": "Viagra \u00ae [Member]", "terseLabel": "Viagra \u00ae" } } }, "localname": "ViagraMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_VoluntaryRecallofValsartanandCertainCombinationsValsartanMedicinesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voluntary Recall of Valsartan and Certain Combinations Valsartan Medicines [Member]", "label": "Voluntary Recall of Valsartan and Certain Combinations Valsartan Medicines [Member]", "terseLabel": "Voluntary Recall of Valsartan and Certain Combinations Valsartan Medicines [Member]" } } }, "localname": "VoluntaryRecallofValsartanandCertainCombinationsValsartanMedicinesMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/BalanceSheetComponentsNarrativeDetails", "http://www.viatris.com/role/BalanceSheetComponentsOtherCurrentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "vtrs_XalabrandsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xalabrands", "label": "Xalabrands [Member]", "terseLabel": "Xalabrands" } } }, "localname": "XalabrandsMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_XanaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xanax \u00ae", "label": "Xanax \u00ae [Member]", "terseLabel": "Xanax \u00ae" } } }, "localname": "XanaxMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_YENTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "YEN Term Loan", "label": "YEN Term Loan [Member]", "terseLabel": "YEN Term Loan" } } }, "localname": "YENTermLoanMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/DebtSeniorNotesDetails", "http://www.viatris.com/role/FinancialInstrumentsandRiskManagementNarrativeDetails" ], "xbrltype": "domainItemType" }, "vtrs_YupelriMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yupelri \u00ae", "label": "Yupelri \u00ae [Member]", "terseLabel": "Yupelri \u00ae" } } }, "localname": "YupelriMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" }, "vtrs_ZoloftMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zoloft \u00ae", "label": "Zoloft \u00ae [Member]", "terseLabel": "Zoloft \u00ae" } } }, "localname": "ZoloftMember", "nsuri": "http://www.viatris.com/20211231", "presentation": [ "http://www.viatris.com/role/RevenueRecognitionandAccountsReceivableDisaggregationofRevenuebyKeyProductsDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 18 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r1000": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r1001": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r1002": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "02" }, "r1003": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(ii)", "Subsection": "01" }, "r1004": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)", "Subsection": "01" }, "r1005": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "01" }, "r1006": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "02" }, "r1007": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "01" }, "r1008": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "02" }, "r1009": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(C)", "Subsection": "02" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r1010": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r1011": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r1012": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r1013": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6283291-111563" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=124268079&loc=d3e32787-111569" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4578-108314" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350" }, "r402": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(b)(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(m)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(s)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r602": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r642": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r694": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r719": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r723": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1),(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r801": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "825", "URI": "http://asc.fasb.org/topic&trid=2134543" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "210-10-S99-1(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r814": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718" }, "r823": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r835": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e526-108580" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(g)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r967": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r968": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r969": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r970": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r971": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r972": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r973": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r974": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r975": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r976": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r977": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r978": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r979": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r980": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r981": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r982": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r983": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r984": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r985": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r986": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r987": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r988": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r989": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r990": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r991": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r992": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r993": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r994": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r995": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r996": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r997": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r998": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r999": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" } }, "version": "2.1" } ZIP 152 0001792044-22-000010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001792044-22-000010-xbrl.zip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�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�#ZBT)@^YZS"5MS-(_( >&\C#,%._"N+ M=("(R(0B /\[7EJ__/[^)^M'\,MLZ^<4#'[YV:'\Z@,YJ,K",Y(-@62)=1PC MXTU) 7!,YM(J/E0Q#F6V;((L8;"N/.\C[Q##](1(R\@I'#"0YEYBW41@1(;V,$X0JT)O-_'A.F1F&@<$P!?YE I\-/<)*HU.BWP [UL+/]IG"U%#.5))M&I&D9[!!7 X,P2I5TF\#CY .9A0H=:VR4!X.8ED/$@NB*ZEI+.SD& MIY/6RM^(3FX43 G7$1Z%*=R$>.\7+)"1T\_3"2$:^[U2;4C5D-X& U'G7',) MFQ08*HXQ&BAQ#H:]0MNI#*B.(JR)P&JRTKU*\@G<>@'T+I?[-F M9(^*[-OBU7/V[T"6!E,)&:?FI5.GX+\%261;)(LU@AU8W7Y"\XS%G0\;0;:^ MSDL:P3U6*$Q.231-S:E/$ 4T'@MT@M$PM8?%T$&)U5YAX[,BC'Z$F0;BE8IR*\)?I&TM.Y]Q/4?4$T^4(K MQX6+4HQ$5^]G(4P)6""(QN@6J%HQM%3B*2<=^3MV)8 M0O^5S2AOO)@S,EEO)@SZ M>?_TJHJH5$=2=/"$?-0%Y/%6I8%L+JX*C>!%1@(ZJS02;8%-Y M)=#6:"JVS(0J>"SZ!E@)@4]_I>!&X-V7[$M-KM5 T[:T"ORYKY"WI"0@6Y(0 MN"GHEV=X3)O2AC<%6HYS$=\("8>MXRMD(F$Y&F8+L/Q10@[;$HPJ%U(!,$IB MEZS10M"%UH[\@#U/A G&C7NBC84<[Y] E7T"_]*/EK'),XQ A[).Y=V M^ 9(3;3#IVRQ"(1DVI\R#Q@1-*CU7LN&ZUP%'R&[J#*PZW#B(+_0<4^2#)/R M*G5460%G&TTSL+)H*;,4NA4'5;'<,,$$YV' X>7;5%G(::,I>XN4B%BBIX73 ML-6?KZT?G7\Y7 :4>K=@-><>]J=LS',^0IJ_UT5*)0PV>\,Z*_>&'E^I8WS* MK2GP"PY;V*NZ9TGSE533T_C]N:C*A*L@[%I6.)OTSV=Y=T[5&!N)0M@ODV!V M@4?74LY>Y5BTFFZ45-<%=![(?/#4.5L92VM)W@1=+1M&CEC9Y])L2Z/J3[+M MYX5?:N84+;S8!V,)3L>A72,RC"D$**_PLOD'!B_9HG B-3%U^$Q?Y"!\.QD3 MW+1#.NF/N2LP>H#M,-@+IBZW:TE5 5OEY_2AWXM_;-Y_.;^J%=-U@Z7NF%7D MK.*<\I4\^RI4O8#.4V[_Z>K]JM@F=M*HK$C7]A<"J9B51 \,G3959T ?-89Q M0" 4_X6/L&R\0G*\/'');_SUU[8F]*M8TK#VIM&,"\RK=M6F5O- M-VKG76IREH63LWQ.VTC+@6]RH/+"LMVL'D)EUW=%Y# JWI,' MH@J%^#87)5(Y?C*)_7%>D&]\G*D+0M$0I:^L"_J$DC2<(3)HH)/F*FN>B6[$385];%^V75B!N"'-@ M!E]2:405M"G]LV]^4JO4ZJM,E+VHLHWU&KX=97XN M5B^%5%&';]Y<+%^: X01I3_@(_)F,9IG)L71BI.+EA=QRI_7=^EVII#R&"N( M5'AB6\)\!GL3EH++N#9K!'8FD,'X\$\_Z!KRRH.P[JL/DK9,+SJ::T8#7NX^ M0.&D0.+U8G+5<]PJ9@"BX4_Y624;\YMI="-K%L48E-TD!2NDCTQ9D/C)?\'_ M0U))/Z+(@6MI1/O7JZ;3VNC?A?>2>_FN%;WY3HX%;Z06BW%10AL319G!%&4M M4\&$N> JU^Y63O4E2W!Y>V#376&Y-TDBD:$*"+@QG]:-A,0!4+]-X#C:,O= MMY6+:RQ4XN2T$*HL2!/3SKTY)B%V>N>"'T:#I#:6KVER8[D=LBMJ[@^%B?25 MN$B$0<;*0 M;7*$NI8,-+T7J-%G6&D_S5,,>VW6L.1?#>WZ2.%6NPS?'H5;E MC9G04U7E('K@7_%5.N=14CC#J,2)>0TIB9LM7\%*ZCB3Z5"SG MX5=T@-]XL M36L6>]DT"RBNH4J;.;D9WHDE\0[F-7,%24+"A0@[S95T% M =?'3V3*5K>_(WTUQE[7 MF= U&4?%47720"G6\20T_N0:H0+C 1$Q[A:E)= MDPG4P,N[ EA^:M34P^_;2N<.<0WOF8X38>7B)07H%HEXI?[P&EVYP%N^\D/B M 7KI=7$XC*: [B#L !DX(B;EGV6@931RNH1,^[1K5_KUJ62UR@QM./CE8>;2^^XL.OC< @5@Z6]YRW^YECB<.MT)#? MJ(/W*3]X/\IK:)_P&II9)["G2*J02*7XU0Z[LRO)GX:F:[-2*U2F*.K%=:@L M\N2E7GN9O_+%2IF31HM7L%:+!*>%\WZ]@0S,1L],B(W+7KD@_2A+7WL^3YY^ MK0+]'C@P:V^AU.(D/0S63A2X^O3IW>=/V[#-NM6N985=6>HA;2R*>JU=K:PY;39G?B M6U:)IV/'U>YT'DN?+)_IAN>.B>>Z@X$S.!S/G99^KB;QK]@T:*.8UBMO[[;R MRN-3/Q[KM^SV:.BT=F2SZJU^4M&VK;ERHOODVNU!V^D>;I^D."C5+;E\9^"1 M]-/)C'%:LK/:M_GY^NK'ZY^O/U^_^V1=_?K6>O?__7[]^=_?XNO4Q9TY>X_% M**O<2Q]N:T[63\ZV.W;?'3FCHS?U3WV?6O:HYS;F\?.9Q]\J$X[7]G+[=K?? M<_J-C5SS?1K8PVYWYS#-8]O(/U F=:M"FF?/U;I87,6%\7LD:[O]P5/D/]N] M]3]_2[)VOU$?G&RG2=8^8K+V.IQ$E>H &I2 MMX].RE/.XE8;%A\14R9;M7L?)2UZBKF6G==?;\.2;G2T7^]G5VY-A ,[!PTS M-\Q\>&8^ARCK3W&4)+)!]IF%5_=COB:Z>F[;= Y6Y<\H!4K=8\\LLGKAVJUV MQQFM^*A-4+4V6S3"Y@\'V:!SL 5^%:D5@" X,SL #GZ[/W+<[?FJL0&>>XOZ ML$$[2.;'UOYKTRCGB)@T:)4BV UB4H.8=+2] 'ZC2^[8#-9G .HCQ1XHX#TC MECI?%5;]23!IFQ%H!R,P2#!CB=$2BYLLX*X ?OA7YL=^CLJ=X^/E7=:YQ5_J M?37_@9&[??4"HJ"GA+5.?;8E< =W5D.4P'$<>5.-;H&-45::$]I6@ODXX%FS M$TW>4 V-E2+8WM2;>X0H/B,<;[F\B7_G!]9"A%[ Z'SJWV.Z54U Y#&"@'LW M'@(;F.U85,LWN1I",HA H$D(;/&55D,WM:,LQ?RA@20Y]6"5_ MDE)+,T8B60#UOOJ(%A\LK1?]UBCO:S:9Q)GL)L*DGY*;8/G,#HV9"-V%C,1)F(5"8CP3@+/GR=40Q_CS7:U MJWZJ>PX@J.D^GA"4/H]\AK [W@*(93 E(7:EP M6S: CQ1^#,Q+-C5("SQ$9Q1;EA.&2Q8JE [NSX%CWXD@6LC>?H2@@VT*?+Z) MSR<#GTTB7).?$-H%S"+Q)7*'9#5NM0<\CRS&L\E4+ENW?.))8=<)P@/0HQ / M8U=FW8"^8@2%"R/[/JD%\D%E)C>Z(1!6A6HH4&YWI #W;0.L0.,JV_+4$UGS M$(7-/:]F041-$+@-H>HO6^@"@,<]2;'OTB+V)T?9(.F:@!_^!':A'=#@.@7P M<%6B4&R7:7W^=,4O?)C!%V-KD<5)YC%HBNRKC0@KV$9KR:A^$A&KB""#4"J( M3L(U#MAHC-I@R'/'>#$\AD8=X8:8"'_D4U.OG(_;7=DF@ 7_!*0YB_#4;(FE MEE9HRZ6^2.\C4BO/Q)HAUDR.D@.KSBE"G<>Q%\Z4.QGX\S%UM904HS592F[2+;H*@8AQVG M5_S@-%^0Y*>Q@%-K=BYZ@)VXLT5U>4:%U2[QA"5X-#BGVV"GT4=5U8J;558K5M MJV];+AP?%_[H=IFEW?YV+9[0. 2Y["/Z&C(NMK5>(;YQDAB@&C%6N4>OH@^) M@ILHDNO0HEI)&800HM9#$DL=/[3P0*X%:'LD1]E3XYI/?HA;$RB"&*U\X)P3W"#O:LU+A'9_[QB1>BZ4=:PTN -<>XGH0-OFE1@%,/ M*C2$C892B"8;@\.D^EK %GCM*TVH(V3#WVGON(F:N<3<+0@++,@V1M[N5TE$ MZ?T2Z\(T09Q%&,NAIO1&6&1]TS(RC<6*&=GIN98VB>',*#G)[$U1 2F%Z!^D M *9VLX:]N=KE3&'P%K_F#O./74WS[D"V%(C&F< O>0$Z\Q3',AM*(]1Y3%G3D$,(9"9$ERN/UE.\"0IP\=+D>L/FQTIWC:[ &!E"?J7 %-E7F7M1Q MM/0"!(3%L ,7!7%S8=5 M<>#8;(V )XZ9XGA;6Q_%R2,73/& M==Z-E@R2JF7K[)(Q8.!_0:M#=]X@52]#8V@<\)^JP_(^N$@R,&22PO&76-L&9#/M.84Q-FSX*]EW6;62D<(_%(BF3?==#(>QW!<8 MW=KPAI(6#)MD4^"#_%8)H#K4,CX2-LY_R$L'?-6XK.R,\?5 MIS=6O]6W:V94JET@'?9&)A=DP.H-]10#*7Q(<]*Q.-2AZ6>&637IDX+Z0F-! MN=KDU(-1(&3N) H,9WSNHZ_/D7N*D(@ MX,;M,GRJ-1_8.[*KN]3/J+S3@(?E9"+9(;*= 5I8*Q/"B(!D+;9%9+@6%XUM M2[6ZID&P#(E$SJH&5I4[?D)F ;9"%6-OM52)_Q4'OHF].69^,)$/[O&?0 ,9 M4(I%FL54%D %/5@82@]&\TBZT.IU(S+%V^&AQ2(#C5<89O*"1+5S2$SS@Y:; MMTW8.CSM8=X&]U\U!U/F#C73$8HMR/M(J,<$_)UA\OC156P.;06Q3;0KO>2VY?PK+G^@.\ES,R_)B!I_G'Z4)@ MU8)_8=KQ,-^$HO=T_I:&-6T8HT#)C4X+1:@- M8D5CN6I4ER%B2:CZ@,J\\P=B[??FI3"J4H!%-Q\;'7)@Y2A/Y.J"D5:AN5@J M^T$%!_+G_C8"V0GR4WJ^TBV/\G(!(]2=2/\^$7I"8BJGA-UX0"J'GBI:4=/+ MO\#Q>O*Y9'55:=,JY^ZEZ^B 1*XBA&T$%\RORPR:,D*$SYF].$:-S9GK0DF1 M+N0BM: 2HR;%J$!KJ4,7$Q2CZ3U*4JG9"C0J='7CA7+)EW*@\Z%UVA4KDO%5 MKKWCUML\'QEW NV++)F?2V:#O$1HQL$1]3.:0YP5015!I@PV/!)!<)G>QE%V MH![900) M=53O>^O>"/B$1OVE^379;8KR1<44%EZVTTFL1D,]IX;ZJ$S@'6W70ZLS'ZW# M5-SP30**-R?*[7#,(&P@,&N.)Q,;J$V$;U6NJV,R3 M3CG'^IX$"*REJ8OF8I[A7V3_H5PFZ4A#BM\9+_<>*D%8034A0\GS0;M5B M0V:]/ L+Q-@[E&D1.#C8/3?QO\J*#O:=L:.[^"O#Y5X4"CY>*CD"AH11'N,Q# (9L4![)I\J6S8DAD"2X)V7B:Q3!5+HM4TCI;H%J.SK8G/\9M91M70JCXDD5)("AFT.KAK,$O)1Q8M MG:[3V56TK-9Y-;)E']GRTX8HVV$%3NYTYG<@Z&_:*C!O%:KJJ5_P[I.'&6C^ MDS_E$FR"];0^*'?UB@P/XL<5C-5:U-GLK\+@C:#C(R2A=,\+X.A1=S M1\B3\T2K P\LS'2UO?RGB"*3G\0DH^;?5W@E4=%,.O'P1*QJ D3@WZA[9=&8 M7%1EPI" H0C9@H5@G-WHFF*9@X[].YPC!M:B6-EN<5*XSI.[V;0@60;,)7$8 M6)QSJ#7)%O(OJXS*=)7EO50"8&Q'B7J%ZS(D(,9CBB2UQ#8:4SW".@B(#], 5?#O81WC(S_!A=37H50EA]0I M13?;SV:%H[8Y+8IM>B3I5[>.Y3Y02[,#5?KB2$J?Z>?D85=*A]O_$6 MJGY#4Z9:C;%1K2\,_!G1F541Z**,D6)T04;O)L5XSO2 )L4/#X8"788 M3L"4>9?9H'">P,;RV(MD,03V7#R5P2^_%4WUMFL-?,AV\)CDJ[U7@K8UM M4Z!$"?E/"/W:.T#GBM'(<=OM?1I7M =.S]VN:<,NPXZ=T+-/MN7T1Z,GF&QGN-^HF[F@,S@6PH[@'#P%79]FKOU!]S$;K9Q%'X^C M:C'QHS1AC4N%U2TF]NR@2?M$[N8O>!U".N7Z<8ZKGS'A M?A%>DC%<@Z+&E9'.0R?VHY@$6-RW'F[U],GTYE9,OB0_6&]DYO4Z23)FKL_D MVV/XR;P\=H8D>D%[LK/1)N,T''#MBWKC.$ MS6&QW4[/Z3?;5.]M MNN@-#M03L=F?[7K7V>W^8)?V@LT6/;L?T'7:S?[4=G]29/17F?DC)IN\/7>I,ZPN[-)VFS2,V\2ME/>55HWF_3<1D]W!+O4-+VN M[P:!I=!L3VVWIS_L.\/#";DS"ZUN U*PCT=P:LF-JB76^QQUW$X3"ZZ_L!NI M'IS-)M5UDUR\K=9L4KTWZ6+0ZC7!QCIOT$Y>4;,]SVTN@->Z:WE[32/!;MMI MU\?NKKYH\QGQ7/:L*Y%7ZCNPW&F4X05]-=^F]NC1"%3STVJWW.XWEB<] I6. MHQ2O.2]G?U[^25 MFL/2')9S.RR=MM-K#DIS4)J#\J"3WVL=KY-/(;T?" SR'\>$PWF8+I6ZH2PC MDE>UI=S<>9+::ZZ^4IBN;"*:WY#B#CX2C+^\5M4IA+JX8RO*F'JH2B#2'*K4 M MB7E6(031AA'I#?']$IV:<[&^ )%U%3P(F>7:0TG9_M ](Z:#O]/O[ 3 ^ M */8>QIXROV@3Q^::[N!?#QER$<3-XP F5>PP\X+4JV*'D7LRT?*?=7:RJO0 M3=1EN4%3>ZKUU]NV=>W^<+COC8,3<_4:9CYZ9AZVVOO><3H6L(A:L]YOZ[RB MLX. Z/3;.R/[-<56S[Y-;=?=.1O=E%LUY59UU-]-)+;FD=@F<]&6[?1O0"*<[=-V=8P49W# M5=]7:GJ86# 7:Q9DV&03^]OF$PRPH2\PS,VMSKG(KNG>8A' (]3Z3+;P+,S> ML?Z/[G:);;SO#3K%V+MNRJDQSZ\P'S8S@_6@01]8[+$+K2HR>$R>M#GR3ED>F\B>QR/LP3>PM8S%O[I MAGNDYO223$D9.!X 'Y*YOGCJZ0[TA7;VU**D3MW.@0<^O;&&K9YM_2A7C(09 M^R'W[SYD;W.5LI1]IZ73MH-0/U;'%^A5E=25E6^+8>^OK#Q__VYHO7;V5KX@7QQG\>H$F('>%3 M27/85MM*,M@,8S!>" E?/-$S/_1AG, G 7F5Y.W<*4-^)X)H0;V>M!3+];"Y$=4 F99_(S9Z(,)$)=A)0L-4P -@!N"Z\!R])EN\C:+M9 M%JCYO:?97N+?4%UHR:=8*ZX:+^^U'?@SW<:87H$5@RPQ6Z;#L<]BT,.4AL<. MR?DH5;RE7C)X1.^@GQA\G%@W4BH[UD/%4J3"I];#ONSMXG9AG'O0]4Z1*W1E*SK"8Y(A* M7>S41KXFIL '>4CI $HQ!8O3PJL@;G1G&&5U)H)9U7XYAHPH1[O),7#U&X5GP5L&@ +LFV-FLK0$?@U4X_1OJH5 MH14AC0?2IK! +C";P1>B.+&+*DSNKG1MX*-C$8(23PMJC=]!5S#*$O0J8Q@+ MW@"B39+"DS0W.#5_\N@3+[D%UR^ZAQ7\*"8>^9HH4.$1TI%^>!<%N 389^^& MNT!*9S:W?,B"EE8/[H6<,V.#P_M :D(2!V\XO,$:A'MM+01>%DYN\><;#8L# M0Z%LIFG0CO_#CBAZE"#UZ%?8*9Q5]@C>"G3GW]+AJ8:F7H]N;S MIJ^P?PQ^K2H^U#NEO=O[6T$[!+^S7T_\X,?T_0GUJ;.2VR@+"K:LO?(]$C72 M)V.NA<;N5BW<$;__MU_^:(] MF\[&LXZ8=@?=67LP;K?$S.V[O=X8?ABT_[<+$I[B4W".,#2!4OYO/WC_6,O8 M:]32/ZB0JVK_CT;+J5 &"X@$18&*U!2"=U+%H""8Q=$\=SJ+=DMJ89_92L48 MA2N6(7J/CO7.(T]]@98,#"^U"@JW_\?>EW:UD23M_A4=WIY[[7.4=%56UN:> MU^=@@SWT-6 ;W&[XTB>K,@L*:V%4DEE^_8W(S%HE818!$M1T#PU2+;G%$WN$ M5+32K4J?&""M&9H&LF$$$,!+/2&?!XBC<+N2S48 GOD?VLZ8CNHMAX)7@[P9W?F\,K>:NZE(E^7-F M[T5UTB@4Z+W1&].8BN(=::90O#,R[3/X9;^T;1I!LG*;&1"PPTA+)Y=:Q3]) MY4]U #0KK2KFV5B>91C>?3P!J!^.+HV:SGOPJ>& )5O53'B,/,HL*UP+\H-Y MF[*59+45Z9<-GU&A-:'LG4\XA(Y3_YIG6BY%SE:81*H6[G1P-H'KD&T.(S3+ M*BPPL]:#746A=;\RQ5QX1?U?]L]ZPTNMJS9%6"5SGNF3-!FGA;91M3%5B%7M M%8HD2K+-)K!Z_YTH\:O2D%L?*YV'H+1'M+7']<->?:^0&<@;$;XX J$)SCH* M+4JKX*71/9=V!S-UT3F9%X709;!AEI2\@CM=!^Z?J3PO+3MJ>RJB($!R#S8' M)<3!1.D-\#UHC4!>([UY6I7#O).Q0LO*5L7I*)[T <*4HP8FCNX565I38SX: M*?-D@5O%,/K\4E&8$3Y1&$8J*PBRE-U+@P(:0C,UZCRY9 H3FQM?\HW)(-7$ MCRDJ?%18&93Q4YL=ZL-=[WQ#V4&?Q\GX9 A"K]9>CR>I-L.GNF%Z=*DN^K"Q M_Z[T&N$G0W6$E7J1CK*QF8'ZZK^PV/GSC!:%UQ4:5R' IXI(U8[TTA]2N;?@ M2.':%>L\O0[U>>,3>OK-J B,LW*JVC:JF%Q%I:CB0'T@ XDZ%@<$1_NI'&FM M!Z<#S"A?GWR3*^<,.,MXO;.=X/K$)\.A=A"BAC-K)91'LE@*-<_;KP._[2HH M24(#R+PI=,Y+E4GKZ=IR/_?ZBHNA)$K4_8T,=+/]P_6 F\S1O=D]2L.=,4NU M"S7J-&=@:GG*5YB5&0RK\S.V8^ J5[@,,H2,A!#XR@?*&$, MN<3\XZYE@XVS4=KKY.E]N!1U@"B!1ATS_*@!U-W.+OQYTMGH2_3'=SM;DQ$L M(/P7/CC&RW:4( 87_KFQ>Z1M)A]!BH?- LD9=@,$C,)JC1+&/ ](Q;[9L#GK MC,:J*5]36>$IFV(N@^(JLT[-YBK&0X/K^3F)/+>)2QYUPAQ^&206TYP!"5OZ9;6\/)Y2S+3I M5Y@G[/4,L%KO?)?ZN/#F4<]C+I*>?J22D(T5O*<(#QZ9#M"P@_>DV0\M]^"! M,G$$(]4:"6%N"/29*E;_4V+0EA',E.A=#%KY6$8#./,5'E^90B0OA^8-B2+" M2[B\B T;"MGKFF@VG$Y!JL8N9-:SU!-JBYS?M_5N^V!SH[#BS'N--K TQ!$. M*#/J&R=?,>ZNCF138P*8.(,U01N, 9 2V30<5#84])3:'<7^:+&[?BYPM/49 MJZU%.!J=H775[&!N:VD 0&X-;"Q:.H"7X+2+.<(=Y1%<-%(\J8Y^2_#0 @UY MIQCP$D%(+:*MEPUS0U"FS"\SA(;:$:[""W#3 ?K$4)8N>:Y2MT"CEC@"K>)@ M-*4.@M.8D0SCB;+5#HP*A/IAY"LL+!!K,<#E%]XWID5P+7F8T*>* M!-?48L:8_U(*]^?*PVR$A>Q-723O_.:L>UXGT@4*<@&]\YN[;KN53QOB>N]T-RN]1>._\9JT'-/]L6I+'[WTK__Y90<3=-C*GQHI[_AI34%.1:N[(]'HW MQ7@\!VC,':,*IS7A02,@K:(5U>3RIDFM]0U7?<.L]0TOQUA:W_ MC^X'8\@P MJ%]'C.Y\!5$; 8TQJ>$>B(Q7\$+=!B@#N!_:!5^ -[KKP;\*&\HO3%$J4#@= M&^-^X>S,+1ZYK))<-Q'TCER#O[E273U:,,[L*;_ M*EY6?;A1*HS!IZJZE:X_?*1MK;O_*C2SE)F2HM:2"K]B M-3IQA$XF)+*F704_\]==W,\ _Z-.M5&RSGH3E$H;AA>\PW;5>+9553/CI:^: MF="B&,E-=/3B\%%=VJ*(L\_ "98FN+25<9^/Z M:775>.954M$,T_>UAW,5/9,Y;"BQ[\% @SI5T/!AYQ\(-&9,8_DA8R"/M14> MS^%ML<._'W8$-X .QU+CNCMT-! #R=];MY8)*=@ZO1%24#RZMT**&2=R%7%B MZI1?W&NM;^J@C5D&<#@+I4&U;@T? MUU/R*FD8_2$,8#@R#FR-*6=#U!W08SP>IUM2779J1I1Q579H1*E.*4$>!$#C [NWAI-1) 1_ZHR(VRDJQ. M7*M56'<94C2#2O*82$]0(;$HK"8_XL'S9 MX-EF(>>$*.&G4PNJT%HE(R@CHG*@7FJ_:F'$O/:HP)H09'.5(Z/0 \@^/VKZ M^5,ONBY>X]C8;53(ACE_LXYG,T;61&UD#6;2&V:E,%(W\#1??FW*8;GR,T>S MBJ!5C9ZLY)54 RFK3*GBT9]-NC5"4-B%[ $]MHK7G17AT/%DQ./\EGI 9O8+ M!ECF"9T,SVN;E96A1 ;F$'B079JS6_J?37"!BG-?($,5Y8!WP5%OZ]@_>U+&&\[-OZ M_OKK;N_BSM(_N-T76G_*A:A;JKG))->4M3R:]PM5(7NYIDR[7 /C"0 M6/7@YYET )TWJ)8])Q#INNQC9>''!:4@$H9.5H/5.^8,X:+*<>ISJVO)%DUWE\R.Y2\>I*+ M2MI7+8RXOM.:BYGKIOG"C*/1!BC?(KZL6($RT7\^056%FB)C54MTJ+WKN@.- M<.:&6 !_%> ZC'49E]B@1U,0TR+&K!BN,EW6U)?1&9RY=S(K76QJZ#,BN&:$ M9QH7R79-AJGZ>(8 #RG&H.91JG7UH)G#6\C/N22D)CXY,X2K@MT9MZZ6[ [-:? 6O=G3^EV)8.6" 'JIU?%(U969"!^Q*YGE_%L>9I++I U+7IZ^PM[4C,.4+TI4:\!84*5Q B7K"3&AX)I; ^R\6A2 MYJ1]Q2")G5)F79G"&'>1.DIIH5*H#"74");"2 9E.08-',U]U%\ I3*!OW\"6U9G D#PKY2#P%UHYWDE MD-,)?"C2L@56+IEUCN5 *L^('L1Z9UY&:YZ:U5#4[RD?-2_[3M5W MP4EED\R8D940QH$-C[OU0S*6\HZ(*9C5I MR]A2LTET:DK[?$Y@&*.:H:&O<6.J6D(%EB:%_QEP&L3G,>!(UMDX'DEUE%Y. M&&I%16IX'A3H^E"MX.A,K2CD]PD M%^D2-$412GTT5 T)Q FX6S',ZZB@20'FZ'>^HRU5XUKIK-.+5_CJ9L!,M^H$ MS!=>E MS+"08)YYK[P^SJ=,WJ^Y<T*T%#("[_P)T&)\C9E?BBG-] N<_H M]7XI8*C@>J;)+P7-*:MFH&(\HLY9-]$GN7!LNAK,>[M24.KAK*Z[;N=,Z%:< M>GGM'Y^ *_1RD7H%CUEAN:C'?.06C)Z:GJI&*G$'4!U%U"XT'',3EGY-^YH= M5=*K\G+EB%@5P;EL',&Q\[C6L[B63LMZU5MVES1P.ZM2PD%7KJCBZE%O/ M5-KA1=G92R4/%[)O6?@KK^L^-BG-TXW,38QO*;3H@7)CDB@2+ O*+(NYYE$F M)3<'U4[#MN$>:9-E ]>)S1)7BO-5ZZ@6AH8BZDY-%2,^03C*RD?@LZ?6:HY/ M/[^W3NMY[4GN M!LA>EG>4HGH*:H@_#>S5,$JUZWVCZE\'Y]./+Y!]&L&=BAK1+*QO+YL;\5,Y MLY7Q$RY_ 7UT(4ZRS)RWRNDQAVT&2:;B?]=^[62Q'6?M1H3\^!T5M:NC,)J^ MUZ$VEYT/IFM3(JK;[*7A6IGO!6S&;OVS,) MP-7.U\F9A*\Q 1R%A:]RT$\'4=KM_,EA6?&C0PG,:V."&F8/[]"C@5M $1;5 M#SXCU>D1[X^5V_!8C7D?6.Q)Y_^!>@L7?T?^;#"UNG8HC(#>#')43Q6(1,'@ MN\S;DT7H2/J95P3,SXVRS9QP,3O<3C]>Y2PIY_U,_IOW]*3FLG,E9[2CE$IJI*:MKI\Z_&NG] M$@OVZ>>V;05J 3'>_("8VX!3N-:&T;1A-#%>%28YO.P[P&# M@#\'IJ,K7YCUO"Y%6Q=CP>NLU]3CE M)N)]60Z@F$$C_[5^%78QTI.L?YXGPEQW;Z6/U2I:GSZH=/&TK_U8JF7EG-W( MFTZ)3K4)L3% 3NV\\:22XB&J'@'&-.55:XL/U('*R[ .DT1[D*L&S>+HU4+# M^K!K*K,9&'E<*4)1&TFO($_<-K%7550JZ\R?RZ)5=MD-1D\8PZ8&I6Q0MFI!^,IU]CPP M8\KXJ;TR:!N8X9E1MO;2()H'.>M@]%\]&OA64? G[T.B\+%6[6<5Q1==/P)F M8EA,X;H(TJJJU4VLUCO[-:OZT3# MT4C5]V\D3:.^@F9_!5"'FS80[]*WSW:U6M9<8JE#T& M(]G+JW'\=P(,I#=5/;W<=>0EU;VLPZ@.5JSV5M.-58H0T:C2KZ@B79O8_+Q> M685P>5;P*)4<_TP"CK912<'<_:]YD[I/>-8/\*QOXBJMJ%VB :XY)>(>I_F4 M-5M5S110D\LJ/4VT4@=G=::+4>%$>?C49^I4FFMJ5/D][\10>;SJ^Z/"-D R M(KJFG3J?7&D[YMEXFCCU4Z !&8]2S@VF3DK64>86G9@X]YJ$8_VSZY=J>DA(Z7-6[)>S MG5%']#=*UZVB/#/FW=B692C\;)CJ7';#J::/?&,G9]$K\B75$6:*DKK313%G MO1T=;#V'H85]G#&"R/@]%?U\M= MUGK9+T.N-S#$:G)VIE.=,<1DDX_Y]9OXJ#@S9XUAFR]0B'E?39F9.4-@2;>6 M:)9@AO5-J=;I*?*_?C6M\?#LC;)(_GNL*+5@+R@48X!K#[BB?)/_\H=(L[,> MOWR3#M1PU$U_U)<(X12E2@P3-ZND%DQ_;9 V#-<#UT&P'8_@_R)_L<'A=87# MOX_%]'>!MVY[=.[7UKH]][OK'FO;ZYX3W.BQOZLAZV'#PN "_^^:LU;R($59 M;^C91<>NGQ8DMN;:Z&59] D*?H7QEK:.HVA7G!$S\=O-25/ X\SJUW2AIO49 MI(#:I,R.-:0N1Y_[:R=LX737KET;0RM(27!M1T%-)Y_DS.Y& M8=>BQFS&.\)%F4]][8&XY8'PPSF;^:#(TH+'4HSE-FI]E8I=)]5ETBJY'9'])17YVPE9UUITH@CVQ64$S_U>?W&WOO.MN;G=WA M>N??Z<6;P7"P.U'="574 \ST*\XH=>S$BFF2.+[MLS#V HM:U.>1"_]&<4+_ MV41#EP7_$/S%IHZ]UAGP/DQ&R/3-!E9X&HYPR[;%FC97".>ORVAS^/,3_?KS MT-F9B-.MGT=P]/M\Z/OAQ>[IUOV M[O<_^T#/DZ.KLQ]['W?8SNG1Z>[!UOGA%;R+PGT'7^S= MCSOGA_#YWO>O)X<'XL=1&EJ'W__,C@[.^GN;AU>'!QO6T>:QM7-U"._Z >_: M[)SN;7W_L;7ZYVCW]VM\[ M@'D=Q/;.Z0<8W];5WF8,8_VK__?5E_'.>^OBT\'6&)Y[OG>P\U-\_(N)__S9 M.Z*]G]'I\&+OXQ8]A*<<]K?=W8,?UL[I#H7GG<"J]0[I$3SOR_G.P:&]\R&X MV-G\ ==LP5IL.WN;W^@_S$ND1^V0.'X4$L8"1B)A^<2!70Y8$%,[LM;>.NS? MO]<.Q=O7+7-^%H ;6"US;L_*K\^*R];>UFQ![TQF]?Z)E#I%<)[;8W5Y,T[: M7NWAF^HTJST).@^D6HZS!&.YY68&K.4X[5FYP5GQ&QRGXG/ 7D)EVD/>&^M0 M-;/8FE_0<851T%]M3@3#[ZXV&_(+-K2RX^_F75Q6>QKSS(FM,+ $8[GE7@;N M,Q4&JN>H/2Z+."Z>=:T\\+X6_?WJ$X9]=[;R[,OK1(3.RDL'N#0K#.HX_-66 M#G &*WY^5GSU5U^TP5FTHLWSX56!]TQ%F\+.T;A?AT.&S4C1\+I T?94W>94 M.==*0%O_G6"Z[S,7=9S5%G6U86 M@E.$5R,5<9P;^5E 6_%90'O6<@"7BL+/"=\#X)6%FC/ MR@W.2KCV=E>5 ;A)GF8+$,]FTX.52:C),UX'0[7BUSQ]UI7JX;^K--FV_(,N M_Q LIOR#VY9_:,L_+&'?DT7ECJY<@:5*.V_8\+S U?8@7L=@"%$LFX7E MO5YF"(II=I(W\KFTO[I4E4C4+?BR MS)0'U+6]X#-LK%MV$=2U1D!-;'^/ZY'62;K*RM=[%V#H)*YY-8MU# MSS16Q.^JE>/',M.W3HJ>B]AC$&MQPE7+U6%GFGR)^NA8-Y/_,.)]>3X<_7BB M-$@]QE?+M6;4LIW73[D@W;PA4'39>;^WOU=K!YJJ_@*F^6&D/=V^"F M<(+-PK&([)GJ=C#&TGI8^#P>=_KPYH+&L0IP-NS6^H5C_;#!9;7+//9JJ]$? MEO;3O:5U5W1=K[]2EHT=/ _([+QZG3Y\X+ MS:K_9K+JA^>'.@O^8N?CUN7.]QUK9W/;W?NXV]_M;YW#9_",/_N[5[%[M!]: M1W^?6''_KP'_'D[V3M^E.@M^Z_SP8/OB\.K+^<[I#W9(X9^##?@,QML_=':O M>KV_K[;H[N:/R]W3V()W7^X<;-P]J;VK0(GC4 Q(J:V+0H< I8WA@,)H7:A!=@"T$]+NPCV!;>K%E> MPL587H+6\M):7I;0\O)UZ_/>UX/.WH?.]N[FUN0_K7'GUK=W!JEWE9[=58+JRE;K'4;729T>XFBRUM7=8\87^I,RQBC<1*, MQNEJ(Q6/3W(1HM+&.CL2X#GGV8@0H@)P%8/I=;" MAJ4+N8)JI=H%VV[G%98CU2)-#YL,)G(TTA8\GJD[UF89V=9>:Z,7%BO71]'4 M,I]ED,M[86&A"GK%KCB'J[BS3JSJA6.(> +<0HTTI MMWR;*R7=]K 3$K['0/2KVBJ]-IK5ZV[UF/S?6XG%LX]4M[0,%%:!PMBN]VRY M3 13%H*\J=GRVPG,UO51&U+"UC[Z.(8CM?^C8SY(KWAAZ<.+#T!"%B 8Z[NR M#)$"R5JW>U5*C E_D-%H@E6=::"VE7:QZ0!@0Z:-Z9/!?['U;Y+B3L]4M&YS MEI:,4&?+#^]4 PA$/"-)+->@Y[;FRN:P&+3C&L#7GK'"FU3?Q=+D M=GVJ;,3F<.#1F'L<9HZB L\@@K^=-,='!V?8S6JVI4*:-2&HKSKU@B%",.4 M(UDS2JD[#/_,#=A%][+9L*O:AR12(/_I9#*>C'0?V1X_+Z4'?G8&8]6]/B8] M(U; 2">].@WNE_>K5B1YJZ\&219S6C+BF,O%2F=;N94WYV-JIIV#DV%6_=9L MH[9LGX,PT>-Z=4"J0)%!+SR^2G4/CG33I%GN4ZXZDI^?2-7G;*[7&2F9Y; MU1;GZ.WM*S&QSX5$'EK"6Q=%FG,)8C;\M_$*Y%PH@!NYG%=E[-F#_X[>KEXJ M?YK36R&*W,_/JT-*^-\ M]!I&^GKTJ*/V)P/X0FG1JK,A8D/^-;:<4^Q(M5X[R;N^CHE1=_3#KCD@.:2- M9/U5PU&3=]6^-OQ*/SXN1#_-,."!K^S71KE5\*()0_E(JU1G^I^774?SY\[& M1'CX*_H:^^ ->S\-OBO^F2IU#/@7J,.#8P4(QC,,JG$7WZH\MZ ]GT[$<:7/ M93DG0T=S=D$,8;3HW.8]^%MQ$^#2*,!6B"27-&9CXYC_D!C\ =1V?C+LR6[> MI0_G#X_N(@A4QE,) IDQ('42NH:"\=I,!]?(?#!9U24ZXP%(WX,J:DUOSA & MFL:*45Z:S5P)'/@X' K5!$XI4/8?=5,3MEP[TR?USXW=HS+43*GO67'35S2G MX")@7'8GN.YD+LNJW%SAG(^7H$AG<&3.9C;-65+HS*5F(UM(;1[BVB=VG)^& M%"X"H1V%&"4H:+O!!G#J7L?8#/*6?[4/:Y:)S@D7G=]L>STL&O/IP)"*P3%_ M8[?SF[MNN\5U>.1^L]8#6KU3DYAJ_M?K#6O@>NVQ+>T?$SRVW5R34+9 #6Y- M3V,]O*98%V3UE;4QZ*J%067.A3&40D8NN(A&[T-E?:L/2G5)57:ZT4A9A-7% MM;$UMJP<8-GH7,?#J0:F>0]=%26)K42)UMI4[T%X/W:'AW>JL!L0#.6,%HWX MEE\LI1Y@_I"ZA%4^RS#'JEJJ>Z?^D',$/:428LOV,ZV&:>:GNWMK_;_=9/_X+]],LEO&A)%8.1RG#)ZQE3P1%4?"W"D8J 1>^EBJ?$/M:U6-8, M0Z$ 4/LYGFCP BS#=1[ %. O-)5U>GPR,.P36?P%+$661^%>I)FQ:*AKE35] MJ.X^G8!D(%(3P_M*2S+*AR128&NHAJ9*4@"6 ((,,)4OF\7P2F6:=T[@!%2" MBKF.^"M&I;G>H&A/+51&A#:]R03&6<\;@$$,I!8:C>BF=-**J&(TY#1;14U% M8?I_AN=:")^IL7P''KHAA'$*&4N>NF))9OO+6%6MFE=,G'E<0*YT7G,X.Z_P M7%,7: M[9E9H@[!OUZCS@YN$Y^T@5:G>;U#U]T;[:!:;^^/I_/%-IH8N^N6RA/^+I6B M.R_ZM4B14-Y0#;<_4QB/.2/S%.)63PU3P+4UM[)2.M'^:9/;?BT3C834K1)%$T0&.@1CRVH<)\#FAB/%)$J5L#T;CW%1,^HU3]4J+B \4D*;X(YC2_-Z:YQ]SZ/1T-0G@;#/L878&3;0$Q 7 9* M @%:9,;:)3!V "7(5#;6LPK'/V'IAI/,R,UF,;2@K<-KRB Z&+**GRV=OS_D MI;$)%=[0G'HK-J66EAZ8EO+0!%CS% ,08J4DS!?IN^A#^A7YX:>EY:\O@6\+ MF.7QY;2];BZ+K1XTI$23L:SY-HPOEC5ZT7: R_R*F?;4&XNA.=W"LT\DOD Y MM!2?B8M0(?@LSH-<-"@8>40Q#W@21K>H/.XR"*=N.ZVB#PHV1OQN#%,+*3KR MK>:U-P"24[]^3DG^=5HW8+ L&MFU'K5=B7U[-5Q_1I=CIC D=Y6]/^&C8QGQ M^$>&D9\CY-(-X]Y4JAT:-(R%&D$LEB,5!@7DIIAL)P:^-@1VE*%W/CY!TW>5%,_T04FE2P'^B4J'"E_0P18F2C_.+YAI(*9T)Y5A QK?0F-3V<@?AC5.)]C;AS3SH?I M&>,)'E1G"[*QAI$\'"#C/8Q)Q3 .XW4?8@$,F'@FMP[&=#:U$-TR=J#V=A-RM-[Y MANRA(U,5+\9'"IPUC.9N3Z5[YB%*,#F>P-SD&*,G:7PNI8E^ M:*Q1&?I73%2#<\YARD=7,C1_#O%6]0 3CJ;'HTVP,8:="#RC.0KJ8W"6(Z5> MH0I(IMJ[VA^";%5U%N8\""-5RKO3SD2E:MA=X>:N/ . DQ]"+*Y?N=MC0Y/XV38TE-I1D#JH"ZUT>A< M;IS0PKT]PY>MK/C9+)5.6?&-TUG6=/%HHB3!,\7J$*W+!09 )).LXJDHOVHN M>'&6JPX%='H,9*];I77] M23\O%5(L4(X7:F#*-%\NSF1@X!##TDVPVLT]$HOS$ZR>>-1:^V$RMY"V#4X_ MC!9+;Y8&])0Y2+-=#JV?X6G-?TT>7+$W3$5! 0%7M'03=C,EB-2,#]I>503( M*GEIK$T=ZND-LT#%$"'XF.MX_)KJ;E D'97F@#:HIAY48[=!-E,?0.:^U M_X)H$YE1M"M:.5H-C!FS8N33EE7V^E='NZS(47&^*.RK^%Y*"Y2V6RR+3GL? M?\F^6O:OH>D\_;=W&#/%4=B]F37Y8=>O%.&6,[SRJ&S\+Z76$=(W4. MA&?K7&:GTF+B$MGJ$CEAY7(H:.?@]WJ%=UJI.AZ%[ MS2A?9>E%![3U\4GVNB@#I<&B\VI\+C&>-?_:D ! :6KJB&/"U9QDI]R ;,2B MNC%^9&@OK9;ST7;FR1E<4\%(!&Y8BDKE<1.%I)Z@7YX_KK!V3UG+>V/I\*+6?>5XZI/>[>""F4">\:3J,#$)59H44(QKA.1WT56G"T73[\#*HQYH)\E&5T MEM%+Q.4 -C;..J^:RDT>V)>K-F4N;Q&!DY=XR,N@8CN-G.1ADE[V??)#R91ZYH]SD4X5Q;S;D)QMO7EY:"41G[F M2C\@9BP[=NA[MVD\=#,ZJM\7W/2V%QGPT3A/=^R1XMIMCY0V3*3MD?)X$[MG MCY3Y86^-&>)HS$?CX9GZ^XEF7.FGVPD_<M>UT7%I-I5 MC&,JW>[9MDVXMK'BTT8K+[9APBMLSSBGFK?"JG7'BJ MM2+70X*_<313O4]4 02=?EH)45"IJ=7J00-@PEG&RRBD.!W%D[ZN"W-=+, MCCKKG7NMD :?S(B<9R BQSG/:78DPC)'9Z:R11%]AZ\:Y'69M+M)7ZXD_,KZ M"E7$I%MU"BL!2+72Q':=O;ST.X;X93PNVUN*-,MMQ@4O0$ 9%W^9!?A#U3FZ M=G-U>>':&T95/UE601D=E=]7^/'KG;W''N:U257;IUBF9Z:_2ZVF>WVJ:MB1 MU(&%,-GAH#=3,.$3V-E158%N%( 35>M7;2WS"DXW))8S53Y#+Q'H3X !,"*L MLU&4L)P,\M&HA0"NG1DOYR33C6DJ.]T83AE?H#=>+18L94\8Y;+D;9HU7==_ M9LDP?C;PO9,QGV1%GX9T<***2.L6!'F9GYM3.E:ZP0X&9IO4:JO-J74T4U5S MLF&W5FQ0J<67C8X9=0$ 2,44M=2^=%..6[<=*KS1A2121!+AJ"*I6A[ F 5( M7 M)J)VOCOZW^G%F\%PL#M1S7?SLCE?T1V2.G9BQ31)'-_V61A[@44MZO/(A7^C M.*'_;**EPX)_"/YB4\=>ZPQX'R8E9/IF0SLI=^&#->T"$\Y?E]'F\.COX=__/_@[]Z\?N9FP=G6X[AZ?;YT??#R]V3[?L MW>]_]H\^PEMZP<7N ;QG\.?)T=59NG>PNLG=/MB\/O7].= MC]OVT<&[WF'_FW78_W!Z>!E:1W^?6''_KP'_'D[V^MONSM5NNO-]!^[[ 6/Z M'I7[V=CW^E1P=?T\/ONZ=_7VV=[QW\L'<.8.Q7V];.YI=_ MI"-MSBU!G"2P"8-U)=Q)X+?(X'B;#X=0$<]<,UWZ^U-*?K MYA$=+S(@P5E,0 )K Q+:@(2G/-ZSG=A_;6\[VSOO@=Y='>SL__MW?[V MYO;&U^VM_>MGO@2C?U]U-;WC/26/[I](.9YNOSH[GL#)PYB7 &I>;0] 0U!M MN] W>H%ZK ZHR*UX^5\ZQ/3UK^:( 1*:KXS5P2[0&!3P$8%I]?A9)M_DO_R! M.F&/7[Y)!VIPZJ8_ZNN%Z -ZCTH;,VNFED]_;8 I#-=]RT=L&H_@_R)_L8&M M=05;OX_%]'>^!P 7SOW:6K?G?G?=8\-USW+N]-3KOW.=NSWU5V-U;_34W]7J MZA6&/<2S\+]KSEHC7O^-U;'5&Z^U>-)T$OR)ZQ?"J M#F(%M2C7%J3PZTF^A/6P:NOQBX."U3>.1P I@I@AQ[&4P*YOO0P .(_/"=0B M;.SO;QWLW^ 4S)VL04455(:XBWREDP_\%F?GEZMYGV?^ZO<62GOM/.-J=YI8Q[Z&0NBW0[^U]?:P])NY7O=0]X8GM_M'M20ZMS0UQZ&,9\PZG_ M=J\I5J]K]KQ,WME).,''-^]@9/TL9 X'^VRF.T,7YO MNB7_A2UJ@(I@A> N[\EMF5^,+7-XN;>YX>R<;IP?'>S0P_Z6M7L@>H<'6\XA MW6:[]-O%[M7)Z6[_J(>VS,/O?V9'!T.&[STZ_<)@'-;>06SM;7YS][X?P6@/ M+WINCO;&ZXA_OFGK__/(GZHK=W>M+?O?JSO[MYC&-P=Z^^L-V#'^Y1 M_^AT%\:Z!_?NTL/SGR=]77\8[^];%IX.M\;&SOP0O/T__V-[UA_W.?4YK-WB]"^27;<8 M]$PQR/&$YT6!;3,6L-!F@; =.Y1!E$CAQ*'&(*O%H"?"H,LZ!KD^%RR0/F&6 M'Q 6B9@$(DD(]>S0CVPK]KBS]C9@;)TM$08M4E1?>K'.9 =D.HSF)YH*N]C: M9:[03F^W$#/1=:4A:%%B4+[R7XN%WY5CHSJM=72%!GC=Q?C-8-(G8J@<(_BT M%I9N!4O?ID0C'MJV[0A)'%L -KG4(@$+0N)[S(\3/[ C0=?>LB[UO/L#TS7@ M\%#"T4WUWA=/RHN2)EI2?C12;D@8@>TGH8@9<:4O"/.LD 0>M8D=PR[&- KC M,$%2#IBS'BP1*;\HT]&V*2B4ROGVW>NPZ*9*VTICT:+$BGRQ+P&"6NQ9'/8< M3EM8PC"1H,B0B :2L"1*2, %):[E,BH\QQ&>O_;6Z8:^O^XOD7ZS:)?(BR?= M18D1+>D^&.DVQ(:0,8=Y(#9(RPL(H](FH<=C$KC X@6SO9#)M;=NE_GV>KA$ MI/NB3!.?,84H-3D]F4FQ,BTW:Q[&UE;QT$*%V8HMO1,; [&'VZ!=]JV>LW# MBJ=D#2%]QW<]1OR$^P1@*21'P:?C*8D#-"'+B5T0,0++)2P, M!0F26!+NP$;ZL66%;@CX9'5#BRY,1[HQB:R0[>,%D_W"_"LMV3\8V3=#-A) MZBBR":-^0IB=@*+!'/C!$RL17N!*&0/9TV[@^>ONJI#]2XJ^_CS"FE/8_P'+ M>NF2)1BN>X;5*MK8CD>RE^@]^(P[ ,K55K[^K65WH?CU8]HIXPO']Y*8 %@! M?L6Q!6)+%!)*/2IE0"/'LM$I8P=!:RAYSJ2\.$-)2\J/1,H-4<07<$P=VR8T MY*B!B)A$G$D2NC)B$>74CD(D9>:&]U= EM1"LNS"QO9@S ?'J:EP)K$NYET% MC!?A*EY^[EHW C#:NC -)C\.A^(\[?5:=%H<.FV=*V12PL;.Q>[F]N4_ MT@T]$8)\ 6CD@*8D&>'2CX@?2X\Z 76\.%A[2[VN[;#GF&/3$O7BXS]:HGYL MHMZI$S5-8C>B$2=.X@@@ZC@DD1-*PJPDB9V0"NF[0-1AUPN[%.<$"H3G[#8HB2P9$ \*["IYT1A"!N% MA.LP?]U:(L)]23:*39G(T4CU%E%EL\?\HA/)@4S2UE#QX!)$OOC;:NT/^$6A MVK30M$!HNIR2*1S&9>P ("6AM$%_ 9TF=!-)?"OT@9>$B9Y\)O+(N)(2R:6+2+0$M;>@G( ,L9S M3599=AE#14^WZ2B/)%148M5WAX.XC0M;. I=3%A \Q7O]+AS>?_;#!X ML?DT+>@N$'2M*.M_;6Q2)%]/Y% MBE8LDZ8%MQ;<'C1KJ 6WQ8);0Z(4CFL%E#+B.)Y'F"=L$@0A)3'HA+$E7( W M:^VM9W==U[F_!VS%\H66N=/*I^V-=]N?M@^VM_95P["M+]^V#PX7U'G%@747 MPPF&!2]QZY6;CO+9:Q^?3+_VZPKTM0U85L<:G3=@Z97[VG9A>1:E-(MRW6?\ M$NO,MLU77DCC@T57'?^LS\_!B O9)M8O7E)F4V8 SW:D]#U*;"YCPJPX(IRY M+G%BP3W)N"U=!VVOGKN @C_+%Y#1(M,S1:9%%U%OD>G!D:D9Q>J(*/8B3@+A M.80E-B!3XL0D#&5HA6[B.[%R[8;6EF4-6]2Y!>IL M3Q?D"( S!!%+2.)129CJS&*Y+O$QMHTF$?<1Z0*F+*-'7FAONYT(\ ]D9 M"6Z8='K#P;$V0 @9C2O=6,HOAA$,F^,-K6GBP46)3[#LJ-9LPFZTAM+%X]9T MG0[A1T)8KB0.P[91'G5(X-@N<3QN)3*1 ?4"U&L"?[G"YUO3Q)+*&"T)/S@) M-Y-I(RJ<) B)+2@CS'$CPOTP(:&P+1XQX5-*,9G6L8*E(N%?"!\BSZ\D794O9J7>EZ-PBG>_%JVD)S@2L!C"V,+AY&I[.![3!VH\3V2>0% M#DA"KD^X$U)B!U+X#H>-DZKOMF>'2Z7#M=:6)96$6C)^%#)N2$..#/S(]2(2 M6S0F+.:"\ CSTR3G@OEVS+#<*>N&W@*2^I?5%+-"3>CN*UE,YT"\M)94"S.^ MM%#UD% UG47K^MSS;3LD$;6Q&X3G8#VDD'#+E[Y(/,I#L?8V[,*V+JQ?YM(D MT2[0,/.":7]A5IN6]A^8]IMBBF.Q,*0AB=W8PI P24)I6<1.F&W'H0SCP%6] M*%UO ;TH'XOX7U(-UD\UWU%K%7E,WU!;7>E!8,J>$E%HD'@6' $BA9T0QI*8 M!#[\YD1Q! !FQ;:%+;W#KF_[Z_82J5.M5619)8V6C!^!C!O21LAH%#M.0!SI M2\*I2XK@<"!Y,A=I&1Q/-]&3D.#46B>U;3Y>K^])(, M&'L+CG1]$6K00\5XM*K0@R"3,Z/'+?5\5R3$]WWT#[L>P6TD;B!C&MJ24BI4 M90#':<,\GC,E/U281TO)#T7)S90;F\72M1(B:10!)2<1"1,6$AEX@>=2[D<4 MNU5W6> LE6GR 2IQ+I=@H0,\VL".99$U*N#40M("(6FZ(%IL>X&(+)L(&B4 M28$+PD4H2>2%#O6HB!W' K6'=1W7NC\FM2$=SY'J'R"DHZ7ZQ5)]0Q#A3BQ< M*B+B2NX09H4A"2*7$Z!WSV=^$%!TDCI!UPV#%Q?+L;QBRM9_)]R$C^3)L ?KE?V?_PFH[?_1D7<_)2^H MU/2-JYJ*]&?^;/,(@M>_L0,UIB>I"S#L]X?XUF'\XTWGM^M8]6:'_,QU+\Q7L36;[:L&NK9=?1=G$67>4?\+/<3K882[!SO6[N:'T\/OV^SP=.,"ULF%=;C<@?G M]\G.P8:[=_#M8N?@\'+WZH>]N_&/YU#'=2DETF.J1 ^(_);-B>\&@@6.(V,A MUMY:Z]:TN-\YXZ/.3]S<;F?NJ5.8E#W"@5.G*]N8C$^&(Z ><3.AL3V%3WX* MK=WS?T3D>*Y-8\)9(@AS.,/BDCYVK_&I%286]V+TMP&2YO^?/H[ZJ'5X<03^ MR#]*LVPBA:Z/,AEG8_@%P?^6I]81EN]+*P@3WV(NVZ MEM]EGC-]+O'8W?*DA8(E8<*#(+88AR/G>I&?<&Y'B>_X83!;AVY/VJJ>M-/# M?Z1MV\)C%N%!"+C',7W;LD(2)C8+ FZY3NSID^9U@]#M>FPZI:K;@P+*Q#$ES;0 HT=$DG7)=2E M(O0LZ5@2H_;I4KG%6@?WDAJ26_J\-WTVH^-B6_B.(X@;QZ@S1@E(1?BG9#;L M5PA24;!T]/FB:D5NP)AQO7D/E/14D'30B?E9.N:]-A#_P>M)%VO_&99^>_!> M+WSKQ%H@)DW'Q46N]*CD%@GB,":,,4X"+P9-+>+4%P[EH,4!)@5=U_$6YKI> M4>_T\Z;CA56;;NGX,>BX(5M0WPO]P/=(X+@,G=&"!(D("'=#R[8#7U)#Q\P) MUH,EHN,755WQJQQS^%!T)!\-[MSVZD6H,8L2*_(EWS(KOA''D_ZDAPZV39FD M<=K&ZRX2F::#X_Q(P%XF,>%6!%I/)$'KL;V0^*&;R%CZ010J'X47+ "86L/$ M\E+TH@2,EJ(?FZ*;L@8/ 8PC01);N$#1MB"<)CX!,2. [8QM%KIK;]VNX]G/ MMJK THL:%:HPS2WB8?]L)$_D($M_RDYOF+VTSA:O'D7\R&">\-N,)CSY?JC4 MH??5W=#9RI]@2W;E>"\YX!-;DG&SG&+B,-?G%G$"!\C8 MI2$)@\0F4HHH9B*&_0O6W@9N,*-XR),0\7-K?M$.N!WPL\L0T8FLO\@ N($Z M_X*SV1;6M![##TQJAD[< 3;:F^#*?=;]_#;&XU$:3<;8]/=@B%GX,([1L ?# M/]Z&$8UDUMH#%LB%OTP7- \=BSG4"PBU0TX8CV,2<$L2[G$J&(C2P)C7WE*K MRT*ZL.8+2Y/^ND#[WPL&C$49!UO 6$; V&GVMV:V[T06B9W((XQ*[%I'(Q)% MMK2%2P/X4M4E#5VVL&"HQ\J24P)5)GI8Z*RH28 M+8[>\-#K@_K&@146PPD W\VYRK5IG4^Q/+\][!H\&X[Z &5D-@9BFK^VO'*! MO'*Z%+]GV79D>XQ$KA42%@";##S;AP7VN81_ AJ#<.VR;L#HPOSGMR*9)Q:P M6PAL(?#Q:NJT$/@($-A0%R)NN;Y@G#@^1A"Y 2.!C^$'/J>V[[.88@219W== MU[E_E?#'A$ ER_ZN5-$\X;!2*://1\?I(!^"C>$&M>(9CE<4SWC[[VCT^]MZ MZF+E28: @$.HLBQGPTR%Z+X9R1['K,<_SE,Q/LD)K'*C>;=5WL(CD-$GX_FW M5%8@EJA//QQ.J">^P>CB-+X>.2B.[ M;@1?^/0?V_77\KM."N7UC!]+$HTD_T%X E-\PWOG_#);^[U^0.%T-HY6\U3, M79HD>;"ET40(\#L[[^V-PZ^;N]WMG??KW[6]O M;F]\W=[:7R+BG#WZ&KR4H(([N'XVK#F#K8!;M13!"BZ:\-,(7A>N ZB$W&@F1>;&!K7<%60T30WWG!NF5Y M<[^VUNVYWUWWV&#=M\([/?7Z[UR'OO2QVC=[ZB_LB7>M>+90X@QNI!G-%G2+ M.=GN32:ET>5IIC4%I6I:AY*/.EO S$1G4\:R'\F1GJEC=VN3?3$[6;&6W,*I ML=R[C,;(14WX)@Z)Y[1P5KMP=UHX.[P-?BRJ0O^36L^^RI]R,)'9F_N4-GVF MGL65&.3CMZIZTO.Z*V%5>&^ZF<2]<^F6;JJWMNH_3Z-]3-V(QAX/N4T9\YT@ MMH5DH<.C*/!]R_UG$T4%"_XA-\T 5I#W833LH_$$A_ ]'9^\GV2P'G*T=6'B M@S:R3,*_8H6R;^+"H'\$]^WTM^CNU9^GNYO'UM'!QL7A02\]/!#IX>FA>_@= MGD._67O[A4'_/^CN738/^]OG>P>'%T>D&V_NX18].OY[L'NPP'.O1P?;%#H7Q?=RRX)E7 M?U_EQORM\<[5EK5SNOV/S[D?RH@2X0141^T'21P2SIGPG(3*F/*UM[;?#>QG MV8RKA:YG"EUA0EW+#RS'<4*6N'9 /4?8+/!\R9F,/ 5=5@Y=-TIU;J'K::'K ML@Y=+N..%PJ/6'$L",.JRU'(8^*Z,J$B88!K+D"7#= 5WK_G1PM=+70]$G1Q M$5G B6/7]T,6NRP,8D99(#POM".'Q@A==FB@RPY;Z%IZZ-IM2%T.P!;EGB#< MLP-,>0Y(:&'C(L8\X46^2Z- 09?C6S-RGI]'V885T'AU?^:1L=.\L!(-MT"L MA$;,\QEW>4"9Y[A1%-F>+;F;R( FDM]53]P=CN>!5HM!M\*@+U.:'_69'4$+0NZI)+>4ND'(;BH_M,==QJ$,\SP7I(71C$@K;(X%% QE9MN\[ M#&M7MT5BGS7I"M<+(I;8(0U!;(S"D $7II$;1(&TO#"YJYK0DN[B2+ M"N"K-DEBQR=,N#;AMAV3"#2"A L@93Y+$O'>(DJGZLPTD$U$Q<+_(\0''7=RUE MB0R9M^A\KI;TGP?I)S(2#(1-P1AEO@!5 _[V8PY_,!D+?E=%I"7]A9+^E"[B M>U3&H'R$//$(PQ^<>3:1@GM^D'#+#9DB?=>RUMU5(?V7$#CZ?IB-,7MI9C!> M:R!Y,&T$UWTO^3@<"I5[+D<_TUAF^\/>#1O3MDAU$Z0ZG-)/8L>/8ND&A >1 M0YB?N"0*0IMXB?2CQ ]"$#S1X-EU;&NI&NJT-L]EUS):DGXDDF[H'2 >2I]3 MA\32H80Y<42 MBWB\0AE1B=,4.\(NC8+[V]Q:"EZ>2EZX8[GD,H _[,7#LBH6>'Q*56X@EN.X[EK[WUNYY%[Q^-V3HW;D6/'T?#+.N< MC89).FY=&\NA3*@]^:RVI 6FQ0%3/"/0B<>6H#9Q8OC!**6VM@Z.1>1=Z+)L@^..O#B3@ZRMD;&R@WQA-3*^RDSR47RB M^@0(^5/VAF=8;;!M+O^(,8-Z"S8&8K/<@"T-)"U/O15/_3&E33NQD]@B"4D< M!2!06\PEH70BXDLOM-V >DQ$:V]!/UI8LY@5E9B?-]4^0+A?2[4+I-IFF!]S M;#=.+$(#3Q)FLX2$F/$7NK$5NK;K .&NO75=MZ7:YTRU#Q"IUU+MXJAVRJ6& M?8)"/R*ACY9KUTT(!UV51"$5,9568H5\[:WG+%=YDQ=6(V!?JG:%W"X"EC=I.%,C4FMT6!5M;Y]-]LKR8 MB8!;Q(;#2UAH@8X0"1 YI$^#2(I$NZ-%RJ/,3XW'/-#5"[6.HRI8AJ<*\Y"!.9=;M#&3KA'A(/22#^<)O4\Y^ MG@X^#;/L*[;WD^)@6.[;?K%M+6C=#K0NIE0.![:*"3\D(94680YW2"!\1IPH MD4GL>T'H)2"3+$+A: VVEO;\A?67[NEX\>BXU=/&G37TN^#T&]#>8 = ;@5$:'<<@FS M/9=$H6#$CR-7;#7V13YOEYU9X5-U^FR:PVZS-EP*K[N/BZ*%QP; MO'#_11'Y:&P=;0V41>+5Y93>$"5>% DW('8,V@*SN46"Q..$>R$ QUI<6 !\: AMX24-?V8!.)C+P(BZ%%) BL MF#B6ZP?<]@3(=NC3M .ZL*KJRY1\1_O+PSE$"F3;'L3#OL3M:^'K=O!U-2/BRN9>Q"D)PM A+* ."7B,51V% M'<$F!J&-(1EL1@G76YM=ED9T:=.;%T+J#^])#XMIOPV"*4)=^&OM+<# ZI0K>@E%"[:!T$8R&^<^E3;KX]&\)OG2 MMXEG=X(@:UJ?L#S?C3Q&F",2#/&."&<\@-]$PIW09X!!F'GFM?D;SYE0%^[: M: GUOH3:T :\)&&<@7#@"2L&;0!(-G#=D(2,4IM&ON4F("NP< 'Q4BVA+B^A M+ERP;PGUOH3:$.JI'U/AVH((Z6*/-=]""YU%I'"BQ/.X8#80JFO[2U7N_"5X M$'23]U>ITF!?Y]+[2TR8>&0'0<.4@-NP.QP,ZR:%%H#N!$#VE$CO!AC.%'G$ ML@36/W4<$GJN1T#*C\,XL8/(C0& %F$U7%'#X I2['*8^5O*72SE-F1\6W#' M][A%_(B!"BZI(&&,F==!3 %]G<3FJOW1PFJ8MO2[A/2[ !&_I=_'H=^&Z.\[ M+.1V9)/ %Z"C,P_HUP\Y<:6T1$ C'O($='1GJ5*:7H+%OAD[%,ED.)(=K0ET MQORBS8M8OOBATM/X833LOU=)[A-8R;TBYNN=VD9]W0%NXM;%>,1A,](!'UUN MCV4_ [3#X8Z&JMY$;NQHH>YV4$>GE SAV)+9-($#:%/";!$23GV?1#[S8>N# M*+3DVEO/8_?*_VICJ)\E9CR"VJ/ MQ1;68ZXUT;Y$#:8EW?N3;D/[<$/?"I@3$Q^3*!CS)0EBVR>1&P0B6:)]>A6A)]?ZDVA#_74< E'*+)%[BHQ^%DD P2A+I)@$0;139 M-HC_SN*:.;:.E)N1VZX<=U[U:LZ4UG&R;(X3W7%6IVBUM206AE-L2AM($DZ! MD0 P\5@0AAUGN? %26CH4^H'@4TIX%27>N&,6A*M2?.%(\##*1%5!&B)_)9$ MOM/T=(8>\QU*?.YRPJ0;D8BY#K%\VQ)A+"+;]]#3.:LW5TOBSY#$GU+E: G[ M'H3]K1EM*2/?LQ-BVV%$F(/M]^S$)B(,HB@(1!(Z&&WI+2RAZJE]#"+-SGK\ M$F#5;ZR7807XFUJ!O6=R5$G.^$CV>'C\2B-)F,>]61G/.S\E7+X(.ML M#^)U?D.%]WO<%25:C9 7H5PPF^K4G.I?%] M$@-G"E=+-\W?[C7%Y98;KU4-/\O1/@+38HU$=*Z&N&50,W^O.E^%3&FU,N4- M9,KMZ2KC@<-=S[$ID4D<$!;[,1;JHR0.PB2V[$A:"78U6;>F"_K<6E=<(G6P M!:+G#D3WM%6U0/300-0L'N@*(4([(IZ#0!3%/@GL)"8.I2)VI<]C&B$0V0NP M2[= U +1PBUI!:ONV0T)$.8;9D)(K"D 3,LCFU M$Y]CG)RU;CW#&BBKHE)NIKW)6(I[E)"\1E=_C@![^P58;OA=:H74G,X6BF\' MQ=,5XT5LA2SV)'%#1Q#F6]CX*D@PM2+DD?1I'/%[JZ2W)HTGCHIL0:X%N250 M=EN0NRO(-=1='DH_H#0@@4LC4'UYBU&E'PW?7D*D M_'?UAQ0=#J/BQU+''62=X62-.X0?3P42+=NS?-/;O)8_RA=F*9H8? MO-34,DW)#YW#G0/(AL:/W4D_DJ.]1#'7;*]$$6.Q;A,]%L:#ITOJ!C()1,@9 M@9UU"..1()P&C%#'D[#C?@+[J1(]K&"I:ONU.:2+)_2%M\JX):&WM'Q+6I[R MC$(PB+ 3<&);"99PF%6%JJ7DYT3)"\_.:"GY82FY MJ1G3P(M#QR*VZP(E"^#/@<,"X,INXB=N;"O/AFN[2U6,Y84%+L_Q,M\A@4Q/ M8Y:&=D]#YJKCV&.I'F8KI^"L53X6"'/3I78=VP\2*;&5!W8%"#",)O0"8ML. MYXYG68Z**5Z,\K%XDEN]3-46:)Y8]9D/-"V6W!)+&LI/X(;2\ZE#')LEA$6^ M0T#<921Q1&(%;LPD5JQ8B/+3(DF+)$^N>K5(LC D:2A?H?"91P$_'(E22<($ MB8(@ -%$^);O,HM1@Y.3G%XJ-YHI6>4M/,J&>'+GWE(9=RRQ[O3#D;UZ MXIMT#&^+KP<"BJ/:^S/X8/^C#N M,@.[N9B/.,%KIQ.X]2%6?^)P%7I(FH@D2AP)(,82ZD?4DHGMV:X;P1<^_0?. M^UI^U\DHG\,9(!6)1I+_(#R!*;[AO7-^F:W]7EN)?CH@C:/5/!5SER9)'FQI M-.D )@]UO?0W0+%RA%?!F/C2C*5S,D*.\S^_WB.V]O9 50P8)GANQ_IX\K?7 M']$4WC08OW$\)2OH*Z/1[V]GG9IBIV9=\J1GWY]Y]O_:WCCXNKW?V=Y]O][9 MV-WL['][M[^]N;WQ=7MK?^E'7\.>$G'T]O;/1O)$#C* Y8XI))%','7FSJS/ M1\= C"4'^F-94.K5]J #C^UAWX+7OQH_,DA7'5==(:/@0HI]PI![_"R3;_)? M_L@+C*0#]6)UTQ_UM4!0:G!.M33Z:X-78;@>N Y"EC%_FA<;-%M7:-:0!O1W M7K!N6=[^YWUSTV6/>M\$Y/O?X[UZ$O?:SVS9[Z"V/X+U4QVYVZ=H:V MI$GS<=2EX%?8I)CVH>2CSA:P#M'9E+%$9:7CV-V:2'S?M:FHNKZT<'9X&[)\%L&K-RCS?(N8RCM4?5RZ%;EU&O[-Y[_< M=KVVI/6=S'JG&[E9SSH\V+".#KZYA]\/+W=.CZV]S1^7>]]WX)HOEX??=^A1 M?\LYVMQA.Z59[WSWZL?%SM47=K3YQ=XYW;9VOG^A>P=;5T/7M?&>S!W."=W[?3?^^ MVC8FO:WQSM66!>]I*UK?K:Q("W8O#^Q>5O7N5<&SRSJ>M<6[6S1[L6C6%BI? M20S;;6P9BALJ/D@ M=2M!LV?OS98=X([I<6X,Q$&Y?Q]Y.D#6NC%*,]B S2P[X M16LF61Q+_C)E)@&2B'P[H,1VHX0P&UAR(&1"G#!P'6K36+K*3.(P:Q&*Q1+I M#L\<'QY7_V]18;51H6%L"&)N6SQTB"VX3UC$71)*.R+2X]*W'):X/%;&4]M9 MMY:H[FD+#8L6'1:@3C^EZ-#BP*UPH*FP>RSQ:! R@IM-&%:DXPYUB:2![WM" M2,NWU]XRVYT1&OTDLL$+*V;S_H0/CF4G11(>R7AX/(";10>5\PX?B,X94,.H M P__F<82%B0;=U0(-UPS'@*9)O!$ ;J[ZO;=.>O!4-K2.,NC12&\?<8/%/:I MJS[#'H[D.!VI$%#3I_TS;MQ&H0F_4[:8%O]NBW_?IK6C**%QD #T,8O#CR0A M/ 0C$-&J1TQ01V^]M9W9JA&;8&-Y2;\1W:0M@2_G 3?4'P M3Y6&FJ'F$_/LI)/TAN>=$RF.8:):Q<'\H9/T[&[ZS.K:=FZ!=%$D?2FBT'$C MR7C"N.-36U+/ F'7HDS>NMC.=4CW'G;I VS2?V"/9&ZZT5CV5<8]GF5I FN8 MFWE:>+LEO!U.Z2X^MT/FAXS8G &\!;"-/' H280 '<8!;3:A:V\=;T;T:VO M?39$[D:6](+0$U9H,>[:D9\XPK(Y:"],B-A9J.K2$OF#$WE#7XDIY3ZSL9@6 M]0EC/":!$_D$B_E*G[DAC1S05X*%%<%IB7P)B5R&H:"1;45N EC/:>2%0C)F MHZ].V)%.$X:4ALP#3NXO M%2=_89Z8V=J*"9.<5EH&<'DZ@#^43K] S65UC32WP#N?Q5.:B^W!+GJ4$6Y+[/,8!"2RL2ZR*]T()%?/\Z.U MM\Q=0)QX:XI=8E.LM"F/ Q%%@728"*,HLJ,HM!QN^RZG<7#WO+26WI^4WAM* M3.(G0-511"QL#L9\3Q#.7$&L. Q"*P:@9S;(-Y8[0XMIO2Y+2^JWL5+X,4ML M]*MZ#I/<"Q);Q-SCH6-S$4BO56!6BL";"HS%+2IC1Q([P@J;?BQ)1(5'@M!V MPIB&TK+"M;=NN.XM$3]_H>X6& JJ+T9SR7TN?3[Z(4V-M?_/WK?_M)5DZ_XK M%N?&,Z&W7$7-RVTTNZ*FR85]H/K]HJ07@Z&;S)CO?DB MJAH_OB^KO9LQ4Y@KT3+/0":I0*2LMG@I,[4A$N%ILIKH9E)S.U)CJ]=U5T@V2$VI+I.*[ZVO5'RW%]\/F@E6 M\;U,?,]$5!RE(8H (O*,;YL$.(\&J+2:26&5G$PB7U3#_[8%5"C;86TW2.9L M.W&?:,G]V@2UC^3:;ZE4*KL;E;V?L4*,M(EQR< *Y3.520>>:061F1"$Q( V MJRI:+\1YVIJ^8 OTK*X;^-MJP53(WQGR4]:)$XGRK*\ 8URP>_E?'PH\"\RTK(*ELT$$<5HZ9P.!Q^ZI02L\[>+*OR_=S8L MK/*PMLKMV:KRU+P\]>+CS,1G%HF/6G!(C,I,5(F 5=$!9YZ99*CT6FSM4GI= ME*2Z4ML-W':T&*\07C2$IP8MV\ PTVT$S.,"H M(';-:VE(FJZXQ M-FJ-CU9TVEU-'@8- O2QP.>OG6WNV5@> X&M?1 M%0L\/,YG+$9#C$S:<& 8LOK(13X\;+888THT2>^5"]EB9-M4RAVQL%&9"\#B M:LS2K*R\\:S\F";XPKFXTNV<=#MEK(42G_ M5L*#]AI=_5Y#/2OC5L;=%,9MA_.CQ_PIX_=.#Z^U&^NO/'B=LG7MSB?[^QL?/-;KMQ4 MP++7ET<:S2<^Z8[SMX7OTP@KJWR#V#D8C/-7C >=9X-^(Z)F&M3+;M_U0]?U M.F_&^0^EVG1TX\-\P!O\[NT8]>T2K_Y;EMN0"K(4DT\<,PF*Q+1G!!-5V?KS M^07-_J2*;UV^ZWAX>0^G[EVV&X?HWH-+^1:?N-Y'=S[:^LIK36] M*VY\-"DM[=%,<)4Y?3!LVA@]R6C&8;DJK\FU9BV=XV$YL?[KQS(26[M'3?.9 M02K[=CS9GNYFO#=?VLW?U!\_X:K1NFYBB1]O[Y_F^+1'A8F^%B:_[3T]>KWW MIK-W\&RG\_3@>>?-KS^_V7N^]_3UWHLWK5_]-S3UE9S*3GCQG[/N^+Q%=W ] M3?UMK]_)']LK?5VW._@I8#D=C]T0.^XD'[3CT=_GNH>+-DR7YU-SZ.9[Z;G3 M$3ZY_.&GV!V=]MSYDVZ_65'SII].W/!=IJR+0ZW0U=2!VWS?Y.4+)K-J1PE9 MR.PBA''QQ1<\M]/PW)0.,7FM!&@IO_%ELD-O?.U['ZMWB!9W^M3OO\:E7?A: M^8ZP=UW/0Z]5[EBY*L]5[BAJ5F2M&3],KT>.3G>HT3Z))V MLZF%=[IR'@SPFU^]VTHO0M535I-M-)[K/^6'J2HK=NEP\/&FMUWC0KO0#Q_$ M561^I"XU)L?3O-:B9F=+[I7K1LBZQS-W6BS$&S.(-^L!O<:Q*U./&]W]Q0T9 M"JW:DG6C7[O10S@[.9O,LI[DTG^;@U(RLA8KUGM3^SH]_J-!H90&0]]:88LX M<"B[Q8GSJ!$-O:-NY;B_/L+UY:[LO>_J(>W=V^V,#,.303^;ZH/P_DLM^T+7 M(7?8+59RC9.WN*:![9A9N]>[$4[\8W^C4]9X^]C[5KNFA90Q1#XYHCWMWI=OBBON-KK"K6[Y%CMP?1[=L\%HO JZ\_H\\;I9 M5W.S+N3468^'9%6I@[J=H_I MQD2@)J TFDZ_#(K[4NUOG1?!<4,"$O!^__N$S0.3I]?_#7Z^[!R;_/#W_Y]=/;H_?DX/FO']_^]9:] M/?KW^0%[(0_R9^P?O3O_8SJIY^3?[."7/?;'\SWQQ]'+X\.C?&]'/W_._G_6NF2OC@* ^@HTD@K&'@?#20N*4Z4<.3<%N[ MDMMM9NRV4HMJ4;UF29.MSXF\'=SOFA+9WHS'>]+<-2GF=^*XVZM1U+@:I#@SKX1YXF/,^F#D$H1, M$DP^[( X2IA*GF+,2J'9EI9>4]-8B;$2XP81(XF)AZS[H6->))^\8P;S?Z01 M@MI$*C&N,#%.:8MYVP<1) (A!69&4%%H3:RQG4J$A@I?QX]5+]NBX/YQ2B+CB6@E-P7.2M2*J M&5B5?XH)O8Y.:U8&(#"^+2S9-FK3H%]UHDW0B>:I"KX;QWVG&+BZRQ['73;= M[H:DJ)U@!&P,'@03'HQ #XD*$P2JX+S?VK767J/_W+4&N/)?JWB@\M\M^,]% M=-9Q%M"(&(21C'NN/4FD4",^&O]5ZW"1Y#C5G$8SRE2D$913 81RQ6^F-5C- M(E(6LIIHMW;IMA#T7JTD5XP>EUBW5"EWK2EWGCXT!H-EWC$1C3!16>V=YMHA M1LH#D=4-M\I$&[XEVN MLL135CM#)MH4)5A&*92.;IIPI9''3+1LFRJ]L%%? MCT2W"TG0^\[T$MUNZCO \8V=?6_E*GN_687]$V\E5* M54I52ILJI7G2\)(EDF4=#PD7(EI#4Q(\Q6*!^6QFS3TE[M5PD+KC4L9;U;.Y MU+-_ST1)G442>4@@J619.[,.?'("@O."N])M2[NLG:D=LZ"!*A6@E4:KE*J4 MJI0>4TK+:%VQEI)_S&&X5)BVSA,%<)C3#Y?.BON4&9A$VY+)36R[%Q]>9CI1D1UL%/Y6>LV84M"$34('&5TLI) M:9[",!(2I<26QF+""N;RSYQJH:TS$5F<.Z#[-/YU-AHW0^J.!E_'L91I+'O] MBUDL#?,UQ/?L"N^]QO^<=4?=,;[!X8=NP%?YW@?Q-8;!NW[S*;^YWAE6)7LN M)3M<::;TGN__]>[/+$+BHG)@@F$@E'7@,#)P26FIA-1*IJU=N0I1X@K[2LY5 M2E5*54I52NLAI9JSN (YBU7%;9F*>\6/+ \^[XD_/=/,,N<@$400UBNP%B50 M9H7DB@C"<45TW W/A"S=Y)K!&(/4*87LPVXH(P]'S7@UU[_\:7!:A#?JX"<< MAFY&79,IN5DIDO-U_0M&Z\B5)Y&AH(Y9CODLU9D474"M\ >L>*7]WX?Q<#1I M4S!I_??\;%B:$S34UO!9\]KA1$(O+@74!,TF'0./L!]QB/'E8/C*G1=>K=T# M%T>/;V=F;"BKG"7)@D5.0&"2X)RSX$3@I7\@5S8T;6&DWF9$+:A=01N#\)O% M [.JT3U)X(9N)?/00-5UY@7S5'%KT,DDDA+$Z+*JD_5;\(I%$(ZKZ&4TAIFM M7;*PKB,5QNV#\<*=^!7&RX;Q](B#<@KKS,$0%3;@I> T$< TY2'CFRC%MW9- MA?&JP;BF'EIUUZ9FH.UJVV\]^Y#[ESQIBSQ7W^GC0&1]CTVR@<1YW M1C@>]["X9HLC'IL^M!WWT0UC;8+9ABA1S0NH4EHY*ER]_S4BVZ-@D9+@H9 C01AM0"K MJ04?K?:8N-&J=&MDU\3N;U\"5J%>";E*J4JI2JE*J4JIIJ:N7\."JM:V)B=U MXBVS3!MG701!/((P6H,SS )201A7FC.GVZ_7UM8&]UG;K'T_ MYSO,*W3]6!-&6Q+'J='Z*J4JI2JEQZT"4EJY()SEJ(-@(1G*B5=4DQBHL=;] MN<<(-;]"(.1R^:XH2]?NB=E0?W:C LJW@Z'@^[_FSL? ^/!@>#?EG' M<-#+RW^WEU=4PE,UQV$NK]*+\W]-YSA0'X+6QH,.*H(028#Q7 ,A*6\Y8[B3 M=FN7[]R[ITS%=&7>*J4JI564TEQCSA)1UA?:)#ZS*37$!J),%,((IS6]^8"\ M(2VPGI2/=%*^^-S$7]Z0S_OYL_??_6E\U#XY#Y3;!,(8!\XQ ]Y++GVPPA-S M_5G9HG3 FD[<)G6::Z=T/@$"P224$RZ*I)S3,C(F$\:'5J>O1G!3]Q-&^(S# M026/^U%_ M=KVFM:T;=YYCP!./PPZGVYV2.W&?]$@_&&;DPGAP^J3(:33H=6/G\F[6B "O MS5$A)%*A&8]%2Y)*^5))P75(U-HH-&DX\#:I*9-LE$E'D9J,LD ^NU2$OKH- M0B ,\P$%S@@/(G@!GN1?F:=F%;V[D5SUF[:& *>F82.SA*?(@3A2FOBJF&U!'X"PH))- MCDF:"5 MK/MG);Y*?.VY[SF(SVE#/'/!<$:%$MZA)EE#8$%X@\2%AR:^VZB% ME15ORXJ_?LN*(K.>-,1 4HIE(S=2L%)+8-$$S)P8371;NV9;";XC*S-69MQD M9O11\""=2R):89AVEE#4)C"-FK.D*S.N,C-.Q=D9AL1-4!!YT11]3(;.AF+4A)PP'3J5@-C#+;384F=B6UFP3+38,^U4KV@2M M:*Z^H7(IF*S_1*U!6!G NA!!&1FC-"9@P! ),\Y*#QR38B DP:$]X ME)J60 6EV\;P^X^%W8[W M*CNY_<-XY,SU)4NU;1O]]J?\_/=?=W/=S74WU]U<=W/=S4OS>\4@:/1$\,A1 M)".\")+3%)TA-%$32K-*1BZ:569S[/8.L%?#0>J._Y6UP&H\S6<\D9E,AI#- MII+1!Y0+ <(9 =X9!4%2&93PQ :ZM:N4W;'WKX-<&3ZKUD0]L>J)M0XG5MW- M=3?7W;Q:N_E!0T05(6N%D'DL%*%I\!@<#X:)X(C7D@8I@J%HJ3"D6BB/8J', MA'>BB8QQ'T!ZQ4$$HL &X!;QU,M MGA(6X,.JE/ 0E##MU$J$,"K1@@\Z@* .P=-2+>)2=#XZ(B1=%4K8\)SDIOX> MO!MA;#Q8&3:3L>OXJ?R,=>!2"WKFY%X&G\ZVPT/L'^>'0T>)J?7%F!Z[URW;C7?^9.NV/7:YBO(;YG M5WCO-?[GK#OJCO$-#C]T [[*]SZ(KS$,WO6;3_G-]>=K:U0O0("KN*SM7*54I52E5*54I/73NVGI+ M_C&=757';9V..^,H^?!7;E J9&GDVLRE&J1.:1\S[(8Q%MH:A/<=U[_\:7!:.&[4P4\X#-U\ M/#5IDIN5'SE?PUWJG)..ZZ"2$%3FWX+PC&@F:;+(U _4ARN==S^,AZ-)-8<4'&(3I;)V)R"TYZ#-BXKDTX[8>G6KM%LVY#V!]QJ M"DU-=%HY*3UF,./UEW.T8>8)1U]IFWZ9V?![=WQ<^KV5LH-JO,U-NK]^2[K6 M*)\]["XWXJS%9L.WQWWT0WC MO1H,KQ[)K5WXO4JI2FD%6M LP-%U0PN:KZD--V8V3 I[,D6^2 G#^.5P<-(H M%S]/)SMD-:-J%7-I%7L?KSK##CZ_(W\:;X@5Q@*-FH-(28 E6D$42O%(D'(= MRHQY?O\>-A7JE9"KE*J4JI2JE*J4VN4'6UG)MZ.S8E5K'UNMO>HL"^+@Z9^1 MFF@]M>")3R DS8JM] *,]5GZG+(BW;8KMAN><_CB4SAV_7=-SN'^>2]__\'. M;SN=P3#?B!N>3]QEHY*BUOFMZ\;#[JB38;93RMU/!OU)1N)FI1[>3(4BX]0K!.%5 MABVB ,&$-NA0Q"BOAVW;PO(5N^N=756E5*54I52EM#E2JOFD+M53 ME+J?,,)G' ZJVCJ_D^AJ/NFGPZ=_(JH8B"9 E'<@!#-@DV 00K22&RIE$E\X MH?7*ZX;GE%ZMS[_J_R[II5=\YXT;N"1EXW##DDD?RS-^&2.\H3!_XAG/M]B\ M-*J>\245W$^:4W*"UFEI(5OI"80U*5.>R9M;$(;2!N2&?-\SOCXY!IN%\B5Z MQW^ \$:/N0+PJKC,B>'];S$LT9AHM2ZA_)@QG AX:;*08N!:TQCR?S.&5Z#S M5L5N"U/4*XJ7W(5A@F+KA/:4!3":4A L43 88T8Q*FTLX=R$ZU'Y4>NU !63 Q$T@B=6 M $I/)6?1*XX+\YRO?I;YCI8KZCPOJ>6E.<.SP8GO]B?STS8KH[S5;O.G8=+O MOC2TK9[S!5?43'G.+;/&:0[6>0^"6PO.T03>":8\Y]H&LK6KC-TV6FP3(5L? M,*RY'ROA.?\6XU5WF1/&4\YSJFP,H42\N)0@M(I@,BQ!ZVBDH#$0RTJRJJWP M75OX+KR/\>WA>YLCNF)[[EXN$VRG%**D1H).49;@=@2?N #-E7*<))-*?SA* MMC5;A29Q%>#KG9M9I52E5*54I;0Y4JK9Z"ON7*_*[$-T<+EPLC,1*3(BP%'/ M0<3B9.^LOU%F]TWYWT]+STUOO97^-X^[P2U_C*TGIXR&ZT5EI MZ%*P=_>)<2L;3'RTMBV7I'=T(8&&_":^]8FT:JN69;5JF=CLF74XM4I!$L:! MH-Z#C1X!)45AF?;&D:U=)K:E-=M$BYH-MS*@7KO$L242QL[5IK M=W2EUY4!;J7759#2G)JMHB*$Z%F0(0IFM<^J$=/"*"JIMI96S;:]K/O^6]9U M2DM/A0"E:-/2S(-/6;,51,7\FJ!:Z:K9KB2HYU"9[@GH[]1I5=UI.?;IIRDW MG&8B9MD%4-*4%M?RX(701IA'0"DD8+(EH*QC$%7@5=HB F:VVU>(&V.Y;RL^LU!0MNW'F. M 4\\#CN<;G<*!.]3H. 'PXA#& ].GQ0YC0:];NQW422;G#&! M"(?$2.5U5!;NW2;$;5MK-Q68M;2O%NH^-90>>3TD^5"OFW$^-]+$^,0336@% L@=6.@'0\,N-U=,YE6C3;@IL=4ZFQ4N,F4R./0B;OA'*6"<.$ MLT;$_"^ER4A*4J7&5:;&,*4Q4FTT*@],:@8B'W_@>50@$[/4AZQ/2K:U*[>Y MHO=OH[EBS%B]9;?TEI799,HCB201$4GP,5%-2VI^U"D2OP!OV36._^HHNRWF MI_(Q%/44>?(%Y"+;AMZ"258!X931P) 3%A?=[7]5,%^UH:H-+8#;'D8;JM'0 M^T0/IM-;C.2:"2T@2Y6 ,-Y R0J&* BS*1%K45=:K+2XOK0X3P4$5S'SHJ%4 M""-*^D>DG%HT/F'DP:J;>?&&++ZG(9R=G/7<&./A^!B'SP8GIT,\QOZH^P$S M5PY.\%^#T>@ QX?IR'VJC#<_XWV>8CR>N)#%$<8-]R DLV!-HH 8?1 Q9 F: MK5TCS0ZY_Z#A5:&Z9:205?KP6"80(; MF0>?#7$:)V>6W?QB/G'N^9*FV;:/?_I2?__[K;JZ[N>[FNIOK;JZ[>6D>+"JB=RH8 M+2(3*22'1$:/,6EB)7.N*6>BE^5,= Y7UJOA('7'Q5M5+:L%6E:?9[(76$1! MM/6@47@0E"5P2#5X$1/S3#.J99/RK^PU9M7<9>4K0W?5V*@'6CW0UN% J[NY M[N:ZFU=K-S]H!*DB9*T0,E<(GB826$I<4RUL4(9D.T4[+_/_?4BL&C#M,V!F M>UM'[2V) 0)G)>L(12G9,Z"B5EP3HPQ-:V#"+'VR9+OYK,EH*0,EOZ:T-%&B MIL-UZ8$]=I\V:YKDVHUTJ%*J4JI2JE*J4JI2JE*J4JI2FLN8M0R%1&&I440H M17TV?$*4GC&=+:00[F[,UFSRQ5NRY)IL^6Z<:__S)UVQZ[7,%]#?,^N\-YKG(P3QSS1OE,)U#!@D0B W B3;9%A03#F 9-T3JA M.2,V'\>4+J#9705^I>>.;RC9;N=9:4?%XW,-B-Q[7BW90-W.*H0)52E=(*%*HL()OHILDH7R(N-P9<)I4KF2)?I(1A_'(X.&G< MBC]/QV .L(Y9G]-U*&>RB SW6CLC0*/5()*UX*A3X$/47 9:!NQM[5*^,^LU MG+MA2\5Z9>0JI2JE*J4JI2JE=CDY5E;R[2C KGKM8^NU,XE#THFH?4205B,( M&7T9#4TA,1T%)38:@NW7;)>8,G1K#UGL?KC\[(N/@'+]$]4XVAX']L_QE+<[OSW]_C@%0X;S$W;NSI8E3>$(40(Y8(+J+)5A,ZKY(R1 M/^ %-LT&&OJ-Z?HO_KJ'_^_U M^1^_QU//A#KX:^_3P>=WG_]X_D?WCU]>]PZ>_WS\QR\OC_?9?O[>/T[>_A4^ M'?S^\OW;OWY.^T=/Y>'1KY_VC]Z>Y_<4NG"*.A^D [2<@_#,@2-, G.,):." M-B%L[9(=/MO9H7,Z:8B993[QX'ZAC[Q!:[!A1<-,54I52E5*54IM&=#TK8KQ M1:^XHFL4U:):#G.K%5.#F&SDZ#6U8,KX)>%36JL1CRGK"UJX@O-T] MGBI8*Z56*54I52FUS]FZLI*O*L]ZJ#PSSE(:B=,<$9R5#H04%JQ2$I!1#&BH MBVA70.FI'?OJE?7*VMBR7EFOK#"I5]8KVPF3VP;2VUS$\;/K-9TLW+CS/.O( M)QZ''4ZW.\68N4^9QL58P\FM34\VO#KTL*C.HT&O&R>OK)XU.5^#"QZ)UDB, MS09D-E"XD28([9,(4BKETY][/^AK<6E'3II43'I;U,84"S0LZ4QCBJ"=-M0$ M4$8D$&@M&!TU!*ULU,@23[29"$KLMB1Z6ZA9\_)>$Y;OA:)'S@5\-*)H&]/> M=8+R_9[,:E+G-4F/=^+-6?=;XV\['O3RLQN]:&H2]_JA=U8>V*O!L*SBZ7@\ M[/JSL(D.A(WY MIR@%&!:)B$X'RW3F5';-B.5*I95**Y7>G4JU8 9#Y,)');A/7O(8%7/"!]3& MA(>FTCK/?I$\.U49:4,*400'-!^9F6>% N\M!YTH%Y2@YTYDGC7;DJO*M95K M*];:J9P[R3#P9#VDF#B(0#E8 M[01X4:;H.FY0V*U=OJV,V3&5:JM;<7%N1>I4B/F.VWR:2@CTCKC E8: BH&@+()I!C!P M@HX)C=*8RK.59RO/+B5YVNB,OVP+96)%88+S KFV/@JCAT.#BFH& MMY)V/T_1;I !:30&F%(>"LV")]&"TC[;R!BSFEN:5FQK(>Z5B;T^C+N,)*?* MXI7%%Z M6R^]2I+'8(SP@9F0J+&16Y&-5Z]4=6&N-'=/U]!83@1G*G,WM0Z$ M"P&,(PA..18%=49(MK7+R+:P;$>OK=D5Y4I3H1,W?-?M7[F' M12-;[%CQ(W S\G]^.AV,FLY=3YK6W-T/^%-YL&YYW)J[6SNFP.QB6 M]ND'@P^3_%NJFOQ;LK.49>H==;N%WBC^B\L$F[2HGY7"QVX<'U^>-%?>>+%A MR->W.)_1?#:^^2U7L!RPG &+WFJ47#Z-YA.?E"9WW7"+Y_,&,8MLG+\BR^[9 MH-_04M,*_V66;S]T7:_S9IS_T$SFO/%A/N -?O=VC)[J]W3EW[+7\BT^<;V/[GRT M]8]O6253RM36FMX5-SZ:E);V:";'2=8P!L.FL>&3LS(7<$(E_^-:LY;.\;"H M:__U8QF),KJA'*Z#5/;M>+(]W>[WMV@W?U-__(2K+VR_^S]^^(_=ZW;-HVYO M?>WV_FWOZ='KO3>=O8-G.YVG!\\[;W[]^\[VGK_=>O&D1.*]?_3?T\I54 M&@F6%H(O>X./-U/,S'']4UM(YV][_4[^V%Z9P?GW'ZV_G.WRAL4W2MG78Z;1 M%_--]-SI")]<_O#3I5+7[3=+:=[TT[=/1\YJ#LWW35Z^("1K=XSDA9,NBH,N MOOB"KG8:NIK2?2>O*;-#B+KQ9;)#;WSM>Q]K=C2Q=_K4[[\F.=OTM=+;?>H/ M2L5:41'V0P7UHB_*=1;,53>9-M?8UYW6X!?[=B<'*D/[DX/KDRAOCU_++RE]2,X MCAMU,Q5ULY.&@Y/.X!2+*=)_URD.P _9JL?1D]OLIIN>Q<*VV0+Z:&W:(C=K M?N$!CCM_ZPU&H[]WLF[0SS__;1_ M)5+U]O<7[/#H9?>/7_[Y_H"](&^/CO/?_OUY_Z\_>H='+\[?_O7Z_?[SER=O M9R)5KX_?'KV5^[__\_W;DW_SMT>OCP]_>7W\Q_/]\X.37^7^T3^[![_\^^/^ M[W]T__?S9?'HB_'^YQ=D_Z^]/PDGVB'3($S)H%56@TLZ C?4!BJ)E:9),6#* M7E/6U*+1& M/SJJ3A*;!8W \&":"(UY+&J0(AJ*EPI"&D\@E)Y$[ M\$Y^=4?)OE4JKDSU1Q,:3@T MHM>*)J#4>A!<>[ T48C6>&],3):'K.&HA942+H)N%N0!61$+\NN\O"8)8(@9 M7*';PTX_FY:7-F5YI?P>BN?D=#@H[9]CQY\OWG72%L=#JS]CD3X.RG98R[?H M?I )%T/G G92.;NV*;4G4CFS1B?H( M1?9K#>T%F-D5VH\,[6FC7-@,X21!"2&SIAPX."$99#F33-AEZ"5N[;)M1A?7 MXJA"NWW07K@U6Z']T-">-H*CIE[2C&KC2S6*"!$,H@<:4U;RJ> 8;(%V%NOA)61<#C,9FVW&0_?&;M/'?Q49L%CYV\>^YBZXQGWYZUX:V6'3#VN MM3$1QUXCC2/WZ<5$%C]/)%%9:2Y6>CMC2]"L/&KI$1R/V9;@D8'+L@)IN/*& M%OU1UAVPSCO 9_$8R0(D5MH79]X"1P@"$XP11QDU(JN<2LMK2B3O>TRU> 3A M6C)Y.X*X%=$+1O24$9FH35IQ!3XQ#T*2 +XT;Z3H7!+YQEFHV91:Q$4V]JEENVH=F!W MPX)0_^J.N^\F(:@1CL>]B^K%$HX:C(]QV. PWQ?V0Q='VR5<6D-3#Y:Z^F$\ M'#UY=NSR\^_V\RI*H+KW16)7!);%4JEJ+JH*,X:#EE%;)BPHQ4M61XS@&0W MN11.6>L3#5N[G/&%]5:IGNKV@7CQ9D(%\3)!?#X=2T9O-.&0^56!0$_ "B6 M"^6T5=GZ)SSK&X36<-.J@?B!#88*WJ6#=]I80.>H1\;SX2M)-A:DAV(F ,_& M R<1T:N25TFOR0)YE SN#0LEE=SA26DI-DT".R9M%,VC?N-X+9^RJ72DUS4=.[&>. *QI-S-J$XJA!:./ D*Q7".JM MXTYJZ=C6KJ+7%)?4&,*Z@'AY(80*XJ6 >,HX0.8(3Q2!!BM!2!;!\90@"J45 M=RDAB5N[PNR("N*U!?'R8@D5Q,L \;21(*D/DBL&/A";0%8],_%TI?WW*[)R6B-HDQ7&2>U1#"0V4;-9+XN0CBV14Y M5!*:BX3>SY@#3)#(8\EK]]Z!"$C!.BJ!<^ZU4MHI77I<4'I-2D)U,ZX+6A=> ML%+1NABT3NG]FAKEHA3 @^(@/!%@+(]Y^W#E@I+>2[6UJVT%ZQJ#=>$E*!6L M"P'KM'[O7&!H:(*0O)D8Z=;F7RV**#4G22N[M2M7JKG"O0=&K<25&Q8..6SR MH_(#@*9_1'>,)S7^\?#QCT8,!Y/([,0#QL1)2,!QI/H\] MRJU=D6W=V1.Y12ZXZD=OG?%;L;QT+.]_B^6@2;9ZG(=,XPE$] A&6P8HK-/4 M62(+EKE2-02VQM!=7@BL0G=QT/WU6^AZ=#'$C%4N2V_EP T8ZCWP$$U0698R M-= EUU32U,#7 X%PDBDZZG3[5WL(CD9X45/3ZSK?[=VCG^!MO7WU,Q;LC[#M MWGA/0\AWDG?9$ -V/Y3Q:=47\1BYF$-T(WR.D__N]2_E\OJ+6.I).-])^'G& M(*6)":DC QHB :%*.$=H Q*SV2&DY5P\>(^/NB$><4.XD@_$K8 46;9J9*+@ M;%00N3"!,=2"F:U=>5T?JA:I2M7*614'147U4E"]/X-JYKDCX*-4((1WX&FV M?RQ54=+$\PXF6[O:W+\F6SA1YX#MV/>.>*'"KAS$R4?A\5,5'&"%FU\R!4]."]-Q"L9-1PHQ6/6;\7U]745L2N V(?0+>OB+T/ M8J>4>A.1$&8D>,X""&\I>")-%HXO?76UUA2W=B5E;4'L)D6 CH8N8L==QH%. MW?GF!8':,6CZ9@_#JXE0&E%5.IJ/CNBLVS\HCL(YB,BRRB^%!(LTC3H MUQC08GET928&7;%2):#XB8C/V@8C.F=(4VKCD03"EP4;&0 N-U!IO M:1E'4??%INT+J8KA*")01BT(3QU8ZQ@0IYV,&$F0V6Y4UEX3/6R'J[,&)UJ7 M/5CQ_'!XGK(9*09KE,W$3A0!@2R!*V1O@E:[2_^5&5 MX]TGAFV$:^L!L@P;.1U>BNF9.^V.7>^@3BN9EZ+XK-%@.%7."S#4*A"F5&2; ME,#X))U37G!#'[?[:]T-#[<;$G>>"!00HW(@F"7@FFBTELR$)-#*,G=:J6NF MU[3#ZUD#%ZTS(6_M&ZJX7ABNITW)+"WDT4!$14$$YL")X,$0YQ@CWD=9$LO5 M-94LM0QM7:#\D"'("N6%07FZA8ZWJ'VV)*-/ 406$WC)2UMHK1AS-J;2_4KQ M:T[HVD'G@4"9-WJGZ:=Z.AQ\Z$:,'7]^U-)9QA&R3&&YILL[HK5V^3:BZQKVZ('_KK3EX MA>(IFWNN+#Q<6LGBL) M+FPD0^6&=>*&A0=B*S<\%C?\.AT!,4QBL$ D4A#(+3@O&(A O7;<9'71%&XP MA-^_2]-#<<."@KAM-K(+>CJI-_AX,<]],L']6_OZ;OUI+Y[%K81TIX:OM_58 M;NXB%^DPTCNZY?ZB9BM/FMYB[/SMU'7CWPOIYYW\G[/NJ%N89I*%T!FDB6>I M>66(<;.RW5N1U/S*G3=3D(\&3R="^/ELE%YCN>] MC[,N(>],\N@@BC)*C00*1BD-LC2,5Y$$4>8>,JWO'[NJ>9"M1?/RPM 5S4M% M\Y0A[DF&*]O&K:B^ %1/&4R M*^VHDC0?PI:6&'3IIB21@R8&+6.2$I.RR2RN:VN\\CV45L&<:-(M.EC&%L7N M^&QXQTCSRF;%/&KZ\@P7O1J6V/_X_%7/]<=/^_%%_NMIN:0RT7Q,-#O7$6,B MJ8SS9-9*$)@- Y=L@D@]4\%[)DBV#H34UXQ%K_FIZP#?A0?M*GR7"-\I"MZ7%>H7ORED"%;Z+@^^4'4 BIXJQ MK/ASET]?A0H,5P0"0Y*,59F-?88OY6TY?3[I[) MO0BH+&@;+ CC*7CF R0B65#$&Z-2MO*YJ1A>4PPOS4RH&%X6AJ=M!2]16Z.A M!/I 6'1@O*! N.4I:69ZR75Z/3"=M[N MG!;KN;$:\-)^WJR0PJ/:#%<8ZDT6S6&J3HT%$=7L(&:&DD05(GAC/0BA$9R+ M ;11-I9V3HX7HC+7]/FMM?+K N'%VPP5PDN$\)2](++ 5*0)=& (@CB5[05- M0&C.2T\VQA&W=MD.K0A>6P0OWF*8!\%7*W92]Q-&^(S#047VW,B>MB)"%IF5 M HB.I40'/1@K$)2@-%BF0_)A*Z/8,,I^:A&Z-RSP<*TQ<:6YXNC,C[JQZS9O M?'-;S(CGW<;'47+##M/79,G*4/,QU.P,9VT\D2Y2H)J4;@3!@F'*02:D$%A@ M4I528ZL65DM8_97M@^Y2S8<*W45!=\IL4 R=LYI"8A&+Y9_ $V> 6A93BIAE MR;+90&JET1I#=ZEV0X7NHJ [91<$IZVDI71?D9"AZPG8;.<#=U)J(9/S7&3H MFE9!=\,B#&?#<.Q&C2EPXH;O<5R&#'1&&,Z&=V^&M[*NC%8D(7U)DMS_(I W M7^1166D^5IJ=Y,NL##1K_" -HR!HS J%XP@AA>1)$BSJTJ.,M"4]LOH@5R7U MJ )WL<"=L@2LHX$++R'JF-4)%!H,50I2Y$%Z6_*1LCI!B;A7LD)%;GN1N_RZ MA(K>GI1A7(BP?RK]-3LC(5LV([V.*NB\R#T2Y!L#280(@* MII0SZ_OG#;8TB+!*HW7.1A@[W?ZU;7_O$TE8LQ;G#QQFN*')X@W-SFNAU;U9 M;':&IS!,Y2[LH01#-P2)5H'1(SGDGJ0A;NY3J1;A 6C/D8(&.S0UF@.6U M6:T,L$0&F"Y_,-%$RA/8Y&-ILBK ZDP(Q'.1Z3V04"J8.*'7*#*5 3:; 98W M)+0RP!(98,J2B<''F+D;5"F.R*SNP+LDP8FLOR6O(DI1>I[(';$"#+"@&$F; MS9KI82:IVW?]L(AA)A?/8GES0F[K(=K<16Y8GM\W,;[N:'26=W(3X^L-^N]@ MC,.3?&#XVC[@48)[>Q?R.$S_RM(XRL)XGF511XPM\#B6,R:Y2]I:ZQA0HA(( M:PEDK2J -51(BD1K6EH*;&M*:DWR&B-[J=&^FY!=P3LG>&=Z%,=L%!$'@2F9 M=6D3(,.604K*()72(M5;N];PVA!DC:&[U/A>A>Z"H#L=T/.9;XU'T,9P$)@4 M&"T=H.(,F46>M\'6KK[&"*Z= AZX1?%BS(.5S31XU&J@UWAZ(89J%2R+G?9G M)QMJ%ER27@!+DH!0S((/7H&3DC*!1C,5MW;%=CY/KE$M:E_3=<#RPBV"BN6' MP?*4D8!:1*)8@(0A9"QS!!/S/YYQQ9,WG)7NIFQ;&%%[%*\IEA=N(E0L/PR6 MIZP&3#XIH1"R;I7/92(\>$$8V)BHDIIYU13_;5-B=F0[L+QA$88K1L/70%G" MVD+@$5H('*:7ER)X-AB-:_!^3OZY9J:A,&BM8!"TR/R#:,!%QT G:8U'[8*3 MQ6M11Z*M)U27UC2@0O7>4)U2^Z6A) 9.(:L&)D-5:W!4*S NI)BE95WBI=%P MA>IZ0G5I70(J5.\-U2FMWEA*3;(*DHTJ:_7<@94R&^S4;'@^%X$@7P@^%P\#'?S&@#9Q2V)5_HJ@_B39%-C4[>C9&N M&4RHHJ4Z2\4P+;+R0")XR2RD:)-%02-KTO3M N845+=A:]&[U)R@[Z"WNA 7 M">WI_F%2!\O*I-% 2_\P$\!9X8LQCRPZG9@L-7C;Q-H=5<&]6N!N1SE-/:27 M@^0ILT&F)'PIHK&V">Q%ERU\HB%*C#0EK:21&G/7=>UHG?Q_PJ M7[EAT9!OZBWP$PY#=])E>30>A/>=P6G9CAL6&FF+^?2FB.!P(H$7%Z*)=3S4 M8MAZ=O@*H@SYO$V@B"ZSWC4'9XB"I),RGG!'K&[C>*CJF%TAH^H&3%?LSHG= MZ>DKB@4IC0/A1:FS4 F,R284\B*BHT$6 MV^_=\?'QH%<>X\O!\$V1UL\NL]:SPN++(RV'P,-CNFQ:08,FT)H-IH M$(0*L*4G6<56QO'0L3U=K2X<&DP/+K ?A M% /K=8:V\H$*YK65K"1/V@KEM83RTC*R*I27#N7I.@P2N'9"@0_6EB%,LM14 M$6 2I:1R,V*-[3"]['2"\Q!*-"N'E0'A_IC5,3)(P,(@*A$<)3GD*DG.A#'66RPQA M<;\*SPKA]D)XB:4;%<++@?"OTZ:^A !^9=TLPG:4KMAKU7/5EU-+8V4V&)D]VO1VQ-&5P0 MDJ?3CDCD4D4$9)2#8,F"$0F!<\_*&(42&UQ8RF %=&L!O<2![Q702P7T=-A ME(,Y1: >12GT3F X(FB5G%!6(U&LC8#>K/C!P: /X6L,X3)J4%#1.1T.XED8 M=YJ'5@,)R[<:/HR'HR]\]7(PS,+Y&M]Y=C6\DU]\-9'.ZT8XU;%Q;P83LU4, M1AO*F0+)A 61)0FV$%KF+Q:8<_D/9:"T5&UI5E&=DVV-+U1D/RZRIR M& _$!99U$V3@=3(@//U/3[% ZC0A/1.&I0\A&QEU$SI-87R M\F:]5R@O&\K39D7T64)& ;>E#6T2'(Q$#AE5Z2B]AH,G*-MA+3<4#G#< M"26QZ6R$L;2KO6Y.^WT"%K<:+KZ>)+8\TR)+K62C92XKV6CQY_-?L_3V^C]T MA-2VF/8()9GL,Q#$)4#YN2 :5N%.L%E2B =/"A6"U1T?P+4<&(DK4M M=W1E@,H #V3G5!7AL>AARO[1T@7+;1FD&2T(9PA8K[(E5$PAX[)V:'TS?$_= M+[7ZH0AB08&4-AM%+U+",.YDZ#:FT2!U0C/.8U0,)/PT^:4S=.,[FD873V2# M>6]YIM%$=H?IQ8687F*D;S_^X3&C -"9-B&7&RFS_D$7$7%JC^BS0B[MF%/"8Y285^$L%_G2U MN?-49NR.QL-N*&UVR^LU'-0RFZ>PVA2S MO?XBL@OF^_8/5ZY\E6]\$/$ES?\NK$L@:$LC"NP)4 FDY@4Q9;(E; M91++RH'0#8@)/7LUM99YZ+VJN/Q7;?? M+YE\@]0Y;8"V665 \]AF*BKE#:5"&%$4J4@YM6A\PLB#57_N/8 V5;EM/F[[ M/&-82>NEE=R 8C$K1]IA:;6>0*:L&6F.,1*RM6LDN2;27AL?K0N879"$^XQH M9J/P+GFF&#J%@7CCF,0"YJ5K-A7,!9AB 4+ZV-703*@G(Z MZZK9$-[:S6Q]_T%L%:)+&URXV]IJ1OY3N8K9EA@?FU&TV* MY7I>VO;T_GMYM[\N!)Y5)7QJC-I M#1AO_]&<297Q*N.M,N-5C]MJ,MZ4D6Y(4(9%A. B <&] %=\;U(KE,HE*P1; MD,>MA@87AM,W9Z>G/2R-;%RO$[NCT!N,SK+MWM2M%;L]]08?.]W^I,JS(/E+ M=\8;HH&W>#Y7!,>S:.+@S/=P1G(W>C47X1G=Y%5N@&.JZ:=?MN]XF#]DPC*C M)W?:L[=-'*J?L6E]4I\-3DX&Y4L'X7VG.QJ=86P&-HR/L9-?\]U^PYCW\3VO MF8Y[W1VNBQJ[\*%U35>Y-_D)=%-^&OUQYK1":4=?&>TWUSO#P_1-?^M?NA^P M3VL+Z\6HN;.C[F10,0CK ).E(&+D95*N!XPRIFS'2$-#&^?I+$@UJ>2UEN2U M\,J Q9%7[2ES7P;;G^XIPZA(-D+^1X&0I1V_"=E:1^N:\NO\:LGAW=;LNM++ M2F&5PMI(80NO3:CZ5RO8:\;-R+3*!B@$E3)[,>'!$1*S.D8YY8E&$ET;]:\? MF,:Q.SKMN?.R6/P^WZWRE1O@>6H&O9?Q[IUX-BSU$\4;,,EV*IQP+Q_4$CV2 M"_0,K>TJ-\N[M=V"J^%66:>-K+-PWU-E MG?NRSI3'2!ED:$F B(2400413* Z_R2X,5HPZK/-Q9G8$95U*NNL!.LLW%U4 M6>>^K#,]^RE0*1A7(+W-"H^U&JQ0 5+@D0KK:=:!MG:9-CNJ1:RSR!%0JV D MCK%4>MTQ=6^R].L,\-N9YVO(N4MX0.M"V4LP3R>[M_#U =;V0'-2]FQ'=ZJI MXTI3T+90-G,.G&$(E%@M@U-&,Y7-4R,6W1YH$3A9C;J(2IF5,A_5MJZ4>3_* MG+*MO<'$"$I@TB$(X2@8;BU$3TN1L^&94;=VI93WMZTK95;*K)3Y"(Z!2IGW MH\SIH6C!"VT$@ZQN2A"./W3@^O@3#E3=>W!+Y M^A;G1X/>V?CFMUQ9=\"RMQ<-:4HN,=U\XI/N.'];^#[*65/,AM@Y&(SS5XP' MG9*552H"76E!'D/I^X=@A^B>P\NY5M\XGH? MW?EHZQ_?/(F3;A^FMM;TKKCQT:2TM$=D>=O7[8:7I&O3GSHV[LNN'5L?&M M7?Y]F.:6T-5LZU9/X/*$@:*1/J'F4DV]V"%0_O)(3XGN7-[]PW_[U&,A.[)Y M#!.5X.#L)']F6("+<6IVKAN?#?$P'9Y>9 2/'EO/^[QWJ>=]^N.7UR<'SU^< M_W'T@A\\_W=^WSMY>/3;\=O?]^3!4=;Q6+[NZ-WG/YY9\L?_'I-P\EO?_6[/ M#O]Z^3Y_7M8+_]G;/PKDX/GKD\/G[^7![R^/W_[UGA[^\NOGMRX?/#][_ M[^<]>O#\Z9\<"1)=QM:JE"U;@AX4 M*.6$D%Y[23&IQ+,UG,G7Y8>-67L^+0PX/,ML/WG8A3:_/NY+G>]"P%-TF%^[ M^,I).7LCFA]^[8_P=P,?/[3&<,FH^?^N\ZXW\)F&CM'UQL?!Y<<4!B=Y4>=- M;GJFJFX_:TL?\,3CL%.\/YV/QX,1=DZZHU'S9!IRPY/3P<=\P2D.3O,!]7$P M[,6L V!YK9=M8LBE%ZVIK8[0WSGAK&'HZ:KP#L< MO!NZT^/SSF#8"=UA.#O)U_<#[G3V3D[+Q.F+I%GGN[WN^+SI%IAEU706S%_Z MSN5UNZR8CYI?1V?YW9ESR^E9SI#C_#C@/V>N>>N5>\]W,S@;YK64=A_-6D[/ MAJ.S[GBG<]C/=W.<5U^LM%&9W/NA6YZ R[>2[ZS_/J]H.YMX64TZN:CI;;[* MY\NST"'T7/ZXO"TG*^Z64Z%\7'YLF)]%&?7[KNCUO?../^OVQF790SS)C[[C MW3 ?=L,LKC 427]ST1;>]\IS/',=FR3=JD MZ.N?.J>#X3CEXW/0;,_\0OZFD\&P$4F_A)IHX,BL.T?_$EMQQS3C:.Z=]]WG_Z)T82E7 6))$1A*$$K&$6.-,J&$F3 MRT][EV[G[3!CCW?<:<%\9J-+@7[!@NLT/#-LYF5G$GB/!8Z9Y4_Q+-O)'5?& M?6R7,723>1]?4)'!%0;O^GE+9H[+NZ-^&HYW.T:2>OZ'.07/,E$66=7_*XA]C_L8;MVDVJI>\15W_ M+.5O;8H-WN1O&VWP=GSQI9Z/,M,G,V]WD7+H9A/S68C_I49NQQ$5[95?JV< MA84])GUQG[[:RUOJ]W(8]_,'C9M3R9^-,DTV_#\W)&IHO_W_GI0[.N[B=K;ILR>VLX/FTUZ@7 M@V%L3MSFL2S9A)G3S?7TS;..(7*[\_/EMKG2;63T,.;6]2O[_^R]:7,4298V M^E?2N&/W[3*3JWV-<*^:%S.JH,KHVQ*U0-? %\Q7*45*J+7WW/<(R(C M%X$$ E(0/5-"RHS%M_.<_9R]T<'EQ&;1T3=)D7#,LC '*WJ!8O<1_/J_%^,9 M'%W ]'S\SD^FQV?+R61Y9P*"ZWB^F,Y0P^??FX;?RPE^T!WKWX$5>!#]G\*;?IY,_:NOSGR?-?(W/OM?D\-W1^S@Z:.W!R>OWCU99[ZGOYX3I@?R?=P?O#D\.WKQ,7C-5!4&B MQ^;NMN+$"JN(BYIY6KMHV8;:SWSM%88.Z10EU=8:JS1+595\K8.RZVK_7Q>G MIZB= 0+T-F.TW(U1NQT?80SX\&!6!U\I0T.(M1$88R&DD\'!6:T=I99+F.SN M\+TK&GX'Z=:/SR>ERN/*+NQ?12]? M0YK83IX?G&WCXT6MS?E\61<]--9S'KP+. X M%_"8^:(Q)9UKI>I6!)WYL2TFU;PFW1-;>XV_.+TH3N5.9()KIYWY%?N! MG"/$Y%,Z&[N+,C]\=QC/EY_L;TI.HT^U9WU>P'HVCT_2H_DB:_U?WZS_51C\ M6Y!9C>)U2D0S9D"]MI+H5#'B*NPB7(FHJWH=_#@=S3'9_UKCM8. M>Y3O0:WIU+Z*L&OMRF2HF,\O3L\+^6;CA\UM=/.2P3BF,X01>]J!)EP?&V@# MS.B,X;;<@2CN2B^/8]G:"?NE=@H-^%?I=C&_NCG MZ.W%O'OE!6CS,W05P)*,SU"9@WG#2LTO_/%RWGLC-/_TU$& ZPD"%\Q\-DJS MZ6G##KH[EMK@.N?<10C[=3J#@W7VR\4,Y@_R5H\#/3@+^<])P?%!( .T4R]# MT+4U,I'(&0>TTQ4Q7D3B1QQW!<0^+):A!-*8;(H4 MA/A5'O 0Y"\[ T)=I7K?G.B>\+;?@^]5%W%&D5RIY]?)]$W!+I#45@U*2X&H M)](5',RR6@)$P:>AI-.M\&B*=J+BN]H8BE>'.KS% 9R?9LCH_CMD\W0.=!F=A*=5 M-G*PS0/(I[X[$(O>\XOP6QCZZ#=@!G/T0D^F<^0F\/V*1 ZH/.T)XK9WQI:; MC-/K'Y!V0)NGXQ*7? S,QJ*3$X=J&RZ3B^WG1)6Z8P70V!B("!#C%,*4F MEF5Q/(MQ= KC.2[@DWT>JR+R^<4,*'X>[Q:]%H01V@*KSX.;=B$8Y8FN@UEH%M'.AG<0&:)LA5DQQ^ M=3U4R=,D^E;.\(V)#6$F"QH9=N(QZ+QH=9ODX!B4'O#SZ1GJL?#$JZ6B?5A, M#&Z[8DPX69QT$8,WUR*L+5X+A!=Y@"@78:@:^F#:JRY!QILWQM,<>U>,K'EV M94:-!I^78^]F(LSH_9L)$EP.!EH;<-ZC,$(?<[$7_._%%%]SFC$+?<<@D6;U MWLVFK] Y/8.)P_1G^@CPIO+$(R*?3$"?S9IU0,YC/ MN_=ERW6

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�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�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